{"ANIDULAFUNGIN": {"indications": "invasive candidiasis (see notes above)", "name": "ANIDULAFUNGIN", "side-effects": "diarrhoea, nausea, vomiting, flushing, convulsion,\r\nheadache, coagulopathy, hypokalaemia, raised serum creatinine, rash,\r\npruritus;less commonlyabdominal pain, cholestasis,\r\nhypertension, hyperglycaemia, urticaria, injection-site pain; also\r\nreported, hypotension, dyspnoea, bronchospasm, hepatitis", "doses": ["By intravenous infusion,adultover 18 years, 200\u00a0mg on first day then 100\u00a0mg\r\nonce daily"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid unless potential\r\nbenefit outweighs risk\u2014present in milk inanimalstudies"}, "ACETYLCYSTEINE": {"indications": "tear deficiency, impaired or abnormal mucus production", "name": "ACETYLCYSTEINE", "doses": ["Apply 3\u20134 times daily"]}, "FLUDROCORTISONE ACETATE": {"indications": "mineralocorticoid replacement in adrenocortical insufficiency", "name": "FLUDROCORTISONE ACETATE", "renal impairment": "section 6.3.2", "cautions": "section 6.3.2;interactions:Appendix 1 (corticosteroids)", "side-effects": "section 6.3.2", "contra-indications": "section 6.3.2", "hepatic impairment": "section 6.3.2", "doses": ["50\u2013300\u00a0micrograms daily;child1 month\u201318 years seeBNF for Children"], "pregnancy": "section 6.3.2", "breast-feeding": "section 6.3.2"}, "ANXIOLYTICS AND HYPNOTICS": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of anxiolytics and hypnotics ", "name": "Anxiolytics and Hypnotics", "backrefs": ["Anxiolytics and Hypnotics"]}}, "EFLORNITHINE": {"indications": "seenotes above", "name": "EFLORNITHINE", "side-effects": "acne, application site reactions including burning\r\nand stinging sensation, rash;less commonlyabnormal\r\nhair texture and growth", "doses": ["Apply thinly twice daily;childunder 12 years not recommended", "Preparation must be rubbed in thoroughly;\r\ncosmetics may be applied over treated area 5 minutes after eflornithine;\r\ndo not wash treated area for 4 hours after application"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises avoid", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "INDOMETACIN": {"indications": "pain and moderate\r\nto severe inflammation in rheumatic disease and other acute musculoskeletal\r\ndisorders; acute gout; dysmenorrhoea; premature labour (section 7.1.3)", "name": "INDOMETACIN", "renal impairment": "avoid in severe impairment; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": " probenecid reduces excretion of indometacin (increased plasma concentration)", "name": "Indometacin", "backrefs": ["Triamterene", "Diuretics", "Desmopressin", "Gentamicin", "Amikacin", "Indometacin"]}, "cautions": "seenotes above; also epilepsy, parkinsonism, psychiatric disturbances; during prolonged therapy\r\nophthalmic and blood examinations particularly advisable; avoid rectal administration in proctitis and haemorrhoids", "side-effects": "seenotes above;rarelyconfusion,\r\nconvulsions, psychiatric disturbances, syncope, blood disorders (particularly\r\nthrombocytopenia), hyperglycaemia, peripheral neuropathy, intestinal\r\nstrictures;also reportedhyperkalaemia; suppositories\r\nmay cause rectal irritation and occasional bleeding", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["75\u00a0mg 1\u20132 times daily (once daily in dysmenorrhoea);childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "amount probably too small to be harmful\u2014manufacturers\r\nadvise avoid; see alsonotes above"}, "CLOTRIMAZOLE": {"indications": "fungal skin infections; vaginal candidiasis (section 7.2.2); otitis\r\nexterna (section 12.1.1)", "name": "CLOTRIMAZOLE", "cautions": "seenotes above", "side-effects": "see notes above", "doses": ["Apply 2\u20133 times daily"], "pregnancy": "minimal absorption from skin; not known to be harmful"}, "VALPROIC ACID": {"indications": "treatment of manic\r\nepisodes associated with bipolar disorder; migraine prophylaxis (section 4.7.4.2)", "name": "VALPROIC ACID", "renal impairment": "see Sodium Valproate,section 4.8.1", "cautions": "seeSodium Valproate,section 4.8.1; monitor closely if dose greater\r\nthan 45\u00a0mg/kg daily", "side-effects": "see Sodium Valproate,section 4.8.1", "contra-indications": "seeSodium Valproate,section 4.8.1", "hepatic impairment": "see Sodium Valproate,section 4.8.1", "doses": ["Mania, initially 750\u00a0mg daily in 2\u20133 divided doses, increased\r\naccording to response, usual dose 1\u20132\u00a0g daily; doses greater than\r\n45\u00a0mg/kg daily require careful monitoring;childunder 18 years not recommended", "Migraine prophylaxis [unlicensed], initially 250\u00a0mg twice daily,\r\nincreased if necessary to 1\u00a0g daily in divided doses"], "pregnancy": "see Sodium Valproate,section 4.8.1", "breast-feeding": "see Sodium Valproate,section 4.8.1"}, "ZONISAMIDE": {"indications": "seenotes above", "name": "ZONISAMIDE", "renal impairment": "initially increase dose at 2-week intervals; discontinue\r\nif renal function deteriorates", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin reduces plasma concentration of zonisamide ", "name": "Zonisamide", "backrefs": ["Zonisamide"]}, "cautions": "elderly; ensure\r\nadequate hydration (especially if predisposition to\r\nnephrolithiasis or in strenuous activity or warm environment); concomitant use of drugs that increase risk of hyperthermia or nephrolithiasis; metabolic acidosis (consider dose reduction\r\nor discontinuation); avoid abrupt withdrawal;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (zonisamide)", "side-effects": "nausea, diarrhoea, abdominal pain, constipation,\r\ndyspepsia, anorexia, weight loss; drowsiness, dizziness, confusion,\r\nagitation, irritability, depression, psychosis, ataxia, speech disorder,\r\nimpaired memory and attention, fatigue, nystagmus, paraesthesia, tremor,\r\npyrexia, insomnia; diplopia; ecchymosis; rash (consider withdrawal);less commonlyvomiting, cholelithiasis, cholecystitis, aggression,\r\nsuicidal ideation, seizures, pneumonia, urinary tract infection, urinary\r\ncalculus, and hypokalaemia;very rarelyhepatitis,\r\npancreatitis, aspiration, dyspnoea, hallucinations, amnesia, coma,\r\nmyasthenic syndrome, neuroleptic malignant syndrome, heat stroke,\r\nhydronephrosis, renal failure, metabolic acidosis, renal tubular acidosis,\r\nblood disorders, rhabdomyolysis, impaired sweating, pruritus, Stevens-Johnson\r\nsyndrome, and toxic epidermal necrolysis", "contra-indications": "hypersensitivity to sulfonamides", "hepatic impairment": "initially increase dose at 2-week intervals if mild\r\nor moderate impairment; avoid in severe impairment", "doses": ["adultover 18 years, initially\r\n50\u00a0mg daily in 2 divided doses, increased after 7 days to 100\u00a0mg daily\r\nin 2 divided doses; then increase if necessary by 100\u00a0mg every 7 days;\r\nusual maintenance 300\u2013500\u00a0mg daily in 1\u20132 divided doses"], "pregnancy": "seePregnancy", "breast-feeding": "manufacturer advises avoid for 4 weeks after\r\nadministration; see alsoBreast-feeding"}, "CALCIUM-CHANNEL BLOCKERS (DIHYDROPYRIDINES)": {"interactions": {"extra": "", "bad": 0, "interaction": " itraconazole possibly inhibits metabolism of dihydropyridines (increased plasma concentration)", "name": "Calcium-channel Blockers (dihydropyridines)", "backrefs": []}}, "LEVONORGESTREL": {"indications": "emergency contraception", "name": "LEVONORGESTREL", "cautions": "seenotes above; past ectopic pregnancy; severe malabsorption syndromes; active trophoblastic disease (until return to normal of urine- and\r\nplasma-gonadotrophin concentration)\u2014seek specialist advice;interactions:seenotes aboveand\r\nAppendix 1 (progestogens)", "side-effects": "menstrual irregularities (see alsonotes above), nausea,\r\nlow abdominal pain, fatigue, headache, dizziness, breast tenderness,\r\nvomiting", "contra-indications": "acute porphyria (section 9.8.2)", "doses": ["1.5\u00a0mg as a single dose as soon as possible after coitus,\r\npreferably within 12 hours but no later than after 72 hours (but see\r\nalsonotes above)"], "pregnancy": "not known to be harmful", "breast-feeding": "progestogen-only contraceptives do not affect\r\nlactation"}, "IRON SUCROSE": {"indications": "iron-deficiency anaemia, seenotes above", "name": "IRON SUCROSE", "cautions": "oral iron should not be given until 5\r\ndays after last injection; infection (discontinue\r\nif ongoing bacteraemia)", "side-effects": "taste disturbances;less commonlynausea, vomiting, abdominal pain, diarrhoea, hypotension, tachycardia,\r\nflushing, palpitation, chest pain, bronchospasm, dyspnoea, headache,\r\ndizziness, fever, myalgia, pruritus, rash, and injection-site reactions;rarelyperipheral oedema, hypertension, anaphylactic reactions\r\n(see Anaphylaxis above), fatigue, asthenia, and paraesthesia; bradycardia,\r\nconfusion, arthralgia, and increased sweating also reported", "contra-indications": "history of allergic disorders including asthma, eczema, and anaphylaxis", "hepatic impairment": "use with caution; avoid in conditions where iron overload\r\nincreases risk of impairment", "doses": ["By slow intravenous injectionorby intravenous infusion, calculated according to\r\nbody-weight and iron deficit, consult product literature;childnot recommended"], "pregnancy": "avoid in first trimester"}, "BIMATOPROST": {"indications": "raised intra-ocular pressure in open-angle glaucoma; ocular hypertension", "name": "BIMATOPROST", "renal impairment": "use with caution\u2014no information available", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nnausea, asthenia, hypertension", "hepatic impairment": "use with caution in moderate to severe impairment\u2014no\r\ninformation available", "doses": ["Apply once daily, preferably in the evening;childunder 18 years, not recommended"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "INSULIN GLARGINE": {"indications": "diabetes mellitus", "name": "INSULIN GLARGINE", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see under Insulin (section 6.1.1.1)", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection,adultandchildover\r\n6 years, according to requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "FLUTICASONE PROPIONATE": {"side-effects": "seenotes above", "indications": "prophylaxis and treatment of\r\nallergic rhinitis and perennial rhinitis; nasal polyps", "name": "FLUTICASONE PROPIONATE", "cautions": "seenotes above;interactions:Appendix 1 (corticosteroids)", "doses": ["nasal polyps,adultandadolescentover 16 years, 200\u00a0micrograms (approx.\r\n6 drops) into each nostril once or twice daily; consider alternative\r\ntreatment if no improvement after 4\u20136 weeks"]}, "DENOSUMAB": {"indications": "see under preparations", "name": "DENOSUMAB", "renal impairment": "increased risk of hypocalcaemia if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2\u2014monitor plasma-calcium concentration", "cautions": "correct hypocalcaemia and vitamin D deficiency before\r\nstarting (monitor plasma-calcium concentration during therapy); consider dental check-up and carry out invasive procedures\r\nbefore initiating treatment (risk of osteoneocrosis of the jaw)", "side-effects": "diarrhoea, constipation, dyspnoea, urinary tract\r\ninfection, upper respiratory tract infection, pain in extremity, sciatica,\r\nhypocalcaemia, hypophosphataemia, cataracts, rash, sweating;less commonlydiverticulitis, cellulitis (seek prompt medical\r\nattention), ear infection;rarelyosteonecrosis of\r\nthe jaw", "doses": ["reduction of bone damage in patients with bone metastases\r\nfrom solid tumours,adultover 18 years,by subcutaneous injection, 120\u00a0mg every 4 weeks"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "CEFRADINE": {"indications": "see underCefaclor; surgical prophylaxis", "name": "CEFRADINE", "renal impairment": "use half normal dose if eGFR 5\u201320\u00a0mL/minute/1.73\u00a0m2; use one-quarter normal dose if eGFR less than 5\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["250\u2013500\u00a0mg every 6 hoursor0.5\u20131\u00a0g every\r\n12 hours; up to 1\u00a0g every 6 hours in severe infections;child7\u201312 years, 25\u201350\u00a0mg/kg daily in 2\u20134 divided\r\ndoses"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "DOCUSATE SODIUM": {"indications": "constipation, adjunct in abdominal radiological procedures", "name": "DOCUSATE SODIUM", "cautions": "seenotes above; do not give withliquid paraffin; rectal preparations\r\nnot indicated if haemorrhoids or anal fissure", "side-effects": "seenotes above; also rash", "contra-indications": "seenotes above", "doses": ["By mouth, chronic constipation, up\r\nto 500\u00a0mg daily in divided doses;child(but seesection\r\n1.6) 6 months\u20132 years 12.5\u00a0mg 3 times daily, adjusted according\r\nto response (use paediatric solution); 2\u201312 years 12.5\u201325\u00a0mg 3 times\r\ndaily, adjusted according to response (use paediatric oral solution)", "Oral preparations act within 1\u20132 days", "With barium meal,adultandchildover 12 years, 400\u00a0mg"], "pregnancy": "not known to be harmful\u2014manufacturer advises caution", "breast-feeding": "present in milk following oral administration\u2014manufacturer\r\nadvises caution; rectal administration not known to be harmful"}, "FLUOCINOLONE ACETONIDE": {"indications": "inflammatory skin disorders such as eczemas;\r\npsoriasis, seenotes above", "name": "FLUOCINOLONE ACETONIDE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily, reducing strength as condition\r\nresponds"]}, "POLYMYXINS": {"indications": "bacterial skin infections", "name": "POLYMYXINS", "renal impairment": "see Cautions above", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of nephrotoxicity when  amphotericin given with polymyxins ", "name": "Polymyxins", "backrefs": ["Polymyxins"]}, "cautions": "large areas, see below", "side-effects": "sensitisation (see alsonotes above)", "doses": ["apply twice daily or more frequently if required"]}, "DIFLUCORTOLONE VALERATE": {"indications": "severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potentcorticosteroids; high\r\nstrength (0.3%), short-term treatment of severe exacerbations; psoriasis,\r\nseenotes above", "name": "DIFLUCORTOLONE VALERATE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily for up to 4 weeks (0.1% preparations)\r\nor 2 weeks (0.3% preparations), reducing strength as condition responds;\r\nmax. 60\u00a0g of 0.3% per week"]}, "NARATRIPTAN": {"indications": "treatment of acute migraine", "name": "NARATRIPTAN", "renal impairment": "max. 2.5\u00a0mg in 24 hours; avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  SSRIs given with naratriptan ", "name": "Naratriptan", "backrefs": ["Naratriptan"]}, "cautions": "see under5HT1-receptor agonistsabove; sensitivity to sulfonamides;interactions:Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; alsoless commonlybradycardia,\r\ntachycardia, palpitation, and visual disturbance;rarelyischaemic colitis, rash, and pruritus", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; previous cerebrovascular accident or transient\r\nischaemic attack; peripheral vascular disease", "hepatic impairment": "max. 2.5\u00a0mg in 24 hours in moderate impairment; avoid\r\nif severe", "doses": ["2.5\u00a0mg, repeated after at least 4 hours if migraine recurs\r\n(patient not responding should not take second dose for same attack);\r\nmax. 5\u00a0mg in 24 hours;childandadolescentunder 18 years not recommended"], "pregnancy": "seenotes above", "breast-feeding": "withhold breast-feeding for 24 hours"}, "MYCOPHENOLATE MOFETIL": {"indications": "prophylaxis of acute renal, cardiac, or hepatic\r\ntransplant rejection (in combination withciclosporinandcorticosteroids) under specialist supervision", "name": "MYCOPHENOLATE MOFETIL", "renal impairment": "no data available in cardiac or hepatic transplant patients\r\nwith renal impairment", "cautions": "seeBioavailability; full blood counts every week for 4 weeks then twice a month for 2\r\nmonths then every month in the first year (consider interrupting treatment if neutropenia develops); exclude pregnancy before starting treatment; elderly (increased risk of infection,\r\ngastro-intestinal haemorrhage and pulmonary oedema); children (higher incidence of side-effects may call\r\nfor temporary reduction of dose or interruption); active\r\nserious gastro-intestinal disease (risk of haemorrhage,\r\nulceration and perforation); delayed graft function; increased susceptibility to skin cancer (avoid exposure to strong sunlight);interactions:Appendix 1 (mycophenolate)", "side-effects": "taste disturbance, gingival hyperplasia, nausea,\r\nconstipation, flatulence, anorexia, weight loss, vomiting, abdominal\r\npain, gastro-intestinal inflammation, ulceration, and bleeding, hepatitis,\r\njaundice, pancreatitis, stomatitis, oedema, tachycardia, hypertension,\r\nhypotension, vasodilatation, cough, dyspnoea, insomnia, agitation,\r\nconfusion, depression, anxiety, convulsions, paraesthesia, myasthenic\r\nsyndrome, tremor, dizziness, headache, influenza-like syndrome, infections,\r\nhyperglycaemia, renal impairment, malignancy (particularly of the\r\nskin), blood disorders (including leucopenia, anaemia, thrombocytopenia,\r\npancytopenia, and red cell aplasia\u2014seenotes above), disturbances of electrolytes\r\nand blood lipids, arthralgia, alopecia, acne, skin hypertrophy, and\r\nrash;also reportedintestinal villous atrophy, progressive\r\nmultifocal leucoencephalopathy, interstitial lung disease, pulmonary\r\nfibrosis", "doses": ["Renal transplantation,by mouth, 1\u00a0g twice\r\ndaily starting within 72 hours of transplantationorby intravenous infusion, 1\u00a0g twice daily starting\r\nwithin 24 hours of transplantation for max. 14 days (then transfer\r\nto oral therapy);childandadolescent2\u201318 years,by mouth600\u00a0mg/m2twice daily (max. 2\u00a0g daily)", "Tablets and capsules not appropriate for\r\ndose titration in children with body surface area less than 1.25\u00a0m2", "Cardiac transplantation,by mouth,adultover 18 years, 1.5\u00a0g twice daily starting within\r\n5 days of transplantation", "Hepatic transplantation,by intravenous infusion,adultover 18 years, 1\u00a0g twice daily\r\nstarting within 24 hours of transplantation for 4 days (up to max.\r\n14 days), thenby mouth, 1.5\u00a0g twice daily as soon\r\nas is tolerated"], "pregnancy": "avoid\u2014congenital malformations reported; effective\r\ncontraception required before treatment, during treatment, and for\r\n6 weeks after discontinuation of treatment", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "FLUDARABINE PHOSPHATE": {"indications": "seenotes above", "name": "FLUDARABINE PHOSPHATE", "renal impairment": "reduce dose by up to 50% if creatinine clearance 30\u201370\u00a0mL/minute;\r\navoid if creatinine clearance less than 30\u00a0mL/minute", "cautions": "seesection 8.1andnotes above; monitor for signs of haemolysis; monitor for neurological toxicity; worsening\r\nof existing and increased susceptibility to skin cancer;interactions:Appendix 1 (fludarabine)", "side-effects": "seesection 8.1andnotes above; also diarrhoea, anorexia; oedema; pneumonia, cough; peripheral\r\nneuropathy, visual disturbances; chills, fever, malaise, weakness;\r\nrash", "contra-indications": "haemolytic anaemia", "doses": ["By mouth,adult40\u00a0mg/m2for 5 days every 28 days usually for 6 cycles", "By intravenous injectionorinfusion, consult product literature"], "pregnancy": "avoid (embryotoxic and teratogenic inanimalstudies); manufacturer advises effective contraception during and\r\nfor at least 6 months after treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "SALMETEROL": {"indications": "reversible airways obstruction (including nocturnal asthma and prevention\r\nof exercise-induced bronchospasm) in patients requiring long-term\r\nregular bronchodilator therapy, see alsoManagement of Chronic Asthma\r\ntable;\r\nchronic obstructive pulmonary disease", "name": "SALMETEROL", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole inhibits metabolism of salmeterol (increased plasma concentration)", "name": "Salmeterol", "backrefs": ["Salmeterol"]}, "cautions": "seenotes above", "side-effects": "seenotes above; nausea, dizziness, arthralgia,\r\nand rash also reported", "doses": ["By inhalation, asthma, 50\u00a0micrograms\r\n(2 puffs or 1 blister) twice daily; up to 100\u00a0micrograms (4 puffs\r\nor 2 blisters) twice daily in more severe airways obstruction;child5\u201312 years, 50\u00a0micrograms (2 puffs or 1 blister)\r\ntwice daily", "Chronic obstructive pulmonary disease 50\u00a0micrograms (2 puffs\r\nor 1 blister) twice daily", "Advise patients thatsalmeterolshouldnotbe used for relief of acute attacks,\r\nnot to exceed prescribed dose, and to follow manufacturer\u2019s directions;\r\nif a previously effective dose of inhaledsalmeterolfails to provide adequate relief, a doctor\u2019s advice should be obtained\r\nas soon as possible"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "PRIMAQUINE": {"indications": "adjunct in the treatment ofPlasmodium vivaxandP. ovalemalaria (eradication of liver stages)", "name": "PRIMAQUINE", "interactions": {"extra": "", "bad": 0, "interaction": " mepacrine increases plasma concentration of primaquine (increased risk of toxicity)", "name": "Primaquine", "backrefs": ["Primaquine", "Mepacrine"]}, "cautions": "G6PD deficiency (test blood, see underBenign Malarias (treatment)); systemic diseases associated with granulocytopenia (e.g. rheumatoid arthritis, lupus erythematosus);interactions:Appendix 1 (primaquine)", "side-effects": "nausea, vomiting, anorexia, abdominal pain; less\r\ncommonly methaemoglobinaemia, haemolytic anaemia especially in G6PD\r\ndeficiency, leucopenia", "doses": ["Treatment of benign malarias, seenotes above"], "pregnancy": "risk of neonatal haemolysis and methaemoglobinaemia\r\nin third trimester; see alsoBenign Malarias (treatment)", "breast-feeding": "no information available; theoretical risk of\r\nhaemolysis in G6PD-deficient infants"}, "APIXABAN": {"indications": "seenotes above", "name": "APIXABAN", "renal impairment": "use with caution if eGFR 15\u201329\u00a0mL/minute/1.73\u00a0m2; manufacturer advises avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2\u2014no information available", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  ritonavir advised by manufacturer of apixaban ", "name": "Apixaban", "backrefs": ["Apixaban"]}, "cautions": "see notes above; also bleeding disorders; active gastro-intestinal\r\nulceration; history of haemorrhagic stroke; severe hypertension; bacterial\r\nendocarditis; recent brain, spinal, or ophthalmic surgery; concomitant\r\nuse of drugs that increase risk of bleeding; anaesthesia with postoperative\r\nindwelling epidural catheter (risk of paralysis\u2014monitor neurological\r\nsigns and wait 20\u201330 hours after apixaban dose before removing catheter\r\nand do not give next dose until at least 5 hours after catheter removal);interactions: Appendix 1 (apixaban)", "side-effects": "nausea, haemorrhage (seenotes above), bruising, anaemia;less\r\ncommonlyhypotension, thrombocytopenia", "contra-indications": "active bleeding", "hepatic impairment": "avoid in severe impairment and in hepatic disease associated\r\nwith coagulopathy", "doses": ["Prophylaxis of venous thromboembolism following knee replacement\r\nsurgery,adultover 18 years, 2.5\u00a0mg\r\ntwice daily for 10\u201314 days, starting 12\u201324 hours after surgery", "Prophylaxis of venous thromboembolism following hip replacement\r\nsurgery,adultover 18 years, 2.5\u00a0mg\r\ntwice daily for 32\u201338 days, starting 12\u201324 hours after surgery"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "LIDOCAINE HYDROCHLORIDE": {"indications": "ventricular arrhythmias, especially\r\nafter myocardial infarction; eye (section 11.7); local anaesthesia (section 15.2)", "name": "LIDOCAINE HYDROCHLORIDE", "renal impairment": "possible accumulation of lidocaine and active metabolite;\r\ncaution in severe impairment", "cautions": "lower doses in congestive cardiac\r\nfailure and following cardiac surgery; monitor ECG and have resuscitation facilities\r\navailable; elderly;interactions:Appendix 1 (lidocaine)", "side-effects": "dizziness, paraesthesia, or drowsiness (particularly\r\nif injection too rapid); other CNS effects include confusion, respiratory\r\ndepression and convulsions; hypotension and bradycardia (may lead\r\nto cardiac arrest);rarelyhypersensitivity reactions\r\nincluding anaphylaxis", "contra-indications": "sino-atrial disorders, all grades of atrioventricular block, severe myocardial depression; acute porphyria (section 9.8.2)", "hepatic impairment": "caution\u2014increased risk of side-effects", "doses": ["By intravenous injection, in patients without\r\ngross circulatory impairment, 100\u00a0mg as a bolus over a few minutes\r\n(50\u00a0mg in lighter patients or those whose circulation is severely\r\nimpaired), followed immediately byinfusionof 4\u00a0mg/minute\r\nfor 30 minutes, 2\u00a0mg/minute for 2 hours, then 1\u00a0mg/minute; reduce\r\nconcentration further if infusion continued beyond 24 hours (ECG monitoring\r\nand specialist advice for infusion)", "Followingintravenous injectionlidocaine has a short duration of action (lasting for 15\u201320 minutes).\r\nIf anintravenous infusionis not immediately available\r\nthe initialintravenous injectionof 50\u2013100\u00a0mg can\r\nbe repeated if necessary once or twice at intervals of not less than\r\n10 minutes"], "pregnancy": "crosses the placenta but not known to be harmful\r\ninanimalstudies\u2014use if benefit outweighs risk", "breast-feeding": "present in milk but amount too small to be harmful"}, "TOREMIFENE": {"indications": "hormone-dependent metastatic breast cancer in postmenopausal women", "name": "TOREMIFENE", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin possibly accelerates metabolism of toremifene ", "name": "Toremifene", "backrefs": ["Toremifene"]}, "cautions": "hypercalcaemia may occur (especially if bone metastases and usually\r\nat beginning of treatment); avoid in acute porphyria (but seesection 9.8.2); history of severe thromboembolic\r\ndisease;interactions:Appendix 1 (toremifene)", "side-effects": "nausea, vomiting; oedema; depression, dizziness,\r\nfatigue; sweating, hot flushes, vaginal bleeding or discharge (important:see Cautions); rash;less commonlyanorexia, constipation, increased weight, thromboembolic events,\r\ndyspnoea, insomnia, headache, endometrial hypertrophy;very\r\nrarelyjaundice, transient corneal opacity, and alopecia", "contra-indications": "endometrial hyperplasia, QT prolongation (avoid concomitant administration of\r\ndrugs that prolong QT interval), electrolyte\r\ndisturbances (particularly uncorrected hypokalaemia), bradycardia, heart failure with reduced left-ventricular\r\nejection fraction, history of arrhythmias", "hepatic impairment": "elimination decreased in hepatic impairment\u2014avoid if\r\nsevere", "doses": ["60\u00a0mg daily"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "CALCITRIOL": {"indications": "seenotes above", "name": "CALCITRIOL", "cautions": "see underErgocalciferol; monitor plasma calcium, phosphate, and creatinine\r\nduring dosage titration", "side-effects": "see underErgocalciferol", "contra-indications": "see underErgocalciferol", "doses": ["By mouth, renal osteodystrophy, initially\r\n250\u00a0nanograms daily, or on alternate days (in patients with normal\r\nor only slightly reduced plasma-calcium concentration), increased\r\nif necessary in steps of 250\u00a0nanograms at intervals of 2\u20134 weeks;\r\nusual dose 0.5\u20131 microgram daily;childnot established", "Established postmenopausal osteoporosis, 250\u00a0nanograms twice\r\ndaily (monitor plasma-calcium concentration and creatinine, consult\r\nproduct literature)"], "pregnancy": "see underErgocalciferol", "breast-feeding": "see underErgocalciferol"}, "ANASTROZOLE": {"indications": "adjuvant treatment of oestrogen-receptor-positive early invasive\r\nbreast cancer in postmenopausal women; adjuvant treatment of oestrogen-receptor-positive\r\nearly breast cancer in postmenopausal women following 2\u20133 years of\r\ntamoxifen therapy; advanced breast cancer in postmenopausal women\r\nwhich is oestrogen-receptor-positive or responsive to tamoxifen", "name": "ANASTROZOLE", "renal impairment": "avoid if creatinine clearance less than 20\u00a0mL/minute", "cautions": "laboratory test for menopause if doubt; susceptibility to osteoporosis (assess bone mineral density before treatment and at regular intervals)", "side-effects": "hot flushes, vaginal dryness, vaginal bleeding,\r\nhair thinning, anorexia, nausea, vomiting, diarrhoea, headache, arthralgia,\r\narthritis, bone fractures, bone pain, rash (including Stevens-Johnson\r\nsyndrome), cutaneous vasculitis; asthenia and drowsiness\u2014may initially\r\naffect ability to drive or operate machinery; slight increases in\r\ntotal cholesterol levels reported; very rarely allergic reactions\r\nincluding angioedema and anaphylaxis", "contra-indications": "not for premenopausal women", "hepatic impairment": "avoid in moderate to severe impairment", "doses": ["1\u00a0mg daily"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "WARFARIN SODIUM": {"indications": "prophylaxis of embolisation in rheumatic heart disease and atrial\r\nfibrillation; prophylaxis after insertion of prosthetic heart valve;\r\nprophylaxis and treatment of venous thrombosis and pulmonary embolism;\r\ntransient ischaemic attacks", "name": "WARFARIN SODIUM", "renal impairment": "seenotes above", "cautions": "seenotes above; also conditions in\r\nwhich risk of bleeding is increased, e.g. history of gastro-intestinal bleeding, peptic ulcer, recent surgery, recent ischaemic stroke, postpartum\r\n(delay warfarin until risk of haemorrhage is low\u2014usually 5\u20137 days\r\nafter delivery), bacterial endocarditis (use only if warfarin otherwise\r\nindicated); uncontrolled hypertension; concomitant use of drugs that increase risk of bleeding; avoid cranberry juice;interactions:Appendix 1 (coumarins)", "side-effects": "haemorrhage\u2014see notes above; also nausea, vomiting,\r\ndiarrhoea, jaundice, hepatic dysfunction, pancreatitis, pyrexia, alopecia,\r\npurpura, rash, \u2018purple toes\u2019, skin necrosis (increased risk in patients\r\nwith protein C or protein S deficiency)", "contra-indications": "haemorrhagic\r\nstroke; significant bleeding; avoid use within 48 hours postpartum", "hepatic impairment": "seenotes above", "doses": ["See notes above"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PACLITAXEL": {"indications": "ovarian cancer (advanced or residual disease following laparotomy)\r\nin combination withcisplatin; metastatic ovarian\r\ncancer where platinum-containing therapy has failed; locally advanced\r\nor metastatic breast cancer (in combination with other cytotoxics\r\nor alone if other cytotoxics have failed or are inappropriate); adjuvant\r\ntreatment of node-positive breast cancer following treatment with\r\nanthracycline and cyclophosphamide; non-small cell lung cancer (in\r\ncombination withcisplatin) when surgery or radiotherapy\r\nnot appropriate; advanced AIDS-related Kaposi\u2019s sarcoma where liposomal\r\nanthracycline therapy has failed", "name": "PACLITAXEL", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir increases plasma concentration of paclitaxel ", "name": "Paclitaxel", "backrefs": ["Paclitaxel"]}, "cautions": "seesection 8.1andnotes\r\nabove; avoid in acute porphyria (but\r\nseesection 9.8.2);interactions:Appendix 1\r\n(paclitaxel)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "seesection 8.1andnotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nensure effective contraception during and for at least 6 months after\r\ntreatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "IRINOTECAN HYDROCHLORIDE": {"indications": "seenotes above", "name": "IRINOTECAN HYDROCHLORIDE", "renal impairment": "manufacturer advises avoid\u2014no information available", "cautions": "seesection 8.1andnotes above; raised plasma-bilirubin concentration (see under Hepatic\r\nimpairment); risk factors for cardiac disease; monitor respiratory function;interactions: Appendix 1 (irinotecan)", "side-effects": "seesection 8.1andnotes above; also acute\r\ncholinergic syndrome (with early diarrhoea) and delayed diarrhoea\r\n(consult product literature);less commonlyinterstitial\r\npulmonary disease", "contra-indications": "seesection 8.1andnotes above; also chronic inflammatory bowel disease, bowel\r\nobstruction", "hepatic impairment": "monitor closely for neutropenia if plasma-bilirubin\r\nconcentration 1.5\u20133 times upper limit of normal range (consult product\r\nliterature); avoid if plasma-bilirubin concentration greater than\r\n3 times upper limit of normal range", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and toxic inanimalstudies); manufacturer advises effective contraception during and\r\nfor up to 1 month after treatment in women and up to 3 months after\r\ntreatment in men; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CABAZITAXEL": {"indications": "seenotes above", "name": "CABAZITAXEL", "renal impairment": "use with caution if creatinine clearance less than 50\u00a0mL/minute", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  ritonavir advised by manufacturer of cabazitaxel ", "name": "Cabazitaxel", "backrefs": ["Cabazitaxel"]}, "cautions": "seesection 8.1; monitor electrolytes\u2014correct\r\ndehydration; avoid in acute porphyria (but seesection 9.8.2);interactions: Appendix 1 (cabazitaxel)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "avoid", "doses": ["SeeDoses"], "pregnancy": "ensure effective contraception during treatment (women)\r\nand for up to 6 months after treatment (men); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "SAXAGLIPTIN": {"indications": "seenotes above", "name": "SAXAGLIPTIN", "renal impairment": "reduce dose to 2.5\u00a0mg once daily in moderate to severe\r\nimpairment; use with caution in severe impairment", "cautions": "elderly; determine\r\nrenal function before treatment and periodically thereafter;interactions:Appendix 1 (antidiabetics)", "side-effects": "vomiting, dyspepsia, gastritis; peripheral oedema;\r\nheadache, dizziness, fatigue; upper respiratory tract infection, urinary\r\ntract infection, gastroenteritis, sinusitis, nasopharyngitis; hypoglycaemia,\r\nmyalgia;less commonlydyslipidaemia, hypertriglyceridaemia,\r\nerectile dysfunction, arthralgia;also reportedrash", "hepatic impairment": "use with caution in moderate impairment; avoid in severe\r\nimpairment", "doses": ["adultover 18 years, 5\u00a0mg\r\nonce daily", "Dose of concomitant sulfonylurea may need\r\nto be reduced"], "pregnancy": "avoid unless essential\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "PROCYCLIDINE HYDROCHLORIDE": {"indications": "parkinsonism; drug-induced extrapyramidal\r\nsymptoms (but not tardive dyskinesia, seenotes above)", "name": "PROCYCLIDINE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\ngingivitis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, 2.5\u00a0mg 3 times daily, increased\r\ngradually in steps of 2.5\u20135\u00a0mg daily every 2\u20133 days if necessary;\r\nusual max. 30\u00a0mg daily in 2\u20134 divided doses (60\u00a0mg daily in exceptional\r\ncircumstances);elderlypreferably\r\nlower end of range", "By intramuscularorintravenous\r\ninjection, acute dystonia, 5\u201310\u00a0mg (occasionally more than\r\n10\u00a0mg), usually effective in 5\u201310 minutes but may need 30 minutes\r\nfor relief;elderlypreferably lower\r\nend of range"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "no information available"}, "PERINDOPRIL ERBUMINE": {"indications": "hypertension (but seenotes above); symptomatic\r\nheart failure (adjunct\u2014seesection 2.5.5); prophylaxis\r\nof cardiac events following myocardial infarction or revascularisation\r\nin stable coronary artery disease", "name": "PERINDOPRIL ERBUMINE", "renal impairment": "seenotes above; max.\r\ninitial dose 2\u00a0mg once daily if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; 2\u00a0mg once daily on alternate days if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nasthenia, mood and sleep disturbances", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Hypertension, initially 4\u00a0mg once daily in the morning\r\nfor 1 month, subsequently adjusted according to response; if used\r\nin addition to diuretic (see notes above),\r\nin elderly, in renal impairment, in cardiac decompensation, or in\r\nvolume depletion, initially 2\u00a0mg once daily; max. 8\u00a0mg daily", "Heart failure (adjunct), initially 2\u00a0mg once daily in the morning\r\nunder close medical supervision (see notes above),\r\nincreased after at least 2 weeks to max. 4\u00a0mg once daily if tolerated", "Following myocardial infarction or revascularisation, initially\r\n4\u00a0mg once daily in the morning increased after 2 weeks to 8\u00a0mg once\r\ndaily if tolerated;elderly2\u00a0mg once\r\ndaily for 1 week, then 4\u00a0mg once daily for 1 week, thereafter increased\r\nto 8\u00a0mg once daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PSEUDOEPHEDRINE": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by pseudoephedrine ", "name": "Pseudoephedrine", "backrefs": ["Pseudoephedrine"]}}, "TAZAROTENE": {"indications": "mild to moderate plaque psoriasis affecting\r\nup to 10% of skin area", "name": "TAZAROTENE", "cautions": "wash hands immediately after use, avoid contact with eyes, face, intertriginous areas, hair-covered\r\nscalp, eczematous or inflamed skin; avoid excessive exposure to UV light (including sunlight,\r\nsolariums, PUVA or UVB treatment); do not\r\napply emollients or cosmetics within 1 hour of application", "side-effects": "local irritation (more common with higher concentration\r\nand may require discontinuation), pruritus, burning, erythema, desquamation,\r\nnon-specific rash, contact dermatitis, and worsening of psoriasis;\r\nrarely stinging and inflamed, dry or painful skin", "doses": ["Apply once daily in the evening usually for up to 12 weeks;childunder 18 years not recommended"], "pregnancy": "avoid; effective contraception required (oral progestogen-only\r\ncontraceptives not considered effective)", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CO-TENIDONE": {"indications": "hypertension", "name": "CO-TENIDONE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2\u2014consider alternative treatment", "cautions": "seenotes aboveandsection 2.2.1; also avoid abrupt withdrawal especially in ischaemic heart disease; first-degree AV block; portal hypertension (risk of deterioration in liver function); history of obstructive airways disease (introduce\r\ncautiously and monitor lung function\u2014seenotes above); diabetes; myasthenia gravis; symptoms of hypoglycaemia and thyrotoxicosis may be masked (also\r\nseenotes above); history of hypersensitivity\u2014may increase sensitivity to allergens\r\nand result in more serious hypersensitivity response, also may reduce response to adrenaline (epinephrine) (see alsosection 3.4.3);interactions:Appendix 1 (beta-blockers, diuretics),important:verapamil interaction, see also VERAPAMILsection 2.6.2", "side-effects": "seenotes above; also gastro-intestinal\r\ndisturbances; bradycardia, heart failure, hypotension, conduction\r\ndisorders, peripheral vasoconstriction (including exacerbation of\r\nintermittent claudication and Raynaud\u2019s phenomenon); bronchospasm,\r\ndyspnoea; headache, fatigue, sleep disturbances, paraesthesia, dizziness,\r\nvertigo, psychoses; sexual dysfunction; altered plasma lipid concentration,\r\nmetabolic and electrolyte disturbances including hypokalaemia (see\r\nalsosection 2.2), hyponatraemia,\r\nhypomagnesaemia, hypercalcaemia, hyperglycaemia, hypochloraemic alkalosis,\r\nhyperuricaemia and gout, purpura, blood disorders including agranulocytosis,\r\nleucopenia, and thrombocytopenia; visual disturbances; exacerbation\r\nof psoriasis, alopecia;rarelypancreatitis, intrahepatic\r\ncholestasis, jaundice, cardiac arrhythmias, dry eyes (reversible on\r\nwithdrawal), hypersensitivity reactions (including rash, pneumonitis,\r\npulmonary oedema, photosensitivity, other severe skin reactions, and\r\nallergic interstitial nephritis);overdosage:seeEmergency Treatment of Poisoning (Beta-blockers)", "contra-indications": "asthma (but seenotes above); uncontrolled heart failure, Prinzmetal\u2019s angina, marked bradycardia, hypotension, sick sinus syndrome, second- or third-degree AV block, cardiogenic shock, metabolic acidosis, severe peripheral arterial disease; phaeochromocytoma\r\n(apart from specific use with alpha-blockers, see alsonotes above); refractory hypokalaemia, hyponatraemia, hypercalcaemia; symptomatic hyperuricaemia; Addison\u2019s disease", "hepatic impairment": "avoid in severe liver disease; hypokalaemia may precipitate\r\ncoma (potassium-sparing diuretic can prevent); increased risk of hypomagnesaemia\r\nin alcoholic cirrhosis", "doses": ["hypertension, 1 tablet daily"], "pregnancy": "avoid; diuretics not used to treat hypertension in\r\npregnancy; see alsosection 2.5", "breast-feeding": "atenolol present in milk in greater amounts\r\nthan some other beta-blockers; possible toxicity due to beta-blockade\u2014monitor\r\ninfant; large doses of chlortalidone may suppress lactation"}, "BOSENTAN": {"indications": "pulmonary arterial hypertension; systemic sclerosis with ongoing\r\ndigital ulcer disease (to reduce number of new digital ulcers)", "name": "BOSENTAN", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of bosentan ", "name": "Bosentan", "backrefs": ["Bosentan"]}, "cautions": "not to be initiated if systemic systolic\r\nblood pressure is below 85\u00a0mmHg; monitor\r\nhaemoglobin before and during treatment (monthly for first 4 months,\r\nthen 3-monthly); avoid abrupt withdrawal; monitor liver function before treatment, at monthly\r\nintervals during treatment, and 2 weeks after dose increase (reduce\r\ndose or suspend treatment if liver enzymes raised significantly)\u2014discontinue\r\nif symptoms of liver impairment;interactions:Appendix 1 (bosentan)", "side-effects": "diarrhoea, gastro-oesophageal reflux, flushing,\r\nhypotension, palpitation, oedema, syncope, headache, anaemia;less commonlythrombocytopenia, neutropenia; leucopenia;rarelyliver cirrhosis, liver failure (see cautions above)", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "avoid in moderate and severe impairment", "doses": ["Pulmonary arterial hypertension, initially 62.5\u00a0mg twice\r\ndaily increased after 4 weeks to 125\u00a0mg twice daily; max. 250\u00a0mg twice\r\ndaily;childunder 18 years seeBNF for Children", "Systemic sclerosis with ongoing digital ulcer disease, initially\r\n62.5\u00a0mg twice daily increased after 4 weeks to 125\u00a0mg twice daily"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\neffective contraception required during administration (hormonal contraception\r\nnot considered effective); monthly pregnancy tests advised", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "KAOLIN": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  tetracyclines possibly reduced by kaolin ", "name": "Kaolin", "backrefs": ["Kaolin", "Tetracyclines", "Chloroquine and Hydroxychloroquine"]}}, "RABIES VACCINE": {"indications": "immunisation against rabies", "name": "RABIES VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1; also\r\nreported paresis", "contra-indications": "seesection 14.1; but see also Post-exposure Management\r\ninnotes above", "doses": ["Pre-exposure prophylaxis,by intramuscular injectionin deltoid region or anterolateral thigh in infants, 1\u00a0mL on days\r\n0, 7, and 21 or 28; for those at continued risk give a single reinforcing\r\ndose 1 year after the primary course is completed and booster doses\r\nevery 3\u20135 years; for those at intermittent risk give booster doses\r\nevery 2\u20135 years", "Post-exposure prophylaxis,by intramuscular injectionin deltoid region or anterolateral thigh in infants, 1\u00a0mL (seenotes above)"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "SODIUM FUSIDATE": {"indications": "penicillin-resistant staphylococcal infection including osteomyelitis;\r\nstaphylococcal endocarditis in combination with other antibacterials\r\n(Table 1,section 5.1)", "name": "SODIUM FUSIDATE", "cautions": "monitor liver function with high doses\r\nor on prolonged therapy; elimination may be reduced\r\nin biliary disease or biliary obstruction;interactions:Appendix 1 (fusidic acid)", "side-effects": "nausea, vomiting, reversible jaundice, especially\r\nafter high dosage or rapid infusion (withdraw therapy if persistent);\r\nrarely hypersensitivity reactions, acute renal failure (usually with\r\njaundice), blood disorders", "hepatic impairment": "impaired biliary excretion; possibly increased risk\r\nof hepatotoxicity; avoid or reduce dose; monitor liver function", "doses": ["asfusidic acid,adult750\u00a0mg every 8 hours;childup to\r\n1 year 50\u00a0mg/kg daily (in 3 divided doses), 1\u20135 years 250\u00a0mg every\r\n8 hours, 5\u201312 years 500\u00a0mg every 8 hours"], "pregnancy": "not known to be harmful; manufacturer advises use\r\nonly if potential benefit outweighs risk", "breast-feeding": "present in milk\u2014manufacturer advises caution"}, "LORATADINE": {"indications": "symptomatic relief of allergy such as hay fever, chronic\r\nidiopathic urticaria", "name": "LORATADINE", "interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of loratadine advises  ketoconazole possibly increases plasma concentration of loratadine ", "name": "Loratadine", "backrefs": ["Loratadine", "Cimetidine"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "reduce dose frequency to alternate days in severe impairment", "doses": ["adultandchildover 12 years 10\u00a0mg once daily;child2\u201312 years, body-weight under 30\u00a0kg, 5\u00a0mg once\r\ndaily; body-weight over 30\u00a0kg, 10\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DRONEDARONE": {"indications": "seenotes above", "name": "DRONEDARONE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  ritonavir advised by manufacturer of dronedarone ", "name": "Dronedarone", "backrefs": ["Dronedarone", "Metoprolol"]}, "cautions": "monitor liver function (see\r\nHepatic Disorders below); monitor for heart failure (see Heart Failure\r\nbelow); perform ECG at least every 6 months\u2014consider discontinuation\r\nif atrial fibrillation reoccurs; coronary artery disease; correct hypokalaemia and hypomagnesaemia before starting and during\r\ntreatment; measure serum creatinine before\r\ntreatment and 7 days after initiation\u2014if raised, measure\r\nagain after a further 7 days and consider discontinuation if creatinine\r\ncontinues to rise;interactions:Appendix 1 (dronedarone)", "side-effects": "gastro-intestinal disturbances, QT-interval prolongation,\r\nbradycardia, heart failure (see also Heart Failure above), malaise,\r\nrash, pruritus, raised serum creatinine;less commonlytaste disturbance, interstitial lung disease including pneumonitis\r\nand pulmonary fibrosis (investigate if symptoms such as dyspnoea or\r\ndry cough develop and discontinue treatment if confirmed), erythema,\r\neczema, dermatitis, photosensitivity;rarelyliver\r\ninjury (including life-threatening acute liver failure\u2014see also Hepatic\r\nDisorders above)", "contra-indications": "liver or lung toxicity associated with previous\r\namiodarone use; second- or third-degree AV block, complete bundle\r\nbranch block, distal block, sinus node dysfunction, atrial conduction\r\ndefects, or sick sinus syndrome (unless pacemaker fitted); permanent\r\natrial fibrillation; bradycardia; prolonged QT interval; existing\r\nor previous heart failure or left ventricular systolic dysfunction\r\n(see also Heart Failure above); haemodynamically unstable patients", "hepatic impairment": "avoid in severe impairment; see also Hepatic Disorders\r\nabove", "doses": ["adultover 18 years, 400\u00a0mg\r\ntwice daily"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CARDIAC GLYCOSIDES": {"interactions": {"extra": "", "bad": 1, "interaction": "hypokalaemia caused by  amphotericin increases cardiac toxicity with cardiac glycosides ", "name": "Cardiac Glycosides", "backrefs": ["Cardiac Glycosides"]}}, "FOSPHENYTOIN SODIUM": {"indications": "status epilepticus; seizures associated\r\nwith neurosurgery or head injury; whenphenytoinby mouth not possible", "name": "FOSPHENYTOIN SODIUM", "renal impairment": "consider 10\u201325% reduction in dose or infusion rate (except\r\ninitial dose for status epilepticus)", "cautions": "seePhenytoin Sodium; resuscitation facilities must be available;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (phenytoin)", "side-effects": "seePhenytoin Sodium; also dry mouth, taste disturbance, vasodilatation, asthenia,\r\ndysarthria, euphoria, incoordination, chills, visual disturbances,\r\ntinnitus, pruritus, ecchymosis;less commonlyhypoaesthesia,\r\nincreased or decreased reflexes, stupor, muscle weakness, muscle spasm,\r\npain, hypoacusis;also reportedextrapyramidal disorder,\r\ntwitching, confusion, hyperglycaemia", "contra-indications": "seePhenytoin Sodium", "hepatic impairment": "consider 10\u201325% reduction in dose or infusion rate\r\n(except initial dose for status epilepticus)", "doses": ["Prescriptions forfosphenytoin\r\nsodiumshould state the dose in terms ofphenytoinsodium equivalent (PE);fosphenytoinsodium 1.5\u00a0mg\r\n\u2261phenytoinsodium 1\u00a0mg", "Status epilepticus,by intravenous infusion(at a rate of 100\u2013150\u00a0mg(PE)/minute), initially 20\u00a0mg(PE)/kg thenby intravenous infusion(at a rate of 50\u2013100\u00a0mg(PE)/minute),\r\n4\u20135\u00a0mg(PE)/kg daily in 1\u20132 divided doses, dose adjusted according\r\nto response and trough plasma-phenytoinconcentration", "child5 years and over,by intravenous infusion(at a rate of 2\u20133\u00a0mg(PE)/kg/minute),\r\ninitially 20\u00a0mg(PE)/kg thenby intravenous infusion(at a rate of 1\u20132\u00a0mg(PE)/kg/minute), 4\u20135\u00a0mg(PE)/kg daily in 1\u20134\r\ndivided doses, dose adjusted according to response and trough plasma-phenytoinconcentration", "Prophylaxis or treatment of seizures associated\r\nwith neurosurgery or head injury,by intramuscular injectionorby intravenous infusion(at a\r\nrate of 50\u2013100\u00a0mg(PE)/minute), initially 10\u201315\u00a0mg(PE)/kg thenby intramuscular injectionorby\r\nintravenous infusion(at a rate of 50\u2013100\u00a0mg(PE)/minute),\r\n4\u20135\u00a0mg(PE)/kg daily (in 1\u20132 divided doses), dose adjusted according\r\nto response and trough plasma-phenytoinconcentration", "child5 years and over,by intravenous infusion(at a rate of 1\u20132\u00a0mg(PE)/kg/minute),\r\ninitially 10\u201315\u00a0mg(PE)/kg then 4\u20135\u00a0mg(PE)/kg daily in 1\u20134 divided\r\ndoses, dose adjusted according to response and trough plasma-phenytoinconcentration", "Temporary substitution for oralphenytoin,by intramuscular injectionorby intravenous infusion(at a rate of 50\u2013100\u00a0mg(PE)/minute),\r\nsame dose and dosing frequency as oralphenytointherapy;child5 years and over,by intravenous infusion(at a rate of 1\u20132\u00a0mg(PE)/kg/minute,\r\nmax. 100\u00a0mg(PE)/minute), same dose and dosing frequency as oralphenytointherapy", "elderlyconsider\r\n10\u201325% reduction in dose or infusion rate", "Fosphenytoin sodium doses in BNF may differ\r\nfrom those in product literature"], "pregnancy": "see Phenytoin,section 4.8.1, andPregnancy", "breast-feeding": "seeBreast-feeding"}, "CYPROHEPTADINE": {"interactions": {"extra": "", "bad": 0, "interaction": "antidepressant effect of  SSRIs possibly antagonised by cyproheptadine ", "name": "Cyproheptadine", "backrefs": ["Cyproheptadine"]}}, "BELIMUMAB": {"indications": "see underCytokine Modulatorsabove", "name": "BELIMUMAB", "renal impairment": "caution in severe impairment\u2014no information available", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of live  vaccines with belimumab (see under Active Immunity, section 14.1)", "name": "Belimumab", "backrefs": ["Belimumab"]}, "cautions": "predisposition to infection; do not initiate until\r\nactive infections controlled; history or development of malignancy;interactions: Appendix 1 (belimumab)", "side-effects": "seenotes above; also\r\ndiarrhoea, nausea, hypersensitivity reactions, vomiting, depression,\r\ninsomnia, migraine, infections, pyrexia, leucopenia, pain in extremities", "doses": ["By intravenous infusion,adultover 18 years, 10\u00a0mg/kg, repeated 2 weeks and\r\n4 weeks after initial infusion, then every 4 weeks; review treatment\r\nif no response within 6 months"], "pregnancy": "avoid unless essential; manufacturer advises adequate\r\ncontraception during treatment and for at least 4 months after last\r\ndose", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "ADRENERGIC NEURONE BLOCKERS": {"interactions": {"extra": "", "bad": 1, "interaction": " isometheptene antagonises hypotensive effect of adrenergic neurone blockers ", "name": "Adrenergic Neurone Blockers", "backrefs": ["Metaraminol", "Adrenergic Neurone Blockers", "Xylometazoline", "Oxymetazoline", "Isometheptene", "Ephedrine", "Noradrenaline (norepinephrine)", "Phenylephrine", "Pseudoephedrine", "Pizotifen"]}}, "ISONIAZID": {"indications": "tuberculosis, in combination with other drugs; prophylaxis\u2014Table\r\n2,section 5.1", "name": "ISONIAZID", "renal impairment": "risk of ototoxicity and peripheral neuropathy; prophylactic\r\npyridoxine recommended, seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  ketoconazole possibly reduced by isoniazid ", "name": "Isoniazid", "backrefs": ["Isoniazid", "Cycloserine"]}, "cautions": "see Monitoring innotes above; also slow acetylator status (increased risk of side-effects); epilepsy; history of psychosis;alcoholdependence, malnutrition, diabetes\r\nmellitus, HIV infection (risk of peripheral\r\nneuritis); acute porphyria (section 9.8.2);interactions:Appendix 1 (isoniazid)", "side-effects": "nausea, vomiting, constipation, dry mouth; peripheral\r\nneuritis with high doses (pyridoxine prophylaxis, see notes above),\r\noptic neuritis, convulsions, psychotic episodes, vertigo; hypersensitivity\r\nreactions including fever, Stevens-Johnson syndrome, purpura; blood\r\ndisorders including agranulocytosis, haemolytic anaemia, aplastic\r\nanaemia; hepatitis (especially over age of 35 years); pancreatitis;\r\ninterstitial pneumonitis; systemic lupus erythematosus-like syndrome,\r\npellagra, hyperreflexia, difficulty with micturition, hyperglycaemia,\r\nand gynaecomastia reported; hearing loss and tinnitus (in patients\r\nwith end-stage renal impairment); when used with tyramine or histamine\r\nrich foods, tachycardia, palpitation, hypotension, flushing, headache,\r\ndizziness, and sweating also reported", "contra-indications": "drug-induced liver disease", "hepatic impairment": "use with caution; monitor liver function regularly\r\nand particularly frequently in first 2 months; see also Hepatic Disorders\r\nabove", "doses": ["By mouthorby\r\nintramuscularorintravenous injection, seenotes above"], "pregnancy": "not known to be harmful; prophylactic pyridoxine\r\nrecommended; see alsoPregnancy", "breast-feeding": "monitor infant for possible toxicity; theoretical\r\nrisk of convulsions and neuropathy; prophylactic pyridoxine advisable\r\nin mother; see alsoBreast-feeding"}, "VANCOMYCIN": {"indications": "see notes above", "name": "VANCOMYCIN", "renal impairment": "reduce dose\u2014monitor plasma-vancomycin concentration and\r\nrenal function regularly; see also Cautions above", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of nephrotoxicity when  amphotericin given with vancomycin ", "name": "Vancomycin", "backrefs": ["Colistimethate Sodium", "Vancomycin", "Capreomycin"]}, "cautions": "avoid rapid infusion (risk of anaphylactoid reactions,\r\nsee Side-effects); rotate infusion sites; elderly; avoid if history\r\nof deafness; all patients require plasma-vancomycinmeasurement (after 3 or 4 doses if renal function\r\nnormal, earlier if renal impairment), blood counts, urinalysis, and renal function tests; monitor auditory function in elderly or if renal impairment; teicoplanin\r\nsensitivity; systemic absorption may follow\r\noral administration especially in inflammatory bowel disorders or following multiple doses;interactions:Appendix 1 (vancomycin)", "side-effects": "after parenteral administration: nephrotoxicity\r\nincluding renal failure and interstitial nephritis; ototoxicity (discontinue\r\nif tinnitus occurs); blood disorders including neutropenia (usually\r\nafter 1 week or cumulative dose of 25\u00a0g), rarely agranulocytosis and\r\nthrombocytopenia; nausea; chills, fever; eosinophilia, anaphylaxis,\r\nrashes (including exfoliative dermatitis, Stevens-Johnson syndrome,\r\ntoxic epidermal necrolysis, and vasculitis); phlebitis (irritant to\r\ntissue); on rapid infusion, severe hypotension (including shock and\r\ncardiac arrest), wheezing, dyspnoea, urticaria, pruritus, flushing\r\nof the upper body (\u2018red man\u2019 syndrome), pain and muscle spasm of back\r\nand chest", "doses": ["By mouth,Clostridium difficileinfection, (see alsonotes above), 125\u00a0mg\r\nevery 6 hours for 10\u201314 days (increased up to 500\u00a0mg every 6 hours\r\nif infection fails to respond or is life-threatening)", "By intravenous infusion, 1\u20131.5\u00a0g\r\nevery 12 hours;elderlyover 65 years,\r\n500\u00a0mg every 12 hoursor1\u00a0g once daily", "Plasma concentration monitoring required\r\n(see Cautions above); pre-dose (\u2018trough\u2019) concentration should be\r\n10\u201315\u00a0mg/litre (15\u201320\u00a0mg/litre for less sensitive strains of meticillin-resistantStaphylococcus aureus)", "Surgical prophylaxis,by intravenous infusion, 1\u00a0g", "childunder 18 years\r\nseeBNF for Children", "Vancomycin doses in BNF may differ from those\r\nin product literature"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014plasma-vancomycin concentration monitoring essential\r\nto reduce risk of fetal toxicity", "breast-feeding": "present in milk\u2014significant absorption following\r\noral administration unlikely"}, "TOLTERODINE TARTRATE": {"indications": "see under Dose", "name": "TOLTERODINE TARTRATE", "renal impairment": "reduce dose to 1\u00a0mg twice daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; avoidDetrusitol\u00aeXLif eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above; history of QT-interval prolongation; concomitant\r\nuse with other drugs known to prolong QT interval", "side-effects": "seenotes above; also\r\nchest pain, peripheral oedema; sinusitis, bronchitis; paraesthesia,\r\nfatigue, vertigo, weight gain; flushing also reported", "contra-indications": "seenotes above", "hepatic impairment": "reduce dose to 1\u00a0mg twice daily; avoidDetrusitol\u00aeXL", "doses": ["Urinary frequency, urgency, and incontinence,adultover 18 years, 2\u00a0mg twice daily; reduce to\r\n1\u00a0mg twice daily if necessary to minimise side-effects;child2\u201318 years seeBNF for Children", "Nocturnal enuresis associated with overactive bladder,child5\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "DACTINOMYCIN": {"indications": "seenotes above", "name": "DACTINOMYCIN", "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant to tissues", "side-effects": "seesection 8.1andnotes above", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "SALBUTAMOL": {"indications": "asthma and other conditions associated\r\nwith reversible airways obstruction; premature labour (section 7.1.3)", "name": "SALBUTAMOL", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  digoxin possibly reduced by salbutamol ", "name": "Salbutamol", "backrefs": ["Salbutamol"]}, "cautions": "seenotes above", "side-effects": "seenotes above; also lactic acidosis with high\r\ndoses", "doses": ["By mouth(but use by inhalation preferred),\r\n4\u00a0mg (elderly and sensitive patients initially 2\u00a0mg) 3\u20134 times daily;\r\nmax. single dose 8\u00a0mg (but unlikely to provide much extra benefit\r\nor to be tolerated);childunder 2\r\nyears seeBNF for Children; 2\u20136 years 1\u20132\u00a0mg 3\u20134 times daily, 6\u201312 years 2\u00a0mg 3\u20134 times\r\ndaily", "By subcutaneousorintramuscular injection, 500\u00a0micrograms, repeated\r\nevery 4 hours if necessary", "By slow intravenous injection(but\r\nsee alsoManagement of Acute Asthma table), (dilute to a concentration\r\nof 50\u00a0micrograms/mL), 250\u00a0micrograms, repeated if necessary;childunder 18 years seeBNF for Children", "By intravenous infusion(but see\r\nalsoManagement of Acute Asthma table), initially 5\u00a0micrograms/minute,\r\nadjusted according to response and heart-rate usually in range 3\u201320\u00a0micrograms/minute,\r\nor more if necessary;childunder 18\r\nyears seeBNF for Children", "By aerosol inhalation(but see alsoManagement of Acute Asthma table,orManagement of Chronic Asthma\r\ntable),\r\n100\u2013200\u00a0micrograms (1\u20132 puffs); for persistent symptoms up to 4 times\r\ndaily;child100\u00a0micrograms (1 puff),\r\nincreased to 200\u00a0micrograms (2 puffs) if necessary; for persistent\r\nsymptoms up to 4 times daily", "Prophylaxis of allergen- or exercise-induced bronchospasm, 200\u00a0micrograms\r\n(2 puffs);child100\u00a0micrograms (1\r\npuff), increased to 200\u00a0micrograms (2 puffs) if necessary", "By inhalation of powder(but see\r\nalsoManagement of Chronic Asthma\r\ntable),\r\n200\u2013400\u00a0micrograms; for persistent symptoms up to 4 times daily;childover 5 years 200\u00a0micrograms; for persistent\r\nsymptoms up to 4 times daily (forAsmasal Clickhaler\u00ae,Salbulin Novolizer\u00ae, andVentolin\r\nAccuhaler\u00ae doses, see under preparations)", "Prophylaxis of allergen- or exercise-induced bronchospasm, 400\u00a0micrograms;child200\u00a0micrograms", "By inhalation of nebulised solution,adultandchildover\r\n5 years 2.5\u20135\u00a0mg, repeated up to 4 times daily or more frequently\r\nin severe cases;childunder 5 years\r\n2.5\u00a0mg, repeated up to 4 times daily or more frequently in severe\r\ncases; see alsoManagement of Acute Asthma tableandManagement of Chronic Asthma\r\ntable"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "PETHIDINE": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir reduces plasma concentration of pethidine , but increases plasma concentration of toxic metabolite of pethidine (avoid concomitant use)", "name": "Pethidine", "backrefs": ["Pethidine", "Rasagiline"]}}, "DOPAMINE": {"interactions": {"extra": "", "bad": 1, "interaction": "risk of hypertensive crisis when  selegiline given with dopamine ", "name": "Dopamine", "backrefs": ["Dopaminergics", "Dopamine"]}}, "RIFAXIMIN": {"indications": "travellers\u2019 diarrhoea that is\r\nnot associated with fever, bloody diarrhoea, blood or leucocytes in\r\nthe stool, or 8 or more unformed stools in the previous 24 hours", "name": "RIFAXIMIN", "side-effects": "nausea, vomiting, abdominal pain, flatulence,\r\nheadache, dizziness;less commonlytaste disturbances,\r\nperipheral oedema, sleep disturbances, nervousness, hypoaesthesia,\r\nparaesthesia, influenza-like symptoms, polyuria, glycosuria, polymenorrhoea,\r\nblood disorders, rash; also reported antibiotic-associated\r\ncolitis, pruritis", "contra-indications": "rifamycin hypersensitivity", "doses": ["adultover 18 years, 200\u00a0mg\r\nevery 8 hours for 3 days"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "unlikely to be present in milk in significant\r\namounts, but manufacturer advises avoid"}, "CO-BENELDOPA": {"indications": "Parkinson\u2019s\r\ndisease, seenotes above", "name": "CO-BENELDOPA", "cautions": "seenotes above", "side-effects": "seenotes above", "doses": ["patients not taking levodopa/dopa-decarboxylase inhibitor\r\ntherapy, initially 1 capsule 3 times daily (max. initial dose 6 capsules\r\ndaily)", "Patients transferring from immediate-release levodopa/dopa-decarboxylase\r\ninhibitor preparations, initially 1 capsule substituted for every\r\n100\u00a0mg oflevodopaand given at same dosage frequency,\r\nincreased every 2\u20133 days according to response; average increase of\r\n50% needed over previouslevodopadose and titration\r\nmay take up to 4 weeksSupplementary dose of immediate-releaseMadopar\u00ae may be needed with first morning dose; if response\r\nstill poor to total daily dose ofMadopar\u00aeCRplusMadopar\u00ae corresponding to 1.2\u00a0glevodopa, consider alternative therapy"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CLOPIDOGREL": {"indications": "prevention of atherothrombotic events in peripheral arterial disease,\r\nor within 35 days of myocardial infarction, or within 6 months of\r\nischaemic stroke; prevention of artherothrombotic events in acute\r\ncoronary syndrome without ST-segment elevation (given with aspirin\u2014see\r\nnotes above) and in acute myocardial infarction with ST-segment elevation\r\n(given with aspirin\u2014see notes above); prevention of atherothrombotic\r\nand thromboembolic events in patients with atrial fibrillation (given\r\nwith aspirin\u2014seenotes above) and for whom warfarin is unsuitable", "name": "CLOPIDOGREL", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": " lansoprazole possibly reduces antiplatelet effect of clopidogrel ", "name": "Clopidogrel", "backrefs": ["Clopidogrel"]}, "cautions": "patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; concomitant use of drugs that increase risk of bleeding; discontinue 7 days before elective surgery if antiplatelet\r\neffect not desirable;interactions:Appendix 1 (clopidogrel)", "side-effects": "dyspepsia, abdominal pain, diarrhoea; bleeding\r\ndisorders (including gastro-intestinal and intracranial);less commonlynausea, vomiting, gastritis, flatulence, constipation,\r\ngastric and duodenal ulcers, headache, dizziness, paraesthesia, leucopenia,\r\ndecreased platelets (very rarely severe thrombocytopenia), eosinophilia,\r\nrash, and pruritus;rarelyvertigo;very\r\nrarelycolitis, pancreatitis, hepatitis, acute liver failure,\r\nvasculitis, confusion, hallucinations, taste disturbance, stomatitis,\r\nbronchospasm, interstitial pneumonitis, blood disorders (including\r\nthrombocytopenic purpura, agranulocytosis and pancytopenia), and hypersensitivity-like\r\nreactions (including fever, glomerulonephritis, arthralgia, Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis, lichen planus)", "contra-indications": "active bleeding", "hepatic impairment": "manufacturer advises caution (risk of bleeding); avoid\r\nin severe impairment", "doses": ["Prevention of atherothrombotic events in peripheral arterial\r\ndisease or after myocardial infarction or ischaemic stroke, 75\u00a0mg\r\nonce daily", "Acute coronary syndrome (without ST-segment elevation), initially\r\n300\u00a0mg then 75\u00a0mg daily (with aspirin\u2014seenotes above)", "Acute myocardial infarction (with ST-segment elevation), initially\r\n300\u00a0mg then 75\u00a0mg daily (with aspirin\u2014seenotes above); initial dose omitted if patient\r\nover 75 years", "Prevention of atherothrombotic and thromboembolic events in\r\npatients with atrial fibrillation (with aspirin\u2014seenotes above), 75\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid"}, "ABIRATERONE ACETATE": {"indications": "see notes above", "name": "ABIRATERONE ACETATE", "renal impairment": "use with caution in severe impairment\u2014no information\r\navailable", "cautions": "history of cardiovascular disease\u2014correct hypertension\r\nand hypokalaemia before treatment; monitor blood pressure, serum potassium\r\nconcentration, and fluid balance before treatment, and at least monthly\r\nduring treatment; monitor liver function before treatment, then every\r\n2 weeks for the first 3 months of treatment, then monthly thereafter\u2014interrupt\r\ntreatment if serum alanine aminotransferase greater than 5 times the\r\nupper limit (consult product literature for details of restarting\r\ntreatment at a lower dose) and discontinue if 20 times the upper limit\r\n(and do not readminister)", "side-effects": "hepatotoxicity (see under Cautions, above), hypertension,\r\nhypertriglyceridaemia, heart failure, angina, arrhythmia, tachycardia,\r\nperipheral oedema, urinary tract infection, hypokalaemia;less commonlyadrenal insufficiency", "hepatic impairment": "avoid in moderate or severe impairment; see also\r\nCautions", "doses": ["1\u00a0g once daily", "Consult product literature for dose of concurrent\r\nprednisone or prednisolone"]}, "ENOXAPARIN SODIUM": {"indications": "see notes above and under preparations", "name": "ENOXAPARIN SODIUM", "renal impairment": "risk of bleeding increased; reduce dose if eGFR less\r\nthan 30\u00a0mL/minute/1.73\u00a0m2\u2014consult product literature for\r\ndetails; monitoring of anti-factor Xa may be required; use of unfractionated\r\nheparin may be preferable", "cautions": "see underHeparinand notes above; low body-weight (increased risk of bleeding)", "side-effects": "see underHeparin", "contra-indications": "see underHeparin", "hepatic impairment": "manufacturer advises caution\u2014no information available", "doses": ["prophylaxis of deep-vein thrombosis especially in surgical\r\npatients,by subcutaneous injection,moderate\r\nrisk, 20\u00a0mg (2000\u00a0units) approx. 2 hours before surgery then\r\n20\u00a0mg (2000\u00a0units) every 24 hours;high risk(e.g.\r\northopaedic surgery), 40\u00a0mg (4000\u00a0units) 12 hours before surgery then\r\n40\u00a0mg (4000\u00a0units) every 24 hours"], "pregnancy": "not known to be harmful; see alsoPregnancy", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "BETA-BLOCKERS": {"interactions": {"extra": "Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind", "bad": 0, "interaction": "hypoglycaemic effect of  insulin enhanced by beta-blockers ", "name": "Beta-blockers", "backrefs": ["Beta-blockers", "Pilocarpine", "Dobutamine"]}}, "LERCANIDIPINE HYDROCHLORIDE": {"indications": "mild to moderate hypertension", "name": "LERCANIDIPINE HYDROCHLORIDE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "left ventricular dysfunction; sick sinus syndrome (if pacemaker not fitted);interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "less commonlyflushing, peripheral\r\noedema, palpitation, tachycardia, headache, dizziness;rarelygastro-intestinal disturbances, angina, asthenia, drowsiness, polyuria,\r\nmyalgia, rash;very rarelygingival hyperplasia,\r\nmyocardial infarction, hypotension;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "aortic stenosis; unstable angina, uncontrolled heart failure; within 1 month of myocardial infarction; acute porphyria (section 9.8.2)", "hepatic impairment": "avoid in severe disease", "doses": ["Initially 10\u00a0mg once daily; increased, if necessary, after\r\nat least 2 weeks to 20\u00a0mg daily"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid"}, "CARBOMERS": {"indications": "dry eyes including keratoconjunctivitis sicca, unstable tear film", "name": "CARBOMERS", "doses": ["Apply 3\u20134 times daily or as required"]}, "PAROXETINE": {"indications": "major depression, obsessive-compulsive disorder, panic disorder;\r\nsocial anxiety disorder; post-traumatic stress disorder; generalised\r\nanxiety disorder", "name": "PAROXETINE", "renal impairment": "reduce dose if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly reduces plasma concentration of paroxetine ", "name": "Paroxetine", "backrefs": ["Asenapine", "Paroxetine", "Procyclidine", "Tamoxifen", "Perphenazine"]}, "cautions": "seenotes above; also achlorhydria or high gastric pH (reduced absorption\r\nof oral suspension)", "side-effects": "seenotes above; also yawning; abnormal dreams;\r\nraised cholesterol;less commonlyarrhythmias, confusion,\r\nurinary incontinence;rarelypanic attacks and paradoxical\r\nincreased anxiety during initial treatment of panic disorder (reduce\r\ndose), depersonalisation, and neuroleptic malignant syndrome-like\r\nevent;rarelyrestless legs syndrome;very\r\nrarelyperipheral oedema, acute glaucoma, hepatic disorders\r\n(e.g. hepatitis), and priapism;also reportedtinnitus,\r\nextrapyramidal reactions (including orofacial dystonias) and withdrawal\r\nreactions (seenotes above)", "contra-indications": "seenotes above", "hepatic impairment": "reduce dose", "doses": ["Major depression, social anxiety disorder, post-traumatic\r\nstress disorder, generalised anxiety disorder,adultover 18 years, recommended dose 20\u00a0mg each morning (no evidence\r\nof greater efficacy at higher doses); max. 50\u00a0mg daily (elderly40\u00a0mg daily);childunder 18 years not recommended (seeDepressive Illness in Children\r\nand Adolescents)", "Obsessive-compulsive disorder,adultover 18 years, initially 20\u00a0mg each morning, increased gradually\r\nin steps of 10\u00a0mg to recommended dose of 40\u00a0mg daily (no evidence\r\nof greater efficacy at higher doses); max. 60\u00a0mg daily (elderly40\u00a0mg daily)", "Panic disorder,adultover 18\r\nyears, initially 10\u00a0mg each morning, increased gradually in steps\r\nof 10\u00a0mg to recommended dose of 40\u00a0mg daily (no evidence of greater\r\nefficacy at higher doses); max. 60\u00a0mg daily (elderly40\u00a0mg daily)"], "pregnancy": "increased risk of congenital malformations, especially\r\nif used in the first trimester; see alsonotes above", "breast-feeding": "present in milk but amount too small to be harmful"}, "MIDAZOLAM": {"indications": "conscious sedation for procedures; sedation in intensive care; sedation\r\nin anaesthesia; premedication; induction of anaesthesia; status epilepticus\r\n(section 4.8.2)", "name": "MIDAZOLAM", "renal impairment": "start with small doses in severe impairment; increased\r\ncerebral sensitivity", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of midazolam (risk of prolonged sedation\u2014avoid concomitant use of oral midazolam)", "name": "Midazolam", "backrefs": ["Midazolam"]}, "cautions": "seenotes above;cardiac disease; respiratory disease; myasthenia\r\ngravis; neonates; children (particularly if cardiovascular impairment); risk of airways obstruction and hypoventilation in\r\nchildren under 6 months (monitor respiratory rate and oxygen saturation); history of drug or alcohol abuse; reduce\r\ndose in elderly and debilitated; risk of severe hypotension in hypovolaemia, vasoconstriction, hypothermia; avoid prolonged use (and abrupt withdrawal thereafter); concentration ofmidazolamin children under 15\u00a0kg not to exceed 1\u00a0mg/mL;interactions:Appendix 1 (anxiolytics and hypnotics)", "side-effects": "seenotes above; gastro-intestinal disturbances,\r\nincreased appetite, jaundice; hypotension, cardiac arrest, heart rate\r\nchanges, anaphylaxis, thrombosis; laryngospasm, bronchospasm, respiratory\r\ndepression and respiratory arrest (particularly with high doses or\r\non rapid injection); drowsiness, confusion, ataxia, amnesia, headache,\r\neuphoria, hallucinations, convulsions (more common in neonates), dizziness,\r\nvertigo, involuntary movements, paradoxical excitement and aggression\r\n(especially in children and elderly), dysarthria; urinary retention,\r\nincontinence, changes in libido; blood disorders; muscle weakness;\r\nvisual disturbances; salivation changes; skin reactions; injection-site\r\nreactions", "contra-indications": "marked neuromuscular\r\nrespiratory weakness including unstable myasthenia\r\ngravis; severe respiratory depression; acute pulmonary insufficiency", "hepatic impairment": "use with caution; can precipitate coma", "doses": ["Conscious sedation for procedures,by slow\r\nintravenous injection(approx. 2\u00a0mg/minute) 5\u201310 minutes before\r\nprocedure, initially 2\u20132.5\u00a0mg (elderly0.5\u20131\u00a0mg), increased if necessary in steps of 1\u00a0mg (elderly0.5\u20131\u00a0mg); usual total dose 3.5\u20135\u00a0mg (max.\r\n7.5\u00a0mg),elderlymax. 3.5\u00a0mg;child1 month\u201318 years seeBNF for Children", "By rectum,child6 months\u201318 years seeBNF for Children", "By mouth,child1 month\u201318 years seeBNF for Children", "By buccal administration,child6 months\u201318 years seeBNF for Children", "Sedative in combined anaesthesia,by intravenous injection, 30\u2013100\u00a0micrograms/kg repeated as required orby continuous\r\nintravenous infusion, 30\u2013100\u00a0micrograms/kg/hour (elderlylower doses needed);childnot recommended", "Premedication,by deep intramuscular injection,adultover 18 years, 70\u2013100\u00a0micrograms/kg\r\n(elderlyor debilitated 25\u201350\u00a0micrograms/kg)\r\n20\u201360 minutes before induction", "By intravenous injection,adultover 18 years, 1\u20132\u00a0mg 5\u201330 minutes before procedure, repeated as\r\nrequired (elderlyor debilitated 0.5\u00a0mg,\r\nrepeat dose slowly as required)", "By rectum,child6 months\u201312 years seeBNF for Children", "By mouth,child1 month\u201318 years seeBNF for Children", "Induction (but rarely used),by slow intravenous injection, 150\u2013200\u00a0micrograms/kg (elderlyor\r\ndebilitated 50\u2013150\u00a0micrograms/kg) given in divided doses (max. 5\u00a0mg)\r\nat intervals of 2 minutes; max. total dose 600\u00a0micrograms/kg;child7\u201318 years initially 150\u00a0micrograms/kg (max.\r\n7.5\u00a0mg) given in steps of 50\u00a0micrograms/kg (max. 2.5\u00a0mg) over 2\u20135\r\nminutes; wait for 2\u20135 minutes then give additional doses of 50\u00a0micrograms/kg\r\n(max. 2.5\u00a0mg) every 2 minutes if necessary; max. total dose 500\u00a0micrograms/kg\r\n(not exceeding 25\u00a0mg)", "Sedation of patients receiving intensive care,by slow\r\nintravenous injection, initially 30\u2013300\u00a0micrograms/kg given\r\nin steps of 1\u20132.5\u00a0mg every 2 minutes, thenby slow intravenous\r\ninjectionorby continuous intravenous\r\ninfusion, 30\u2013200\u00a0micrograms/kg/hour; reduce dose (or reduce\r\nor omit initial dose) in hypovolaemia, vasoconstriction, or hypothermia;\r\nlower doses may be adequate if opioid analgesic also used;childunder 12 years seeBNF for Children"], "pregnancy": "avoid regular use (risk of neonatal withdrawal symptoms);\r\nuse only if clear indication such as seizure control (high doses during\r\nlate pregnancy or labour may cause neonatal hypothermia, hypotonia,\r\nand respiratory depression)", "breast-feeding": "present in milk\u2014avoid breast-feeding for 24\r\nhours after administration"}, "ALTEPLASE": {"indications": "acute myocardial infarction (see\r\nnotes above andsection 2.10.1); pulmonary embolism; acute\r\nischaemic stroke (treatment under specialist neurology physicianonly); thrombolytic treatment of occluded central venous\r\naccess devices (including those used for haemodialysis)", "name": "ALTEPLASE", "cautions": "seenotes above;in acute stroke, monitor for intracranial haemorrhage, monitor blood pressure (antihypertensive recommended if systolic\r\nabove 180\u00a0mmHg or diastolic above 105\u00a0mmHg)", "side-effects": "seenotes above; also\r\nrisk of cerebral bleeding increased in acute stroke", "contra-indications": "seenotes above;in acute stroke, convulsion accompanying stroke,\r\nsevere stroke, history of stroke in patients with diabetes, stroke\r\nin last 3 months, hypoglycaemia, hyperglycaemia", "hepatic impairment": "seenotes above", "doses": ["myocardial infarction, accelerated regimen (initiated\r\nwithin 6 hours of symptom onset), 15\u00a0mgby intravenous injection, followedby intravenous infusionof 50\u00a0mg over 30\r\nminutes, then 35\u00a0mg over 60 minutes (total dose 100\u00a0mg over 90 minutes);\r\nin patients less than 65\u00a0kg, 15\u00a0mgby intravenous injection, followedby intravenous infusionof 0.75\u00a0mg/kg over\r\n30 minutes, then 0.5\u00a0mg/kg over 60 minutes (max. total dose 100\u00a0mg\r\nover 90 minutes)", "Myocardial infarction, initiated within 6\u201312 hours\r\nof symptom onset, 10\u00a0mgby intravenous injection, followedby intravenous infusionof 50\u00a0mg over 60 minutes, then 4infusionseach of 10\u00a0mg over 30 minutes (total dose 100\u00a0mg\r\nover 3 hours; max. 1.5\u00a0mg/kg in patients less than 65\u00a0kg)", "Pulmonary embolism, 10\u00a0mgby intravenous injectionover 1\u20132 minutes, followedby intravenous infusionof 90\u00a0mg over 2 hours; max. 1.5\u00a0mg/kg in patients less than 65\u00a0kg", "Acute stroke (treatmentmustbegin within 3\r\nhours of symptom onset),by intravenous administrationover 60 minutes, 900\u00a0micrograms/kg (max. 90\u00a0mg); initial 10% of\r\ndose by intravenous injection, remainder by intravenous infusion;elderlyover 80 years not recommended"], "pregnancy": "seenotes above"}, "BIPHASIC ISOPHANE INSULIN": {"indications": "diabetes mellitus", "name": "BIPHASIC ISOPHANE INSULIN", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin(section 6.1.1.1);\r\nprotamine may cause allergic reactions", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection, according to\r\nrequirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "FEBUXOSTAT": {"indications": "treatment of chronic hyperuricaemia\r\nin gout (but see alsoNICE guidance)", "name": "FEBUXOSTAT", "renal impairment": "use with caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2\u2014no information available", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  mercaptopurine advised by manufacturer of febuxostat ", "name": "Febuxostat", "backrefs": ["Febuxostat"]}, "cautions": "administer prophylactic NSAID (notaspirin or salicylates) or colchicine for at least 6\r\nmonths after starting febuxostat to avoid precipitating an acute attack; transplant recipients; monitor liver function tests before and periodically during treatment\r\nas indicated; thyroid disorders;interactions:Appendix 1 (febuxostat)", "side-effects": "gastro-intestinal disturbances, abnormal liver\r\nfunction tests; headache; rash;less commonlytaste\r\ndisturbances, increased appetite; hypertension, oedema, flushing;\r\ndizziness, paraesthesia, drowsiness; influenza-like symptoms; haematuria,\r\nnephrolithiasis, increased urinary frequency, decreased libido; myalgia;\r\ndermatitis, pruritus, urticaria;rarelythirst, palpitation, asthenia, nervousness, insomnia, and renal impairment", "contra-indications": "not a treatment for acute gout\r\nbut continue if attack develops when already receiving febuxostat,\r\nand treat attack separately (seenotes above); ischaemic heart disease; congestive heart\r\nfailure", "hepatic impairment": "max. 80\u00a0mg daily in mild impairment; no dose information\r\navailable in moderate or severe impairment", "doses": ["adultover 18 years, 80\u00a0mg\r\nonce daily, if after 2\u20134 weeks serum uric acid greater than 6\u00a0mg/100\u00a0mL,\r\nincrease to 120\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid\u2014limited information available", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CARBOPLATIN": {"indications": "seenotes above", "name": "CARBOPLATIN", "renal impairment": "reduce dose and monitor haematological parameters and\r\nrenal function; avoid if creatinine clearance less than 20\u00a0mL/minute", "cautions": "seesection 8.1andnotes above;interactions: Appendix 1 (platinum compounds)", "side-effects": "seesection 8.1andnotes above", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and embryotoxic inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "PHENYLEPHRINE": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by phenylephrine ", "name": "Phenylephrine", "backrefs": ["Phenylephrine"]}}, "PENCICLOVIR": {"side-effects": "transient stinging, burning, numbness; hypersensitivity\r\nreactions also reported", "indications": "seenotes above", "name": "PENCICLOVIR", "cautions": "avoid contact with eyes and mucous membranes", "doses": ["herpes labialis, apply to lesions every 2 hours during\r\nwaking hours for 4 days, starting at first sign of attack;childunder 12 years, not recommended"]}, "PROPYLTHIOURACIL": {"indications": "hyperthyroidism", "name": "PROPYLTHIOURACIL", "renal impairment": "use three-quarters normal dose if eGFR 10\u201350\u00a0mL/minute/1.73\u00a0m2; use half normal dose if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "monitor for hepatotoxicity", "side-effects": "see underCarbimazole; leucopenia;\r\nrarely cutaneous vasculitis, thrombocytopenia, aplastic anaemia, hypoprothrombinaemia,\r\nhepatic disorders (including hepatitis, hepatic failure, encephalopathy,\r\nhepatic necrosis; see also Hepatotoxicity above), nephritis, lupus\r\nerythematous-like syndromes", "hepatic impairment": "reduce dose (see also Hepatotoxicity above)", "doses": ["Seenotes above"], "pregnancy": "neonatal goitre and hypothyroidism; see alsonotes above", "breast-feeding": "monitor infant\u2019s thyroid status but amount in\r\nmilk probably too small to affect infant; high doses may affect neonatal\r\nthyroid function; see alsonotes above"}, "TETRACYCLINES": {"interactions": {"extra": "", "bad": 0, "interaction": " kaolin possibly reduces absorption of tetracyclines ", "name": "Tetracyclines", "backrefs": ["Kaolin", "Quinapril", "Tetracyclines", "Retinoids", "Strontium Ranelate", "Dairy Products", "Tripotassium Dicitratobismuthate"]}}, "CATUMAXOMAB": {"indications": "seenotes above", "name": "CATUMAXOMAB", "cautions": "seesection 8.1andnotes above; haemodynamic insufficiency, oedema,\r\nhypoproteinaemia", "side-effects": "seesection 8.1andnotes above; also abdominal pain,\r\ndiarrhoea, constipation, dyspepsia, flatulence, ileus, anorexia, dehydration,\r\ncholangitis, tachycardia, hypotension, hypertension, flushing, dyspnoea,\r\npleural effusion, cough, hypoxia, insomnia, anxiety, headache, dizziness,\r\ninfection, hyperglycaemia, electrolyte disturbances, proteinuria,\r\nhaematuria, leukocyturea, myalgia, arthralgia, vertigo, rash, sweating,\r\nskin reactions,less commonlygastro-intestinal haemorrhage,\r\nintestinal obstruction, seizures, acute renal failure", "doses": ["Consult product literature"], "pregnancy": "avoid\u2014limited information available", "breast-feeding": "avoid\u2014no information available"}, "CYTOTOXICS": {"interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  clozapine with cytotoxics (increased risk of agranulocytosis)", "name": "Cytotoxics", "backrefs": ["Cytotoxics"]}}, "BEVACIZUMAB": {"indications": "seenotes above", "name": "BEVACIZUMAB", "cautions": "seesection 8.1; intra-abdominal inflammation (risk of gastro-intestinal perforation); increased\r\nrisk of fistulas (discontinue permanently if tracheo-oesophageal or\r\ngrade 4 fistula develops); withhold treatment\r\nfor elective surgery and avoid for at least\r\n28 days after major surgery or until wound fully healed; history of hypertension (increased risk\r\nof proteinuria\u2014discontinue if nephrotic syndrome); uncontrolled hypertension; monitor blood pressure; history of arterial\r\nthromboembolism; history of cardiovascular\r\ndisease (increased risk of cardiovascular events especially in the\r\nelderly); monitor for congestive heart\r\nfailure; increased risk of haemorrhage\r\n(especially tumour-associated haemorrhage); monitor for reversible posterior leucoencephalopathy syndrome (presenting\r\nas seizures, headache, altered mental status, visual disturbance or\r\ncortical blindness, with or without hypertension); untreated CNS metastases; consider dental check-up\r\nbefore initiating treatment (risk of osteonecrosis of the jaw, seeMHRA/CHM advice)", "side-effects": "seesection 8.1; gastro-intestinal perforation, intestinal obstruction,\r\nabdominal pain, diarrhoea, constipation, taste disturbances; mucocutaneous\r\nbleeding, haemorrhage, hypoxia, arterial thromboembolism, congestive\r\nheart failure, syncope, supraventricular tachycardia, hypertension\r\n(see also Cautions); dyspnoea, rhinitis; anorexia, drowsiness, headache,\r\nperipheral neuropathy, asthenia, lethargy; pyrexia; proteinuria; dehydration;\r\neye disorders; fistulas, pulmonary hypertension, impaired wound healing,\r\nosteonecrosis of the jaw (seeMHRA/CHM advice), hand-foot syndrome, exfoliative\r\ndermatitis, dry skin, skin discoloration, and hypersensitivity reactions\r\n(including flushing, rash, hypotension, chest pain, and rigors) also\r\nreported", "doses": ["SeeDoses"], "pregnancy": "avoid\u2014toxicity inanimalstudies;\r\neffective contraception required during and for at least 6 months\r\nafter treatment in women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid breast-feeding during\r\nand for at least 6 months after treatment"}, "ENOXIMONE": {"indications": "congestive heart failure where cardiac output reduced and filling\r\npressures increased", "name": "ENOXIMONE", "renal impairment": "consider dose reduction", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  anagrelide advises avoid concomitant use with enoximone ", "name": "Enoximone", "backrefs": ["Enoximone"]}, "cautions": "heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive\r\nvalvular disease or other outlet obstruction; monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count, hepatic enzymes; avoid extravasation;interactions:Appendix 1 (phosphodiesterase\r\ntype-3 inhibitors)", "side-effects": "ectopic beats; less frequently ventricular tachycardia\r\nor supraventricular arrhythmias (more likely in patients with pre-existing\r\narrhythmias); hypotension; also headache, insomnia, nausea and vomiting,\r\ndiarrhoea; occasionally, chills, oliguria, fever, urinary retention;\r\nupper and lower limb pain", "hepatic impairment": "dose reduction may be required", "doses": ["By slow intravenous injection(rate not\r\nexceeding 12.5\u00a0mg/minute), diluted before use, initially 0.5\u20131\u00a0mg/kg,\r\nthen 500\u00a0micrograms/kg every 30\u00a0minutes until satisfactory response\r\nor total of 3\u00a0mg/kg given; maintenance, initial dose of up to 3\u00a0mg/kg\r\nmay be repeated every 3\u20136\u00a0hours as required", "By intravenous infusion, initially\r\n90\u00a0micrograms/kg/minute over 10\u201330\u00a0minutes, followed by continuous\r\nor intermittent infusion of 5\u201320\u00a0micrograms/kg/minute", "Total dose over 24\u00a0hours should not usually exceed 24\u00a0mg/kg"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "TOPOTECAN": {"indications": "seenotes above", "name": "TOPOTECAN", "renal impairment": "reduce dose; avoid infusion if creatinine clearance less\r\nthan 20\u00a0mL/minute; avoid oral route if creatinine clearance less than\r\n60\u00a0mL/minute", "cautions": "seesection 8.1andnotes above", "side-effects": "seesection 8.1andnotes above", "contra-indications": "seesection 8.1andnotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenicity and fetal loss inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "BENPERIDOL": {"indications": "control of deviant antisocial sexual behaviour (but see notes above)", "name": "BENPERIDOL", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  moxifloxacin given with benperidol\u2014manufacturer of benperidol advises avoid concomitant use", "name": "Benperidol", "backrefs": ["Benperidol"]}, "cautions": "seenotes above; also manufacturer advises regular blood counts and liver function tests\r\nduring long-term treatment; risk factors\r\nfor stroke", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["0.25\u20131.5\u00a0mg daily in divided doses, adjusted according\r\nto response;elderly(or debilitated)\r\ninitially half adult dose;childnot\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "AMIODARONE HYDROCHLORIDE": {"indications": "see notes above (should be initiated in hospital or under specialist\r\nsupervision)", "name": "AMIODARONE HYDROCHLORIDE", "cautions": "liver-function and thyroid-function tests\r\nrequired before treatment and then every 6 months (seenotes abovefor tests of thyroid function); hypokalaemia (measure serum-potassium concentration before treatment); chest x-ray required before treatment; heart failure; elderly; severe bradycardia and conduction disturbances in\r\nexcessive dosage; intravenous use may cause\r\nmoderate and transient fall in blood pressure (circulatory collapse\r\nprecipitated by rapid administration or overdosage) or\r\nsevere hepatocellular toxicity (monitor transaminases closely); administration by central venous catheter recommended if repeated\r\nor continuous infusion required\u2014infusion via peripheral veins may\r\ncause pain and inflammation; ECG monitoring\r\nand resuscitation facilities must be available during intravenous\r\nuse; acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(amiodarone)", "side-effects": "nausea, vomiting, taste disturbances, raised serum\r\ntransaminases (may require dose reduction or withdrawal if accompanied\r\nby acute liver disorders), jaundice; bradycardia (see Cautions); pulmonary\r\ntoxicity (including pneumonitis and fibrosis); tremor, sleep disorders;\r\nhypothyroidism, hyperthyroidism; reversible corneal microdeposits\r\n(sometimes with night glare); phototoxicity, persistent slate-grey\r\nskin discoloration (see also notes above), injection-site reactions;less commonlyonset or worsening of arrhythmia, conduction\r\ndisturbances (see Cautions), peripheral neuropathy and myopathy (usually\r\nreversible on withdrawal);very rarelychronic liver\r\ndisease including cirrhosis, sinus arrest, bronchospasm (in patients\r\nwith severe respiratory failure), ataxia, benign intracranial hypertension,\r\nheadache, vertigo, epididymo-orchitis, impotence, haemolytic or aplastic\r\nanaemia, thrombocytopenia, rash (including exfoliative dermatitis),\r\nhypersensitivity including vasculitis, alopecia, impaired vision due\r\nto optic neuritis or optic neuropathy (including blindness), anaphylaxis\r\non rapid injection, also hypotension, respiratory distress syndrome,\r\nsweating, and hot flushes", "contra-indications": "(except in cardiac arrest) sinus\r\nbradycardia, sino-atrial heart block; unless pacemaker fitted avoid in severe conduction disturbances or sinus\r\nnode disease; thyroid dysfunction; iodine sensitivity; avoidintravenous\r\nusein severe respiratory failure, circulatory collapse, or severe arterial hypotension; avoid bolus injection in congestive heart failure or cardiomyopathy", "doses": ["By mouth, 200\u00a0mg 3 times daily for 1 week\r\nreduced to 200\u00a0mg twice daily for a further week; maintenance, usually\r\n200\u00a0mg daily or the minimum required to control the arrhythmia", "By intravenous infusion(see Cautions above),\r\ninitially 5\u00a0mg/kg over 20\u2013120 minutes with ECG monitoring; subsequent\r\ninfusion given if necessary according to response up to max. 1.2\u00a0g\r\nin 24 hours", "Ventricular fibrillation or pulseless ventricular tachycardia\r\nrefractory to defibrillation,section 2.7.3"], "pregnancy": "possible risk of neonatal goitre; use only if no\r\nalternative", "breast-feeding": "avoid; present in milk in significant amounts;\r\ntheoretical risk of neonatal hypothyroidism from release of iodine"}, "COLESTIPOL HYDROCHLORIDE": {"indications": "hyperlipidaemias, particularly type IIa, in patients who have not\r\nresponded adequately to diet and other appropriate measures", "name": "COLESTIPOL HYDROCHLORIDE", "cautions": "seenotes above;interactions:Appendix 1 (colestipol)", "side-effects": "seenotes above", "doses": ["Initially 5\u00a0g 1\u20132 times daily in liquid increased if necessary\r\nin 5-g increments at intervals of 1 month to max. 30\u00a0g daily (in 1\u20132\r\ndivided doses)", "the contents of each sachet should be mixed\r\nwith at least 100\u00a0mL of water or other suitable liquid such as fruit\r\njuice or skimmed milk; alternatively it can be mixed with thin soups,\r\ncereals, yoghurt, or pulpy fruits ensuring at least 100\u00a0mL of liquid\r\nis provided"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "3.9.2 Demulcent and expectorant cough preparations": {"name": "3.9.2 Demulcent and expectorant cough preparations", "doses": ["child1 month\u201312 years\r\n5\u201310\u00a0mL 3\u20134 times daily"]}, "VILDAGLIPTIN WITH METFORMIN": {"indications": "type 2 diabetes mellitus not controlled\r\nby metformin alone", "name": "VILDAGLIPTIN WITH METFORMIN", "renal impairment": "see under Cautions", "cautions": "determine renal function before treatment\r\nand at least annually (at least twice a year in patients with additional\r\nrisk factors for renal impairment, or if deterioration suspected); monitor liver function (see below);interactions:Appendix 1 (antidiabetics)", "side-effects": "nausea, vomiting, diarrhoea (usually transient),\r\nabdominal pain, taste disturbance, peripheral oedema, headache, tremor,\r\nanorexia, asthenia, dizziness;less commonlyconstipation,\r\nhypoglycaemia, arthralgia;rarelyhepatic dysfunction\r\n(see also Liver Toxicity above), lactic acidosis (withdraw treatment),\r\ndecreased vitamin-B12absorption, erythema, pruritus, and\r\nurticaria;very rarelynasopharyngitis, upper respiratory\r\ntract infection; pancreatitisalso reported", "contra-indications": "ketoacidosis, see\r\nalso Lactic Acidosis above; use of general anaesthesia\r\n(suspend treatment on the morning of surgery and restart when renal\r\nfunction returns to baseline)", "hepatic impairment": "avoid", "doses": ["adultover 18 years, 1\r\ntablet twice daily (based on patient\u2019s current metformin dose)"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "MAGNESIUM CARBONATE": {"indications": "dyspepsia", "name": "MAGNESIUM CARBONATE", "renal impairment": "seenotes above; magnesium\r\ncarbonate mixture has a high sodium content", "cautions": "seenotes above;interactions:Appendix\u00a01 (antacids)", "side-effects": "diarrhoea; belching due to liberated carbon dioxide", "contra-indications": "hypophosphataemia", "hepatic impairment": "seenotes above", "doses": ["10\u00a0mL 3 times daily in water"]}, "PIOGLITAZONE": {"indications": "type 2 diabetes mellitus (alone or combined with metformin or a sulfonylurea,\r\nor with both, or with insulin\u2014see also notes above)", "name": "PIOGLITAZONE", "cautions": "monitor liver function (see below); cardiovascular\r\ndisease or in combination with insulin (risk of heart failure\u2014seeMHRA/CHM advice); substitute insulin during peri-operative period (omit pioglitazone\r\non morning of surgery and recommence when eating and drinking normally); increased risk of bone fractures, particularly\r\nin women; avoid in acute porphyria (but seesection 9.8.2); risk factors for bladder cancer\r\n(seeRisk of Bladder Cancer); elderly (increased risk of heart failure, fractures,\r\nand bladder cancer);interactions:Appendix 1 (antidiabetics)", "side-effects": "gastro-intestinal disturbances, weight gain, oedema,\r\nanaemia, headache, visual disturbances, dizziness, arthralgia, hypoaesthesia,\r\nhaematuria, impotence;less commonlyhypoglycaemia,\r\nfatigue, insomnia, vertigo, sweating, altered blood lipids, proteinuria,\r\nbladder cancer; see also Liver Toxicity above", "contra-indications": "history of heart failure; uninvestigated macroscopic haematuria, previous\r\nor active bladder cancer", "hepatic impairment": "avoid; see also Cautions above", "doses": ["adultover 18 years, initially\r\n15\u201330\u00a0mg once daily increased to 45\u00a0mg once daily according to response,\r\n(elderly, initiate with lowest possible\r\ndose and increase gradually); review treatment after 3\u20136 months and\r\nregularly thereafter", "Dose of concomitant sulfonylurea or insulin\r\nmay need to be reduced"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "LARONIDASE": {"indications": "(specialist use only) non-neurological\r\nmanifestations of mucopolysaccharidosis I", "name": "LARONIDASE", "interactions": {"extra": "", "bad": 0, "interaction": " chloroquine and hydroxychloroquine possibly inhibit effects of laronidase (manufacturer of laronidase advises avoid concomitant use)", "name": "Laronidase", "backrefs": ["Laronidase"]}, "cautions": "monitor immunoglobulin G (IgG) antibody\r\nconcentration;interactions:Appendix\r\n1 (laronidase)", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain; cold\r\nextremities, pallor, flushing, tachycardia, blood pressure changes;\r\ndyspnoea, cough, angioedema, anaphylaxis; headache, paraesthesia,\r\ndizziness, fatigue, restlessness; influenza-like symptoms; musculoskeletal\r\npain, pain in extremities; rash, pruritus, urticaria, alopecia, infusion-site\r\nreactions; bronchospasm and respiratory arrest also reported", "doses": ["By intravenous infusion, 100\u00a0units/kg once\r\nweekly;childseeBNF for Children"], "pregnancy": "manufacturer advises avoid unless essential\u2014no information\r\navailable", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "ADENOSINE": {"indications": "rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias,\r\nincluding those associated with accessory conducting pathways (e.g.\r\nWolff-Parkinson-White syndrome); aid to diagnosis of broad or narrow\r\ncomplex supraventricular tachycardias; in conjunction with radionuclide\r\nmyocardial perfusion imaging in patients who cannot exercise adequately\r\nor for whom exercise is inappropriate", "name": "ADENOSINE", "interactions": {"extra": "Possibility of interaction with drugs tending to impair myocardial conduction", "bad": 0, "interaction": " nicotine possibly enhances effects of adenosine ", "name": "Adenosine", "backrefs": ["Nicotine", "Adenosine"]}, "cautions": "monitor ECG and have resuscitation facilities available; atrial fibrillation or flutter with accessory pathway (conduction\r\ndown anomalous pathway may increase); first-degree AV\r\nblock; bundle branch block; left main coronary artery stenosis; uncorrected hypovolaemia; stenotic valvular\r\nheart disease; left to right shunt; pericarditis; pericardial\r\neffusion; autonomic dysfunction; stenotic carotid artery disease with cerebrovascular\r\ninsufficiency; recent myocardial infarction; heart failure; heart transplant (see below);interactions:Appendix 1 (adenosine)", "side-effects": "nausea; arrhythmia (discontinue if asystole or\r\nsevere bradycardia occur), sinus pause, AV block, flushing, angina\r\n(discontinue), dizziness; dyspnoea; headache;less commonlymetallic taste; palpitation, hyperventilation, weakness, blurred\r\nvision, sweating;very rarelytransient worsening\r\nof intracranial hypertension, bronchospasm, injection-site reactions;also reportedvomiting, syncope, hypotension (discontinue\r\nif severe), cardiac arrest, respiratory failure (discontinue), and\r\nconvulsions", "contra-indications": "second- or third-degree AV block and sick sinus syndrome\r\n(unless pacemaker fitted); long QT syndrome; severe hypotension; decompensated\r\nheart failure; chronic obstructive lung disease (including asthma)", "doses": ["By rapid intravenous injectioninto central\r\nor large peripheral vein, 6\u00a0mg over 2 seconds with cardiac monitoring;\r\nif necessary followed by 12\u00a0mg after 1\u20132 minutes, and then by 12\u00a0mg\r\nafter a further 1\u20132 minutes; increments should not be given if high\r\nlevel AV block develops at any particular dose", "Patients with aheart transplantare very sensitive to effects of adenosine and should receive initial\r\ndose of 3\u00a0mg over 2 seconds, followed if necessary by 6\u00a0mg after 1\u20132\r\nminutes, and then by 12\u00a0mg after a further 1\u20132 minutes.", "Also, if essential to give withdipyridamolereduce adenosine dose to a quarter of the usual dose", "Adenosine doses in the BNF may differ from\r\nthose in product literature", "By intravenous infusionin conjunction with radionuclide\r\nmyocardial perfusion imaging\u2014consult product literature"], "pregnancy": "large doses may produce foetal toxicity; manufacturer\r\nadvises use only if potential benefit outweighs risk", "breast-feeding": "no information available\u2014unlikely to be present\r\nin milk owing to short half-life"}, "DIAMORPHINE HYDROCHLORIDE": {"indications": "see under Dose", "name": "DIAMORPHINE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; also severe diarrhoea; toxic psychosis, CNS depression; severe\r\ncor pulmonale", "side-effects": "seenotes above; also\r\nanorexia, taste disturbance; syncope; asthenia, raised intracranial\r\npressure; myocardial infarction also reported", "contra-indications": "seenotes above; also delayed gastric emptying; phaeochromocytoma", "hepatic impairment": "seenotes above", "doses": ["Acute pain,by subcutaneousorintramuscular injection, 5\u00a0mg repeated every 4 hours\r\nif necessary (up to 10\u00a0mg for heavier well-muscled patients);by slow intravenous injection, quarter to half corresponding\r\nintramuscular dose", "Myocardial infarction,by slow intravenous injection(1\u20132\u00a0mg/minute), 5\u00a0mg followed by a further 2.5\u20135\u00a0mg if necessary;elderlyor frail patients, reduce dose by half", "Acute pulmonary oedema,by slow intravenous injection(1\u00a0mg/minute) 2.5\u20135\u00a0mg", "Chronic pain,by subcutaneousorintramuscular injection,adultnot currently treatedwith a strong opioid analgesic,\r\ninitially 2.5\u20135\u00a0mg every 4 hours, adjusted according to response;adultcurrently treatedwith a strong\r\nopioid analgesic\u2014seePrescribing in Palliative\r\nCare;by subcutaneous infusion,adultnot currently treatedwith a strong opioid analgesic,\r\ninitially 5\u201310\u00a0mg over 24 hours, adjusted according to response;adultcurrently treatedwith a strong\r\nopioid analgesic\u2014seePrescribing in Palliative\r\nCare"], "pregnancy": "seenotes above", "breast-feeding": "therapeutic doses unlikely to affect infant;\r\nwithdrawal symptoms in infants of dependent mothers; breast-feeding\r\nnot best method of treating dependence in offspring"}, "PHOLCODINE": {"indications": "dry cough", "name": "PHOLCODINE", "renal impairment": "use with caution; avoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of pholcodine for 2 weeks after stopping  MAOIs advised by manufacturer of pholcodine ", "name": "Pholcodine", "backrefs": ["Pholcodine"]}, "cautions": "asthma; chronic, persistent,\r\nor productive cough;interactions: Appendix 1 (pholcodine)", "side-effects": "nausea, vomiting, constipation, sputum retention,\r\ndrowsiness, dizziness, excitation, confusion, rash", "contra-indications": "chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, patients\r\nat risk of respiratory failure", "hepatic impairment": "avoid", "doses": ["child(but not generally\r\nrecommended, seenotes above) 6\u201312\r\nyears 10\u00a0mL 3 times daily"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid unless potential\r\nbenefit outweighs risk\u2014no information available"}, "MORPHINE": {"indications": "see notes above; cough in terminal disease\r\n(section 3.9.1); pain (section 4.7.2)", "name": "MORPHINE", "renal impairment": "section 4.7.2", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly reduces plasma concentration of morphine ", "name": "Morphine", "backrefs": ["Apomorphine", "Esmolol", "Morphine"]}, "cautions": "seenotes aboveand under Morphine Salts (section 4.7.2)", "side-effects": "see notes above and under Morphine Salts (section 4.7.2); sedation\r\nand the risk of dependence are greater", "contra-indications": "see notes above and under Morphine Salts\r\n(section 4.7.2)", "hepatic impairment": "section 4.7.2", "doses": ["adultandchildover 12 years, 10\u00a0mL every 6 hours in water"], "pregnancy": "section 4.7.2", "breast-feeding": "see under Morphine Salts (section 4.7.2)"}, "AZELAIC ACID": {"side-effects": "local irritation (reduce frequency or discontinue\r\ntemporarily);less commonlyskin discoloration;very rarelyphotosensitisation", "indications": "see preparations", "name": "AZELAIC ACID", "cautions": "avoid contact with eyes, mouth, and mucous membranes", "doses": ["acne vulgaris, apply twice daily (sensitive skin, once\r\ndaily for first week). Extended treatment may be required but manufacturer\r\nadvises period of treatment should not exceed 6 months"]}, "METOPROLOL TARTRATE": {"indications": "see under Dose", "name": "METOPROLOL TARTRATE", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "hepatic impairment": "reduce dose in severe impairment", "doses": ["hypertension, 200\u00a0mg daily; angina, 200\u2013400\u00a0mg daily;\r\nmigraine prophylaxis, 200\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "YELLOW FEVER VACCINE, LIVE": {"indications": "immunisation against yellow fever", "name": "YELLOW FEVER VACCINE, LIVE", "cautions": "seesection 14.1;alsoindividuals over 60 years\u2014greater risk of vaccine-associated adverse\r\neffects, seenotes above;interactions:Appendix 1 (vaccines)", "side-effects": "seesection 14.1; also\r\nreported neurotropic disease and viscerotropic disease (seenotes above)", "contra-indications": "seesection 14.1andnotes above;alsochildren under 6 months; history of thymus\r\ndysfunction", "doses": ["By deep subcutaneous injection,adultandchildover\r\n9 months, 0.5\u00a0mL (see alsonotes above)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "METOCLOPRAMIDE": {"interactions": {"extra": "", "bad": 0, "interaction": "antiparkinsonian effect of  pergolide antagonised by metoclopramide ", "name": "Metoclopramide", "backrefs": ["Rotigotine", "Pergolide", "Ropinirole", "Paracetamol", "Metoclopramide", "Tetrabenazine"]}}, "Oral vitamin B complex preparations": {"name": "Oral vitamin B complex preparations", "doses": ["treatment of vitamin-B deficiency, 1\u20132 tablets 3 times\r\ndaily"]}, "NORETHISTERONE": {"indications": "see under Dose; HRT (section 6.4.1.1); contraception (section 7.3.1andsection 7.3.2); malignant disease (section\r\n8.3.2)", "name": "NORETHISTERONE", "renal impairment": "use\r\nwith caution", "interactions": {"extra": "", "bad": 0, "interaction": " atazanavir increases plasma concentration of norethisterone ", "name": "Norethisterone", "backrefs": ["Norethisterone"]}, "cautions": "seenotes above", "side-effects": "see notes above", "contra-indications": "seenotes above", "hepatic impairment": "section 8.3.2", "doses": ["Endometriosis,by mouth, 10\u201315\u00a0mg daily\r\nfor 4\u20136 months or longer, starting on day 5 of cycle (if spotting\r\noccurs increase dose to 20\u201325\u00a0mg daily, reduced once bleeding has\r\nstopped)", "Dysfunctional uterine bleeding, menorrhagia (but see notes above),by mouth, 5\u00a0mg 3 times daily for 10 days to arrest bleeding;\r\nto prevent bleeding 5\u00a0mg twice daily from day 19 to 26", "Dysmenorrhoea (but see notes above),by mouth, 5\u00a0mg 3 times daily from day 5 to 24 for 3\u20134 cycles", "Premenstrual syndrome (but not recommended, see notes above),by mouth, 5\u00a0mg 2\u20133 times daily from day 19 to 26 for several\r\ncycles", "Postponement of menstruation,by mouth, 5\u00a0mg\r\n3 times daily starting 3 days before expected onset (menstruation\r\noccurs 2\u20133 days after stopping)"], "pregnancy": "section 8.3.2", "breast-feeding": "section 8.3.2"}, "FINASTERIDE": {"side-effects": "see notes above; also testicular pain, hypersensitivity\r\nreactions (including lip and face swelling, pruritus and rash); male\r\nbreast cancer also reported (see Cautions above)", "indications": "benign prostatic hyperplasia;\r\nmale-pattern baldness in men (section 13.9)", "name": "FINASTERIDE", "cautions": "seenotes above; alsoobstructive\r\nuropathy", "doses": ["5\u00a0mg daily, review treatment at 3\u20136 months and then every\r\n6\u201312 months (may require several months\u2019 treatment before benefit\r\nis obtained)"]}, "INSULIN": {"indications": "diabetes mellitus; diabetic ketoacidosis\r\n(section 6.1.3)", "name": "INSULIN", "renal impairment": "section 6.1.1", "interactions": {"extra": "", "bad": 0, "interaction": " lanreotide possibly reduces requirements for insulin ", "name": "Insulin", "backrefs": ["Octreotide", "Lanreotide", "Beta-blockers", "Disopyramide", "Fibrates", "Insulin"]}, "cautions": "section 6.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see notes above; transient\r\noedema; local reactions and fat hypertrophy at injection site;rarelyhypersensitivity reactions including urticaria, rash;\r\noverdose causes hypoglycaemia", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous,intramuscularorintravenous injectionorintravenous infusion, according to requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "ANTIMUSCARINICS": {"interactions": {"extra": "Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation", "bad": 0, "interaction": "absorption of  ketoconazole reduced by antimuscarinics ", "name": "Antimuscarinics", "backrefs": ["Parasympathomimetics", "Antimuscarinics"]}}, "ALDESLEUKIN": {"indications": "seenotes above", "name": "ALDESLEUKIN", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with aldesleukin ", "name": "Aldesleukin", "backrefs": ["Aldesleukin", "Dacarbazine"]}, "cautions": "consult product literature;interactions:Appendix 1 (aldesleukin)", "side-effects": "seesection 8.1,notes above, and consult product literature", "contra-indications": "consult product literature", "doses": ["Consult product literature"], "pregnancy": "use only if potential benefit outweighs risk (toxicity\r\ninanimalstudies); ensure effective contraception\r\nduring treatment in men and women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "TYPHOID VACCINE": {"indications": "immunisation against typhoid fever", "name": "TYPHOID VACCINE", "cautions": "section 14.1;interactions:seeaboveand Appendix\r\n1 (typhoid vaccine (oral) )", "side-effects": "section 14.1", "contra-indications": "section 14.1; also fororalvaccine, acute gastro-intestinal illness", "doses": ["See under preparations"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "RIFAMPICIN WITH ISONIAZID": {"indications": "tuberculosis, seenotes above; prevention of tuberculosis (Table\r\n2,section 5.1)", "name": "RIFAMPICIN WITH ISONIAZID", "renal impairment": "risk of ototoxicity and peripheral neuropathy with isoniazid;\r\nprophylactic pyridoxine recommended, seenotes above", "cautions": "see Monitoring innotes above; also\r\nliver function tests and blood counts in hepatic disorders, alcohol dependence, and on prolonged therapy (see also below); slow acetylator status (increased risk of side-effects); epilepsy; history of psychosis; alcohol dependence, malnutrition, diabetes mellitus, HIV\r\ninfection (risk of peripheral neuritis); acute porphyria (section9.8.2);important:effectiveness of hormonal contraceptives is reduced and alternative\r\nfamily planning advice should be offered (see also section7.3.1); discolours soft contact lenses; see also notes above;interactions:Appendix 1 (rifamycins, isoniazid)", "side-effects": "gastro-intestinal symptoms including anorexia,\r\nnausea, vomiting, constipation, diarrhoea (antibiotic-associated colitis\r\nreported), alterations in liver function, jaundice, hepatitis (especially\r\nover age of 35 years); peripheral neuritis with high doses (pyridoxine\r\nprophylaxis, see notes above), optic neuritis, headache, drowsiness,\r\nconvulsions, psychotic episodes, vertigo; blood disorders (including\r\nleucopenia, haemolytic anaemia, aplastic anaemia, eosinophilia); dry\r\nmouth; flushing, urticaria, rash (including erythema multiforme),\r\npurpura; also reported pancreatitis, oedema, interstitial pneumonitis,\r\npsychoses, hyperreflexia, hyperglycaemia, adrenal insufficiency, gynaecomastia,\r\nmenstrual disturbances, difficulty with micturition, muscular weakness,\r\nmyopathy, systemic lupus erythematosus-like syndrome, pellagra, exfoliative\r\ndermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome,\r\nand pemphigoid reactions; urine, saliva, and other body secretions\r\ncoloured orange-red; hearing loss and tinnitus (in patients with end\r\nstage renal impairment); those occurring mainly on intermittent therapy\r\ninclude influenza-like symptoms (with chills, fever, dizziness, bone\r\npain), respiratory symptoms (including shortness of breath), collapse\r\nand shock,  haemolytic anaemia, thrombocytopenic purpura, disseminated\r\nintravascular coagulation, and acute renal failure; when used with\r\ntyramine or histamine rich foods, tachycardia, palpitation, hypotension,\r\nflushing, headache, dizziness, and sweating also reported", "contra-indications": "jaundice; drug-induced liver disease; rifamycin hypersensitivity", "hepatic impairment": "impaired elimination; avoid or do not exceed rifampicin\r\n8\u00a0mg/kg daily; monitor liver function regularly and particularly frequently\r\nin first 2 months; see also Cautions above", "doses": ["adult50\u00a0kg and over, 2\r\ntablets daily, preferably before breakfast"], "pregnancy": "seePregnancy; isoniazid\r\nnot known to be harmful, but prophylactic pyridoxine recommended;\r\nmanufacturers advise very high doses of rifampicin teratogenic inanimalstudies in first trimester; risk of neonatal bleeding\r\nmay be increased by rifampicin in third trimester", "breast-feeding": "seeBreast-feeding; monitor\r\ninfant for possible isoniazid toxicity; theoretical risk of convulsions\r\nand neuropathy; prophylactic pyridoxine advisable in mother. Amount\r\nof rifampicin too small to be harmful"}, "OLMESARTAN MEDOXOMIL": {"indications": "hypertension (see also notes above)", "name": "OLMESARTAN MEDOXOMIL", "renal impairment": "max. 20\u00a0mg daily if eGFR 20\u201360\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; also gastro-intestinal disturbances;\r\nchest pain, peripheral oedema, hypertriglyceridaemia; fatigue; influenza-like\r\nsymptoms, cough, pharyngitis, rhinitis; urinary-tract infection; haematuria,\r\nhyperuricaemia; arthritis, musculoskeletal pain;less commonlyangina, vertigo, rash;very rarelyheadache, thrombocytopenia,\r\nmyalgia, pruritus, urticaria", "contra-indications": "biliary obstruction", "hepatic impairment": "dose should not exceed 20\u00a0mg daily in moderate impairment;\r\nmanufacturer advises avoid in severe impairment\u2014no information available", "doses": ["Initially 10\u00a0mg once daily; if necessary increased to\r\n20\u00a0mg once daily; max. 40\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ETORICOXIB": {"indications": "pain and inflammation in osteoarthritis, rheumatoid arthritis, and\r\nankylosing spondylitis; acute gout", "name": "ETORICOXIB", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; see alsonotes above", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  ethinylestradiol increased by etoricoxib ", "name": "Etoricoxib", "backrefs": ["Etoricoxib"]}, "cautions": "seenotes above; also dehydration; monitor blood pressure before\r\ntreatment, 2 weeks after initiation and periodically during treatment", "side-effects": "seenotes above; also palpitation, fatigue, influenza-like\r\nsymptoms, ecchymosis;less commonlydry mouth, taste\r\ndisturbance, mouth ulcer, appetite and weight change, atrial fibrillation,\r\ntransient ischaemic attack, chest pain, flushing, cough, dyspnoea,\r\nepistaxis, anxiety, mental acuity impaired, paraesthesia, electrolyte\r\ndisturbance, myalgia and arthralgia;very rarelyconfusion\r\nand hallucinations", "contra-indications": "seenotes above; inflammatory bowel disease; uncontrolled hypertension\r\n(persistently above 140/90\u00a0mmHg)", "hepatic impairment": "max. 60\u00a0mg daily in mild impairment; max. 60\u00a0mg on\r\nalternate days or 30\u00a0mg once daily in moderate impairment; see alsonotes above", "doses": ["Osteoarthritis,adultandchildover 16 years, 30\u00a0mg once daily, increased\r\nif necessary to 60\u00a0mg once daily", "Rheumatoid arthritis and ankylosing spondylitis,adultandchildover\r\n16 years, 90\u00a0mg once daily", "Acute gout,adultandchildover 16 years, 120\u00a0mg once daily for max. 8\r\ndays"], "pregnancy": "manufacturer advises avoid (teratogenic inanimalstudies); see alsonotes above", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies; see alsonotes above"}, "ISOPHANE INSULIN": {"indications": "diabetes mellitus", "name": "ISOPHANE INSULIN", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin(section 6.1.1.1);\r\nprotamine may cause allergic reactions", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection, according to\r\nrequirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "CO-PHENOTROPE": {"indications": "adjunct to rehydration in acute diarrhoea\r\n(but see notes above); control of faecal consistency after colostomy\r\nor ileostomy (section 1.8)", "name": "CO-PHENOTROPE", "renal impairment": "section 4.7.2", "cautions": "section 4.7.2; also young children are particularly susceptible tooverdosageand symptoms may be delayed and observation is needed for at least\r\n48 hours after ingestion; presence of subclinical\r\ndoses of atropine may give rise to atropine side-effects in susceptible\r\nindividuals or in overdosage (section 1.2);interactions:Appendix 1 (antimuscarinics, opioidanalgesics)", "side-effects": "section 4.7.2and\r\nalso see under Antimuscarinics (section 1.2); also\r\nabdominal pain, anorexia, and fever", "contra-indications": "section 4.7.2and\r\nalso see under Antimuscarinics (section 1.2)", "hepatic impairment": "section 4.7.2; also\r\navoid in jaundice", "doses": ["See preparations"], "pregnancy": "section 4.7.2and\r\nalso see under Atropine Sulphate (section 1.2)", "breast-feeding": "may be present in milk"}, "BIPHASIC INSULIN ASPART": {"indications": "diabetes mellitus", "name": "BIPHASIC INSULIN ASPART", "renal impairment": "section 6.1.1", "cautions": "seesection 6.1.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see under Insulin (section 6.1.1.1);\r\nprotamine may cause allergic reactions", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection, up to 10 minutes\r\nbefore or soon after a meal, according to requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "REBOXETINE": {"indications": "major depression", "name": "REBOXETINE", "renal impairment": "initial dose 2\u00a0mg twice daily, increased according to\r\ntolerance", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  triazoles advised by manufacturer of reboxetine ", "name": "Reboxetine", "backrefs": ["Reboxetine"]}, "cautions": "history of cardiovascular disease and epilepsy; bipolar disorder; urinary retention; prostatic\r\nhypertrophy; susceptibility to angle-closure\r\nglaucoma; avoid abrupt withdrawal;interactions:Appendix 1 (reboxetine)", "side-effects": "nausea, dry mouth, constipation, anorexia; tachycardia,\r\npalpitation, vasodilation, postural hypotension; headache, insomnia,\r\ndizziness; chills; impotence; urinary retention; impaired visual accommodation;\r\nsweating; lowering of plasma-potassium concentration on prolonged\r\nadministration in the elderly;very rarelyangle-closure\r\nglaucoma;also reportedvomiting, hypertension, paraesthesia,\r\nagitation, anxiety, irritability, hallucinations, aggression, Raynaud\u2019s\r\nsyndrome, hyponatraemia, testicular pain, cold extremities,\r\nand rash; suicidal behaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy)", "hepatic impairment": "initial dose 2\u00a0mg twice daily, increased according\r\nto tolerance", "doses": ["4\u00a0mg twice daily increased if necessary after 3\u20134 weeks\r\nto 10\u00a0mg daily in divided doses, max. 12\u00a0mg daily;childunder 18 years andelderlynot recommended"], "pregnancy": "use only if potential benefit outweighs risk\u2014limited\r\ninformation available", "breast-feeding": "small amount present in milk\u2014use only if potential\r\nbenefit outweighs risk"}, "ADEFOVIR": {"interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  tenofovir advises avoid concomitant use with adefovir ", "name": "Adefovir", "backrefs": ["Adefovir", "Tenofovir"]}}, "NAPROXEN": {"indications": "pain and inflammation in rheumatic disease (including\r\njuvenile idiopathic arthritis) and other musculoskeletal disorders;\r\ndysmenorrhoea; acute gout", "name": "NAPROXEN", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": " probenecid reduces excretion of naproxen (increased plasma concentration)", "name": "Naproxen", "backrefs": ["Naproxen"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["patients requiringnaproxenfor rheumatoid\r\narthritis, osteoarthritis, or ankylosing spondylitis, with prophylaxis\r\nagainst NSAID-induced gastroduodenal ulceration, 1naproxen500-mg tablet and 1misoprostol200-microgram\r\ntablet taken together twice daily with food;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful but manufacturer\r\nadvises avoid; see alsonotes above"}, "STERCULIA": {"indications": "see notes above", "name": "STERCULIA", "cautions": "see underIspaghulaHusk", "side-effects": "see underIspaghulaHusk", "contra-indications": "see underIspaghulaHusk", "doses": ["constipation and after haemorrhoidectomy, 1\u20132 heaped 5-mL\r\nspoonfulsorthe contents of 1\u20132 sachets washed down\r\nwithout chewing with plenty of liquid once or twice daily after meals;child6\u201312 years seeBNF for Children"]}, "VENLAFAXINE": {"indications": "major depression, generalised anxiety disorder", "name": "VENLAFAXINE", "renal impairment": "use with caution; use half normal dose (immediate-release\r\ntablets may be given once daily) if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  5HT1 agonists given with venlafaxine ", "name": "Venlafaxine", "backrefs": ["Venlafaxine"]}, "cautions": "heart disease (monitor\r\nblood pressure); diabetes; history of epilepsy; history or family history\r\nof mania; susceptibility to angle-closure glaucoma; concomitant use of drugs that increase risk of bleeding, history of bleeding disorders;interactions:Appendix 1 (venlafaxine)", "side-effects": "constipation, nausea, anorexia, weight changes,\r\nvomiting; hypertension, palpitation, vasodilatation, changes in serum\r\ncholesterol; chills, yawning; dizziness, dry mouth, insomnia, nervousness,\r\ndrowsiness, asthenia, headache, abnormal dreams, anxiety, confusion,\r\nhypertonia, sensory disturbances, tremor; difficulty with micturition,\r\nsexual dysfunction, menstrual disturbances; visual disturbances, mydriasis\r\n(very rarelyangle-closure glaucoma); sweating;less commonlybruxism, diarrhoea, taste disturbance, postural\r\nhypotension, arrhythmias, agitation, apathy, incoordination, hallucinations,\r\nmyoclonus, angioedema, urinary retention, bleeding disorders (including\r\necchymosis and gastro-intestinal haemorrhage), tinnitus, alopecia,\r\nphotosensitivity, and rash;rarelymania, hypomania,\r\nseizures, extrapyramidal symptoms including akathisia, urinary incontinence;also reportedhepatitis, pancreatitis, hypotension, QT-interval\r\nprolongation, aggression, neuroleptic malignant syndrome, delirium,\r\nvertigo, syndrome of inappropriate anti-diuretic hormone secretion\r\n(seeHyponatraemia and Antidepressant\r\nTherapy),\r\nhyperprolactinaemia, blood dyscrasias, rhabdomyolysis, pruritus, urticaria,\r\nStevens-Johnson syndrome; suicidal behaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy)", "contra-indications": "conditions associated with high\r\nrisk of cardiac arrhythmia, uncontrolled hypertension", "hepatic impairment": "consider reducing dose by 50% in mild or moderate impairment;\r\nuse with caution and reduce dose by at least 50% in severe impairment", "doses": ["depression,adultover\r\n18 years, 75\u00a0mg once daily, increased if necessary at intervals of\r\nat least 2 weeks; max. 375\u00a0mg once daily;childunder 18 years not recommended (seeDepressive Illness in Children\r\nand Adolescents)", "Faster dose titration may be necessary in\r\nsome patients"], "pregnancy": "avoid unless potential benefit outweighs risk\u2014toxicity\r\ninanimalstudies; risk of withdrawal effects in\r\nneonate", "breast-feeding": "present in milk\u2014avoid"}, "FLUOXETINE": {"indications": "see under Dose", "name": "FLUOXETINE", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  mirtazapine given with fluoxetine ", "name": "Fluoxetine", "backrefs": ["Fluoxetine"]}, "cautions": "seenotes above", "side-effects": "seenotes above; also diarrhoea, dysphagia, vasodilatation,\r\nhypotension, flushing, palpitation, pharyngitis, dyspnoea, chills,\r\ntaste disturbance, sleep disturbances, malaise, euphoria, confusion,\r\nyawning, impaired concentration, changes in blood sugar, alopecia,\r\nurinary frequency; haemorrhage, pulmonary inflammation and fibrosis,\r\nhepatitis, toxic epidermal necrolysis, priapism, and neuroleptic malignant\r\nsyndrome-like event also reported", "contra-indications": "seenotes above", "hepatic impairment": "reduce dose or increase dose interval", "doses": ["Major depression, 20\u00a0mg daily increased after 3\u20134 weeks\r\nif necessary, and at appropriate intervals thereafter; max. 60\u00a0mg\r\ndaily (elderlyusual max. 40\u00a0mg daily\r\nbut 60\u00a0mg can be used);child8\u201318\r\nyears, 10\u00a0mg daily increased after 1\u20132 weeks if necessary, max. 20\u00a0mg\r\ndaily (but see alsoDepressive Illness in Children\r\nand Adolescents)", "Daily dose may be administered as a single\r\nor divided dose", "Bulimia nervosa,adultover 18\r\nyears, 60\u00a0mg daily as a single or divided dose", "Obsessive-compulsive disorder,adultover 18 years, 20\u00a0mg daily; increased gradually if necessary to\r\nmax. 60\u00a0mg daily (elderlyusual max.\r\n40\u00a0mg daily but 60\u00a0mg can be used); review treatment if inadequate\r\nresponse after 10 weeks", "Daily dose may be administered as a single\r\nor divided dose", "Consider\r\nthe long half-life offluoxetinewhen adjusting\r\ndosage (or in overdosage)"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014avoid"}, "DILOXANIDE FUROATE": {"indications": "see notes above; chronic amoebiasis and as adjunct\r\ntometronidazoleortinidazolein acute amoebiasis", "name": "DILOXANIDE FUROATE", "side-effects": "flatulence, vomiting, urticaria, pruritus", "doses": ["500\u00a0mg every 8 hours for 10 days;childbody-weight over 25\u00a0kg, 20\u00a0mg/kg daily in 3\r\ndivided doses for 10 days; body-weight under 25\u00a0kg, seeBNF for Children", "See also notes above"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid"}, "MEGESTROL ACETATE": {"indications": "seenotes above", "name": "MEGESTROL ACETATE", "cautions": "see underMedroxyprogesterone acetate(section\r\n6.4.1.2) andnotes above;interactions:Appendix 1 (progestogens)", "side-effects": "see underMedroxyprogesterone acetate(section\r\n6.4.1.2) andnotes above;also reportedvomiting, carpal tunnel syndrome, Cushing\u2019s syndrome, and tumour\r\nflare (with or without hypercalcaemia)", "contra-indications": "see underMedroxyprogesterone acetate(section\r\n6.4.1.2) andnotes above", "hepatic impairment": "avoid", "doses": ["Breast cancer, 160\u00a0mg once daily"], "pregnancy": "avoid; reversible feminisation of male fetuses reported\r\ninanimalstudies; risk of hypospadias in male fetuses\r\nand masculinisation of female fetuses", "breast-feeding": "discontinue breast-feeding"}, "HYDROCORTISONE": {"indications": "mild inflammatory skin disorders such as eczemas\r\n(but for over-the-counter preparations, see below); nappy rash (see\r\nalsosection 13.2.2)", "name": "HYDROCORTISONE", "cautions": "seenotes above", "side-effects": "see notes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily"]}, "ALPHA TOCOPHEROL": {"indications": "vitamin E deficiency because of malabsorption\r\nin congenital or hereditary chronic cholestasis", "name": "ALPHA TOCOPHEROL", "renal impairment": "manufacturer advises caution and monitor closely; risk\r\nof renal toxicity due to polyethylene glycol content", "cautions": "predisposition to thrombosis;interactions:Appendix 1 (Vitamin E)", "side-effects": "diarrhoea;less commonlyasthenia,\r\nheadache, disturbances in serum-potassium and serum-sodium concentrations,\r\nalopecia, pruritus, and rash", "contra-indications": "preterm neonates", "hepatic impairment": "manufacturer advises caution and monitor closely\u2014no\r\ninformation available", "doses": ["childunder 18 years, 17\u00a0mg/kg\r\ndaily, adjusted as necessary"], "pregnancy": "manufacturer advises caution, no evidence of harm\r\ninanimalstudies", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available"}, "METYRAPONE": {"indications": "see notes above and under Dose (specialist supervision in hospital)", "name": "METYRAPONE", "cautions": "gross hypopituitarism (risk of precipitating\r\nacute adrenal failure); hypertension on\r\nlong-term administration; hypothyroidism\r\n(delayed response); many drugs\r\ninterfere with diagnostic estimation of steroids; avoid in acute porphyria (section 9.8.2)", "side-effects": "occasional nausea, vomiting, dizziness, headache,\r\nhypotension, sedation; rarely abdominal pain, allergic skin reactions,\r\nhypoadrenalism, hirsutism", "contra-indications": "adrenocortical insufficiency (see Cautions)", "hepatic impairment": "use with caution in hepatic impairment (delayed response)", "doses": ["Differential diagnosis of ACTH-dependent Cushing\u2019s syndrome,\r\n750\u00a0mg every 4 hours for 6 doses;child15\u00a0mg/kg (minimum 250\u00a0mg) every 4 hours for 6 doses", "Management of Cushing\u2019s syndrome, range 0.25\u20136\u00a0g daily, tailored\r\nto cortisol production; see notes above", "Resistant oedema due to increased aldosterone secretion in cirrhosis,\r\nnephrotic syndrome, and congestive heart failure (with glucocorticoid\r\nreplacement therapy) 3\u00a0g daily in divided doses"], "pregnancy": "avoid (may impair biosynthesis of fetal-placental\r\nsteroids)", "breast-feeding": "avoid\u2014no information available"}, "LEFLUNOMIDE": {"indications": "(specialist use only) moderate to severe\r\nactive rheumatoid arthritis; active psoriatic arthritis", "name": "LEFLUNOMIDE", "renal impairment": "manufacturer advises avoid in moderate or severe impairment\u2014no\r\ninformation available", "interactions": {"extra": "Increased risk of toxicity with other haematotoxic and hepatotoxic drugs", "bad": 0, "interaction": "anticoagulant effect of  warfarin possibly enhanced by leflunomide ", "name": "Leflunomide", "backrefs": ["Leflunomide"]}, "cautions": "impaired bone-marrow function including anaemia,\r\nleucopenia or thrombocytopenia (avoid if significant and due to causes\r\nother than rheumatoid arthritis); recent treatment with other hepatotoxic\r\nor myelotoxic disease-modifying antirheumatic drugs; washout procedures\r\nrecommended for serious adverse effects or before switching to other\r\ndisease-modifying antirheumatic drugs (consult product literature\r\nand see Washout Procedure, below); history of tuberculosis; exclude pregnancy before treatment; effective contraceptionessentialduring treatment and for at least 2 years after\r\ntreatment in women and at least 3 months after treatment in men (plasma\r\nconcentration monitoring required; waiting time before conception\r\nmay be reduced with washout procedure\u2014consult product literature and\r\nsee Washout Procedure, below); monitor full blood count (including differential white\r\ncell count and platelet count) before treatment and every 2 weeks\r\nfor 6 months then every 8 weeks; monitor\r\nliver function\u2014see Hepatotoxicity, below; monitor blood pressure;interactions:Appendix 1 (leflunomide)", "side-effects": "diarrhoea, nausea, vomiting, anorexia, oral mucosal\r\ndisorders, abdominal pain; increased blood pressure; headache, dizziness,\r\nasthenia, paraesthesia; leucopenia; tenosynovitis; alopecia, rash,\r\ndry skin, pruritus;less commonlytaste disturbance,\r\nanxiety, hyperlipidaemia, hypokalaemia, hypophosphataemia, anaemia,\r\nthrombocytopenia, and tendon rupture;rarelyhepatitis,\r\njaundice (see Hepatotoxicity, above), interstitial lung disease, severe\r\ninfection, eosinophilia, and pancytopenia;very rarelypancreatitis, hepatic failure (see Hepatotoxicity, above), peripheral\r\nneuropathy, vasculitis, progressive multifocal leucoencephalopathy,\r\nStevens-Johnson syndrome, and toxic epidermal necrolysis; hypouricaemia,\r\nreduced sperm count, and renal failure also reported;important:discontinue treatment and institute washout procedure (see Washout\r\nProcedure under Cautions) in case of serious side-effect", "contra-indications": "severe immunodeficiency; severe hypoproteinaemia; serious\r\ninfection", "hepatic impairment": "avoid\u2014active metabolite may accumulate; see also Cautions\r\nabove", "doses": ["Rheumatoid arthritis,adultover 18 years, initially 100\u00a0mg once daily for 3 days, then 10\u201320\u00a0mg\r\nonce daily", "Psoriatic arthritis,adultover\r\n18 years, initially 100\u00a0mg once daily for 3 days, then 20\u00a0mg once\r\ndaily"], "pregnancy": "avoid\u2014active metabolite teratogenic inanimalstudies; effective contraception essential during treatment and\r\nfor at least 2 years after treatment in women and at least 3 months\r\nafter treatment in men (see also Cautions above)", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid"}, "SOTALOL": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  saquinavir given with sotalol\u2014avoid concomitant use", "name": "Sotalol", "backrefs": ["Sotalol"]}}, "PIPOTIAZINE PALMITATE": {"indications": "maintenance in schizophrenia and other psychoses", "name": "PIPOTIAZINE PALMITATE", "renal impairment": "seesection 4.2.1", "cautions": "seesection 4.2.1andnotes above; also thyrotoxicosis; hypothyroidism", "side-effects": "seesection 4.2.1andnotes above", "contra-indications": "seesection 4.2.1andnotes above", "hepatic impairment": "seesection 4.2.1", "doses": ["By deep intramuscular injectioninto the\r\ngluteal muscle, test dose 25\u00a0mg, then a further 25\u201350\u00a0mg after 4\u20137\r\ndays, then adjusted according to response at intervals of 4 weeks;\r\nusual maintenance range 50\u2013100\u00a0mg (max. 200\u00a0mg) every 4 weeks;elderlyinitially 5\u201310\u00a0mg;childnot recommended"], "pregnancy": "seesection 4.2.1", "breast-feeding": "avoid unless essential"}, "BUDESONIDE WITH FORMOTEROL FUMARATE": {"indications": "see under preparations (see alsoManagement of Chronic Asthma\r\ntable)", "name": "BUDESONIDE WITH FORMOTEROL FUMARATE", "cautions": "seesection 3.1.1.1and\r\nCautions of Inhaled Corticosteroids (section 3.2)", "side-effects": "see Formoterol (section 3.1.1.1) and Side-effects of Inhaled\r\nCorticosteroids (section 3.2)", "doses": ["by inhalation of powder, asthma maintenance\r\ntherapy, 1 puff twice daily increased if necessary to max. 2 puffs\r\ntwice daily, reduced to 1 puff once daily if control maintained;child12\u201317 years 1 puff twice daily reduced to 1\r\npuff once daily if control maintained"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "IDARUBICIN": {"interactions": {"extra": "", "bad": 1, "interaction": " ciclosporin increases plasma concentration of idarubicin ", "name": "Idarubicin", "backrefs": ["Idarubicin"]}}, "POLYMYXIN B SULPHATE": {"side-effects": "local irritation and dermatitis", "indications": "seenotes above", "name": "POLYMYXIN B SULPHATE", "doses": ["SeeAdministrationin\r\nnotes above"]}, "HEPATITIS A VACCINE": {"indications": "immunisation against hepatitis A infection", "name": "HEPATITIS A VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1; for\r\ncombination vaccines, see alsoTyphoid vaccine", "contra-indications": "seesection 14.1", "doses": ["by intramuscular injection(see note below),adultandchildover\r\n15 years, 1\u00a0mL as a single dose; booster doses, see under single componenthepatitis A vaccine(above) and under polysaccharidetyphoid vaccine"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "KAOLIN, LIGHT": {"indications": "diarrhoea but see notes above", "name": "KAOLIN, LIGHT", "cautions": "interactions:Appendix 1 (kaolin)", "doses": ["10\u201320\u00a0mL every 4 hours"]}, "EXENATIDE": {"indications": "seenotes above", "name": "EXENATIDE", "renal impairment": "forstandard-releaseinjection, use with\r\ncaution if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR\r\nless than 30\u00a0mL/minute/1.73m2", "interactions": {"extra": "Other oral drugs may be taken at least 1 hour before or 4 hours after exenatide injection, or taken with a meal when exenatide is not administered, to minimise possible interference with absorption", "bad": 0, "interaction": "anticoagulant effect of  warfarin possibly enhanced by exenatide ", "name": "Exenatide", "backrefs": ["Exenatide"]}, "cautions": "elderly; pancreatitis (see below); may cause weight loss greater than 1.5\u00a0kg weekly;interactions:Appendix 1 (antidiabetics)", "side-effects": "gastro-intestinal disturbances including nausea,\r\nvomiting, diarrhoea, dyspepsia, abdominal pain and distension, gastro-oesophageal\r\nreflux disease, decreased appetite, weight loss, headache, dizziness,\r\nagitation, asthenia, hypoglycaemia, increased sweating, injection-site\r\nreactions, antibody formation;less commonlypancreatitis\r\n(see Cautions above);rarelyalopecia;very\r\nrarelyanaphylactic reactions; also reported constipation,\r\nflatulence, eructation, dehydration, taste disturbance, renal impairment,\r\ndrowsiness, rash, pruritus, urticaria, and angioedema", "contra-indications": "ketoacidosis; severe gastro-intestinal disease", "doses": ["by subcutaneous injection,adultover 18 years, 2\u00a0mg once weekly"], "pregnancy": "avoid\u2014toxicity inanimalstudies.\r\nWomen of child-bearing age should use effective contraception during\r\ntreatment with modified-release exenatide and for 12 weeks after discontinuation", "breast-feeding": "avoid\u2014no information available"}, "TROSPIUM CHLORIDE": {"indications": "urinary frequency, urgency and incontinence", "name": "TROSPIUM CHLORIDE", "renal impairment": "use with caution; reduce dose to 20\u00a0mg once daily or\r\n20\u00a0mg on alternate days if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; avoidRegurin\u00aeXL", "cautions": "seenotes above", "side-effects": "seenotes above;rarelychest pain, dyspnoea, and asthenia;very\r\nrarelymyalgia and arthralgia", "contra-indications": "seenotes above", "hepatic impairment": "manufacturer advises caution in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["adultandchildover 12 years, 20\u00a0mg twice daily before food"], "pregnancy": "manufacturer advises caution", "breast-feeding": "manufacturer advises caution"}, "ETANERCEPT": {"indications": "see notes above; ankylosing spondylitis,\r\npsoriatic arthritis, polyarticular course juvenile idiopathic arthritis,\r\nrheumatoid arthritis (section 10.1.3)", "name": "ETANERCEPT", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  anakinra with etanercept ", "name": "Etanercept", "backrefs": ["Etanercept"]}, "cautions": "section 10.1.3", "side-effects": "section 10.1.3", "contra-indications": "section 10.1.3", "hepatic impairment": "section 10.1.3", "doses": ["By subcutaneous injection, plaque psoriasis,\r\n25\u00a0mg twice weekly or 50\u00a0mg once weekly for up to 24 weeks; discontinue\r\nif no response after 12 weeks;child6\u201318 years, 800\u00a0micrograms/kg (max. 50\u00a0mg) once weekly for up to\r\n24 weeks; discontinue if no response after 12 weeks"], "pregnancy": "section 10.1.3", "breast-feeding": "section 10.1.3"}, "TOBRAMYCIN": {"indications": "see underGentamicinand notes above", "name": "TOBRAMYCIN", "renal impairment": "seenotes above", "cautions": "seenotes above;interactions:Appendix 1 (aminoglycosides)", "side-effects": "seenotes above;on inhalation, cough (more frequent by inhalation of powder),\r\nbronchospasm (see Cautions), dysphonia, taste disturbances, pharyngitis,\r\nmouth ulcers, salivary hypersecretion, laryngitis, haemoptysis, epistaxis", "contra-indications": "seenotes above", "doses": ["To avoid excessive dosage in obese patients, use ideal\r\nweight for height to calculate parenteral dose and monitor serum-tobramycin\r\nconcentration closely", "By intramuscular injectionorby slow intravenous injectionorby intravenous infusion, 3\u00a0mg/kg daily in divided\r\ndoses every 8 hours, see also notes above; in severe infections up\r\nto 5\u00a0mg/kg daily in divided doses every 6\u20138 hours (reduced to 3\u00a0mg/kg\r\nas soon as clinically indicated);childunder 18 years seeBNF for Children", "Urinary-tract infection,by intramuscular injection, 2\u20133\u00a0mg/kg daily as a single dose", "One-hour (\u2018peak\u2019) serum concentration should\r\nnot exceed 10\u00a0mg/litre; pre-dose (\u2018trough\u2019) concentration should be\r\nless than 2\u00a0mg/litre", "Chronic pulmonaryPseudomonas aeruginosainfection in patients with cystic fibrosis,by inhalation\r\nof nebulised solution,adultandchildover 6 years, 300\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin nebuliser solution", "By inhalation of powder,adultandchildover 6 years, 112\u00a0mg every\r\n12 hours for 28 days, subsequent courses repeated after 28-day interval\r\nwithout tobramycin inhalation powder"], "pregnancy": "seenotes above"}, "ICATIBANT": {"indications": "acute attacks of hereditary angioedema\r\nin patients with C1-esterase inhibitor deficiency", "name": "ICATIBANT", "cautions": "ischaemic heart disease, stroke", "side-effects": "dizziness, headache, injection-site reactions,\r\nrash, pruritus, erythema", "doses": ["By subcutaneous injection,adultover 18 years, 30\u00a0mg as a single dose, repeated\r\nafter 6 hours if necessary; a third dose may be given after a further\r\n6 hours (max. 3 doses in 24 hours)"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid for 12 hours after\r\nadministration"}, "THYMOL": {"indications": "oral hygiene, seenotes above", "name": "THYMOL", "doses": ["dissolve 1 tablet in a tumblerful of warm water"]}, "THIAMINE": {"indications": "see notes above", "cautions": "anaphylaxis may occasionally follow injection (see MHRA/CHM advice below)", "name": "THIAMINE", "breast-feeding": "severely thiamine-deficient mothers should avoid\r\nbreast-feeding as toxic methyl-glyoxal present in milk", "doses": ["see MHRA/CHM advice above"]}, "ENFUVIRTIDE": {"indications": "HIV infection in combination with other antiretroviral drugs for resistant infection or for patients intolerant\r\nto other antiretroviral regimens", "name": "ENFUVIRTIDE", "cautions": "Hypersensitivity\r\nreactions including rash, fever, nausea, vomiting, chills, rigors,\r\nlow blood pressure, respiratory distress, glomerulonephritis, and\r\nraised liver enzymes reported; discontinue\r\nimmediately if any signs or symptoms of systemic hypersensitivity\r\ndevelop and do not rechallenge", "side-effects": "injection-site reactions; pancreatitis, gastro-oesophageal\r\nreflux disease, anorexia, weight loss; hypertriglyceridaemia; peripheral\r\nneuropathy, asthenia, tremor, anxiety, nightmares, irritability, impaired\r\nconcentration, vertigo; pneumonia, sinusitis, influenza-like illness;\r\ndiabetes mellitus; haematuria; renal calculi, lymphadenopathy; myalgia;\r\nconjunctivitis; dry skin, acne, erythema, skin papilloma;less commonlyhypersensitivity reactions (see Cautions);\r\nsee alsoOsteonecrosis", "hepatic impairment": "manufacturer advises caution\u2014no information available;\r\nchronic hepatitis B or C (possibly greater risk of hepatic side-effects)", "doses": ["By subcutaneous injection, 90\u00a0mg twice\r\ndaily;child6\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "seeBreast-feeding"}, "BELATACEPT": {"indications": "see notes above", "name": "BELATACEPT", "cautions": "increased risk of infection; risk factors for post-transplant\r\nlymphoproliferative disorder; avoid excessive exposure to UV light\r\nincluding sunlight", "side-effects": "(reported when used in combination with basiliximab,\r\nmycophenolate mofetil and corticosteroids) diarrhoea, constipation,\r\nnausea, vomiting, hypertension, peripheral oedema, cough, headache,\r\npyrexia, infection, malignancy, anaemia, leucopenia, dehydration,\r\nhypophosphataemia;less commonlyinfusion related\r\nreactions, progressive multifocal leukoencephalopathy", "doses": ["Consult product literature"], "pregnancy": "use only if essential; adequate contraception must\r\nbe used during treatment and for up to 8 weeks after last dose", "breast-feeding": "avoid\u2014no information available"}, "BILASTINE": {"indications": "symptomatic relief of allergic rhinoconjunctivitis and urticaria", "name": "BILASTINE", "interactions": {"extra": "", "bad": 0, "interaction": " grapefruit juice reduces plasma concentration of bilastine ", "name": "Bilastine", "backrefs": ["Bilastine"]}, "cautions": "seenotes above", "side-effects": "headache, malaise;less commonlyabdominal pain, diarrhoea, increased appetite, weight gain, thirst,\r\ngastritis, prolongation of the QT interval, dyspnoea, anxiety, insomnia,\r\nvertigo, dizziness, pyrexia, oral herpes, tinnitus", "contra-indications": "seenotes above", "doses": ["adultandchildover 12 years, 20\u00a0mg once daily", "Advise patient to take tablet 1 hour\r\nbefore or 2 hours after food or fruit juice"], "pregnancy": "avoid\u2014limited information available; see alsonotes above", "breast-feeding": "avoid\u2014no information available; see alsonotes above"}, "INDORAMIN": {"indications": "hypertension (see notes above); benign\r\nprostatic hyperplasia (section 7.4.1)", "name": "INDORAMIN", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  MAOIs advised by manufacturer of indoramin ", "name": "Indoramin", "backrefs": ["Indoramin"]}, "cautions": "avoidalcohol(enhances rate and\r\nextent of absorption); control incipient\r\nheart failure before initiating indoramin;elderly;Parkinson\u2019s disease (extrapyramidal\r\ndisorders reported); epilepsy (convulsions inanimalstudies); history\r\nof depression; cataract surgery (risk of\r\nintra-operative floppy iris syndrome);interactions:Appendix 1 (alpha-blockers)", "side-effects": "seesection 7.4.1; also\r\nsedation;less commonlyfatigue, weight gain, failure\r\nof ejaculation; also reported extrapyramidal disorders, urinary frequency, and incontinence", "contra-indications": "established\r\nheart failure", "hepatic impairment": "manufacturer advises caution", "doses": ["Hypertension, initially 25\u00a0mg twice daily, increased by\r\n25\u201350\u00a0mg daily at intervals of 2 weeks; max. daily dose 200\u00a0mg in\r\n2\u20133 divided doses"], "pregnancy": "no evidence of teratogenicity; manufacturers advise\r\nuse only when potential benefit outweighs risk", "breast-feeding": "no information available"}, "COMBINED HORMONAL CONTRACEPTIVES": {"indications": "contraception; menstrual\r\nsymptoms (section\r\n6.4.1.2)", "name": "COMBINED HORMONAL CONTRACEPTIVES", "cautions": "seenotes above; risk factors for venous thromboembolism (see below\r\nand alsonotes above), arterial\r\ndisease and migraine, see below; personal or family history of hypertriglyceridaemia\r\n(increased risk of pancreatitis); hyperprolactinaemia\r\n(seek specialist advice); history of severe\r\ndepression especially if induced by hormonal contraceptive; undiagnosed breast mass; gene mutations associated with breast cancer (e.g.\r\nBRCA 1); sickle-cell disease; inflammatory bowel disease including Crohn\u2019s\r\ndisease; reduced efficacy of contraceptive\r\npatch in women with body-weight \u2265\u00a090\u00a0kg; active trophoblastic disease (until return to normal of urine- and\r\nplasma-gonadotrophin concentration)\u2014seek specialist advice;interactions:see aboveand Appendix 1 (oestrogens, progestogens)", "side-effects": "seenotes above; also nausea,\r\nvomiting, abdominal cramps, liver impairment, hepatic tumours; fluid\r\nretention, thrombosis (more common when factor V Leiden present or\r\nin blood groups A, B, and AB; see also notes above), hypertension,\r\nchanges in lipid metabolism; headache, depression, chorea, nervousness,\r\nirritability; changes in libido, breast tenderness, enlargement, and\r\nsecretion; reduced menstrual loss, \u2018spotting\u2019 in early cycles, absence\r\nof withdrawal bleeding, amenorrhoea after discontinuation, changes\r\nin vaginal discharge, cervical erosion; contact lenses may irritate,\r\nvisual disturbances; leg cramps; skin reactions, chloasma, photosensitivity;\r\nrarely gallstones and systemic lupus erythematosus", "contra-indications": "seenotes above;personal history of venous or arterial thrombosis, severe or multiple risk factors for arterial disease or for venous\r\nthromboembolism (see above), heart disease associated with\r\npulmonary hypertension or risk of embolus; sclerosing treatment for varicose veins; migraine with\r\naura (see alsoabove); transient cerebral ischaemic\r\nattacks without headaches; systemic lupus erythematosus\r\nwith (or unknown) antiphospholipid antibodies; acute porphyria (section 9.8.2); gallstones; history of haemolytic uraemic syndrome or history during\r\npregnancy of pruritus, cholestatic jaundice, chorea, pemphigoid gestationis;\r\nhistory of breast cancer but can be used after 5 years if no evidence\r\nof disease and non-hormonal methods unacceptable; undiagnosed vaginal\r\nbleeding", "hepatic impairment": "avoid in active liver disease including disorders of\r\nhepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective\r\nhepatitis (until liver function returns to normal), and liver tumours", "doses": ["By\r\nmouth, each tablet should be taken at approximately\r\nsame time each day; if delayed, contraceptive protection may be lost\r\n(seemissed pill)", "21-day combined (monophasic) preparations,\r\n1 tablet daily for 21 days; subsequent courses repeated after a 7-day\r\ninterval (during which withdrawal bleeding occurs); if reasonably\r\ncertain woman is not pregnant, first course can be started on any\r\nday of cycle\u2014if starting on day 6 of cycle or later, additional precautions\r\n(barrier methods) necessary during first 7 days", "Every day (ED) combined (monophasic) preparations, 1activetablet daily for 21 days, followed by\r\n1inactivetablet daily for 7 days (see also Combined\r\nOral Contraceptivestable, below); subsequent\r\ncourses repeated without interval (withdrawal bleeding occurs wheninactivetablets being taken); if reasonably certain woman\r\nis not pregnant, first course can be started on any day of cycle\u2014if\r\nstarting on day 6 of cycle or later, additional precautions (barrier\r\nmethods) necessary during first 7 days", "Phasic preparations, see Combined Oral Contraceptivestable, below", "If previous contraceptive used correctly, or pregnancy can reasonably\r\nbe excluded, start the firstactivetablet of new\r\nbrand immediately", "Changing to Qlaira\u00ae: start the firstactive Qlaira\u00aetablet on the day after taking the last\r\nactive tablet of the previous brand", "Changing from Qlaira\u00ae: start the new brand\r\nafter taking the last activeQlaira\u00aetablet; if the\r\ninactive tablets are taken before starting new brand, additional precautions\r\n(barrier methods) should be used during first 7 days of taking the\r\nnew brand", "If previous\r\ncontraceptive used correctly, or pregnancy can reasonably be excluded,\r\nstart new brand immediately, additional precautions (barrier methods)\r\nnecessary for first 7 days", "Changing to Qlaira\u00ae: start any day, additional\r\nprecautions (barrier methods) necessary for first 9 days", "Start\r\nany day, additional precautions (barrier methods) necessary during\r\nfirst 7 days (9 days forQlaira\u00ae)", "Start 3\r\nweeks after birth (increased risk of thrombosis if started earlier);\r\nlater than 3 weeks postpartum additional precautions (barrier methods)\r\nnecessary for first 7 days (9 days forQlaira\u00ae)", "Start same day", "By transdermal application, apply first\r\npatch on day 1 of cycle, change patch on days 8 and 15; remove third\r\npatch on day 22 and apply new patch after 7-day patch-free interval\r\nto start subsequent contraceptive cycle", "If first patch applied later than day 1,\r\nadditional precautions (barrier methods) should be used for the next\r\n7 days", "Apply\r\npatch on the first day of withdrawal bleeding; if no withdrawal bleeding\r\nwithin 5 days of taking lastactivetablet, rule\r\nout pregnancy before applying first patch. Unless patch is applied\r\non first day of withdrawal bleeding, additional precautions (barrier\r\nmethods) should be used concurrently for first 7 days", "From an\r\nimplant, apply first patch on the day implant removed; from an injection,\r\napply first patch when next injection due; from oral progestogen,\r\nfirst patch may be applied on any day after stopping pill. For all\r\nmethods additional precautions (barrier methods) should be used concurrently\r\nfor first 7 days", "Start 4\r\nweeks after birth; if started later than 4 weeks after birth additional\r\nprecautions (barrier methods) should be used for first 7 days", "Before 20 weeks\u2019\r\ngestation start immediately; no additional contraception required\r\nif started immediately. After 20 weeks\u2019 gestation start on day 21\r\nafter abortion or on the first day of first spontaneous menstruation;\r\nadditional precautions (barrier methods) should be used for first\r\n7 days after applying the patch", "By vagina, insert ring into vagina on day 1 of cycle and\r\nleave in for 3 weeks; remove ring on day 22; subsequent courses repeated\r\nafter 7-day ring-free interval (during which withdrawal bleeding occurs)", "If first ring inserted later than day 1,\r\nadditional precautions (barrier methods) should be used for the next\r\n7 days", "Insert ring at the latest on the day after the usual tablet-free,\r\npatch-free, or inactive-tablet interval. If previous contraceptive\r\nused correctly, or pregnancy can reasonably be excluded, can switch\r\nto ring on any day of cycle", "From an\r\nimplant or intra-uterine progestogen-only device, insert ring on the\r\nday implant or intra-uterine progestogen-only device removed; from\r\nan injection, insert ring when next injection due; from oral preparation,\r\nfirst ring may be inserted on any day after stopping pill. For all\r\nmethods additional precautions (barrier methods) should be used concurrently\r\nfor first 7 days", "Start immediately", "Start 4 weeks after birth or abortion; if started later than\r\n4 weeks after birth or abortion, additional precautions (barrier methods)\r\nshould be used for first 7 days"], "pregnancy": "not known to be harmful", "breast-feeding": "avoid until weaning or for 6 months after birth\r\n(adverse effects on lactation)"}, "2.2.4 Potassium-sparing diuretics with other diuretics": {"name": "2.2.4 Potassium-sparing diuretics with other diuretics", "doses": ["hypertension, 1 tablet daily after breakfast, increased\r\nif necessary, max. 4 daily"]}, "PERGOLIDE": {"indications": "alone or as adjunct to co-beneldopa or co-careldopa in Parkinson\u2019s\r\ndisease where dopamine-receptor agonists other than ergot derivative\r\nnot appropriate", "name": "PERGOLIDE", "interactions": {"extra": "", "bad": 0, "interaction": " metoclopramide antagonises antiparkinsonian effect of pergolide ", "name": "Pergolide", "backrefs": ["Pergolide", "Metoclopramide", "Antipsychotics"]}, "cautions": "seenotes above; arrhythmias or underlying cardiac disease; history of confusion, psychosis, or hallucinations, dyskinesia (may exacerbate); acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(pergolide)", "side-effects": "seenotes above; also\r\nnausea, vomiting, dyspepsia, abdominal pain; dyspnoea, rhinitis; hallucinations,\r\ndyskinesia, drowsiness (includingsudden onset of sleep);\r\ndiplopia; also reported constipation, diarrhoea, hiccups, tachycardia,\r\natrial premature contractions, palpitation, hypotension, syncope,\r\nRaynaud\u2019s phenomenon, compulsive behaviour (seenotes above), insomnia,\r\nconfusion, dizziness, fever, erythromelalgia, and rash", "contra-indications": "history of fibrotic disorders; cardiac valvulopathy\r\n(exclude before treatment, seeFibrotic Reactions)", "doses": ["Monotherapy, 50\u00a0micrograms at night on day 1, then\r\n50\u00a0micrograms twice daily on days 2\u20134, then increased by 100\u2013250\u00a0micrograms\r\ndaily every 3\u20134 days to 1.5\u00a0mg daily in 3 divided doses at day 28;\r\nafter day 30, further increases every 3\u20134 days of up to 250\u00a0micrograms\r\ndaily; usual maintenance dose 2.1\u20132.5\u00a0mg daily; max. 3\u00a0mg daily", "Adjunctive therapy withlevodopa, 50\u00a0micrograms daily for 2 days, increased gradually by 100\u2013150\u00a0micrograms\r\nevery 3 days over next 12 days, usually given in 3 divided doses;\r\nfurther increases of 250\u00a0micrograms every 3 days; max. 3\u00a0mg daily", "During pergolide titration levodopa dose\r\nmay be reduced cautiously"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "may suppress lactation"}, "DEXRAZOXANE": {"indications": "seenotes aboveand under\r\npreparations", "name": "DEXRAZOXANE", "renal impairment": "use with caution\u2014risk of accumulation; manufacturer ofCardioxane\u00ae advises reduce dose by 50% if creatinine clearance\r\nless than 40\u00a0mL/minute", "cautions": "seenotes above; monitor full blood count", "side-effects": "nausea, vomiting, dyspepsia, abdominal pain, diarrhoea,\r\nstomatitis, dry mouth, anorexia; dyspnoea; dizziness, syncope, asthenia,\r\nparaesthesia, tremor, fatigue, drowsiness; pyrexia; vaginal haemorrhage;\r\nmyalgia; blood disorders (including anaemia, leucopenia, neutropenia,\r\nthrombocytopenia, and increased myelosuppression); alopecia, pruritus;\r\nperipheral oedema, injection-site reactions including phlebitis;also reportedsecondary malignancies", "hepatic impairment": "monitor liver function", "doses": ["prevention of anthracycline-induced cardiotoxicity,adultover 18 years,by intravenous infusion(30 minutes before anthracycline administration), 10 times the doxorubicin-equivalent\r\ndose or 10 times the epirubicin-equivalent dose"], "pregnancy": "avoid unless essential (toxicity inanimalstudies); ensure effective contraception during and for at least\r\n3 months after treatment in men and women", "breast-feeding": "discontinue breast-feeding"}, "TETRACOSACTIDE": {"indications": "see notes above", "name": "TETRACOSACTIDE", "renal impairment": "seesection 6.3.2", "cautions": "as forcorticosteroids,section 6.3.2;important:risk\r\nof anaphylaxis (medical supervision; consult product literature); history of atopic allergy (e.g. asthma, eczema, hayfever); history of hypersensitivity;interactions:Appendix 1 (corticosteroids)", "side-effects": "as forcorticosteroids,section 6.3.2", "contra-indications": "as forcorticosteroids,section 6.3.2; avoid injections containing benzyl alcohol\r\nin neonates (see under preparations); history\r\nof hypersensitivity to corticotrophins", "hepatic impairment": "seesection 6.3.2", "doses": ["diagnostic (5-hour test),by intramuscular injection, 1\u00a0mg as a single dose"], "pregnancy": "avoid (but may be used diagnostically if essential)", "breast-feeding": "avoid (but may be used diagnostically if essential)"}, "TRAVOPROST": {"indications": "raised intra-ocular pressure in open-angle glaucoma; ocular hypertension", "name": "TRAVOPROST", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nreported hypotension, bradycardia, browache", "doses": ["Apply once daily, preferably in the evening;childunder 18 years, not recommended"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "present in milk inanimalstudies;\r\nmanufacturer advises avoid"}, "HEPARINS": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of bleeding when  NSAIDs given with heparins ", "name": "Heparins", "backrefs": ["Anticoagulants", "Dipyridamole", "Glyceryl Trinitrate", "Heparins"]}}, "AMPHOTERICIN": {"indications": "See under Dose", "name": "AMPHOTERICIN", "renal impairment": "use only if no alternative; nephrotoxicity may be reduced\r\nwith use of lipid formulation", "interactions": {"extra": "Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics", "bad": 0, "interaction": " triazoles possibly antagonise effects of amphotericin ", "name": "Amphotericin", "backrefs": ["Cardiac Glycosides", "Flucytosine", "Polymyxins", "Vancomycin", "Amphotericin"]}, "cautions": "when given parenterally, toxicity common\r\n(close supervision necessary and test dose required;\r\nsee Anaphylaxis below); hepatic and renal function tests,\r\nblood counts, and plasma electrolyte (including plasma-potassium and\r\nmagnesium concentration) monitoring required;corticosteroids(avoid except to control reactions); avoid rapid infusion (risk of arrhythmias);interactions:Appendix 1 (amphotericin)", "side-effects": "when given parenterally, anorexia, nausea and\r\nvomiting, diarrhoea, epigastric pain; febrile reactions, headache,\r\nmuscle and joint pain; anaemia; disturbances in renal function (including\r\nhypokalaemia and hypomagnesaemia) and renal toxicity; also cardiovascular\r\ntoxicity (including arrhythmias, blood pressure changes), blood disorders,\r\nneurological disorders (including hearing loss, diplopia, convulsions,\r\nperipheral neuropathy, encephalopathy), abnormal liver function (discontinue\r\ntreatment), rash, anaphylactoid reactions (see Anaphylaxis, above);\r\npain and thrombophlebitis at injection site", "doses": ["by intravenous infusion, severe systemic\r\nor deep mycoses where toxicity (particularly nephrotoxicity) precludes\r\nuse of conventionalamphotericin; suspected or\r\nproven infection in febrile neutropenic patients unresponsive to broad-spectrum\r\nantibacterials; aspergillosis, initial test dose 1\u00a0mg\r\nover 10 minutes then 3\u00a0mg/kg once daily; max. 5\u00a0mg/kg once daily [unlicensed\r\ndose];childunder 18 years seeBNF for Children"], "pregnancy": "not known to be harmful but manufacturers advise\r\navoid unless potential benefit outweighs risk", "breast-feeding": "no information available"}, "DEXMEDETOMIDINE": {"indications": "maintenance of sedation during intensive\r\ncare", "name": "DEXMEDETOMIDINE", "cautions": "monitor cardiac function; monitor respiratory function\r\nin non-intubated patients; severe neurological disorders; bradycardia;\r\nischaemic heart disease or severe cerebrovascular disease (especially\r\nat higher doses); spinal cord injury; abrupt withdrawal after prolonged\r\nuse; malignant hyperthermia", "side-effects": "nausea, vomiting, dry mouth, bradycardia, myocardial\r\nischaemia, myocardial infarction, tachycardia, blood pressure changes,\r\nagitation, changes in blood sugar, hyperthermia;less commonlyabdominal distension, AV block, decreased cardiac output, dyspnoea,\r\nhallucination, metabolic acidosis, hypoalbuminaemia, thirst", "contra-indications": "second- or third-degree AV block (unless\r\npacemaker fitted); uncontrolled hypotension; acute cerebrovascular\r\ndisorders", "hepatic impairment": "manufacturer advises caution\u2014dose reduction may be\r\nrequired", "doses": ["By intravenous infusion,adultover 18 years, 0.7\u00a0micrograms/kg/hour adjusted\r\naccording to response (usual range 0.2\u20131.4\u00a0micrograms/kg/hour)"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid unless potential\r\nbenefit outweighs risk\u2014present in milk inanimalstudies"}, "CHLORPHENAMINE MALEATE": {"indications": "symptomatic relief of allergy such as hay fever, urticaria; emergency\r\ntreatment of anaphylactic reactions (section 3.4.3)", "name": "CHLORPHENAMINE MALEATE", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nexfoliative dermatitis and tinnitus reported; injections may cause\r\ntransient hypotension or CNS stimulation and may be irritant", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, 4\u00a0mg every 4\u20136 hours, max. 24\u00a0mg\r\ndaily (elderlymax. 12\u00a0mg daily);childunder 1 year seeBNF for Children; 1\u20132 years\r\n1\u00a0mg twice daily; 2\u20136 years 1\u00a0mg every 4\u20136 hours, max. 6\u00a0mg daily;\r\n6\u201312 years 2\u00a0mg every 4\u20136 hours, max. 12\u00a0mg daily", "By intramuscular injectionorby intravenous injectionover 1 minute, 10\u00a0mg, repeated\r\nif required up to max. 4 doses in 24 hours;childunder 6 months 250\u00a0micrograms/kg (max. 2.5\u00a0mg); 6 months\u20136 years\r\n2.5\u00a0mg; 6\u201312 years 5\u00a0mg; these doses may be repeated if required up\r\nto max. 4 doses in 24 hours"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "RASBURICASE": {"indications": "prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy\r\nfor haematological malignancy", "name": "RASBURICASE", "cautions": "monitor closely for hypersensitivity; atopic allergies; may interfere\r\nwith test for uric acid\u2014consult product literature", "side-effects": "fever;less commonlynausea,\r\nvomiting, diarrhoea, headache, hypersensitivity reactions (including\r\nrash, bronchospasm and anaphylaxis); haemolytic anaemia, methaemoglobinaemia", "contra-indications": "G6PD deficiency (section 9.1.5)", "doses": ["By intravenous infusion, 200\u00a0micrograms/kg\r\nonce daily for up to 7 days according to plasma-uric acid concentration"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "QUINAPRIL": {"indications": "essential hypertension; congestive heart failure\r\n(adjunct\u2014seesection 2.5.5)", "name": "QUINAPRIL", "renal impairment": "seenotes above; max.\r\ninitial dose 2.5\u00a0mg once daily if eGFR less than 40\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  tetracyclines reduced by quinapril tablets (quinapril tablets contain magnesium carbonate)", "name": "Quinapril", "backrefs": ["Quinapril"]}, "cautions": "seenotes above", "side-effects": "see notes above; asthenia, chest pain, oedema,\r\nflatulence, nervousness, depression, insomnia, blurred vision, impotence,\r\nand back pain", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Hypertension, initially 10\u00a0mg once daily; with a diuretic\r\n(see notes above),\r\nin elderly, or in renal impairment initially 2.5\u00a0mg daily; usual maintenance\r\ndose 20\u201340\u00a0mg daily in single or 2 divided doses; up to 80\u00a0mg daily\r\nhas been given", "Heart failure (adjunct), initial dose 2.5\u00a0mg daily under close\r\nmedical supervision (see notes above),\r\nincreased gradually to 10\u201320\u00a0mg daily in 1\u20132 divided doses if tolerated;\r\nmax. 40\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "HISTAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": " antihistamines theoretically antagonise effects of histamine\u2014manufacturer of histamine advises avoid concomitant use", "name": "Histamine", "backrefs": ["Histamine H2-antagonists", "Antihistamines", "Antihistamines, Sedating", "Betahistine", "Cefpodoxime", "Antihistamines, Non-sedating", "Histamine"]}}, "MIRTAZAPINE": {"indications": "major depression", "name": "MIRTAZAPINE", "renal impairment": "clearance reduced by 30% if eGFR less than 40\u00a0mL/minute/1.73\u00a0m2; clearance reduced by 50% if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  warfarin enhanced by mirtazapine ", "name": "Mirtazapine", "backrefs": ["Tramadol", "Mirtazapine", "Alcohol", "Fluoxetine", "Clonidine"]}, "cautions": "elderly, cardiac\r\ndisorders, hypotension, history of urinary retention, susceptibility\r\nto angle-closure glaucoma, diabetes mellitus, psychoses (may aggravate psychotic symptoms), history of seizures or bipolar depression;interactions:Appendix 1\r\n(mirtazapine)", "side-effects": "increased appetite, weight gain, dry mouth; postural\r\nhypotension, peripheral oedema; drowsiness, fatigue, tremor, dizziness,\r\nabnormal dreams, confusion, anxiety, insomnia; arthralgia, myalgia;less commonlysyncope, hypotension, mania, hallucinations,\r\nmovement disorders;rarelymyoclonus;very\r\nrarelyblood disorders (see Cautions), convulsions, hyponatraemia\r\n(seeHyponatraemia and Antidepressant\r\nTherapy),\r\nsuicidal behaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy),\r\nand angle-closure glaucoma", "hepatic impairment": "use with caution; discontinue if jaundice occurs", "doses": ["Initially 15\u201330\u00a0mg daily at bedtime increased within 2\u20134\r\nweeks according to response; max. 45\u00a0mg daily as a single dose at\r\nbedtime or in 2 divided doses;childunder 18 years not recommended (seeDepressive Illness in Children\r\nand Adolescents)"], "pregnancy": "use with caution\u2014limited experience; monitor neonate\r\nfor withdrawal effects", "breast-feeding": "present in milk; use only if potential benefit\r\noutweighs risk"}, "DIURETICS, THIAZIDE AND RELATED": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium reduced by thiazides and related diuretics (increased plasma concentration and risk of toxicity)\u2014loop diuretics safer than thiazides", "name": "Diuretics, Thiazide and related", "backrefs": []}}, "ACE INHIBITORS": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium reduced by ACE inhibitors (increased plasma concentration)", "name": "ACE Inhibitors", "backrefs": ["ACE Inhibitors"]}}, "ROCURONIUM BROMIDE": {"indications": "neuromuscular blockade (intermediate duration) for surgery or during\r\nintensive care", "name": "ROCURONIUM BROMIDE", "renal impairment": "reduce maintenance dose; prolonged paralysis", "cautions": "seenotes above", "side-effects": "seenotes above", "hepatic impairment": "reduce dose", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "Intubation,adultandchildover 1 month,by intravenous injection, initially 600\u00a0micrograms/kg; maintenanceby intravenous\r\ninjection, 150\u00a0micrograms/kg (elderly75\u2013100\u00a0micrograms/kg)ormaintenanceby\r\nintravenous infusion, 300\u2013600\u00a0micrograms/kg/hour (elderlyup to 400\u00a0micrograms/kg/hour) adjusted according\r\nto response", "Intensive care,by intravenous injection,adultinitially 600\u00a0micrograms/kg (optional); maintenanceby intravenous infusion, 300\u2013600\u00a0micrograms/kg/hour for first\r\nhour, then adjusted according to response;child1 month\u201318 years seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "EPROSARTAN": {"indications": "hypertension (see also notes above)", "name": "EPROSARTAN", "renal impairment": "halve initial dose if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2", "cautions": "see notes above", "side-effects": "see notes above; also flatulence, hypertriglyceridaemia,\r\narthralgia, rhinitis;rarelyheadache, asthenia,\r\nanaemia, hypersensitivity reactions (including rash, pruritus, urticaria);very rarelynausea", "hepatic impairment": "halve initial dose in mild or moderate liver disease;\r\navoid if severe", "doses": ["600\u00a0mg once daily (elderly over 75 years, initially 300\u00a0mg\r\nonce daily); if necessary increased after 2\u20133 weeks to 800\u00a0mg once\r\ndaily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CLOBETASOL PROPIONATE": {"indications": "short-term treatment only of severe\r\nresistant inflammatory skin disorders such as recalcitrant eczemas\r\nunresponsive to less potentcorticosteroids; psoriasis,\r\nseenotes above", "name": "CLOBETASOL PROPIONATE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily for up to 4 weeks; max. 50\u00a0g\r\nof 0.05% preparation per week"]}, "TRAZODONE": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of trazodone (increased risk of toxicity)", "name": "Trazodone", "backrefs": ["Trazodone"]}}, "GLYCERYL TRINITRATE": {"indications": "anal fissure (section 1.7.4); extravasation (section 10.3)", "name": "GLYCERYL TRINITRATE", "renal impairment": "manufacturers advise use with caution in severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  heparins reduced by infusion of glyceryl trinitrate ", "name": "Glyceryl Trinitrate", "backrefs": ["Glyceryl Trinitrate"]}, "cautions": "hypothyroidism; malnutrition; hypothermia; recent history of myocardial infarction; heart failure due to obstruction; hypoxaemia or other ventilation and perfusion\r\nabnormalities; susceptibility to angle-closure\r\nglaucoma; metal-containing transdermal systems should\r\nbe removed before magnetic resonance imaging procedures, cardioversion,\r\nor diathermy; avoid abrupt withdrawal; monitor blood pressure and heart rate during intravenous infusion; tolerance (seenotes above);interactions:Appendix 1 (nitrates)", "side-effects": "postural hypotension, tachycardia (but paradoxical\r\nbradycardia also reported); throbbing headache, dizziness;less commonlynausea, vomiting, heartburn, flushing, syncope,\r\ntemporary hypoxaemia, rash, application site reactions with transdermal\r\npatches;very rarelyangle-closure glaucoma", "contra-indications": "hypersensitivity\r\nto nitrates; hypotensive conditions and hypovolaemia; hypertrophic\r\ncardiomyopathy; aortic stenosis; cardiac tamponade; constrictive\r\npericarditis; mitral stenosis; toxic pulmonary oedema; raised intracranial\r\npressure due to cerebral haemorrhage or head trauma; marked\r\nanaemia", "hepatic impairment": "caution in severe impairment", "doses": ["treatment or prophylaxis of angina, spray 1\u20132 doses under\r\ntongue and then close mouth"], "pregnancy": "not known to be harmful", "breast-feeding": "no information available\u2014manufacturers advise\r\nuse only if potential benefit outweighs risk"}, "TRIPTORELIN": {"indications": "endometriosis; precocious puberty; reduction in\r\nsize of uterine fibroids; male hypersexuality with severe sexual\r\ndeviation; advanced prostate cancer (section 8.3.4.2)", "name": "TRIPTORELIN", "cautions": "seenotes above", "side-effects": "seenotes above; also gastro-intestinal\r\ndisturbances; in precocious puberty, withdrawal bleeding in females\r\nmay occur in the first month of treatment; asthenia", "contra-indications": "seenotes above", "doses": ["See under preparations below"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "MEDROXYPROGESTERONE ACETATE": {"indications": "seenotes above; contraception (section 7.3.2.2); other\r\nindications (section\r\n6.4.1.2)", "name": "MEDROXYPROGESTERONE ACETATE", "cautions": "seesection\r\n6.4.1.2andnotes above;interactions:Appendix 1 (progestogens)", "side-effects": "seesection\r\n6.4.1.2andnotes above; glucocorticoid effects at high\r\ndose may lead to a cushingoid syndrome", "contra-indications": "seesection\r\n6.4.1.2andnotes above", "hepatic impairment": "avoid; see also oral Progestogen-only Contraceptives\r\n(section 7.3.2.1)", "doses": ["endometrial and renal cell cancer, 200\u2013400\u00a0mg daily;\r\nbreast cancer, 400\u2013800\u00a0mg daily"], "pregnancy": "avoid\u2014genital malformations and cardiac defects reported;\r\nsee also Parenteral Progestogen-only Contraceptives (section 7.3.2.2)", "breast-feeding": "present in milk\u2014no adverse effects reported;\r\nsee also Parenteral Progestogen-only Contraceptives (section 7.3.2.2)"}, "TAPENTADOL": {"indications": "moderate to severe pain which can be managed only with opioid analgesics", "name": "TAPENTADOL", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\ndecreased appetite, diarrhoea, dyspepsia, abdominal discomfort, weight\r\nloss, anxiety, tremor, ataxia, dysarthria, hypoaesthesia, paraesthesia,\r\nseizures, malaise, muscle spasms", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; forimmediate-release tablets, initial max. daily dose 150\u00a0mg;\r\nformodified-release tablets, initial max. daily\r\ndose 50\u00a0mg", "doses": ["severe chronic pain, initally 50\u00a0mg every 12 hours, adjusted\r\naccording to response; max. 500\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "avoid\u2014no information available"}, "OESTROGENS, TOPICAL": {"indications": "see notes above", "name": "OESTROGENS, TOPICAL", "cautions": "seenotes above; see alsoOestrogens for\r\nHRT(section 6.4.1.1); interrupt treatment periodically\r\nto assess need for continued treatment", "side-effects": "see notes above; see alsoOestrogens\r\nfor HRT(section 6.4.1.1); local irritation", "contra-indications": "see notes above; see alsoOestrogens\r\nfor HRT(section 6.4.1.1)", "hepatic impairment": "see Combined Hormonal Contraceptives,section 7.3.1", "doses": ["insert 1 vaginal tablet daily for 2 weeks then reduce\r\nto 1 tablet twice weekly; initiate therapy with 10\u00a0microgram vaginal\r\ntablets, increased after 3 months to 25\u00a0microgram vaginal tablet if\r\nresponse inadequate"], "pregnancy": "see Combined Hormonal Contraceptives,section 7.3.1", "breast-feeding": "avoid; adverse effects on lactation; see also\r\nCombined Hormonal Contraceptives,section 7.3.1"}, "VINORELBINE": {"indications": "seenotes above", "name": "VINORELBINE", "interactions": {"extra": "", "bad": 1, "interaction": " itraconazole possibly inhibits metabolism of vinorelbine (increased risk of neurotoxicity)", "name": "Vinorelbine", "backrefs": ["Vinorelbine"]}, "cautions": "seesection 8.1andnotes above; ischaemic heart disease; caution in handling;interactions: Appendix 1 (vinorelbine)", "side-effects": "seesection 8.1andnotes above; alsorarelypancreatitis; hyponatraemia and inappropriate\r\nsecretion of antidiuretic hormone also reported; irritant to tissues", "contra-indications": "seesection 8.1andnotes above;with capsulesprevious significant surgical resection\r\nof stomach or small bowel, long-term oxygen therapy, concurrent radiotherapy\r\nif treating the liver", "hepatic impairment": "reduceoraldose in moderate impairment,\r\navoidoraluse in severe impairment; reduceintravenousdose in severe impairment; consult product literature", "doses": ["By mouth, 60\u00a0mg/m2once weekly\r\nfor 3 weeks, increased if tolerated to 80\u00a0mg/m2once weekly;\r\nmax. 160\u00a0mg once weekly", "By intravenous injectionorinfusion, consult product literature"], "pregnancy": "avoid unless essential (teratogenicity, and fetal\r\nloss inanimalstudies); manufacturer advises effective\r\ncontraception during and for 3 months after treatment; men must avoid\r\nfathering a child during and for at least 3 months after treatment;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "DANAPAROID SODIUM": {"indications": "prevention of deep-vein thrombosis\r\nin general or orthopaedic surgery; thromboembolic disease in patients\r\nwith history of heparin-induced thrombocytopenia", "name": "DANAPAROID SODIUM", "renal impairment": "caution in moderate impairment; increased risk of bleeding\r\n(monitor anti-Factor Xa activity); avoid in severe impairment unless\r\npatient has heparin-induced thrombocytopenia and no alternative available", "cautions": "recent bleeding or risk of bleeding; concomitant use of drugs\r\nthat increase risk of bleeding;  antibodies\r\nto heparins (risk of antibody-induced thrombocytopenia); body-weight over 90\u00a0kg (monitor anti factor Xa activity)", "side-effects": "bleeding; hypersensitivity reactions (including\r\nrash)", "contra-indications": "haemophilia and other haemorrhagic disorders, thrombocytopenia (unless\r\npatient has heparin-induced thrombocytopenia), recent cerebral haemorrhage, severe hypertension, active peptic ulcer (unless this is the reason for operation), diabetic retinopathy, acute bacterial\r\nendocarditis, spinal or epidural anaesthesia with treatment\r\ndoses of danaparoid", "hepatic impairment": "caution in moderate impairment (increased risk of bleeding);\r\navoid in severe impairment unless patient has heparin-induced thrombocytopenia\r\nand no alternative available", "doses": ["Prevention of deep-vein thrombosis,by subcutaneous\r\ninjection, 750\u00a0units twice daily for 7\u201310 days; initiate treatment\r\nbefore operation (with last pre-operative dose 1\u20134 hours before surgery)", "Thromboembolic disease in patients with history of heparin-induced\r\nthrombocytopenia,by intravenous injection, 2500\u00a0units\r\n(1250\u00a0units if body-weight under 55\u00a0kg, 3750\u00a0units if over 90\u00a0kg),\r\nfollowed byintravenous infusionof 400\u00a0units/hour\r\nfor 2 hours,then300\u00a0units/hour for 2 hours,then200\u00a0units/hour for 5 days"], "pregnancy": "manufacturer advises avoid\u2014limited information available\r\nbut not known to be harmful", "breast-feeding": "amount probably too small to be harmful but\r\nmanufacturer advises avoid"}, "FERROUS GLUCONATE": {"side-effects": "seenotes above", "indications": "iron-deficiency anaemia", "name": "FERROUS GLUCONATE", "cautions": "interactions:Appendix 1 (iron)", "doses": ["prophylactic, 2 tablets daily before food; therapeutic,\r\n4\u20136 tablets daily in divided doses before food;child6\u201312 years, prophylactic and therapeutic, 1\u20133 tablets daily"]}, "EVEROLIMUS": {"indications": "seenotes above", "name": "EVEROLIMUS", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of everolimus\u2014manufacturer of everolimus advises avoid concomitant use", "name": "Everolimus", "backrefs": ["Everolimus"]}, "cautions": "see section 8.1; monitor blood-glucose\r\nconcentration before treatment and periodically thereafter; monitor renal function before treatment and periodically thereafter; reduce dose or discontinue if severe side-effects occur\u2014consult product\r\nliterature;interactions:Appendix\r\n1 (everolimus)", "side-effects": "seesection 8.1; also\r\ndiarrhoea, dry mouth, abdominal pain, dysphagia, anorexia, taste disturbance;\r\nchest pain, hypertension, hyperlipidaemia, hypercholesterolaemia,\r\nperipheral oedema; pneumonitis (including interstitial lung disease);\r\nasthenia, anxiety, fatigue, headache, insomnia; increased susceptibility\r\nto infections (including pneumonia, aspergillosis, and candidiasis);\r\nhyperglycaemia, hypoglycaemia, dehydration; eyelid oedema; renal failure,\r\nelectrolyte disturbance; arthralgia; epistaxis; skin and nail disorders\r\n(including hand-foot syndrome);less commonlycongestive\r\nheart failure, flushing, and impaired wound healing; hepatitis B reactivation\r\nand haemorrhage also reported", "hepatic impairment": "reduce dose to 5\u00a0mg daily in moderate impairment (consult\r\nproduct literature for patients with subependymal giant cell astrocytoma);\r\navoid in severe impairment\u2014no information available", "doses": ["subependymal giant cell astrocytoma,adultandchildover 3 years, consult product\r\nliterature"], "pregnancy": "manufacturer advises avoid (toxicity inanimalstudies); effective contraception must be used during and for up\r\nto 8 weeks after treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid"}, "ETHOSUXIMIDE": {"indications": "seenotes above", "name": "ETHOSUXIMIDE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  phenytoin possibly increased by ethosuximide , also plasma concentration of ethosuximide possibly reduced", "name": "Ethosuximide", "backrefs": ["Ethosuximide"]}, "cautions": "avoid abrupt withdrawal; avoid in acute porphyria (section 9.8.2);interactions:seeInteractionsin section\r\n4.8.1 and Appendix 1 (ethosuximide)", "side-effects": "gastro-intestinal disturbances (including nausea,\r\nvomiting, diarrhoea, abdominal pain, anorexia, weight loss);less frequentlyheadache, fatigue, drowsiness, dizziness,\r\nhiccup, ataxia, euphoria, irritability, aggression, impaired concentration;rarelytongue swelling, sleep disturbances, depression,\r\npsychosis, photophobia, dyskinesia, increased libido, vaginal bleeding,\r\nmyopia, gingival hypertrophy, rash;also reportedhyperactivity, increase in seizure frequency, blood disorders (including\r\nleucopenia, agranulocytosis, pancytopenia, and aplastic anaemia\u2014blood\r\ncounts required if features of infection), systemic lupus erythematosus,\r\nStevens-Johnson syndrome; suicidal ideation", "hepatic impairment": "use with caution", "doses": ["adultandchildover 6 years, initially 500\u00a0mg daily in 2 divided\r\ndoses, increased by 250\u00a0mg every 5\u20137 days to usual dose of 1\u20131.5\u00a0g\r\ndaily in 2 divided doses; occasionally up to 2\u00a0g daily may be needed;child1 month\u20136 years, initially 10\u00a0mg/kg (max. 250\u00a0mg)\r\ndaily in 2 divided doses, increased every 5\u20137 days to usual dose of\r\n20\u201340\u00a0mg/kg (max. 1\u00a0g) daily in 2 divided doses; total daily dose\r\nmay be given in 3 divided doses"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "MAGNESIUM CITRATE": {"indications": "see preparations", "name": "MAGNESIUM CITRATE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2\u2014risk of hypermagnesaemia", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "avoid in hepatic coma if risk of renal failure", "doses": ["bowel evacuation for surgery, colonoscopy or radiological\r\nexamination, on day before procedure, 1 sachet at 8 a.m. and 1 sachet\r\nbetween 2 and 4 p.m.;child5\u201310 years\r\none-third adult dose; over 10 years and frailelderlyone-half adult dose"], "pregnancy": "caution", "breast-feeding": "caution"}, "ARTEMETHER WITH LUMEFANTRINE": {"indications": "treatment of acute uncomplicated falciparum malaria; treatment of\r\nbenign malaria [unlicensed indication]", "name": "ARTEMETHER WITH LUMEFANTRINE", "renal impairment": "manufacturer advises caution in severe impairment\u2014monitor\r\nECG and plasma potassium concentration", "interactions": {"extra": "", "bad": 0, "interaction": "caution with  ritonavir advised by manufacturer of artemether/lumefantrine ", "name": "Artemether with Lumefantrine", "backrefs": []}, "cautions": "electrolyte disturbances, concomitant use with other drugs known to cause QT-interval\r\nprolongation; monitor patients unable to\r\ntake food (greater risk of recrudescence); avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (artemether with lumefantrine)", "side-effects": "abdominal pain, anorexia, diarrhoea, vomiting,\r\nnausea; palpitation, prolonged QT interval; cough; headache, dizziness,\r\nsleep disturbances, asthenia, paraesthesia; arthralgia, myalgia; pruritus,\r\nrash;less commonlyataxia, hypoaesthesia, and clonus", "contra-indications": "history of arrhythmias, of clinically relevant bradycardia, and of congestive\r\nheart failure accompanied by reduced left ventricular ejection fraction; family history of sudden death or of congenital QT interval\r\nprolongation", "hepatic impairment": "manufacturer advises caution in severe impairment\u2014monitor\r\nECG and plasma-potassium concentration", "doses": ["Treatment of malaria, seenotes above"], "pregnancy": "toxicity inanimalstudies with\r\nartemether; manufacturer advises use only if potential benefit outweighs\r\nrisk", "breast-feeding": "manufacturer advises avoid breast-feeding for\r\nat least 1 week after last dose; present in milk inanimalstudies"}, "TRANEXAMIC ACID": {"indications": "see notes above", "name": "TRANEXAMIC ACID", "renal impairment": "reduce dose\u2014consult product literature for details", "cautions": "massive haematuria (avoid if risk of ureteric\r\nobstruction); irregular menstrual bleeding (exclude structural\r\nor histological causes of menorrhagia, or fibroids causing distortion\r\nof the uterine cavity, before initiating treatment);\r\npatients receiving oral contraceptives (increased risk of thrombosis); regular liver function tests in long-term treatment of hereditary\r\nangioedema", "side-effects": "nausea, vomiting, diarrhoea (reduce dose);rarelydisturbances in colour vision (discontinue), thromboembolic\r\nevents, convulsions, allergic skin reactions; dizziness and hypotension\r\non rapid intravenous injection", "contra-indications": "thromboembolic disease; fibrinolytic conditions following disseminated intravascular coagulation;\r\nhistory of convulsions", "doses": ["By mouth, local fibrinolysis, 1\u20131.5\u00a0g\r\n(or15\u201325\u00a0mg/kg) 2\u20133 times daily", "Menorrhagia (initiated when menstruation has started), 1\u00a0g 3\r\ntimes daily for up to 4 days; max. 4\u00a0g daily", "Hereditary angioedema, 1\u20131.5\u00a0g 2\u20133 times daily", "Epistaxis, 1\u00a0g 3 times daily for 7 days", "By slow intravenous injection, local fibrinolysis,\r\n0.5\u20131\u00a0g 3 times daily", "By continuous intravenous infusion, local fibrinolysis, following initial treatmentby intravenous\r\ninjection, 25\u201350\u00a0mg/kg over 24 hours"], "pregnancy": "no evidence of teratogenicity inanimalstudies; manufacturer advises use only if potential benefit outweighs\r\nrisk\u2014crosses the placenta", "breast-feeding": "small amount present in milk\u2014antifibrinolytic\r\neffect in infant unlikely"}, "NITRAZEPAM": {"indications": "insomnia (short-term use; seenotes above)", "name": "NITRAZEPAM", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid possibly reduces excretion of nitrazepam (increased plasma concentration)", "name": "Nitrazepam", "backrefs": ["Nitrazepam"]}, "cautions": "respiratory disease; muscle\r\nweakness and myasthenia gravis; history of drug oralcoholabuse; hypoalbuminaemia; marked\r\npersonality disorder; reduce dose in elderly and debilitated; avoid prolonged\r\nuse (and abrupt withdrawal thereafter); acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(anxiolytics and hypnotics)", "side-effects": "drowsiness and lightheadedness the next day; confusion\r\nand ataxia (especially in the elderly); amnesia may occur; dependence;\r\nsee also underDiazepam(section\r\n4.1.2);overdosage:seeEmergency Treatment of Poisoning", "contra-indications": "respiratory\r\ndepression; marked neuromuscular respiratory\r\nweakness including unstable myasthenia gravis; acute pulmonary insufficiency; sleep apnoea syndrome; not for use alone to\r\ntreat depression (or anxiety associated with depression) or chronic\r\npsychosis", "hepatic impairment": "seenotes above", "doses": ["5\u201310\u00a0mg at bedtime;elderly(or debilitated) 2.5\u20135\u00a0mg;child1\r\nmonth\u20132 years (infantile spasms) seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PROPAFENONE HYDROCHLORIDE": {"indications": "ventricular arrhythmias; paroxysmal supraventricular tachyarrhythmias\r\nwhich include paroxysmal atrial flutter or fibrillation and paroxysmal\r\nre-entrant tachycardias involving the AV node or accessory pathway,\r\nwhere standard therapy ineffective or contra-indicated", "name": "PROPAFENONE HYDROCHLORIDE", "cautions": "heart failure; elderly; pacemaker patients; potential for conversion of paroxysmal atrial fibrillation\r\nto atrial flutter with 2:1 or 1:1 conduction block;\r\ngreat caution in obstructive airways disease owing to beta-blocking activity (contra-indicated if severe);interactions:Appendix 1 (propafenone)", "side-effects": "gastro-intestinal disturbances, dry mouth, bitter\r\ntaste, anorexia, jaundice, cholestasis, hepatitis; chest pain, bradycardia,\r\nsino-atrial, atrioventricular, or intraventricular blocks, hypotension\r\n(including postural hypotension), dizziness, syncope, pro-arhythmic\r\neffects; anxiety, confusion, ataxia, restlessness, headache, sleep\r\ndisorders, paraesthesia, fatigue, seizures, extrapyramidal symptoms;\r\nimpotence, reduced sperm count; blood disorders; lupus syndrome; blurred\r\nvision; hypersensitivity (including skin reactions)", "contra-indications": "uncontrolled congestive heart\r\nfailure, cardiogenic shock (except arrhythmia\r\ninduced), severe bradycardia, electrolyte disturbances, severe obstructive\r\npulmonary disease, marked hypotension; myasthenia gravis; unless adequately\r\npaced avoid in sinus node dysfunction, atrial conduction\r\ndefects, second degree or greater AV block, bundle branch block or\r\ndistal block", "hepatic impairment": "reduce dose", "doses": ["Body-weight 70\u00a0kg and over, initially 150\u00a0mg 3 times\r\ndaily after food under direct hospital supervision with ECG monitoring\r\nand blood pressure control (if QRS interval prolonged by more than\r\n20%, reduce dose or discontinue until ECG returns to normal limits);\r\nmay be increased at intervals of at least 3 days to 300\u00a0mg twice daily\r\nand, if necessary, to max. 300\u00a0mg 3 times daily; body-weight under\r\n70\u00a0kg, reduce dose;elderlymay respond\r\nto lower doses"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "AMIKACIN": {"indications": "serious Gram-negative infections resistant togentamicin", "name": "AMIKACIN", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " indometacin possibly increases plasma concentration of amikacin in neonates", "name": "Amikacin", "backrefs": ["Amikacin"]}, "cautions": "seenotes above;interactions:Appendix 1 (aminoglycosides)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["To avoid excessive dosage in obese patients, use ideal\r\nweight for height to calculate dose and monitor serum-amikacin concentration\r\nclosely", "Multiple daily dose regimen,by intramuscularorby slow intravenous injectionorby infusion, 15\u00a0mg/kg daily in\r\n2 divided doses, increased to 22.5\u00a0mg/kg daily in 3 divided doses\r\nin severe infections; max. 1.5\u00a0g daily for up to 10 days (max. cumulative\r\ndose 15\u00a0g);childunder 18 years seeBNF for Children", "Once daily dose regimen (not for endocarditis, febrile neutropenia,\r\nor meningitis; see notes above and also consult local guidelines),by intravenous infusion, initially 15\u00a0mg/kg (max. 1.5\u00a0g),\r\nthen adjust according to serum-amikacin concentration; max. cumulative\r\ndose 15\u00a0g;childunder 18 years seeBNF for Children", "For multiple daily dose regimen, one-hour\r\n(\u2018peak\u2019) serum concentration should not exceed 30\u00a0mg/litre; pre-dose\r\n(\u2018trough\u2019) concentration should be less than 10\u00a0mg/litre. For once\r\ndaily dose regimen, pre-dose (\u2018trough\u2019) concentration should be less\r\nthan 5\u00a0mg/litre"], "pregnancy": "seenotes above"}, "PROBENECID": {"indications": "prevention of nephrotoxicity associated withcidofovir(section 5.3.2.2)", "name": "PROBENECID", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73m2", "interactions": {"extra": "", "bad": 0, "interaction": "excretion of  nitrofurantoin reduced by probenecid (increased risk of side-effects)", "name": "Probenecid", "backrefs": ["Aciclovir", "Zidovudine", "Nitrazepam", "Naproxen", "Ganciclovir", "Probenecid", "Lorazepam", "Famciclovir", "Sodium Benzoate", "Cephalosporins", "Indometacin", "Dexketoprofen", "Ciprofloxacin", "Doripenem", "Dapsone", "Captopril", "Norfloxacin", "Thiopental", "Sodium Phenylbutyrate", "Meropenem", "Ketoprofen"]}, "cautions": "ensure adequate fluid intake (about 2\u20133 litres\r\ndaily) and render urine alkaline if uric\r\nacid overload is high; peptic ulceration; transient false-positive Benedict\u2019s test; G6PD-deficiency (section 9.1.5);interactions:Appendix 1\r\n(probenecid)", "side-effects": "gastro-intestinal disturbances;less commonlysore gums, flushing, headache, dizziness, urinary frequency, anaemia,\r\nalopecia; hepatic necrosis, hypersensitivity reactions (including\r\nanaphylaxis, pruritus, urticaria, fever, and Stevens-Johnson syndrome),\r\nnephrotic syndrome, haemolytic anaemia, leucopenia, and aplastic anaemia\r\nalso reported", "contra-indications": "history of blood disorders, nephrolithiasis, acute porphyria (section 9.8.2), acute gout attack;\r\navoidaspirinandsalicylates", "doses": ["Used withcidofovir, seesection 5.3.2.2"], "breast-feeding": "present in milk"}, "IDOXURIDINE IN DIMETHYL SULFOXIDE": {"indications": "herpes simplex and herpes\r\nzoster infection but of little value", "name": "IDOXURIDINE IN DIMETHYL SULFOXIDE", "cautions": "avoid contact with the eyes, mucous membranes, and textiles;interactions:Appendix 1 (dimethyl sulfoxide)", "side-effects": "stinging on application, changes in taste; overuse\r\nmay cause maceration", "contra-indications": "notto be used\r\nin mouth", "doses": ["apply to lesions 4 times daily for 4 days, starting at\r\nfirst sign of attack;childunder 12\r\nyears, not recommended"], "pregnancy": "teratogenic inanimalstudies\u2014manufacturer\r\nadvises avoid", "breast-feeding": "may make milk taste unpleasant"}, "EPOPROSTENOL": {"indications": "see notes above", "name": "EPOPROSTENOL", "cautions": "anticoagulant monitoring required when\r\ngiven with anticoagulants; haemorrhagic\r\ndiathesis; concomitant use of drugs that\r\nincrease risk of bleeding; dose titration\r\nfor pulmonary hypertension should be in hospital (risk of pulmonary\r\noedema); avoid abrupt withdrawal when used for primary\r\npulmonary hypertension (risk of rebound pulmonary hypertension)", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain, bleeding,\r\nbradycardia, tachycardia, hypotension, flushing, chest pain, anxiety,\r\nheadache, sepsis, jaw pain, arthralgia;less commonlydry mouth, pulmonary oedema, sweating;rarelyagitation,\r\npallor", "contra-indications": "severe left ventricular dysfunction", "doses": ["See product literature"], "pregnancy": "manufacturer advises caution\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "THYROID HORMONES": {"interactions": {"extra": "", "bad": 0, "interaction": " phenytoin accelerates metabolism of thyroid hormones (may increase requirements in hypothyroidism), also plasma concentration of phenytoin possibly increased", "name": "Thyroid Hormones", "backrefs": ["Thyroid Hormones", "Colestipol"]}}, "CALCIUM SALTS": {"indications": "see notes above; calcium deficiency", "name": "CALCIUM SALTS", "renal impairment": "use with caution (but see alsoCalcium Gluconate injection)", "interactions": {"extra": "see also Antacids", "bad": 0, "interaction": " corticosteroids reduce absorption of calcium salts ", "name": "Calcium Salts", "backrefs": ["Fluorides", "Calcium Salts"]}, "cautions": "sarcoidosis; history of nephrolithiasis; avoid calcium chloride in respiratory acidosis or\r\nrespiratory failure;interactions:Appendix 1 (antacids, calcium\r\nsalts)", "side-effects": "rarelygastro-intestinal disturbances;with injection, bradycardia, arrhythmias, peripheral vasodilatation,\r\nfall in blood pressure, sweating, injection-site reactions, severe\r\ntissue damage with extravasation", "contra-indications": "conditions associated with hypercalcaemia\r\nand hypercalciuria (e.g. some forms of malignant disease)", "doses": ["By mouth, daily in divided doses, seenotes above", "By slow intravenous injection, acute hypocalcaemia,\r\ncalcium gluconate 1\u20132\u00a0g (Ca2+2.25\u20134.5\u00a0mmol);childseeBNF for Children"]}, "CHLOROQUINE": {"indications": "chemoprophylaxis and treatment of malaria;\r\nrheumatoid arthritis and lupus erythematosus (section 10.1.3)", "name": "CHLOROQUINE", "renal impairment": "manufacturers advise caution; see alsoProphylaxis Against Malaria", "cautions": "may exacerbate psoriasis; neurological disorders (avoid for prophylaxis if history of epilepsy, seenotes above); may aggravate myasthenia gravis; severe\r\ngastro-intestinal disorders; G6PD deficiency (seesection 9.1.5); ophthalmic examination and long-term therapy,\r\nsee underChloroquine,section 10.1.3; avoid concurrent therapy with hepatotoxic drugs\u2014otherinteractions:Appendix 1 (chloroquineandhydroxychloroquine)", "side-effects": "gastro-intestinal disturbances, headache; also\r\nhypotension, convulsions, visual disturbances, depigmentation or loss\r\nof hair, skin reactions (rashes, pruritus); rarely, bone-marrow suppression,\r\nhypersensitivity reactions such as urticaria and angioedema; other\r\nside-effects (not usually associated with malaria prophylaxis or treatment),\r\nsee underChloroquine,section 10.1.3; very\r\ntoxic inoverdosage\u2014immediate advice from poisons\r\ncentres essential (see alsoEmergency Treatment of Poisoning)", "hepatic impairment": "use with caution in moderate to severe impairment", "doses": ["Doses expressed as chloroquine base", "Prophylaxis of malaria, preferably started 1 week before entering\r\nendemic area and continued for 4 weeks after leaving (see notes above),\r\n310\u00a0mg once weekly;infantup to 12\r\nweeks body-weight under 6\u00a0kg, 37.5\u00a0mg once weekly; 12 weeks\u20131 year\r\nbody-weight 6\u201310\u00a0kg, 75\u00a0mg once weekly;child1\u20134 years body-weight 10\u201316\u00a0kg, 112.5\u00a0mg once weekly; 4\u20138 years\r\nbody-weight 16\u201325\u00a0kg, 150\u00a0mg once weekly (or 155\u00a0mg once weekly if\r\ntablets used); 8\u201313 years body-weight 25\u201345\u00a0kg, 225\u00a0mg once weekly\r\n(or 232.5\u00a0mg once weekly if tablets used); over 13 years body-weight\r\nover 45\u00a0kg, adult dose", "Treatment of benign malarias, seenotes above", "Warn travellers aboutimportanceof avoiding mosquito bites,importanceof taking\r\nprophylaxis regularly, andimportanceof immediate\r\nvisit to doctor if ill within 1 year andespeciallywithin 3 months of return. For details, see notes above", "Chloroquinedoses in BNF\r\nmay differ from those in product literature"], "pregnancy": "benefit of prophylaxis and treatment in malaria outweighs\r\nrisk; see alsoBenign Malarias (treatment)andProphylaxis Against Malaria", "breast-feeding": "amount in milk probably too small to be harmful;\r\nsee alsoProphylaxis Against Malaria"}, "PEGAPTANIB SODIUM": {"indications": "seenotes above\u2014specialist use only", "name": "PEGAPTANIB SODIUM", "cautions": "monitor intra-ocular pressure following\r\ninjection", "side-effects": "rhinorrhoea; headache; eye pain, anterior chamber\r\ninflammation, raised intra-ocular pressure, punctate keratitis, vitreous\r\nfloaters, cataract, conjunctival and retinal haemorrhage, local oedema,\r\nconjunctivitis, corneal dystrophy, dry eye, endophthalmitis, eye discharge,\r\neye irritation, macular degeneration, mydriasis, periorbital haematoma,\r\nphotophobia, flashing lights, vitreous disorders;less commonlyvomiting, dyspepsia, palpitation, chest pain, hypertension, aortic\r\naneurysm, influenza-like symptoms, nightmares, depression, back pain,\r\nasthenopia, blepharitis, corneal deposits, vitreous haemorrhage, chalazion,\r\nretinal exudates, eyelid ptosis, decreased intra-ocular pressure,\r\ninjection-site reactions, retinal detachment, occlusion of retinal\r\nblood vessels, ectropion, eye movement disorder, pupillary disorder,\r\niritis, optic nerve cupping, nasopharyngitis, deafness, vertigo, eczema,\r\nchanges in hair colour, rash, pruritus, night sweats", "contra-indications": "ocular or periocular infection", "doses": ["By intravitreal injection, 300\u00a0micrograms\r\nonce every 6 weeks into the affected eye", "For further information on administration,\r\nconsult product literature. Review treatment if no benefit after 2\r\nconsecutive injections"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "BRIMONIDINE TARTRATE": {"indications": "raised intra-ocular pressure, see notes above", "name": "BRIMONIDINE TARTRATE", "renal impairment": "manufacturer advises use with caution", "cautions": "severe cardiovascular disease; cerebral or coronary\r\ninsufficiency, Raynaud\u2019s syndrome, thromboangiitis obliterans, postural hypotension, depression; children 2\u201312 years (increased risk of drowsiness);interactions:Appendix 1 (brimonidine)", "side-effects": "dry mouth, gastro-intestinal disturbances, taste\r\ndisturbances, upper respiratory symptoms, headache, drowsiness, dizziness,\r\nmalaise, ocular disturbances (including hyperaemia, burning, stinging,\r\npruritus, pain and dryness), visual disturbances, eyelid inflammation,\r\nphotophobia, corneal erosion and staining, conjunctival disturbances\r\n(including blanching, follicles, and infection);less commonlypalpitation, arrhythmia, bradycardia, tachycardia, depression, nasal\r\ndryness;rarelydyspnoea;very rarelyhypertension, hypotension, syncope, insomnia, iritis, miosis", "contra-indications": "neonate or child\r\nunder 2 years", "hepatic impairment": "manufacturer advises use with caution", "doses": ["Apply twice daily"], "pregnancy": "manufacturer advises use only if benefit outweighs\r\nrisk", "breast-feeding": "manufacturer advises avoid"}, "OXYCODONE": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin possibly accelerates metabolism of oxycodone ", "name": "Oxycodone", "backrefs": ["Oxycodone"]}}, "DISODIUM PAMIDRONATE": {"indications": "see under Dose", "name": "DISODIUM PAMIDRONATE", "renal impairment": "max. infusion rate 20\u00a0mg/hour; avoid if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2, except in life-threatening hypercalcaemia\r\nif benefit outweighs risk; if renal function deteriorates in patients\r\nwith bone metastases, withhold dose until serum creatinine returns\r\nto within 10% of baseline value", "cautions": "assess renal function before each dose; ensure adequate hydration; cardiac disease (especially in elderly); previous thyroid surgery (risk of hypocalcaemia); monitor\r\nserum electrolytes, calcium and phosphate\u2014possibility of convulsions\r\ndue to electrolyte changes; avoid concurrent use with other bisphosphonates; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, seeMHRA/CHM advice;interactions:Appendix 1 (bisphosphonates)", "side-effects": "hypophosphataemia, fever and influenza-like symptoms\r\n(sometimes accompanied by malaise, rigors, fatigue and flushes); nausea,\r\nvomiting, anorexia, abdominal pain, diarrhoea, constipation; symptomatic\r\nhypocalcaemia (paraesthesia, tetany), hypomagnesaemia, headache, insomnia,\r\ndrowsiness; hypertension; anaemia, thrombocytopenia, lymphocytopenia;\r\nrash; arthralgia, myalgia, bone pain;rarelymuscle\r\ncramps, atypical femoral fractures (seeMHRA/CHM advice),\r\ndyspepsia, agitation, confusion, dizziness, lethargy; leucopenia,\r\nhypotension, pruritus, hyperkalaemia or hypokalaemia, and hypernatraemia;\r\nosteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw),\r\nisolated cases of seizures, hallucinations, haematuria, acute renal\r\nfailure, deterioration of renal disease, conjunctivitis and other\r\nocular symptoms; atrial fibrillation, and reactivation of herpes simplex\r\nand zoster also reported; also injection-site reactions", "hepatic impairment": "caution in severe hepatic impairment\u2014no information\r\navailable", "doses": ["By slow intravenous infusion(via\r\ncannula in a relatively large vein), see also Appendix 4", "Hypercalcaemia of malignancy, according to serum calcium concentration\r\n15\u201360\u00a0mg in single infusion or in divided doses over 2\u20134 days; max.\r\n90\u00a0mg per treatment course", "Osteolytic lesions and bone pain in bone metastases associated\r\nwith breast cancer or multiple myeloma, 90\u00a0mg every 4 weeks (or every\r\n3 weeks to coincide with chemotherapy in breast cancer)", "Paget\u2019s disease of bone, 30\u00a0mg once a week for 6 weeks (total\r\ndose 180\u00a0mg)or30\u00a0mg in first week then 60\u00a0mg every\r\nother week (total dose 210\u00a0mg); max. total 360\u00a0mg (in divided doses\r\nof 60\u00a0mg) per treatment course; may be repeated every 6 months", "childnot recommended", "Oral supplements\r\nare advised to minimise potential risk of hypocalcaemia for those\r\nwith mainly lytic bone metastases or multiple myeloma at risk of calcium\r\nor vitamin D deficiency (e.g. through malabsorption or lack of exposure\r\nto sunlight) and in those with Paget\u2019s disease"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "TIROFIBAN": {"indications": "prevention of early myocardial infarction (in combination with unfractionated\r\nheparin and aspirin) in patients with unstable angina or non-ST-segment-elevation\r\nmyocardial infarction and with last episode of chest pain within 12\r\nhours (use under specialist supervision)", "name": "TIROFIBAN", "renal impairment": "increased risk of bleeding; monitor carefully if eGFR\r\nless than 60\u00a0mL/minute/1.73\u00a0m2; use half normal dose if\r\neGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of bleeding when  iloprost given with tirofiban ", "name": "Tirofiban", "backrefs": ["Tirofiban"]}, "cautions": "major surgery or severe trauma within\r\n3 months (avoid if within 6 weeks); traumatic or protracted cardiopulmonary\r\nresuscitation, organ biopsy or lithotripsy within last 2 weeks; risk of bleeding including active peptic ulcer within 3 months, uncontrolled\r\nsevere hypertension, acute pericarditis, aortic dissection, haemorrhagic\r\nretinopathy, vasculitis, haematuria, faecal occult blood, elderly, low body-weight; severe heart failure, cardiogenic\r\nshock, anaemia; puncture of non-compressible vessel within 24 hours; concomitant drugs that increase risk of bleeding (including\r\nwithin 48 hours of thrombolytic administration); monitor platelet count, haemoglobin and haematocrit before treatment,\r\n2\u20136 hours after start of treatment and then at least once daily; discontinue if thrombolytic therapy, intra-aortic\r\nballoon pump or emergency cardiac surgery necessary; discontinue immediately if serious or uncontrollable bleeding occurs;interactions:Appendix 1 (tirofiban)", "side-effects": "nausea, headache, fever, bleeding manifestations,\r\nreversible thrombocytopenia", "contra-indications": "abnormal bleeding within 30 days; stroke within 30 days or any\r\nhistory of haemorrhagic stroke, intracranial disease (aneurysm,\r\nneoplasm or arteriovenous malformation); severe hypertension; increased prothrombin time or INR; thrombocytopenia", "hepatic impairment": "caution in mild to moderate liver disease; avoid in\r\nsevere liver disease\u2014increased risk of bleeding", "doses": ["Angiography planned for 4\u201348 hours after diagnosis,by intravenous infusion, initially 400\u00a0nanograms/kg/minute\r\nfor 30 minutes, then 100\u00a0nanograms/kg/minute for at least 48 hours\r\n(continue during and for 12\u201324 hours after percutaneous coronary intervention);\r\nmax. duration of treatment 108 hours", "Angiographywithin4 hours of diagnosis,by intravenous injection, 25\u00a0micrograms/kg given over 3 minutes\r\nat start of percutaneous coronary intervention, thenby intravenous infusion, 150\u00a0nanograms/kg/minute for 18\u201324\r\nhours; max. duration of treatment 48 hours"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "TARS": {"indications": "psoriasis and occasionally\r\nchronic atopic eczema", "name": "TARS", "cautions": "application to face and skin flexures; use suitable chemical protection gloves for extemporaneous\r\npreparation", "side-effects": "skin irritation and acne-like eruptions, photosensitivity;\r\nstains skin, hair, and fabric", "contra-indications": "not for use in sore, acute, or pustular\r\npsoriasis or in presence of infection; avoid eyes, mucosa, genital or rectal\r\nareas; broken or inflamed skin", "doses": ["psoriasis, apply to skin or scalp 2\u20133 times daily;childunder 12 years andelderly, lotion can be diluted with a few drops of water before applying"]}, "NAFARELIN": {"indications": "see under Dose", "name": "NAFARELIN", "cautions": "seenotes above", "side-effects": "see notes above; acne", "contra-indications": "seenotes above", "doses": ["Endometriosis, women over 18 years, 200\u00a0micrograms twice\r\ndaily as one spray in one nostril in the morning and one spray in\r\nthe other nostril in the evening (starting on days 2\u20134 of menstruation),\r\nmax. duration of treatment 6 months (do not repeat)", "Pituitary desensitisation before induction of ovulation by gonadotrophins\r\nforin vitrofertilisation (under specialist supervision),\r\n400\u00a0micrograms (one spray in each nostril) twice daily starting in\r\nearly follicular phase (day 2) or, after exclusion of pregnancy, in\r\nmidluteal phase (day 21) and continued until down-regulation achieved\r\n(usually within 4 weeks) then maintained (usually for 8\u201312 days) during\r\ngonadotrophin administration (stopping gonadotrophin andnafarelinon administration ofchorionic gonadotrophinat follicular maturity); discontinue if down-regulation not achieved\r\nwithin 12 weeks", "Avoid use of nasal decongestants before\r\nand for at least 30\u00a0minutes after treatment; repeat dose if sneezing\r\noccurs during or immediately after administration"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "OFLOXACIN": {"indications": "seenotes above", "name": "OFLOXACIN", "interactions": {"extra": "", "bad": 0, "interaction": "oral  iron reduces absorption of ofloxacin ", "name": "Ofloxacin", "backrefs": ["Levofloxacin", "Ofloxacin", "Zinc", "Iron", "Ciprofloxacin"]}, "side-effects": "local irritation including photophobia; dizziness,\r\nnumbness, nausea and headache reported", "doses": ["Apply every 2\u20134 hours for the first 2 days then reduce\r\nfrequency to 4 times daily (max. 10 days treatment)"], "pregnancy": "manufacturer advises use only if benefit outweighs\r\nrisk; systemic quinolones have caused arthropathy inanimalstudies", "breast-feeding": "manufacturer advises avoid"}, "STAVUDINE": {"indications": "HIV infection in combination with other antiretroviral drugs when\r\nno suitable alternative available and when prescribed for shortest\r\nperiod possible", "name": "STAVUDINE", "renal impairment": "risk of peripheral neuropathy; use half normal dose every\r\n12 hours if eGFR 25\u201350\u00a0mL/minute/1.73\u00a0m2; use half normal\r\ndose every 24 hours if eGFR less than 25\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of toxicity when  hydroxycarbamide given with stavudine\u2014avoid concomitant use", "name": "Stavudine", "backrefs": ["Stavudine"]}, "cautions": "seenotes above; also history of peripheral neuropathy, excessive\r\nalcohol intake, concomitant use of isoniazid\u2014risk\r\nof peripheral neuropathy (see under Side-effects); history of pancreatitis or concomitant\r\nuse with other drugs associated with pancreatitis;interactions:Appendix 1 (stavudine)", "side-effects": "see notes above; also peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops), abnormal dreams, cognitive dysfunction, drowsiness, depression,\r\npruritus;less commonlyanxiety, gynaecomastia", "hepatic impairment": "seenotes above", "doses": ["adultunder 60\u00a0kg, 30\u00a0mg\r\nevery 12 hours preferably at least 1 hour before food; 60\u00a0kg and over,\r\n40\u00a0mg every 12 hours;child1 month\u201318\r\nyears seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "seeBreast-feeding"}, "ANTI-ARRHYTHMICS": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  antipsychotics that prolong the QT interval given with anti-arrhythmics that prolong the QT interval", "name": "Anti-arrhythmics", "backrefs": ["Ropivacaine", "Levobupivacaine", "Prilocaine", "Anti-arrhythmics"]}}, "CHLORPROMAZINE": {"interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of both drugs may increase when  propranolol given with chlorpromazine ", "name": "Chlorpromazine", "backrefs": ["Chlorpromazine"]}}, "PRILOCAINE HYDROCHLORIDE": {"indications": "see under preparations", "name": "PRILOCAINE HYDROCHLORIDE", "renal impairment": "use with caution; lower doses may be required for intrathecal\r\nanaesthesia", "cautions": "seeCautions of Local Anaesthetics;\r\nsevere or untreated hypertension; concomitant use of drugs that cause methaemoglobinaemia; acute porphyria (section 9.8.2);interactions:Appendix 1 (prilocaine)", "side-effects": "seenotes aboveandToxicity and Side-effects;\r\nalso hypertension", "contra-indications": "seeContra-indications of Local\r\nAnaesthetics; anaemia or congenital or acquired methaemoglobinaemia", "hepatic impairment": "use with caution; lower doses may be required for intrathecal\r\nanaesthesia", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "See under preparations\u2014important:see also\r\nAdministration,section 15.2"], "pregnancy": "large doses during delivery can cause neonatal respiratory\r\ndepression, hypotonia, and bradycardia after epidural block; avoid\r\nparacervical or pudendal block in obstetrics (neonatal methaemoglobinaemia\r\nreported); use lower doses for intrathecal use during late pregnancy", "breast-feeding": "present in milk but not known to be harmful"}, "FOSAPREPITANT": {"indications": "adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and\r\nvomiting associated with moderately and highly emetogenic chemotherapy", "name": "FOSAPREPITANT", "cautions": "interactions:Appendix 1 (aprepitant)", "side-effects": "seeAprepitant", "hepatic impairment": "seeAprepitant", "doses": ["By intravenous infusion, over 20\u201330 minutes,adultover 18 years, 150\u00a0mg 30 minutes before chemotherapy\r\non day 1 of cycle only; consult product literature for dose of concomitant\r\ncorticosteroid and 5HT3-receptor antagonist"], "pregnancy": "seeAprepitant", "breast-feeding": "seeAprepitant"}, "AMLODIPINE": {"indications": "hypertension, prophylaxis of angina", "name": "AMLODIPINE", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of myopathy when  simvastatin given with amlodipine ", "name": "Amlodipine", "backrefs": ["Amlodipine"]}, "cautions": "acute porphyria (but seesection 9.8.2);interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "abdominal pain, nausea; palpitation, flushing,\r\noedema; headache, dizziness, sleep disturbances, fatigue;less commonlygastro-intestinal disturbances, dry mouth,\r\ntaste disturbances, hypotension, syncope, chest pain, dyspnoea, rhinitis,\r\nmood changes, asthenia, tremor, paraesthesia, urinary disturbances,\r\nimpotence, gynaecomastia, weight changes, myalgia, muscle cramps,\r\nback pain, arthralgia, visual disturbances, tinnitus, pruritus, rashes\r\n(including isolated reports of erythema multiforme), sweating, alopecia,\r\npurpura, and skin discolouration;very rarelygastritis,\r\npancreatitis, hepatitis, jaundice, cholestasis, gingival hyperplasia,\r\nmyocardial infarction, arrhythmias, tachycardia, vasculitis, coughing,\r\nperipheral neuropathy, hyperglycaemia, thrombocytopenia, angioedema,\r\nand urticaria;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "cardiogenic shock, unstable angina, significant\r\naortic stenosis", "hepatic impairment": "may need dose reduction\u2014half-life prolonged", "doses": ["Hypertension or angina, initially 5\u00a0mg once daily; max.\r\n10\u00a0mg once daily", "Tablets from various suppliers may contain\r\ndifferent salts (e.g. amlodipine besilate, amlodipine maleate, and\r\namlodipine mesilate) but the strength is expressed in terms of amlodipine\r\n(base); tablets containing different salts are considered interchangeable"], "pregnancy": "no information available\u2014manufacturer advises avoid,\r\nbut risk to fetus should be balanced against risk of uncontrolled\r\nmaternal hypertension", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "LANREOTIDE": {"indications": "see notes above", "name": "LANREOTIDE", "interactions": {"extra": "", "bad": 0, "interaction": "requirements for  insulin possibly reduced by lanreotide ", "name": "Lanreotide", "backrefs": ["Lanreotide", "Insulin", "Repaglinide", "Metformin"]}, "cautions": "seenotes above; cardiac disorders (including bradycardia);interactions:Appendix 1 (lanreotide)", "side-effects": "seenotes above; also reported\r\nconstipation, dyspepsia, bradycardia, asthenia, dizziness, fatigue,\r\nraised bilirubin, biliary dilatation, alopecia;less commonlyskin nodule, hot flushes, leg pain, malaise, headache, insomnia,\r\ntenesmus, decreased libido, drowsiness, pruritus, increased\r\nsweating;rarelyhypothyroidism (monitor as necessary)", "doses": ["by intramuscular injection, acromegaly\r\nand neuroendocrine (particularly carcinoid) tumours, initially 30\u00a0mg\r\nevery 14 days, frequency increased to every 7\u201310 days according to\r\nresponse"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "NANDROLONE": {"indications": "osteoporosis in postmenopausal women (but not recommended, see notes\r\nabove); aplastic anaemia (section 9.1.3)", "name": "NANDROLONE", "renal impairment": "use with caution\u2014may cause sodium and water retention", "cautions": "cardiac  impairment, hypertension, diabetes mellitus, epilepsy, migraine; monitor skeletal maturation in young patients; skeletal metastases (risk of hypercalcaemia);interactions:Appendix 1 (anabolic steroids)", "side-effects": "acne, sodium retention with oedema, virilisation\r\nwith high doses including voice changes (sometimes irreversible),\r\namenorrhoea, inhibition of spermatogenesis, premature epiphyseal closure;\r\nabnormal liver-function tests reported with high doses; liver tumours\r\nreported occasionally on prolonged treatment with anabolic steroids", "contra-indications": "prostate cancer, male breast cancer, acute porphyria (section 9.8.2)", "hepatic impairment": "use in severe hepatic impairment only if benefit outweighs\r\nrisk", "doses": ["by deep intramuscular injection, 50\u00a0mg\r\nevery 3 weeks"]}, "EMEDASTINE": {"side-effects": "transient burning or stinging; blurred vision,\r\nlocal oedema, keratitis, irritation, dry eye, lacrimation, corneal\r\ninfiltrates (discontinue) and staining; photophobia; headache, and\r\nrhinitis occasionally reported", "indications": "seasonal allergic conjunctivitis", "name": "EMEDASTINE", "doses": ["adultandchildover 3 years, apply twice daily"]}, "SULFAMETHOXAZOLE": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of haematological toxicity when  methotrexate given with sulfamethoxazole (as co-trimoxazole)", "name": "Sulfamethoxazole", "backrefs": ["Mercaptopurine", "Azathioprine", "Amiodarone", "Sulfamethoxazole", "Methotrexate"]}}, "GEMEPROST": {"indications": "see\r\nunder Dose", "name": "GEMEPROST", "renal impairment": "manufacturer advises avoid", "cautions": "obstructive airways disease, cardiovascular insufficiency, raised intra-ocular pressure, cervicitis or vaginitis;interactions:Appendix 1 (prostaglandins)", "side-effects": "vaginal bleeding and uterine pain; nausea, vomiting,\r\nor diarrhoea; headache, muscle weakness, dizziness, flushing, chills,\r\nbackache, dyspnoea, chest pain, palpitation and mild pyrexia; uterine\r\nrupture reported (most commonly in multiparas or if history of uterine\r\nsurgery or if given with intravenous oxytocics); also reported severe\r\nhypotension, coronary artery spasm and myocardial infarction", "contra-indications": "unexplained vaginal bleeding, uterine scarring, placenta praevia", "doses": ["By vagina, cervical ripening prior to first\r\ntrimester surgical abortion, 1\u00a0mg inserted into posterior fornix 3\r\nhours before surgery", "Second trimester abortion, 1\u00a0mg inserted into posterior fornix\r\nevery 3 hours for max. of 5 administrations; second course may begin\r\n24 hours after start of treatment (if treatment fails pregnancy should\r\nbe terminated by another method)", "Second trimester intra-uterine death, 1\u00a0mg inserted into posterior\r\nfornix every 3 hours for max. of 5 administrations only; monitor for\r\ncoagulopathy", "If used in combination with mifepristone,\r\ncarefully monitor blood pressure and pulse for 3 hours"]}, "POSACONAZOLE": {"indications": "invasive aspergillosis (see notes above); fusariosis either unresponsive to, or in patients intolerant\r\nof, amphotericin; chromoblastomycosis and mycetoma either unresponsive\r\nto, or in patients intolerant of,  itraconazole; coccidioidomycosis\r\neither unresponsive to, or in patients intolerant of, amphotericin,\r\nitraconazole, or fluconazole; see also under Dose", "name": "POSACONAZOLE", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of myopathy when  simvastatin given with posaconazole (avoid concomitant use)", "name": "Posaconazole", "backrefs": ["Posaconazole"]}, "cautions": "cardiomyopathy, bradycardia, symptomatic arrhythmias, history of QT interval prolongation, concomitant use with other drugs known to cause QT-interval prolongation; monitor electrolytes (including potassium, magnesium,\r\nand calcium) before and during therapy, monitor liver function;interactions:Appendix 1 (antifungals, triazole)", "side-effects": "gastro-intestinal disturbances (including nausea,\r\nvomiting, abdominal pain, diarrhoea, dyspepsia, and flatulence); dizziness,\r\nheadache, paraesthesia, drowsiness, fatigue, fever, anorexia; blood\r\ndisorders (including anaemia, neutropenia, and thrombocytopenia),\r\nelectrolyte disturbances; dry mouth; rash;less commonlypancreatitis, hepatic disorders, arrhythmias, palpitation, changes\r\nin blood pressure, oedema, convulsions, neuropathy, tremor, hyperglycaemia,\r\nmenstrual disorders, renal failure, musculoskeletal pain, visual disturbances,\r\nmouth ulcers, and alopecia;rarelyileus, cardiac\r\nfailure, myocardial infarction, stroke, thrombosis, syncope, pneumonitis,\r\npsychosis, depression, encephalopathy, adrenal insufficiency, breast\r\npain, hearing impairment, and Stevens-Johnson syndrome", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "monitor liver function; manufacturer advises caution", "doses": ["400\u00a0mg twice daily with foodorif food\r\nnot tolerated, 200\u00a0mg 4 times daily", "Oropharyngeal candidiasis (severe infection or in immunocompromised\r\npatients only), 200\u00a0mg with food on first day, then 100\u00a0mg once daily\r\nwith food for 13 days", "Prophylaxis of invasive fungal infections in patients undergoing\r\nbone-marrow transplantation or receiving chemotherapy for acute myeloid\r\nleukaemia and myelodysplastic syndrome who are expected to become\r\nneutropenic, and who are intolerant of fluconazole or itraconazole,\r\n200\u00a0mg 3 times daily with food, starting before transplantation or\r\nbefore chemotherapy and continued until neutrophil count recovers", "childunder 18 years not recommended"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk and recommends effective contraception during treatment;\r\ntoxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CHARCOAL, ACTIVATED": {"side-effects": "black stools", "indications": "reduction of absorption of poisons in\r\nthe gastro-intestinal system; see also active elimination techniques,above", "name": "CHARCOAL, ACTIVATED", "cautions": "drowsy or comatose patient (risk\r\nof aspiration\u2014ensure airway protected); reduced gastro-intestinal motility (risk of obstruction);notfor poisoning with petroleum distillates, corrosive substances, alcohols, malathion, cyanides, and metal\r\nsalts including iron and lithium salts", "doses": ["Reduction of absorption,adultandchildover 12 years, 50\u00a0g;childunder 12 years, 1\u00a0g/kg (max. 50\u00a0g)", "Active elimination, seenotes above", "Activated charcoal doses in BNF may differ\r\nfrom those in product literature. Suspension or reconstituted powder\r\nmay be mixed with soft drinks (e.g. caffeine-free diet cola) or fruit\r\njuices to mask the taste"]}, "VELAGLUCERASE ALFA": {"indications": "(specialist use only) type I Gaucher\u2019s\r\ndisease", "name": "VELAGLUCERASE ALFA", "cautions": "monitor immunoglobulin G (IgG) antibody\r\nconcentration in severe infusion-related reactions or if there is a lack or loss of effect with velaglucerase alfa", "side-effects": "nausea, abdominal pain, tachycardia, hypertension,\r\nhypotension, flushing, headache, dizziness, malaise, pyrexia, arthralgia,\r\nbone pain, back pain, hypersensitivity reactions, rash, urticaria", "doses": ["By intravenous infusion, 60\u00a0units/kg once\r\nevery 2 weeks; adjusted according to response to 15\u201360\u00a0units/kg once\r\nevery 2 weeks;childunder 18 years\r\nseeBNF for Children"], "pregnancy": "manufacturer advises use with caution\u2014limited information\r\navailable", "breast-feeding": "manufacturer advises use with caution\u2014no information\r\navailable"}, "MEMANTINE HYDROCHLORIDE": {"indications": "moderate to severe dementia in Alzheimer\u2019s disease", "name": "MEMANTINE HYDROCHLORIDE", "renal impairment": "reduce dose to 10\u00a0mg daily if eGFR 30\u201349\u00a0mL/minute/1.73\u00a0m2, if well tolerated after at least 7 days dose can be increased\r\nin steps to 20\u00a0mg daily; reduce dose to 10\u00a0mg daily if eGFR 5\u201329\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 5\u00a0mL/minute/1.73\u00a0m2", "cautions": "history of convulsions;interactions:Appendix 1 (memantine)", "side-effects": "constipation; hypertension; dyspnoea; headache,\r\ndizziness, drowsiness;less commonlyvomiting, thrombosis,\r\nheart failure, confusion, fatigue, hallucinations, and abnormal gait;very rarelyseizures; pancreatitis, psychosis, depression,\r\nand suicidal ideation also reported", "hepatic impairment": "avoid in severe impairment\u2014no information available", "doses": ["Initially 5\u00a0mg once daily, increased in steps of 5\u00a0mg\r\nat weekly intervals to max. 20\u00a0mg daily"]}, "IODINE AND IODIDE": {"indications": "thyrotoxicosis (pre-operative)", "name": "IODINE AND IODIDE", "cautions": "children; not for long-term treatment", "side-effects": "hypersensitivity reactions including coryza-like\r\nsymptoms, headache, lacrimation, conjunctivitis, pain in salivary\r\nglands, laryngitis, bronchitis, rashes; on prolonged treatment depression,\r\ninsomnia, impotence; goitre in infants of mothers taking iodides", "doses": ["0.1\u20130.3\u00a0mL 3 times daily well diluted with milk or water"], "pregnancy": "neonatal goitre and hypothyroidism; see alsonotes above", "breast-feeding": "stop breast-feeding; danger of neonatal hypothyroidism\r\nor goitre; appears to be concentrated in milk; see alsonotes above"}, "CALCITONIN (SALMON)/SALCATONIN": {"indications": "see under Dose", "name": "CALCITONIN (SALMON)/SALCATONIN", "renal impairment": "use with caution", "cautions": "history of allergy (skin test advised); heart failure", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain; flushing;\r\ndizziness, headache, taste disturbances; musculoskeletal pain; with\r\nnasal spray nose and throat irritation, rhinitis, sinusitis and epistaxis;less commonlydiuresis, oedema, cough, visual disturbances,\r\ninjection-site reactions, rash, hypersensitivity reactions including\r\npruritus", "contra-indications": "hypocalcaemia", "doses": ["Hypercalcaemia of malignancy (see alsosection 9.5.1.2),adultover 18 years,by subcutaneousorintramuscular injection, 100\u00a0units\r\nevery 6\u20138 hours adjusted according to response; max. 400\u00a0units every\r\n6\u20138 hours; in severe or emergency cases,by intravenous infusion, up to 10\u00a0units/kg over at least 6 hours", "Paget\u2019s disease of bone,adultover 18 years,by subcutaneousorintramuscular injection, 50\u00a0units 3 times weekly to\r\n100\u00a0units daily adjusted according to response", "Postmenopausal osteoporosis to reduce risk of vertebral fractures,intranasally, 200\u00a0units (1 spray) into one nostril daily,\r\nwith dietary calcium and vitamin D supplements (section 9.5.1.1andsection\r\n9.6.4)", "Prevention of acute bone loss due to sudden immobility,adultover 18 years,by subcutaneousorintramuscular injection, 100\u00a0units\r\ndaily in 1\u20132 divided doses for 2\u20134 weeks, reduced to 50\u00a0units daily\r\nat start of mobilisation and continued until fully mobile"], "pregnancy": "avoid unless potential benefit outweighs risk (toxicity\r\ninanimalstudies)", "breast-feeding": "avoid; inhibits lactation inanimals"}, "PARATHYROID HORMONE": {"indications": "treatment of osteoporosis in postmenopausal women\r\nat high risk of fractures (to reduce the risk of vertebral fractures)\r\n(see also notes above)", "name": "PARATHYROID HORMONE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73m2", "cautions": "monitor serum or urinary calcium concentration\r\nat 1, 3 and 6 months after initiation of treatment (consult product literature for guidance if serum-calcium concentration\r\nraised); active or previous urolithiasis; concomitant cardiac glycosides", "side-effects": "nausea, vomiting, dyspepsia, constipation, diarrhoea;\r\npalpitation; headache, dizziness, fatigue, asthenia; transient hypercalcaemia,\r\nhypercalciuria; muscle cramp, pain in extremities, back pain; injection-site\r\nreactions;less commonlyabdominal pain, altered\r\nsense of smell, taste disturbance, anorexia, influenza, hyperuricaemia", "contra-indications": "previous radiation therapy to\r\nskeleton, pre-existing hypercalcaemia, metabolic bone disease (including hyperparathyroidism and Paget\u2019s disease), unexplained raised levels of alkaline phosphatase", "hepatic impairment": "avoid", "doses": ["By subcutaneous injection, 100\u00a0micrograms\r\ndaily, max. duration of treatment 24 months"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "OPIOID ANALGESICS": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  domperidone on gastro-intestinal activity antagonised by opioid analgesics ", "name": "Opioid Analgesics", "backrefs": ["Opioid Analgesics", "Anaesthetics, General (intravenous)", "Antihistamines, Sedating"]}}, "TESTOLACTONE": {"interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  phenindione enhanced by testolactone ", "name": "Testolactone", "backrefs": ["Testolactone"]}}, "PEPPERMINT OIL": {"indications": "relief of abdominal colic and distension, particularly\r\nin irritable bowel syndrome", "name": "PEPPERMINT OIL", "cautions": "sensitivity to menthol", "side-effects": "heartburn, perianal irritation; rarely, allergic\r\nreactions (including rash, headache, bradycardia, muscle tremor, ataxia)", "doses": ["adultover 18 years, 1\u20132\r\ncapsules swallowed whole with water, 3 times daily before meals for\r\nup to 2\u20133 months if necessary"], "pregnancy": "not known to be harmful", "breast-feeding": "significant levels of menthol in breast milk\r\nunlikely"}, "DEXKETOPROFEN": {"indications": "short-term treatment of mild to moderate pain including dysmenorrhoea", "name": "DEXKETOPROFEN", "renal impairment": "reduce initial dose to 50\u00a0mg daily; avoid in moderate\r\nto severe impairment; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": " probenecid reduces excretion of dexketoprofen (increased plasma concentration)", "name": "Dexketoprofen", "backrefs": ["Dexketoprofen"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "reduce initial dose to max. 50\u00a0mg daily in mild to\r\nmoderate impairment; see alsonotes above", "doses": ["12.5\u00a0mg every 4\u20136 hoursor25\u00a0mg every\r\n8 hours; max. 75\u00a0mg daily;elderlyinitially\r\nmax. 50\u00a0mg daily;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid\u2014no information available;\r\nsee alsonotes above"}, "LENALIDOMIDE": {"indications": "seenotes above", "name": "LENALIDOMIDE", "renal impairment": "starting dose 10\u00a0mg once daily if creatinine clearance\r\n30\u201350\u00a0mL/minute; starting dose 15\u00a0mg on alternate days if creatinine\r\nclearance less than 30\u00a0mL/minute", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  digoxin possibly increased by lenalidomide ", "name": "Lenalidomide", "backrefs": ["Lenalidomide"]}, "cautions": "seenotes above; monitor full blood\r\ncount (including differential white cell count and platelet count)\r\nbefore treatment and every week for the first 8 weeks then every 4\r\nweeks (reduce dose or interrupt treatment\r\nif neutropenia or thrombocytopenia develop\u2014consult product literature); monitor for arterial or venous thromboembolism (consider\r\npermanent discontinuation if thromboembolic event occurs) and use caution with concomitant drugs that increase\r\nthe risk of thromboembolism\u2014see also Thromboembolism\r\nbelow; high tumour burden\u2014risk oftumour lysis syndrome; monitor thyroid\r\nfunction; risk factors for myocardial infarction;interactions:Appendix 1 (lenalidomide)", "side-effects": "myocardial infarction, hypotension, deep vein\r\nthrombosis; pneumonia, dyspnoea; tremor, hypoaesthesia, fatigue, asthenia;\r\nneutropenia, thrombocytopenia, anaemia, lymphopenia, leucopenia; muscle\r\ncramp; pruritus, rash;rarelyStevens-Johnson syndrome\r\nand toxic epidermal necrolysis;also reportedinterstitial\r\npneumonitis, pancreatitis, pulmonary embolism, cerebrovascular events,\r\nsecondary malignancies", "doses": ["adultover 18 years, 25\u00a0mg\r\nonce daily for 21 consecutive days of a 28-day cycle; for doses of\r\ndexamethasone, consult product literature"], "pregnancy": "important: teratogenic risk; see\r\nalsonotes above", "breast-feeding": "discontinue breast-feeding\u2014no information available"}, "PIZOTIFEN": {"indications": "prevention of vascular headache including classical migraine, common\r\nmigraine, and cluster headache", "name": "PIZOTIFEN", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by pizotifen ", "name": "Pizotifen", "backrefs": ["Pizotifen"]}, "cautions": "urinary retention; susceptibility to angle-closure glaucoma; history of epilepsy;interactions:Appendix 1 (pizotifen)", "side-effects": "dry mouth, nausea; dizziness, drowsiness, increased\r\nappetite, weight gain;less commonlyconstipation;rarelyanxiety, aggression, insomnia, paraesthesia, hallucination,\r\ndepression, arthralgia, myalgia;very rarelyseizures,\r\nurticaria, rash; jaundice, hepatitis, and muscle cramps\r\nalso reported", "hepatic impairment": "use with caution", "doses": ["Initially 500\u00a0micrograms at night increased gradually\r\nto usual dose of 1.5\u00a0mg at nightorin 3 divided\r\ndoses; may be further increased up to max. daily dose 4.5\u00a0mg (but\r\nrarely necessary), max. single dose 3\u00a0mg;childover 5 years, up to 1.5\u00a0mg daily in divided doses; max. single dose\r\nat night 1\u00a0mg"], "pregnancy": "avoid unless potential benefit outweighs risk", "breast-feeding": "amount probably too small to be harmful, but\r\nmanufacturer advises avoid"}, "PERINDOPRIL ARGININE": {"indications": "see underPerindopril Erbumineandnotes above", "name": "PERINDOPRIL ARGININE", "renal impairment": "seenotes above; max.\r\ninitial dose 2.5\u00a0mg once daily if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; 2.5\u00a0mg once daily on alternate days if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see underPerindopril Erbumineandnotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Hypertension, initially 5\u00a0mg once daily in the morning\r\nfor 1 month, subsequently adjusted according to response; if used\r\nin addition to diuretic (see notes above),\r\nin elderly, in renal impairment, in cardiac decompensation, or in\r\nvolume depletion, initially 2.5\u00a0mg once daily; max. 10\u00a0mg daily", "Heart failure (adjunct), initially 2.5\u00a0mg once daily in the\r\nmorning under close medical supervision (see notes above),\r\nincreased after 2 weeks to max. 5\u00a0mg once daily if tolerated", "Following myocardial infarction or revascularisation, initially\r\n5\u00a0mg once daily in the morning increased after 2 weeks to 10\u00a0mg once\r\ndaily if tolerated;elderly2.5\u00a0mg\r\nonce daily for 1 week, then 5\u00a0mg once daily for 1 week, thereafter\r\nincreased to 10\u00a0mg once daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ZALEPLON": {"indications": "insomnia (short-term use\u2014up to 2 weeks)", "name": "ZALEPLON", "renal impairment": "avoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits metabolism of zaleplon (increased plasma concentration)", "name": "Zaleplon", "backrefs": ["Zaleplon"]}, "cautions": "respiratory insufficiency (avoid if severe); muscle weakness and myasthenia gravis, history of drug oralcoholabuse; depression (risk of suicidal ideation); avoid prolonged\r\nuse (risk of tolerance and withdrawal symptoms);interactions:Appendix 1 (anxiolytics\r\nand hypnotics)", "side-effects": "amnesia, paraesthesia, drowsiness; dysmenorrhea;less commonlynausea, anorexia, asthenia, incoordination,\r\nconfusion, impaired concentration, depression, depersonalisation,\r\ndizziness, hallucinations, disturbances of smell, hearing, speech,\r\nand vision; photosensitivity; paradoxical effects (seeParadoxical Effects) and sleep-walking also reported", "contra-indications": "sleep apnoea syndrome, marked neuromuscular respiratory weakness including unstable myasthenia gravis", "hepatic impairment": "can precipitate coma; reduce dose to 5\u00a0mg (avoid if\r\nsevere impairment)", "doses": ["adultover 18 years, 10\u00a0mg\r\nat bedtime or after going to bed if difficulty falling asleep;elderly5\u00a0mg", "Patients should be advised not to take a\r\nsecond dose during a single night"], "pregnancy": "use only if necessary and restrict to occasional\r\nshort-term use; risk of withdrawal symptoms in neonate if used in\r\nlate pregnancy", "breast-feeding": "present in milk but amount probably too small\r\nto be harmful"}, "INTERFERON GAMMA-1b": {"indications": "seenotes above", "name": "INTERFERON GAMMA-1b", "renal impairment": "manufacturer advises caution in severe impairment\u2014risk\r\nof accumulation", "cautions": "seizure disorders (including seizures associated with fever); cardiac\r\ndisease (including ischaemia, congestive heart failure, and arrhythmias); monitor before and during\r\ntreatment: haematological tests (including full blood count, differential\r\nwhite cell count, and platelet count), blood chemistry tests (including\r\nrenal and liver function tests) and urinalysis; avoid simultaneous administration of foreign proteins including immunological products (risk of exaggerated immune response);interactions:Appendix 1 (interferons)", "side-effects": "nausea, vomiting; headache, fatigue, fever; myalgia,\r\narthralgia; rash, injection-site reactions;rarelyconfusion and systemic lupus erythematosus; also reported, neutropenia,\r\nthrombocytopenia, and raised liver enzymes", "hepatic impairment": "manufacturer advises caution in severe impairment\u2014risk\r\nof accumulation", "doses": ["See under preparation"], "pregnancy": "manufacturers recommend avoid unless potential benefit\r\noutweighs risk (toxicity inanimalstudies); effective\r\ncontraception required during treatment\u2014consult product literature", "breast-feeding": "manufacturers advise avoid\u2014no information available"}, "RABEPRAZOLE": {"interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  saquinavir possibly increased by rabeprazole\u2014manufacturer of saquinavir advises avoid concomitant use", "name": "Rabeprazole", "backrefs": ["Rabeprazole"]}}, "FERROUS SULPHATE": {"side-effects": "seenotes above", "indications": "iron-deficiency anaemia", "name": "FERROUS SULPHATE", "cautions": "interactions:Appendix 1 (iron)", "doses": ["adultandchildover 12 years, 1 tablet daily before food"]}, "METOCLOPRAMIDE HYDROCHLORIDE": {"indications": "adults, nausea and vomiting, particularly\r\nin gastro-intestinal disorders (section 1.2) and treatment\r\nwith cytotoxics or radiotherapy; migraine (section 4.7.4.1)", "name": "METOCLOPRAMIDE HYDROCHLORIDE", "renal impairment": "avoid or use small dose in severe impairment; increased\r\nrisk of extrapyramidal reactions", "cautions": "elderly, young\r\nadults (15\u201319 years old), and children; atopic allergy (including asthma); cardiac conduction disturbances (and concomitant\r\nuse of other drugs affecting cardiac conduction);  may mask underlying disorders such as cerebral irritation; acute porphyria (section 9.8.2); epilepsy;interactions:Appendix 1 (metoclopramide)", "side-effects": "extrapyramidal effects (especially in children\r\nand young adults (15\u201319 years old)\u2014seeabove),\r\nhyperprolactinaemia, occasionally tardive dyskinesia on prolonged\r\nadministration; also reported, dyspnoea, anxiety, confusion, drowsiness,\r\ndizziness, tremor, restlessness, diarrhoea, depression, neuroleptic\r\nmalignant syndrome, visual disturbances, rashes, pruritus, oedema;\r\ncardiac conduction abnormalities reported following intravenous administration;rarelymethaemoglobinaemia (more severe in G6PD deficiency)", "contra-indications": "gastro-intestinal obstruction, perforation or haemorrhage; 3\u20134 days\r\nafter gastro-intestinal surgery; phaeochromocytoma", "hepatic impairment": "reduce dose", "doses": ["By mouthorby intramuscular injectionorby\r\nintravenous injectionover 1\u20132 minutes, nausea and vomiting,\r\n10\u00a0mg (5\u00a0mg in young adults 15\u201319 years, body-weight under 60\u00a0kg)\r\n3 times daily;childup to 1 year (body-weight\r\nup to 10\u00a0kg) 100\u00a0micrograms/kg (max. 1\u00a0mg) twice daily, 1\u20133 years\r\n(body-weight 10\u201314\u00a0kg) 1\u00a0mg 2\u20133 times daily, 3\u20135 years (body-weight\r\n15\u201319\u00a0kg) 2\u00a0mg 2\u20133 times daily, 5\u20139 years (body-weight 20\u201329\u00a0kg) 2.5\u00a0mg\r\n3 times daily, 9\u201315 years (body-weight 30\u00a0kg and over) 5\u00a0mg 3 times\r\ndaily", "Daily dose of metoclopramide should not normally\r\nexceed 500\u00a0micrograms/kg, particularly for children and young adults\r\n(restricted use, see above)", "For diagnostic procedures, as a single dose 5\u201310 minutes before\r\nexamination, 10\u201320\u00a0mg (10\u00a0mg in young adults 15\u201319 years);childunder 3 years 1\u00a0mg, 3\u20135 years 2\u00a0mg, 5\u20139 years\r\n2.5\u00a0mg, 9\u201314 years 5\u00a0mg"], "pregnancy": "not known to be harmful", "breast-feeding": "small amount present in milk; avoid"}, "VITAMIN K (PHYTOMENADIONE)": {"interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  phenindione antagonised by vitamin K ", "name": "Vitamin K (Phytomenadione)", "backrefs": []}}, "PIROXICAM": {"indications": "rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis\r\n(see also CHMP advice below)", "name": "PIROXICAM", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of piroxicam (risk of toxicity)\u2014avoid concomitant use", "name": "Piroxicam", "backrefs": ["Piroxicam"]}, "cautions": "seenotes aboveand CHMP\r\nadvice below", "side-effects": "seenotes above", "contra-indications": "inflammatory bowel disease; see alsonotes above", "hepatic impairment": "seenotes above", "doses": ["osteoarthritis, rheumatic disease and acute musculoskeletal\r\ndisorders, 1 tablet daily (may be halved in elderly);childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful; see alsonotes above"}, "LODOXAMIDE": {"side-effects": "burning, stinging, itching, blurred vision, tear\r\nproduction disturbance, and ocular discomfort;less commonlyflushing, nasal dryness, dizziness, drowsiness, headache, blepharitis\r\nand keratitis", "indications": "allergic conjunctivitis", "name": "LODOXAMIDE", "doses": ["adultandchildover 4 years, apply 4 times daily; improvement\r\nof symptoms may sometimes require treatment for up to 4 weeks"]}, "LEVOFLOXACIN": {"indications": "see under Dose", "name": "LEVOFLOXACIN", "renal impairment": "usual initial dose then use half normal dose if eGFR\r\n20\u201350\u00a0mL/minute/1.73\u00a0m2; consult product literature if\r\neGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "oral  iron reduces absorption of levofloxacin ", "name": "Levofloxacin", "backrefs": ["Levofloxacin"]}, "cautions": "seenotes above; history of psychiatric\r\nillness;interactions:Appendix 1 (quinolones)", "side-effects": "seenotes above;\r\nalso flatulence, constipation;rarelytachycardia;very rarelypneumonitis, peripheral neuropathy, and hypoglycaemia;\r\nalso reported, rhabdomyolysis, potentially life-threatening hepatic\r\nfailure; local reactions and transient hypotension reported with infusion", "contra-indications": "seenotes above", "doses": ["By mouth, acute sinusitis, 500\u00a0mg\r\ndaily for 10\u201314 days", "Exacerbation of chronic bronchitis, 250\u2013500\u00a0mg daily for 7\u201310\r\ndays", "Community-acquired pneumonia, 500\u00a0mg once or twice daily for\r\n7\u201314 days", "Urinary-tract infections, 250\u00a0mg daily for 7\u201310 days (for 3\r\ndays in uncomplicated infection)", "Chronic prostatitis, 500\u00a0mg once daily for 28 days", "Skin and soft tissue infections, 250\u00a0mg dailyor500\u00a0mg once or twice daily for 7\u201314 days", "By intravenous infusion(over at\r\nleast 60 minutes for 500\u00a0mg), community-acquired pneumonia, 500\u00a0mg\r\nonce or twice daily", "Complicated urinary-tract infections, 250\u00a0mg daily, increased\r\nin severe infections", "Skin and soft tissue infections, 500\u00a0mg twice daily"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid"}, "VORICONAZOLE": {"indications": "invasive aspergillosis; serious infections caused byScedosporiumspp.,Fusariumspp., or invasive fluconazole-resistantCandidaspp. (includingC. krusei)", "name": "VORICONAZOLE", "renal impairment": "intravenous vehicle may accumulate if eGFR less than\r\n50\u00a0mL/minute/1.73\u00a0m2\u2014use intravenous infusion only if potential\r\nbenefit outweighs risk, and monitor renal function; alternatively,\r\nuse tablets or oral suspension (no dose adjustment required)", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir reduces plasma concentration of voriconazole\u2014avoid concomitant use", "name": "Voriconazole", "backrefs": ["Voriconazole"]}, "cautions": "electrolyte disturbances, cardiomyopathy, bradycardia, symptomatic arrhythmias, history of QT interval prolongation, concomitant\r\nuse with other drugs that prolong QT interval; avoid exposure to sunlight; patients at\r\nrisk of pancreatitis; monitor renal function;interactions:Appendix 1 (antifungals, triazole)", "side-effects": "nausea, vomiting, abdominal pain, diarrhoea, jaundice\r\n(see Hepatotoxicity above), oedema, hypotension, chest pain, respiratory\r\ndistress syndrome, sinusitis, headache, dizziness, asthenia, anxiety,\r\ndepression, confusion, agitation, hallucinations, paraesthesia, tremor,\r\ninfluenza-like symptoms, hypoglycaemia, haematuria, blood disorders\r\n(including anaemia, thrombocytopenia, leucopenia, pancytopenia), acute\r\nrenal failure, hypokalaemia, visual disturbances (including altered\r\nperception, blurred vision, and photophobia), rash, pruritus, photosensitivity,\r\nalopecia, cheilitis, injection-site reactions;less commonlydyspepsia, duodenitis, cholecystitis, pancreatitis, hepatitis (see\r\nHepatotoxicity above), constipation, arrhythmias (including QT interval\r\nprolongation), syncope, raised serum cholesterol, hypersensitivity\r\nreactions (including flushing), ataxia, nystagmus, hypoaesthesia,\r\nadrenocortical insufficiency, arthritis, blepharitis, optic neuritis,\r\nscleritis, glossitis, gingivitis, psoriasis, Stevens-Johnson syndrome;rarelypseudomembranous colitis, taste disturbances (more\r\ncommon with oral suspension), convulsions, insomnia, tinnitus, hearing\r\ndisturbances, extrapyramidal effects, hypertonia, hypothyroidism,\r\nhyperthyroidism, discoid lupus erythematosus, toxic epidermal necrolysis,\r\npseudoporphyria, retinal haemorrhage, optic atrophy; also reported\r\nsquamous cell carcinoma of skin (particularly in presence of phototoxicity\r\nor in the immunosuppressed)", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "in mild to moderate hepatic cirrhosis use usual initial\r\ndose then halve subsequent doses; no information available for severe\r\nhepatic cirrhosis\u2014manufacturer advises use only if potential benefit\r\noutweighs risk. See also Hepatotoxicity above", "doses": ["By mouth,adultandchildover 12 years, body-weight\r\nover 40\u00a0kg, 400\u00a0mg every 12 hours for 2 doses then 200\u00a0mg every 12\r\nhours, increased if necessary to 300\u00a0mg every 12 hours; body-weight\r\nunder 40\u00a0kg, 200\u00a0mg every 12 hours for 2 doses then 100\u00a0mg every 12\r\nhours, increased if necessary to 150\u00a0mg every 12 hours;child2\u201312 years, (oral suspension recommended) 200\u00a0mg\r\nevery 12 hours", "By intravenous infusion, 6\u00a0mg/kg every 12 hours\r\nfor 2 doses, then 4\u00a0mg/kg every 12 hours (reduced to 3\u00a0mg/kg every\r\n12 hours if not tolerated) for max. 6 months;child2\u201318 years seeBNF for Children"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises avoid unless potential benefit outweighs risk; effective contraception\r\nrequired during treatment", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "DILTIAZEM HYDROCHLORIDE": {"indications": "prophylaxis and treatment of angina; hypertension", "name": "DILTIAZEM HYDROCHLORIDE", "renal impairment": "start with smaller dose", "cautions": "heart failure or significantly impaired left ventricular function, bradycardia (avoid if severe), first degree\r\nAV block, or prolonged PR interval;interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "bradycardia, sino-atrial block, AV block, palpitation,\r\ndizziness, hypotension, malaise, asthenia, headache, hot flushes,\r\ngastro-intestinal disturbances, oedema (notably of ankles); rarely\r\nrashes (including erythema multiforme and exfoliative dermatitis),\r\nphotosensitivity; hepatitis, gynaecomastia, gum hyperplasia, extrapyramidal\r\nsymptoms, depression reported;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "severe bradycardia, left ventricular failure with pulmonary congestion, second- or third-degree AV block (unless pacemaker fitted), sick sinus syndrome; acute porphyria (section 9.8.2)", "hepatic impairment": "reduce dose", "doses": ["angina and mild to moderate hypertension, initially 240\u00a0mg\r\nonce daily (elderly and in hepatic and renal impairment, dose form\r\nnot appropriate for initial dose titration); increased if necessary\r\nto 300\u00a0mg once daily"], "pregnancy": "avoid", "breast-feeding": "significant amount present in milk\u2014no evidence\r\nof harm but avoid unless no safer alternative"}, "ATENOLOL": {"indications": "see under Dose", "name": "ATENOLOL", "renal impairment": "max. 50\u00a0mg daily (10\u00a0mg on alternate daysintravenously) if eGFR 15\u201335\u00a0mL/minute/1.73\u00a0m2; max. 25\u00a0mg daily or\r\n50\u00a0mg on alternate days (10\u00a0mg every 4 daysintravenously) if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "doses": ["hypertension, 1 capsule daily, increased if necessary\r\nto twice daily;elderly, 1 daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "OXYCODONE WITH NALOXONE": {"indications": "severe pain requiring opioid\r\nanalgesia", "name": "OXYCODONE WITH NALOXONE", "renal impairment": "seenotes aboveand underOxycodone Hydrochloride", "cautions": "seenotes aboveand underOxycodone Hydrochloride; also hypertension", "side-effects": "see underOxycodone Hydrochloride; withdrawal symptoms\r\nmay be provoked in patients switching from other chronic high-dose\r\nopioid treatment; also weight changes, angina, hypertension, rhinorrhoea,\r\nmalaise;rarelyyawning", "contra-indications": "seenotes aboveand underOxycodone Hydrochloride", "hepatic impairment": "seenotes aboveand underOxycodone Hydrochloride", "doses": ["See under preparations"], "pregnancy": "seenotes above", "breast-feeding": "see underOxycodone Hydrochloride"}, "STREPTOMYCIN": {"indications": "tuberculosis, in combination with other drugs; adjunct todoxycyclinein brucellosis; enterococcal endocarditis (Table\r\n1,section 5.1)", "name": "STREPTOMYCIN", "renal impairment": "see under Aminoglycosides,section 5.1.4", "cautions": "see under Aminoglycosides,section 5.1.4;interactions:Appendix 1 (aminoglycosides)", "side-effects": "see under Aminoglycosides,section 5.1.4; also\r\nhypersensitivity reactions, paraesthesia of mouth", "contra-indications": "see under Aminoglycosides,section 5.1.4", "doses": ["By deep intramuscular injection,\r\ntuberculosis  [unlicensed], 15\u00a0mg/kg (max. 1\u00a0g) daily (reduced in\r\nthose under 50\u00a0kg, those over 40 years, or those with renal impairment)", "Brucellosis, expert advice essential", "Side-effects increase after\r\na cumulative dose of 100\u00a0g, which should only be exceeded in exceptional\r\ncircumstances", "One-hour (\u2018peak\u2019) concentration should be\r\n15\u201340\u00a0mg/litre; pre-dose (\u2018trough\u2019) concentration should be less than\r\n5\u00a0mg/litre (less than 1\u00a0mg/litre in renal impairment or in those over\r\n50 years)"], "pregnancy": "see under Aminoglycosides,section 5.1.4"}, "BRINZOLAMIDE": {"indications": "reduction of intra-ocular pressure in ocular hypertension and open-angle\r\nglaucomaeitheras adjunct to beta-blockers or prostaglandin\r\nanaloguesorused alone in patients unresponsive\r\nto beta-blockers or if beta-blockers contra-indicated", "name": "BRINZOLAMIDE", "renal impairment": "see Cautions above; also avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "systemic absorption follows topical application; renal tubular immaturity or abnormality;interactions:Appendix 1 (brinzolamide)", "side-effects": "seenotes above; also taste\r\ndisturbances, dry mouth, headache, ocular disturbances (including\r\ncorneal erosion, corneal oedema, photophobia, and reduced visual acuity);less commonlynausea, vomiting, diarrhoea, dyspepsia, oesophagitis,\r\nflatulence, oral hypoaesthesia and paraesthesia, chest pain, bradycardia,\r\npalpitation, dyspnoea, cough, upper respiratory tract congestion,\r\npharyngitis, depression, sleep disturbances, nervousness, malaise,\r\ndrowsiness, amnesia, dizziness, paraesthesia, sinusitis, decreased\r\nlibido, erectile dysfunction, renal pain, epistaxis, nasal dryness,\r\nthroat irritation, tinnitus, alopecia;also reportedarrhythmia, tachycardia, hypertension, peripheral oedema, asthma,\r\ntremor, vertigo, rhinitis, dermatitis, erythema", "contra-indications": "hyperchloraemic acidosis; sulfonamide hypersensitivity", "hepatic impairment": "manufacturer advises avoid", "doses": ["Apply twice daily increased to max. 3 times daily if necessary"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "use only if benefit outweighs risk"}, "Other preparations for urinary disorders": {"name": "Other preparations for urinary disorders", "doses": ["1\u20132 capsules 3\u20134 times daily before food;childnot recommended"]}, "THEOPHYLLINE": {"indications": "reversible airways obstruction, severe acute asthma; see alsoManagement of Chronic Asthma\r\ntableandManagement of Acute Asthma\r\ntable", "name": "THEOPHYLLINE", "interactions": {"extra": "", "bad": 0, "interaction": "excretion of  lithium increased by theophylline (reduced plasma concentration)", "name": "Theophylline", "backrefs": ["Theophylline"]}, "cautions": "seenotes above, also cardiac arrhythmias or other cardiac disease; hypertension; hyperthyroidism; peptic ulcer; epilepsy; elderly; fever; hypokalaemia risk, seesection 3.1.1.1; avoid in acute porphyria (section 9.8.2); monitor plasma-theophylline concentration (seenotes above); dose adjustment\r\nmay be necessary if smoking started or stopped during treatment", "side-effects": "nausea, vomiting, gastric irritation, diarrhoea,\r\npalpitation, tachycardia, arrhythmias, headache, CNS stimulation,\r\ninsomnia, convulsions;overdosage:seeEmergency Treatment of Poisoning", "hepatic impairment": "reduce dose", "doses": ["200\u00a0mg every 12 hours, increased according to response\r\nto 400\u00a0mg every 12 hours;child2\u201312\r\nyears, 9\u00a0mg/kg (up to 200\u00a0mg) every 12 hours; some children with chronic\r\nasthma may require 10\u201316\u00a0mg/kg (max. 400\u00a0mg) every 12 hours", "May be appropriate to give larger evening\r\nor morning dose to achieve optimum therapeutic effect when symptoms\r\nmost severe; in patients whose night or daytime symptoms persist despite\r\nother therapy, who are not currently receivingtheophylline, total daily requirement may be added as single evening or morning\r\ndose"], "pregnancy": "neonatal irritability and apnoea have been reported;\r\nsee alsosection 3.1", "breast-feeding": "present in milk\u2014irritability in infant reported;\r\nmodified-release preparations preferable; see alsosection 3.1"}, "BETAHISTINE DIHYDROCHLORIDE": {"indications": "vertigo, tinnitus and hearing loss associated with M\u00e9ni\u00e8re\u2019s\r\ndisease", "name": "BETAHISTINE DIHYDROCHLORIDE", "cautions": "asthma, history\r\nof peptic ulcer;interactions:Appendix\r\n1 (betahistine)", "side-effects": "gastro-intestinal disturbances; headache, rashes\r\nand pruritus reported", "contra-indications": "phaeochromocytoma", "doses": ["Initially 16\u00a0mg 3 times daily, preferably with food; maintenance\r\n24\u201348\u00a0mg daily;childnot recommended"], "pregnancy": "avoid unless clearly necessary\u2014no information available", "breast-feeding": "use only if potential benefit outweighs risk\u2014no\r\ninformation available"}, "ANTIDEPRESSANTS, TRICYCLIC (RELATED)": {"interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  brimonidine advises avoid concomitant use with tricyclic-related antidepressants ", "name": "Antidepressants, Tricyclic (related)", "backrefs": []}}, "DEGARELIX": {"indications": "seenotes above", "name": "DEGARELIX", "renal impairment": "manufacturer advises caution in severe impairment\u2014no\r\ninformation available", "cautions": "susceptibility to QT-interval prolongation\r\n(avoid concomitant use of drugs that prolong QT interval); monitor bone density; diabetes", "side-effects": "nausea; dizziness, headache, drowsiness, insomnia,\r\nasthenia; influenza-like symptoms; hot flushes, sweating (including\r\nnight sweats), weight gain; injection-site reactions;less\r\ncommonlydiarrhoea, vomiting, abdominal discomfort, dry mouth,\r\nconstipation, anorexia, atrio-ventricular block, QT-interval prolongation,\r\nfainting, hypertension, hypersensitivity reactions, depression, anxiety,\r\noedema, gynaecomastia, micturition urgency, renal impairment, sexual\r\ndysfunction, pelvic pain, prostatitis, testicular pain, anaemia, musculoskeletal\r\npain, tinnitus, urticaria, alopecia, and rash", "hepatic impairment": "manufacturer advises caution in severe impairment\u2014no\r\ninformation available", "doses": ["By subcutaneous injectioninto the abdominal\r\nregion,adultover 18 years, initially\r\n240\u00a0mg (administered as 2 injections of 120\u00a0mg), then 80\u00a0mg every\r\n28 days"]}, "PIPERACILLIN": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  non-depolarising muscle relaxants enhanced by piperacillin ", "name": "Piperacillin", "backrefs": ["Piperacillin"]}}, "AMITRIPTYLINE": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  duloxetine given with amitriptyline ", "name": "Amitriptyline", "backrefs": ["Amitriptyline"]}}, "IBANDRONIC ACID": {"indications": "see under Dose", "name": "IBANDRONIC ACID", "renal impairment": "for treatment of osteoporosis, avoid if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2; for reduction of bone damage in bone\r\nmetastases, if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2reduceintravenous doseto 4\u00a0mg and infuse over 1 hour, reduceoral doseto 50\u00a0mg on alternative days, if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2reduceintravenous doseto 2\u00a0mg and infuse over 1 hour, reduceoral doseto 50\u00a0mg once weekly", "cautions": "consider dental check-up before initiating\r\nbisphosphonate (risk of osteonecrosis of\r\nthe jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, seeMHRA/CHM advice; monitor renal function and serum calcium, phosphate\r\nand magnesium; cardiac disease (avoid fluid overload);interactions:Appendix 1 (bisphosphonates)", "side-effects": "hypocalcaemia, hypophosphataemia, influenza-like\r\nsymptoms (including fever, chills, and muscle pain), bone pain; oesophageal\r\nreactions (see below), diarrhoea, nausea, vomiting, gastritis, abdominal\r\npain, dyspepsia, pharyngitis; headache, asthenia, rash;rarelyanaemia, atypical femoral fractures (seeMHRA/CHM advice),\r\nhypersensitivity reactions (pruritus, bronchospasm and angioedema\r\nreported); urticaria; injection-site reactions;very rarelyosteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw)", "contra-indications": "hypocalcaemia;oral routeabnormalities of the oesophagus and other factors which delay emptying\r\n(e.g. stricture or achalasia)", "doses": ["Reduction of bone damage in bone metastases in breast\r\ncancer,by mouth, 50\u00a0mg daily,orby intravenous infusion, 6\u00a0mg every 3\u20134 weeks", "Hypercalcaemia of malignancyby intravenous infusion, according to serum calcium concentration, 2\u20134\u00a0mg in single infusion", "Treatment of postmenopausal osteoporosis,by mouth, 150\u00a0mg once a monthorby intravenous injectionover 15\u201330\u00a0seconds, 3\u00a0mg every 3 months", "childnot recommended", "Tablets should be swallowed whole\r\nwith plenty of water while sitting or standing; to be taken on an\r\nempty stomach at least 30 minutes (ibandronic acid tablets, 50\u00a0mg)\r\nor 1 hour (Bonviva\u00ae tablets, 150\u00a0mg) before first\r\nfood or drink (other than water) of the day, or another oral medicine;\r\npatient should stand or sit upright for at least 1 hour after taking\r\ntablet"], "pregnancy": "avoid", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "DANAZOL": {"indications": "see notes above and under Dose", "name": "DANAZOL", "renal impairment": "caution in renal impairment (avoid if severe)", "interactions": {"extra": "", "bad": 1, "interaction": "possible increased risk of myopathy when  simvastatin given with danazol ", "name": "Danazol", "backrefs": ["Danazol"]}, "cautions": "cardiac impairment (avoid\r\nif severe), elderly, polycythaemia, epilepsy, diabetes mellitus, hypertension, migraine, lipoprotein disorder, history of thrombosis or thromboembolic\r\ndisease; withdraw if\r\nvirilisation (may be irreversible on continued use); non-hormonal contraceptive methods should be used, if appropriate;interactions:Appendix 1 (danazol)", "side-effects": "nausea, dizziness, skin reactions including rashes,\r\nphotosensitivity and exfoliative dermatitis, fever, backache, nervousness,\r\nmood changes, anxiety, changes in libido, vertigo, fatigue, epigastric\r\nand pleuritic pain, headache, weight gain; menstrual disturbances,\r\nvaginal dryness and irritation, flushing and reduction in breast size;\r\nmusculo-skeletal spasm, joint pain and swelling, hair loss; androgenic\r\neffects including acne, oily skin, oedema, hirsutism, voice changes\r\nand rarely clitoral hypertrophy (see also Cautions); temporary alteration\r\nin lipoproteins and other metabolic changes, insulin resistance; thrombotic\r\nevents; leucopenia, thrombocytopenia, eosinophilia, reversible erythrocytosis\r\nor polycythaemia reported; headache and visual disturbances may indicate\r\nbenign intracranial hypertension; rarely cholestatic jaundice, pancreatitis,\r\npeliosis hepatis and benign hepatic adenomata", "contra-indications": "ensure that patients with amenorrhoea\r\nare not pregnant; thromboembolic disease; undiagnosed genital bleeding; androgen-dependent tumours; acute porphyria (section 9.8.2)", "hepatic impairment": "caution in hepatic impairment (avoid if severe)", "doses": ["In women of child-bearing potential, treatment\r\nshould start during menstruation, preferably on day 1", "Endometriosis, 200\u2013800\u00a0mg daily in up to 4 divided doses, adjusted\r\nto achieve amenorrhoea, usually for 3\u20136 months", "Severe pain and tenderness in benign fibrocystic breast disease\r\nnot responding to other treatment, 300\u00a0mg daily in divided doses usually\r\nfor 3\u20136 months", "Hereditary angioedema [unlicensed indication], initially 200\u00a0mg\r\n2\u20133 times daily, then reduced according to response"], "pregnancy": "avoid; has weak androgenic effects and virilisation\r\nof female fetus reported", "breast-feeding": "no data available but avoid because of possible\r\nandrogenic effects in infant"}, "QUININE": {"indications": "falciparum malaria; nocturnal leg cramps, seesection 10.2.2", "name": "QUININE", "renal impairment": "for treatment of malaria in severe impairment, reduce\r\nparenteral maintenance dose to 5\u20137\u00a0mg/kg of quinine salt", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of quinine (increased risk of toxicity)", "name": "Quinine", "backrefs": ["Quinine"]}, "cautions": "cardiac disease (including atrial fibrillation, conduction defects, heart block), elderly\u2014monitor\r\nECG during parenteral treatment; monitor blood glucose\r\nand electrolyte concentration during parenteral treatment; G6PD deficiency (seesection 9.1.5);interactions:Appendix 1\r\n(quinine)", "side-effects": "cinchonism, including tinnitus, hearing impairment,\r\nvertigo, headache, nausea, vomiting, abdominal pain, diarrhoea, visual\r\ndisturbances (including temporary blindness), confusion; cardiovascular\r\neffects (see Cautions); dyspnoea; hypersensitivity reactions including\r\nangioedema, rashes, hot and flushed skin; hypoglycaemia (especially\r\nafter parenteral administration); blood disorders (including thrombocytopenia\r\nand intravascular coagulation); acute renal failure; muscle weakness;\r\nphotosensitivity; very toxic inoverdosage\u2014immediate\r\nadvice from poisons centres essential (see alsoEmergency Treatment of Poisoning)", "contra-indications": "haemoglobinuria, myasthenia gravis, optic neuritis, tinnitus", "hepatic impairment": "for treatment of malaria in severe impairment, reduce\r\nparenteral maintenance dose to 5\u20137\u00a0mg/kg of quinine salt", "doses": ["Treatment of malaria, seenotes above", "Quinine(anhydrous base)\r\n100\u00a0mg\u00a0\u2261quininebisulphate 169\u00a0mg\u00a0\u2261quininedihydrochloride 122\u00a0mg\u00a0\u2261quininehydrochloride\r\n122\u00a0mg\u00a0\u2261quininesulphate 121\u00a0mg.Quininebisulphate 300-mg tablets are available but provide lessquininethan 300\u00a0mg of the dihydrochloride, hydrochloride,\r\nor sulphate"], "pregnancy": "high doses are teratogenic infirst trimester; but in malaria benefit of treatment outweighs risk; see alsoFalciparum Malaria (treatment)", "breast-feeding": "present in milk but not known to be harmful"}, "INSULIN GLULISINE": {"indications": "diabetes mellitus", "name": "INSULIN GLULISINE", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection,adultandchildover\r\n6 years, immediately before meals or when necessary shortly after\r\nmeals, according to requirements", "By subcutaneous infusionorintravenous infusionadultandchildover 6 years, according\r\nto requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "DIHYDROCODEINE TARTRATE": {"indications": "moderate to severe pain", "name": "DIHYDROCODEINE TARTRATE", "renal impairment": "seenotes above", "cautions": "seenotes above; also pancreatitis; severe cor pulmonale", "side-effects": "seenotes above; also\r\nparalytic ileus, abdominal pain, diarrhoea, seizures, and\r\nparaesthesia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["adultandchildover 12 years, chronic severe pain, 60\u2013120\u00a0mg\r\nevery 12 hours"], "pregnancy": "seenotes above", "breast-feeding": "use only if potential benefit outweighs risk"}, "MERCAPTOPURINE": {"indications": "acute leukaemias and chronic\r\nmyeloid leukaemia; inflammatory bowel disease [unlicensed indication]\r\n(section 1.5.3)", "name": "MERCAPTOPURINE", "renal impairment": "reduce dose", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of haematological toxicity when  sulfamethoxazole (as co-trimoxazole) given with mercaptopurine ", "name": "Mercaptopurine", "backrefs": ["Mercaptopurine", "Aminosalicylates", "Febuxostat"]}, "cautions": "seesection 8.1andnotes above; thiopurine methyltransferase status (seesection 8.2.1); monitor liver\r\nfunction;interactions:Appendix 1 (mercaptopurine)", "side-effects": "seesection 8.1andnotes above; also hepatotoxicity;rarelyintestinal ulceration,\r\npancreatitis;very rarelylymphoma", "hepatic impairment": "may need dose reduction", "doses": ["Initially 2.5\u00a0mg/kg daily"], "pregnancy": "avoid (teratogenic); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "DOMPERIDONE": {"indications": "nausea and vomiting, dyspepsia, gastro-oesophageal\r\nreflux", "name": "DOMPERIDONE", "renal impairment": "reduce dose", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  ketoconazole advises avoid concomitant use with domperidone (risk of ventricular arrhythmias)", "name": "Domperidone", "backrefs": ["Opioid Analgesics", "Domperidone", "Cabergoline"]}, "cautions": "children;interactions:Appendix 1 (domperidone)", "side-effects": "rarelygastro-intestinal disturbances\r\n(including cramps) and hyperprolactinaemia;very rarelyventricular arrhythmias, agitation, drowsiness, nervousness, seizures,\r\nextrapyramidal effects, headache, and rashes; also reported QT-interval\r\nprolongation", "contra-indications": "prolactinoma; if increased gastro-intestinal motility harmful", "hepatic impairment": "avoid", "doses": ["By mouth,adultandchildbody-weight over 35\u00a0kg,\r\n10\u201320\u00a0mg 3\u20134 times daily; max. 80\u00a0mg daily;childbody-weight up to 35\u00a0kg (nausea and vomiting only), 250\u2013500\u00a0micrograms/kg\r\n3\u20134 times daily; max. 2.4\u00a0mg/kg daily", "By rectum,adultandchildbody-weight over 35\u00a0kg,\r\n60\u00a0mg twice daily;child15\u201335\u00a0kg (nausea\r\nand vomiting only), 30\u00a0mg twice daily;childbody-weight under 15\u00a0kg, not recommended"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "amount too small to be harmful"}, "ATOSIBAN": {"indications": "uncomplicated premature labour (see notes above)", "name": "ATOSIBAN", "renal impairment": "no information available", "cautions": "monitor blood loss after delivery; intra-uterine growth restriction; abnormal placental site", "side-effects": "nausea, vomiting, tachycardia, hypotension, headache,\r\ndizziness, hot flushes, hyperglycaemia, injection-site reaction;less commonlypruritus, rash, fever, insomnia", "contra-indications": "eclampsia and severe pre-eclampsia, intra-uterine infection, intra-uterine fetal death, antepartum\r\nhaemorrhage (requiring immediate delivery), placenta praevia, abruptio placenta, intra-uterine growth restriction with abnormal fetal\r\nheart rate, premature rupture of membranes\r\nafter 30 weeks\u2019 gestation", "hepatic impairment": "no information available", "doses": ["By intravenous injection, initially 6.75\u00a0mg\r\nover 1 minute, thenby intravenous infusion18\u00a0mg/hour\r\nfor 3 hours, then 6\u00a0mg/hour for up to 45 hours; max. duration of treatment\r\n48 hours"]}, "PALIVIZUMAB": {"side-effects": "fever, injection-site reactions, nervousness;less commonlydiarrhoea, vomiting, constipation, haemorrhage,\r\nrhinitis, cough, wheeze, pain, drowsiness, asthenia, hyperkinesia,\r\nleucopenia, and rash; also reported, apnoea, hypersensitivity reactions\r\n(including anaphylaxis), convulsions and thombocytopenia", "indications": "seenotes above", "name": "PALIVIZUMAB", "cautions": "moderate to severe acute infection or febrile illness; thrombocytopenia; serum-palivizumab concentration\r\nmay be reduced after cardiac surgery; hypersensitivity\r\nto humanised monoclonal antibodies", "doses": ["By intramuscular injection(preferably\r\nin anterolateral thigh), 15\u00a0mg/kg once a month during season of RSV\r\nrisk (child undergoing cardiac bypass surgery, 15\u00a0mg/kg as soon as\r\nstable after surgery, then once a month during season of risk); injection\r\nvolume over 1\u00a0mL should be divided between more than one site"]}, "NORGESTIMATE": {"interactions": {"extra": "", "bad": 0, "interaction": " rosuvastatin increases plasma concentration of active metabolite of norgestimate ", "name": "Norgestimate", "backrefs": ["Norgestimate"]}}, "FLUCONAZOLE": {"indications": "see under Dose", "name": "FLUCONAZOLE", "renal impairment": "usual initial dose then halve subsequent doses if eGFR\r\nless than 50\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "In general, fluconazole interactions relate to multiple-dose treatment", "bad": 1, "interaction": "plasma concentration of  nevirapine increased by fluconazole ", "name": "Fluconazole", "backrefs": ["Fluconazole", "Flurbiprofen", "Hydrochlorothiazide", "Parecoxib"]}, "cautions": "concomitant use with hepatotoxic drugs, monitor liver function with high doses or extended courses\u2014discontinue if signs or symptoms of hepatic disease\r\n(risk of hepatic necrosis); susceptibility\r\nto QT interval prolongation;interactions:Appendix 1 (antifungals, triazole)", "side-effects": "nausea, abdominal discomfort, diarrhoea, flatulence,\r\nheadache, rash (discontinue treatment or monitor closely if infection\r\ninvasive or systemic); less frequently dyspepsia, vomiting, taste\r\ndisturbance, hepatic disorders, hypersensitivity reactions, anaphylaxis,\r\ndizziness, seizures, alopecia, pruritus, toxic epidermal necrolysis,\r\nStevens-Johnson syndrome (severe cutaneous reactions more likely in\r\nHIV-positive patients), hyperlipidaemia, leucopenia,\r\nthrombocytopenia, and hypokalaemia reported", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "toxicity with related drugs", "doses": ["Vaginal candidiasis (see also Recurrent Vulvovaginal Candidiasis,section 7.2.2) and\r\ncandidal balanitis,adultandchildover 16 years,by mouth, a single\r\ndose of 150\u00a0mg", "Mucosal candidiasis (except genital),by mouth, 50\u00a0mg daily (100\u00a0mg daily in unusually difficult infections) given\r\nfor 7\u201314 days in oropharyngeal candidiasis (max. 14 days except in\r\nseverely immunocompromised patients); for 14 days in atrophic oral\r\ncandidiasis associated with dentures; for 14\u201330 days in other mucosal\r\ninfections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary\r\ninfections);childby mouthorby intravenous infusion, 3\u20136\u00a0mg/kg\r\non first day then 3\u00a0mg/kg daily (every 72 hours inneonateup to 2 weeks old, every 48 hours in neonate\r\n2\u20134 weeks old)", "Tinea pedis, corporis, cruris, pityriasis versicolor, and dermal\r\ncandidiasis,by mouth, 50\u00a0mg daily for 2\u20134 weeks (for\r\nup to 6 weeks in tinea pedis); max. duration of treatment 6 weeks", "Invasive candidal infections (including candidaemia and disseminated\r\ncandidiasis) and cryptococcal infections (including meningitis),by mouthorintravenous infusion, 400\u00a0mg on first day then 200\u2013400\u00a0mg daily; max. 800\u00a0mg daily in\r\nsevere infections [unlicensed dose]; treatment continued according\r\nto response (at least 8 weeks for cryptococcal meningitis);child6\u201312\u00a0mg/kg daily (every 72 hours inneonateup to 2 weeks old, every 48 hours inneonate2\u20134 weeks old); max. 800\u00a0mg daily [unlicensed\r\ndose]", "Prevention of relapse of cryptococcal meningitis in HIV-infected\r\npatients after completion of primary therapy,by mouthorby intravenous infusion, 200\u00a0mg\r\ndaily", "Prevention of fungal infections in immunocompromised patients,by mouthorby intravenous infusion, 50\u2013400\u00a0mg daily adjusted according to risk; 400\u00a0mg daily if high\r\nrisk of systemic infections e.g. following bone-marrow transplantation;\r\ncommence treatment before anticipated onset of neutropenia and continue\r\nfor 7 days after neutrophil count in desirable range;childaccording to extent and duration of neutropenia,\r\n3\u201312\u00a0mg/kg daily (every 72 hours inneonateup to 2 weeks old, every 48 hours inneonate2\u20134 weeks old); max. 400\u00a0mg daily"], "pregnancy": "manufacturer advises avoid\u2014multiple congenital abnormalities\r\nreported with long-term high doses", "breast-feeding": "present in milk but amount probably too small\r\nto be harmful"}, "TERBUTALINE SULPHATE": {"indications": "uncomplicated premature labour (seenotes above); asthma\r\n(section 3.1.1)", "name": "TERBUTALINE SULPHATE", "cautions": "seenotes above;interactions:Appendix 1 (sympathomimetics, beta2)", "side-effects": "seenotes above; also\r\nreported sleep disturbances and behavioural disturbances", "contra-indications": "seenotes above", "doses": ["By intravenous infusion, 5\u00a0micrograms/minute\r\nfor 20 minutes, increased every 20 minutes in steps of 2.5\u00a0micrograms/minute\r\nuntil contractions have ceased (more than 10\u00a0micrograms/minute shouldseldombe given\u201420\u00a0micrograms/minute shouldnotbe exceeded), continue for 1 hour then decrease every 20 minutes\r\nin steps of 2.5\u00a0micrograms/minute to lowest dose that maintains suppression,\r\ncontinue at this level for 12 hours thenby mouth(but\r\nsee notes above), 5\u00a0mg every 8 hours for as long as is desirable to\r\nprolong pregnancy (or alternatively follow the intravenous infusionby subcutaneous injection250\u00a0micrograms every 6 hours for\r\na few days thenby mouthas above)"]}, "TERIPARATIDE": {"indications": "treatment of osteoporosis in postmenopausal\r\nwomen and in men at increased risk of fractures; treatment of corticosteroid-induced\r\nosteoporosis; see also notes above", "name": "TERIPARATIDE", "renal impairment": "caution in moderate impairment; avoid if severe", "side-effects": "gastro-intestinal disorders (including nausea,\r\nreflux and haemorrhoids); palpitation; dyspnoea; headache, fatigue,\r\nasthenia, depression, dizziness, vertigo; anaemia, increased sweating,\r\nmuscle cramps, sciatica, myalgia, arthralgia;less commonlyurinary disorders, hypercalcaemia; injection-site reactions;rarelyhypersensitivity reactions", "contra-indications": "pre-existing hypercalcaemia, skeletal malignancies or bone\r\nmetastases, metabolic bone diseases, including Paget\u2019s disease and hyperparathyroidism, unexplained raised alkaline\r\nphosphatase, previous radiation therapy to\r\nthe skeleton", "doses": ["By subcutaneous injection, 20\u00a0micrograms\r\ndaily; max. duration of treatment 24 months (course not to be repeated)"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "XYLOMETAZOLINE": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by xylometazoline ", "name": "Xylometazoline", "backrefs": ["Xylometazoline"]}}, "ANTACIDS": {"interactions": {"extra": "Antacids should preferably not be taken at the same time as other drugs since they may impair absorption", "bad": 0, "interaction": "absorption of  lansoprazole possibly reduced by antacids ", "name": "Antacids", "backrefs": ["Antacids", "Deflazacort", "Fosinopril", "Bile Acids", "Gabapentin", "Cefaclor", "Enalapril"]}}, "LITHIUM CITRATE": {"indications": "see underLithium Carbonateand notes above", "name": "LITHIUM CITRATE", "renal impairment": "seeLithium Carbonate", "cautions": "see underLithium Carbonateandnotes above", "side-effects": "see underLithium Carbonateand notes above", "contra-indications": "seeLithium Carbonate", "doses": ["(see Dose above for advice on bioavailability and serum\r\nmonitoring):Treatment and prophylaxis, initially 1.04\u20133.12\u00a0g\r\ndaily in 2 divided doses (elderly or patients less than 50\u00a0kg, 520\u00a0mg\r\ntwice daily);childnot recommended"], "pregnancy": "seeLithium Carbonate", "breast-feeding": "seeLithium Carbonate"}, "NICARDIPINE": {"interactions": {"extra": "", "bad": 0, "interaction": " grapefruit juice increases plasma concentration of nicardipine ", "name": "Nicardipine", "backrefs": ["Nicardipine"]}}, "DEFLAZACORT": {"indications": "suppression of inflammatory and allergic\r\ndisorders", "name": "DEFLAZACORT", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " antacids reduce absorption of deflazacort ", "name": "Deflazacort", "backrefs": ["Deflazacort"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Usual maintenance 3\u201318\u00a0mg daily (acute disorders,\r\ninitially up to 120\u00a0mg daily); see also Administration (above)", "child0.25\u20131.5\u00a0mg/kg daily (or\r\non alternate days); see also Administration (above)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "VECURONIUM": {"interactions": {"extra": "", "bad": 0, "interaction": " corticosteroids possibly antagonise effects of vecuronium ", "name": "Vecuronium", "backrefs": ["Vecuronium"]}}, "GRAPEFRUIT JUICE": {"interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  vardenafil possibly increased by grapefruit juice\u2014avoid concomitant use", "name": "Grapefruit Juice", "backrefs": ["Nimodipine", "Bilastine", "Isradipine", "Lacidipine", "Nicardipine", "Grapefruit Juice"]}}, "ESCITALOPRAM": {"indications": "see under Dose", "name": "ESCITALOPRAM", "renal impairment": "caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " omeprazole increases plasma concentration of escitalopram ", "name": "Escitalopram", "backrefs": ["Escitalopram"]}, "cautions": "seenotes above; susceptibility\r\nto QT-interval prolongation", "side-effects": "seenotes above; also sinusitis, yawning; fatigue,\r\nrestlessness, abnormal dreams, paraesthesia; pyrexia;less\r\ncommonlytaste disturbance, bruxism, syncope, tachycardia,\r\noedema, confusion, menstrual disturbances, epistaxis, mydriasis, tinnitus,\r\npruritus, and alopecia;rarelybradycardia, aggression,\r\nand depersonalisation; hepatitis, postural hypotension, QT interval\r\nprolongation, and thrombocytopenia also reported; paradoxical increased\r\nanxiety during initial treatment of panic disorder (reduce dose)", "contra-indications": "seenotes above; QT-interval prolongation (avoid\r\nconcomitant administration of drugs that prolong QT interval)", "hepatic impairment": "initial dose 5\u00a0mg daily for 2 weeks, thereafter increased\r\nto max. 10\u00a0mg daily according to response; particular caution in severe\r\nimpairment", "doses": ["adultover 18 years, depressive\r\nillness, generalised anxiety disorder, and obsessive-compulsive disorder,\r\n10\u00a0mg once daily increased if necessary to max. 20\u00a0mg daily;elderlyover 65 years, initially half adult dose,\r\nlower maintenance dose may be sufficient; max. 10\u00a0mg daily;childnot recommended (seeDepressive Illness in Children\r\nand Adolescents)", "adultover 18 years, panic disorder,\r\ninitially 5\u00a0mg once daily increased to 10\u00a0mg daily after 7 days; max.\r\n20\u00a0mg daily;elderlyover 65 years, initially half adult dose, lower maintenance dose may be sufficient;\r\nmax. 10\u00a0mg daily", "adultover 18 years, social anxiety\r\ndisorder, initially 10\u00a0mg once daily adjusted after 2\u20134 weeks; usual\r\ndose 5\u201320\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "present in milk; avoid"}, "CRISANTASPASE": {"indications": "seenotes above", "name": "CRISANTASPASE", "cautions": "seenotes above", "side-effects": "seesection 8.1; also\r\nliver dysfunction, pancreatitis, diarrhoea; coagulation disorders;\r\nlethargy, drowsiness, confusion, dizziness, neurotoxicity, convulsions,\r\nheadache;less commonlychanges in blood lipids,\r\nanaphylaxis, hyperglycaemia;rarelyCNS depression;very rarelymyalgia; abdominal pain and hypertension also\r\nreported", "contra-indications": "history of pancreatitis related\r\nto asparaginase therapy", "doses": ["SeeDoses"], "pregnancy": "avoid; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "TRIHEXYPHENIDYL HYDROCHLORIDE": {"indications": "parkinsonism; drug-induced\r\nextrapyramidal symptoms (but not tardive dyskinesia, seenotes above)", "name": "TRIHEXYPHENIDYL HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["1\u00a0mg daily, increased by 2\u00a0mg every 3\u20135 days according\r\nto response; usual maintenance dose 5\u201315\u00a0mg daily in 3\u20134 divided doses\r\n(max. 20\u00a0mg daily);elderlypreferably\r\nlower end of range;childunder 18\r\nyears seeBNF for Children", "Not recommended for use in\r\nParkinson\u2019s disease because of toxicity in the elderly and the risk\r\nof aggravating dementia. However, if using in combination with co-careldopa\r\nor co-beneldopa the usual maintenance dose is 2\u20136\u00a0mg daily in divided\r\ndoses"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "avoid"}, "ACEMETACIN": {"indications": "pain and inflammation in rheumatic disease and other musculoskeletal\r\ndisorders; postoperative analgesia", "name": "ACEMETACIN", "renal impairment": "seenotes above", "cautions": "see underIndometacinandnotes above", "side-effects": "see underIndometacinandnotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["120\u00a0mg daily in divided doses with food, increased if\r\nnecessary to 180\u00a0mg daily;childnot\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid; see alsonotes above"}, "TELBIVUDINE": {"indications": "chronic hepatitis B infection with\r\ncompensated liver disease, evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis", "name": "TELBIVUDINE", "renal impairment": "600\u00a0mg every 48 hours if eGFR 30\u201349\u00a0mL/minute/1.73\u00a0m2; 600\u00a0mg every 72 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of peripheral neuropathy when  interferon alfa given with telbivudine ", "name": "Telbivudine", "backrefs": ["Telbivudine", "Interferon Alfa"]}, "cautions": "monitor liver function tests every 3\r\nmonths and viral markers of hepatitis B every 3\u20136 months during treatment\r\n(continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation); lamivudine-resistant chronic hepatitis B\u2014risk of telbivudine resistance; discontinue if deterioration in liver function, hepatic\r\nsteatosis, progressive hepatomegaly or unexplained lactic acidosis;interactions:Appendix 1 (telbivudine)", "side-effects": "nausea, diarrhoea, abdominal pain, raised serum\r\namylase and lipase; cough; dizziness, headache, fatigue; rash;less commonlytaste disturbance, arthralgia, myalgia, myopathy\r\n(discontinue treatment), and peripheral neuropathy; also reported,\r\nlactic acidosis and rhabdomyolysis", "doses": ["adultandchildover 16 years, 600\u00a0mg once daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "SENNA": {"indications": "constipation", "name": "SENNA", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["10\u201320\u00a0mL, usually at bedtime;child(but seesection\r\n1.6) 1\u00a0month\u20132 years seeBNF for Children, 2\u20134 years\r\n2.5\u201310\u00a0mL once daily, adjusted according to response; 4\u201318 years 2.5\u201320\u00a0mL\r\nonce daily, adjusted according to response"], "pregnancy": "seePregnancy", "breast-feeding": "not known to be harmful"}, "BENZYL BENZOATE": {"indications": "scabies (but see notes above)", "name": "BENZYL BENZOATE", "cautions": "children (not recommended, see also under Dose, below), avoid contact with eyes and mucous membranes; do not use\r\non broken or secondarily infected skin", "side-effects": "skin irritation, burning sensation especially\r\non genitalia and excoriations, occasionally rashes", "doses": ["Apply over the whole body; repeat without bathing on the\r\nfollowing day and wash off 24 hours later; a third application may\r\nbe required in some cases", "Not recommended for children\u2014dilution to\r\nreduce irritant effect also reduces efficacy. Some manufacturers recommend\r\napplication to the body but to exclude the head and neck. However,\r\napplication should be extended to the scalp, neck, face, and ears"], "breast-feeding": "suspend feeding until product has been washed\r\noff"}, "METARAMINOL": {"indications": "acute hypotension (see notes above); priapism (section 7.4.5) [unlicensed\r\nindication]", "name": "METARAMINOL", "interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by metaraminol ", "name": "Metaraminol", "backrefs": ["Metaraminol"]}, "cautions": "see underNoradrenaline; longer duration of action than noradrenaline (norepinephrine), see below; cirrhosis", "side-effects": "see under Noradrenaline; also tachycardia; fatal\r\nventricular arrhythmia reported in Laennec\u2019s cirrhosis", "contra-indications": "see underNoradrenaline", "doses": ["By intravenous infusion, 15\u2013100\u00a0mg, adjusted\r\naccording to response", "In emergency,by intravenous injection, 0.5\u20135\u00a0mg\r\nthenby intravenous infusion, 15\u2013100\u00a0mg, adjusted according\r\nto response"], "pregnancy": "may reduce placental perfusion\u2014manufacturer advises\r\nuse only if potential benefit outweighs risk", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "DIURETICS": {"interactions": {"extra": "", "bad": 0, "interaction": " indometacin antagonises effects of diuretics ", "name": "Diuretics", "backrefs": ["Diuretics", "Diuretics, Loop", "Lymecycline", "Diuretics, Potassium-sparing and Aldosterone Antagonists", "Diuretics, Thiazide and related", "Platinum Compounds"]}}, "USTEKINUMAB": {"indications": "seenotes above", "name": "USTEKINUMAB", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of live  vaccines with ustekinumab (see under Active Immunity, section 14.1)", "name": "Ustekinumab", "backrefs": ["Ustekinumab"]}, "cautions": "predisposition to infection; history or development\r\nof malignancy; elderly;interactions: Appendix 1 (ustekinumab)", "side-effects": "infections (sometimes severe); diarrhoea; hypersensitivity\r\nreactions (possibly delayed onset), pain in pharynx and\r\nlarynx; headache, fatigue, dizziness, depression; arthralgia; myalgia;\r\nnasal congestion; pruritus, injection-site reactions", "contra-indications": "active infection", "doses": ["By subcutaneous injection, plaque psoriasis,adultover 18 years, body-weight under 100\u00a0kg, initially\r\n45\u00a0mg, then 45\u00a0mg 4 weeks after initial dose, then 45\u00a0mg every 12\r\nweeks; body-weight over 100\u00a0kg, initially 45\u201390\u00a0mg, then 45\u201390\u00a0mg\r\n4 weeks after initial dose, then 45\u201390\u00a0mg every 12 weeks", "Discontinue if no response within 16 weeks"], "pregnancy": "avoid; manufacturer advises effective contraception\r\nduring treatment and for 15 weeks after stopping treatment", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "LOMUSTINE": {"indications": "seenotes above", "name": "LOMUSTINE", "renal impairment": "avoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine possibly enhances myelosuppressive effects of lomustine ", "name": "Lomustine", "backrefs": ["Lomustine"]}, "cautions": "seesection 8.1andnotes above;\r\navoid in acute porphyria (but seesection 9.8.2);interactions: Appendix 1\r\n(lomustine)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "coeliac disease", "doses": ["Used alone, 120\u2013130\u00a0mg/m2body-surface every\r\n6\u20138 weeks"], "pregnancy": "avoid (manufacturer advises effective contraception\r\nduring and for at least 6 months after treatment in men or women);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ABATACEPT": {"indications": "see underCytokine Modulators, above", "name": "ABATACEPT", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of live  vaccines with abatacept (see under Active Immunity, section 14.1)", "name": "Abatacept", "backrefs": ["Abatacept"]}, "cautions": "predisposition to infection (screen for\r\nlatent tuberculosis and viral hepatitis); do not initiate until active infections are controlled; children should be brought up to date with current immunisation\r\nschedule (section 14.1) before\r\ninitiating therapy; progressive multifocal leucoencephalopathy\u2014discontinue treatment\r\nif neurological symptoms present; elderly\r\n(increased risk of side-effects);interactions:Appendix 1 (abatacept)", "side-effects": "abdominal pain, diarrhoea, dyspepsia, nausea;\r\nflushing, hypertension; cough; dizziness, fatigue, headache; infection,\r\nrhinitis; rash;less commonlygastritis, stomatitis,\r\ntachycardia, bradycardia, palpitation, hypotension, dyspnoea, paraesthesia,\r\nweight gain, depression, anxiety, amenorrhoea, basal cell carcinoma,\r\nthrombocytopenia, leucopenia, arthralgia, pain in extremities, conjunctivitis,\r\nvisual disturbance, vertigo, bruising, alopecia, and dry skin", "contra-indications": "severe infection (see\r\nalso Cautions)", "doses": ["By intravenous infusion, rheumatoid\r\narthritis (seenotes above),adultover 18 years, body-weight less than 60\u00a0kg,\r\n500\u00a0mg, repeated 2 weeks and 4 weeks after initial infusion, then\r\nevery 4 weeks; body-weight 60\u2013100\u00a0kg, 750\u00a0mg repeated 2 weeks and\r\n4 weeks after initial infusion, then every 4 weeks; body-weight over\r\n100\u00a0kg, 1\u00a0g repeated 2 weeks and 4 weeks after initial infusion, then\r\nevery 4 weeks", "Polyarticular juvenile idiopathic arthritis (seenotes above),child6\u201317 years, body-weight less than 75\u00a0kg, 10\u00a0mg/kg,\r\nrepeated 2 weeks and 4 weeks after initial infusion, then every 4\r\nweeks; body-weight 75\u2013100\u00a0kg, 750\u00a0mg, repeated 2 weeks and 4 weeks\r\nafter initial infusion, then every 4 weeks; body-weight over 100\u00a0kg,\r\n1\u00a0g, repeated 2 weeks and 4 weeks after initial infusion, then every\r\n4 weeks", "Review treatment if no response within 6\r\nmonths"], "pregnancy": "manufacturer advises avoid unless essential\u2014effective\r\ncontraception required during treatment and for 14 weeks after last\r\ndose", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid breast-feeding during treatment and for 14 weeks after\r\nlast dose"}, "Other preparations used in peripheral vascular disease": {"name": "Other preparations used in peripheral vascular disease", "doses": ["relief of symptoms of oedema associated with chronic venous\r\ninsufficiency, 500\u00a0mg twice daily"]}, "FAMPRIDINE": {"indications": "(specialist use only) improvement of\r\nwalking disability in multiple sclerosis", "name": "FAMPRIDINE", "renal impairment": "avoid if eGFR less than 80\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  cimetidine advised by manufacturer of fampridine ", "name": "Fampridine", "backrefs": ["Fampridine"]}, "cautions": "predisposition to seizures including concomitant use\r\nof drugs that lower seizure threshold; symptomatic cardiac rhythm\r\ndisorders, sinoatrial or atrioventricular conduction\r\ndisorders;interactions: Appendix 1 (fampridine)", "side-effects": "nausea, vomiting, constipation, dyspepsia, dyspnoea,\r\npharyngolaryngeal pain, dizziness, headache, paraesthesia, tremor,\r\nmalaise, insomnia, anxiety, urinary tract infection, back pain;less commonlyseizures", "contra-indications": "history of seizures (discontinue treatment\r\nif seizures occur)", "doses": ["adultover 18 years, 10\u00a0mg\r\nevery 12 hours; discontinue treatment if no improvement within 2 weeks"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014no information available"}, "VERTEPORFIN": {"indications": "see notes above\u2014specialist use only", "name": "VERTEPORFIN", "cautions": "photosensitivity\u2014avoid exposure of unprotected\r\nskin and eyes to bright light during infusion and for 48 hours afterwards; concomitant use with other photosensitising drugs; biliary obstruction; avoid\r\nextravasation", "side-effects": "nausea, hypercholesterolaemia, malaise, back pain,\r\nphotosensitivity, visual disturbances (including reduced visual acuity,\r\nflashing lights, visual-field defects),less commonlyhypertension, hyperaesthesia, pyrexia, retinal detachment, haemorrhage,rarelyretinal or choroidal vessel non-perfusion;also reportedchest pain, myocardial infarction", "contra-indications": "acute porphyria", "hepatic impairment": "use with caution in moderate impairment; avoid in severe\r\nimpairment", "doses": ["By intravenous infusionover 10 minutes,\r\n6\u00a0mg/m2", "For information on administration and light\r\nactivation, consult product literature"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk (teratogenic inanimalstudies)", "breast-feeding": "no information available\u2014manufacturer advises\r\navoid breast-feeding for 48 hours after administration"}, "PREPARATIONS FOR OTHER VAGINAL INFECTIONS": {"side-effects": "local effects including irritation, candidiasis,\r\nabnormal discharge, pelvic discomfort", "cautions": "not recommended during menstruation; some absorption may occur, seesection 5.1.11for systemic effects", "name": "PREPARATIONS FOR OTHER VAGINAL INFECTIONS", "doses": ["bacterial vaginosis, insert 5-g applicatorful at night\r\nfor 5 nights"]}, "IPRATROPIUM BROMIDE": {"indications": "reversible airways obstruction, particularly\r\nin chronic obstructive pulmonary disease; rhinitis (section 12.2.2)", "name": "IPRATROPIUM BROMIDE", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nthroat irritation;less commonlyvomiting, diarrhoea,\r\nlaryngospasm, pharyngeal oedema, conjunctival hyperaemia, mydriasis", "doses": ["By aerosol inhalation, 20\u201340\u00a0micrograms\r\n3\u20134 times daily;childup to 6 years\r\n20\u00a0micrograms 3 times daily, 6\u201312 years 20\u201340\u00a0micrograms 3 times daily", "By inhalation of powder,adultandchildover\r\n12 years, 40\u00a0micrograms 3\u20134 times daily (may be doubled in less responsive\r\npatients)", "By inhalation of nebulised solution, reversible airways obstruction in chronic obstructive pulmonary\r\ndisease, 250\u2013500\u00a0micrograms 3\u20134 times daily", "Acute bronchospasm (but see alsoManagement of Acute Asthma\r\ntable),\r\n500\u00a0micrograms repeated as necessary;childunder 5 years 125\u2013250\u00a0micrograms, max. 1\u00a0mg daily; 6\u201312 years 250\u00a0micrograms,\r\nmax. 1\u00a0mg daily", "Advise patient not\r\nto exceed prescribed dose and to follow manufacturer\u2019s directions"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "TIGECYCLINE": {"indications": "seenotes above", "name": "TIGECYCLINE", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  coumarins possibly enhanced by tigecycline ", "name": "Tigecycline", "backrefs": ["Tigecycline"]}, "cautions": "cholestasis;interactions:Appendix 1 (tigecycline)", "side-effects": "seenotes above; also nausea, vomiting, abdominal\r\npain, dyspepsia, diarrhoea, anorexia, bilirubinaemia, dizziness, headache,\r\nhypoglycaemia, prolonged prothrombin time, prolonged activated partial\r\nthromboplastin time, rash, pruritus, and injection-site reactions;less commonlypancreatitis, cholestatic jaundice, and hypoproteinaemia;\r\nalso reported, antibiotic-associated colitis, hepatic failure, thrombocytopenia,\r\nStevens-Johnson syndrome", "contra-indications": "hypersensitivity to tetracyclines", "hepatic impairment": "initially 100\u00a0mg then 25\u00a0mg every 12 hours in severe\r\nimpairment", "doses": ["By intravenous infusion,adultover 18 years, initially 100\u00a0mg, then 50\u00a0mg\r\nevery 12 hours for 5\u201314 days"], "pregnancy": "see underTetracyclines", "breast-feeding": "manufacturer advises caution\u2014present in milk\r\ninanimalstudies"}, "PROCARBAZINE": {"indications": "seenotes above", "name": "PROCARBAZINE", "renal impairment": "caution in mild to moderate impairment; avoid in severe\r\nimpairment", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  digoxin tablets possibly reduced by procarbazine ", "name": "Procarbazine", "backrefs": ["Procarbazine"]}, "cautions": "seesection 8.1andnotes above; cardiovascular or cerebrovascular disease; phaeochromocytoma; epilepsy;interactions:Appendix 1 (procarbazine)", "side-effects": "seesection 8.1andnotes above; also loss of appetite; jaundice\r\nalso reported", "hepatic impairment": "caution in mild to moderate impairment; avoid in severe\r\nimpairment", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies\r\nand isolated reports in humans); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "SEVELAMER HYDROCHLORIDE": {"indications": "hyperphosphataemia in patients on haemodialysis or peritoneal dialysis", "name": "SEVELAMER HYDROCHLORIDE", "cautions": "gastro-intestinal disorders;interactions: Appendix 1 (sevelamer)", "side-effects": "nausea, vomiting, abdominal pain, constipation,\r\ndiarrhoea, dyspepsia, flatulence;very rarelyintestinal\r\nobstruction;also reportedintestinal perforation,\r\nileus, diverticulitis, pruritus, rash", "contra-indications": "bowel obstruction", "doses": ["adultover 18 years, initially\r\n2.4\u20134.8\u00a0g daily in 3 divided doses with meals, adjusted according\r\nto serum-phosphate concentration (usual dose range 2.4\u201312\u00a0g daily\r\nin 3 divided doses);childseeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk"}, "FELODIPINE": {"indications": "hypertension, prophylaxis of angina", "name": "FELODIPINE", "interactions": {"extra": "", "bad": 1, "interaction": " itraconazole inhibits metabolism of felodipine (increased plasma concentration)", "name": "Felodipine", "backrefs": ["Felodipine"]}, "cautions": "withdraw if ischaemic pain\r\noccurs or existing pain worsens shortly after initiating treatment\r\nor if cardiogenic shock develops; severe left ventricular\r\ndysfunction; acute porphyria (but seesection 9.8.2);interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "flushing, headache, palpitation, dizziness, fatigue,\r\ngravitational oedema; rarely rash, pruritus, cutaneous vasculitis,\r\ngum hyperplasia, urinary frequency, impotence, fever;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "unstable angina, uncontrolled heart failure; significant aortic\r\nstenosis; within 1 month of myocardial infarction", "hepatic impairment": "reduce dose", "doses": ["Hypertension, initially 5\u00a0mg (elderly 2.5\u00a0mg) daily in\r\nthe morning; usual maintenance 5\u201310\u00a0mg once daily; doses above 20\u00a0mg\r\ndaily rarely needed", "Angina, initially 5\u00a0mg daily in the morning, increased if necessary\r\nto 10\u00a0mg once daily"], "pregnancy": "avoid; toxicity inanimalstudies;\r\nmay inhibit labour", "breast-feeding": "present in milk"}, "TREOSULFAN": {"indications": "seenotes above", "name": "TREOSULFAN", "cautions": "seesection 8.1;\r\navoid in acute porphyria (but seesection 9.8.2)", "side-effects": "seesection 8.1andnotes above", "doses": ["Consult product literature"], "pregnancy": "avoid; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "PROGUANIL HYDROCHLORIDE WITH ATOVAQUONE": {"indications": "treatment of acute uncomplicated falciparum malaria and prophylaxis\r\nof falciparum malaria, particularly where resistance to other antimalarial\r\ndrugs suspected; treatment of benign malaria [unlicensed indication]", "name": "PROGUANIL HYDROCHLORIDE WITH ATOVAQUONE", "renal impairment": "avoid for malaria prophylaxis (and if possible for malaria\r\ntreatment) if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "diarrhoea or vomiting (reduced absorption ofatovaquone); efficacy not evaluated in cerebral or complicated malaria (including\r\nhyperparasitaemia, pulmonary oedema or renal failure);interactions:see Appendix 1 (proguanil,atovaquone)", "side-effects": "abdominal pain, nausea, vomiting, diarrhoea; cough;\r\nheadache, dizziness, insomnia, abnormal dreams, depression, anorexia,\r\nfever; rash, pruritus;less frequentlystomatitis,\r\npalpitation, anxiety, blood disorders, hyponatraemia, and hair loss;\r\nalso reported, hepatitis, cholestasis, tachycardia, hallucinations,\r\nseizures, vasculitis, mouth ulcers, photosensitivity, and Stevens-Johnson\r\nsyndrome", "doses": ["prophylaxis of malaria, started 1\u20132 days before entering\r\nendemic area and continued for 1 week after leaving,adultandchildover\r\n40\u00a0kg, 1 tablet daily"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "use only if no suitable alternative available;\r\nsee alsoBreast-feeding"}, "Heparin flushes": {"name": "Heparin flushes", "doses": ["to maintain patency of catheters, cannulas, etc. 10\u2013200\u00a0units\r\nflushed through every 4\u20138 hours. Not for therapeutic\r\nuse"]}, "DEXAMETHASONE": {"indications": "local treatment of inflammation (short-term)", "name": "DEXAMETHASONE", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of dexamethasone ", "name": "Dexamethasone", "backrefs": ["Dexamethasone"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "doses": ["Apply eye drops every 30\u201360 minutes until controlled\r\nthen reduce frequency to 4\u20136 times daily"]}, "CLINDAMYCIN": {"indications": "see notes above; staphylococcal bone and joint infections, peritonitis;\r\nfalciparum malaria (section 5.4.1)", "name": "CLINDAMYCIN", "interactions": {"extra": "", "bad": 1, "interaction": "effects of  non-depolarising muscle relaxants enhanced by clindamycin ", "name": "Clindamycin", "backrefs": ["Clindamycin"]}, "cautions": "discontinue\r\nimmediately if diarrhoea or colitis develops; monitor liver\r\nand renal function if treatment exceeds 10 days, and in neonates and\r\ninfants; avoid rapid intravenous administration; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (clindamycin)", "side-effects": "diarrhoea (discontinue treatment), abdominal discomfort,\r\noesophagitis, oesophageal ulcers, taste disturbances, nausea, vomiting,\r\nantibiotic-associated colitis; jaundice; leucopenia, eosinophilia,\r\nand thrombocytopenia reported; polyarthritis reported; rash, pruritus,\r\nurticaria, anaphylactoid reactions, Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis, exfoliative and vesiculobullous dermatitis reported;\r\npain, induration, and abscess after intramuscular injection; thrombophlebitis\r\nafter intravenous injection", "contra-indications": "diarrhoeal states; avoid injections containing benzylalcoholin neonates (see under preparations below)", "doses": ["By mouth, 150\u2013300\u00a0mg every 6 hours; up\r\nto 450\u00a0mg every 6 hours in severe infections;child, 3\u20136\u00a0mg/kg every 6 hours", "Patients should discontinue immediately\r\nand contact doctor if diarrhoea develops; capsules should be swallowed\r\nwith a glass of water.", "By deep intramuscular injectionorby intravenous infusion, 0.6\u20132.7\u00a0g daily\r\n(in 2\u20134 divided doses); life-threatening infection, up to 4.8\u00a0g daily;\r\nsingle doses above 600\u00a0mg by intravenous infusion only; single doses\r\nby intravenous infusion not to exceed 1.2\u00a0g;childover 1 month, 15\u201340\u00a0mg/kg daily in 3\u20134 divided doses; severe infections,\r\nat least 300\u00a0mg daily regardless of weight"], "pregnancy": "not known to be harmful", "breast-feeding": "amount probably too small to be harmful but\r\nbloody diarrhoea reported in 1 infant"}, "LIOTHYRONINE SODIUM": {"indications": "see notes above", "name": "LIOTHYRONINE SODIUM", "cautions": "see underLevothyroxine Sodium;interactions:Appendix 1 (thyroid hormones)", "side-effects": "see under Levothyroxine Sodium", "contra-indications": "see underLevothyroxine Sodium", "doses": ["By mouth, initially 10\u201320\u00a0micrograms daily\r\ngradually increased to 60\u00a0micrograms daily in 2\u20133 divided doses;elderlysmaller initial doses;child, adult dose reduced in proportion to body-weight", "By slow intravenous injection, hypothyroid coma,\r\n5\u201320\u00a0micrograms repeated every 12 hours or as often as every 4 hours\r\nif necessary;alternativelyinitially 50\u00a0micrograms\r\nthen 25\u00a0micrograms every 8 hours reducing to 25\u00a0micrograms twice daily"], "pregnancy": "does not cross the placenta in significant amounts;\r\nmonitor maternal thyroid function tests\u2014dosage adjustment may be necessary", "breast-feeding": "amount too small to affect tests for neonatal\r\nhypothyroidism"}, "SULINDAC": {"indications": "pain and inflammation in rheumatic disease and other musculoskeletal\r\ndisorders; acute gout", "name": "SULINDAC", "renal impairment": "avoid in severe impairment; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  dimethyl sulfoxide with sulindac ", "name": "Sulindac", "backrefs": ["Sulindac", "Dimethyl sulfoxide"]}, "cautions": "seenotes above; also history of renal stones and ensure adequate\r\nhydration", "side-effects": "seenotes above; jaundice with fever, cholestasis,\r\nhepatitis, hepatic failure; also urine discoloration occasionally\r\nreported", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["200\u00a0mg twice daily (may be reduced according to response);\r\nmax. 400\u00a0mg daily; acute gout should respond within 7 days; limit\r\ntreatment of peri-articular disorders to 7\u201310 days;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ATOMOXETINE": {"indications": "attention deficit hyperactivity disorder (initiated by a specialist\r\nphysician experienced in managing the condition)", "name": "ATOMOXETINE", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  antipsychotics that prolong the QT interval given with atomoxetine ", "name": "Atomoxetine", "backrefs": ["Atomoxetine"]}, "cautions": "seenotes above; also cardiovascular disease including hypertension and tachycardia; structural\r\ncardiac abnormalities; QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval); psychosis or mania; monitor for appearance of depression or tics; history\r\nof seizures; aggressive behaviour, hostility, or emotional\r\nlability; susceptibility to angle-closure\r\nglaucoma;interactions:Appendix 1\r\n(atomoxetine)", "side-effects": "anorexia, dry mouth, nausea, vomiting, abdominal\r\npain, constipation, dyspepsia, flatulence; palpitation, tachycardia,\r\nincreased blood pressure, postural hypotension, hot flushes; sleep\r\ndisturbance, dizziness, headache, fatigue, lethargy, drowsiness, irritability,\r\ntremor, rigors; urinary retention, enuresis, prostatitis, sexual dysfunction,\r\nmenstrual disturbances, conjunctivitis; dermatitis, pruritus, rash,\r\nsweating, weight changes;less commonlysuicidal\r\nideation (see Suicidal Ideation, above), aggression, hostility, emotional\r\nlability, cold extremities, mydriasis;very rarelyangle-closure glaucoma; also reported hepatic disorders (see Hepatic\r\nDisorders, above), psychosis, hypoaesthesia, anxiety, depression,\r\nseizures, and Raynaud\u2019s phenomenon", "contra-indications": "pheochromocytoma", "hepatic impairment": "halve dose in moderate impairment; quarter dose in\r\nsevere impairment; see also Hepatic Disorders above", "doses": ["adultover 18 years, body-weight\r\nover 70\u00a0kg, initially 40\u00a0mg daily for 7 days, increased according\r\nto response; usual maintenance 80\u2013100\u00a0mg daily, but may be increased\r\nto max. 120\u00a0mg daily [unlicensed] under the direction of a specialist;child6\u201318 years, body-weight over 70\u00a0kg, initially\r\n40\u00a0mg daily for 7 days, increased according to response; usual maintenance\r\n80\u00a0mg daily, but may be increased to max. 120\u00a0mg daily [unlicensed]\r\nunder the direction of a specialist;adultandchildover 6 years, body-weight\r\nunder 70\u00a0kg, initially 500\u00a0micrograms/kg daily for 7 days, increased\r\naccording to response; usual maintenance 1.2\u00a0mg/kg daily, but may\r\nbe increased to 1.8\u00a0mg/kg daily (max. 120\u00a0mg daily) [unlicensed] under\r\nthe direction of a specialist", "Total daily dose may be giveneitheras a single dose in the morningorin 2 divided\r\ndoses with last dose no later than early evening"], "pregnancy": "no information available; avoid unless potential\r\nbenefit outweighs risk", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "SUCRALFATE": {"indications": "see under Dose", "name": "SUCRALFATE", "renal impairment": "use with caution; aluminium is absorbed and may accumulate", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  lansoprazole possibly reduced by sucralfate ", "name": "Sucralfate", "backrefs": ["Sucralfate"]}, "cautions": "administration ofsucralfateand enteral feeds should be separated by 1 hour;interactions:Appendix 1 (sucralfate)", "side-effects": "constipation;less frequentlydiarrhoea, nausea, indigestion, flatulence, gastric discomfort,\r\nback pain, dizziness, headache, drowsiness, bezoar formation (see\r\nabove), dry mouth and rash", "doses": ["Benign gastric and duodenal ulceration and chronic gastritis,adultandchildover\r\n15 years, 2\u00a0g twice daily (on rising and at bedtime)or1\u00a0g 4 times daily 1 hour before meals and at bedtime, taken for\r\n4\u20136 weeks or in resistant cases up to 12 weeks; max. 8\u00a0g daily", "Prophylaxis of stress ulceration,adultandchildover 15 years, 1\u00a0g 6 times\r\ndaily; max. 8\u00a0g daily", "childunder 15 years seeBNF for Children"], "pregnancy": "no evidence of harm; absorption from gastro-intestinal\r\ntract negligible", "breast-feeding": "amount probably too small to be harmful"}, "MELPHALAN": {"indications": "seenotes above", "name": "MELPHALAN", "renal impairment": "reduce dose initially (consult product literature)", "interactions": {"extra": "", "bad": 0, "interaction": " nalidixic acid increases risk of melphalan toxicity", "name": "Melphalan", "backrefs": ["Melphalan"]}, "cautions": "seesection 8.1andnotes above; avoid in acute porphyria (but seesection 9.8.2);interactions:Appendix 1\r\n(melphalan)", "side-effects": "seesection 8.1andnotes above", "doses": ["By mouth, multiple myeloma, dose\r\nmay vary according to regimen; typical dose 150\u00a0micrograms/kg daily\r\nfor 4 days, repeated every 6 weeks", "Polycythaemia vera, initially, 6\u201310\u00a0mg daily reduced after 5\u20137\r\ndays to 2\u20134\u00a0mg daily until satisfactory response then further reduce\r\nto 2\u20136\u00a0mgper week", "By intravenous injectionorinfusionor byregional arterial\r\nperfusion, consult product literature"], "pregnancy": "avoid (manufacturer advises adequate contraception\r\nduring treatment in men or women); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CARBOCISTEINE": {"indications": "reduction of sputum viscosity, seenotes above", "name": "CARBOCISTEINE", "cautions": "seenotes above", "side-effects": "rarelygastro-intestinal bleeding;\r\nhypersensitivity reactions (including rash and anaphylaxis) also reported", "contra-indications": "active peptic ulceration", "doses": ["Initially 2.25\u00a0g daily in divided doses, then 1.5\u00a0g daily\r\nin divided doses as condition improves;child2\u20135 years 62.5\u2013125\u00a0mg 4 times daily, 5\u201312 years 250\u00a0mg 3 times daily"], "pregnancy": "manufacturer advises avoid in first trimester", "breast-feeding": "no information available"}, "DIMETHYL SULFOXIDE": {"interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  sulindac with dimethyl sulfoxide ", "name": "Dimethyl sulfoxide", "backrefs": ["Sulindac", "Dimethyl sulfoxide"]}}, "IRON DEXTRAN": {"indications": "iron-deficiency\r\nanaemia, seenotes above", "name": "IRON DEXTRAN", "renal impairment": "avoid in acute renal failure", "cautions": "oral iron should not be given until 5\r\ndays after last injection", "side-effects": "less commonlynausea, vomiting,\r\nabdominal pain, flushing, dyspnoea, anaphylactic reactions (see Anaphylaxis\r\nabove), numbness, cramps, blurred vision, pruritus, and rash;rarelydiarrhoea, chest pain, hypotension, angioedema,\r\narrhythmias, tachycardia, dizziness, restlessness, fatigue, seizures,\r\ntremor, impaired consciousness, myalgia, arthralgia, sweating, and\r\ninjection-site reactions;very rarelyhypertension,\r\npalpitation, headache, paraesthesia, haemolysis, and transient deafness", "contra-indications": "history of allergic disorders including asthma, and eczema; infection; active rheumatoid arthritis", "hepatic impairment": "avoid in severe impairment", "doses": ["By deep intramuscular injectioninto\r\nthe gluteal muscleorby slow intravenous\r\ninjectionorby intravenous infusion, calculated according to body-weight and iron deficit, consult product\r\nliterature", "childunder 14 years, not recommended"], "pregnancy": "avoid in first trimester"}, "RIMEXOLONE": {"side-effects": "seenotes above", "indications": "local treatment of inflammation (short-term)", "name": "RIMEXOLONE", "cautions": "seenotes above", "doses": ["Postoperative inflammation, apply 4 times daily\r\nfor 2 weeks, beginning 24 hours after surgery", "Steroid-responsive inflammation, apply at least\r\n4 times daily for up to 4 weeks", "Uveitis, apply every hour during daytime in week\r\n1, then every 2 hours in week 2, then 4 times daily in week 3, then\r\ntwice daily for first 4 days of week 4, then once daily for remaining\r\n3 days of week 4"]}, "GLYCEROL": {"indications": "constipation", "name": "GLYCEROL", "doses": ["1 suppository moistened with water before use, when required.\r\nThe usual sizes are forinfantunder\r\n1 year, small (1-g mould),child1\u201312\r\nyears medium (2-g mould),adultandchildover 12 years, large (4-g mould)"]}, "ACEBUTOLOL": {"indications": "see under Dose", "name": "ACEBUTOLOL", "renal impairment": "halve dose if eGFR 25\u201350\u00a0mL/minute/1.73\u00a0m2; use quarter dose if eGFR less than 25\u00a0mL/minute/1.73\u00a0m2; do not administer more than once daily", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "doses": ["Hypertension, initially 400\u00a0mg once dailyor200\u00a0mg twice daily, increased after 2 weeks to 400\u00a0mg twice daily\r\nif necessary; up to 1.2\u00a0g daily has been used", "Angina, initially 400\u00a0mg once dailyor200\u00a0mg\r\ntwice daily; 300\u00a0mg 3\u00a0times daily in severe angina; up to 1.2\u00a0g daily\r\nhas been used", "Arrhythmias, 0.4\u20131.2\u00a0g daily in 2\u20133 divided doses"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "RASAGILINE": {"indications": "Parkinson\u2019s disease, used alone or\r\nas adjunct to co-beneldopa or co-careldopa", "name": "RASAGILINE", "interactions": {"extra": "Rasagiline is a MAO-B inhibitor", "bad": 1, "interaction": "risk of CNS toxicity when  pethidine given with rasagiline (avoid pethidine for 2 weeks after rasagiline)", "name": "Rasagiline", "backrefs": ["Rasagiline", "Dextromethorphan"]}, "cautions": "avoid abrupt withdrawal;interactions:Appendix 1 (rasagiline)", "side-effects": "dry mouth, dyspepsia, constipation, flatulence;\r\nangina; headache, depression, anorexia, weight loss, abnormal dreams,\r\nvertigo, hallucinations; influenza-like symptoms; urinary urgency;\r\nleucopenia; arthralgia; conjunctivitis; rhinitis; rash, skin carcinoma;less commonlymyocardial infarction, and cerebrovascular\r\naccident", "hepatic impairment": "use with caution in mild impairment; avoid in moderate\r\nto severe impairment", "doses": ["1\u00a0mg daily"], "pregnancy": "use with caution", "breast-feeding": "use with caution\u2014may suppress lactation"}, "Poultices": {"name": "Poultices", "doses": ["warm and apply directly or between layers of muslin; avoid\r\napplication of overheated poultice"]}, "COLISTIMETHATE SODIUM": {"indications": "see notes above", "name": "COLISTIMETHATE SODIUM", "renal impairment": "reduce dose and monitor plasma-colistimethate sodium\r\nconcentration during parenteral treatment\u2014consult product literature", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of nephrotoxicity and ototoxicity when  vancomycin given with colistimethate sodium ", "name": "Colistimethate Sodium", "backrefs": ["Colistimethate Sodium"]}, "cautions": "acute porphyria (section 9.8.2); risk of bronchospasm on inhalation\u2014may\r\nbe prevented or treated with a selective beta2agonist;interactions:Appendix 1 (polymyxins)", "side-effects": "Neurotoxicity reported especially with excessive doses (including\r\napnoea, perioral and peripheral paraesthesia, vertigo, headache, muscle\r\nweakness; rarely vasomotor instability, slurred speech, confusion,\r\npsychosis, visual disturbances), nephrotoxicity, rash", "contra-indications": "myasthenia gravis", "doses": ["By slow intravenous injectioninto a totally\r\nimplantable venous access device,orby intravenous\r\ninfusion(but see notes above),adultandchildbody-weight under 60\u00a0kg,\r\n50\u00a0000\u201375\u00a0000\u00a0units/kg daily in 3 divided doses; body-weight over\r\n60\u00a0kg, 1\u20132\u00a0million units every 8 hours", "Plasma concentration monitoring required\r\nin renal impairment; recommended \u2018peak\u2019 plasma-colistimethate sodium\r\nconcentration (approx. 30 minutes after intravenous injection or infusion)\r\n10\u201315\u00a0mg/litre (125\u2013200\u00a0units/mL)", "By inhalation of nebulised solution,adultandchildover\r\n2 years, 1\u20132\u00a0million\u00a0units twice daily; increased to 2 million\u00a0units\r\n3 times daily for subsequent respiratory isolates ofPs.\r\naeruginosa;child1 month\u20132\r\nyears, 0.5\u20131\u00a0million\u00a0units twice daily; increased to 1 million\u00a0units\r\n3 times daily for subsequent respiratory isolates ofPs.\r\naeruginosa"], "pregnancy": "avoid\u2014possible risk of fetal toxicity especially\r\nin second and third trimesters", "breast-feeding": "present in milk but poorly absorbed from gut;\r\nmanufacturers advise avoid (or use only if potential benefit outweighs\r\nrisk)"}, "POTASSIUM PERMANGANATE": {"indications": "cleansing and deodorising suppurating eczematous reactions and wounds", "name": "POTASSIUM PERMANGANATE", "cautions": "irritant to mucous membranes", "doses": ["Wet dressings or baths, approx. 0.01% solution", "Stains skin and clothing"]}, "ERYTHROMYCIN": {"indications": "susceptible infections in patients with penicillin hypersensitivity;\r\noral infections (see notes above); campylobacter enteritis, syphilis,\r\nnon-gonococcal urethritis, respiratory-tract infections (including\r\nLegionella infection), skin infections (Table 1,section 5.1); chronic\r\nprostatitis; prophylaxis of diphtheria, group A streptococcal infection,\r\nand pneumococcal infection (Table 2,section 5.1), and\r\npertussis; acne vulgaris and rosacea (section 13.6)", "name": "ERYTHROMYCIN", "renal impairment": "max. 1.5\u00a0g daily in severe renal impairment (ototoxicity)", "interactions": {"extra": "Interactions do not apply to small amounts of erythromycin used topically", "bad": 0, "interaction": "in vitro studies suggest a possible interaction between  docetaxel and erythromycin (consult docetaxel product literature)", "name": "Erythromycin", "backrefs": ["Erythromycin", "Pravastatin", "Dienogest", "Estradiol"]}, "cautions": "seenotes above; neonate under\r\n2 weeks (risk of hypertrophic pyloric stenosis);avoid in acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(macrolides)", "side-effects": "seenotes above", "hepatic impairment": "may cause idiosyncratic hepatotoxicity", "doses": ["By mouth,adultandchildover 8 years, 250\u2013500\u00a0mg\r\nevery 6 hoursor0.5\u20131\u00a0g every 12 hours (see notes\r\nabove); up to 4\u00a0g daily in divided doses in severe infections;neonate12.5\u00a0mg/kg every 6 hours;child1 month\u20132 years 125\u00a0mg every 6 hoursor250\u00a0mg every 12 hours, 2\u20138 years 250\u00a0mg every 6\u00a0hoursor500\u00a0mg every 12 hours, doses doubled for severe infections", "Early syphilis, 500\u00a0mg 4 times daily for 14 days;child12\u201318 years seeBNF for Children", "Uncomplicated genital chlamydia, non-gonococcal urethritis,\r\n500\u00a0mg twice daily for 14 days;childunder 18 years seeBNF for Children", "Lyme disease (see alsosection 5.1.1.3), 500\u00a0mg 4 times daily for\r\n14\u201321\u00a0days;childunder 18 years seeBNF for Children", "By intravenous infusion,adultandchildsevere\r\ninfections, 12.5\u00a0mg/kg every 6 hours; mild infections (when oral treatment\r\nnot possible), 6.25\u00a0mg/kg every 6 hours;neonateseeBNF for Children"], "pregnancy": "not known to be harmful", "breast-feeding": "only small amounts in milk\u2014not known to be harmful"}, "IRON": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  ofloxacin reduced by oral iron ", "name": "Iron", "backrefs": ["Tranylcypromine", "Levofloxacin", "Ofloxacin", "Mitotane", "Trientine", "Iron", "Eltrombopag", "Buspirone", "Mycophenolate", "Bisphosphonates", "Spironolactone", "Aspirin", "Trimethoprim"]}}, "NORADRENALINE/NOREPINEPHRINE": {"indications": "see under dose", "name": "NORADRENALINE/NOREPINEPHRINE", "cautions": "coronary, mesenteric,\r\nor peripheral vascular thrombosis; following myocardial infarction, Prinzmetal\u2019s\r\nvariant angina, hyperthyroidism, diabetes mellitus; hypoxia or hypercapnia; uncorrected\r\nhypovolaemia; elderly; extravasation at injection site may cause necrosis;interactions:Appendix 1 (sympathomimetics)", "side-effects": "anorexia, nausea, vomiting, hypoxia, arrhythmias,\r\nperipheral ischaemia, palpitation, hypertension, bradycardia, tachycardia,\r\ndyspnoea, headache, insomnia, confusion, anxiety, psychosis, weakness,\r\ntremor, urinary retention, angle-closure glaucoma", "contra-indications": "hypertension (monitor blood pressure and rate of flow frequently)", "doses": ["Acute hypotension,by intravenous infusion, via central venous catheter, of a solution containing noradrenaline\r\n40\u00a0micrograms (base)/mL at an initial rate of 0.16\u20130.33\u00a0mL/minute,\r\nadjusted according to response", "1\u00a0mg of noradrenaline base is equivalent\r\nto 2\u00a0mg of noradrenaline acid tartrate. Dose expressed as the base"], "pregnancy": "avoid\u2014may reduce placental perfusion"}, "VALACICLOVIR": {"indications": "treatment of herpes zoster; treatment\r\nof initial and suppression of recurrent herpes simplex infections\r\nof skin and mucous membranes including initial and recurrent genital\r\nherpes; reduction of transmission of genital herpes; prevention of\r\ncytomegalovirus disease following solid organ transplantation when\r\nvalganciclovir or ganciclovir cannot be used", "name": "VALACICLOVIR", "renal impairment": "maintain adequate hydration; forherpes zoster, 1\u00a0g every 12 hours if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2(1\u00a0g\r\nevery 24 hours if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; 500\u00a0mg\r\nevery 24 hours if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2);\r\nfortreatment of herpes simplex, 500\u00a0mg (1\u00a0g in immunocompromised\r\nor HIV-positive patients) every 24 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; fortreatment of herpes labialis, if eGFR\r\n30\u201350\u00a0mL/minute/1.73\u00a0m2, initially 1\u00a0g, then 1\u00a0g 12 hours\r\nafter initial dose (if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2, initally\r\n500\u00a0mg, then 500\u00a0mg 12 hours after initial dose; if eGFR less than\r\n10\u00a0mL/minute/1.73\u00a0m2, 500\u00a0mg as a single dose); forsuppression of herpes simplex, 250\u00a0mg (500\u00a0mg in immunocompromised\r\nor HIV-positive patients) every 24 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; forreduction of genital herpes transmission, 250\u00a0mg every 24 hours if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2; reduce dose according to eGFR forcytomegalovirus\r\nprophylaxisfollowing solid organ transplantation (consult\r\nproduct literature)", "cautions": "see underAciclovir", "side-effects": "see under Aciclovir but neurological reactions\r\nmore frequent with high doses", "hepatic impairment": "manufacturer advises caution with high doses used for\r\nherpes labialis and prevention of cytomegalovirus disease\u2014no information\r\navailable", "doses": ["Herpes zoster, 1\u00a0g 3 times daily for 7 days (in immunocompromised\r\ncontinue for 2 days after crusting of lesions);child12\u201318 years seeBNF for Children", "Herpes simplex, treatment offirst episode,\r\n500\u00a0mg twice daily for 5 days, longer if new lesions appear during\r\ntreatment or if healing incomplete (1\u00a0g twice daily for 10 days in\r\nimmunocompromised or HIV-positive patients); treatment ofrecurrent infection, 500\u00a0mg twice daily for 3\u20135 days (1\u00a0g\r\ntwice daily for 5\u201310 days in immunocompromised or HIV-positive patients);child12\u201318 years seeBNF for Children", "Herpes labialis, treatment,adultandchildover 12 years, initially\r\n2\u00a0g, then 2\u00a0g 12 hours after initial dose", "Herpes simplex, suppression, 500\u00a0mg daily in 1\u20132 divided doses\r\n(in immunocompromised or HIV positive patients, 500\u00a0mg twice daily);\r\ntherapy interrupted every 6\u201312 months to reassess recurrence frequency\u2014consider\r\nrestarting after two or more recurrences;child12\u201318 years seeBNF for Children", "Reduction of transmission of genital herpes, seek specialist\r\nadvice, 500\u00a0mg once daily to be taken by the infected partner", "Prevention of cytomegalovirus disease following solid organ\r\ntransplantation (preferably starting within 72 hours of transplantation),\r\n2\u00a0g 4 times daily usually for 90 days;child12\u201318 years seeBNF for Children"], "pregnancy": "see underAciclovir", "breast-feeding": "see underAciclovir"}, "AZATHIOPRINE": {"indications": "seenotes above; inflammatory bowel disease [unlicensed\r\nindication] (section 1.5.3); rheumatoid arthritis (section 10.1.3); severe\r\nrefractory eczema [unlicensed indication] (section 13.5.3)", "name": "AZATHIOPRINE", "renal impairment": "reduce dose; see also Cautions", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of haematological toxicity when  sulfamethoxazole (as co-trimoxazole) given with azathioprine ", "name": "Azathioprine", "backrefs": ["Azathioprine"]}, "cautions": "seeBioavailability;\r\nthiopurine methyltransferase status (see notes above);monitor\r\nfor toxicity throughout treatment; monitor full blood\r\ncount weekly (more frequently with higher doses or if severe hepatic\r\nor renal impairment) for first 4 weeks (manufacturer advises weekly\r\nmonitoring for 8 weeks but evidence of practical value unsatisfactory),\r\nthereafter reduce frequency of monitoring to at least every 3 months; reduce dose in elderly;interactions:Appendix 1 (azathioprine)", "side-effects": "hypersensitivity reactions (including malaise,\r\ndizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia,\r\nrash, hypotension and interstitial nephritis\u2014calling for immediate\r\nwithdrawal); dose-related bone marrow suppression (see also Cautions);\r\nliver impairment, cholestatic jaundice, hair loss and increased susceptibility\r\nto infections and colitis in patients also receiving corticosteroids;\r\nnausea;rarelypancreatitis, pneumonitis, hepatic\r\nveno-occlusive disease, lymphoma, red cell aplasia\u2014seenotes above", "contra-indications": "see notes above; hypersensitivity tomercaptopurine", "hepatic impairment": "reduce dose; monitor liver function; see also Cautions", "doses": ["By mouth,or(if\r\noral administration not possible\u2014intravenous solution very irritant,\r\nsee below)by intravenous injectionover at least 1\r\nminute (followed by 50\u00a0mLsodium chlorideintravenous\r\ninfusion),orby intravenous infusion", "Autoimmune conditions, 1\u20133\u00a0mg/kg daily, adjusted according to\r\nresponse (consider withdrawal if no improvement within 3 months)", "Suppression of transplant rejection, 1\u20132.5\u00a0mg/kg daily adjusted according\r\nto response", "Azathioprine doses in BNF may differ from\r\nthose in product literature", "Intravenous injection is alkaline and very irritant, intravenous route should therefore\r\nbe usedonlyif oral route not feasible, see also\r\nAppendix 4"], "pregnancy": "treatment should not generally be initiated during\r\npregnancy; see alsoImmunosuppressant therapy", "breast-feeding": "present in milk in low concentration; no evidence\r\nof harm in small studies\u2014use if potential benefit outweighs risk"}, "LANTHANUM": {"indications": "seenotes above", "name": "LANTHANUM", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of   ketoconazole possibly reduced by lanthanum (give at least 2 hours apart)", "name": "Lanthanum", "backrefs": ["Lanthanum"]}, "cautions": "acute peptic ulcer; ulcerative colitis; Crohn\u2019s disease; bowel obstruction;interactions: Appendix 1 (lanthanum)", "side-effects": "gastro-intestinal disturbances; hypocalcaemia;less commonlyanorexia, increased appetite, taste disturbances,\r\ndry mouth, thirst, stomatitis, chest pain, peripheral oedema, headache,\r\ndizziness, vertigo, asthenia, fatigue, malaise, hyperglycaemia, hyperparathyroidism,\r\nhypercalcaemia, hypophosphataemia, eosinophilia, arthralgia, myalgia,\r\nosteoporosis, sweating, alopecia, pruritus, and erythematous rash;\r\naccumulation of lanthanum in bone, and transient changes in QT interval\r\nalso reported", "hepatic impairment": "lanthanum excreted in bile\u2014possible accumulation in\r\nobstructive jaundice", "doses": ["adultover 18 years, usual\r\ndose range 1.5\u20133\u00a0g daily in divided doses chewed with or immediately\r\nafter meals, adjusted according to serum-phosphate concentration every\r\n2\u20133 weeks"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "RAMIPRIL WITH FELODIPINE": {"indications": "hypertension in patients stabilised\r\non the individual components in the same proportions", "name": "RAMIPRIL WITH FELODIPINE", "renal impairment": "seenotes above; max.\r\ndaily ramipril dose 5\u00a0mg if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; max. initial ramipril dose 1.25\u00a0mg once daily (do not exceed 5\u00a0mg\r\nonce daily) if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; max. initial\r\nramipril dose 1.25\u00a0mg once daily (do not exceed 2.5\u00a0mg once daily)\r\nif eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above; withdraw if ischaemic pain occurs or existing pain worsens shortly\r\nafter initiating treatment or if cardiogenic shock develops; severe left ventricular dysfunction; avoid grapefruit juice (may affect metabolism);interactions:Appendix 1 (ACE inhibitors, calcium\r\nchannel blockers)", "side-effects": "seenotes above; also\r\narrhythmias, gravitational oedema, flushing, headache, palpitation;\r\ndizziness, fatigue; conjunctivitis; skin reactions such as pruritus\r\nand rash;rarelyloss of appetite, stomatitis, dry\r\nmouth; angina, syncope; bronchitis; confusion, anxiety, nervousness,\r\ndepression, fever; urinary frequency, impotence, decreased libido;\r\nmuscle cramps; gingival hyperplasia, cutaneous vasculitis;very rarelycerebrovascular accident, myocardial infarction;\r\nprecipitation or intensification of Raynaud\u2019s phenomenon; Stevens-Johnson\r\nsyndrome, pemphigoid exanthema, alopecia, onycholysis", "contra-indications": "seenotes above; unstable angina; uncontrolled heart failure; significant aortic stenosis; within 1 month of myocardial infarction; second- or third-degree AV block", "hepatic impairment": "seenotes above; max.\r\ndaily ramipril dose 2.5\u00a0mg; reduce felodipine dose", "doses": ["1 tablet daily; max. 2 tablets once daily"], "pregnancy": "seenotes above; toxicity\r\ninanimalstudies with felodipine; may inhibit labour;\r\navoid", "breast-feeding": "seenotes above; felodipine\r\npresent in milk"}, "HYDROCORTISONE ACETATE": {"side-effects": "seenotes above", "indications": "local treatment of inflammation (short-term)", "name": "HYDROCORTISONE ACETATE", "cautions": "seenotes above", "doses": ["Apply eye drops every 30\u201360 minutes until controlled then\r\nreduce frequency to every 4 hours"]}, "SIROLIMUS": {"indications": "prophylaxis of organ rejection in kidney allograft recipients (initially\r\nin combination with ciclosporin and corticosteroid, then with corticosteroid\r\nonly); see also under Dose", "name": "SIROLIMUS", "interactions": {"extra": "", "bad": 1, "interaction": " itraconazole increases plasma concentration of sirolimus\u2014avoid concomitant use", "name": "Sirolimus", "backrefs": ["Temsirolimus", "Sirolimus"]}, "cautions": "monitor kidney function when given with\r\nciclosporin; monitor whole blood-sirolimus\r\ntrough concentration (Afro-Caribbean patients may require higher doses); hyperlipidaemia (monitor lipids); monitor urine proteins; increased susceptibility\r\nto infection (especially urinary-tract infection); increased susceptibility to lymphoma and other malignancies, particularly\r\nof the skin (limit exposure to UV light);interactions:Appendix 1 (sirolimus)", "side-effects": "abdominal pain, constipation, nausea, diarrhoea,\r\nascites, stomatitis; oedema, tachycardia, hypertension, hypercholesterolaemia,\r\nhypertriglyceridaemia, venous thromboembolism; pleural effusion, pneumonitis;\r\nheadache; pyrexia; proteinuria, haemolytic uraemic syndrome; anaemia,\r\nthrombocytopenia, thrombotic thrombocytopenic purpura, leucopenia,\r\nneutropenia, hypokalaemia, hypophosphataemia, hyperglycaemia, lymphocele;\r\narthralgia, osteonecrosis; epistaxis; acne, rash, impaired healing;less commonlypancreatitis, pulmonary embolism, pulmonary\r\nhaemorrhage, pericardial effusion, nephrotic syndrome, pancytopenia;rarelyinterstitial lung disease, alveolar proteinosis,\r\nhepatic necrosis, lymphoedema, and hypersensitivity reactions including\r\nanaphylactic reactions, angioedema, exfoliative dermatitis, and hypersensitivity\r\nvasculitis; focal segmental glomerulosclerosis and reversible impairment\r\nof male fertility also reported", "hepatic impairment": "monitor whole blood-sirolimus level closely and consult\r\nlocal treatment protocol; clearance reduced in mild to moderate impairment;\r\nin severe impairment decrease dose by 50% and monitor whole blood-sirolimus\r\ntrough concentration every 5\u20137 days until 3 consecutive measurements\r\nhave shown stable blood-sirolimus concentration", "doses": ["Initially 6\u00a0mg, after surgery (once wound has healed),\r\nthen 2\u00a0mg once daily (dose adjusted according to whole blood-sirolimus\r\ntrough concentration) in combination with ciclosporin and corticosteroid\r\nfor 2\u20133 months (sirolimus given 4 hours after ciclosporin); ciclosporin\r\nshould then be withdrawn over 4\u20138 weeks (if not possible, sirolimus\r\nshould be discontinued and an alternate immunosuppressive regimen\r\nused)", "Manufacturer advises pre-dose (\u2018trough\u2019)\r\nwhole blood-sirolimus concentration (usingchromatographicassay) when used with ciclosporin should be 4\u201312\u00a0micrograms/litre\r\n(local treatment protocols may differ); after withdrawal of ciclosporin\r\npre-dose whole blood-sirolimus concentration should be 12\u201320\u00a0micrograms/litre\r\n(local treatment protocols may differ); close monitoring\r\nof whole blood-sirolimus concentration required if concomitant treatment\r\nwith potent inducers or inhibitors of metabolism and after discontinuing\r\nthem, or if ciclosporin dose reduced significantly or stopped; see\r\nalso Hepatic Impairment above", "When changing between oral solution and tablets, measurement\r\nof whole blood \u2018trough\u2019 sirolimus concentration after 1\u20132 weeks is\r\nrecommended", "Sirolimus whole-blood\r\nconcentration is measured using either high performance liquid chromatography\r\n(HPLC) or immunoassay. Switching between different immunoassays or\r\nbetween an immunoassay and HPLC can lead to clinically significant\r\ndifferences in results and therefore incorrect dose adjustments. Adjustment\r\nto the target therapeutic dose range should be made with knowledge\r\nof the assay used and corresponding reference range"], "pregnancy": "avoid unless essential\u2014(toxicity inanimalstudies); effective contraception must be used during treatment\r\nand for 12 weeks after stopping", "breast-feeding": "discontinue breast-feeding"}, "OMEGA-3-ACID ETHYL ESTERS": {"indications": "adjunct to diet and statin in type\r\nIIb or III hypertriglyceridaemia; adjunct to diet in type IV hypertriglyceridaemia;\r\nadjunct in secondary prevention in those who have had a myocardial\r\ninfarction in the preceding 3 months", "name": "OMEGA-3-ACID ETHYL ESTERS", "cautions": "haemorrhagic disorders, anticoagulant treatment (bleeding time increased)", "side-effects": "gastro-intestinal disturbances;less commonlytaste disturbances, dizziness, and hypersensitivity reactions;rarelyhepatic disorders, headache, hyperglycaemia, acne,\r\nand rash;very rarelyhypotension, nasal dryness,\r\nurticaria, and increased white cell count", "hepatic impairment": "monitor liver function", "doses": ["hypertriglyceridaemia, initially 2 capsules daily with\r\nfood, increased if necessary to 4 capsules daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "ERGOMETRINE": {"interactions": {"extra": "", "bad": 0, "interaction": " halothane reduces effects of ergometrine on the parturient uterus", "name": "Ergometrine", "backrefs": ["Ergometrine", "Halothane"]}}, "CHLORDIAZEPOXIDE HYDROCHLORIDE": {"indications": "short-term use in anxiety (seesection 4.1);\r\nadjunct in acutealcoholwithdrawal (section 4.10.1)", "name": "CHLORDIAZEPOXIDE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "see underDiazepam", "side-effects": "see underDiazepam", "contra-indications": "see underDiazepam", "hepatic impairment": "seenotes above", "doses": ["Anxiety, 10\u00a0mg 3 times daily increased if necessary to\r\n60\u2013100\u00a0mg daily in divided doses;elderly(or debilitated) half adult dose;childnot recommended", "Treatment of alcohol withdrawal in moderate dependence, 10\u201330\u00a0mg\r\n4 times daily (according to local protocol), gradually reduced over\r\n5\u20137 days", "Treatment of alcohol withdrawal in severe dependence, 10\u201350\u00a0mg\r\n4 times daily (with 10\u201340\u00a0mg as required, if necessary, for the first\r\n2 days; max. total daily dose 250\u00a0mg) (according to local protocol),\r\ngradually reduced over 7\u201310 days"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLUPHENAZINE": {"interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  clozapine with depot formulation of fluphenazine as cannot be withdrawn quickly if neutropenia occurs", "name": "Fluphenazine", "backrefs": ["Fluphenazine"]}}, "TRANDOLAPRIL": {"indications": "mild to moderate hypertension; following myocardial\r\ninfarction in patients with left ventricular dysfunction", "name": "TRANDOLAPRIL", "renal impairment": "seenotes above; max.\r\n2\u00a0mg daily if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; also ileus, dry mouth; tachycardia,\r\npalpitation, arrhythmias, angina, transient ischaemic attacks, cerebral\r\nhaemorrhage, myocardial infarction, syncope; dyspnoea, bronchitis;\r\nasthenia, nervousness, sleep disturbances; hot flushes; alopecia,\r\nsweating, skin reactions including Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis, and psoriasis-like efflorescence", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Hypertension, initially 500\u00a0micrograms once daily, increased\r\nat intervals of 2\u20134 weeks; usual range 1\u20132\u00a0mg once daily; max. 4\u00a0mg\r\ndaily; if used in addition to diureticsee notes above", "Prophylaxis after myocardial infarction (starting as early as\r\n3 days after infarction), initially 500\u00a0micrograms once daily, gradually\r\nincreased to max. 4\u00a0mg once daily", "If symptomatic hypotension develops during\r\ntitration, do not increase dose further; if possible, reduce dose\r\nof any adjunctive treatment and if this is not effective or feasible,\r\nreduce dose oftrandolapril"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "VINBLASTINE": {"interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of vinblastine ", "name": "Vinblastine", "backrefs": ["Vinblastine"]}}, "GANCICLOVIR": {"indications": "life-threatening or sight-threatening\r\ncytomegalovirus infections in immunocompromised patients only; prevention\r\nof cytomegalovirus disease during immunosuppressive therapy following\r\norgan transplantation; local treatment of CMV retinitis (section\r\n11.3.3)", "name": "GANCICLOVIR", "renal impairment": "reduce dose if eGFR less than 70\u00a0mL/minute/1.73\u00a0m2; consult product literature", "interactions": {"extra": "Increased risk of myelosuppression with other myelosuppressive drugs\u2014consult product literature", "bad": 0, "interaction": " probenecid reduces excretion of ganciclovir (increased plasma concentration and risk of toxicity)", "name": "Ganciclovir", "backrefs": ["Ganciclovir", "Imipenem with Cilastatin"]}, "cautions": "close monitoring of full blood count (severe deterioration\r\nmay require correction and possibly treatment interruption); history of cytopenia; potential\r\ncarcinogen and teratogen; radiotherapy;ensure adequate hydration during intravenous\r\nadministration; vesicant\u2014infuse into vein\r\nwith adequate flow preferably using plastic cannula;children\r\n(possible risk of long-term carcinogenic or reproductive toxicity);interactions:Appendix 1 (ganciclovir)", "side-effects": "diarrhoea, nausea, vomiting, dyspepsia, abdominal\r\npain, constipation, flatulence, dysphagia, taste disturbance, hepatic\r\ndysfunction; dyspnoea, chest pain, cough; headache, insomnia, convulsions,\r\ndizziness, peripheral neuropathy, depression, anxiety, confusion,\r\nabnormal thinking, fatigue, weight loss, anorexia; infection, pyrexia,\r\nnight sweats; anaemia, leucopenia, thrombocytopenia, pancytopenia,\r\nrenal impairment; myalgia, arthralgia; macular oedema, retinal detachment,\r\nvitreous floaters, eye pain; ear pain; dermatitis, pruritus; injection-site\r\nreactions;less commonlymouth ulcers, pancreatitis,\r\narrhythmias, hypotension, anaphylactic reactions, psychosis, tremor,\r\nmale infertility, haematuria, disturbances in hearing and vision,\r\nand alopecia", "contra-indications": "hypersensitivity tovalganciclovir,ganciclovir,aciclovir, orvalaciclovir; abnormally low haemoglobin, neutrophil, or platelet counts (consult\r\nproduct literature)", "doses": ["By intravenous infusion, initially\r\n(induction) 5\u00a0mg/kg every 12 hours for 14\u201321 days for treatment or\r\nfor 7\u201314 days for prevention; maintenance (for patients at risk of\r\nrelapse of retinitis) 6\u00a0mg/kg daily on 5 days per weekor5\u00a0mg/kg daily until adequate recovery of immunity; if retinitis\r\nprogresses initial induction treatment may be repeated;childunder 18 years, seeBNF for Children"], "pregnancy": "avoid\u2014teratogenic risk; ensure effective contraception\r\nduring treatment and barrier contraception for men during\r\nand for at least 90 days after treatment", "breast-feeding": "avoid\u2014no information available"}, "OMEGA-3-MARINE TRIGLYCERIDES": {"side-effects": "occasional nausea and belching", "indications": "adjunct in the reduction of plasma triglycerides\r\nin severe hypertriglyceridaemia", "name": "OMEGA-3-MARINE TRIGLYCERIDES", "cautions": "haemorrhagic disorders, anticoagulant treatment;aspirin-sensitive asthma; type 2 diabetes", "doses": ["5\u00a0mL twice daily with food"]}, "PIVMECILLINAM HYDROCHLORIDE": {"indications": "see under Dose below", "name": "PIVMECILLINAM HYDROCHLORIDE", "cautions": "see underBenzylpenicillin(section 5.1.1.1); also liver\r\nand renal function tests required in long-term use; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (penicillins)", "side-effects": "see underBenzylpenicillin(section 5.1.1.1); nausea,\r\nvomiting, abdominal pain, headache, dizziness; also reported mouth\r\nulcers, oesophagitis, reduced serum and total bodycarnitine(especially with long-term or repeated use)", "contra-indications": "see underBenzylpenicillin(section 5.1.1.1); alsocarnitinedeficiency, oesophageal\r\nstrictures, gastro-intestinal obstruction, infants under 3 months", "doses": ["Acute uncomplicated cystitis,adultandchildover 40\u00a0kg, initially 400\u00a0mg\r\nthen 200\u00a0mg every 8 hours for 3 days", "Chronic or recurrent bacteriuria,adultandchildover 40\u00a0kg, 400\u00a0mg every\r\n6\u20138 hours", "Urinary-tract infections,childunder 40\u00a0kg, 20\u201340\u00a0mg/kg daily in 3\u20134 divided doses", "Salmonellosis, not recommended therefore no dose stated", "Tablets should be swallowed whole\r\nwith plenty of fluid during meals while sitting or standing"], "pregnancy": "not known to be harmful, but manufacturer advises\r\navoid", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "VARENICLINE": {"indications": "seenotes above", "name": "VARENICLINE", "renal impairment": "if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2, initial\r\ndose 500\u00a0micrograms once daily, increased after 3 days to 1\u00a0mg once\r\ndaily", "cautions": "risk of relapse, irritability, depression,\r\nand insomnia on discontinuation (consider dose tapering on completion\r\nof 12-week course); history of psychiatric\r\nillness (may exacerbate underlying illness including depression); history of cardiovascular disease", "side-effects": "gastro-intestinal disturbances, appetite changes,\r\ndry mouth, taste disturbance; headache, drowsiness, dizziness, sleep\r\ndisorders, abnormal dreams;less commonlythirst,\r\nweight gain, aphthous stomatitis, gingival pain, chest pain, hypertension,\r\ntachycardia, atrial fibrillation, palpitation, depression, anxiety,\r\nhallucinations, panic attack, mood swings, dysarthria, asthenia, tremor,\r\nincoordination, hypertonia, restlessness, hypoaesthesia, impaired\r\ntemperature regulation, menorrhagia, vaginal discharge, sexual dysfunction,\r\ndysuria, arthralgia, muscle spasm, visual disturbances, eye pain,\r\nlacrimation, tinnitus, acne, sweating, rash, and pruritus; myocardial\r\ninfarction, anxiety, depression, aggression, irrational behaviour,\r\npsychosis, suicidal ideation (see MHRA/CHM advice above), and Stevens-Johnson\r\nsyndrome also reported", "doses": ["adultover 18 years, starting\r\nusually 1\u20132 weeks before target stop date (up to max. 5 weeks before\r\ntarget stop date), initially 500\u00a0micrograms once daily for 3 days,\r\nincreased to 500\u00a0micrograms twice daily for 4 days, then 1\u00a0mg twice\r\ndaily for 11 weeks (reduce to 500\u00a0micrograms twice daily if not tolerated);\r\n12-week course can be repeated in abstinent individuals to reduce\r\nrisk of relapse"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "PROMETHAZINE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of promethazine for 2 weeks after stopping  MAOIs advised by manufacturer of promethazine ", "name": "Promethazine", "backrefs": ["MAOIs", "Promethazine"]}}, "PARICALCITOL": {"indications": "see under preparations below", "name": "PARICALCITOL", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole possibly increases plasma concentration of paricalcitol ", "name": "Paricalcitol", "backrefs": ["Paricalcitol"]}, "cautions": "monitor plasma calcium and phosphate\r\nduring dose titration and at least monthly when stabilised; monitor parathyroid hormone concentration;interactions:Appendix 1 (vitamins)", "side-effects": "see underErgocalciferol; also\r\ndyspepsia, taste disturbance, breast tenderness, acne, pruritus, and\r\nrash", "contra-indications": "see underErgocalciferol", "doses": ["Consult product literature"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises avoid unless potential benefit outweighs risk; see also underErgocalciferol", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable; see also underErgocalciferol"}, "PENICILLINS": {"interactions": {"extra": "", "bad": 0, "interaction": " sulfinpyrazone reduces excretion of penicillins ", "name": "Penicillins", "backrefs": ["Penicillins"]}}, "OLOPATADINE": {"side-effects": "local irritation; less commonly keratitis, dry\r\neye, local oedema, photophobia; headache, asthenia, dizziness; dry\r\nnose also reported", "indications": "seasonal allergic conjunctivitis", "name": "OLOPATADINE", "doses": ["adultandchildover 3 years, apply twice daily; max. duration\r\nof treatment 4 months"]}, "LANSOPRAZOLE": {"indications": "see under Dose", "name": "LANSOPRAZOLE", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  saquinavir possibly increased by lansoprazole\u2014manufacturer of saquinavir advises avoid concomitant use", "name": "Lansoprazole", "backrefs": ["Erlotinib", "Fluvoxamine", "Antacids", "Sucralfate", "Lansoprazole", "Clopidogrel"]}, "cautions": "seenotes above;interactions:Appendix 1 (proton pump inhibitors)", "side-effects": "seenotes above; also glossitis, pancreatitis,\r\nanorexia, restlessness, tremor, impotence, petechiae, and purpura;very rarelycolitis, raised serum cholesterol or triglycerides", "hepatic impairment": "use half normal dose in moderate to severe liver disease", "doses": ["Benign gastric ulcer, 30\u00a0mg daily in the morning for 8\r\nweeks", "Duodenal ulcer, 30\u00a0mg daily in the morning for 4 weeks; maintenance\r\n15\u00a0mg daily", "NSAID-associated duodenal or gastric ulcer, 30\u00a0mg once daily\r\nfor 4 weeks, continued for further 4 weeks if not fully healed; prophylaxis,\r\n15\u201330\u00a0mg once daily", "Eradication ofHelicobacter pyloriassociated\r\nwith duodenal ulcer or ulcer-like dyspepsia, seeRecommended Regimens forHelicobacter pyloriEradication", "Zollinger-Ellison syndrome (and other hypersecretory conditions),\r\ninitially 60\u00a0mg once daily adjusted according to response; daily doses\r\nof 120\u00a0mg or more given in two divided doses", "Gastro-oesophageal reflux disease, 30\u00a0mg daily in the morning\r\nfor 4 weeks, continued for further 4 weeks if not fully healed; maintenance\r\n15\u201330\u00a0mg daily", "Acid-related dyspepsia, 15\u201330\u00a0mg daily in the morning for 2\u20134\r\nweeks", "childunder 18 years seeBNF for Children", "Lansoprazole doses in BNF may differ from\r\nthose in product literature"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "FLAVOXATE HYDROCHLORIDE": {"indications": "urinary frequency and incontinence, dysuria, urgency; bladder spasms\r\ndue to catheterisation, cytoscopy, or surgery", "name": "FLAVOXATE HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nvertigo, eosinophilia, leucopenia, urticaria, erythema, and pruritus", "contra-indications": "seenotes above; gastro-intestinal haemorrhage", "doses": ["adultandchildover 12 years, 200\u00a0mg 3 times daily"], "pregnancy": "manufacturer advises avoid unless no safer alternative", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "LOFEPRAMINE": {"indications": "depressive illness", "name": "LOFEPRAMINE", "renal impairment": "avoid in severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\noedema and hepatic disorders reported", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["140\u2013210\u00a0mg daily in divided doses;elderlymay respond to lower doses;childunder 18 years not recommended"], "pregnancy": "neonatal withdrawal symptoms and respiratory depression\r\nreported if used during third trimester", "breast-feeding": "seenotes above"}, "LERCANIDIPINE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  ritonavir advised by manufacturer of lercanidipine ", "name": "Lercanidipine", "backrefs": ["Lercanidipine"]}}, "RABIES IMMUNOGLOBULIN": {"side-effects": "injection site swelling and pain;very\r\nrarelyanaphylaxis; buccal ulceration, glossitis, chest tightness,\r\ndyspnoea, tremor, dizziness, arthralgia, and facial oedema also reported", "indications": "post-exposure prophylaxis against rabies\r\ninfection", "name": "RABIES IMMUNOGLOBULIN", "cautions": "IgA deficiency; interference with live virus vaccines\u2014see underNormal Immunoglobulin", "doses": ["20\u00a0units/kgby infiltrationin and around\r\nthe cleansed wound; if wound not visible or healed or if infiltration\r\nof whole volume not possible, give remainderby intramuscular\r\ninjectioninto anterolateral thigh (remote from vaccination\r\nsite)"]}, "CHLORHEXIDINE GLUCONATE": {"side-effects": "mucosal irritation (if desquamation occurs, discontinue\r\ntreatment or dilute mouthwash with an equal volume of water); taste\r\ndisturbance; reversible brown staining of teeth, and of silicate or\r\ncomposite restorations; tongue discoloration; parotid gland swelling\r\nreported", "indications": "see under preparations below", "name": "CHLORHEXIDINE GLUCONATE", "doses": ["oral hygiene and plaque inhibition, oral candidiasis,\r\ngingivitis, and management of aphthous ulcers, rinse mouth with 10\u00a0mL\r\nfor about 1 minute twice daily"]}, "NATALIZUMAB": {"indications": "seenotes above", "name": "NATALIZUMAB", "cautions": "seenotes aboveand consult product\r\nliterature; prior treatment with immunosuppressants\r\n(increased risk of progressive multifocal leukoencephalopathy); monitor liver function (see below)", "side-effects": "seenotes above; also urinary-tract infection,\r\nnasopharyngitis, autoantibodies, and arthralgia;less commonlyhypersensitivity reactions (see above); liver toxicity also reported", "contra-indications": "progressive multifocal leucoencephalopathy; active infection (see notes above); concurrent use of interferon beta or glatiramer acetate; immunosuppression; active malignancies (except cutaneous basal cell carcinoma)", "doses": ["By intravenous infusion,adultover 18 years, 300\u00a0mg once every 4 weeks; discontinue\r\nif no response after 6 months"], "pregnancy": "avoid unless essential\u2014toxicity inanimalstudies", "breast-feeding": "present in milk inanimalstudies\u2014avoid"}, "GLUCOSE": {"side-effects": "glucoseinjections especially\r\nif hypertonic may have a low pH and may cause venous irritation and\r\nthrombophlebitis", "indications": "fluid replacement (see notes above),\r\nprovision of energy (section 9.3); hypoglycaemia (section 6.1.4)", "name": "GLUCOSE", "doses": ["Water replacement, see notes above; energy source, 1\u20133\u00a0litres\r\ndaily of 20\u201350% solution"]}, "HYDROXYZINE HYDROCHLORIDE": {"indications": "pruritus", "name": "HYDROXYZINE HYDROCHLORIDE", "renal impairment": "reduce daily dose by half", "cautions": "seenotes above; also susceptibility to QT-interval prolongation", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "reduce daily dose by one-third; see alsonotes above", "doses": ["Pruritus, initially 25\u00a0mg at night increased if necessary\r\nto 25\u00a0mg 3\u20134 times daily;child1\u20136\r\nyears initially 5\u201315\u00a0mg at night increased if necessary to 50\u00a0mg daily\r\nin 3\u20134 divided doses; 6\u201312 years initially 15\u201325\u00a0mg at night increased\r\nif necessary to 50\u2013100\u00a0mg daily in 3\u20134 divided doses;childunder 1 year seeBNF for Children"], "pregnancy": "toxicity inanimalstudies with\r\nhigh doses; see alsonotes above", "breast-feeding": "manufacturer advises avoid; see alsonotes above"}, "CETUXIMAB": {"indications": "seenotes aboveand product literature", "name": "CETUXIMAB", "cautions": "cardiovascular disease, cardiopulmonary disease, pulmonary disease\u2014discontinue\r\nif interstitial lung disease; history of, or risk factors\r\nfor keratitis, ulcerative keratitis (including contact lens use),\r\nor severe dry eye", "side-effects": "infusion-related reactions including dyspnoea,\r\ndizziness, chills, fever, and hypersensitivity reactions (possibly\r\ndelayed onset) such as rash, urticaria, bronchospasm, hypotension,\r\nhypertension, and shock; nausea, vomiting, diarrhoea, headache, aseptic\r\nmeningitis, hypomagnesaemia, hypocalcaemia, conjunctivitis, blepharitis,\r\nkeratitis, skin reactions including acne, pruritus, dry skin, desquamation,\r\nhypertrichosis, and nail disorders; Stevens-Johnson syndrome and toxic\r\nepidermal necrolysis also reported", "contra-indications": "KRAS mutated colorectal tumours\r\n(avoid if KRAS tumour status unknown)", "doses": ["SeeDoses"], "pregnancy": "use only if potential benefit outweighs risk\u2014no information\r\navailable; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "avoid breast-feeding during and for 2 months\r\nafter treatment\u2014no information available"}, "FROVATRIPTAN": {"indications": "treatment of acute migraine", "name": "FROVATRIPTAN", "interactions": {"extra": "", "bad": 0, "interaction": " fluvoxamine inhibits the metabolism of frovatriptan ", "name": "Frovatriptan", "backrefs": ["Frovatriptan"]}, "cautions": "see under5HT1-receptor agonistsabove;interactions:Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; also dry mouth, dyspepsia, abdominal pain,\r\nparaesthesia, drowsiness, headache, visual disturbances, sweating;less commonlydiarrhoea, dysphagia, flatulence, tachycardia,\r\npalpitation, hypertension, rhinitis, pharyngitis, sinusitis, laryngitis,\r\ntremor, anxiety, asthenia, insomnia, confusion, nervousness, impaired\r\nconcentration, agitation, depression, depersonalisation, taste disturbances,\r\nmicturition disorders, thirst, dehydration, arthralgia, muscle stiffness,\r\ntinnitus, vertigo, pruritus;rarelyconstipation,\r\ngastro-oesophageal reflux, irritable bowel syndrome, hiccup, peptic\r\nulcer, stomatitis, bradycardia, hyperventilation, amnesia, abnormal\r\ndreams, hypertonia, hypotonia, breast tenderness, hypocalcaemia, hypoglycaemia,\r\nbilirubinaemia, epistaxis, urticaria, pyrexia, and purpura", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; previous cerebrovascular attack or transient\r\nischaemic attack; peripheral vascular disease", "hepatic impairment": "avoid in severe impairment", "doses": ["2.5\u00a0mg as soon as possible after onset repeated after\r\n2 hours if migraine recurs (patient not responding should not take\r\nsecond dose for same attack); max. 5\u00a0mg in 24 hours;childandadolescentunder 18 years not recommended"], "pregnancy": "seenotes above", "breast-feeding": "present in milk inanimalstudies\u2014withhold\r\nbreast-feeding for 24 hours"}, "TENECTEPLASE": {"indications": "acute myocardial infarction (see notes above andsection 2.10.1)", "name": "TENECTEPLASE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By intravenous injectionover 10 seconds\r\n(initiated within 6 hours of symptom onset), 30\u201350\u00a0mg according to\r\nbody-weight\u2014consult product literature; max. 50\u00a0mg"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid breast-feeding for\r\n24 hours after dose (express and discard milk during this time)"}, "MECYSTEINE HYDROCHLORIDE": {"indications": "reduction of sputum viscosity", "name": "MECYSTEINE HYDROCHLORIDE", "cautions": "seenotes above", "doses": ["200\u00a0mg 4 times daily for 2 days, then 200\u00a0mg 3 times daily\r\nfor 6 weeks, then 200\u00a0mg twice daily;child5\u201312 years 100\u00a0mg 3 times daily"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "manufacturer advises avoid"}, "ELTROMBOPAG": {"indications": "seenotes above", "name": "ELTROMBOPAG", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "oral  iron possibly reduces absorption of eltrombopag (give at least 4 hours apart)", "name": "Eltrombopag", "backrefs": ["Eltrombopag"]}, "cautions": "patients of East Asian origin (see under Dose); risk factors for thromboembolism; monitor full blood count including platelet count and peripheral\r\nblood smears every week during treatment until a stable platelet count\r\nis reached (50 \u00d7 109/litre or more for at least 4 weeks),\r\nthen monthly thereafter; monitor liver function before\r\ntreatment, every two weeks when adjusting the dose, and monthly thereafter; regular ophthalmological examinations for cataract\r\nformation recommended;interactions:Appendix 1 (eltrombopag)", "side-effects": "gastro-intestinal disturbances including nausea,\r\ndiarrhoea, abdominal pain, and constipation; peripheral oedema; headache,\r\ninsomnia, paraesthesia, fatigue; arthralgia, bone pain, myalgia; cataract,\r\ndry eye; pruritus, rash, alopecia;less commonlydry\r\nmouth, gingival bleeding, haemorrhoids, taste disturbances, cholestasis,\r\nhepatitis, anorexia, changes in appetite, weight gain, flushing, palpitation,\r\nQT-interval prolongation, hypertension, tachycardia, thromboembolic\r\nevents (including deep vein thrombosis, pulmonary embolism, and acute\r\nmyocardial infarction), cough, sleep disorders, mood changes, depression,\r\nanxiety, dizziness, migraine, hemiparesis, tremor, peripheral neuropathy,\r\nrespiratory and urinary tract infections, renal failure, nocturia,\r\nrectosigmoid cancer, blood disorders (including anaemia, and thrombocytopenia),\r\ngout, eye disorders, vertigo, epistaxis, skin reactions including\r\necchymosis, and sweating", "hepatic impairment": "avoid unless potential benefit outweighs risk\u2014reduce\r\ninitial dose to 25\u00a0mg once daily", "doses": ["adultover 18 years, initially\r\n50\u00a0mg once daily (patients ofeast asianorigin such as Chinese, Japanese, Taiwanese, or Korean, initially\r\n25\u00a0mg once daily), adjusted to achieve a platelet count of 50 \u00d7 109/litre or more (consult product literature for dose adjustments);\r\nmax. 75\u00a0mg once daily; discontinue if inadequate response after 4\r\nweeks at maximum dose", "Each dose should be taken at least\r\n4 hours before or after any dairy products (or foods containing calcium),\r\nindigestion remedies, or medicines containing aluminium, calcium,\r\niron, magnesium, zinc, or selenium to reduce possible interference\r\nwith absorption"], "pregnancy": "avoid\u2014toxicity inanimalstudies;\r\nensure effective contraception during treatment", "breast-feeding": "manufacturer advises avoid"}, "BORTEZOMIB": {"indications": "seenotes above", "name": "BORTEZOMIB", "renal impairment": "no information available for creatinine clearance less\r\nthan 20\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of bortezomib ", "name": "Bortezomib", "backrefs": ["Bortezomib"]}, "cautions": "seesection 8.1; cardiovascular disease; pulmonary disease (chest x-ray recommended before\r\ntreatment\u2014discontinue if interstitial lung disease develops); consider antiviral prophylaxis for herpes zoster infection; history of seizures; amyloidosis; risk of neuropathy\u2014consult product literature; monitor blood-glucose concentration in patients on\r\noral antidiabetics;interactions:Appendix\r\n1 (bortezomib)", "side-effects": "seesection 8.1; also gastro-intestinal disturbances\r\nincluding constipation (cases of ileus reported), taste disturbance,\r\ndry mouth, decreased appetite; postural hypotension, hypertension,\r\nhaematoma, phlebitis, chest pain, oedema; dyspnoea, cough; confusion,\r\ndepression, insomnia, anxiety, peripheral neuropathy, paraesthesia,\r\nheadache, dizziness, tremor, asthenia, fatigue; reactivation of herpes\r\nzoster infection, influenza-like symptoms; renal impairment, dysuria;\r\ndehydration, hypokalaemia, hyperglycaemia; muscle cramps, arthralgia,\r\nbone pain; blurred vision, eye pain; epistaxis; urticaria, pruritus,\r\nerythema, dry skin, eczema, rash, increased sweating;less\r\ncommonlysyncope, seizures; reversible posterior leucoencephalopathy\r\nsyndrome (discontinue treatment), toxic epidermal necrolysis, Sweet\u2019s\r\nsyndrome, and vasculitic rash also reported", "contra-indications": "acute diffuse infiltrative pulmonary\r\ndisease; pericardial disease", "hepatic impairment": "reduce dose in moderate to severe impairment\u2014consult\r\nproduct literature", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises effective contraception during\r\nand for 3 months after treatment in men or women\u2014toxicity inanimalstudies; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CLOZAPINE": {"indications": "schizophrenia (including psychosis in Parkinson\u2019s disease) in patients\r\nunresponsive to, or intolerant of, conventional antipsychotic drugs", "name": "CLOZAPINE", "renal impairment": "avoid in severe impairment", "interactions": {"extra": "Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects and possibly neurotoxicity when  lithium given with clozapine ", "name": "Clozapine", "backrefs": ["Fluphenazine", "Risperidone", "Cytotoxics", "Pipotiazine", "Clozapine"]}, "cautions": "seenotes above; elderly; monitor leucocyte and differential blood counts (see\r\nAgranulocytosis, below); prostatic hypertrophy, susceptibility to angle-closure glaucoma; taper off other antipsychotics before starting; close medical supervision during initiation (risk of collapse because of hypotension); dose adjustment\r\nmay be necessary if smoking started or stopped during treatment", "side-effects": "seenotes above; also\r\nconstipation (see Cautions), hypersalivation, dry mouth, nausea, vomiting,\r\nanorexia; tachycardia, ECG changes, hypertension; drowsiness, dizziness,\r\nheadache, dysarthria, tremor, seizures, fatigue, impaired temperature\r\nregulation; urinary incontinence and retention; leucopenia, eosinophilia,\r\nleucocytosis; blurred vision; sweating;less commonlyspeech disorder, agranulocytosis (important:see\r\nCautions);rarelydysphagia, hepatitis, cholestatic\r\njaundice, pancreatitis, circulatory collapse, arrhythmia, myocarditis\r\n(important:see Cautions), pericarditis, agitation,\r\nconfusion, delirium, pneumonia, anaemia;very rarelyparotid gland enlargement, intestinal obstruction (see Cautions),\r\ncardiomyopathy, myocardial infarction, respiratory depression, obsessive\r\ncompulsive disorder, priapism, interstitial nephritis, thrombocytopenia,\r\nthrombocythaemia, hypertriglyceridaemia, hypercholesterolaemia, hyperlipidaemia,\r\nangle-closure glaucoma, fulminant hepatic necrosis, and skin reactions", "contra-indications": "severe cardiac disorders (e.g. myocarditis; see Cautions); history of neutropenia or agranulocytosis (see Cautions); bone-marrow disorders; paralytic ileus (see Cautions);alcoholic and toxic psychoses; history of circulatory collapse; drug intoxication; coma or severe CNS depression; uncontrolled\r\nepilepsy", "hepatic impairment": "monitor hepatic function regularly; avoid in symptomatic\r\nor progressive liver disease or hepatic failure", "doses": ["Schizophrenia,adultover\r\n16 years, 12.5\u00a0mg once or twice (elderly12.5\u00a0mg once) on first day then 25\u201350\u00a0mg (elderly25\u201337.5\u00a0mg) on second day then increased gradually (if well tolerated)\r\nin steps of 25\u201350\u00a0mg daily (elderlymax. increment 25\u00a0mg daily) over 14\u201321 days up to 300\u00a0mg daily in\r\ndivided doses (larger dose at night, up to 200\u00a0mg daily may be taken\r\nas a single dose at bedtime); if necessary may be further increased\r\nin steps of 50\u2013100\u00a0mg once (preferably) or twice weekly; usual dose\r\n200\u2013450\u00a0mg daily (max. 900\u00a0mg daily)", "Restartingafterinterval of more than 2 days, 12.5\u00a0mg once or twice on first\r\nday (but may be feasible to increase more quickly than on initiation)\u2014extreme\r\ncaution if previous respiratory or cardiac arrest with initial dosing", "Psychosis in Parkinson\u2019s disease,adultover 16 years, 12.5\u00a0mg at bedtime then increased according to response\r\nin steps of 12.5\u00a0mg up to twice weekly; usual dose range 25\u201337.5\u00a0mg\r\nat bedtime, usual max. 50\u00a0mg daily; exceptionally, dose may be increased\r\nfurther in steps of 12.5\u00a0mg weekly to max. 100\u00a0mg daily in 1\u20132 divided\r\ndoses"], "pregnancy": "seePregnancy notes; also use with caution", "breast-feeding": "avoid"}, "INFLUENZA VACCINES": {"indications": "annual immunisation against seasonal\r\ninfluenza", "name": "INFLUENZA VACCINES", "cautions": "seesection 14.1; increased\r\nrisk of fever in child under 5 years withViroflu\u00ae, and in child 5\u20139 years withEnzira\u00ae or preparations\r\nmarketed by Pfizer or CSL Biotherapies;interactions:Appendix 1 (vaccines)", "side-effects": "seesection 14.1; also\r\nreported febrile convulsions and transient thrombocytopenia", "contra-indications": "seesection 14.1; avoidEnzira\u00ae or preparations marketed by Pfizer, or CSL Biotherapies in child\r\nunder 5 years\u2014increased risk of febrile convulsions", "doses": ["By intramuscular injection,adultandchildover\r\n13 years, 0.5\u00a0mL as a single dose;child6 months\u20133 years, 0.25\u20130.5\u00a0mL; 3\u201313 years 0.5\u00a0mL; for children 6\r\nmonths to 13 years who have not received seasonal influenza vaccine\r\npreviously, repeat after 4\u20136 weeks", "By intradermal injection, see underIntanza\u00aebelow"], "pregnancy": "not known to be harmful", "breast-feeding": "not known to be harmful"}, "Alginate raft-forming oral suspensions": {"name": "Alginate raft-forming oral suspensions", "doses": ["10\u201320\u00a0mL after meals and at bedtime;child6\u201312 years 5\u201310\u00a0mL after meals and at bedtime"]}, "TEMOCILLIN": {"indications": "septicaemia, urinary-tract infections, lower respiratory-tract infections\r\ncaused by susceptible Gram-negative bacteria", "name": "TEMOCILLIN", "renal impairment": "1\u00a0g every 12 hours if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; 1\u00a0g every 24 hours if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; 1\u00a0g every 48 hoursor500\u00a0mg every 24 hours if\r\neGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "see under Benzylpenicillin (section 5.1.1.1);interactions:Appendix 1 (penicillins)", "side-effects": "see under Benzylpenicillin (section 5.1.1.1)", "contra-indications": "see under Benzylpenicillin (section 5.1.1.1)", "doses": ["adultover 18 years,by intramuscular injectionorby\r\nintravenous injectionover 3\u20134 minutes,orby intravenous infusion, 1\u20132\u00a0g every 12 hours"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk"}, "ILOPROST": {"indications": "idiopathic or familial pulmonary arterial hypertension", "name": "ILOPROST", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of bleeding when  eptifibatide given with iloprost ", "name": "Iloprost", "backrefs": ["Iloprost", "Tirofiban", "Eptifibatide"]}, "cautions": "unstable pulmonary hypertension with\r\nadvanced right heart failure; hypotension (do not initiate if systolic blood pressure below 85\u00a0mmHg); acute pulmonary infection; chronic obstructive pulmonary disease; severe asthma;interactions:Appendix\r\n1 (iloprost)", "side-effects": "vasodilatation, hypotension, syncope, cough, headache,\r\nthroat or jaw pain; nausea, vomiting, diarrhoea, chest pain, dyspnoea,\r\nbronchospasm, and wheezing also reported", "contra-indications": "unstable angina; within 6 months of myocardial infarction; decompensated cardiac failure (unless under close medical supervision); severe arrhythmias; congenital or acquired heart-valve defects; within 3 months of cerebrovascular\r\nevents; pulmonary veno-occlusive disease; conditions which increase risk of bleeding", "hepatic impairment": "elimination reduced\u2014initially 2.5\u00a0micrograms no more\r\nfrequently than every 3 hours (max. 6 times daily), adjusted according\r\nto response (consult product literature)", "doses": ["By inhalation of nebulised solution, initial\r\ndose 2.5\u00a0micrograms increased to 5\u00a0micrograms for second dose, if\r\ntolerated maintain at 5\u00a0micrograms 6\u20139 times daily according to response;\r\nreduce to 2.5\u00a0micrograms 6\u20139 times daily if higher dose not tolerated;child8\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid (toxicity inanimalstudies); effective contraception must be used during treatment", "breast-feeding": "manufacturer advises avoid\u2014no information\r\navailable"}, "FOSINOPRIL": {"interactions": {"extra": "", "bad": 0, "interaction": " antacids reduce absorption of fosinopril ", "name": "Fosinopril", "backrefs": ["Fosinopril"]}}, "FONDAPARINUX SODIUM": {"indications": "prophylaxis of venous thromboembolism in medical patients immobilised\r\nbecause of acute illness, and patients undergoing major orthopaedic\r\nsurgery of the hip or leg, or abdominal surgery; treatment of deep-vein\r\nthrombosis, superficial-vein thrombosis, and pulmonary embolism; treatment\r\nof unstable angina or non-ST-segment elevation myocardial infarction;\r\ntreatment of ST-segment elevation myocardial infarction", "name": "FONDAPARINUX SODIUM", "renal impairment": "increased risk of bleeding; fortreatment of\r\nacute coronary syndromesavoid if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2; fortreatment of venous thromboembolismuse with caution if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2, avoid\r\nif eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; forprophylaxis\r\nof venous thromboembolismandtreatment of superficial-vein\r\nthrombosisreduce dose to 1.5\u00a0mg daily if eGFR 20\u201350\u00a0mL/minute/1.73\u00a0m2, avoid if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "cautions": "bleeding disorders, active gastro-intestinal ulcer disease; recent intracranial haemorrhage; brain, spinal, or ophthalmic surgery; spinal or epidural anaesthesia (risk of spinal haematoma\u2014avoid if using treatment doses); risk of catheter thrombus during percutaneous coronary intervention; low body-weight; elderly\r\npatients; concomitant use of drugs that\r\nincrease risk of bleeding", "side-effects": "bleeding, purpura, anaemia;less commonlygastro-intestinal disturbances, oedema, hepatic impairment, chest\r\npain, dyspnoea, thrombocytopenia, thrombocythaemia, rash, pruritus;rarelyhypotension, flushing, cough, vertigo, dizziness,\r\nanxiety, drowsiness, confusion, headache, hypokalaemia, hyperbilirubinaemia,\r\ninjection-site reactions; also reported atrial fibrillation, tachycardia,\r\nand pyrexia", "contra-indications": "active bleeding; bacterial endocarditis", "hepatic impairment": "caution in severe impairment (increased risk of bleeding)", "doses": ["Prophylaxis of venous thromboembolism after surgery,by subcutaneous injection, 2.5\u00a0mg 6 hours after surgery then\r\n2.5\u00a0mg once daily;childunder 17 years\r\nnot recommended", "Prophylaxis of venous thromboembolism in medical patients,by subcutaneous injection, 2.5\u00a0mg once daily;childunder 17 years not recommended", "Treatment of superficial-vein thrombosis,by subcutaneous\r\ninjection,adultbody-weight\r\nover 50\u00a0kg, 2.5\u00a0mg once daily for at least 30 days (max. 45 days if\r\nhigh risk of thromboembolic complications); treatment should be stopped\r\n24 hours before surgery and restarted at least 6 hours post operatively;childunder 17 years not recommended", "Unstable angina and non-ST-segment elevation myocardial\r\ninfarction,by subcutaneous injection, 2.5\u00a0mg once\r\ndaily for up to 8 days (or until hospital discharge if sooner); treatment\r\nshould be stopped 24 hours before coronary artery bypass graft surgery\r\n(where possible) and restarted 48 hours post operatively;childunder 17 years not recommended", "ST-segment elevation myocardial infarction, initiallyby intravenous injectionorinfusion, 2.5\u00a0mg\r\nfor first day, thereafterby subcutaneous injection2.5\u00a0mg once daily for up to 8 days (or until hospital discharge\r\nif sooner); treatment should be stopped 24 hours before coronary artery\r\nbypass graft surgery (where possible) and restarted 48 hours post\r\noperatively;childunder 17 years not\r\nrecommended", "Treatment of deep-vein thrombosis and of pulmonary embolism,by subcutaneous injection,adultbody-weight under 50\u00a0kg, 5\u00a0mg every 24 hours; body-weight 50\u2013100\u00a0kg,\r\n7.5\u00a0mg every 24 hours; body-weight over 100\u00a0kg, 10\u00a0mg every 24 hours;childunder 17 years not recommended", "NoteAn oral anticoagulant (usually warfarin,section 2.8.2) is started at the same time\r\nas fondaparinux (fondaparinux should be continued for at least 5 days\r\nand until INR \u22652 for at least 24 hours)"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs possible risk\u2014no information available", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid"}, "SODIUM AUROTHIOMALATE": {"indications": "active\r\nprogressive rheumatoid arthritis", "name": "SODIUM AUROTHIOMALATE", "renal impairment": "caution in mild to moderate impairment; avoid in severe\r\nimpairment", "interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  penicillamine advises avoid concomitant use with sodium aurothiomalate (increased risk of toxicity)", "name": "Sodium Aurothiomalate", "backrefs": ["Penicillamine", "Sodium Aurothiomalate"]}, "cautions": "seenotes above; elderly, history of urticaria, eczema, colitis; monitor for pulmonary fibrosis\r\nwith annual chest X-ray;interactions:Appendix 1 (sodium aurothiomalate)", "side-effects": "seenotes above; also\r\nsevere anaphylactic reactions; stomatitis, taste disturbances, colitis,\r\nhepatotoxicity with cholestatic jaundice, pulmonary fibrosis, peripheral\r\nneuropathy, mouth ulcers, proteinuria, blood disorders (sometimes\r\nsudden and fatal), nephrotic syndrome, gold deposits in eye, alopecia,\r\nand skin reactions (including, on prolonged parenteral treatment,\r\nirreversible pigmentation in sun-exposed areas)", "contra-indications": "history of blood disorders\r\nor bone marrow aplasia, exfoliative\r\ndermatitis, systemic lupus erythematosus, necrotising enterocolitis, pulmonary\r\nfibrosis; acute porphyria (section 9.8.2)", "hepatic impairment": "caution in mild to moderate impairment, avoid in severe\r\nimpairment", "doses": ["By deep intramuscular injection, administered\r\non expert advice, see notes above"], "pregnancy": "manufacturer advises avoid but limited data suggests\r\nusually not necessary to withdraw if condition well controlled\u2014consider\r\nreducing dose and frequency", "breast-feeding": "manufacturer advises avoid\u2014present in milk;\r\ntheoretical possibility of rashes and idiosyncratic reactions"}, "CHLORPHENAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": " lopinavir possibly increases plasma concentration of chlorphenamine ", "name": "Chlorphenamine", "backrefs": ["Chlorphenamine"]}}, "MOXIFLOXACIN": {"indications": "seenotes above", "name": "MOXIFLOXACIN", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  zuclopenthixol given with moxifloxacin\u2014avoid concomitant use", "name": "Moxifloxacin", "backrefs": ["Benperidol", "Moxifloxacin"]}, "cautions": "not recommended for neonates", "side-effects": "taste disturbances, ocular discomfort (including\r\npain, irritation and dryness), hyperaemia;less commonlyvomiting, headache, paraesthesia, corneal disorders (including keratitis,\r\nerosion, and staining), conjunctival haemorrhage, eyelid erythema,\r\nvisual disturbances, nasal discomfort, pharyngolaryngeal pain;also reportednausea, palpitation, dyspnoea, dizziness,\r\nraised intra-ocular pressure, photophobia, rash, pruritus", "doses": ["adultandchildover 1 month, apply 3 times daily (continue\r\ntreatment for 2\u20133 days after infection improves; review if no improvement\r\nwithin 5 days)"]}, "TICARCILLIN WITH CLAVULANIC ACID": {"indications": "infections due toPseudomonasandProteusspp, see notes above", "name": "TICARCILLIN WITH CLAVULANIC ACID", "renal impairment": "reduce dose to 3.2\u00a0g every eight hours if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; 1.6\u00a0g every eight hours if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; 1.6\u00a0g every twelve hours if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underBenzylpenicillin(section 5.1.1.1);interactions:Appendix 1 (penicillins)", "side-effects": "see underBenzylpenicillin(section 5.1.1.1); also\r\nnausea, vomiting, coagulation disorders, haemorrhagic cystitis (more\r\nfrequent in children), injection-site reactions, Stevens-Johnson syndrome,\r\ntoxic epidermal necrolysis, hypokalaemia, eosinophilia", "contra-indications": "see underBenzylpenicillin(section 5.1.1.1)", "hepatic impairment": "manufacturer advises caution in severe impairment;\r\nalso cholestatic jaundice, see underCo-amoxiclav", "doses": ["Expressed as a combination of ticarcillin\r\n(as sodium salt) and clavulanic acid (as potassium salt) in a ratio\r\nof 15:1", "By intravenous infusion, 3.2\u00a0g every 6\u20138 hours\r\nincreased to every 4 hours in more severe infections;child1 month\u201318 years, body-weight under 40\u00a0kg,\r\n80\u00a0mg/kg every 8 hours, increased to every 6 hours in more severe\r\ninfections; body-weight over 40\u00a0kg, adult dose"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "ONDANSETRON": {"indications": "see under Dose", "name": "ONDANSETRON", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin accelerates metabolism of ondansetron (reduced effect)", "name": "Ondansetron", "backrefs": ["Ondansetron"]}, "cautions": "QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval); subacute intestinal obstruction; adenotonsillar surgery;interactions:Appendix 1 (ondansetron)", "side-effects": "constipation; headache; flushing; injection site-reactions;less commonlyhiccups, hypotension, bradycardia, chest pain,\r\narrhythmias, movement disorders, seizures;on intravenous\r\nadministration,rarelydizziness, transient\r\nvisual disturbances (very rarelytransient blindness);\r\nsuppositories may cause rectal irritation", "hepatic impairment": "max. 8\u00a0mg daily in moderate or severe impairment", "doses": ["Moderately emetogenic chemotherapy or radiotherapy,adultover 18 years,by mouth, 8\u00a0mg\r\n1\u20132 hours before treatmentorby rectum, 16\u00a0mg 1\u20132 hours before treatmentorby\r\nintramuscular injectionorslow intravenous\r\ninjection, 8\u00a0mg immediately before treatment", "thenby mouth, 8\u00a0mg every 12\r\nhours for up to 5 daysorby rectum, 16\u00a0mg daily for up to 5 days", "Severely emetogenic chemotherapy (consult product\r\nliterature for dose of concomitant corticosteroid),adultover 18 years,by intramuscular injectionorslow intravenous injection, 8\u00a0mg\r\nimmediately before treatment, where necessary followed by 2 further\r\ndoses of 8\u00a0mg at intervals of 2\u20134 hours (orfollowed\r\nby 1\u00a0mg/hourby continuous intravenous infusionfor\r\nup to 24 hours)", "thenby mouth, 8\u00a0mg every 12\r\nhours for up to 5 daysorby rectum, 16\u00a0mg daily for up to 5 days;", "alternatively,by intravenous infusionover at least 15 minutes, 32\u00a0mg immediately before treatmentorby mouth, 24\u00a0mg 1\u20132 hours before treatmentorby rectum, 16\u00a0mg 1\u20132 hours before treatment", "thenby mouth, 8\u00a0mg every 12\r\nhours for up to 5 daysorby rectum, 16\u00a0mg daily for up to 5 days", "Chemotherapy-induced nausea and vomiting,child6 months\u201318 years,by intravenous infusionover at least 15 minutes, 5\u00a0mg/m2(max. 8\u00a0mg) immediately\r\nbefore chemotherapy,thenfor body-surface area less\r\nthan 0.6\u00a0m22\u00a0mgby mouthevery 12 hours\r\nfor up to 5 days; for body-surface area 0.6\u00a0m2or greater\r\n4\u00a0mgby mouthevery 12 hours for up to 5 days; max.\r\ntotal daily dose 32\u00a0mg", "alternatively,by intravenous infusionover at least 15 minutes, 150\u00a0micrograms/kg (max. 8\u00a0mg) immediately\r\nbefore chemotherapy repeated at intervals of 4 hours for 2 further\r\ndoses,thenfor body-weight 10\u00a0kg or less 2\u00a0mgby mouthevery 12 hours for up to 5 days; for body-weight\r\nover 10\u00a0kg 4\u00a0mgby mouthevery 12 hours for up to 5\r\ndays; max. total daily dose 32\u00a0mg", "For chemotherapy-induced nausea and vomiting,\r\noral dosing can start 12 hours after intravenous administration", "Prevention of postoperative nausea and vomiting,by mouth, 16\u00a0mg 1 hour before anaesthesiaor8\u00a0mg 1 hour before anaesthesia followed by 8\u00a0mg at intervals of\r\n8 hours for 2 further doses", "alternatively,by intramuscularorslow intravenous injection, 4\u00a0mg\r\nat induction of anaesthesia;child1\r\nmonth\u201318 years,by slow intravenous injectionover\r\nat least 30 seconds, 100\u00a0micrograms/kg (max. 4\u00a0mg) before, during,\r\nor after induction of anaesthesia", "Treatment of postoperative nausea and vomiting,by intramuscularorslow intravenous injection, 4\u00a0mg;child1 month\u201318 years,by slow intravenous\r\ninjectionover at least 30 seconds, 100\u00a0micrograms/kg (max.\r\n4\u00a0mg)"], "pregnancy": "no information available; avoid unless potential\r\nbenefit outweighs risk", "breast-feeding": "present in milk inanimalstudies\u2014avoid"}, "PROTAMINE ZINC INSULIN": {"indications": "diabetes mellitus", "name": "PROTAMINE ZINC INSULIN", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1.1; see\r\nalsonotes above;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin(section 6.1.1.1);\r\nprotamine may cause allergic reactions", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection, according to\r\nrequirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "ALGLUCOSIDASE ALFA": {"indications": "(specialist use only) Pompe disease", "name": "ALGLUCOSIDASE ALFA", "cautions": "cardiac and respiratory dysfunction\u2014monitor\r\nclosely; monitor immunoglobulin G (IgG)\r\nantibody concentration", "side-effects": "nausea, vomiting, diarrhoea; flushing, tachycardia,\r\nblood pressure changes, cold extremities, cyanosis, facial oedema,\r\nchest discomfort; cough, tachypnoea, bronchospasm; headache, agitation,\r\ntremor, irritability, restlessness, paraesthesia, dizziness, fatigue;\r\npyrexia; antibody formation; myalgia, muscle spasm; sweating, rash,\r\npruritus, urticaria, injection-site reactions; hypersensitivity reactions\r\n(including anaphylaxis); severe skin reactions (including ulcerative\r\nand necrotising skin lesions) also reported", "doses": ["By intravenous infusion,adultandchild20\u00a0mg/kg\r\nevery 2 weeks"], "pregnancy": "toxicity inanimalstudies, but\r\ntreatment should not be withheld", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "CO-CYPRINDIOL": {"indications": "severe acne in women refractory to prolonged\r\noral antibacterial therapy (but see notes above); moderately severe hirsutism", "name": "CO-CYPRINDIOL", "cautions": "see underCombined Hormonal Contraceptives,section 7.3.1", "side-effects": "see underCombined Hormonal Contraceptives,section 7.3.1", "contra-indications": "see underCombined Hormonal Contraceptives,section 7.3.1andnotes above", "hepatic impairment": "see under Combined Hormonal Contraceptives,section 7.3.1", "doses": ["1 tablet daily for 21 days starting on day 1 of menstrual\r\ncycle and repeated after a 7-day interval, usually for several months;\r\nwithdraw 3\u20134 months after acne or hirsutism completely resolved (repeat\r\ncourses may be given if recurrence); long-term treatment may be necessary\r\nfor severe symptoms"], "pregnancy": "avoid\u2014risk of feminisation of male fetus with cyproterone", "breast-feeding": "manufacturer advises avoid; possibility of anti-androgen\r\neffects in neonate with cyproterone"}, "LOPINAVIR WITH RITONAVIR": {"indications": "HIV infection in combination with other antiretroviral\r\ndrugs", "name": "LOPINAVIR WITH RITONAVIR", "renal impairment": "avoid oral solution due to propylene glycol content;\r\nuse tablets with caution in severe impairment", "cautions": "seenotes above; concomitant use with drugs that prolong QT or PR interval; cardiac conduction disorders, structural heart disease; patients at\r\nhigh risk of cardiovascular disease (especially if 10-year cardiovascular\r\nrisk greater than 20%); pancreatitis (see below); monitor liver function before and during\r\ntreatment;interactions:Appendix 1\r\n(lopinavir, ritonavir)", "side-effects": "see notes above; also colitis, weight changes,\r\nhypertension, anxiety, neuropathy, sexual dysfunction, amenorrhoea,\r\nmenorrhagia, arthralgia, night sweats;less commonlygastro-intestinal ulcer, rectal bleeding, dry mouth, stomatitis,\r\nmyocardial infarction, AV block, cerebrovascular accident, deep vein\r\nthrombosis, abnormal dreams, convulsions, tremor, nephritis, haematuria,\r\nvisual disturbances, tinnitus, alopecia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\navoid oral solution due to propylene glycol content; manufacturer\r\nadvises avoid capsules and tablets in severe impairment", "doses": ["5\u00a0mL twice daily with food;child2\u201318 years seeBNF for Children"], "pregnancy": "avoid oral solution due to high propylene glycol\r\ncontent; use tablets only if potential benefit outweighs risk (toxicity\r\ninanimalstudies)", "breast-feeding": "seeBreast-feeding"}, "12.2.3 Nasal preparations for infection": {"name": "12.2.3 Nasal preparations for infection", "doses": ["nose, 2\u20133 drops into each nostril 2\u20133 times\r\ndaily;eye,section 11.4.1;ear,section\r\n12.1.1"]}, "MAGNESIUM (PARENTERAL)": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  non-depolarising muscle relaxants enhanced by parenteral magnesium ", "name": "Magnesium (parenteral)", "backrefs": []}}, "RANIBIZUMAB": {"indications": "see notes above\u2014specialist use only", "name": "RANIBIZUMAB", "cautions": "history of stroke or transient\r\nischaemic attack; patients at risk of retinal pigment epithelial tear; monitor intra-ocular pressure and for signs of ocular\r\ninfection following injection", "side-effects": "nausea, headache, nasopharyngitis, cough, anxiety,\r\nanaemia, urinary tract infections, arthralgia, raised intra-ocular\r\npressure, visual disturbance, conjuctival retinal and vitreous disorders,\r\neye inflammation and irritation, eye haemorrhage, allergic skin reactions;less commonlyatrial fibrillation, blindness, corneal disorders,\r\niris adhesion, injection site reactions", "contra-indications": "ocular or periocular infection; severe\r\nintra-ocular inflammation; signs of irreversible\r\nischaemic visual function loss in patients with retinal vein occlusion", "doses": ["Neovascular (wet) age-related macular degeneration,by intravitreal injection,adult, 500\u00a0micrograms once a month into the affected eye; monitor visual\r\nacuity monthly; continue treatment until visual acuity is stable for\r\n3 consecutive months; thereafter monitor visual acuity monthly; if\r\nnecessary subsequent doses may be given at least 1 month apart", "Diabetic macular oedema, macular oedema secondary to retinal\r\nvein occlusion,by intravitreal injection,adult, 500\u00a0micrograms once a month into the affected\r\neye; monitor visual acuity monthly; continue treatment until visual\r\nacuity is stable for 3 consecutive months (discontinue treatment if\r\nno improvement in visual acuity after initial 3 injections); thereafter\r\nmonitor visual acuity monthly; if necessary subsequent doses may be\r\ngiven at least 1 month apart", "Concomitant treatment of diabetic macular oedema, or macular\r\noedema secondary to branch retinal vein occlusion, with laser photocoagulation,by intravitreal injection,adult, 500\u00a0micrograms at least 30 minutes after laser photocoagulation", "For further information on administration,\r\nconsult product literature", "Antimicrobial eye drops should be administered into the affected\r\neye 4 times daily for 3 days before and 3 days after each injection"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk and recommends effective contraception during, and\r\nfor at least 3 months after, treatment", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "VITAMIN E": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  ciclosporin possibly affected by vitamin E ", "name": "Vitamin E", "backrefs": ["Vitamin E"]}}, "PORFIMER SODIUM": {"indications": "non-small cell lung cancer; oesophageal cancer; seenotes above", "name": "PORFIMER SODIUM", "cautions": "seesection 8.1; avoid exposure of skin and eyes\r\nto direct sunlight or bright indoor light for at least 30 days", "side-effects": "seesection 8.1; photosensitivity (see Cautions\r\nabove\u2014sunscreens offer no protection), constipation", "contra-indications": "seesection 8.1; tracheo-oesophageal or broncho-oesophageal\r\nfistula; acute porphyria (section 9.8.2)", "hepatic impairment": "avoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "no information available\u2014manufacturer advises\r\navoid"}, "FUROSEMIDE": {"indications": "oedema (seenotes above); resistant hypertension (seenotes above)", "name": "FUROSEMIDE", "renal impairment": "seenotes above; also\r\nlower rate of infusion may be necessary", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin antagonises effects of furosemide ", "name": "Furosemide", "backrefs": ["Furosemide", "Metolazone"]}, "cautions": "seenotes above; also hypoproteinaemia may reduce diuretic effect and increase risk of\r\nside-effects; hepatorenal syndrome; intravenous administration rate should not usually\r\nexceed 4\u00a0mg/minute, however single doses of up to 80\u00a0mg may be administered\r\nmore rapidly", "side-effects": "seenotes above; also\r\nintrahepatic cholestasis and gout", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, oedema, initially 40\u00a0mg\r\nin the morning; maintenance 20\u201340\u00a0mg daily;childunder 18 years seeBNF for Children", "Resistant oedema, 80\u2013120\u00a0mg daily", "Resistant hypertension, 40\u201380\u00a0mg daily", "By intramuscular injectionorslow intravenous injection(rate of administration,\r\nsee Cautions above), initially 20\u201350\u00a0mg, increased if necessary in\r\nsteps of 20\u00a0mg not less than every 2 hours; doses greater than 50\u00a0mgby intravenous infusiononly; max. 1.5\u00a0g daily;childunder 18 years seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful; may inhibit\r\nlactation"}, "FENOFIBRATE": {"indications": "hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nalso see notes above", "name": "FENOFIBRATE", "renal impairment": "reduce dose to 134\u00a0mg daily if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2; reduce dose to 67\u00a0mg daily if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2;\r\nsee alsoMyotoxicityunder\r\nBezafibrate", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of renal impairment when  ciclosporin given with fenofibrate ", "name": "Fenofibrate", "backrefs": ["Fenofibrate"]}, "cautions": "see underBezafibrate; liver function tests recommended every 3 months for first year (discontinue\r\ntreatment if significantly raised)", "side-effects": "see underBezafibrate; alsovery rarelyhepatitis, pancreatitis, and interstitial pneumopathies", "contra-indications": "gall bladder disease; pancreatitis (unless due to severe hypertriglyceridaemia); photosensitivity to ketoprofen", "hepatic impairment": "avoid in severe liver disease", "doses": ["160\u00a0mg daily (dose form not appropriate for children or\r\nin renal impairment)"], "pregnancy": "manufacturers advise avoid\u2014embryotoxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "IMIPRAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": " propranolol increases plasma concentration of imipramine ", "name": "Imipramine", "backrefs": ["Imipramine"]}}, "SUXAMETHONIUM": {"interactions": {"extra": "", "bad": 0, "interaction": " parenteral magnesium enhances effects of suxamethonium ", "name": "Suxamethonium", "backrefs": ["Promazine", "Suxamethonium", "Phenelzine", "Bambuterol", "Thiotepa", "Propofol"]}}, "METRONIDAZOLE": {"indications": "see preparations; rosacea (see alsosection 13.6);Helicobacter pylorieradication\r\n(section 1.3); anaerobic infections (section 5.1.11andsection 7.2.2); protozoal infections (section 5.4.2)", "name": "METRONIDAZOLE", "interactions": {"extra": "Interactions do not apply to topical metronidazole preparations ", "bad": 0, "interaction": "increased risk of  lithium toxicity when given with metronidazole ", "name": "Metronidazole", "backrefs": ["Metronidazole"]}, "cautions": "avoid exposure to strong sunlight or UV light", "side-effects": "skin irritation", "doses": ["acute inflammatory exacerbation of rosacea, apply thinly\r\ntwice daily for 8\u20139 weeks"]}, "PRASUGREL": {"indications": "in combination with aspirin for the\r\nprevention of atherothrombotic events in patients with acute coronary\r\nsyndrome undergoing percutaneous coronary intervention", "name": "PRASUGREL", "renal impairment": "use with caution\u2014increased risk of bleeding", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of bleeding when  NSAIDs given with prasugrel ", "name": "Prasugrel", "backrefs": ["Prasugrel"]}, "cautions": "patients at increased risk of bleeding\r\n(e.g. from recent trauma, surgery, gastro-intestinal bleeding, or\r\nactive peptic ulcer disease); concomitant\r\nuse of drugs that increase risk of bleeding; discontinue at least 7 days before elective surgery if antiplatelet\r\neffect not desirable; elderly; body-weight less than 60\u00a0kg; history of hypersensitivity reactions to thienopyridines (e.g. clopidogrel);interactions:Appendix 1 (prasugrel)", "side-effects": "haemorrhage (including gastro-intestinal and intracranial),\r\nhaematoma, haematuria, anaemia, rash;less commonlyhypersensitivity reactions including angioedema;rarelythrombocytopenia;also reportedthrombotic thrombocytopenic\r\npurpura", "contra-indications": "active bleeding; history of stroke or transient ischaemic attack", "hepatic impairment": "use with caution\u2014increased risk of bleeding; avoid\r\nin severe impairment", "doses": ["adultover 18 years, (with\r\naspirin\u2014seenotes above) initially 60\u00a0mg as a single dose\r\nthen body-weight over 60\u00a0kg, 10\u00a0mg once dailyorbody-weight\r\nunder 60\u00a0kg orelderlyover 75 years,\r\n5\u00a0mg once daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "METOLAZONE": {"indications": "oedema, hypertension (see also notes above)", "name": "METOLAZONE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "profound diuresis possible when  furosemide given with metolazone ", "name": "Metolazone", "backrefs": ["Metolazone"]}, "cautions": "seenotes above; also acute porphyria (section 9.8.2)", "side-effects": "seenotes above; also\r\nchills, chest pain", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Oedema, 5\u201310\u00a0mg daily in the morning, increased if necessary\r\nto 20\u00a0mg daily in resistant oedema, max. 80\u00a0mg daily", "Hypertension, initially 5\u00a0mg daily in the morning; maintenance\r\n5\u00a0mg on alternate days"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PERICYAZINE": {"indications": "see under Dose", "name": "PERICYAZINE", "renal impairment": "seenotes above; avoid\r\nin renal impairment", "cautions": "seenotes above", "side-effects": "seenotes above; more\r\nsedating; hypotension common when treatment initiated; respiratory\r\ndepression", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Schizophrenia and other psychoses, initially 75\u00a0mg daily\r\nin divided doses increased at weekly intervals by steps of 25\u00a0mg according\r\nto response; usual max. 300\u00a0mg daily (elderly initially 15\u201330\u00a0mg daily);childandinfantover\r\n1 year (schizophrenia or behavioural disorders only), initially, 500\u00a0micrograms\r\ndaily for 10-kg child, increased by 1\u00a0mg for each additional 5\u00a0kg\r\nbody-weight to max. total daily dose of 10\u00a0mg; dose may be gradually\r\nincreased according to response but maintenance should not exceed\r\ntwice initial dose", "Short-term adjunctive management of severe anxiety, psychomotor\r\nagitation, and violent or dangerously impulsive behaviour, initially\r\n15\u201330\u00a0mg (elderly 5\u201310\u00a0mg) daily divided into 2 doses, taking the\r\nlarger dose at bedtime, adjusted according to response;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CYPROHEPTADINE HYDROCHLORIDE": {"indications": "symptomatic relief of allergy such as hay fever, urticaria", "name": "CYPROHEPTADINE HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Allergy, usual dose 4\u00a0mg 3\u20134 times daily; usual range\r\n4\u201320\u00a0mg daily, max. 32\u00a0mg daily;child2\u20136 years 2\u00a0mg 2\u20133 times daily, max. 12\u00a0mg daily; 7\u201314 years 4\u00a0mg\r\n2\u20133 times daily, max. 16\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLUPHENAZINE DECANOATE": {"indications": "maintenance in schizophrenia and other\r\npsychoses", "name": "FLUPHENAZINE DECANOATE", "renal impairment": "seesection 4.2.1; manufacturer\r\nadvises caution; avoid in renal failure", "cautions": "seesection 4.2.1andnotes above; dose adjustment may be necessary if smoking started or stopped during\r\ntreatment; QT-interval prolongation (avoid concomitant drugs that prolong QT interval)", "side-effects": "seesection 4.2.1andnotes above;\r\nless sedating and fewer antimuscarinic or hypotensive symptoms, but\r\nextrapyramidal symptoms, particularly dystonic reactions and akathisia,\r\nmore frequent; systemic lupus erythematosus, inappropriate antidiuretic\r\nhormone secretion, and oedema also reported; extrapyramidal symptoms\r\nusually appear a few hours after injection and continue for about\r\n2 days but may be delayed", "contra-indications": "seesection 4.2.1andnotes above; also marked cerebral atherosclerosis", "hepatic impairment": "seesection 4.2.1; avoid\r\nin hepatic failure", "doses": ["By deep intramuscular injectioninto the\r\ngluteal muscle, test dose 12.5\u00a0mg (6.25\u00a0mg in elderly), then after\r\n4\u20137 days 12.5\u2013100\u00a0mg repeated at intervals of 14\u201335 days, adjusted\r\naccording to response;childnot recommended"], "pregnancy": "seesection 4.2.1", "breast-feeding": "seesection 4.2.1"}, "PERMETHRIN": {"side-effects": "pruritus, erythema, and stinging; rarely rashes\r\nand oedema", "indications": "see notes above and under Dose", "name": "PERMETHRIN", "cautions": "avoid contact with eyes; do not use on broken or secondarily infected skin; children under 6 months, medical\r\nsupervision required for cream rinse (head lice); children aged 2 months\u20132 years, medical supervision required for\r\ndermal cream (scabies)", "doses": ["Scabies, apply 5% preparation over whole body and wash\r\noff after 8\u201312 hours;child(see also\r\nCautions, above) apply over whole body including face, neck, scalp\r\nand ears; if hands washed with soap within 8 hours of application,\r\nthey should be treated again with cream (see notes above); repeat\r\napplication after 7 days", "Manufacturer recommends application to the\r\nbody but to exclude head and neck. However, application should be\r\nextended to the scalp, neck, face, and ears", "Larger patients may require up to two 30-g packs for adequate\r\ntreatment", "Crab lice,adultover 18 years,\r\napply 5% cream over whole body, allow to dry naturally and wash off\r\nafter 12 hours or after leaving on overnight; repeat application after\r\n7 days"]}, "TRIAMTERENE": {"indications": "oedema, potassium conservation with thiazide and loop diuretics", "name": "TRIAMTERENE", "renal impairment": "monitor plasma-potassium concentration (high risk of\r\nhyperkalaemia in renal impairment); manufacturers advise avoid in\r\nsevere impairment", "interactions": {"extra": "", "bad": 1, "interaction": "occasional reports of reduced renal function when  indometacin given with triamterene\u2014avoid concomitant use", "name": "Triamterene", "backrefs": ["Triamterene"]}, "cautions": "see underAmiloride Hydrochloride; may cause blue fluorescence of urine", "side-effects": "include gastro-intestinal disturbances, dry mouth,\r\nrashes; slight decrease in blood pressure, hyperkalaemia, hyponatraemia;\r\nphotosensitivity and blood disorders also reported;triamterenefound in kidney stones", "contra-indications": "see underAmiloride Hydrochloride", "doses": ["Initially 150\u2013250\u00a0mg daily, reducing to alternate days\r\nafter 1 week; taken in divided doses after breakfast and lunch; lower\r\ninitial dose when given with other diuretics", "Urine may look slightly blue in some\r\nlights"], "pregnancy": "not used to treat gestational hypertension", "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "LINEZOLID": {"indications": "pneumonia, complicated skin and soft-tissue infections caused by\r\nGram-positive bacteria (initiated under expert supervision)", "name": "LINEZOLID", "renal impairment": "manufacturer advises metabolites may accumulate if eGFR\r\nless than 30\u00a0mL/minute/1.73\u00a0m2; see also Blood Disorders,\r\nabove", "interactions": {"extra": "Linezolid is a reversible, non-selective MAO inhibitor\u2014see interactions of MAOIs", "bad": 0, "interaction": " rifampicin reduces plasma concentration of linezolid (possible therapeutic failure of linezolid)", "name": "Linezolid", "backrefs": ["Linezolid"]}, "cautions": "monitor full blood count (including platelet\r\ncount) weekly (see also Blood disorders below); history of seizures; unless close observation and blood-pressure\r\nmonitoring possible, avoid in uncontrolled hypertension, phaeochromocytoma, carcinoid tumour, thyrotoxicosis, bipolar depression,\r\nschizophrenia, or acute confusional states;interactions:Appendix 1 (MAOIs)", "side-effects": "diarrhoea (antibiotic-associated colitis reported),\r\nnausea, vomiting, taste disturbances, headache;less commonlythirst, dry mouth, glossitis, stomatitis, tongue discoloration,\r\nabdominal pain, dyspepsia, gastritis, constipation, pancreatitis,\r\nhypertension, fever, fatigue, dizziness, insomnia, hypoaesthesia,\r\nparaesthesia, tinnitus, polyuria, leucopenia, thrombocytopenia, eosinophilia,\r\nelectrolyte disturbances, blurred vision, rash, pruritus, diaphoresis,\r\ninjection-site reactions;rarelytachycardia, transient\r\nischaemic attacks, renal failure; also reported tooth discoloration,\r\nconvulsions, lactic acidosis, hyponatraemia, pancytopenia,\r\nanaemia, Stevens-Johnson syndrome, toxic epidermal necrolysis; peripheral\r\nand optic neuropathy reported on prolonged therapy (see also CHM advice\r\nabove)", "contra-indications": "see Monoamine Oxidase Inhibition above", "hepatic impairment": "in severe hepatic impairment manufacturer advises use\r\nonly if potential benefit outweighs risk", "doses": ["By mouth, 600\u00a0mg every 12 hours usually\r\nfor 10\u201314 days (max. duration of treatment 28 days);child[unlicensed] 1 week\u201312 years, 10\u00a0mg/kg every\r\n8 hours; 12\u201318 years, adult dose", "By intravenous infusionover 30\u2013120\r\nminutes, 600\u00a0mg every 12 hours;child[unlicensed] 1 week\u201312 years, 10\u00a0mg/kg every 8 hours; 12\u201318 years,\r\nadult dose"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "GLICLAZIDE": {"indications": "type 2 diabetes mellitus", "name": "GLICLAZIDE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " disopyramide possibly enhances hypoglycaemic effect of gliclazide ", "name": "Gliclazide", "backrefs": ["Gliclazide"]}, "cautions": "seenotes above;interactions:Appendix 1 (antidiabetics)", "side-effects": "see notes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially, 40\u201380\u00a0mg daily, adjusted according to response;\r\nup to 160\u00a0mg as a single dose, with breakfast; higher doses divided;\r\nmax. 320\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLUTICASONE": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of inhaled and intranasal fluticasone ", "name": "Fluticasone", "backrefs": ["Fluticasone", "Telaprevir", "Nelfinavir"]}}, "AMOXICILLIN": {"indications": "see underAmpicillin; also oral infections, Lyme\r\ndisease (see notes above); endocarditis treatment (Table 1,section 5.1); anthrax (section 5.1.12); adjunct in listerial meningitis\r\n(Table 1,section 5.1); pneumococcal infection prophylaxis\r\n(Table 2,section 5.1);Helicobacter pylorieradication (section 1.3)", "name": "AMOXICILLIN", "renal impairment": "risk of crystalluria with high doses (particularly during\r\nparenteral therapy). Reduce dose in severe impairment; rashes more\r\ncommon", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of rash when  allopurinol given with amoxicillin ", "name": "Amoxicillin", "backrefs": ["Amoxicillin"]}, "cautions": "see underAmpicillin; maintain adequate\r\nhydration with high doses (particularly during parenteral therapy);interactions:Appendix 1 (penicillins)", "side-effects": "see underAmpicillin", "contra-indications": "see underAmpicillin", "doses": ["By mouth,adultandchildover 5 years, 250\u00a0mg every\r\n8 hours, dose doubled in severe infection;child, 1 month\u20131 year, 62.5\u00a0mg every 8 hours, dose doubled in severe infection;\r\n1\u20135 years, 125\u00a0mg every 8 hours, dose doubled in severe infection", "Otitis media, 500\u00a0mg every 8 hours;child40\u00a0mg/kg daily in 3 divided doses (max. 1.5\u00a0g daily)", "Pneumonia,adultover 18 years,\r\n0.5\u20131\u00a0g every 8 hours", "Lyme disease (see alsonotes above),adultandchildover 5 years, 500\u00a0mg every\r\n8 hours for 14\u201321 days (for 28 days in Lyme arthritis) [unlicensed\r\nindication];child1 month\u20135 years\r\nseeBNF for Children", "Anthrax (treatment and post-exposure prophylaxis\u2014see alsosection 5.1.12), 500\u00a0mg every 8 hours;childbody-weight under 20\u00a0kg, 80\u00a0mg/kg daily in 3 divided doses, body-weight\r\nover 20\u00a0kg, adult dose", "Short-course oral therapy", "Dental abscess,adultover 18\r\nyears, 3\u00a0g repeated after 8 hours", "Urinary-tract infections,adultover 18 years, 3\u00a0g repeated after 10\u201312 hours", "By intramuscular injection,adultover 18 years, 500\u00a0mg every 8 hours", "By intravenous injectionorinfusion, 500\u00a0mg every 8 hours increased to 1\u00a0g every\r\n6 hours in severe infection;child1\r\nmonth\u201318 years, 20\u201330\u00a0mg/kg (max. 500\u00a0mg) every 8 hours; dose doubled\r\nin severe infection (max. 4\u00a0g daily)", "Listerial meningitis (in combination with another\r\nantibiotic, see Table 1,section 5.1),by intravenous infusion,adultover 18 years, 2\u00a0g every 4\r\nhours;childunder 18\r\nyears seeBNF for Children", "Endocarditis (in combination with another antibiotic\r\nif necessary, see Table 1,section 5.1),by intravenous infusion,adultover 18 years, 2\u00a0g every 6\r\nhours, increased to 2\u00a0g every 4 hours e.g. in enterococcal endocarditis\r\nor if amoxicillin used alone;childunder 18 years seeBNF for Children", "Amoxicillindoses in BNF\r\nmay differ from those in product literature"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "ETHAMBUTOL HYDROCHLORIDE": {"indications": "tuberculosis, in combination with other drugs", "name": "ETHAMBUTOL HYDROCHLORIDE", "renal impairment": "if creatinine clearance less than 30\u00a0mL/minute, use 15\u201325\u00a0mg/kg\r\n(max. 2.5\u00a0g) 3 times a week and monitor plasma-ethambutol concentration;\r\noptic nerve damage", "cautions": "elderly; test\r\nvisual acuity before treatment and warn\r\npatients to report visual changes\u2014see Monitoring innotes above; young\r\nchildren (see notes above)\u2014routine ophthalmological monitoring recommended", "side-effects": "optic neuritis, red/green colour blindness, peripheral\r\nneuritis, rarely rash, pruritus, urticaria, thrombocytopenia", "contra-indications": "optic neuritis, poor vision", "doses": ["Seenotes above", "\u2018Peak\u2019 concentration (2\u20132.5 hours after dose)\r\nshould be 2\u20136\u00a0mg/litre (7\u201322\u00a0micromol/litre); \u2018trough\u2019 (pre-dose)\r\nconcentration should be less than 1\u00a0mg/litre (4\u00a0micromol/litre); see\r\nRenal Impairment above"], "pregnancy": "not known to be harmful; see alsoPregnancy", "breast-feeding": "amount too small to be harmful; see alsoBreast-feeding"}, "CHLORTALIDONE": {"indications": "ascites due to cirrhosis in stable patients (under close supervision),\r\noedema due to nephrotic syndrome, hypertension (see also notes above),\r\nmild to moderate chronic heart failure; diabetes insipidus (seesection 6.5.2)", "name": "CHLORTALIDONE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; alsorarelyjaundice and allergic interstitial nephritis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Oedema, up to 50\u00a0mg daily", "Hypertension, 25\u00a0mg daily in the morning, increased to 50\u00a0mg\r\ndaily if necessary (but see notes above)", "Heart failure, 25\u201350\u00a0mg daily in the morning, increased if necessary\r\nto 100\u2013200\u00a0mg daily (reduce to lowest effective dose for maintenance)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "NEVIRAPINE": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "NEVIRAPINE", "renal impairment": "manufacturer advises avoid modified-release preparation\u2014no\r\ninformation available", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  warfarin may be enhanced or reduced by nevirapine ", "name": "Nevirapine", "backrefs": ["Methadone", "Indinavir", "Fluconazole", "Itraconazole", "Progestogens", "Fosamprenavir", "Lopinavir", "Rifampicin", "Etravirine", "Oestrogens", "Clarithromycin", "Atazanavir", "Warfarin", "Caspofungin", "Efavirenz", "Aripiprazole", "Nevirapine", "Rifabutin"]}, "cautions": "chronic hepatitis B or C, high CD4 cell count, and\r\nwomen (all at greater risk of hepatic side-effects\u2014if plasma HIV-1\r\nRNA detectable, manufacturer advises avoid in women with CD4 cell\r\ncount greater than 250 cells/mm3or in men with CD4 cell\r\ncount greater than 400 cells/mm3unless potential benefit\r\noutweighs risk);interactions:Appendix 1 (nevirapine)", "side-effects": "rash including Stevens-Johnson syndrome and rarely,\r\ntoxic epidermal necrolysis (see also Cautions above); nausea, hepatitis\r\n(see also Hepatic Disease above), headache;less commonlyvomiting, abdominal pain, fatigue, fever, and myalgia;rarelydiarrhoea, angioedema, anaphylaxis, hypersensitivity reactions (may\r\ninvolve hepatic reactions and rash, see Hepatic Disease above), arthralgia,\r\nanaemia, and granulocytopenia (more frequent in children); see alsoOsteonecrosis", "contra-indications": "acute porphyria (but\r\nseesection 9.8.2); post-exposure prophylaxis", "hepatic impairment": "manufacturer advises avoid modified-release preparation\u2014no\r\ninformation available; use \u2018immediate-release\u2019 preparation with caution\r\nin moderate impairment and avoid in severe impairment; see also Hepatic\r\nDisease, above", "doses": ["200\u00a0mg once daily of \u2018immediate-release\u2019 preparation\r\nfor first 14 days then (if no rash present) 200\u00a0mg twice daily of\r\n\u2018immediate-release\u2019 preparation or 400\u00a0mg once daily of modified-release\r\npreparation;childunder 18 years seeBNF for children", "Duration of once daily dose regimen of \u2018immediate-release\u2019\r\npreparation should not exceed 28 days; if rash not resolved within\r\n28 days, alternative treatment should be sought. If treatment interrupted\r\nfor more than 7 days, restart using the once daily dose regimen of\r\nthe \u2018immediate-release\u2019 preparation for the first 14 days as for new\r\ntreatment", "If a dose is more than 8 hours late\r\nwith the \u2018immediate-release\u2019 preparation (or more than 12 hours late\r\nwith the modified-release preparation), the missed dose should not\r\nbe taken and the next dose should be taken at the usual time"], "pregnancy": "although manufacturer advises caution, may be appropriate\r\nto use if clearly indicated; see alsoPregnancy", "breast-feeding": "seeBreast-feeding"}, "IRBESARTAN": {"indications": "hypertension; renal disease in hypertensive type 2 diabetes mellitus\r\n(see also notes above)", "name": "IRBESARTAN", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  aliskiren possibly reduced by irbesartan ", "name": "Irbesartan", "backrefs": ["Irbesartan"]}, "cautions": "seenotes above", "side-effects": "see notes above; also nausea, vomiting; fatigue;\r\nmusculoskeletal pain;less commonlydiarrhoea, dyspepsia,\r\nflushing, tachycardia, chest pain, cough, and sexual dysfunction;rarelyrash, urticaria;very rarelyheadache,\r\nmyalgia, arthralgia, tinnitus, taste disturbance, hepatitis, renal\r\ndysfunction, and cutaneous vasculitis", "doses": ["Hypertension, initially 150\u00a0mg once daily, increased if\r\nnecessary to 300\u00a0mg once daily (in haemodialysis or inelderlyover 75 years, initial dose of 75\u00a0mg once\r\ndaily may be used);childnot recommended", "Renal disease in hypertensive type 2 diabetes mellitus, initially\r\n150\u00a0mg once daily, increased to 300\u00a0mg once daily if tolerated (in\r\nhaemodialysis or inelderlyover 75\r\nyears, consider initial dose of 75\u00a0mg once daily);childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PRILOCAINE": {"interactions": {"extra": "", "bad": 0, "interaction": "increased myocardial depression when  anti-arrhythmics given with prilocaine ", "name": "Prilocaine", "backrefs": ["Prilocaine"]}}, "AZACITIDINE": {"indications": "seenotes above", "name": "AZACITIDINE", "renal impairment": "delay next treatment cycle if serum-creatinine or blood\r\nurea nitrogen greater than twice baseline value and above the upper\r\nlevel of normal until values return to normal or baseline, and then\r\nreduce dose by 50% on the next treatment cycle. Reduce dose by 50%\r\non the next treatment cycle if serum-bicarbonate concentration less\r\nthan 20\u00a0mmol/litre", "cautions": "seesection 8.1; history of severe\r\ncongestive heart failure, unstable cardiac or pulmonary\r\ndisease; monitor for\r\nbleeding; monitor serum bicarbonate", "side-effects": "seesection 8.1; also\r\ngastro-intestinal disturbances (including diarrhoea, constipation,\r\nabdominal pain, and dyspepsia), anorexia; hypertension, hypotension;\r\ndyspnoea, pneumonia; anxiety, insomnia, dizziness, headache, drowsiness;\r\nhaematuria; hypokalaemia; arthralgia, myalgia; injection-site reactions,\r\nrash, haematoma; haemorrhage (including cerebral haemorrhage);less commonlyhypersensitivity reactions (including anaphylactic\r\nreactions); hepatic coma, hepatic failure and renal failure also reported", "contra-indications": "advanced malignant hepatic tumour", "hepatic impairment": "caution in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nmanufacturer advises effective contraception during and for 3 months\r\nafter treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ESLICARBAZEPINE ACETATE": {"indications": "seenotes above", "name": "ESLICARBAZEPINE ACETATE", "renal impairment": "reduce initial dose to 400\u00a0mg every other day for 2 weeks\r\nthen 400\u00a0mg once daily if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2,\r\nadjusted according to response; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "avoid abrupt withdrawal; hyponatraemia (monitor plasma-sodium\r\nconcentration in patients at risk and discontinue treatment if hyponatraemia occurs); PR-interval prolongation (avoid concomitant\r\nadministration of drugs that prolong PR interval); elderly;interactions:seeInteractionsin section\r\n4.8.1 and Appendix 1 (eslicarbazepine)", "side-effects": "gastro-intestinal disturbances; dizziness, drowsiness,\r\nheadache, impaired coordination, tremor, visual disturbances, fatigue;\r\nrash;less commonlydry mouth, dehydration, gingival\r\nhyperplasia, stomatitis; palpitation, bradycardia, hypertension, hypotension,\r\nepistaxis, appetite changes, weight changes, agitation, hyperactivity,\r\nconfusion, mood changes, psychosis, impaired memory, insomnia, dysaesthesia,\r\ndystonia, parosmia, movement disorders, convulsions, peripheral neuropathy,\r\nnystagmus, dysarthria, taste disturbance, liver disorders, hypothyroidism,\r\nanaemia, hyponatraemia (see Cautions), electrolyte imbalance, tinnitus,\r\nalopecia, sweating, nail disorder, myalgia, nocturia, menstruation\r\nchanges, malaise, chills, peripheral oedema;very rarelypancreatitis, thrombocytopenia, and leucopenia; PR-interval prolongation\r\nalso reported; suicidal ideation", "contra-indications": "second- or third-degree AV block", "hepatic impairment": "avoid in severe impairment\u2014no information available", "doses": ["adultover 18 years, initially\r\n400\u00a0mg once daily, increased after 1\u20132 weeks to 800\u00a0mg once daily;\r\nmax. 1.2\u00a0g"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "MODAFINIL": {"indications": "excessive sleepiness\r\nassociated with narcolepsy with or without cataplexy", "name": "MODAFINIL", "renal impairment": "use with caution\u2014limited information available", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  ciclosporin reduced by modafinil ", "name": "Modafinil", "backrefs": ["Modafinil"]}, "cautions": "monitor blood pressure and heart rate\r\nin hypertensive patients (but see Contra-indications); ECG required before initiation; history\r\nof psychosis, depression, mania, alcohol or drug abuse; discontinue treatment if psychiatric symptoms develop; possibility of dependence; discontinue treatment if rash develops;interactions:Appendix 1 (modafinil)", "side-effects": "dry mouth, appetite changes, gastro-intestinal\r\ndisturbances (including nausea, diarrhoea, constipation, and dyspepsia),\r\nabdominal pain; tachycardia, vasodilatation, chest pain, palpitation;\r\nheadache (uncommonly migraine), anxiety, sleep disturbances, dizziness,\r\ndrowsiness, depression, confusion, paraesthesia, asthenia; visual\r\ndisturbances;less commonlyflatulence, reflux, vomiting,\r\nmouth ulcers, glossitis, dysphagia, taste disturbance, weight changes,\r\nhypertension, hypotension, bradycardia, arrhythmia, peripheral oedema,\r\nhypercholesterolaemia, rhinitis, dyspnoea, epistaxis, dyskinesia,\r\namnesia, emotional lability, abnormal dreams, suicidal ideation, tremor,\r\ndecreased libido, agitation, aggression, hyperglycaemia, thirst, urinary\r\nfrequency, menstrual disturbances, eosinophilia, leucopenia, myasthenia,\r\nmuscle cramps, hypertonia, myalgia, arthralgia, dry eye, sinusitis,\r\nacne, sweating, rash, and pruritus;rarelyhallucinations,\r\nmania, psychosis; multi-organ hypersensitivity reaction, Stevens-Johnson\r\nsyndrome, and toxic epidermal necrolysis also reported", "contra-indications": "moderate to severe uncontrolled\r\nhypertension, arrhythmia; history of left ventricular hypertrophy, cor pulmonale, or\r\nof clinically significant signs of CNS stimulant-induced mitral valve\r\nprolapse (including ischaemic ECG changes, chest pain and arrhythmias)", "hepatic impairment": "halve dose in severe impairment", "doses": ["Narcolepsyadultover 18\r\nyears, initially 200\u00a0mg daily,eitherin 2 divided\r\ndoses morning and at noonoras a single dose in\r\nthe morning, dose adjusted according to response to 200\u2013400\u00a0mg daily\r\nin 2 divided doses or as a single dose;elderlyinitiate at 100\u00a0mg daily;child5\u201318\r\nyears seeBNF for Children"], "pregnancy": "avoid", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "AMIFAMPRIDINE": {"indications": "(specialist use only) symptomatic treatment\r\nof Lambert-Eaton myasthenic syndrome", "name": "AMIFAMPRIDINE", "renal impairment": "use with caution; in mild impairment reduce initial dose\r\nto 10\u00a0mg daily in divided doses, increased in steps of 5\u00a0mg every\r\n7 days; in moderate or severe impairment reduce initial dose to 5\u00a0mg\r\ndaily divided doses, increased in steps of 5\u00a0mg every 7 days", "cautions": "concomitant use of drugs that lower convulsive\r\nthreshold; non-paraneoplastic form of Lambert-Eaton\r\nmyasthenic syndrome; clinical and ECG monitoring\r\nrequired at treatment initiation and yearly thereafter", "side-effects": "gastro-intestinal disorders; paraesthesia; palpitations,\r\narrhythmias, Raynaud\u2019s syndrome, cough, bronchial hypersecretion,\r\nexacerbation or precipitation of asthma, sleep disturbances, convulsions,\r\nanxiety, drowsiness, dizziness, weakness, headache, chorea, myoclonia,\r\nand blurred vision also reported", "contra-indications": "epilepsy; uncontrolled asthma; congenital QT syndromes; avoid concomitant use of drugs that prolong QT interval; avoid concomitant use of drugs with a narrow therapeutic\r\nindex", "hepatic impairment": "use with caution; in mild impairment reduce initial\r\ndose to 10\u00a0mg daily in divided doses, increased in steps of 5\u00a0mg every\r\n7 days; in moderate or severe impairment reduce initial dose to 5\u00a0mg\r\ndaily in divided doses, increased in steps of 5\u00a0mg every 7 days", "doses": ["adultover 18 years, initially\r\n15\u00a0mg daily in 3 divided doses, increased in steps of 5\u00a0mg every 4\u20135\r\ndays, to max. 60\u00a0mg daily in 3\u20134 divided doses; max. single dose 20\u00a0mg"], "pregnancy": "manufacturer advises avoid\u2014ensure effective contraception\r\nduring treatment in men and women", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "ACARBOSE": {"indications": "diabetes mellitus inadequately controlled by diet or by diet with\r\noral antidiabetic drugs", "name": "ACARBOSE", "renal impairment": "avoid if eGFR less than 25\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  orlistat advises avoid concomitant use with acarbose ", "name": "Acarbose", "backrefs": ["Pancreatin", "Acarbose"]}, "cautions": "monitor liver function; may enhance hypoglycaemic effects of insulin and sulfonylureas (hypoglycaemic\r\nepisodes may be treated with oralglucosebut not\r\nwith sucrose);interactions:Appendix\r\n1 (antidiabetics)", "side-effects": "flatulence, soft stools, diarrhoea (may need to\r\nreduce dose or withdraw), abdominal distention and pain;rarely, nausea, abnormal liver function tests and skin reactions;very rarelyileus, oedema, jaundice, and hepatitis", "contra-indications": "inflammatory bowel disease, predisposition to partial intestinal obstruction; hernia, previous abdominal surgery", "hepatic impairment": "avoid", "doses": ["adultover 18 years, initially\r\n50\u00a0mg daily increased to 50\u00a0mg 3 times daily, then increased if necessary\r\nafter 6\u20138 weeks to 100\u00a0mg 3 times daily; max. 200\u00a0mg 3 times daily", "Tablets should be chewed with first\r\nmouthful of food or swallowed whole with a little liquid immediately\r\nbefore food. To counteract possible hypoglycaemia, patients receiving\r\ninsulin or a sulfonylurea as well asacarboseneed\r\nto carry glucose (not sucrose\u2014acarboseinterferes\r\nwith sucrose absorption)"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "TENOFOVIR": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  adefovir advised by manufacturer of tenofovir ", "name": "Tenofovir", "backrefs": ["Adefovir", "Tenofovir", "Cidofovir"]}}, "TRIAMTERENE WITH FUROSEMIDE": {"indications": "oedema", "name": "TRIAMTERENE WITH FUROSEMIDE", "renal impairment": "may need high doses; monitor plasma-potassium concentration\r\n(high risk of hyperkalaemia); avoid in severe impairment", "cautions": "hypotension; diabetes mellitus; prostatic enlargement; impaired micturition; gout; monitor electrolytes; elderly; hepatorenal syndrome; may\r\ncause blue fluorescence of urine;interactions:Appendix 1 (diuretics)", "side-effects": "gastro-intestinal disturbances, dry mouth; hypotension;\r\nhyperglycaemia (less common than with thiazides); electrolyte disturbances\r\nincluding hypokalaemia (section 2.2), hyperkalaemia,\r\nhyponatraemia, hypocalcaemia, hypomagnesaemia, hyperuricaemia and\r\ngout, metabolic alkalosis;rarelypancreatitis, intrahepatic\r\ncholestasis, paraesthesia, blood disorders (including thrombocytopenia,\r\nleucopenia, agranulocytosis, aplastic anaemia, haemolytic anaemia),\r\nbone marrow depression (withdraw treatment), tinnitus and deafness\r\n(usually in renal impairment or in hypoproteinaemia), hypersensitivity\r\nreactions (including rashes, photosensitivity, eosinophilia, exfoliative\r\ndermatitis, purpura, and anaphylaxis); temporary increase in plasma\r\ncholesterol and triglyceride concentration also reported; triamterene\r\nfound in kidney stones", "contra-indications": "hypovolaemia; dehydration; severe hyponatraemia; severe hypokalaemia; hyperkalaemia; comatose or precomatose states associated with liver\r\ncirrhosis; renal failure; anuria", "hepatic impairment": "increased risk of hypomagnesaemia in alcoholic cirrhosis;\r\nhypokalaemia may precipitate coma", "doses": ["\u00bd\u20132\u00a0tablets daily in the morning"], "breast-feeding": "triamterene present in milk\u2014manufacturer advises\r\navoid; furosemide may inhibit lactation"}, "FILGRASTIM": {"indications": "(specialist use only) reduction in duration of neutropenia and incidence\r\nof febrile neutropenia in cytotoxic chemotherapy for malignancy (except\r\nchronic myeloid leukaemia and myelodysplastic syndromes); reduction\r\nin duration of neutropenia (and associated sequelae) in myeloablative\r\ntherapy followed by bone-marrow transplantation; mobilisation of peripheral\r\nblood progenitor cells for harvesting and subsequent autologous or\r\nallogeneic infusion; severe congenital neutropenia, cyclic neutropenia,\r\nor idiopathic neutropenia and history of severe or recurrent infections\r\n(distinguish carefully from other haematological disorders, consult\r\nproduct literature); persistent neutropenia in advanced HIV infection", "name": "FILGRASTIM", "interactions": {"extra": "", "bad": 0, "interaction": "neutropenia possibly exacerbated when  fluorouracil given with filgrastim ", "name": "Filgrastim", "backrefs": ["Filgrastim"]}, "cautions": "seenotes above; also\r\nregular morphological and cytogenetic bone-marrow examinations recommended\r\nin severe congenital neutropenia (possible risk of myelodysplastic\r\nsyndromes or leukaemia); secondary acute myeloid leukaemia; osteoporotic bone disease (monitor bone\r\ndensity if given for more than 6 months);interactions:Appendix 1 (filgrastim)", "side-effects": "seenotes above; also\r\nmucositis, splenic enlargement, hepatomegaly, transient hypotension,\r\nepistaxis, urinary abnormalities (including dysuria, proteinuria,\r\nand haematuria), osteoporosis, exacerbation of rheumatoid arthritis,\r\nanaemia, transient decrease in blood glucose, pseudogout, and raised\r\nuric acid;very rarelysplenic rupture", "contra-indications": "severe congenital neutropenia\r\n(Kostmann\u2019s syndrome) with abnormal cytogenetics", "doses": ["Cytotoxic-induced neutropenia, preferablyby subcutaneous\r\ninjectionorby intravenous infusion(over 30 minutes),adultandchild, 500\u00a0000\u00a0units/kg daily started at least 24\r\nhours after cytotoxic chemotherapy, continued until neutrophil count\r\nin normal range, usually for up to 14 days (up to 38 days in acute\r\nmyeloid leukaemia)", "Myeloablative therapy followed by bone-marrow transplantation,by intravenous infusionover 30 minutes or over 24 hoursorby subcutaneous infusionover 24 hours,\r\n1\u00a0million\u00a0units/kg daily, started at least 24 hours following cytotoxic\r\nchemotherapy (and within 24 hours of bone-marrow infusion), then adjusted\r\naccording to neutrophil count (consult product literature)", "Mobilisation of peripheral blood progenitor cells for autologous\r\ninfusion, used alone,by subcutaneous injectionorby subcutaneous infusionover 24 hours,\r\n1 million\u00a0units/kg daily for 5\u20137 days; used following adjunctive myelosuppressive\r\nchemotherapy (to improve yield),by subcutaneous injection, 500\u00a0000\u00a0units/kg daily, started the day after completing chemotherapy\r\nand continued until neutrophil count in normal range; for timing of\r\nleucopheresis consult product literature", "Mobilisation of peripheral blood progenitor cells in normal\r\ndonors for allogeneic infusion,by subcutaneous injection,adultunder 60 years andchildover 16 years, 1\u00a0million units/kg daily for\r\n4\u20135 days; for timing of leucopheresis consult product literature", "Severe chronic neutropenia,by subcutaneous injection,adultandchild, in severe congenital neutropenia, initially 1.2 million\u00a0units/kg\r\ndaily in single or divided doses (initially 500\u00a0000\u00a0units/kg daily\r\nin idiopathic or cyclic neutropenia), adjusted according to response\r\n(consult product literature)", "Persistent neutropenia in HIV infection,by subcutaneous\r\ninjection, initially 100\u00a0000\u00a0units/kg daily, increased as\r\nnecessary until neutrophil count in normal range (usual max. 400\u00a0000\u00a0units/kg\r\ndaily), then adjusted to maintain neutrophil count in normal range\r\n(consult product literature)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "BUSPIRONE HYDROCHLORIDE": {"indications": "anxiety (short-term use)", "name": "BUSPIRONE HYDROCHLORIDE", "renal impairment": "reduce dose; avoid if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "cautions": "does not alleviate benzodiazepine withdrawal (seenotes above);interactions:Appendix 1 (anxiolytics and hypnotics)", "side-effects": "nausea; dizziness, headache, nervousness, excitement;rarelydry mouth, tachycardia, palpitation, chest pain,\r\ndrowsiness, confusion, seizures, fatigue, and sweating", "contra-indications": "epilepsy; acute porphyria (section 9.8.2)", "hepatic impairment": "reduce dose in mild to moderate disease; avoid in severe\r\ndisease", "doses": ["adultover 18 years, 5\u00a0mg\r\n2\u20133 times daily, increased as necessary every 2\u20133 days; usual range\r\n15\u201330\u00a0mg daily in divided doses; max. 45\u00a0mg daily"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "ECONAZOLE NITRATE": {"indications": "fungal skin infections; vaginal candidiasis (section 7.2.2)", "name": "ECONAZOLE NITRATE", "cautions": "seenotes above", "side-effects": "see notes above", "doses": ["Skin infections apply twice daily; nail infections, apply\r\nonce daily under occlusive dressing"], "pregnancy": "minimal absorption from skin; not known to be harmful"}, "PREGABALIN": {"indications": "peripheral and central neuropathic\r\npain (section 4.7.3); adjunctive therapy for focal\r\nseizures with or without secondary generalisation; generalised anxiety\r\ndisorder (section 4.3)", "name": "PREGABALIN", "renal impairment": "initially 75\u00a0mg daily and max. 300\u00a0mg daily if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; initially 25\u201350\u00a0mg daily and max. 150\u00a0mg daily in 1\u20132 divided\r\ndoses if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2; initially 25\u00a0mg\r\nonce daily and max. 75\u00a0mg once daily if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2", "cautions": "avoid abrupt withdrawal (taper over at least 1 week); severe congestive heart\r\nfailure; conditions that may precipitate\r\nencephalopathy", "side-effects": "dry mouth, constipation, vomiting, flatulence,\r\noedema, dizziness, drowsiness, irritability, impaired attention, disturbances\r\nin muscle control and movement, speech disorder, impaired memory,\r\nparaesthesia, euphoria, confusion, malaise, appetite changes, insomnia,\r\nweight gain, sexual dysfunction, visual disturbances (including blurred\r\nvision, diplopia, visual field defects);less commonlyabdominal distension, hypersalivation, gastro-oesophageal reflux\r\ndisease, thirst, taste disturbance, flushing, hypotension, hypertension,\r\ntachycardia, syncope, first-degree AV block, dyspnoea, nasal dryness,\r\nstupor, depersonalisation, depression, abnormal dreams, hallucinations,\r\nagitation, cognitive impairment, panic attacks, chills, hypoglycaemia,\r\nthrombocytopenia, urinary incontinence, dysuria, myalgia, arthralgia,\r\ndry eye, lacrimation, hyperacusis, nasopharyngitis, sweating, rash;rarelyascites, dysphagia, pancreatitis, weight loss, cold\r\nextremities, arrhythmia, bradycardia, cough, epistaxis, rhinitis,\r\nparosmia, hyperglycaemia, renal failure, oliguria, menstrual disturbances,\r\nbreast pain, breast discharge, breast hypertrophy, neutropenia, hypokalaemia,\r\nleucopenia, rhabdomyolysis, urticaria;also reporteddiarrhoea, nausea, congestive heart failure, QT-interval prolongation,\r\naggression, headache, convulsions, encephalopathy, urinary retention,\r\nkeratitis, Stevens-Johnson syndrome, pruritus; suicidal ideation", "doses": ["Neuropathic pain,adultover 18 years, initially 150\u00a0mg daily in 2\u20133 divided doses, increased\r\nif necessary after 3\u20137 days to 300\u00a0mg daily in 2\u20133 divided doses,\r\nincreased further if necessary after 7 days to max. 600\u00a0mg daily in\r\n2\u20133 divided doses", "Epilepsy,adultover 18 years,\r\ninitially 25\u00a0mg twice daily, increased at 7-day intervals in steps\r\nof 50\u00a0mg daily to 300\u00a0mg daily in 2\u20133 divided doses, increased further\r\nif necessary after 7 days to max. 600\u00a0mg daily in 2\u20133 divided doses", "Generalised anxiety disorder,adultover 18 years, initially 150\u00a0mg daily in 2\u20133 divided doses, increased\r\nif necessary at 7-day intervals in steps of 150\u00a0mg daily; max. 600\u00a0mg\r\ndaily in 2\u20133 divided doses", "Pregabalin doses in BNF may differ from those\r\nin product literature"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "ACAMPROSATE CALCIUM": {"indications": "seenotes above", "name": "ACAMPROSATE CALCIUM", "renal impairment": "avoid if serum-creatinine greater than 120\u00a0micromol/litre", "cautions": "continuedalcoholabuse (risk of treatment failure)", "side-effects": "diarrhoea, nausea, vomiting, abdominal pain; fluctuation\r\nin libido; pruritus, maculopapular rash;rarelybullous\r\nskin reactions", "hepatic impairment": "avoid if severe", "doses": ["adult18\u201365 years, body-weight\r\n60\u00a0kg and over, 666\u00a0mg 3 times daily; body-weight less than 60\u00a0kg,\r\n666\u00a0mg at breakfast, 333\u00a0mg at midday, and 333\u00a0mg at night", "child16\u201318 years (under specialist\r\nsupervision) [unlicensed], body-weight 60\u00a0kg and over, 666\u00a0mg 3 times\r\ndaily; body-weight less than 60\u00a0kg, 666\u00a0mg at breakfast, 333\u00a0mg at\r\nmidday, and 333\u00a0mg at night"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "CYTARABINE": {"indications": "seenotes above", "name": "CYTARABINE", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  digoxin tablets possibly reduced by cytarabine ", "name": "Cytarabine", "backrefs": ["Cytarabine"]}, "cautions": "seesection 8.1andnotes above;interactions:Appendix 1 (cytarabine)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "reduce dose\u2014consult product literature", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "EDROPHONIUM": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  non-depolarising muscle relaxants antagonised by edrophonium ", "name": "Edrophonium", "backrefs": ["Edrophonium"]}}, "RAMIPRIL": {"indications": "hypertension; symptomatic heart failure (adjunct\u2014seesection 2.5.5); following\r\nmyocardial infarction in patients with clinical evidence of heart\r\nfailure; prevention of cardiovascular events in patients with atherosclerotic\r\ncardiovascular disease or with diabetes mellitus and at least one\r\nadditional risk factor for cardiovascular disease; nephropathy (consult\r\nproduct literature)", "name": "RAMIPRIL", "renal impairment": "seenotes above; max.\r\ndaily dose 5\u00a0mg if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; max. initial\r\ndose 1.25\u00a0mg once daily (do not exceed 5\u00a0mg once daily) if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; max. initial dose 1.25\u00a0mg once daily (do not exceed 2.5\u00a0mg\r\nonce daily) if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; arrhythmias, angina, chest pain,\r\nsyncope, cerebrovascular accident, myocardial infarction, loss of\r\nappetite, stomatitis, dry mouth, skin reactions including erythema\r\nmultiforme and pemphigoid exanthema; precipitation or exacerbation\r\nof Raynaud\u2019s syndrome; conjunctivitis, onycholysis, confusion, nervousness,\r\ndepression, anxiety, impotence, decreased libido, alopecia, bronchitis\r\nand muscle cramps", "contra-indications": "seenotes above", "hepatic impairment": "max. daily dose 2.5\u00a0mg; see alsonotes above", "doses": ["Hypertension, initially 1.25\u20132.5\u00a0mg once daily, increased\r\nat intervals of 2\u20134 weeks to max. 10\u00a0mg once daily; if used in addition\r\nto diureticsee notes above", "Heart failure (adjunct), initially 1.25\u00a0mg once daily under\r\nclose medical supervision (see notes above),\r\nincreased gradually at intervals of 1\u20132 weeks to max. 10\u00a0mg daily\r\nif tolerated (preferably taken in 2 divided doses)", "Prophylaxis after myocardial infarction (started at least 48\r\nhours after infarction), initially 2.5\u00a0mg twice daily, increased after\r\n3 days to 5\u00a0mg twice daily", "If initial 2.5-mg dose not tolerated, give\r\n1.25\u00a0mg twice daily for 2 days before increasing to 2.5\u00a0mg twice daily,\r\nthen 5\u00a0mg twice daily; withdraw if dose cannot be increased to 2.5\u00a0mg\r\ntwice daily", "Prophylaxis of cardiovascular events, initially 2.5\u00a0mg once\r\ndaily, increased after 1\u20132 weeks to 5\u00a0mg once daily, then increased\r\nafter a further 2\u20133 weeks to 10\u00a0mg once daily", "Nephropathy, initially 1.25\u00a0mg once daily, increased after 2\r\nweeks to 2.5\u00a0mg once daily, then increased after a further 2 weeks\r\nto 5\u00a0mg once daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "POVIDONE": {"indications": "dry eye conditions", "name": "POVIDONE", "doses": ["Apply 4 times daily or as required"]}, "FORMALDEHYDE": {"side-effects": "see underSalicylic Acid", "indications": "see under preparations", "name": "FORMALDEHYDE", "cautions": "see underSalicylic Acid", "doses": ["for warts, particularly plantar warts, apply twice daily"]}, "CLARITHROMYCIN": {"indications": "respiratory-tract infections, mild to moderate skin and soft-tissue\r\ninfections, otitis media; Lyme disease (see alsosection 5.1.1.3); prevention of pertussis (Table\r\n2,section 5.1);Helicobacter pylorieradication (section 1.3)", "name": "CLARITHROMYCIN", "renal impairment": "use half normal dose if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; avoidKlaricid XL\u00ae if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " nevirapine reduces plasma concentration of clarithromycin (but concentration of an active metabolite increased), also plasma concentration of nevirapine increased", "name": "Clarithromycin", "backrefs": ["Clarithromycin"]}, "cautions": "seenotes above;interactions:Appendix 1 (macrolides)", "side-effects": "seenotes above; also\r\ndyspepsia, tooth and tongue discoloration, smell and taste disturbances,\r\nstomatitis, glossitis, and headache;less commonlyarthralgia and myalgia;rarelytinnitus;very rarelydizziness, insomnia, nightmares, anxiety, confusion,\r\npsychosis, paraesthesia, convulsions, hypoglycaemia, renal failure,\r\ninterstitial nephritis, leucopenia, and thrombocytopenia", "hepatic impairment": "hepatic dysfunction including jaundice reported", "doses": ["500\u00a0mg once daily (doubled in severe infections) for 7\u201314\r\ndays"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid unless potential\r\nbenefit outweighs risk\u2014present in milk"}, "ALVERINE CITRATE": {"indications": "adjunct in gastro-intestinal disorders characterised by smooth muscle\r\nspasm; dysmenorrhoea", "name": "ALVERINE CITRATE", "side-effects": "nausea; dyspnoea; headache, dizziness; pruritus,\r\nrash; hepatitis also reported", "contra-indications": "paralytic ileus", "doses": ["adultandchildover 12 years, 60\u2013120\u00a0mg 1\u20133 times daily"], "pregnancy": "use with caution", "breast-feeding": "manufacturer advises avoid\u2014limited information\r\navailable"}, "SODIUM THIOSULPHATE": {"indications": "in conjunction with sodium nitrite for cyanide poisoning", "name": "SODIUM THIOSULPHATE", "doses": ["By intravenous injectionover 10 minutes\r\n(as sodium thiosulphate injection 500\u00a0mg/mL), 12.5\u00a0g; dose may be\r\nrepeated in severe cyanide poisoning if dicobalt edetate not available;child400\u00a0mg/kg (max. 12.5\u00a0g); dose may be repeated\r\nin severe cyanide poisoning if dicobalt edetate not available"]}, "DAIRY PRODUCTS": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  tetracyclines (except doxycycline and minocycline) reduced by dairy products ", "name": "Dairy Products", "backrefs": ["Dairy Products"]}}, "ACICLOVIR": {"indications": "seenotes above; herpes simplex and varicella\u2013zoster\r\ninfections (section 5.3.2.1); eye infections (section 11.3.3)", "name": "ACICLOVIR", "interactions": {"extra": "Interactions do not apply to topical aciclovir preparations", "bad": 0, "interaction": " probenecid reduces excretion of aciclovir (increased plasma concentration)", "name": "Aciclovir", "backrefs": ["Aciclovir"]}, "cautions": "avoid contact with eyes and mucous membranes", "side-effects": "transient stinging or burning; occasionally erythema,\r\nitching or drying of the skin", "doses": ["Apply to lesions every 4 hours (5 times daily) for 5\u201310\r\ndays, starting at first sign of attack"], "pregnancy": "not known to be harmful\u2014manufacturers advise use\r\nonly when potential benefit outweighs risk; limited absorption from\r\ntopical aciclovir preparations"}, "TOLBUTAMIDE": {"indications": "type 2 diabetes mellitus", "name": "TOLBUTAMIDE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of tolbutamide ", "name": "Tolbutamide", "backrefs": ["Tolbutamide"]}, "cautions": "seenotes above;interactions:Appendix 1 (antidiabetics)", "side-effects": "see notes above; also headache, tinnitus", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["0.5\u20131.5\u00a0g (max. 2\u00a0g) daily in divided doses with or immediately\r\nafter mealsoras a single dose with or immediately\r\nafter breakfast"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "TRIAMCINOLONE ACETONIDE": {"side-effects": "seenotes above", "indications": "prophylaxis and treatment of allergic\r\nrhinitis", "name": "TRIAMCINOLONE ACETONIDE", "cautions": "seenotes above", "doses": ["adultandchildover 12 years, 110\u00a0micrograms (2 sprays) into\r\neach nostril once daily; when control achieved, reduce to 55\u00a0micrograms\r\n(1 spray) into each nostril once daily;child6\u201312 years, 55\u00a0micrograms (1 spray) into each nostril once daily,\r\nincreased if necessary to 110\u00a0micrograms (2 sprays) into each nostril\r\nonce daily; when control achieved, reduce to 55\u00a0micrograms (1 spray)\r\ninto each nostril once daily; max. duration of treatment 3 months;child2\u20136 years seeBNF for Children", "Preparations of triamcinolone acetonide can\r\nbe sold to the public for nasal administration as a non-pressurised\r\nnasal spray if supplied for the symptomatic treatment of seasonal\r\nallergic rhinitis in adults over 18 years, subject to max. daily dose\r\nof 110\u00a0micrograms per nostril for max. 3 months, and a pack size of\r\n3.575\u00a0mg"]}, "STRONTIUM RANELATE": {"indications": "seenotes above", "name": "STRONTIUM RANELATE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  tetracyclines reduced by strontium ranelate (manufacturer of strontium ranelate advises avoid concomitant use)", "name": "Strontium Ranelate", "backrefs": ["Strontium Ranelate"]}, "cautions": "predisposition to thromboembolism; interferes with colorimetric measurements of calcium\r\nin blood and urine;interactions: Appendix\r\n1 (strontium ranelate)", "side-effects": "nausea, diarrhoea; venous thromboembolism; headache;\r\ndermatitis, eczema;very rarelyvomiting, abdominal\r\npain, stomatitis, and hypersensitivity reactions, including rash,\r\npruritus, urticaria and angioedema\u2014see Severe Allergic Reactions,\r\nbelow", "doses": ["2\u00a0g once daily in water, preferably at bedtime", "Avoid food for 2 hours before and\r\nafter taking granules, particularly calcium-containing products e.g.\r\nmilk; also preferably avoid concomitant antacids containing aluminium\r\nand magnesium hydroxides for 2 hours after taking granules"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid"}, "SODIUM NITRITE": {"side-effects": "flushing and headache due to vasodilatation", "indications": "poisoning with cyanides (used in conjunction withsodium\r\nthiosulphate)", "name": "SODIUM NITRITE", "doses": ["By intravenous injectionover 5\u201320 minutes\r\n(as sodium nitrite injection 30\u00a0mg/mL), 300\u00a0mg;child4\u201310\u00a0mg/kg (max. 300\u00a0mg)"]}, "ANTIFUNGALS, IMIDAZOLE": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  saquinavir possibly increased by imidazoles ", "name": "Antifungals, Imidazole", "backrefs": []}}, "FLUDROXYCORTIDE": {"indications": "inflammatory skin disorders such as eczemas", "name": "FLUDROXYCORTIDE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["for chronic localised recalcitrant dermatoses (but not\r\nacute or weeping), cut tape to fit lesion, apply to clean, dry skin\r\nshorn of hair, usually for 12 hours daily"]}, "PETHIDINE HYDROCHLORIDE": {"indications": "moderate to severe pain, obstetric analgesia; peri-operative analgesia", "name": "PETHIDINE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; not suitable for severe continuing pain; accumulation of metabolites may result in neurotoxicity; cardiac arrhythmias, severe\r\ncor pulmonale", "side-effects": "seenotes above; also\r\nrestlessness, tremor, and hypothermia; convulsions reported inoverdosage", "contra-indications": "seenotes above; phaeochromocytoma", "hepatic impairment": "seenotes above", "doses": ["by intramuscular injection, premedication,\r\n2\u00a0mL 60\u201390 minutes before operation;child8\u201312 years 0.75\u00a0mL, 13\u201316 years 1\u00a0mL"], "pregnancy": "seenotes above", "breast-feeding": "present in milk but not known to be harmful"}, "STREPTOKINASE": {"indications": "acute myocardial infarction (see notes above andsection 2.10.1); deep-vein thrombosis, pulmonary\r\nembolism, acute arterial thromboembolism, and central retinal venous\r\nor arterial thrombosis", "name": "STREPTOKINASE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Myocardial infarction (initiated within 12 hours of symptom\r\nonset),by intravenous infusion, 1.5 million units\r\nover 60 minutes", "Deep-vein thrombosis, pulmonary embolism, acute arterial thromboembolism,\r\ncentral retinal venous or arterial thrombosis,by intravenous\r\ninfusion, 250\u00a0000\u00a0units over 30 minutes, then 100\u00a0000\u00a0units\r\nevery hour for up to 12\u201372 hours according to condition with monitoring\r\nof clotting parameters (consult product literature)"], "pregnancy": "seenotes above"}, "QUINOLONES": {"interactions": {"extra": "", "bad": 0, "interaction": "metabolism of  zolmitriptan possibly inhibited by quinolones (reduce dose of zolmitriptan)", "name": "Quinolones", "backrefs": ["Quinolones"]}}, "GOSERELIN": {"indications": "locally advanced prostate cancer as\r\nan alternative to surgical castration; adjuvant treatment to radiotherapy\r\nor radical prostatectomy in patients with high-risk localised or locally\r\nadvanced prostate cancer; neoadjuvant treatment prior to radiotherapy\r\nin patients with high-risk localised or locally advanced prostate\r\ncancer;  metastatic prostate cancer; advanced breast cancer; oestrogen-receptor-positive\r\nearly breast cancer (section 8.3.4.1); endometriosis, endometrial\r\nthinning, uterine fibroids, assisted reproduction (section 6.7.2)", "name": "GOSERELIN", "cautions": "seenotes above; diabetes; risk of ureteric obstruction\r\nand spinal cord compression in men", "side-effects": "seenotes above; also\r\ntransient changes in blood pressure; paraesthesia;rarelyhypercalcaemia (in patients with metastatic breast cancer)", "contra-indications": "undiagnosed vaginal bleeding", "doses": ["breast cancer and prostate cancer (see indications above)by subcutaneous injectioninto anterior abdominal wall, 3.6\u00a0mg\r\nevery 28 days"], "pregnancy": "see Goserelin,section 6.7.2", "breast-feeding": "see Goserelin,section 6.7.2"}, "ORLISTAT": {"indications": "adjunct in obesity (see notes above)", "name": "ORLISTAT", "interactions": {"extra": "", "bad": 1, "interaction": "absorption of  ciclosporin possibly reduced by orlistat ", "name": "Orlistat", "backrefs": ["Orlistat", "Acarbose"]}, "cautions": "may impair absorption of fat-soluble\r\nvitamins; chronic kidney disease or volume depletion;interactions:Appendix 1 (orlistat)", "side-effects": "oily leakage from rectum, flatulence, faecal urgency,\r\nliquid or oily stools, faecal incontinence, abdominal distension and\r\npain (gastro-intestinal effects minimised by reduced fat intake),\r\ntooth and gingival disorders, respiratory infections, malaise, anxiety,\r\nheadache, menstrual disturbances, urinary-tract infection, hypoglycaemia;also reportedrectal bleeding, diverticulitis, cholelithiasis,\r\nhepatitis, hypothyroidism, oxalate nephropathy, bullous eruptions", "contra-indications": "chronic malabsorption syndrome; cholestasis", "doses": ["adultover 18 years, 120\u00a0mg\r\ntaken immediately before, during, or up to 1 hour after each main\r\nmeal (max. 120\u00a0mg 3 times daily); continue treatment beyond 12 weeks\r\nonly if weight loss since start of treatment exceeds 5% (target for\r\ninitial weight loss may be lower in patients with type 2 diabetes);childover 12 years seeBNF for Children", "If a meal is missed or contains no fat, the\r\ndose oforlistatshould be omitted"], "pregnancy": "use with caution", "breast-feeding": "avoid\u2014no information available"}, "SODIUM BENZOATE": {"interactions": {"extra": "", "bad": 0, "interaction": " probenecid possibly reduces excretion of conjugate formed by sodium benzoate ", "name": "Sodium Benzoate", "backrefs": ["Sodium Benzoate"]}}, "THALIDOMIDE": {"indications": "seenotes above", "name": "THALIDOMIDE", "renal impairment": "caution in severe impairment\u2014 no information available", "cautions": "seenotes above; high\r\ntumour burden\u2014risk oftumour lysis syndrome; monitor for\r\narterial or venous thromboembolism and\r\nuse caution with concomitant drugs that increase the risk of peripheral\r\nneuropathy or thromboembolism\u2014see also Thromboembolism,\r\nbelow", "side-effects": "vomiting, dry mouth, dyspepsia, constipation;\r\nbradycardia, cardiac failure, deep vein thrombosis; dyspnoea, interstitial\r\nlung disease, pulmonary embolism, peripheral oedema; asthenia, confusion,\r\ndepression, dizziness, drowsiness, peripheral neuropathy, dysaesthesia,\r\nparaesthesia, syncope, tremor; pyrexia; pneumonia; anaemia, leucopenia,\r\nneutropenia, lymphopenia, thrombocytopenia; skin reactions including\r\nStevens-Johnson syndrome;also reportedtoxic epidermal\r\nnecrolysis, intestinal obstruction, gastro-intestinal perforation,\r\nhypothyroidism, sexual dysfunction, myocardial infarction, cerebrovascular\r\nevents", "hepatic impairment": "caution in severe impairment\u2014 no information available", "doses": ["adultover 18 years, 200\u00a0mg\r\nonce daily at bedtime for 6-week cycle; max. 12 cycles"], "pregnancy": "important teratogenic risk; see\r\nalsonotes above", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "MOXONIDINE": {"indications": "mild to moderate essential hypertension", "name": "MOXONIDINE", "renal impairment": "max. single dose 200\u00a0micrograms and max. daily dose 400\u00a0micrograms\r\nif eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with moxonidine ", "name": "Moxonidine", "backrefs": ["Moxonidine"]}, "cautions": "avoid abrupt withdrawal (if concomitant treatment with beta-blocker has to\r\nbe stopped, discontinue beta-blocker first, thenmoxonidineafter a few days); severe coronary artery\r\ndisease; unstable angina; first-degree AV block; moderate heart\r\nfailure;interactions:see Appendix\r\n1 (moxonidine)", "side-effects": "dry mouth, diarrhoea, nausea, vomiting, dyspepsia,\r\ndizziness, somnolence, insomnia, back pain, rash, pruritus;less commonlybradycardia, tinnitus, angioedema, oedema,\r\nnervousness, neck pain", "contra-indications": "conduction disorders (sick sinus syndrome, sino-atrial\r\nblock, second- or third-degree\r\nAV block); bradycardia; severe heart failure", "doses": ["200\u00a0micrograms once daily in the morning, increased if\r\nnecessary after 3 weeks to 400\u00a0micrograms daily in 1\u20132 divided doses;\r\nmax. 600\u00a0micrograms daily in 2 divided doses (max. single dose 400\u00a0micrograms)"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "PENTOSTATIN": {"indications": "seenotes above", "name": "PENTOSTATIN", "renal impairment": "avoid if creatinine clearance less than 60\u00a0mL/minute", "interactions": {"extra": "", "bad": 1, "interaction": "increased pulmonary toxicity when  fludarabine given with pentostatin (unacceptably high incidence of fatalities)", "name": "Pentostatin", "backrefs": ["Pentostatin"]}, "cautions": "seesection 8.1andnotes above;interactions:Appendix 1 (pentostatin)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "manufacturer advises caution\u2014limited information available", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nmanufacturer advises that men should not father children during and\r\nfor 6 months after treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "LEVOBUNOLOL HYDROCHLORIDE": {"indications": "seenotes above", "name": "LEVOBUNOLOL HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above; anterior uveitis occasionally\r\nreported", "contra-indications": "seenotes above", "doses": ["Apply once or twice daily"]}, "TETANUS IMMUNOGLOBULIN": {"side-effects": "injection site swelling and pain;rarelyanaphylaxis", "indications": "post-exposure prophylaxis and treatment\r\nof tetanus infection", "name": "TETANUS IMMUNOGLOBULIN", "cautions": "IgA deficiency; interference with live virus vaccines\u2014seeNormal Immunoglobulins", "doses": ["Post-exposure prophylaxis, byintramuscular injection250\u00a0units, increased to 500\u00a0units if more than 24 hours have elapsed\r\nor there is risk of heavy contamination or following burns"]}, "OSELTAMIVIR": {"indications": "see notes above", "name": "OSELTAMIVIR", "renal impairment": "fortreatment, use 30\u00a0mg twice daily\r\nif eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2(30\u00a0mg once daily if eGFR\r\n10\u201330\u00a0mL/minute/1.73\u00a0m2); forprevention, use 30\u00a0mg once daily if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2(30\u00a0mg every 48 hours if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2); avoid fortreatmentandpreventionif eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "side-effects": "nausea, vomiting, abdominal pain, diarrhoea; headache;\r\nconjunctivitis;less commonlyeczema; also reported\r\nhepatitis, gastro-intestinal bleeding, arrhythmias, neuropsychiatric\r\ndisorders (more frequent in children and adolescents), thrombocytopenia,\r\nvisual disturbances, Stevens-Johnson syndrome, and toxic epidermal\r\nnecrolysis", "doses": ["Prevention of influenza,adultandchildover 13 years, 75\u00a0mg once\r\ndaily for 10 days for post-exposure prophylaxis; for up to 6 weeks\r\nduring an epidemic;childunder 1 month\r\n(seenotes above), 2\u00a0mg/kg\r\nonce daily for 10 days for post-exposure prophylaxis; 1\u20133 months (seenotes above), 2.5\u00a0mg/kg\r\nonce daily for 10 days for post\u2013exposure prophylaxis; 3 months\u20131 year\r\n(seenotes above), 3\u00a0mg/kg\r\nonce daily for 10 days for post-exposure prophylaxis; 1\u201313 years,\r\nbody-weight under 15\u00a0kg, 30\u00a0mg once daily for 10 days for post-exposure\r\nprophylaxis (for up to 6 weeks during an epidemic); body-weight 15\u201323\u00a0kg,\r\n45\u00a0mg once daily for 10 days for post-exposure prophylaxis (for up\r\nto 6 weeks during an epidemic); body-weight 23\u201340\u00a0kg, 60\u00a0mg once daily\r\nfor 10 days for post-exposure prophylaxis (for up to 6 weeks during\r\nan epidemic); body-weight over 40\u00a0kg, adult dose", "Treatment of influenza,adultandchildover 13 years, 75\u00a0mg every\r\n12 hours for 5 days;childunder 1\r\nmonth (seenotes above), 2\u00a0mg/kg\r\nevery 12 hours for 5 days; 1\u20133 months (seenotes above), 2.5\u00a0mg/kg\r\nevery 12 hours for 5 days; 3 months\u20131 year (seenotes above), 3\u00a0mg/kg\r\nevery 12 hours for 5 days; 1\u201313 years, body-weight under 15\u00a0kg, 30\u00a0mg\r\nevery 12 hours for 5 days, body-weight 15\u201323\u00a0kg, 45\u00a0mg every 12 hours\r\nfor 5 days, body-weight 23\u201340\u00a0kg, 60\u00a0mg every 12 hours for 5 days,\r\nbody-weight over 40\u00a0kg, adult dose", "Not licensed for use in children under 1\r\nyear of age unless there is a pandemic"], "pregnancy": "use only if potential benefit outweighs risk (e.g.\r\nduring a pandemic); see alsoPregnancy and Breast-feeding", "breast-feeding": "amount probably too small to be harmful; use\r\nonly if potential benefit outweighs risk (e.g. during a pandemic);\r\nsee alsoPregnancy and Breast-feeding"}, "PROGESTOGENS": {"interactions": {"extra": "Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see section 7.3.1. For further information on interactions of oral progestogen-only contraceptives, see also section 7.3.2.1; parenteral progestogen-only contraceptives, see also section 7.3.2.2; the intra-uterine progestogen-only device, see also section 7.3.2.3; hormonal emergency contraception, see also section 7.3.5", "bad": 1, "interaction": " nevirapine accelerates metabolism of progestogens (reduced contraceptive effect\u2014see section 7.3.1)", "name": "Progestogens", "backrefs": ["Progestogens"]}}, "ARTICAINE HYDROCHLORIDE WITH ADRENALINE": {"indications": "infiltration anaesthesia in dentistry", "name": "ARTICAINE HYDROCHLORIDE WITH ADRENALINE", "renal impairment": "see Adrenaline,section 2.7.3", "cautions": "seeCautions of Local Anaestheticsand\r\nAdrenaline,section 2.7.3", "side-effects": "seeToxicity and Side-effectsand\r\nAdrenaline,section 2.7.3; also methaemoglobinaemia (seePrilocainefor treatment)", "contra-indications": "seeContra-indications of Local\r\nAnaestheticsand\r\nAdrenaline,section 2.7.3", "hepatic impairment": "use with caution; increased risk of side-effects in\r\nsevere impairment", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "adultandchildover 4 years, consult expert dental sources;important: see alsoAdministration"], "pregnancy": "use only if potential benefit outweighs risk\u2014no information\r\navailable", "breast-feeding": "avoid breast-feeding for 48 hours after administration"}, "ROPINIROLE": {"indications": "Parkinson\u2019s disease, either used alone or as adjunct to co-beneldopa\r\nor co-careldopa; moderate to severe restless legs syndrome", "name": "ROPINIROLE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  metoclopramide advised by manufacturer of ropinirole (antagonism of effect)", "name": "Ropinirole", "backrefs": ["Ropinirole"]}, "cautions": "seenotes above; severe cardiovascular disease (risk of hypotension\u2014monitor\r\nblood pressure), major psychotic disorders; elderly; avoid abrupt withdrawal; dose adjustment\r\nmay be necessary if smoking started or stopped during treatment;interactions:Appendix 1 (ropinirole)", "side-effects": "seenotes above; also\r\nnausea, vomiting, abdominal pain, dyspepsia, gastro-oesophageal reflux\r\ndisease, constipation; hypotension; syncope, peripheral oedema; drowsiness\r\n(includingsudden onset of sleep),\r\ndizziness, nervousness, fatigue, dyskinesia, hallucinations, confusion;less commonlypsychosis, compulsive behaviour (seenotes above);very rarelyhepatic disorders;also reportedparadoxical worsening of restless legs syndrome", "hepatic impairment": "avoid\u2014no information available", "doses": ["Parkinson\u2019s disease, initially 750\u00a0micrograms daily\r\nin 3 divided doses, increased by increments of 750\u00a0micrograms daily\r\nat weekly intervals to 3\u00a0mg daily in 3 divided doses; further increased\r\nby increments of 1.5\u20133\u00a0mg daily at weekly intervals according to response;\r\nusual range 9\u201316\u00a0mg daily in 3 divided doses (but higher doses may\r\nbe required if used with levodopa); max. 24\u00a0mg daily in 3 divided\r\ndoses", "When administered as adjunct tolevodopa, concurrent dose of levodopa may be reduced by\r\napprox. 20%;ropiniroledoses in the BNF may differ\r\nfrom those in product literature", "Restless legs syndrome,adultover 18 years initially 250\u00a0micrograms at night for 2 days, increased\r\nif tolerated to 500\u00a0micrograms at night for 5 days and then to 1\u00a0mg\r\nat night for 7 days; further increased at weekly intervals in steps\r\nof 500\u00a0micrograms daily according to response; usual dose 2\u00a0mg at\r\nnight; max. 4\u00a0mg daily", "Repeat dose titration if restarting after\r\ninterval of more than a few days"], "pregnancy": "avoid unless potential benefit outweighs risk\u2014toxicity\r\ninanimalstudies", "breast-feeding": "may suppress lactation\u2014avoid"}, "RUPATADINE": {"indications": "symptomatic relief of allergic rhinitis,\r\nurticaria", "name": "RUPATADINE", "renal impairment": "manufacturer advises avoid\u2014no information available", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of rupatadine ", "name": "Rupatadine", "backrefs": ["Rupatadine"]}, "cautions": "seenotes above; also susceptibility to QT-interval prolongation (including cardiac disease and hypokalaemia); elderly", "side-effects": "seenotes above; also\r\nasthenia;less commonlypyrexia, irritability, increased\r\nappetite, arthralgia, and myalgia", "hepatic impairment": "manufacturer advises avoid\u2014no information available", "doses": ["adultandchildover 12 years, 10\u00a0mg once daily"], "pregnancy": "manufacturer advises caution\u2014limited information\r\navailable; see alsonotes above", "breast-feeding": "manufacturer advises caution; see alsonotes above"}, "FOSCARNET": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of hypocalcaemia when parenteral  pentamidine isetionate given with foscarnet ", "name": "Foscarnet", "backrefs": ["Foscarnet"]}}, "MANNITOL": {"indications": "see notes above; glaucoma (section 11.6)", "name": "MANNITOL", "renal impairment": "use with caution in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of nephrotoxicity when  ciclosporin given with mannitol ", "name": "Mannitol", "backrefs": ["Mannitol"]}, "cautions": "extravasation causes inflammation and\r\nthrombophlebitis; monitor fluid and electrolyte\r\nbalance, serum osmolality, and pulmonary and renal function; assess cardiac function before and during treatment;interactions: Appendix 1 (mannitol)", "side-effects": "less commonlyhypotension, thrombophlebitis,\r\nfluid and electrolyte imbalance;rarelydry mouth,\r\nthirst, nausea, vomiting, oedema, raised intracranial pressure, arrhythmia,\r\nhypertension, pulmonary oedema, chest pain, headache, convulsions,\r\ndizziness, chills, fever, urinary retention, focal osmotic nephrosis,\r\ndehydration, cramp, blurred vision, rhinitis, skin necrosis, and hypersensitivity\r\nreactions (including urticaria and anaphylaxis);very rarelycongestive heart failure and acute renal failure", "contra-indications": "severe cardiac failure; severe pulmonary oedema; intracranial\r\nbleeding (except during craniotomy); anuria; severe dehydration", "doses": ["Cerebral oedema and raised intra-ocular pressure,by intravenous infusionover 30\u201360 minutes, 0.25\u20132\u00a0g/kg repeated\r\nif necessary 1\u20132 times after 4\u20138 hours", "For mannitol 20%, an in-line filter is recommended\r\n(15-micron filters have been used)"], "pregnancy": "manufacturer advises avoid unless essential\u2014no information\r\navailable", "breast-feeding": "manufacturer advises avoid unless essential\u2014no\r\ninformation available"}, "CICLESONIDE": {"indications": "prophylaxis of asthma", "name": "CICLESONIDE", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of active metabolite of ciclesonide ", "name": "Ciclesonide", "backrefs": ["Ciclesonide"]}, "cautions": "seenotes above", "side-effects": "seenotes above; alsoless commonlynausea, taste disturbances", "doses": ["By aerosol inhalation, 160\u00a0micrograms daily\r\nas a single dose reduced to 80\u00a0micrograms daily if control maintained;\r\ndose may be increased to max. 320\u00a0micrograms twice daily if necessary\r\nin severe asthma [unlicensed];child12\u201318 years, 160\u00a0micrograms daily as a single dose reduced to 80\u00a0micrograms\r\ndaily if control maintained"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "PEGVISOMANT": {"indications": "see notes above", "name": "PEGVISOMANT", "cautions": "liver disease (monitor liver enzymes\r\nevery 4\u20136 weeks for 6 months or if symptoms of hepatitis develop); diabetes mellitus (adjustment of antidiabetic therapy\r\nmay be necessary); possible increase in\r\nfemale fertility", "side-effects": "diarrhoea, constipation, nausea, vomiting, abdominal\r\ndistension, dyspepsia, flatulence, elevated liver enzymes; hypertension;\r\nheadache, asthenia, dizziness, drowsiness, tremor, sleep disturbances;\r\ninfluenza-like syndrome, weight gain, hyperglycaemia, hypoglycaemia;\r\narthralgia, myalgia; injection-site reactions (rotate injection sites\r\nto avoid lipohypertrophy), sweating, pruritus, rash; fatigue; hypercholesterolaemia;\r\nless commonly thrombocytopenia, leucopenia, leucocytosis, bleeding\r\ntendency", "doses": ["By subcutaneous injection, initially 80\u00a0mg,\r\nthen 10\u00a0mg daily, increased in steps of 5\u00a0mg daily according to response;\r\nmax. 30\u00a0mg daily;childnot recommended"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "FINGOLIMOD": {"indications": "seenotes above", "name": "FINGOLIMOD", "interactions": {"extra": "", "bad": 1, "interaction": " ketoconazole increases plasma concentration of fingolimod ", "name": "Fingolimod", "backrefs": ["Fingolimod"]}, "cautions": "monitor blood pressure; monitor for bradycardia for 6 hours after first dose; susceptibility to QT-interval prolongation (including\r\nelectrolyte disturbances, concomitant use of drugs that prolong QT\r\ninterval); severe respiratory disease; pulmonary fibrosis; chronic\r\nobstructive pulmonary disease; risk of\r\nmacular oedema\u2014eye examination recommended 3\u20134 months after initiation\r\nof treatment (and before initiation of treatment in patients with\r\ndiabetes or history of uveitis);interactions: Appendix 1 (fingolimod)", "side-effects": "diarrhoea, weight loss, AV block, bradycardia,\r\nhypertension, cough, dyspnoea, depression, malaise, headache, migraine,\r\ndizziness, paraesthesia, influenza, herpes, bronchitis, sinusitis,\r\ngastroenteritis, tinea, lymphopenia, leucopenia, back pain, blurred\r\nvision, eye pain, eczema, alopecia, pruritus;less commonlypneumonia, neutropenia, macular oedema;also reportedlymphoma", "contra-indications": "immunosuppression; active infection; active\r\nmalignancies (except cutaneous basal cell carcinoma)", "hepatic impairment": "use with caution in mild to moderate impairment; avoid\r\nin severe impairment", "doses": ["adultover 18 years, 500\u00a0micrograms\r\nonce daily"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nexclude pregnancy before treatment and ensure effective contraception\r\nduring and for at least 2 months after treatment", "breast-feeding": "avoid"}, "FERRIC CARBOXYMALTOSE": {"indications": "iron-deficiency anaemia, seenotes above", "name": "FERRIC CARBOXYMALTOSE", "cautions": "hypersensitivity can occur with parenteral\r\niron and facilities for cardiopulmonary resuscitation must be available; oral iron should not be given until 5 days after last\r\ninjection; allergic disorders including\r\nasthma and eczema; infection (discontinue\r\nif ongoing bacteraemia)", "side-effects": "gastro-intestinal disturbances; headache, dizziness;\r\nrash, injection-site reactions;less commonlyhypertension,\r\nhypotension, flushing, chest pain, peripheral oedema, hypersensitivity\r\nreactions (including anaphylaxis), fatigue, paraesthesia, malaise,\r\npyrexia, rigors, myalgia, arthralgia, back pain, pruritus, and urticaria;rarelydyspnoea", "hepatic impairment": "use with caution; avoid in conditions where iron overload\r\nincreases risk of impairment", "doses": ["By slow intravenous injectionorby intravenous infusion,adultandchildover 14 years, calculated\r\naccording to body-weight and iron deficit, consult product literature"], "pregnancy": "avoid in first trimester; crosses the placenta inanimalstudies; may influence skeletal development"}, "MEPIVACAINE HYDROCHLORIDE": {"indications": "infiltration anaesthesia and nerve\r\nblock in dentistry", "name": "MEPIVACAINE HYDROCHLORIDE", "renal impairment": "use with caution; increased risk of side-effects", "cautions": "seeCautions of Local Anaesthetics", "side-effects": "seeToxicity and Side-effects", "contra-indications": "seeContra-indications of Local\r\nAnaesthetics", "hepatic impairment": "use with caution; increased risk of side-effects in\r\nsevere impairment", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "adultandchildover 3 years, consult expert dental sources;important: see alsoAdministration"], "pregnancy": "use with caution in early pregnancy", "breast-feeding": "use with caution"}, "TACALCITOL": {"indications": "plaque psoriasis", "name": "TACALCITOL", "cautions": "seenotes above; avoid eyes; monitor serum calcium if risk\r\nof hypercalcaemia; if used in conjunction\r\nwith UV treatment, UV radiation should be given in the morning andtacalcitolapplied at bedtime", "side-effects": "see notes above", "contra-indications": "seenotes above", "doses": ["adultandchildover 12 years, apply once daily preferably\r\nat bedtime; max. 10\u00a0gointmentor 10\u00a0mLlotiondaily", "When lotion and ointment used together, max.\r\ntotal tacalcitol 280\u00a0micrograms in any one week (e.g. lotion 30\u00a0mL\r\nwith ointment 40\u00a0g)"], "pregnancy": "manufacturer advises avoid unless no safer alternative\u2014no\r\ninformation available", "breast-feeding": "manufacturer advises avoid application to breast\r\narea; no information available on presence in milk"}, "PROGESTERONE": {"indications": "see under preparations", "name": "PROGESTERONE", "renal impairment": "use with caution", "cautions": "seenotes above", "side-effects": "see notes above; injection-site reactions; pain,\r\ndiarrhoea and flatulence can occur with rectal administration", "contra-indications": "seenotes above; missed\r\nor incomplete miscarriage", "hepatic impairment": "avoid; see also Combined Hormonal Contraceptives,section 7.3.1", "doses": ["by vagina, infertility due to inadequate\r\nluteal phase, insert 1 applicatorful daily starting either after documented\r\novulation or on day 18\u201321 of cycle.In vitrofertilisation,\r\ndaily application continued for 30 days after laboratory evidence\r\nof pregnancy"], "pregnancy": "not known to be harmful", "breast-feeding": "avoid\u2014present in milk"}, "SUNITINIB": {"indications": "seenotes above", "name": "SUNITINIB", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole inhibits metabolism of sunitinib (increased plasma concentration)", "name": "Sunitinib", "backrefs": ["Sunitinib"]}, "cautions": "seesection 8.1; cardiovascular disease\u2014discontinue\r\nif congestive heart failure develops; susceptibility\r\nto QT-interval prolongation; hypertension; increased risk of bleeding; monitor for thyroid dysfunction; consider dental check-up\r\nbefore initiating treatment (risk of osteonecrosis of the jaw, seeMHRA/CHM advice);interactions:Appendix 1 (sunitinib)", "side-effects": "seesection 8.1; also\r\nabdominal pain, diarrhoea, constipation, anorexia, taste disturbance,\r\ndehydration; hypertension, oedema; dyspnoea, cough; fatigue, dizziness,\r\nheadache, insomnia, peripheral neuropathy, paraesthesia; hypothyroidism;\r\narthralgia, myalgia; increased lacrimation; epistaxis; skin, hair,\r\nand urine discoloration, hand-foot syndrome, dry skin, and rash; gastro-intestinal\r\nperforation, fistula formation (interrupt treatment if occurs) pancreatitis,\r\nosteonecrosis of the jaw (seeMHRA/CHM advice), hepatic failure, proteinuria\r\n(rarelynephrotic syndrome) and seizures reported", "doses": ["Gastro-intestinal stromal tumours and metastatic renal\r\ncell carcinoma, 50\u00a0mg once daily for 4 weeks, followed by a 2-week\r\ntreatment-free period to complete 6-week cycle; adjust dose in steps\r\nof 12.5\u00a0mg according to tolerability; dose range 25\u201375\u00a0mg daily", "Pancreatic neuroendocrine tumours, 37.5\u00a0mg once daily,\r\nwithout a treatment-free period; adjust dose in steps of 12.5\u00a0mg according\r\nto tolerability; max. dose 50\u00a0mg daily"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies; effective\r\ncontraception required during treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "HALOTHANE": {"indications": "seenotes above", "name": "HALOTHANE", "interactions": {"extra": "", "bad": 0, "interaction": "effects of  ergometrine on the parturient uterus reduced by halothane ", "name": "Halothane", "backrefs": ["Ergometrine", "Halothane"]}, "cautions": "seenotes above(important: seeHalothane Hepatotoxicity,above); avoid for dental procedures in those under 18 years unless treated\r\nin hospital (high risk of arrhythmia); avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "avoid if history of unexplained pyrexia or jaundice\r\nfollowing previous exposure to halothane", "doses": ["Induction of anaesthesia,by inhalationusing specifically calibrated vaporiser, in oxygen or nitrous oxide\u2013oxygen,adultandchildover\r\n1 month, initially 0.5% then increased gradually according to response\r\nto 2\u20134%", "Maintenance of anaesthesia,by inhalationusing\r\nspecifically calibrated vaporiser, in oxygen, oxygen-air, or nitrous\r\noxide\u2013oxygen,adultandchildover 1 month, 0.5\u20132%"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "VACCINES": {"interactions": {"extra": "For a general warning on live vaccines and high doses of corticosteroids or other immunosuppressive drugs, see section 14.1; for advice on live vaccines and immunoglobulins, see under Normal Immunoglobulin, section 14.5.1", "bad": 1, "interaction": "avoid concomitant use of  anakinra with live vaccines (see under Active Immunity, section 14.1)", "name": "Vaccines", "backrefs": ["Tocilizumab", "Typhoid Vaccine (oral)", "Belimumab", "Antibacterials", "Ustekinumab", "Vaccines", "Interferon Gamma", "Anakinra", "Abatacept"]}}, "HUMAN PAPILLOMA VIRUS VACCINES": {"indications": "seenotes aboveand under\r\npreparations", "name": "HUMAN PAPILLOMA VIRUS VACCINES", "cautions": "seesection 14.1", "side-effects": "seesection 14.1", "contra-indications": "seesection 14.1", "doses": ["Seenotes aboveand under\r\npreparations", "To avoid confusion, prescribers should specify\r\nthe brand to be dispensed"], "pregnancy": "not known to be harmful, but vaccination should be\r\npostponed until completion of pregnancy", "breast-feeding": "seesection 14.1"}, "APOMORPHINE HYDROCHLORIDE": {"indications": "refractory motor fluctuations in Parkinson\u2019s disease (\u2018off\u2019 episodes)\r\ninadequately controlled by co-beneldopa or co-careldopa or other dopaminergics\r\n(for capable and motivated patients under specialist supervision)", "name": "APOMORPHINE HYDROCHLORIDE", "renal impairment": "use with caution", "cautions": "seenotes above; pulmonary disease, cardiovascular disease, history of postural hypotension (special care on initiation); susceptibility to QT-interval prolongation; neuropsychiatric conditions; monitor hepatic, haemopoietic, renal, and cardiovascular function;with concomitantlevodopatest initially and every 6 months for haemolytic anaemia\r\nand thrombocytopenia (development\r\ncalls for specialist haematological care with dose reduction and possible\r\ndiscontinuation);interactions:Appendix 1 (apomorphine)", "side-effects": "seenotes above; also\r\nnausea, vomiting (seenotes above); yawning; drowsiness (including\r\nsudden onset of sleep), confusion, hallucinations;less commonlypostural hypotension, dyspnoea, dyskinesia during \u2018on\u2019 periods (may\r\nrequire discontinuation), haemolytic anaemia and thrombocytopenia\r\nwith levodopa (see Cautions), and rash;rarelyeosinophilia;\r\nperipheral oedema, compulsive behaviour (seenotes above), and\r\ndizziness also reported", "contra-indications": "respiratory depression, dementia, hypersensitivity to opioids, psychosis; avoid if \u2018on\u2019 response to levodopa marred by severe\r\ndyskinesia or dystonia", "hepatic impairment": "avoid", "doses": ["By subcutaneous injection,adultover 18 years, to determine threshold dose\r\n(see alsonotes above), initially 1\u00a0mg at the first sign\r\nof \u2018off\u2019 episode; if inadequate or no response after 30 minutes, then\r\na further 2\u00a0mg should be given; thereafter increase dose at minimum\r\n40-minute intervals until satisfactory response obtained; usual range\r\n3\u201330\u00a0mg daily in divided doses; subcutaneous infusion may be preferable\r\nin those requiring division of injections into more than 10 doses\r\ndaily; max. single dose 10\u00a0mg", "By continuous subcutaneous infusion,adultover 18 years, (those requiring division into\r\nmore than 10 injections daily) initially 1\u00a0mg/hour increased according\r\nto response (not more often than every 4 hours) in max. steps of 500\u00a0micrograms/hour,\r\nto usual rate of 1\u20134\u00a0mg/hour (15\u201360\u00a0micrograms/kg/hour); change infusion\r\nsite every 12 hours and give during waking hours only (tolerance may\r\noccur unless there is a 4-hour treatment-free period at night\u201424-hour\r\ninfusions not recommended unless severe night-time symptoms); intermittent\r\nbolus doses may be needed", "Total daily dose by either route (or combined\r\nroutes) max. 100\u00a0mg"], "pregnancy": "avoid unless clearly necessary", "breast-feeding": "no information available; may suppress lactation"}, "AMANTADINE HYDROCHLORIDE": {"indications": "see under Dose; parkinsonism (section 4.9.1)", "name": "AMANTADINE HYDROCHLORIDE", "renal impairment": "section 4.9.1", "cautions": "section 4.9.1", "side-effects": "section 4.9.1", "contra-indications": "section 4.9.1", "doses": ["Influenza A (see also notes above),adultandchildover\r\n10 years, treatment, 100\u00a0mg daily for 4\u20135 days; prophylaxis, 100\u00a0mg\r\ndaily usually for 6 weeksorwith influenza vaccination\r\nfor 2\u20133 weeks after vaccination"], "pregnancy": "section 4.9.1", "breast-feeding": "section 4.9.1"}, "FULVESTRANT": {"indications": "treatment of oestrogen-receptor-positive metastatic or locally advanced\r\nbreast cancer in postmenopausal women in whom disease progresses or\r\nrelapses while on, or after, other anti-oestrogen therapy", "name": "FULVESTRANT", "renal impairment": "manufacturer advises caution if creatinine clearance\r\nless than 30\u00a0mL/minute\u2014no information available", "side-effects": "nausea, vomiting, diarrhoea; venous thromboembolism;\r\nanorexia, headache, asthenia; urinary-tract infections; hot flushes;\r\nback pain; rash, injection-site reactions, hypersensitivity reactions;less commonlyvaginal haemorrhage, vaginal candidiasis,\r\nand leucorrhoea", "hepatic impairment": "manufacturer advises caution in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["By deep intramuscular injectioninto buttock,\r\n500\u00a0mg every 2 weeks for the first 3 doses, then 500\u00a0mg every month", "500\u00a0mg dose should be administered as one\r\n250-mg injection (slowly over 1\u20132 minutes) into each buttock"], "pregnancy": "manufacturer advises avoid\u2014increased incidence of\r\nfetal abnormalities and death inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "Botulism antitoxin": {"name": "Botulism antitoxin", "doses": ["prophylaxis, consult product literature"]}, "SODIUM STIBOGLUCONATE": {"indications": "leishmaniasis", "name": "SODIUM STIBOGLUCONATE", "renal impairment": "avoid in significant impairment", "cautions": "intravenous injections must be given\r\nslowly over 5 minutes (to reduce risk of local thrombosis) and stopped\r\nif coughing or substernal pain; mucocutaneous\r\ndisease (see below); monitor ECG before\r\nand during treatment; heart disease (withdraw if conduction disturbances occur); treat intercurrent infection (e.g. pneumonia)", "side-effects": "anorexia, nausea, vomiting, abdominal pain, diarrhoea;\r\nECG changes; coughing (see Cautions); headache, lethargy; arthralgia,\r\nmyalgia;rarelyjaundice, flushing, bleeding from\r\nnose or gum, substernal pain (see Cautions), vertigo, fever, sweating,\r\nand rash; also reported pancreatitis and anaphylaxis; pain and thrombosis\r\non intravenous administration, intramuscular injection also painful", "hepatic impairment": "use with caution", "doses": ["See notes above"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "amount probably too small to be harmful"}, "CELIPROLOL HYDROCHLORIDE": {"indications": "mild to moderate hypertension", "name": "CELIPROLOL HYDROCHLORIDE", "renal impairment": "reduce dose by half if eGFR 15\u201340\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see under Propranolol Hydrochloride; also hot\r\nflushes;rarelydepression, pneumonitis", "contra-indications": "see underPropranolol Hydrochloride", "hepatic impairment": "consider dose reduction", "doses": ["200\u00a0mg once daily in the morning, increased to 400\u00a0mg\r\nonce daily if necessary"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PHENYLEPHRINE HYDROCHLORIDE": {"indications": "acute hypotension (see notes above); priapism\r\n(section 7.4.5) [unlicensed\r\nindication]", "name": "PHENYLEPHRINE HYDROCHLORIDE", "cautions": "see underNoradrenaline; longer duration of action than noradrenaline (norepinephrine), see below; coronary disease", "side-effects": "see under Noradrenaline; also tachycardia or reflex\r\nbradycardia", "contra-indications": "see underNoradrenaline; severe hyperthyroidism", "doses": ["By subcutaneousorintramuscular injection, 2\u20135\u00a0mg, followed if necessary\r\nafter at least 15 minutes by further doses of 1\u201310\u00a0mg", "By slow intravenous injectionof\r\na 1\u00a0mg/mL solution, 100\u2013500\u00a0micrograms repeated as necessary after\r\nat least 15 minutes", "By intravenous infusion, initial\r\nrate up to 180\u00a0micrograms/minute reduced to 30\u201360\u00a0micrograms/minute\r\naccording to response"], "pregnancy": "avoid if possible; malformations reported following\r\nuse in first trimester; fetal hypoxia and bradycardia reported in\r\nlate pregnancy and labour"}, "HAEMOPHILUS TYPE B CONJUGATE VACCINE": {"indications": "seenotes above", "name": "HAEMOPHILUS TYPE B CONJUGATE VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1; also\r\natopic dermatitis and hypotonia", "contra-indications": "seesection 14.1", "doses": ["Primary immunisation, see underDiphtheria", "Booster dose, seenotes aboveand under\r\npreparation below"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "BUSULFAN": {"indications": "see notes above", "name": "BUSULFAN", "interactions": {"extra": "", "bad": 0, "interaction": " itraconazole inhibits metabolism of busulfan (increased risk of toxicity)", "name": "Busulfan", "backrefs": ["Busulfan", "Tioguanine"]}, "cautions": "seesection 8.1andnotes above; monitor cardiac function; previous radiation therapy; avoid in acute\r\nporphyria (but seesection 9.8.2);interactions:Appendix 1\r\n(busulfan)", "side-effects": "seesection 8.1andnotes above; also hepatotoxicity (including\r\nhepatic veno-occlusive disease, hyperbilirubinaemia, jaundice and\r\nfibrosis); cardiac tamponade in thalassaemia; pneumonia; skin hyperpigmentation", "hepatic impairment": "manufacturer advises monitor liver function\u2014no information\r\navailable", "doses": ["Chronic myeloid leukaemia, induction of remission,by mouth, 60\u00a0micrograms/kg daily (max. 4\u00a0mg); maintenance,\r\nusually 0.5\u20132\u00a0mg daily", "Conditioning treatment before haematopoietic stem-cell\r\ntransplantation,by mouthorby intravenous infusion, consult product literature"], "pregnancy": "avoid (teratogenic inanimals);\r\nmanufacturers advise effective contraception during and for 6 months\r\nafter treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "INDACATEROL": {"indications": "maintenance treatment of chronic obstructive\r\npulmonary disease", "name": "INDACATEROL", "cautions": "seenotes above; convulsive disorders", "side-effects": "seenotes above; also peripheral oedema, cough,\r\npharyngolaryngeal pain, nasopharyngitis, sinusitis, rhinorrhoea;less commonlyatrial fibrillation, non-cardiac chest pain,\r\nparaesthesia", "hepatic impairment": "use with caution in severe impairment\u2014no information\r\navailable", "doses": ["By inhalation of powder,adultover 18 years, 150\u00a0micrograms once daily, increased\r\nto max. 300\u00a0micrograms once daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014present in milk inanimalstudies"}, "DEFERASIROX": {"indications": "seenotes above", "name": "DEFERASIROX", "renal impairment": "reduce dose by 10\u00a0mg/kg if eGFR 60\u201390\u00a0mL/minute/1.73\u00a0m2and if serum creatinine increased by more than 33% of baseline\r\nmeasurement on 2 consecutive occasions\u2014interrupt treatment if deterioration\r\nin renal function persists after dose reduction; avoid if eGFR less\r\nthan 60\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  repaglinide increased by deferasirox ", "name": "Deferasirox", "backrefs": ["Deferasirox"]}, "cautions": "eye and ear examinations required before\r\ntreatment and annually during treatment; monitor body-weight, height, and sexual development in children annually; monitor serum-ferritin concentration monthly; elderly (increased risk of side-effects); risk of gastro-intestinal ulceration and haemorrhage; platelet count less than 50 \u00d7 109/litre; consider treatment interruption if unexplained cytopenia occurs; not recommended in conditions which may reduce life\r\nexpectancy (e.g. high-risk myelodysplastic syndromes); history of liver cirrhosis; test liver function before treatment, then every 2 weeks during the\r\nfirst month, and then monthly; measure\r\nbaseline serum creatinine and monitor renal function weekly during\r\nthe first month of treatment and monthly thereafter; test for proteinuria monthly;interactions:Appendix 1 (deferasirox)", "side-effects": "gastro-intestinal disturbances (including ulceration\r\nand fatal haemorrhage); headache; proteinuria; pruritus, rash;less commonlyhepatitis, cholelithiasis, oedema, fatigue,\r\nanxiety, sleep disorder, dizziness, pyrexia, pharyngitis, glucosuria,\r\nrenal tubulopathy, disturbances of hearing and vision (including lens\r\nopacity and maculopathy), and skin pigmentation; hepatic failure,\r\nacute renal failure, blood disorders (including agranulocytosis, neutropenia,\r\npancytopenia, and thrombocytopenia), hypersensitivity reactions (including\r\nanaphylaxis and angioedema), alopecia also reported", "hepatic impairment": "manufacturer advises caution\u2014no information available;\r\navoid in severe impairment", "doses": ["adultandchildover 2 years initially 10\u201330\u00a0mg/kg once daily\r\naccording to serum-ferritin concentration and amount of transfused\r\nblood (consult product literature); maintenance, adjust dose every\r\n3\u20136 months in steps of 5\u201310\u00a0mg/kg according to serum-ferritin concentration;\r\nusual max. 30\u00a0mg/kg daily, but may be increased to max. 40\u00a0mg/kg daily\r\nand reduced in steps of 5\u201310\u00a0mg/kg once control achieved"], "pregnancy": "manufacturer advises avoid unless essential\u2014toxicity\r\ninanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "MARAVIROC": {"indications": "CCR5-tropic HIV infection in combination\r\nwith other antiretroviral drugs in patients previously treated with\r\nantiretrovirals", "name": "MARAVIROC", "renal impairment": "if eGFR less than 80\u00a0mL/minute/1.73\u00a0m2, consult\r\nproduct literature", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir increases plasma concentration of maraviroc ", "name": "Maraviroc", "backrefs": ["Maraviroc"]}, "cautions": "cardiovascular disease; chronic hepatitis B or C;interactions:Appendix 1 (maraviroc)", "side-effects": "nausea, diarrhoea, abdominal pain, flatulence,\r\nanorexia, depression, insomnia, malaise, headache, anaemia, rash;less commonlyseizures, renal failure, proteinuria, myositis;rarelyhepatitis, angina, pancytopenia, granulocytopenia,\r\nStevens-Johnson syndrome; see alsoOsteonecrosis", "hepatic impairment": "manufacturer advises caution", "doses": ["adultover 18 years, 300\u00a0mg\r\ntwice daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "seeBreast-feeding"}, "ERLOTINIB": {"indications": "seenotes above", "name": "ERLOTINIB", "renal impairment": "manufacturer advises avoid in severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  lansoprazole advised by manufacturer of erlotinib ", "name": "Erlotinib", "backrefs": ["Nizatidine", "Erlotinib", "Famotidine", "Ranitidine"]}, "cautions": "seesection 8.1; pre-existing liver disease or concomitant\r\nuse with hepatotoxic drugs\u2014monitor liver function; dose adjustment\r\nmay be necessary if smoking started or stopped during treatment;interactions:Appendix 1 (erlotinib)", "side-effects": "seesection 8.1andnotes above; also diarrhoea, abdominal pain, dyspepsia, flatulence; anorexia,\r\ndepression, neuropathy, headache; fatigue, rigor; conjunctivitis;\r\npruritus, dry skin;less commonlygastro-intestinal\r\nperforation, interstitial lung disease\u2014discontinue if unexplained\r\nsymptoms such as dyspnoea, cough or fever occur; eyelash changes;rarelyhepatic failure;very rarelycorneal\r\nperforation or ulceration, Stevens-Johnson syndrome, and toxic epidermal\r\nnecrolysis", "hepatic impairment": "manufacturer advises caution in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["Non-small cell lung cancer, 150\u00a0mg once daily", "Pancreatic cancer, 100\u00a0mg once daily in combination\r\nwith gemcitabine"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies; effective contraception required during and for at least\r\n2 weeks after treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "AMITRIPTYLINE HYDROCHLORIDE": {"indications": "depressive illness (but not recommended, see\r\nnotes above); neuropathic pain [unlicensed] (section 4.7.3); migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2)", "name": "AMITRIPTYLINE HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nabdominal pain, stomatitis, palpitation, oedema, hypertension, restlessness,\r\nfatigue, mydriasis, and increased intra-ocular pressure; high rate\r\nof fatality in overdose\u2014seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["depression with anxiety,adultover 18 years, 1 tablet 3 times daily; an additional\r\ntablet may be taken at bedtime when required"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "seenotes above"}, "DEXTRAN 70": {"indications": "short-term blood volume expansion", "name": "DEXTRAN 70", "cautions": "seenotes above; can interfere with some laboratory tests (seealso above); where possible, monitor central venous pressure", "side-effects": "seenotes above", "hepatic impairment": "use with caution in severe impairment", "doses": ["See under preparation below"], "pregnancy": "avoid\u2014reports of anaphylaxis in mother causing fetal\r\nanoxia, neurological damage and death"}, "OXYBUTYNIN HYDROCHLORIDE": {"indications": "urinary frequency, urgency and incontinence, neurogenic bladder instability,\r\nand nocturnal enuresis associated with overactive bladder", "name": "OXYBUTYNIN HYDROCHLORIDE", "renal impairment": "manufacturer advises caution", "cautions": "seenotes above; acute porphyria  (section 9.8.2)", "side-effects": "seenotes above; alsoless commonlyanorexia, facial flushing;rarelynight terrors; application site reactions withpatches; also reported cognitive impairment", "contra-indications": "seenotes above", "hepatic impairment": "manufacturer advises caution", "doses": ["initially 5\u00a0mg once daily, adjusted according to response\r\nin steps of 5\u00a0mg at weekly intervals; max. 20\u00a0mg once daily;childover 6 years, neurogenic bladder instability,\r\ninitially 5\u00a0mg once daily, adjusted according to response in steps\r\nof 5\u00a0mg at weekly intervals; max. 15\u00a0mg once daily"], "pregnancy": "manufacturers advise avoid unless essential\u2014toxicity\r\ninanimalstudies", "breast-feeding": "manufacturers advise avoid\u2014present in milk"}, "LEVOCETIRIZINE HYDROCHLORIDE": {"indications": "symptomatic relief of allergy such as hay fever, urticaria", "name": "LEVOCETIRIZINE HYDROCHLORIDE", "renal impairment": "5\u00a0mg on alternate days if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; 5\u00a0mg every 3 days if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "seenotes above;very rarelyweight gain", "contra-indications": "seenotes above", "doses": ["adultandchildover 6 years, 5\u00a0mg once daily;childunder 6 years seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLUVASTATIN": {"indications": "adjunct to diet in primary hypercholesterolaemia or combined (mixed)\r\nhyperlipidaemia (types IIa and IIb); prevention of coronary events\r\nafter percutaneous coronary intervention", "name": "FLUVASTATIN", "renal impairment": "manufacturer advises doses above 40\u00a0mg daily should be\r\ninitiated with caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "combination of  phenytoin with fluvastatin may increase plasma concentration of either drug (or both)", "name": "Fluvastatin", "backrefs": ["Fluvastatin"]}, "cautions": "seenotes above", "side-effects": "see notes above; alsovery rarelyvasculitis", "hepatic impairment": "seenotes above", "doses": ["80\u00a0mg once daily (dose form not appropriate for initial\r\ndose titration)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "RABEPRAZOLE SODIUM": {"indications": "see under Dose", "name": "RABEPRAZOLE SODIUM", "cautions": "seenotes above;interactions:Appendix 1 (proton pump inhibitors)", "side-effects": "seenotes above; also cough, influenza-like syndrome,\r\nand rhinitis;less commonlychest pain and nervousness;rarelyanorexia and weight gain", "hepatic impairment": "manufacturer advises caution in severe hepatic dysfunction", "doses": ["Benign gastric ulcer, 20\u00a0mg daily in the morning for 8\r\nweeks", "Duodenal ulcer, 20\u00a0mg daily in the morning for 4 weeks", "Duodenal and benign gastric ulcer associated withHelicobacter pylori, seeRecommended Regimens forHelicobacter pyloriEradication", "Gastro-oesophageal reflux disease, 20\u00a0mg once daily for 4\u20138\r\nweeks; maintenance 10\u201320\u00a0mg daily; symptomatic treatment in the absence\r\nof oesophagitis, 10\u00a0mg daily for up to 4 weeks, then 10\u00a0mg daily when\r\nrequired", "Zollinger\u2013Ellison syndrome, initially 60\u00a0mg once daily adjusted\r\naccording to response (max. 120\u00a0mg daily); doses above 100\u00a0mg daily\r\ngiven in 2 divided doses", "childnot recommended"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "ULIPRISTAL": {"interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  ritonavir advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)", "name": "Ulipristal", "backrefs": ["Ulipristal"]}}, "CAPECITABINE": {"indications": "seenotes above", "name": "CAPECITABINE", "renal impairment": "reduce starting dose of 1.25\u00a0g/m2to 75% if\r\ncreatinine clearance 30\u201350\u00a0mL/minute; avoid if creatinine clearance\r\nless than 30\u00a0mL/minute", "interactions": {"extra": "Capecitabine is a prodrug of fluorouracil", "bad": 1, "interaction": "avoidance of  allopurinol advised by manufacturer of capecitabine ", "name": "Capecitabine", "backrefs": ["Capecitabine"]}, "cautions": "seesection 8.1; history of significant cardiovascular\r\ndisease, arrhythmias; monitor plasma-calcium concentration; diabetes mellitus;interactions:Appendix\r\n1 (fluorouracil)", "side-effects": "seesection 8.1; hand\u2013foot (desquamative) syndrome;\r\ndiarrhoea;also reportedQT-prolongation", "hepatic impairment": "manufacturer advises avoid in severe impairment", "doses": ["Stage III colon cancer, adjuvant following surgery,\r\nmonotherapy,adultover 18 years 1.25\u00a0g/m2twice daily for 14 days, subsequent courses repeated after\r\na 7-day interval; recommended duration of treatment 6 months", "Stage III colon cancer, adjuvant following surgery,\r\nin combination therapy,adultover\r\n18 years 0.8\u20131\u00a0g/m2twice daily for 14 days, subsequent\r\ncourses repeated after a 7\u2013day interval; recommended duration of treatment\r\n6 months", "Metastatic colorectal cancer, monotherapy,adultover 18 years 1.25\u00a0g/m2twice daily\r\nfor 14 days, subsequent courses repeated after a 7-day interval", "Metastatic colorectal cancer, in combination therapy,adultover 18 years 0.8\u20131\u00a0g/m2twice daily\r\nfor 14 days, subsequent courses repeated after a 7-day interval", "Advanced gastric cancer, in combination with a platinum-based\r\nregimen,adultover 18 years 0.8\u20131\u00a0g/m2twice daily for 14 days, subsequent courses repeated after\r\na 7-day intervalor625\u00a0mg/m2twice daily given continuously", "Locally advanced or metastatic breast cancer, monotherapy\r\nor in combination with docetaxel,adultover 18 years 1.25\u00a0g/m2twice daily for 14 days, subsequent\r\ncourses repeated after a 7-day interval", "Adjust dose according to tolerability\u2014consult\r\nproduct literature"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "HYDROCORTISONE BUTYRATE": {"indications": "severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potentcorticosteroids; psoriasis,\r\nseenotes above", "name": "HYDROCORTISONE BUTYRATE", "cautions": "seenotes above", "side-effects": "see notes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily"]}, "PROPAMIDINE ISETIONATE": {"indications": "local treatment of infections (but seenotes above)", "name": "PROPAMIDINE ISETIONATE", "doses": ["apply 1\u20132 times daily"]}, "CYCLOPHOSPHAMIDE": {"indications": "seenotes above; rheumatoid arthritis (section 10.1.3)", "name": "CYCLOPHOSPHAMIDE", "renal impairment": "reduce dose if serum creatinine concentration greater\r\nthan 120\u00a0micromol/litre", "interactions": {"extra": "", "bad": 0, "interaction": " itraconazole possibly increases side-effects of cyclophosphamide ", "name": "Cyclophosphamide", "backrefs": ["Cyclophosphamide"]}, "cautions": "seesection 8.1andnotes above; previous or concurrent mediastinal irradiation\u2014risk of cardiotoxicity; diabetes mellitus; avoid in\r\nacute porphyria (but seesection 9.8.2);interactions:Appendix 1\r\n(cyclophosphamide)", "side-effects": "seesection 8.1and notes above; also anorexia;\r\npancreatitis; cardiotoxicity at high doses; interstitial pulmonary\r\nfibrosis; inappropriate secretion of anti-diuretic hormone, disturbances\r\nof carbohydrate metabolism; urothelial toxicity; pigmentation of palms,\r\nnails, and soles:rarelyhepatotoxicity and renal\r\ndysfunction", "contra-indications": "haemorrhagic cystitis", "hepatic impairment": "reduce dose\u2014consult local treatment protocol for details", "doses": ["SeeDoses"], "pregnancy": "avoid (manufacturer advises effective contraception\r\nduring and for at least 3 months after treatment in men or women);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding during and for 36\r\nhours after stopping treatment"}, "PYRAZINAMIDE": {"indications": "tuberculosis in combination with other drugs [unlicensed]", "name": "PYRAZINAMIDE", "renal impairment": "monitor for gout; 25\u201330\u00a0mg/kg 3 times a week if eGFR\r\nless than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "effects of  sulfinpyrazone antagonised by pyrazinamide ", "name": "Pyrazinamide", "backrefs": ["Pyrazinamide"]}, "cautions": "see Monitoring innotes above; also diabetes; gout (avoid in acute attack);interactions:Appendix 1\r\n(pyrazinamide)", "side-effects": "hepatotoxicity including fever, anorexia, hepatomegaly,\r\nsplenomegaly, jaundice, liver failure; nausea, vomiting, flushing,\r\ndysuria, arthralgia, sideroblastic anaemia, thrombocytopenia, rash\r\nand occasionally photosensitivity", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "monitor hepatic function\u2014idiosyncratic hepatotoxicity\r\nmore common; avoid in severe hepatic impairment; see also Hepatic\r\nDisorders above", "doses": ["Seenotes above"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk; see alsoPregnancy", "breast-feeding": "amount too small to be harmful; see alsoBreast-feeding"}, "BENDROFLUMETHIAZIDE": {"indications": "oedema, hypertension (see also notes above)", "name": "BENDROFLUMETHIAZIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Oedema, initially 5\u201310\u00a0mg daily in the morningoron alternate days; maintenance 5\u201310\u00a0mg 1\u20133 times weekly", "Hypertension, 2.5\u00a0mg daily in the morning; higher doses rarely\r\nnecessary (see notes above)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DANTROLENE SODIUM": {"indications": "malignant hyperthermia; chronic\r\nsevere spasticity of voluntary muscle (section 10.2.2)", "name": "DANTROLENE SODIUM", "cautions": "avoid extravasation (risk of tissue necrosis);interactions:Appendix 1 (muscle relaxants)", "side-effects": "hepatotoxicity, pulmonary oedema, dizziness, weakness,\r\nand injection-site reactions including erythema, rash, swelling, and\r\nthrombophlebitis", "doses": ["By rapid intravenous injection,adult, initially 2\u20133\u00a0mg/kg, then 1\u00a0mg/kg repeated\r\nas required to a cumulative max. of 10\u00a0mg/kg;child1 month\u201318 years seeBNF for Children"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "present in milk\u2014 use only if potential benefit\r\noutweighs risk"}, "HISTRELIN": {"side-effects": "seenotes above; also\r\nhepatic disorder, dyspnoea, depression, asthenia, elevated blood glucose-concentration,\r\nincreased urinary frequency, hypertrichosis;less commonlyhypercholesterolaemia, palpitation, ventricular extrasystole, haematoma,\r\ntremor, anaemia, renal failure, nephrolithiasis, hypercalcaemia", "indications": "advanced prostate cancer", "name": "HISTRELIN", "cautions": "seenotes above; monitor patients at high risk of metabolic disease (e.g. bone disease,\r\nworsening diabetes) or cardiovascular disease before and during treatment; risk of ureteric obstruction and spinal\r\ncord compression", "doses": ["By subcutaneous implantationinto upper\r\narm, 1\u00a0implant (50\u00a0mg) every 12 months; remove after 12 months of\r\ntreatment", "Avoid wetting arm containing implant\r\nfor 24 hours and avoid lifting heavy objects or strenuous physical\r\nactivity for 7 days after implantation"]}, "CEPHALOSPORINS": {"interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of cephalosporins (increased plasma concentration)", "name": "Cephalosporins", "backrefs": ["Aminoglycosides", "Cephalosporins"]}}, "BUPROPION": {"interactions": {"extra": "", "bad": 0, "interaction": " ritonavir reduces plasma concentration of bupropion ", "name": "Bupropion", "backrefs": ["Bupropion"]}}, "NABUMETONE": {"indications": "pain and inflammation in osteoarthritis and rheumatoid arthritis", "name": "NABUMETONE", "renal impairment": "avoid in severe impairment; see alsonotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["1\u00a0g at night; severe or persistent symptoms 0.5\u20131\u00a0g in\r\nmorning and 1\u00a0g at night;elderly0.5\u20131\u00a0g\r\ndaily;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid; see alsonotes above"}, "CHLORAMBUCIL": {"indications": "seenotes above", "name": "CHLORAMBUCIL", "cautions": "seesection 8.1andnotes above; history of epilepsy and children with nephrotic syndrome\r\n(increased risk of seizures); avoid in acute\r\nporphyria (but seesection 9.8.2)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "manufacturer advises consider dose reduction in severe\r\nimpairment\u2014limited information available", "doses": ["SeeDoses"], "pregnancy": "avoid; manufacturer advises effective contraception\r\nduring treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ALEMTUZUMAB": {"indications": "see notes above", "name": "ALEMTUZUMAB", "cautions": "seenotes above\u2014for full details consult product literature", "side-effects": "see notes above\u2014for full details (including monitoring\r\nand management of side-effects) consult product literature", "contra-indications": "for full details consult product\r\nliterature", "doses": ["Consult product literature"], "pregnancy": "avoid; use effective contraception during and for\r\n6 months after treatment in men or women", "breast-feeding": "avoid breast-feeding during treatment and for\r\nat least 4 weeks after administration"}, "PHENOBARBITAL": {"indications": "all forms of epilepsy except typical absence\r\nseizures; status epilepticus (section 4.8.2)", "name": "PHENOBARBITAL", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  montelukast reduced by phenobarbital ", "name": "Phenobarbital", "backrefs": ["Phenobarbital", "Montelukast"]}, "cautions": "seenotes above;elderly; debilitated; children; respiratory depression (avoid if severe); avoid abrupt withdrawal (dependence\r\nwith prolonged use); history of drug or alcohol abuse; consider vitamin D supplementation in patients who are immobilised\r\nfor long periods or who have inadequate sun exposure or dietary intake\r\nof calcium; avoid in acute porphyria (section 9.8.2);interactions:seeInteractionsin section 4.8.1 and Appendix 1 (phenobarbital)", "side-effects": "hepatitis, cholestasis; hypotension; respiratory\r\ndepression; behavioural disturbances, nystagmus, irritability, drowsiness,\r\nlethargy, depression, ataxia, paradoxical excitement, hallucinations,\r\nimpaired memory and cognition, hyperactivity particularly in the elderly\r\nand in children; osteomalacia (see Cautions); megaloblastic anaemia\r\n(may be treated withfolic acid), agranulocytosis,\r\nthrombocytopenia; allergic skin reactions;very rarelyStevens-Johnson syndrome and toxic epidermal necrolysis; suicidal\r\nideation;Antiepileptic Hypersensitivity\r\nSyndrome;overdosage:seeEmergency Treatment of Poisoning", "hepatic impairment": "may precipitate coma; avoid in severe impairment", "doses": ["By mouth, 60\u2013180\u00a0mg at night;child5\u20138\u00a0mg/kg daily"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "TOLCAPONE": {"indications": "adjunct to co-beneldopa or co-careldopa in Parkinson\u2019s disease with\r\n\u2018end-of-dose\u2019 motor fluctuations if another inhibitor of peripheral\r\ncatechol-O-methyltransferase inappropriate (under\r\nspecialist supervision)", "name": "TOLCAPONE", "renal impairment": "caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "avoid concomitant use of  MAOIs with tolcapone ", "name": "Tolcapone", "backrefs": ["Tolcapone"]}, "cautions": "avoid abrupt withdrawal; most patients receiving more than 600\u00a0mg levodopa\r\ndaily require reduction of levodopa dose by about 30%;interactions:Appendix 1 (tolcapone)", "side-effects": "diarrhoea, constipation, dyspepsia, abdominal\r\npain, nausea, vomiting, anorexia, xerostomia, hepatotoxicity (see\r\nabove); chest pain; confusion, dystonia, dyskinesia, drowsiness, headache,\r\ndizziness, sleep disturbances, excessive dreaming, hallucinations;\r\nsyncope; urine discoloration; sweating; neuroleptic malignant syndrome\r\nand rhabdomyolysis reported on dose reduction or withdrawal", "contra-indications": "severe dyskinesia, phaeochromocytoma, previous history of\r\nneuroleptic malignant syndrome, rhabdomyolysis, or hyperthermia", "hepatic impairment": "avoid; see also under Cautions", "doses": ["100\u00a0mg 3 times daily, leave 6 hours between each dose;\r\nmax. 200\u00a0mg 3 times daily in exceptional circumstances; first daily\r\ndose should be taken at the same time as levodopa with dopa-decarboxylase\r\ninhibitor", "Continue beyond 3 weeksonlyif substantial improvement"], "pregnancy": "toxicity inanimalstudies\u2014use only\r\nif potential benefit outweighs risk", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "BETAMETHASONE SODIUM PHOSPHATE": {"side-effects": "seenotes above", "indications": "non-infected inflammatory\r\nconditions of nose", "name": "BETAMETHASONE SODIUM PHOSPHATE", "cautions": "seenotes above", "doses": ["nose, 2\u20133 drops into each nostril twice\r\ndaily;ear,section\r\n12.1.1;eye,section 11.4.1"]}, "Diagnostic agents": {"name": "Diagnostic agents", "doses": ["by intradermal injection, for Mantoux test,\r\n2\u00a0units (0.1\u00a0mL of 20\u00a0units/mL strength) for routine Mantoux test;\r\nif first test is negative and a further test is considered appropriate\r\n10\u00a0units (0.1\u00a0mL of 100\u00a0units/mL strength)"]}, "CILAZAPRIL": {"indications": "essential hypertension; congestive heart failure\r\n(adjunct\u2014seesection 2.5.5)", "name": "CILAZAPRIL", "renal impairment": "seenotes above; max.\r\ninitial dose 500\u00a0micrograms once daily (do not exceed 2.5\u00a0mg once\r\ndaily) if eGFR 10\u201340\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less\r\nthan 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; alsoless commonlydry mouth, decreased appetite, aphthous stomatitis, angina, tachycardia,\r\npalpitation, flushing, dyspnoea, impotence, excessive sweating;rarelyglossitis, bronchitis, interstitial lung disease,\r\ngynaecomastia, peripheral neuropathy, Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; max.\r\ndose 500\u00a0micrograms daily in liver cirrhosis; manufacturer advises\r\navoid in ascites", "doses": ["Hypertension, initially 1\u00a0mg once daily (reduced to 500\u00a0micrograms\r\ndaily if used in addition to diuretic (see notes above),\r\nor in cardiac decompensation, in severe hypertension, in volume depletion,\r\nin the elderly, or in renal impairment), then adjusted according to\r\nresponse; usual maintenance dose 2.5\u20135\u00a0mg once daily; max. 5\u00a0mg daily", "Heart failure (adjunct), initially 500\u00a0micrograms once daily\r\nunder close medical supervision (see notes above),\r\nincreased at weekly intervals to 1\u20132.5\u00a0mg once daily if tolerated;\r\nmax. 5\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PODOPHYLLOTOXIN": {"indications": "see under preparations", "name": "PODOPHYLLOTOXIN", "cautions": "avoid normal skin and open\r\nwounds; keep away from face; very irritant to eyes", "side-effects": "local irritation", "doses": ["condylomata acuminata affecting the penis or the female\r\nexternal genitalia, apply twice daily for 3 consecutive days; treatment\r\nmay be repeated at weekly intervals if necessary for a total of four\r\n3-day treatment courses; direct medical supervision for\r\nlesions greater than 4\u00a0cm2; max. 50 single\r\napplications (\u2018loops\u2019) per session (consult product literature);child2\u201318 years seeBNF for Children"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA": {"indications": "see under Dose below", "name": "METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA", "cautions": "seeEpoetin", "side-effects": "seeEpoetin; also hot flushes reported", "contra-indications": "seeEpoetin", "doses": ["Symptomatic anaemia associated with chronic kidney disease\r\nin patients on dialysis andnotcurrently treated\r\nwith erythropoietins (see alsoMHRA/CHM advice),adultover 18 years,by subcutaneousorintravenous injection, initially\r\n600\u00a0nanograms/kg once every 2 weeks, adjusted according to response\r\nat intervals of at least 4 weeks; maintenance dose of double the previous\r\nfortnightly dose may be given every 4 weeks", "Symptomatic anaemia associated with chronic kidney disease in\r\npatientsnoton dialysis andnotcurrently treated with erythropoietins (see alsoMHRA/CHM advice),adultover 18 years,by subcutaneous injection, initially 1.2\u00a0micrograms/kg once every 4 weeks,alternativelyby subcutaneousorintravenous\r\ninjection, initially 600\u00a0nanograms/kg once every 2 weeks;\r\ndose adjusted according to response at intervals of at least 4 weeks;\r\npatients treated once every 2 weeks may be given a maintenance dose\r\nof double the previous fortnightly dose every 4 weeks", "Symptomatic anaemia associated with chronic kidney disease in\r\npatients currently treated with erythropoietins (see alsoMHRA/CHM advice),adultover 18 years,by subcutaneousorintravenous injection, consult\r\nproduct literature", "Subcutaneous route preferred in patients\r\nnot on haemodialysis. Reduce dose by approximately 25% if rise in\r\nhaemoglobin concentration exceeds 2\u00a0g/100\u00a0mL over 4 weeks, or if haemoglobin\r\nconcentration approaches or exceeds 12\u00a0g/100\u00a0mL; if haemoglobin concentration\r\ncontinues to rise, despite dose reduction, suspend treatment until\r\nhaemoglobin concentration decreases and then restart at a dose approximately\r\n25% lower than the previous dose"], "pregnancy": "no evidence of harm inanimalstudies\u2014manufacturer\r\nadvises caution", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014present in milk inanimalstudies"}, "ALMOTRIPTAN": {"indications": "treatment of acute migraine", "name": "ALMOTRIPTAN", "renal impairment": "max. 12.5\u00a0mg in 24 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of almotriptan (increased risk of toxicity)", "name": "Almotriptan", "backrefs": ["Almotriptan"]}, "cautions": "see under5HT1-receptor agonistsabove; sensitivity to sulfonamides;interactions:Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; also transient increase in blood pressure,\r\ndrowsiness;less commonlydiarrhoea, dyspepsia, dry\r\nmouth, chest pain, palpitation, paraesthesia, headache, myalgia, bone\r\npain, tinnitus;very rarelymyocardial infarction,\r\nand tachycardia; seizures also reported", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; previous cerebrovascular accident or transient\r\nischaemic attack; peripheral vascular disease", "hepatic impairment": "caution in mild to moderate impairment; avoid in severe\r\nimpairment", "doses": ["12.5\u00a0mg as soon as possible after onset repeated after\r\n2 hours if migraine recurs (patient not responding should not take\r\nsecond dose for same attack); max. 25\u00a0mg in 24 hours;childandadolescentunder 18 years not recommended"], "pregnancy": "seenotes above", "breast-feeding": "present in milk inanimalstudies\u2014withhold\r\nbreast-feeding for 24 hours"}, "AMINOPHYLLINE": {"indications": "reversible airways obstruction, severe\r\nacute asthma", "name": "AMINOPHYLLINE", "cautions": "see underTheophylline", "side-effects": "see underTheophylline; also allergy to ethylenediamine can cause urticaria, erythema,\r\nand exfoliative dermatitis; hypotension, arrhythmias, and convulsions\r\nespecially if given rapidly by intravenous injection", "hepatic impairment": "see underTheophylline", "doses": ["initially 1 tablet twice daily, increased after 1 week\r\nto 2 tablets twice daily if necessary"], "pregnancy": "see underTheophylline", "breast-feeding": "see underTheophylline"}, "1.7.2 Compound haemorrhoidal preparations with corticosteroids": {"name": "1.7.2 Compound haemorrhoidal preparations with corticosteroids", "doses": ["apply several times daily; short-term use only"]}, "PROGUANIL HYDROCHLORIDE": {"indications": "chemoprophylaxis of malaria", "name": "PROGUANIL HYDROCHLORIDE", "renal impairment": "100\u00a0mg once daily if eGFR 20\u201360\u00a0mL/minute/1.73\u00a0m2; 50\u00a0mg on alternate days if eGFR 10\u201320\u00a0mL/minute/1.73\u00a0m2; 50\u00a0mg once weekly if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2(increased risk of haematological toxicity)", "cautions": "interactions:Appendix 1 (proguanil)", "side-effects": "mild gastric intolerance, diarrhoea, and constipation;\r\noccasionally mouth ulcers and stomatitis;very rarelycholestasis, vasculitis, skin reactions, and hair loss", "doses": ["Prophylaxis of malaria, preferably started 1 week before\r\nentering endemic area and continued for 4 weeks after leaving (see\r\nnotes above), 200\u00a0mg once daily;infantup to 12 weeks body-weight under 6\u00a0kg, 25\u00a0mg once daily; 12 weeks\u20131\r\nyear body-weight 6\u201310\u00a0kg, 50\u00a0mg once daily;child1\u20134 years body-weight 10\u201316\u00a0kg, 75\u00a0mg once daily; 4\u20138 years body-weight\r\n16\u201325\u00a0kg, 100\u00a0mg once daily; 8\u201313 years, body-weight 25\u201345\u00a0kg, 150\u00a0mg\r\nonce daily; over 13 years body-weight over 45\u00a0kg, adult dose", "Warn travellers aboutimportanceof avoiding mosquito bites,importanceof taking\r\nprophylaxis regularly, andimportanceof immediate\r\nvisit to doctor if ill within 1 year andespeciallywithin 3 months of return. For details, see notes above", "Proguanil doses in BNF may differ from those\r\nin product literature."], "pregnancy": "benefit of prophylaxis in malaria outweighs risk;\r\nadequate folate supplements should be given to mother; see alsoProphylaxis Against Malaria", "breast-feeding": "amount in milk probably too small to be harmful\r\nwhen used for malaria prophylaxis; see alsoProphylaxis Against Malaria"}, "NEFOPAM HYDROCHLORIDE": {"indications": "moderate pain", "name": "NEFOPAM HYDROCHLORIDE", "renal impairment": "caution", "cautions": "elderly, urinary\r\nretention;interactions:Appendix 1\r\n(nefopam)", "side-effects": "nausea, nervousness, urinary retention, dry mouth,\r\nlightheadedness;less commonlyvomiting, blurred\r\nvision, drowsiness, sweating, insomnia, tachycardia, headache; confusion\r\nand hallucinationsalso reported; may colour urine\r\n(pink)", "contra-indications": "convulsive disorders; not indicated for myocardial infarction", "hepatic impairment": "caution", "doses": ["By mouth, initially 60\u00a0mg (elderly30\u00a0mg) 3 times daily, adjusted\r\naccording to response; usual range 30\u201390\u00a0mg 3 times daily;childnot recommended"], "pregnancy": "no information available\u2014avoid unless no safer treatment"}, "PRIMIDONE": {"indications": "all forms of epilepsy except typical absence seizures; essential\r\ntremor (section 4.9.3)", "name": "PRIMIDONE", "renal impairment": "seePhenobarbital", "cautions": "see underPhenobarbital;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (phenobarbital)", "side-effects": "seePhenobarbital; also nausea, visual\r\ndisturbances;less commonlyvomiting, headache, dizziness;rarelypsychosis, lupus erythematosus, arthralgia;also reportedDupuytren\u2019s contracture", "hepatic impairment": "reduce dose; may precipitate coma", "doses": ["Epilepsy,adultandchildover 9 years, initially 125\u00a0mg daily at bedtime,\r\nincreased by 125\u00a0mg every 3 days to 500\u00a0mg daily in 2 divided doses,\r\nthen increased according to response by 250\u00a0mg every 3 days to usual\r\nmaintenance 0.75\u20131.5\u00a0g daily in 2 divided doses;childunder 9 years, initially 125\u00a0mg daily at bedtime, increased by 125\u00a0mg\r\nevery 3 days according to response; usual maintenance,childunder 2 years, 250\u2013500\u00a0mg daily in 2 divided\r\ndoses; 2\u20135 years, 500\u2013750\u00a0mg daily in 2 divided doses; 5\u20139 years 0.75\u20131\u00a0g\r\ndaily in 2 divided doses", "Essential tremor, initially 50\u00a0mg daily, increased gradually\r\nover 2\u20133 weeks according to response; max. 750\u00a0mg daily", "Monitor plasma concentrations\r\nof derivedphenobarbital; optimum\r\nrange as forphenobarbital"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "BENZODIAZEPINES": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  levodopa possibly antagonised by benzodiazepines ", "name": "Benzodiazepines", "backrefs": ["Benzodiazepines"]}}, "COUMARINS": {"interactions": {"extra": "Change in patient\u2019s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control", "bad": 1, "interaction": " ritonavir possibly enhances anticoagulant effect of coumarins ", "name": "Coumarins", "backrefs": ["Ifosfamide", "Raloxifene", "Cranberry Juice", "Tigecycline", "Lactulose", "Bicalutamide", "Chloral", "Aztreonam", "Flutamide", "Coumarins"]}}, "CETRORELIX": {"indications": "adjunct in the treatment of female infertility (under specialist\r\nsupervision)", "name": "CETRORELIX", "renal impairment": "avoid in moderate or severe renal impairment", "side-effects": "nausea, headache, injection site reactions; rarely\r\nhypersensitivity reactions", "hepatic impairment": "avoid in moderate or severe liver impairment", "doses": ["By subcutaneous injectioninto the\r\nlower abdominal wall,", "either250\u00a0micrograms in the morning, starting\r\non day 5 or 6 of ovarian stimulation with gonadotrophins (oreach evening starting on day 5 of ovarian stimulation);\r\ncontinue throughout administration of gonadotrophin including day\r\nof ovulation induction (orevening before ovulation\r\ninduction)", "or3\u00a0mg on day 7 of ovarian stimulation with\r\ngonadotrophins; if ovulation induction not possible on day 5 after\r\n3-mg dose, additional 250\u00a0micrograms once daily until day of ovulation\r\ninduction"], "pregnancy": "avoid in confirmed pregnancy", "breast-feeding": "avoid"}, "PANCURONIUM": {"interactions": {"extra": "", "bad": 0, "interaction": " corticosteroids possibly antagonise effects of pancuronium ", "name": "Pancuronium", "backrefs": ["Pancuronium"]}}, "IDARUBICIN HYDROCHLORIDE": {"indications": "acute leukaemias (seenotes above); advanced breast cancer after\r\nfailure of first-line chemotherapy (not including anthracyclines)", "name": "IDARUBICIN HYDROCHLORIDE", "renal impairment": "reduce dose; avoid in severe impairment", "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant\r\nto tissues;interactions: Appendix\r\n1 (idarubicin)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "severe myocardial insufficiency; recent myocardial infarction; severe arrhythmias; previous\r\ntreatment with maximum cumulative dose of idarubicin or other anthracycline", "hepatic impairment": "reduce dose according to serum-bilirubin concentration;\r\navoid in severe impairment", "doses": ["By mouth, acute non-lymphocytic leukaemia,\r\nmonotherapy, 30\u00a0mg/m2daily for 3 daysorin combination therapy, 15\u201330\u00a0mg/m2daily for 3 days", "Advanced breast cancer, monotherapy, 45\u00a0mg/m2as\r\na single doseor15\u00a0mg/m2daily for 3\r\nconsecutive days; repeat every 3\u20134 weeks", "Max. cumulative doseby mouth(for all indications) 400\u00a0mg/m2", "By intravenous administration, consult product\r\nliterature"], "pregnancy": "avoid (teratogenic and toxic inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "BETAHISTINE": {"interactions": {"extra": "", "bad": 0, "interaction": " antihistamines theoretically antagonise effect of betahistine ", "name": "Betahistine", "backrefs": ["Antihistamines", "Betahistine"]}}, "IMIDAPRIL HYDROCHLORIDE": {"indications": "essential hypertension", "name": "IMIDAPRIL HYDROCHLORIDE", "renal impairment": "seenotes above; initial\r\ndose 2.5\u00a0mg daily if eGFR 30\u201380\u00a0mL/minute/1.73\u00a0m2; avoid\r\nif eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; dry mouth, glossitis, ileus;\r\nbronchitis, dyspnoea; sleep disturbances, depression, confusion, blurred\r\nvision, tinnitus, impotence", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially 5\u00a0mg daily before food; if used in addition\r\nto diuretic (see notes above),\r\nin elderly, in patients with heart failure, angina or cerebrovascular\r\ndisease, or in renal or hepatic impairment, initially 2.5\u00a0mg daily;\r\nif necessary increase dose at intervals of at least 3 weeks; usual\r\nmaintenance dose 10\u00a0mg once daily; max. 20\u00a0mg daily (elderly, 10\u00a0mg\r\ndaily)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "COLESEVELAM HYDROCHLORIDE": {"indications": "primary hypercholesterolaemia as an adjunct to dietary measures,\r\neither alone or with a statin; primary and familial hypercholesterolaemia,\r\nin combination with ezetimibe, either with or without a statin", "name": "COLESEVELAM HYDROCHLORIDE", "cautions": "seenotes above; also gastro-intestinal motility disorders, major gastro-intestinal surgery, inflammatory\r\nbowel disease; patients receiving ciclosporin\r\nshould have their blood-ciclosporin concentration monitored before,\r\nduring, and after treatment with colesevelam;interactions:Appendix 1 (colesevelam)", "side-effects": "seenotes above; also\r\nheadache; myalgia", "contra-indications": "bowel or biliary obstruction", "hepatic impairment": "manufacturer advises caution", "doses": ["Monotherapy, 3.75\u00a0g daily in 1\u20132 divided doses; max. 4.375\u00a0g\r\ndaily", "Combination therapy with a statin, or ezetimibe, or both, 2.5\u20133.75\u00a0g\r\ndaily in 1\u20132 divided doses"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ATORVASTATIN": {"indications": "primary hypercholesterolaemia, heterozygous familial hypercholesterolaemia,\r\nhomozygous familial hypercholesterolaemia or combined (mixed) hyperlipidaemia\r\nin patients who have not responded adequately to diet and other appropriate\r\nmeasures; prevention of cardiovascular events in patients at high\r\nrisk of a first cardiovascular event", "name": "ATORVASTATIN", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of myopathy when  ritonavir given with atorvastatin ", "name": "Atorvastatin", "backrefs": ["Atorvastatin"]}, "cautions": "seenotes above; also haemorrhagic\r\nstroke", "side-effects": "seenotes above; also nasopharyngitis, epistaxis,\r\npharyngeolaryngeal pain, back pain, hyperglycaemia;less commonlyblurred vision, pyrexia, anorexia, malaise, chest pain, weight gain,\r\nhypoglycaemia, tinnitus, peripheral oedema, neck pain;rarelycholestasis, Stevens-Johnson syndrome, toxic epidermal necrolysis;very rarelygynaecomastia, hearing loss", "hepatic impairment": "seenotes above", "doses": ["Primary hypercholesterolaemia and combined hyperlipidaemia,\r\nusually 10\u00a0mg once daily; if necessary, may be increased at intervals\r\nof at least 4 weeks to max. 80\u00a0mg once daily;childunder 18 years seeBNF for Children", "Familial hypercholesterolaemia, initially 10\u00a0mg daily, increased\r\nat intervals of at least 4 weeks to 40\u00a0mg once daily; if necessary,\r\nfurther increased to max. 80\u00a0mg once daily (or 40\u00a0mg once daily combined\r\nwith anion-exchange resin in heterozygous familial hypercholesterolaemia);childunder 18 years seeBNF for Children", "Prevention of cardiovascular events initially 10\u00a0mg once daily\r\nadjusted according to response"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FOLIC ACID": {"indications": "seenotes aboveand under dose", "name": "FOLIC ACID", "interactions": {"extra": "", "bad": 0, "interaction": " sulfasalazine possibly reduces absorption of folic acid ", "name": "Folic Acid", "backrefs": ["Sulfasalazine", "Folic Acid"]}, "cautions": "should never be given alone for pernicious anaemia\r\nand other vitamin B12deficiency states (may precipitate\r\nsubacute combined degeneration of the spinal cord);interactions:Appendix 1 (folates)", "side-effects": "rarelygastro-intestinal disturbances", "doses": ["Folate-deficient megaloblastic anaemia,by\r\nmouth,adultandchildover 1 year, 5\u00a0mg daily for 4 months (until\r\nterm in pregnant women); up to 15\u00a0mg daily may be required in malabsorption\r\nstates;childunder 1 year, 500\u00a0micrograms/kg\r\ndaily (max. 5\u00a0mg) for up to 4 months; up to 10\u00a0mg daily may be required\r\nin malabsorption states", "Prevention of neural tube defects,by mouth, seenotes above", "Prevention of methotrexate-induced side-effects\r\nin severe Crohn\u2019s disease [unlicensed],by mouth, seesection 1.5.3", "Prevention of methotrexate-induced side-effects\r\nin rheumatic disease [unlicensed],by mouth,adultover 18 years 5\u00a0mg once weekly;child2\u201318 years seeBNF for Children", "Prevention of methotrexate-induced side-effects\r\nin severe psoriasis [unlicensed],by mouth, seesection 13.5.3", "Prophylaxis in chronic haemolytic states,by mouth,adult5\u00a0mg every\r\n1\u20137 days depending on underlying disease", "Prophylaxis of folate deficiency in dialysis,by mouth,adult5\u00a0mg every\r\n1\u20137 days;child1\u201312 years 250\u00a0micrograms/kg\r\n(max. 10\u00a0mg) once daily,child12\u201318\r\nyears 5\u201310\u00a0mg once daily"]}, "ALFENTANIL": {"indications": "analgesia especially during short operative procedure and outpatient\r\nsurgery; enhancement of anaesthesia; analgesia and suppression of\r\nrespiratory activity in patients receiving intensive care, with assisted\r\nventilation, for up to 4 days", "name": "ALFENTANIL", "renal impairment": "section 4.7.2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of alfentanil ", "name": "Alfentanil", "backrefs": ["Alfentanil"]}, "cautions": "section 4.7.2andnotes above", "side-effects": "section 4.7.2andnotes above; also hypertension, myoclonic movements;less commonlyarrhythmias, hiccup, laryngospasm;rarelyepistaxis; also reported cardiac arrest, cough, convulsions,\r\nand pyrexia", "contra-indications": "section 4.7.2", "hepatic impairment": "section 4.7.2", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "By intravenous injection, spontaneous\r\nrespiration,adult, initially up to\r\n500\u00a0micrograms over 30 seconds; supplemental, 250\u00a0micrograms", "With assisted ventilation,adultover 18 years, initially 30\u201350\u00a0micrograms/kg; supplemental, 15\u00a0micrograms/kg;child1 month\u201318 years, initially 10\u201320\u00a0micrograms/kg;\r\nsupplemental doses up to 10\u00a0micrograms/kg", "By intravenous infusion, with assisted\r\nventilation,adultandchild, initially 50\u2013100\u00a0micrograms/kg over 10 minutesoras a bolus, followed by maintenance of 0.5\u20131\u00a0micrograms/kg/minute", "Analgesia and suppression of respiratory activity during intensive\r\ncare, with assisted ventilation,by intravenous infusion, initially 2\u00a0mg/hour subsequently adjusted according to response\r\n(usual range 0.5\u201310\u00a0mg/hour); more rapid initial control may be obtained\r\nwith an intravenous dose of 5\u00a0mg given in divided portions over 10\r\nminutes (slowing if hypotension or bradycardia occur); additional\r\ndoses of 0.5\u20131\u00a0mg may be given by intravenous injection during short\r\npainful procedures"], "pregnancy": "section 4.7.2", "breast-feeding": "present in milk\u2014 withhold breast-feeding for\r\n24 hours"}, "METHENAMINE HIPPURATE": {"indications": "prophylaxis and long-term treatment of chronic or recurrent lower\r\nurinary-tract infections", "name": "METHENAMINE HIPPURATE", "renal impairment": "avoid if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2\u2014risk of hippurate crystalluria", "cautions": "avoid concurrent administration with sulfonamides\r\n(risk of crystalluria) or urinary alkalinising agents;interactions:Appendix 1 (methenamine)", "side-effects": "gastro-intestinal disturbances, bladder irritation,\r\nrash", "contra-indications": "severe dehydration, gout, metabolic acidosis", "hepatic impairment": "avoid", "doses": ["1\u00a0g every 12 hours (may be increased in patients with\r\ncatheters to 1\u00a0g every 8 hours);child6\u201312 years 500\u00a0mg every 12 hours"], "pregnancy": "use with caution", "breast-feeding": "amount too small to be harmful"}, "MONTELUKAST": {"indications": "prophylaxis of asthma, see notes above andManagement of Chronic Asthma\r\ntable;\r\nsymptomatic relief of seasonal allergic rhinitis in patients with\r\nasthma", "name": "MONTELUKAST", "interactions": {"extra": "", "bad": 0, "interaction": " phenobarbital reduces plasma concentration of montelukast ", "name": "Montelukast", "backrefs": ["Phenobarbital", "Montelukast"]}, "cautions": "interactions:Appendix 1 (leukotriene\r\nreceptor antagonists)", "side-effects": "abdominal pain, thirst, headache, hyperkinesia\r\n(in young children);less commonlydry mouth, dyspepsia,\r\noedema, dizziness, malaise, paraesthesia, hypoaesthesia, seizure,\r\nabnormal dreams, insomnia, sleep-walking, irritability, anxiety, restlessness,\r\nagitation, aggression, depression, arthralgia, myalgia, epistaxis,\r\nbruising, urticaria, pruritus;rarelypalpitation,\r\ntremor, increased bleeding;very rarelyhepatic disorders,\r\nhallucinations, suicidal thoughts and behaviour, Churg-Strauss syndrome\r\n(seenotes above), erythema\r\nnodosum", "doses": ["Prophylaxis of asthma,adultandchildover 15 years, 10\u00a0mg once\r\ndaily in the evening;child6 months\u20136\r\nyears 4\u00a0mg once daily in the evening, 6\u201315 years 5\u00a0mg once daily in\r\nthe evening", "Seasonal allergic rhinitis,adultandchildover 15 years, 10\u00a0mg once\r\ndaily in the evening"], "pregnancy": "manufacturer advises avoid unless essential, see\r\nalsonotes above", "breast-feeding": "manufacturer advises avoid unless essential"}, "MALATHION": {"side-effects": "skin irritation and hypersensitivity reactions;\r\nchemical burns also reported", "indications": "see notes above and under preparations", "name": "MALATHION", "cautions": "avoid contact with eyes; do not use on broken or secondarily infected skin; children under 6 months, medical\r\nsupervision required", "doses": ["Head lice, rub 0.5% preparation into dry hair and scalp,\r\nallow to dry naturally, remove by washing after 12 hours (see also\r\nnotes above); repeat application after 7 days", "Crab lice, apply 0.5% aqueous preparation over whole body, allow\r\nto dry naturally, wash off after 12 hours or overnight; repeat application\r\nafter 7 days", "Scabies, apply 0.5% preparation over whole body, and wash off\r\nafter 24 hours; if hands are washed with soap within 24 hours, they\r\nshould be retreated; see also notes above; repeat application after\r\n7 days", "For scabies, manufacturer recommends application\r\nto the body but not necessarily to the head and neck. However, application\r\nshould be extended to the scalp, neck, face, and ears"]}, "INSULIN LISPRO": {"indications": "diabetes mellitus", "name": "INSULIN LISPRO", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1;children\r\n(use only if benefit likely compared tosoluble insulin);interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injectionshortly before\r\nmeals or when necessary shortly after meals, according to requirements", "By subcutaneous infusion,orintravenous injection,orintravenous infusion, according to requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "PENTAZOCINE": {"indications": "moderate to severe pain, but see notes above", "name": "PENTAZOCINE", "renal impairment": "seenotes above", "cautions": "seenotes above; also pancreatitis, arterial or pulmonary hypertension, cardiac arrhythmias, myocardial\r\ninfarction, phaeochromocytoma; effects only partially reversed by naloxone", "side-effects": "seenotes above; also\r\nabdominal pain, hypertension, syncope, seizures, paraesthesia, tremor,\r\nraised intracranial pressure, disorientation, hypothermia, chills,\r\nblood disorders, myalgia, and toxic epidermal necrolysis", "contra-indications": "seenotes above; patients dependent on opioids (can precipitate withdrawal); heart failure secondary to chronic lung disease; acute porphyria (section 9.8.2)", "hepatic impairment": "seenotes above", "doses": ["By mouth,pentazocinehydrochloride 50\u00a0mg every 3\u20134 hours preferably after food (range\r\n25\u2013100\u00a0mg); max. 600\u00a0mg daily;child6\u201312 years 25\u00a0mg", "By subcutaneous,intramuscular, orintravenous injection, moderate pain,pentazocine30\u00a0mg, severe pain 45\u201360\u00a0mg every 3\u20134 hours\r\nwhen necessary; max. 360\u00a0mg daily;childover 1 year,by subcutaneousorintramuscular injection, up to 1\u00a0mg/kg,by\r\nintravenous injectionup to 500\u00a0micrograms/kg"], "pregnancy": "seenotes above", "breast-feeding": "use with caution\u2014limited information available"}, "NIMODIPINE": {"indications": "prevention and treatment of ischaemic neurological deficits following\r\naneurysmal subarachnoid haemorrhage", "name": "NIMODIPINE", "renal impairment": "manufacturer advises monitor renal function closely with\r\nintravenous administration", "interactions": {"extra": "", "bad": 0, "interaction": " grapefruit juice increases plasma concentration of nimodipine ", "name": "Nimodipine", "backrefs": ["Nimodipine"]}, "cautions": "cerebral oedema or severely raised intracranial pressure; hypotension; avoid concomitant administration ofnimodipinetablets and infusion, other calcium-channel blockers, or beta-blockers; concomitant nephrotoxic drugs;interactions:Appendix 1 (calcium-channel blockers,alcohol(infusion only))", "side-effects": "hypotension, variation in heart-rate, flushing,\r\nheadache, gastro-intestinal disorders, nausea, sweating and feeling\r\nof warmth; thrombocytopenia and ileus reported;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "within 1 month of myocardial\r\ninfarction; unstable angina; acute porphyria (section 9.8.2)", "hepatic impairment": "elimination reduced in cirrhosis\u2014monitor blood pressure", "doses": ["Prevention,by mouth, 60\u00a0mg every 4 hours,\r\nstarting within 4 days of aneurysmal subarachnoid haemorrhage and\r\ncontinued for 21 days", "Treatment,by intravenous infusionvia central\r\ncatheter, initially 1\u00a0mg/hour (up to 500\u00a0micrograms/hour if body-weight\r\nless than 70\u00a0kg or if blood pressure unstable), increased after 2\r\nhours to 2\u00a0mg/hour if no severe fall in blood pressure; continue for\r\nat least 5 days (max. 14 days); if surgical intervention during treatment,\r\ncontinue for at least 5 days after surgery; max. total duration of\r\nnimodipine use 21 days"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid\u2014present in milk"}, "IFOSFAMIDE": {"indications": "seenotes above", "name": "IFOSFAMIDE", "renal impairment": "avoid if serum creatinine concentration greater than\r\n120\u00a0micromol/litre", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  coumarins possibly enhanced by ifosfamide ", "name": "Ifosfamide", "backrefs": ["Ifosfamide"]}, "cautions": "seesection 8.1andnotes above; ensure satisfactory\r\nelectrolyte balance and renal function before each course (risk of tubular dysfunction, Fanconi\u2019s syndrome or\r\ndiabetes insipidus if renal toxicity not treated promptly); diabetes mellitus; avoid in acute porphyria (but seesection 9.8.2);interactions:Appendix 1\r\n(ifosfamide)", "side-effects": "seesection 8.1andnotes above; also drowsiness, confusion, disorientation,\r\nrestlessness, psychosis; urothelial toxicity, renal toxicity (see\r\nCautions above);less commonlysevere encephalopathy;rarelydiarrhoea, constipation, convulsions, anorexia,very rarelyjaundice, thrombophlebitis, syndrome of inappropriate\r\nantidiuretic hormone secretion; acute pancreatitis, arrhythmias, and\r\nheart failure also reported", "contra-indications": "urinary-tract obstruction; acute infection (including urinary-tract infection); urothelial damage", "hepatic impairment": "avoid", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and carcinogenic inanimals); manufacturer advises adequate contraception during and for at\r\nleast 6 months after treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "FOLATES": {"interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  raltitrexed advises avoid concomitant use with folates ", "name": "Folates", "backrefs": ["Raltitrexed", "Folates"]}}, "ALCOHOL": {"interactions": {"extra": "", "bad": 1, "interaction": "increased sedative effect when  mirtazapine given with alcohol ", "name": "Alcohol", "backrefs": ["Methocarbamol", "Lofexidine", "Tinidazole", "Alcohol", "Hyoscine"]}}, "AMINOSALICYLATES": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of leucopenia when  mercaptopurine given with aminosalicylates ", "name": "Aminosalicylates", "backrefs": ["Aminosalicylates"]}}, "OESTROGENS FOR HRT": {"indications": "see notes above and under preparations", "name": "OESTROGENS FOR HRT", "renal impairment": "see Other Conditions, above", "cautions": "prolonged exposure\r\nto unopposed oestrogens may increase risk of developing endometrial\r\ncancer (seenotes above); migraine (or migraine-like headaches);diabetes\r\n(increased risk of heart disease); history of breast\r\nnodules or fibrocystic disease\u2014closely monitor breast status (risk\r\nof breast cancer, seenotes above); risk factors\r\nfor oestrogen-dependent tumours (e.g. breast cancer in first-degree\r\nrelative); uterine fibroids may increase\r\nin size, symptoms of endometriosis may\r\nbe exacerbated; history of endometrial\r\nhyperplasia; factors predisposing to thromboembolism (seenotes above); presence of antiphospholipid antibodies (increased risk of thrombotic\r\nevents); increased risk of gall-bladder\r\ndisease reported; hypophyseal tumours; acute porphyria (seesection 9.8.2);interactions:Appendix 1\r\n(oestrogens)", "side-effects": "see notes above for risks of long-term use; nausea\r\nand vomiting, abdominal cramps and bloating, weight changes, breast\r\nenlargement and tenderness, premenstrual-like syndrome, sodium and\r\nfluid retention, cholestatic jaundice, glucose intolerance, altered\r\nblood lipids\u2014may lead to pancreatitis, rashes and chloasma, changes\r\nin libido, depression, mood changes, headache, migraine, dizziness,\r\nleg cramps (rule out venous thrombosis), vaginal candidiasis, contact\r\nlenses may irritate; transdermal delivery systems may cause contact\r\nsensitisation (possible severe hypersensitivity reaction on continued\r\nexposure), and headache has been reported on vigorous exercise", "contra-indications": "oestrogen-dependent cancer, history\r\nof breast cancer, active thrombophlebitis, active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction), venous\r\nthromboembolism, or history of recurrent venous\r\nthromboembolism (unless already on anticoagulant treatment), thrombophilic disorder, liver disease (where liver function\r\ntests have failed to return to normal), Dubin-Johnson\r\nand Rotor syndromes (or monitor closely), untreated endometrial hyperplasia, undiagnosed vaginal bleeding", "hepatic impairment": "see Combined Hormonal Contraceptives,section 7.3.1", "doses": ["menopausal symptoms and osteoporosis prophylaxis (see section 6.6)\r\nin women with a uterus whose last menstrual period occurred over 3\r\nyears previously, 1 tablet daily continuously; initiate therapy withIndivina\u00ae1\u00a0mg/2.5\u00a0mgtablets and adjust\r\naccording to response; start at end of scheduled bleed if changing\r\nfrom cyclical HRT"], "pregnancy": "see Combined Hormonal Contraceptives,section 7.3.1", "breast-feeding": "see Combined Hormonal Contraceptives,section 7.3.1"}, "AMPICILLIN": {"indications": "urinary-tract infections, otitis media, sinusitis, oral infections\r\n(see notes above), bronchitis, low or moderate-severity community-acquired\r\npneumonia (Table 1,section 5.1), invasive\r\nsalmonellosis; listerial meningitis (Table 1,section 5.1)", "name": "AMPICILLIN", "renal impairment": "reduce dose if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2; rashes more common", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of rash when  allopurinol given with ampicillin ", "name": "Ampicillin", "backrefs": ["Ampicillin", "Allopurinol"]}, "cautions": "history of allergy;erythematous\r\nrashes common in glandular fever (seenotes above); increased risk of erythematous\r\nrashes in cytomegalovirus infection, and acute or chronic lymphocytic\r\nleukaemia (seenotes above);interactions:Appendix 1 (penicillins)", "side-effects": "nausea, vomiting, diarrhoea; rashes (discontinue\r\ntreatment); rarely, antibiotic-associated colitis; see also underBenzylpenicillin(section 5.1.1.1)", "contra-indications": "penicillin hypersensitivity", "doses": ["By mouth, 0.25\u20131\u00a0g every 6 hours;child1 month\u20131 year, 62.5\u00a0mg every 6 hours, dose\r\ndoubled in severe infection; 1\u20135 years, 125\u00a0mg every 6 hours, dose\r\ndoubled in severe infection; 5\u201312 years, 250\u00a0mg every 6 hours, dose\r\ndoubled in severe infection", "By intramuscular injectionorintravenous injectionorinfusion, 500\u00a0mg every 4\u20136 hours;childunder\r\n18 years seeBNF for Children", "Endocarditis (in combination with another antibiotic if necessary,\r\nsee Table 1,section 5.1),by intravenous infusion,adultover 18 years, 2\u00a0g every 6\r\nhours, increased to 2\u00a0g every 4 hours e.g. in enterococcal endocarditis\r\nor if ampicillin used alone;childunder\r\n18 years seeBNF for Children", "Listerial meningitis (in combination with another antibiotic,\r\nsee Table 1,section 5.1),by intravenous infusion,adultover 18 years, 2\u00a0g every 4\r\nhours;childunder 18\r\nyears seeBNF for Children", "Ampicillindoses in BNF\r\nmay differ from those in product literature"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "IRON ISOMALTOSIDE 1000": {"indications": "iron deficiency anaemia, seenotes above", "name": "IRON ISOMALTOSIDE 1000", "cautions": "hypersensitivity can occur with parenteral\r\niron and facilities for cardiopulmonary resuscitation must be available\u2014risk of allergic reactions increased in immune or inflammatory conditions; oral iron should not be given until 5 days after last\r\ninjection; infection (discontinue if ongoing\r\nbacteraemia)", "side-effects": "less commonlynausea, vomiting,\r\nconstipation, abdominal pain, dyspnoea, dysphonia, flushing, numbness,\r\nfever, cramps, blurred vision, pruritus, rash, hypersensitivity reactions\r\n(including anaphylaxis), injection-site reactions;rarelydiarrhoea, angioedema, tachycardia, arrhythmias, hypotension, chest\r\npain, malaise, seizures, tremor, dizziness, restlessness, loss of\r\n consciousness, altered mental status, myalgia, arthralgia, sweating;very rarelyhypertension, foetal bradycardia, palpitation,\r\nheadache, paraesthesia, haemolysis, transient deafness", "contra-indications": "history of allergic disorders including asthma, and eczema; active rheumatoid arthritis", "hepatic impairment": "avoid in decompensated liver disease and hepatitis", "doses": ["By slow intravenous injectionorby intravenous infusion,adultover 18 years, calculated according to body-weight and iron deficit,\r\nconsult product literature"], "pregnancy": "avoid in first trimester"}, "ZAFIRLUKAST": {"indications": "prophylaxis of asthma, see notes above andManagement of Chronic Asthma\r\ntable", "name": "ZAFIRLUKAST", "renal impairment": "manufacturer advises caution in moderate to severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  warfarin enhanced by zafirlukast ", "name": "Zafirlukast", "backrefs": ["Zafirlukast"]}, "cautions": "elderly;interactions:Appendix 1 (leukotriene receptor antagonists)", "side-effects": "gastro-intestinal disturbances, respiratory infections,\r\nheadache, insomnia, malaise;rarelybleeding disorders,\r\nhypersensitivity reactions including angioedema and skin reactions,\r\narthralgia, myalgia, hepatitis, hyperbilirubinaemia, thrombocytopenia;very rarelyChurg-Strauss syndrome (seenotes above), agranulocytosis", "hepatic impairment": "manufacturer advises avoid", "doses": ["adultandchildover 12 years, 20\u00a0mg twice daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk; see alsonotes above", "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "IMIPENEM WITH CILASTATIN": {"indications": "aerobic and anaerobic Gram-positive and Gram-negative infections;\r\nhospital-acquired septicaemia (Table 1,section 5.1); not indicated for CNS infections", "name": "IMIPENEM WITH CILASTATIN", "renal impairment": "risk of CNS side-effects; reduce dose if eGFR less than\r\n70\u00a0mL/minute/1.73\u00a0m2\u2014consult product literature", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of convulsions when  ganciclovir given with imipenem with cilastatin ", "name": "Imipenem with Cilastatin", "backrefs": ["Imipenem with Cilastatin"]}, "cautions": "sensitivity to beta-lactam antibacterials (avoid if history of immediate hypersensitivity reaction, seeHypersensitivity Reactions); CNS disorders (e.g. epilepsy);interactions:Appendix 1 (imipenem with cilastatin)", "side-effects": "nausea (may reduce rate of infusion), vomiting,\r\ndiarrhoea (rarely antibiotic-associated colitis), eosinophilia, rash\r\n(rarely toxic epidermal necrolysis and Stevens-Johnson syndrome);less commonlyhypotension, seizures, myoclonic activity,\r\ndizziness, drowsiness, hallucinations, confusion, leucopenia, thrombocytopenia,\r\nthrombocytosis, positive Coombs\u2019 test;rarelytaste\r\ndisturbances, hepatitis, encephalopathy, anaphylactic reactions, paraesthesia,\r\ntremor, acute renal failure, polyuria, tooth, tongue or urine discoloration,\r\nhearing loss;very rarely, abdominal pain, heartburn,\r\nglossitis, tachycardia, palpitation, flushing, cyanosis, dyspnoea,\r\nhyperventilation, headache, asthenia, haemolytic anaemia, aggravation\r\nof myasthenia gravis, polyarthralgia, tinnitus, hypersalivation, hyperhidrosis", "doses": ["By intravenous infusion, in terms\r\nof imipenem, 500\u00a0mg every 6 hoursor1\u00a0g every 8\r\nhours; less sensitive organisms or life-threatening infection, 1\u00a0g\r\nevery 6 hours;childunder 1 year seeBNF for Children; 1 year and\r\nolder, 15\u00a0mg/kg (max. 500\u00a0mg) every 6 hours; less sensitive organisms\r\nor life-threatening infection, 25\u00a0mg/kg (max. 1\u00a0g) every\r\n6 hours"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk (toxicity inanimalstudies)", "breast-feeding": "present in milk but unlikely to be absorbed"}, "DIMETICONE": {"side-effects": "skin irritation", "indications": "head lice", "name": "DIMETICONE", "cautions": "avoid contact with eyes; children under 6 months, medical supervision required", "doses": ["Rub into dry hair and scalp, allow to dry naturally, shampoo\r\nafter minimum 8 hours (or overnight); repeat application after 7 days"]}, "ANTI-D (Rh0) IMMUNOGLOBULIN": {"indications": "see notes above", "name": "ANTI-D (Rh0) IMMUNOGLOBULIN", "cautions": "immunoglobulin A deficiency; possible interference with live virus vaccines, see underNormal Immunoglobulins, section 14.5.1,\r\nbut seenotes aboveabout\r\nadministration with MMR vaccine", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain; hypotension,\r\nhypertension, headache, fever, malaise, asthenia, drowsiness, dizziness,\r\nback pain, arthralgia, myalgia; pruritus, rash, sweating, injection\r\nsite pain;rarelytachycardia, anaphylaxis, dyspnoea,\r\nhypotension, and urticaria; (for side-effects associated withintravenousimmunoglobulins, seesection 14.5.1", "contra-indications": "treatment of idiopathic thrombocytopenia\r\npurpura in rhesus negative or splenectomised patients", "doses": ["by deep intramuscular injection, to rhesus-negative\r\nwoman for prevention of Rh0(D) sensitisation:"]}, "HYDROGEN PEROXIDE": {"indications": "see under preparations below", "name": "HYDROGEN PEROXIDE", "cautions": "large or deep wounds; avoid on healthy skin and eyes; bleaches fabric; incompatible with products containing\r\niodine orpotassium permanganate", "doses": ["superficial bacterial skin infection, apply 2\u20133 times\r\ndaily for up to 3\u00a0weeks"]}, "MIFAMURTIDE": {"indications": "seenotes above", "name": "MIFAMURTIDE", "renal impairment": "use with caution\u2014no information available", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  tacrolimus advised by manufacturer of mifamurtide ", "name": "Mifamurtide", "backrefs": ["Mifamurtide"]}, "cautions": "asthma and chronic obstructive pulmonary disease\u2014consider\r\nprophylactic bronchodilator therapy; history of\r\nautoimmune, inflammatory, or collagen disease; monitor renal function, hepatic function and clotting parameters; monitor patients with history of venous thrombosis, vasculitis,\r\nor unstable cardiovascular disorders for persistent or worsening symptoms\r\nduring administration\u2014consult product literature;interactions:Appendix 1 (mifamurtide)", "side-effects": "gastro-intestinal disturbances (including anorexia,\r\nnausea, vomiting, diarrhoea, constipation, abdominal pain, dyspepsia);\r\ntachycardia, hypertension, palpitations, hypotension, phlebitis, flushing;\r\noedema, respiratory disorders (including dyspnoea, epistaxis, cough,\r\ntachypnoea, haemoptysis, pleural effusion); confusion, depression,\r\ninsomnia, headache, dizziness, paraesthesia, hypoaesthesia, tremor,\r\ndrowsiness, anxiety; hypokalaemia, anaemia, leucopenia, thrombocytopenia,\r\ngranulocytopenia; haematuria, dysuria, pollakiuria; musculoskeletal\r\npain; blurred vision; vertigo, tinnitus, hearing loss; sweating, alopecia,\r\nrash, dry skin", "hepatic impairment": "use with caution\u2014no information available", "doses": ["SeeDoses"], "pregnancy": "avoid; effective contraception required", "breast-feeding": "avoid\u2014no information available"}, "DOXAZOSIN": {"indications": "benign prostatic hyperplasia; hypertension\r\n(section 2.5.4)", "name": "DOXAZOSIN", "interactions": {"extra": "", "bad": 1, "interaction": "enhanced hypotensive effect when  tadalafil given with doxazosin\u2014manufacturer of tadalafil advises avoid concomitant use", "name": "Doxazosin", "backrefs": ["Doxazosin"]}, "cautions": "seenotes aboveandsection 2.5.4", "side-effects": "seenotes aboveandsection 2.5.4", "contra-indications": "seenotes above", "hepatic impairment": "section 2.5.4", "doses": ["Initially 1\u00a0mg daily; dose may be doubled at intervals\r\nof 1\u20132 weeks according to response, up to max. 8\u00a0mg daily; usual maintenance\r\n2\u20134\u00a0mg daily"]}, "ANABOLIC STEROIDS": {"interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  phenindione enhanced by anabolic steroids ", "name": "Anabolic Steroids", "backrefs": ["Anabolic Steroids"]}}, "PARACETAMOL": {"indications": "mild to moderate pain, pyrexia", "name": "PARACETAMOL", "renal impairment": "increaseinfusiondose interval to every\r\n6 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; note also\r\nsodium content of effervescent tablets (see under relevant preparation\r\nentry)", "interactions": {"extra": "", "bad": 0, "interaction": " metoclopramide increases rate of absorption of paracetamol ", "name": "Paracetamol", "backrefs": ["Colestyramine", "Paracetamol"]}, "cautions": "alcoholdependence; max. daily infusion dose 3\u00a0g in patients with hepatocellular\r\ninsufficiency, chronic alcoholism, chronic malnutrition,\r\nor dehydration; before administering, check when paracetamol last administered and\r\ncumulative paracetamol dose over previous 24 hours;interactions:Appendix 1 (paracetamol)", "side-effects": "side-effects rare, but rashes, blood disorders\r\n(including thrombocytopenia, leucopenia, neutropenia) reported; hypotension,\r\nflushing, and tachycardia also reported on infusion;important:liver damage (and less frequently renal damage) followingoverdosage, seeEmergency Treatment of Poisoning", "hepatic impairment": "dose-related toxicity\u2014avoid large doses; see also Cautions", "doses": ["migraine, 2 capsules at onset of attack, followed by 1\r\ncapsule every hour if necessary; max. 5 capsules in 12 hours;childnot recommended"], "pregnancy": "not known to be harmful", "breast-feeding": "amount too small to be harmful"}, "SUMATRIPTAN": {"indications": "treatment of acute migraine; cluster headache", "name": "SUMATRIPTAN", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "possible risk of toxicity when  lithium given with sumatriptan ", "name": "Sumatriptan", "backrefs": ["Sumatriptan"]}, "cautions": "see under5HT1-receptor agonistsabove; history of seizures; sensitivity to sulfonamides;interactions:Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; also dyspnoea, drowsiness, transient increase\r\nin blood pressure, myalgia;also reporteddiarrhoea,\r\nischaemic colitis, hypotension, bradycardia or tachycardia, palpitation,\r\narrhythmias, myocardial infarction, Raynaud\u2019s syndrome, anxiety, seizures,\r\ntremor, dystonia, nystagmus, arthralgia, visual disturbances, and\r\nsweating; epistaxis with nasal spray", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; previous cerebrovascular accident or transient\r\nischaemic attack; peripheral vascular disease; moderate and severe hypertension", "hepatic impairment": "reduce oral dose to 25\u201350\u00a0mg; avoid in severe impairment", "doses": ["By mouth, migraine, 50\u00a0mg (some patients\r\nmay require 100\u00a0mg); dose may be repeated after at least 2 hours if\r\nmigraine recurs; max. 300\u00a0mg in 24 hours;childunder 18 years seeBNF for Children", "By subcutaneous injectioncluster\r\nheadache or migraine, using auto-injector, 6\u00a0mg; dose may be repeated\r\nonce after at least 1 hour if headache recurs; max. 12\u00a0mg in 24 hours;child10\u201318 years seeBNF for Children", "Notfor intravenous\r\ninjection which may cause coronary vasospasm and angina", "Intranasally, cluster headache [unlicensed]\r\nor migraine, 10\u201320\u00a0mg into one nostril; dose may be repeated once\r\nafter at least 2 hours if headache recurs; max. 40\u00a0mg in 24 hours;child12\u201318 years seeBNF for Children", "Patient not responding to initial dose should\r\nnot take second dose for same attack"], "pregnancy": "seenotes above", "breast-feeding": "present in milk but amount probably too small\r\nto be harmful; withhold breast-feeding for 12 hours"}, "FLUTICASONE PROPIONATE WITH SALMETEROL": {"indications": "see under preparations (see alsoManagement of Chronic Asthma\r\ntable)", "name": "FLUTICASONE PROPIONATE WITH SALMETEROL", "cautions": "seesection 3.1.1.1and\r\nCautions of Inhaled Corticosteroids (section 3.2)", "side-effects": "seesection 3.1.1.1and Side-effects of Inhaled\r\nCorticosteroids (section 3.2); also sinusitis, nasopharyngitis,very rarelydyspepsia, hyperglycaemia, arthralgia;also reportednausea, dizziness, rash", "doses": ["by aerosol inhalation, prophylaxis of asthma,adultandchildover\r\n12 years, 2 puffs twice daily"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "CALCIUM-CHANNEL BLOCKERS": {"interactions": {"extra": "Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of calcium-channel blockers ", "name": "Calcium-channel Blockers", "backrefs": ["Isoflurane", "Calcium-channel Blockers"]}}, "WARFARIN": {"interactions": {"extra": "", "bad": 1, "interaction": " nevirapine may enhance or reduce anticoagulant effect of warfarin ", "name": "Warfarin", "backrefs": ["Glucosamine", "Exenatide", "Imatinib", "Memantine", "Entacapone", "Mirtazapine", "Proguanil", "Gefitinib", "Ubidecarenone", "Influenza Vaccine", "Levamisole", "Zafirlukast", "Eslicarbazepine", "Warfarin", "Leflunomide", "Gemcitabine", "Nevirapine"]}}, "ENTACAPONE": {"indications": "adjunct to co-beneldopa or co-careldopa in Parkinson\u2019s disease with\r\n\u2018end-of-dose\u2019 motor fluctuations", "name": "ENTACAPONE", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  warfarin enhanced by entacapone ", "name": "Entacapone", "backrefs": ["Entacapone"]}, "cautions": "ischaemic heart disease; avoid abrupt withdrawal; concurrentlevodopadose may need to be reduced\r\nby about 10\u201330%;interactions:Appendix\r\n1 (entacapone)", "side-effects": "nausea, vomiting, abdominal pain, constipation,\r\ndiarrhoea, urine may be coloured reddish-brown, dry mouth; ischaemic\r\nheart disease; confusion, dizziness, abnormal dreams, fatigue, insomnia,\r\ndystonia, dyskinesia, hallucinations; sweating;less commonlymyocardial infarction;rarelyrash;very\r\nrarelyanorexia, weight loss, agitation, and urticaria;also reportedhepatitis, colitis, neuroleptic malignant\r\nsyndrome, rhabdomyolysis, and skin, hair, and nail discoloration", "contra-indications": "phaeochromocytoma; history of neuroleptic malignant syndrome or non-traumatic rhabdomyolysis", "hepatic impairment": "avoid", "doses": ["200\u00a0mg with each dose oflevodopawith\r\ndopa-decarboxylase inhibitor; max. 2\u00a0g daily"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "FESOTERODINE FUMARATE": {"indications": "urinary frequency, urgency, and urge\r\nincontinence", "name": "FESOTERODINE FUMARATE", "renal impairment": "increase dose cautiously if eGFR 30\u201380\u00a0mL/minute/1.73\u00a0m2; max. 4\u00a0mg daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; consult product literature before concomitant use of cytochrome\r\nP450 enzyme inhibitors", "cautions": "seenotes above; gastro-oesophageal reflux", "side-effects": "seenotes above; also\r\ninsomnia;less commonlynasal dryness, pharyngolaryngeal\r\npain, cough, and vertigo", "contra-indications": "seenotes above", "hepatic impairment": "manufacturer advises increase dose cautiously; max.\r\n4\u00a0mg daily in moderate impairment; avoid in severe impairment; consult\r\nproduct literature before concomitant use of cytochrome P450 enzyme\r\ninhibitors", "doses": ["adultover 18 years, 4\u00a0mg\r\nonce daily, increased if necessary to max. 8\u00a0mg once daily", "Max. 4\u00a0mg daily with concomitant atazanavir,\r\nclarithromycin, indinavir, itraconazole, ketoconazole, nelfinavir,\r\nritonavir, saquinavir, or telithromycin; in patients with hepatic\r\nor renal impairment, consult product literature before concomitant\r\nuse with amprenavir, aprepitant, atazanavir, clarithromycin, diltiazem,\r\nerythromycin, fluconazole, fosamprenavir, indinavir, itraconazole,\r\nketoconazole, nelfinavir, ritonavir, saquinavir, telithromycin, verapamil,\r\nor grapefruit juice"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PREPARATIONS FOR VAGINAL AND VULVAL\r\nCANDIDIASIS": {"indications": "seenotes above", "name": "PREPARATIONS FOR VAGINAL AND VULVAL\r\nCANDIDIASIS", "cautions": "interactions:Appendix 1 (miconazole)", "side-effects": "occasional local irritation", "doses": ["insert 1 pessary at night as a single dose; can be repeated\r\nonce if necessary"], "pregnancy": "seenotes above"}, "ZINC ACETATE": {"indications": "Wilson\u2019s disease (initiated under specialist\r\nsupervision)", "name": "ZINC ACETATE", "cautions": "portal hypertension (risk of hepatic\r\ndecompensation when switching from chelating agent); monitor full blood count and serum cholesterol;interactions:Appendix 1 (zinc)", "side-effects": "gastric irritation (usually transient; may be\r\nreduced if first dose taken mid-morning or with a little protein);less commonlysideroblastic anaemia and leucopenia", "doses": ["Dose expressed as\r\nelemental zinc", "Wilson\u2019s disease, 50\u00a0mg 3 times daily (max. 50\u00a0mg 5 times daily),\r\nadjusted according to response;child1\u20136 years, 25\u00a0mg twice daily; 6\u201316 years, body-weight under 57\u00a0kg,\r\n25\u00a0mg 3 times daily, body-weight over 57\u00a0kg, 50\u00a0mg 3 times daily;adolescent16\u201318 years, 50\u00a0mg 3 times daily"], "pregnancy": "reduce dose to 25\u00a0mg 3 times daily adjusted according\r\nto plasma-copper concentration and urinary copper excretion", "breast-feeding": "manufacturer advises avoid; present in milk\u2014may\r\ncause zinc-induced copper deficiency in infant"}, "ACENOCOUMAROL": {"indications": "see underWarfarin Sodium", "name": "ACENOCOUMAROL", "renal impairment": "seenotes above", "cautions": "see underWarfarin Sodium", "side-effects": "see underWarfarin Sodium", "contra-indications": "see underWarfarin Sodium", "hepatic impairment": "seenotes above", "doses": ["4\u00a0mg on first day, 4\u20138\u00a0mg on second day; maintenance dose\r\nusually 1\u20138\u00a0mg daily adjusted according to response"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DORZOLAMIDE": {"indications": "raised intra-ocular pressure in ocular hypertension, open-angle glaucoma,\r\npseudo-exfoliative glaucomaeitheras adjunct to\r\nbeta-blockerorused alone in patients unresponsive\r\nto beta-blockers or if beta-blockers contra-indicated", "name": "DORZOLAMIDE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "systemic absorption follows topical application; history of renal calculi; chronic corneal defects, history of intra-ocular\r\nsurgery;interactions:Appendix 1 (dorzolamide)", "side-effects": "seenotes above; also nausea,\r\nbitter taste, dry mouth; headache, asthenia; ocular irritation, blurred\r\nvision, lacrimation, conjunctivitis, superficial punctuate keratitis,\r\neyelid inflammation;less commonlyiridocyclitis;rarelyhypersensitivity reactions (including urticaria,\r\nangioedema, bronchospasm), dizziness, paraesthesia, urolithiasis,\r\neyelid crusting, transient myopia, corneal oedema, epistaxis, throat\r\nirritation", "contra-indications": "hyperchloraemic acidosis, sulfonamide hypersensitivity", "hepatic impairment": "manufacturer advises caution\u2014no information available", "doses": ["Used alone, apply 3 times daily", "With topical beta-blocker, apply twice daily"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "UROKINASE": {"indications": "thromboembolic occlusive vascular disease\r\nincluding deep-vein thrombosis, pulmonary embolism, and occlusive\r\nperipheral arterial disease; occluded arteriovenous haemodialysis\r\nshunts, and intravenous catheters and cannulas blocked by fibrin clots", "name": "UROKINASE", "renal impairment": "dose reduction may be required", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "dose reduction may be required; see alsonotes above", "doses": ["deep-vein thrombosis,by intravenous infusion, initially 4400\u00a0units/kg over 10\u201320 minutes, followed by 100\u00a0000\u00a0units/hour\r\nfor 2\u20133 days", "Pulmonary embolism,by intravenous infusion,\r\ninitially 4400\u00a0units/kg over 10\u201320 minutes, followed by 4400\u00a0units/kg/hour\r\nfor 12 hours", "Occlusive peripheral arterial disease, consult product literature", "Occluded central venous catheters,by injection directly\r\ninto catheter, dissolve in sodium chloride 0.9% to a concentration\r\nof 5000\u00a0units/mL; use a volume sufficient to fill the catheter lumen; leave for 20\u201360 minutes then aspirate the lysate; repeat\r\nif necessary", "Occluded arteriovenous haemodialysis shunts, consult product\r\nliterature"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "ORAL REHYDRATION SALTS (ORS)": {"indications": "fluid and electrolyte loss in\r\ndiarrhoea, see notes above", "name": "ORAL REHYDRATION SALTS (ORS)", "doses": ["According to fluid loss, usually 200\u2013400\u00a0mL solution after\r\nevery loose motion;infant1\u20131\u00bd times\r\nusual feed volume;child200\u00a0mL after\r\nevery loose motion"]}, "ST JOHN'S WORT": {"interactions": {"extra": "", "bad": 1, "interaction": "increased serotonergic effects when  5HT1 agonists given with St John's wort\u2014avoid concomitant use", "name": "St John's Wort", "backrefs": ["St John's Wort"]}}, "AMIFOSTINE": {"indications": "see under Dose", "name": "AMIFOSTINE", "renal impairment": "avoid\u2014no information available", "cautions": "ensure adequate hydration before treatment; infuse with patient supine and monitor arterial blood\r\npressure (interrupt infusion if blood pressure decreases significantly,\r\nconsult product literature); during chemotherapy\r\ninterrupt antihypertensive therapy 24 hours before treatment withamifostineand monitor closely; during radiotherapy monitor closely if concomitant antihypertensive\r\ntherapy; monitor serum-calcium concentration\r\nin patients at risk of hypocalcaemia; patients at risk\r\nof renal impairment; caution in handling\u2014risk of cutaneous\r\nreactions", "side-effects": "nausea, vomiting, hiccups; hypotension (managed\r\nby infusion of sodium chloride 0.9% and postural management), hypertension,\r\nflushing, arrhythmias (includingrarelyatrial fibrillation,\r\nsupraventricular tachycardia); sneezing; drowsiness, dizziness, syncope;\r\nhypocalcaemia;rarelychest pain, apnoea, seizures,\r\nserious skin reactions (including Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis, andvery rarelyexfoliative\r\nand bullous dermatitis, toxicoderma), and renal failure;very\r\nrarelymyocardial infarction, laryngeal oedema, and respiratory\r\narrest", "hepatic impairment": "avoid\u2014no information available", "doses": ["Reduction of neutropenia-related risk of infection due\r\ntocyclophosphamideandcisplatintreatment in patients with advanced ovarian carcinoma,by\r\nintravenous infusionover 15 minutes,adultunder 70 years, 910\u00a0mg/m2started within 30 minutes before\r\nchemotherapy (reduced to 740\u00a0mg/m2for subsequent cycles\r\nif full dose could not be given first time due to hypotension lasting\r\nmore than 5 minutes after interruption, consult product literature)", "Reduction of nephrotoxicity associated withcisplatinin patients with advanced solid tumours of non-germ-cell origin,\r\nconsult product literature", "Prevention of xerostomia during radiotherapy for head and neck\r\ncancer, consult product literature"], "pregnancy": "toxicity inanimalstudies; avoid", "breast-feeding": "avoid\u2014no information available"}, "CYCLOSERINE": {"indications": "in combination with other drugs, tuberculosis resistant to first-line\r\ndrugs", "name": "CYCLOSERINE", "renal impairment": "increase interval between doses if creatinine clearance\r\nless than 50\u00a0mL/minute and monitor blood-cycloserine concentration", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of CNS toxicity when  isoniazid given with cycloserine ", "name": "Cycloserine", "backrefs": ["Cycloserine"]}, "cautions": "monitor haematological, renal, and hepatic\r\nfunction;interactions:Appendix 1\r\n(cycloserine)", "side-effects": "mainly neurological, including headache, dizziness,\r\nvertigo, drowsiness, tremor, convulsions, confusion, psychosis, depression\r\n(discontinue or reduce dose if symptoms of CNS toxicity); rashes,\r\nallergic dermatitis (discontinue or reduce dose); megaloblastic anaemia;\r\nchanges in liver function tests; heart failure at high doses reported", "contra-indications": "epilepsy, depression, severe anxiety, psychotic states,alcoholdependence, acute porphyria (section 9.8.2)", "doses": ["Initially 250\u00a0mg every 12 hours for 2 weeks increased\r\naccording to blood concentration and response to max. 500\u00a0mg every\r\n12 hours;child2\u201318 years seeBNF for Children", "Blood concentration monitoring required especially\r\nin renal impairment or if dose exceeds 500\u00a0mg daily or if signs of\r\ntoxicity; blood concentration should not exceed 30\u00a0mg/litre"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014crosses the placenta", "breast-feeding": "amount too small to be harmful"}, "CLOMIFENE CITRATE": {"indications": "anovulatory infertility\u2014see notes above", "name": "CLOMIFENE CITRATE", "cautions": "seenotes above; polycystic ovary\r\nsyndrome (cysts may enlarge during treatment, also risk of exaggerated\r\nresponse to usual doses), ovarian hyperstimulation syndrome, uterine\r\nfibroids, ectopic pregnancy, incidence of multiple births increased (consider ultrasound\r\nmonitoring), visual symptoms (discontinue\r\nand initiate ophthalmological examination)", "side-effects": "visual disturbances (withdraw), ovarian hyperstimulation\r\n(withdraw), hot flushes, abdominal discomfort, occasionally nausea,\r\nvomiting, depression, insomnia, breast tenderness, headache, intermenstrual\r\nspotting, menorrhagia, endometriosis, convulsions, weight gain, rashes,\r\ndizziness, hair loss", "contra-indications": "ovarian cysts, hormone-dependent tumours or abnormal uterine\r\nbleeding of undetermined cause", "hepatic impairment": "avoid in severe liver disease", "doses": ["50\u00a0mg daily for 5 days, starting within about 5 days of\r\nonset of menstruation (preferably on 2nd day) or at any time (normally\r\npreceded by a progestogen-induced withdrawal bleed) if cycles have\r\nceased; second course of 100\u00a0mg daily for 5 days may be given in absence\r\nof ovulation; most patients who are going to respond will do so to\r\nfirst course; 3 courses should constitute adequate therapeutic trial;\r\nlong-term cyclical therapy not recommended\u2014see CSM advice, above"], "pregnancy": "exclude pregnancy before treatment; possible effects\r\non fetal development", "breast-feeding": "may inhibit lactation"}, "PROTON PUMP INHIBITORS": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  itraconazole reduced by proton pump inhibitors ", "name": "Proton Pump Inhibitors", "backrefs": ["Proton Pump Inhibitors"]}}, "SODIUM VALPROATE": {"indications": "all forms of epilepsy; migraine prophylaxis [unlicensed]\r\n(section 4.7.4.2); mania\r\n(section 4.2.3)", "name": "SODIUM VALPROATE", "renal impairment": "reduce dose", "cautions": "monitor liver function\r\nbefore therapy and during first 6 months especially in patients most\r\nat risk (see also below); measure full\r\nblood count and ensure no undue potential\r\nfor bleeding before starting and before surgery; systemic lupus erythematosus; false-positive\r\nurine tests for ketones; avoid abrupt withdrawal; consider vitamin D supplementation in patients that\r\nare immobilised for long periods or who have inadequate sun exposure\r\nor dietary intake of calcium;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (valproate)", "side-effects": "nausea, gastric irritation, diarrhoea; weight\r\ngain; hyperammonaemia, thrombocytopenia; transient hair loss (regrowth\r\nmay be curly);less frequentlyincreased alertness,\r\naggression, hyperactivity, behavioural disturbances, ataxia, tremor,\r\nand vasculitis;rarelyhepatic dysfunction (see under\r\nCautions; withdraw treatment immediately if persistent vomiting and\r\nabdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or\r\nloss of seizure control), lethargy, drowsiness, confusion, stupor,\r\nhallucinations, blood disorders (including anaemia, leucopenia, pancytopenia),\r\nhearing loss, and rash;very rarelypancreatitis\r\n(see under Cautions), peripheral oedema, increase in bleeding time,\r\nextrapyramidal symptoms, dementia, encephalopathy, coma, gynaecomastia,\r\nFanconi\u2019s syndrome, hirsutism, acne, enuresis, hyponatraemia, toxic\r\nepidermal necrolysis, and Stevens-Johnson syndrome; suicidal ideation;\r\nreduced bone mineral density (see Cautions);also reportedmenstrual disturbances, male infertility, syndrome of inappropriate\r\nsecretion of antidiuretic hormone", "contra-indications": "family history\r\nof severe hepatic dysfunction; acute porphyria (section 9.8.2)", "hepatic impairment": "avoid if possible\u2014hepatotoxicity and hepatic failure\r\nmay occasionally occur (usually in first 6 months); avoid in active\r\nliver disease; see also under Cautions", "doses": ["epilepsy,adultandchildover 20\u00a0kg, as above, total daily dose given\r\nin 1\u20132 divided doses"], "pregnancy": "seePregnancy;\r\nneonatal bleeding (related to hypofibrinaemia) and neonatal hepatotoxicity\r\nalso reported", "breast-feeding": "seeBreast-feeding"}, "LOPRAZOLAM": {"indications": "insomnia (short-term use; seenotes above)", "name": "LOPRAZOLAM", "renal impairment": "seenotes above", "cautions": "see underNitrazepam", "side-effects": "see underNitrazepam; shorter\r\nacting", "contra-indications": "see underNitrazepam", "hepatic impairment": "seenotes above", "doses": ["1\u00a0mg at bedtime, increased to 1.5 or 2\u00a0mg if required;elderly(or debilitated) 0.5 or 1\u00a0mg;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CROTAMITON": {"indications": "pruritus (including pruritus after scabies\u2014section 13.10.4); see notes above", "contra-indications": "acute exudative dermatoses", "name": "CROTAMITON", "cautions": "avoid use near eyes and\r\nbroken skin; use on doctor\u2019s\r\nadvice for children under 3 years", "doses": ["Pruritus, apply 2\u20133 times daily;childunder 3 years, apply once daily"]}, "VINCRISTINE": {"interactions": {"extra": "", "bad": 1, "interaction": " itraconazole possibly inhibits metabolism of vincristine (increased risk of neurotoxicity)", "name": "Vincristine", "backrefs": ["Vincristine"]}}, "DOBUTAMINE": {"indications": "inotropic support in infarction, cardiac surgery, cardiomyopathies,\r\nseptic shock, and cardiogenic shock; cardiac stress testing (consult\r\nproduct literature)", "name": "DOBUTAMINE", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of severe hypertension and bradycardia when non-cardioselective  beta-blockers given with dobutamine ", "name": "Dobutamine", "backrefs": ["Dobutamine"]}, "cautions": "arrhythmias, acute myocardial infarction, acute heart\r\nfailure, severe hypotension, marked obstruction of cardiac ejection (such as idiopathic\r\nhypertrophic subaortic stenosis); correct hypovolaemia before starting\r\ntreatment; tolerance may develop with continuous\r\ninfusions longer than 72 hours; hyperthyroidism;interactions:Appendix 1 (sympathomimetics)", "side-effects": "nausea; hypotension, hypertension (marked increase\r\nin systolic blood pressure indicates overdose), arrhythmias, palpitations,\r\nchest pain; dyspnoea, bronchospasm; headache; fever; increased urinary\r\nurgency; eosinophilia; rash, phlebitis;very rarelymyocardial infarction, hypokalaemia; coronary artery spasm and thrombocytopenia\r\nalso reported", "contra-indications": "phaeochromocytoma", "doses": ["By intravenous infusion, 2.5\u201310\u00a0micrograms/kg/minute,\r\nadjusted according to response"], "pregnancy": "no evidence of harm inanimalstudies\u2014manufacturers\r\nadvise use only if potential benefit outweighs risk", "breast-feeding": "manufacturers advise avoid\u2014no information available"}, "CYPROTERONE ACETATE": {"indications": "see notes above; prostate\r\ncancer (section 8.3.4.2)", "name": "CYPROTERONE ACETATE", "cautions": "ineffective for male hypersexuality in\r\nchronicalcoholism (relevance to prostate cancer\r\nnot known); blood counts initially and\r\nthroughout treatment; monitor hepatic function\r\nregularly (liver function tests should\r\nbe performed before treatment, see also under Side-effects\r\nbelow); monitor adrenocortical function regularly; diabetes mellitus (see also Contra-indications)", "side-effects": "fatigue and lassitude, breathlessness, weight\r\nchanges, reduced sebum production (may clear acne), changes in hair\r\npattern, gynaecomastia (rarely leading to galactorrhoea and benign\r\nbreast nodules); rarely hypersensitivity reactions, rash and osteoporosis;\r\ninhibition of spermatogenesis (see notes above); hepatotoxicity reported\r\n(including jaundice, hepatitis and hepatic failure (fatalities reported\r\nat dosages of 100\u00a0mg and above, usually in men treated for advanced\r\nprostate cancer), seesection 8.3.4.2for details and warnings)", "contra-indications": "(do not apply in prostate cancer), severe\r\ndiabetes (with vascular changes), sickle-cell anaemia, liver-disease including\r\nDubin-Johnson and Rotor syndromes, previous or existing liver tumours,\r\nmalignant or wasting diseases, meningioma or history of meningioma, severe depression, history of\r\nthromboembolic disorders; youths under 18 years (may arrest bone maturation\r\nand testicular development)", "hepatic impairment": "avoid\u2014dose-related toxicity; see also side-effectssection 8.3.4.2", "doses": ["adultover 18 years, male\r\nhypersexuality, 50\u00a0mg twice daily after food"]}, "CO-AMOXICLAV": {"indications": "infections due to beta-lactamase-producing\r\nstrains (whereamoxicillinalone not appropriate)\r\nincluding respiratory-tract infections, bone and joint infections,\r\ngenito-urinary and abdominal infections, cellulitis, animal bites,\r\nsevere dental infection with spreading cellulitis or dental infection\r\nnot responding to first-line antibacterial", "name": "CO-AMOXICLAV", "renal impairment": "risk of crystalluria with high doses (particularly during\r\nparenteral therapy).", "cautions": "see underAmpicillinand notes above; maintain adequate hydration with high doses (particularly during\r\nparenteral therapy);interactions:Appendix\r\n1 (penicillins)", "side-effects": "see underAmpicillin; hepatitis,\r\ncholestatic jaundice (see above); Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis, exfoliative dermatitis, vasculitis reported;\r\nrarely prolongation of bleeding time, dizziness, headache, convulsions\r\n(particularly with high doses or in renal impairment); superficial\r\nstaining of teeth with suspension, phlebitis at injection site", "contra-indications": "penicillin hypersensitivity, history ofco-amoxiclav-associated or penicillin-associated jaundice or hepatic dysfunction", "hepatic impairment": "monitor liver function in liver disease; see also Cholestatic\r\nJaundice above", "doses": ["By mouth, expressed asco-amoxiclav, one250/125strength tablet every 8 hours; increased\r\nin severe infection to one500/125strength tablet\r\nevery 8 hours;neonate0.25\u00a0mL/kg of125/31suspension every 8 hours;child1 month\u20131 year, 0.25\u00a0mL/kg of125/31suspension\r\nevery 8 hours, dose doubled in severe infection; 1\u20136 years, 5\u00a0mL of125/31suspension every 8 hoursor0.25\u00a0mL/kg\r\nof125/31suspension every 8 hours, dose doubled\r\nin severe infection; 6\u201312 years, 5\u00a0mL of250/62suspension\r\nevery 8 hoursor0.15\u00a0mL/kg of250/62suspension every 8 hours, dose doubled in severe infection", "Severe dental infections (but not generally first-line, seenotes above), expressed\r\nasco-amoxiclav,adultandchildover 12 years, one250/125strength tablet every 8 hours for 5 days", "By intravenous injectionover 3\u20134\r\nminutesorby intravenous infusion, expressed asco-amoxiclav, 1.2\u00a0g every 8 hours;neonate30\u00a0mg/kg every 12 hours;child1\u20133 months 30\u00a0mg/kg every 12 hours;child3 months\u201318 years, 30\u00a0mg/kg (max. 1.2\u00a0g) every 8 hours", "Surgical prophylaxis, expressed asco-amoxiclav, 1.2\u00a0g up to 30 minutes before the procedure; for high risk procedures\r\nup to 2\u20133 further doses of 1.2\u00a0g may be given every 8 hours"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "NORADRENALINE (NOREPINEPHRINE)": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by noradrenaline (norepinephrine) ", "name": "Noradrenaline (norepinephrine)", "backrefs": ["Noradrenaline (norepinephrine)"]}}, "VERAPAMIL HYDROCHLORIDE": {"indications": "see under Dose and preparations", "name": "VERAPAMIL HYDROCHLORIDE", "cautions": "first-degree AV block; acute phase of myocardial infarction (avoid if bradycardia, hypotension, left ventricular\r\nfailure); patients taking beta-blockers (important:see below);interactions: Appendix 1 (calcium-channel blockers)", "side-effects": "constipation; less commonly nausea, vomiting,\r\nflushing, headache, dizziness, fatigue, ankle oedema; rarely allergic\r\nreactions (erythema, pruritus, urticaria, angioedema, Stevens-Johnson\r\nsyndrome); myalgia, arthralgia, paraesthesia, erythromelalgia; increased\r\nprolactin concentration; rarely gynaecomastia and gingival hyperplasia\r\nafter long-term treatment; after intravenous administration or high\r\ndoses, hypotension, heart failure, bradycardia, heart block, and asystole;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "hypotension, bradycardia, second- and third-degree AV block, sick sinus syndrome, cardiogenic shock, sino-atrial\r\nblock; history of\r\nheart failure or significantly impaired left ventricular function,\r\neven if controlled by therapy; atrial flutter or fibrillation\r\nassociated with accessory conducting pathways (e.g. Wolff-Parkinson-White\r\nsyndrome); acute porphyria (section 9.8.2)", "hepatic impairment": "oral dose may need to be reduced", "doses": ["mild to moderate hypertension, 240\u00a0mg daily, increased\r\nto twice daily if necessary; angina, 240\u00a0mg twice daily (may sometimes\r\nbe reduced to once daily)"], "pregnancy": "may reduce uterine blood flow with fetal hypoxia;\r\nmanufacturer advises avoid in first trimester unless absolutely necessary;\r\nmay inhibit labour", "breast-feeding": "amount too small to be harmful"}, "OMEPRAZOLE": {"indications": "see under Dose", "name": "OMEPRAZOLE", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  saquinavir increased by omeprazole\u2014manufacturer of saquinavir advises avoid concomitant use", "name": "Omeprazole", "backrefs": ["Esomeprazole", "Raltegravir", "Omeprazole", "Escitalopram"]}, "cautions": "seenotes above;interactions:Appendix 1 (proton pump inhibitors)", "side-effects": "seenotes above; also agitation and impotence", "hepatic impairment": "not more than 20\u00a0mg daily should be needed", "doses": ["By mouth, benign gastric and duodenal\r\nulcers, 20\u00a0mg once daily for 4 weeks in duodenal ulceration or 8 weeks\r\nin gastric ulceration; in severe or recurrent cases increase to 40\u00a0mg\r\ndaily; prevention of relapse in gastric ulcer, 20\u00a0mg once daily, increased\r\nto 40\u00a0mg once daily if necessary; prevention of relapse in duodenal\r\nulcer, 20\u00a0mg once daily (range 10\u201340\u00a0mg daily)", "NSAID-associated duodenal or gastric ulcer and gastroduodenal\r\nerosions, 20\u00a0mg once daily for 4 weeks, continued for further 4 weeks\r\nif not fully healed; prophylaxis in patients with a history of NSAID-associated\r\nduodenal or gastric ulcers, gastroduodenal lesions, or dyspeptic symptoms\r\nwho require continued NSAID treatment, 20\u00a0mg once daily", "Duodenal or benign gastric ulcer associated withHelicobacter\r\npylori, seeRecommended Regimens forHelicobacter pyloriEradication", "Zollinger\u2013Ellison syndrome, initially 60\u00a0mg once daily; usual\r\nrange 20\u2013120\u00a0mg daily (above 80\u00a0mg in 2 divided doses)", "Gastric acid reduction during general anaesthesia (prophylaxis\r\nof acid aspiration), 40\u00a0mg on the preceding evening then 40\u00a0mg 2\u20136\r\nhours before surgery", "Gastro-oesophageal reflux disease, 20\u00a0mg once daily for 4 weeks,\r\ncontinued for further 4\u20138 weeks if not fully healed; 40\u00a0mg once daily\r\nhas been given for 8 weeks in gastro-oesophageal reflux disease refractory\r\nto other treatment; maintenance 20\u00a0mg once daily", "Acid reflux disease (long-term management), 10\u00a0mg daily increasing\r\nto 20\u00a0mg once daily if symptoms return", "Acid-related dyspepsia, 10\u201320\u00a0mg once daily for 2\u20134 weeks according\r\nto response", "Severe ulcerating reflux oesophagitis,childover 1 year, body-weight 10\u201320\u00a0kg, 10\u00a0mg once daily increased if\r\nnecessary to 20\u00a0mg once daily for 4\u201312 weeks; body-weight over 20\u00a0kg,\r\n20\u00a0mg once daily increased if necessary to 40\u00a0mg once daily for 4\u201312\r\nweeks; to be initiated by hospital paediatrician", "By intravenous injectionover 5 minutesorby intravenous infusionover 20\u201330 minutes,\r\nprophylaxis of acid aspiration [unlicensed indication], 40\u00a0mg completed\r\n1 hour before surgery", "Treatment and prevention of benign gastric ulcers, duodenal\r\nulcers, or NSAID-associated ulcers, gastro-oesophageal reflux disease,\r\n40\u00a0mg once daily until oral administration possible", "Zollinger-Ellison syndrome, initially 60\u00a0mg once daily, adjusted\r\naccording to response; daily doses above 60\u00a0mg given in 2 divided\r\ndoses", "Major peptic ulcer bleeding (following endoscopic treatment)\r\n[unlicensed indication], initialintravenous infusionof 80\u00a0mg over 40\u201360 minutes, thenby continuous intravenous\r\ninfusion, 8\u00a0mg/hour for 72 hours (then change to oral therapy)", "Swallow whole,ordisperseMUPS\u00ae tablets in water,ormix capsule contents orMUPS\u00ae tablets with fruit\r\njuice or yoghurt. Preparations consisting of an e/c tablet within\r\na capsule shouldnotbe opened"], "pregnancy": "not known to be harmful", "breast-feeding": "present in milk but not known to be harmful"}, "FLUOCORTOLONE": {"indications": "severe inflammatory skin disorders such as eczemas unresponsive to\r\nless potentcorticosteroids; psoriasis, seenotes above", "name": "FLUOCORTOLONE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily, reducing strength as condition\r\nresponds"]}, "MIZOLASTINE": {"indications": "symptomatic relief of allergy such as hay fever, urticaria", "name": "MIZOLASTINE", "interactions": {"extra": "", "bad": 1, "interaction": " itraconazole inhibits metabolism of mizolastine\u2014avoid concomitant use", "name": "Mizolastine", "backrefs": ["Mizolastine"]}, "cautions": "seenotes above", "side-effects": "seenotes above; weight\r\ngain; anxiety, asthenia;less commonlyarthralgia\r\nand myalgia", "contra-indications": "seenotes above; also susceptibility to QT-interval prolongation (including cardiac disease and hypokalaemia)", "hepatic impairment": "manufacturer advises avoid in significant impairment", "doses": ["adultandchildover 12 years, 10\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "HEPARIN": {"indications": "see under Dose", "name": "HEPARIN", "renal impairment": "risk of bleeding increased in severe impairment\u2014dose\r\nmay need to be reduced", "cautions": "seenotes above; also elderly; concomitant use of drugs that increase risk of bleeding;interactions: Appendix 1 (heparin)", "side-effects": "haemorrhage (seenotes above), thrombocytopenia (see Cautions),rarelyrebound hyperlipidaemia following unfractionated\r\nheparin withdrawal, priapism, hyperkalaemia (see Cautions), osteoporosis\r\n(risk lower with low molecular weight heparins), alopecia on prolonged\r\nuse, injection-site reactions, skin necrosis, and hypersensitivity\r\nreactions (including urticaria, angioedema, and anaphylaxis)", "contra-indications": "haemophilia and other haemorrhagic disorders, thrombocytopenia (including history ofheparin-induced thrombocytopenia), recent cerebral haemorrhage, severe hypertension; peptic ulcer; after major trauma or recent surgery to eye or nervous system; acute bacterial endocarditis; spinal or\r\nepidural anaesthesia with treatment doses of unfractionated or low\r\nmolecular weight heparin; hypersensitivity to unfractionated\r\nor low molecular weight heparin", "hepatic impairment": "risk of bleeding increased\u2014reduce dose or avoid in\r\nsevere impairment (including oesophageal varices)", "doses": ["Treatment of deep-vein thrombosis, pulmonary embolism,\r\nunstable angina, and acute peripheral arterial occlusion,by\r\nintravenous injection, loading dose of 5000\u00a0unitsor75\u00a0units/kg (10\u00a0000\u00a0units in severe pulmonary embolism),\r\nfollowedby continuous intravenous infusionof 18\u00a0units/kg/hourortreatment of deep-vein thrombosis,by subcutaneous\r\ninjectionof 15\u00a0000\u00a0units every 12 hours (laboratory monitoring\r\nessential\u2014preferably on a daily basis, and dose adjusted accordingly);childunder 18 years seeBNF for Children", "Thromboprophylaxis in medical patients (see alsonotes above),by subcutaneous injection, 5000\u00a0units every 8\u201312 hours", "Thrombophylaxis in surgical patients (see alsonotes above),by subcutaneous injection, 5000\u00a0units 2 hours before surgery,\r\nthen every 8\u201312 hours", "Thromboprophylaxis during pregnancy, (but seenotes above),by subcutaneous injection, 5000\u201310\u00a0000\u00a0units every 12 hours\r\n(with monitoring);important:prevention of prosthetic\r\nheart-valve thrombosis in pregnancy calls forspecialist management", "Haemodialysisby intravenous injectioninitially\r\n1000\u20135000\u00a0units, followed bycontinuous intravenous infusionof 250\u20131000\u00a0units/hour", "Myocardial infarction, seesection 2.10.1", "Prevention of clotting in extracorporeal circuits, consult product\r\nliterature", "Doses above take into account the guidelines of the\r\nBritish Society for Haematology; for doses of the low molecular weight\r\nheparins, see  underLow Molecular Weight Heparins"], "pregnancy": "does not cross the placenta; maternal osteoporosis\r\nreported after prolonged use; multidose vials may contain benzyl alcohol\u2014some\r\nmanufacturers advise avoid; see alsonotes above", "breast-feeding": "not excreted into milk due to high molecular\r\nweight"}, "Supplementary preparations": {"name": "Supplementary preparations", "doses": ["amino acid supplement for hypercatabolic or hypermetabolic\r\nstates, 300\u2013400\u00a0mg/kg daily; max. 400\u00a0mg/kg daily, dose not to exceed\r\n20% of total amino acid intake"]}, "DIDANOSINE": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "DIDANOSINE", "renal impairment": "reduce dose if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2; consult product literature", "interactions": {"extra": "Antacids in tablet formulation may affect absorption of other drugs", "bad": 1, "interaction": " allopurinol increases plasma concentration of didanosine (risk of toxicity)\u2014avoid concomitant use", "name": "Didanosine", "backrefs": ["Hydroxycarbamide", "Didanosine"]}, "cautions": "seenotes above; also history\r\nof pancreatitis (preferably avoid, otherwise extreme caution, see\r\nalso below); peripheral neuropathy or hyperuricaemia (see under Side-effects); ophthalmological examination (including visual acuity, colour vision,\r\nand dilated fundus examination) recommended annually or if visual changes occur;interactions:Appendix 1 (didanosine)", "side-effects": "see notes above; also pancreatitis (see also under\r\nCautions), liver failure, non-cirrhotic portal hypertension, anaphylactic\r\nreactions, peripheral neuropathy (switch to another antiretroviral\r\nif peripheral neuropathy develops), diabetes mellitus, hypoglycaemia,\r\nacute renal failure, rhabdomyolysis, dry eyes, retinal and optic nerve\r\nchanges, dry mouth, parotid gland enlargement, sialadenitis, alopecia,\r\nhyperuricaemia (suspend if raised significantly)", "hepatic impairment": "seenotes above; also\r\ninsufficient information but monitor for toxicity", "doses": ["adultunder 60\u00a0kg 250\u00a0mg\r\ndaily in 1\u20132 divided doses, 60\u00a0kg and over 400\u00a0mg daily in 1\u20132 divided\r\ndoses;childunder 18 years seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "seeBreast-feeding"}, "PAPAVERETUM": {"indications": "premedication; enhancement of anaesthesia\r\n(but see section 15.1.4.3); postoperative analgesia; severe chronic\r\npain", "name": "PAPAVERETUM", "renal impairment": "seenotes above", "cautions": "seenotes above; supraventricular tachycardia", "side-effects": "seenotes above; also\r\nhypothermia", "contra-indications": "seenotes above; heart failure secondary to chronic lung disease; phaeochromocytoma", "hepatic impairment": "seenotes above", "doses": ["premedication,by subcutaneousorintramuscular injection, 0.5\u20131\u00a0mL"], "pregnancy": "seenotes above", "breast-feeding": "therapeutic doses unlikely to affect infant"}, "PREDNISOLONE SODIUM PHOSPHATE": {"indications": "eczematous inflammation in otitis externa (see notes\r\nabove)", "name": "PREDNISOLONE SODIUM PHOSPHATE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["ear, apply 2\u20133 drops every 2\u20133 hours; reduce\r\nfrequency when relief obtained;eye,section 11.4.1"]}, "DESFERRIOXAMINE MESILATE": {"indications": "seenotes above; iron poisoning, seeEmergency Treatment of Poisoning", "name": "DESFERRIOXAMINE MESILATE", "renal impairment": "use with caution", "cautions": "eye and ear examinations before treatment and at 3-month intervals\r\nduring treatment; monitor body-weight and\r\nheight in children at 3-month intervals\u2014risk of growth retardation\r\nwith excessive doses; aluminium-related\r\nencephalopathy (may exacerbate neurological dysfunction);interactions:Appendix 1 (desferrioxamine)", "side-effects": "nausea, vomiting, abdominal pain; headache; pyrexia;\r\ngrowth retardation and bone disorders (see Cautions); arthralgia,\r\nmyalgia; hearing disturbances; injection-site reactions;rarelydiarrhoea, hepatic impairment, hypotension (especially when given\r\ntoo rapidly by intravenous injection), anaphylaxis, Yersinia and mucormycosis\r\ninfections, blood dyscrasias (including thrombocytopenia and leucopenia),\r\nleg cramps, bone pain,  visual disturbances (including lens opacity\r\nand retinopathy), rash;very rarelyacute respiratory\r\ndistress, neurological disturbances (including dizziness, neuropathy,\r\nconvulsions, and paraesthesia), renal impairment; muscle spasms also\r\nreported", "doses": ["See notes above; iron poisoning, seeEmergency Treatment of Poisoning", "For full details and warnings relating to\r\nadministration, consult product literature"], "pregnancy": "teratogenic inanimalstudies; manufacturer\r\nadvises use only if potential benefit outweighs risk", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available"}, "NIZATIDINE": {"indications": "see under Dose", "name": "NIZATIDINE", "renal impairment": "use half normal dose if eGFR 20\u201350\u00a0mL/minute/1.73\u00a0m2; use one-quarter normal dose if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  erlotinib advises avoid concomitant use with nizatidine ", "name": "Nizatidine", "backrefs": ["Nizatidine"]}, "cautions": "see notes above; also avoid rapid intravenous\r\ninjection (risk of arrhythmias and postural hypotension);interactions:Appendix 1 (histamine H2-antagonists) and notes above", "side-effects": "see notes above; also sweating;rarelynausea, fever, vasculitis, hyperuricaemia", "hepatic impairment": "manufacturer advises caution", "doses": ["Benign gastric, duodenal or NSAID-associated ulceration,\r\ntreatment, 300\u00a0mg in the eveningor150\u00a0mg twice\r\ndaily for 4\u20138 weeks; maintenance, 150\u00a0mg at night", "Gastro-oesophageal reflux disease, 150\u2013300\u00a0mg twice daily for\r\nup to 12 weeks", "childnot recommended"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "amount too small to be harmful"}, "FLUMETASONE PIVALATE": {"indications": "eczematous inflammation in otitis externa (seenotes above)", "name": "FLUMETASONE PIVALATE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "iodine sensitivity", "doses": ["adultandchildover 2 years apply 2\u20133 drops into the ear twice\r\ndaily for 7\u201310 days"]}, "SILDENAFIL": {"indications": "erectile dysfunction; pulmonary hypertension\r\n(section 2.5.1)", "name": "SILDENAFIL", "renal impairment": "initial dose 25\u00a0mg if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir significantly increases plasma concentration of sildenafil\u2014avoid concomitant use", "name": "Sildenafil", "backrefs": ["Sildenafil"]}, "cautions": "seenotes above; alsobleeding\r\ndisorders or active peptic ulceration;interactions:Appendix 1 (sildenafil)", "side-effects": "seenotes above; alsoless commonlychest pain, drowsiness, hypoaesthesia, vertigo,\r\ntinnitus, dry mouth, fatigue;rarelycerebrovascular\r\naccident and atrial fibrillation", "contra-indications": "seenotes above; alsohereditary degenerative retinal disorders", "hepatic impairment": "initial dose 25\u00a0mg; manufacturer advises avoid in severe\r\nimpairment", "doses": ["adultover 18 years initially\r\n50\u00a0mg approx. 1 hour before sexual activity, subsequent doses adjusted\r\naccording to response to 25\u2013100\u00a0mg as a single dose as needed; max.\r\n1 dose in 24 hours (max. single dose 100\u00a0mg)", "Onset of effect may be delayed if taken with\r\nfood"]}, "ATRACURIUM BESILATE": {"indications": "neuromuscular blockade (short to intermediate duration) for surgery\r\nor during intensive care", "name": "ATRACURIUM BESILATE", "cautions": "seenotes above", "side-effects": "seenotes above; seizures\r\nalso reported", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "Intubation and surgery,adultandchildover 1 month,by\r\nintravenous injection, initially 300\u2013600\u00a0micrograms/kg, then\r\n100\u2013200\u00a0micrograms/kg as requiredorinitiallyby intravenous injection, 200\u2013600\u00a0micrograms/kg followedby intravenous infusion, 300\u2013600\u00a0micrograms/kg/hour", "Intensive care,adultandchildover 1 month,by intravenous injection, initially 300\u2013600\u00a0micrograms/kg (optional) thenby intravenous\r\ninfusion270\u20131770\u00a0micrograms/kg/hour (usual dose 650\u2013780\u00a0micrograms/kg/hour)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ESTRAMUSTINE PHOSPHATE": {"indications": "prostate cancer", "name": "ESTRAMUSTINE PHOSPHATE", "renal impairment": "manufacturer advises caution", "cautions": "seesection 8.1; congestive heart failure; diabetes; hypertension; epilepsy; hypercalcaemia; avoid in acute porphyria (but seesection 9.8.2);interactions: Appendix 1\r\n(estramustine)", "side-effects": "seesection 8.1; also diarrhoea; congestive heart\r\nfailure, ischaemic heart disease, myocardial infarction; oedema (rarely\r\nangioneurotic) impotence, gynaecomastia; altered liver function", "contra-indications": "peptic ulceration, severe cardiovascular disease", "hepatic impairment": "manufacturer advises caution and regular liver function\r\ntests; avoid in severe impairment", "doses": ["0.14\u20131.4\u00a0g daily in divided doses (usual initial dose\r\n560\u2013840\u00a0mg daily)", "Each dose should be taken not less\r\nthan 1 hour before or 2 hours after meals and should not be taken\r\nwith dairy products"]}, "ENTERAL FOODS": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  phenytoin possibly reduced by enteral feeds ", "name": "Enteral Foods", "backrefs": []}}, "ROSUVASTATIN": {"indications": "primary hypercholesterolaemia (type IIa including heterozygous familial\r\nhypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous\r\nfamilial hypercholesterolaemia in patients who have not responded\r\nadequately to diet and other appropriate measures; prevention of cardiovascular\r\nevents in patients at high risk of a first cardiovascular event", "name": "ROSUVASTATIN", "renal impairment": "initially 5\u00a0mg once daily (do not exceed 20\u00a0mg daily)\r\nif eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "possible increased risk of myopathy when  ritonavir given with rosuvastatin\u2014manufacturer of rosuvastatin advises avoid concomitant use", "name": "Rosuvastatin", "backrefs": ["Rosuvastatin", "Norgestimate", "Norgestrel"]}, "cautions": "seenotes above; patients of Asian\r\norigin (see under Dose); max. dose 20\u00a0mg in patients\r\nwith risk factors for myopathy or rhabdomyolysis\r\n(including personal or family history of muscular disorders or toxicity)", "side-effects": "seenotes above; also diabetes mellitus; proteinuria;very rarelyhaematuria", "hepatic impairment": "seenotes above", "doses": ["Hypercholesterolaemia, initially 5\u201310\u00a0mg once daily increased\r\nif necessary at intervals of at least 4 weeks to 20\u00a0mg once daily,\r\nincreased after further 4 weeks to 40\u00a0mg daily only in severe hypercholesterolaemia\r\nwith high cardiovascular risk and under specialist supervision;elderlyinitially 5\u00a0mg once daily; patient ofasianorigin, initially 5\u00a0mg once daily increased\r\nif necessary to max. 20\u00a0mg daily;childunder 18 years seeBNF\r\nfor Children", "Initially 5\u00a0mg once daily with concomitant\r\nfibrate increased if necessary to max. 20\u00a0mg daily", "Prevention of cardiovascular events, 20\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CILOSTAZOL": {"indications": "intermittent claudication in patients without rest pain and no peripheral\r\ntissue necrosis (but see notes above)", "name": "CILOSTAZOL", "renal impairment": "avoid if eGFR less than 25\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of cilostazol (consider reducing dose of cilostazol)", "name": "Cilostazol", "backrefs": ["Cilostazol"]}, "cautions": "atrial or ventricular\r\nectopy, atrial fibrillation, atrial flutter; diabetes\r\nmellitus (higher risk of intra-ocular bleeding); concomitant drugs that increase risk of bleeding;interactions:Appendix 1 (cilostazol)", "side-effects": "gastro-intestinal disturbances; tachycardia, palpitation,\r\nangina, arrhythmia, chest pain, oedema; rhinitis; dizziness, headache;\r\nasthenia; rash, pruritus, ecchymosis;less commonlygastritis, congestive heart failure, postural hypotension, dyspnoea,\r\npneumonia, cough, insomnia, abnormal dreams, anxiety, hyperglycaemia,\r\ndiabetes mellitus, anaemia, haemorrhage, myalgia, hypersensitivity\r\nreactions (including Stevens-Johnson syndrome and toxic epidermal\r\nnecrolysis in rare cases);rarelyanorexia, hypertension,\r\nparesis, increased urinary frequency, bleeding disorders, renal impairment,\r\nconjunctivitis, tinnitus, and jaundice", "contra-indications": "predisposition to bleeding (e.g. active peptic ulcer, haemorrhagic\r\nstroke in previous 6 months, surgery in previous\r\n3 months, proliferative diabetic retinopathy, poorly controlled hypertension); history of ventricular tachycardia, of ventricular fibrillation and of multifocal\r\nventricular ectopics, prolongation of QT interval, congestive heart failure", "hepatic impairment": "avoid in moderate or severe liver disease", "doses": ["100\u00a0mg twice daily (30 minutes before or 2 hours after\r\nfood)"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid"}, "TELITHROMYCIN": {"indications": "see notes above", "name": "TELITHROMYCIN", "renal impairment": "manufacturer advises avoid if possible if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2\u2014if no alternative, use alternating\r\ndaily doses of 800\u00a0mg and 400\u00a0mg, starting with 800\u00a0mg dose", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of concomitant  ritonavir in severe renal and hepatic impairment advised by manufacturer of telithromycin ", "name": "Telithromycin", "backrefs": ["Telithromycin"]}, "cautions": "coronary heart disease, ventricular arrhythmias, bradycardia, hypokalaemia,\r\nhypomagnesaemia\u2014risk of QT interval prolongation; concomitant\r\nadministration of drugs that prolong QT-interval; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (telithromycin)", "side-effects": "diarrhoea, nausea, vomiting, flatulence, abdominal\r\npain, taste disturbances; dizziness, headache;less commonlyconstipation, stomatitis, anorexia, hepatitis, flushing, palpitations,\r\ndrowsiness, insomnia, nervousness, eosinophilia, blurred vision, rash,\r\nurticaria, and pruritus;rarelycholestatic jaundice,\r\narrhythmias, hypotension, transient loss of consciousness, paraesthesia,\r\nand diplopia;very rarelyantibiotic-associated colitis,\r\naltered sense of smell, muscle cramp, erythema multiforme; also reported\r\npancreatitis, confusion, hallucinations and arthralgia", "contra-indications": "myasthenia gravis; history of telithromycin-associated hepatitis or jaundice; prolongation of QT interval; congenital or family history of QT interval prolongation (if not excluded by ECG)", "hepatic impairment": "manufacturer advises caution; see also Hepatic Disorders\r\nabove", "doses": ["800\u00a0mg once daily for 5 days for sinusitis or exacerbation\r\nof chronic bronchitisorfor 7\u201310 days in community-acquired\r\npneumonia;childunder 18 years safety\r\nand efficacy not established", "Tonsillitis or pharyngitis caused byStreptococcus\r\npyogenes,adultandchildover 12 years, 800\u00a0mg once daily for 5 days"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises use only if potential benefit outweighs risk", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "NICOTINIC ACID": {"indications": "adjunct to statin in dyslipidaemia or\r\nused alone if statin not tolerated (see alsolipid-regulating drugs)", "name": "NICOTINIC ACID", "renal impairment": "manufacturer advises use with caution\u2014no information\r\navailable", "interactions": {"extra": "Interactions apply to lipid-regulating doses of nicotinic acid", "bad": 1, "interaction": "increased risk of myopathy when  statins given with nicotinic acid (applies to lipid regulating doses of nicotinic acid)", "name": "Nicotinic Acid", "backrefs": ["Nicotinic Acid"]}, "cautions": "unstable angina, acute myocardial infarction, diabetes\r\nmellitus, gout, history of peptic ulceration;interactions:Appendix 1 (nicotinic acid)", "side-effects": "diarrhoea, nausea, vomiting, abdominal pain, dyspepsia;\r\nflushing; pruritus, rash;less commonlytachycardia,\r\npalpitation, shortness of breath, peripheral oedema, headache, dizziness,\r\nincrease in uric acid, hypophosphataemia, prolonged prothrombin time,\r\nand reduced platelet count;rarelyhypotension, syncope,\r\nrhinitis, insomnia, reduced glucose tolerance, myalgia, myopathy,\r\nmyasthenia;very rarelyanorexia, rhabdomyolysis,\r\nvisual disturbance, and jaundice also reported", "contra-indications": "arterial bleeding; active peptic ulcer disease", "hepatic impairment": "manufacturer advises monitor liver function in mild\r\nto moderate impairment and avoid in severe impairment; discontinue\r\nif severe abnormalities in liver function tests", "doses": ["See under preparation"], "pregnancy": "no information available\u2014manufacturer advises avoid\r\nunless potential benefit outweighs risk", "breast-feeding": "present in milk\u2014avoid"}, "BISACODYL": {"indications": "see under Dose", "name": "BISACODYL", "cautions": "seenotes above", "side-effects": "seenotes above; nausea and vomiting; colitis also\r\nreported;suppositories, local irritation", "contra-indications": "seenotes above, acute surgical abdominal\r\nconditions, acute inflammatory bowel disease, severe dehydration", "doses": ["Constipation,by mouth, 5\u201310\u00a0mg at\r\nnight, increased if necessary to max. 20\u00a0mg at night;child(but seesection\r\n1.6) 4\u201318 years 5\u201320\u00a0mg once daily, adjusted according to response", "By rectumin suppositories, 10\u00a0mg in the morning;child(but seesection\r\n1.6) 2\u201318 years 5\u201310\u00a0mg once daily, adjusted according to response", "Before radiological procedures and surgery,by mouth, 10\u00a0mg in the morning and 10\u00a0mg in the evening on\r\nthe day before procedure, andby rectumin suppositories,\r\n10\u00a0mg 1\u20132 hours before procedure the following day;child4\u201318 years seeBNF for Children", "tablets act in 10\u201312 hours; suppositories\r\nact in 20\u201360 minutes"], "pregnancy": "seePregnancy"}, "DIPIPANONE HYDROCHLORIDE": {"indications": "moderate to severe pain", "name": "DIPIPANONE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; also diabetes mellitus; phaeochromocytoma", "side-effects": "seenotes above; also\r\npsychosis, restlessness, raised intracranial pressure", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["See preparation below"], "pregnancy": "seenotes above", "breast-feeding": "no information available"}, "MAOIS": {"interactions": {"extra": "For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor", "bad": 0, "interaction": "manufacturer of  promethazine advises avoid for 2 weeks after stopping MAOIs ", "name": "MAOIs", "backrefs": ["Apraclonidine", "Tolcapone", "Pholcodine", "MAOIs", "Nefopam", "Brimonidine", "Indoramin", "Promethazine"]}}, "CARBAMAZEPINE": {"indications": "focal and secondary generalised tonic-clonic\r\nseizures, primary generalised tonic-clonic seizures; trigeminal neuralgia;\r\nprophylaxis of bipolar disorder unresponsive to lithium; adjunct in\r\nacute alcohol withdrawal [unlicensed] (section 4.10.1); diabetic neuropathy [unlicensed]\r\n(section 6.1.5)", "name": "CARBAMAZEPINE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "neurotoxicity may occur when  lithium given with carbamazepine without increased plasma concentration of lithium", "name": "Carbamazepine", "backrefs": ["Carbamazepine", "Paliperidone", "Isotretinoin", "Levetiracetam"]}, "cautions": "cardiac disease (see also\r\nContra-indications); skin reactions (see\r\nalso Blood, Hepatic, or Skin Disorders, below and under Side-effects); test for\r\nHLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid\r\nunless no alternative\u2014risk of Stevens-Johnson syndrome in presence\r\nof HLA-B*1502 allele); history of haematological reactions\r\nto other drugs; manufacturer recommends\r\nblood counts and hepatic and renal function tests (but evidence of\r\npractical value uncertain); may exacerbate\r\nabsence and myoclonic seizures; consider\r\nvitamin D supplementation in patients who are immobilised for long\r\nperiods or who have inadequate sun exposure or dietary intake of calcium; susceptibility to angle-closure glaucoma; cross-sensitivity reported with oxcarbazepine and with phenytoin\r\n(see alsoAntiepileptic Hypersensitivity\r\nSyndrome); avoid abrupt withdrawal;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (carbamazepine)", "side-effects": "seenotes above; also dry\r\nmouth, nausea, vomiting, oedema, ataxia, dizziness, drowsiness, fatigue,\r\nheadache, hyponatraemia (leading in rare cases to water intoxication),\r\nblood disorders (including eosinophilia, leucopenia, thrombocytopenia,\r\nhaemolytic anaemia, and aplastic anaemia), dermatitis, urticaria;less commonlydiarrhoea, constipation, involuntary movements\r\n(including nystagmus), visual disturbances;rarelyabdominal pain, anorexia, hepatitis, jaundice, vanishing bile duct\r\nsyndrome, cardiac conduction disorders, hypertension, hypotension,\r\nperipheral neuropathy, dysarthria, aggression, agitation, confusion,\r\ndepression, hallucinations, restlessness, paraesthesia, lymph node\r\nenlargement, muscle weakness, systemic lupus erythematosus, delayed\r\nmulti-organ hypersensitivity disorder (see alsoAntiepileptic Hypersensitivity\r\nSyndrome);very rarelypancreatitis, stomatitis, hepatic failure, taste\r\ndisturbance, exacerbation of coronary artery disease, AV block with\r\nsyncope, circulatory collapse, hypercholesterolaemia, thrombophlebitis,\r\nthromboembolism, pulmonary hypersensitivity (with dyspnoea, pneumonitis,\r\nor pneumonia), psychosis, neuroleptic malignant syndrome, osteomalacia\r\n(see Cautions), osteoporosis, galactorrhoea, gynaecomastia, impaired\r\nmale fertility, interstitial nephritis, renal failure, sexual dysfunction,\r\nurinary frequency, urinary retention, arthralgia, muscle pain, muscle\r\nspasm, conjunctivitis, angle-closure glaucoma, hearing disorders,\r\nacne, alterations in skin pigmentation, alopecia, hirsutism, sweating,\r\nphotosensitivity, purpura, Stevens-Johnson syndrome, toxic epidermal\r\nnecrolysis, aseptic meningitis; suicidal ideation", "contra-indications": "AV conduction abnormalities (unless\r\npaced); history of bone-marrow depression, acute porphyria (section 9.8.2)", "hepatic impairment": "metabolism impaired in advanced liver disease; see\r\nalso Blood, Hepatic, or Skin Disorders, above", "doses": ["Different preparations may vary in bioavailability;\r\nto avoid reduced effect or excessive side-effects, it may be prudent\r\nto avoid changing the formulation", "Epilepsy,by mouth, initially 100\u2013200\u00a0mg\r\n1\u20132 times daily, increased slowly (seenotes above) to usual\r\ndose of 0.8\u20131.2\u00a0g daily in divided doses; in some cases 1.6\u20132\u00a0g daily\r\nin divided doses may be needed;elderlyreduce initial dose;childdaily\r\nin divided doses, up to 1 year 100\u2013200\u00a0mg, 1\u20135 years 200\u2013400\u00a0mg, 5\u201310\r\nyears 400\u2013600\u00a0mg, 10\u201315 years 0.6\u20131\u00a0g", "By rectum, for short-term use (max. 7 days) when\r\noral therapy temporarily not possible; 125-mg suppository approx.\r\nequivalent to 100-mg tablet, but final adjustment should always depend\r\non clinical response (plasma concentration monitoring recommended);\r\nmax. 1\u00a0g daily in 4 divided doses", "Trigeminal neuralgia,by mouth, initially\r\n100\u00a0mg 1\u20132 times daily (but some patients may require higher initial\r\ndose), increased gradually according to response; usual dose 200\u00a0mg\r\n3\u20134 times daily, up to 1.6\u00a0g daily in some patients", "Prophylaxis of bipolar disorder unresponsive to\r\nlithium (see alsosection 4.2.3),by mouth, initially 400\u00a0mg\r\ndaily in divided doses increased until symptoms controlled; usual\r\nrange 400\u2013600\u00a0mg daily; max. 1.6\u00a0g daily", "Treatment of alcohol withdrawal [unlicensed indication],by mouth, initially 800\u00a0mg daily in divided doses, reduced\r\ngradually over 5 days to 200\u00a0mg daily; usual treatment duration 7\u201310\r\ndays", "Diabetic neuropathy [unlicensed indication],by mouth, initially 100\u00a0mg 1\u20132 times daily, increased gradually\r\naccording to response; usual dose 200\u00a0mg 3\u20134 times daily, up to 1.6\u00a0g\r\ndaily in some patients", "Plasma concentration for optimum response\r\n4\u201312\u00a0mg/litre (20\u201350\u00a0micromol/litre)"], "pregnancy": "seePregnancy;\r\nmonitor plasma-carbamazepine concentration", "breast-feeding": "seeBreast-feeding"}, "SPIRONOLACTONE": {"indications": "oedema\r\nand ascites in cirrhosis of the liver; malignant ascites; nephrotic\r\nsyndrome; oedema in congestive heart failure; moderate to severe heart\r\nfailure (adjunct\u2014see alsosection 2.5.5); resistant hypertension [unlicensed\r\nindication] (adjunct\u2014see alsosection 2.5); treatment\r\nof primary hyperaldosteronism", "name": "SPIRONOLACTONE", "renal impairment": "monitor plasma-potassium concentration (high risk of\r\nhyperkalaemia in renal impairment); avoid in acute renal insufficiency\r\nor severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  mitotane advises avoid concomitant use of spironolactone (antagonism of effect)", "name": "Spironolactone", "backrefs": ["Mitotane", "Spironolactone", "Aspirin", "Trimethoprim"]}, "cautions": "potential metabolic products carcinogenic\r\ninrodents; elderly; monitor electrolytes\u2014discontinue if hyperkalaemia\r\noccurs (insevere heart failuremonitor potassium\r\nand creatinine 1 week after initiation and after any dose increase,\r\nmonthly for first 3 months, then every 3 months for 1 year, and then\r\nevery 6 months); acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(diuretics)", "side-effects": "gastro-intestinal disturbances, hepatotoxicity;\r\nmalaise, confusion, drowsiness, dizziness, gynaecomastia, benign breast\r\ntumour, breast pain, menstrual disturbances, changes in libido, hypertrichosis,\r\nelectrolyte disturbances including hyperkalaemia (discontinue) and\r\nhyponatraemia, acute renal failure, hyperuricaemia, leucopenia, agranulocytosis,\r\nthrombocytopenia, leg cramps, alopecia, rash, Stevens-Johnson syndrome", "contra-indications": "hyperkalaemia; anuria; Addison\u2019s disease", "doses": ["Oedema and ascites in cirrhosis of the liver, 100\u2013400\u00a0mg\r\ndaily, adjusted according to response", "Malignant ascites, initially 100\u2013200\u00a0mg daily, increased to\r\n400\u00a0mg daily if required; maintenance dose adjusted according to response", "Nephrotic syndrome, 100\u2013200\u00a0mg daily", "Oedema in congestive heart failure, initially 100\u00a0mg (range\r\n25\u2013200\u00a0mg) daily in single or divided doses; maintenance dose adjusted\r\naccording to response", "Moderate to severe heart failure (adjunct), initially 25\u00a0mg\r\nonce daily, increased according to response to max. 50\u00a0mg once daily\r\n(seesection 2.5.5)", "Resistant hypertension (adjunct), 25\u00a0mg once daily [unlicensed\r\nindication] (seesection 2.5)", "Primary hyperaldosteronism in patients awaiting surgery, 100\u2013400\u00a0mg\r\ndaily; long-term maintenance if surgery inappropriate, use lowest\r\neffective dose", "childunder 18 years\r\nseeBNF for Children"], "pregnancy": "use only if potential benefit outweighs risk\u2014feminisation\r\nof male fetus inanimalstudies", "breast-feeding": "metabolites present in milk, but amount probably\r\ntoo small to be harmful"}, "PHOSPHATES (RECTAL)": {"indications": "rectal use in constipation; bowel evacuation before\r\nabdominal radiological procedures, endoscopy, and surgery", "name": "PHOSPHATES (RECTAL)", "renal impairment": "use enema with caution", "cautions": "elderly and debilitated;with enema, electrolyte disturbances, congestive heart failure,\r\nascites, uncontrolled hypertension, maintain adequate hydration", "side-effects": "local irritation;with enema,\r\nelectrolyte disturbances", "contra-indications": "acute gastro-intestinal conditions (including gastro-intestinal obstruction, inflammatory bowel disease, and conditions\r\nassociated with increased colonic absorption)", "doses": ["constipation,adultandchildover 12 years, 1 suppository, inserted 30 minutes\r\nbefore evacuation required; moisten with water before use"]}, "GLYCOPYRRONIUM BROMIDE": {"indications": "drying secretions\r\n(seePrescribing in Palliative\r\nCare); premedication; intra-operative bradycardia;with neostigminefor reversal of non-depolarising neuromuscular block; hyperhidrosis\r\n(section 13.12)", "name": "GLYCOPYRRONIUM BROMIDE", "cautions": "section 1.2", "side-effects": "section 1.2", "contra-indications": "section 1.2", "doses": ["Premedication,by intramuscularorintravenous injection, 200\u2013400\u00a0microgramsor4\u20135\u00a0micrograms/kg (max. 400\u00a0micrograms);child1 month\u201312 years, 4\u20138\u00a0micrograms/kg (max. 200\u00a0micrograms)", "Intra-operative bradycardia,by intravenous\r\ninjection, 200\u2013400\u00a0microgramsor4\u20135\u00a0micrograms/kg\r\n(max. 400\u00a0micrograms), repeated if necessary;child1 month\u201318 years, 4\u20138\u00a0micrograms/kg (max. 200\u00a0micrograms), repeated\r\nif necessary", "Control of muscarinic side-effects ofneostigminein reversal of non-depolarising neuromuscular block,by intravenous\r\ninjection, 200\u00a0micrograms per 1\u00a0mg of neostigmine,or10\u201315\u00a0micrograms/kg;child1 month\u201312 years, 10\u00a0micrograms/kg (max. 500\u00a0micrograms)"]}, "TOLFENAMIC ACID": {"indications": "treatment of acute migraine", "name": "TOLFENAMIC ACID", "renal impairment": "section 10.1.1", "cautions": "see NSAIDs,section 10.1.1", "side-effects": "see NSAIDs,section 10.1.1; also dysuria (most commonly\r\nin men), confusion, malaise, hallucination, paraesthesia, tremor,\r\neuphoria, fatigue, and visual disturbances reported", "contra-indications": "see NSAIDs,section 10.1.1", "hepatic impairment": "section 10.1.1", "doses": ["adultover 18 years, 200\u00a0mg\r\nat onset repeated once after 1\u20132 hours if necessary"], "pregnancy": "section 10.1.1", "breast-feeding": "amount too small to be harmful"}, "DISTIGMINE BROMIDE": {"indications": "postoperative urinary retention (see\r\nnotes above), neurogenic bladder; myasthenia gravis (section 10.2.1)", "name": "DISTIGMINE BROMIDE", "cautions": "peptic ulcer; conditions where increased motility of the urinary or gastro-intestinal\r\ntract could be harmful; oesophagitis; cardiovascular\r\ndisease; bronchospasm; epilepsy; parkinsonism;interactions:Appendix 1 (parasympathomimetics)", "side-effects": "abdominal pain, diarrhoea, increased salivation;\r\nbradycardia, AV block, hypotension; dyspnoea; muscle twitching; increased\r\nlacrimation, miosis; increased sweating", "contra-indications": "intestinal or urinary\r\nobstruction; severe circulatory insufficiency; asthma", "doses": ["Urinary retention, 5\u00a0mg daily, half an hour before breakfast", "Neurogenic bladder, 5\u00a0mg daily or on alternate days, half an\r\nhour before breakfast"], "pregnancy": "manufacturer advises avoid (may stimulate uterine\r\ncontractions)", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "BICALUTAMIDE": {"indications": "locally advanced prostate cancer at high risk of disease progression,\r\neither alone or as adjuvant treatment to prostatectomy or radiotherapy;\r\nlocally advanced, non-metastatic prostate cancer when surgical castration\r\nor other medical intervention inappropriate; advanced prostate cancer\r\nin combination with gonadorelin analogue or surgical castration", "name": "BICALUTAMIDE", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  coumarins possibly enhanced by bicalutamide ", "name": "Bicalutamide", "backrefs": ["Bicalutamide"]}, "cautions": "consider periodic liver function tests;interactions:Appendix 1 (bicalutamide)", "side-effects": "nausea, diarrhoea, cholestasis, jaundice; asthenia,\r\nweight gain; gynaecomastia, breast tenderness, hot flushes, impotence,\r\ndecreased libido; anaemia; alopecia, dry skin, hirsutism, pruritus;less commonlyvomiting, abdominal pain, dyspepsia, interstitial\r\nlung disease, pulmonary fibrosis, depression, haematuria, thrombocytopenia,\r\nhypersensitivity reactions including angioneurotic oedema and urticaria;rarelycardiovascular disorders (including angina, heart\r\nfailure, and arrhythmias), and hepatic failure", "hepatic impairment": "increased accumulation possible in moderate to severe\r\nimpairment", "doses": ["Locally advanced prostate cancer at high risk of disease\r\nprogression, 150\u00a0mg once daily", "Locally advanced, non-metastatic prostate cancer when surgical\r\ncastration or other medical intervention inappropriate, 150\u00a0mg once\r\ndaily", "Advanced prostate cancer, in combination with gonadorelin analogue\r\nor surgical castration, 50\u00a0mg once daily (started at the same time\r\nas surgical castration or at least 3 days before gonadorelin therapy,\r\nsee alsonotes above)"]}, "ALPROSTADIL": {"indications": "erectile dysfunction (including aid to diagnosis)", "name": "ALPROSTADIL", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with alprostadil ", "name": "Alprostadil", "backrefs": ["Alprostadil"]}, "cautions": "priapism\u2014patients\r\nshould be instructed to report any erection lasting 4\u00a0hours or longer\u2014for management,see section 7.4.5; anatomical deformations of\r\npenis (painful erection more likely)\u2014follow up regularly to detect\r\nsigns of penile fibrosis (consider discontinuation if\r\nangulation, cavernosal fibrosis or Peyronie\u2019s disease develop);interactions:Appendix 1 (prostaglandins)", "side-effects": "hypotension, hypertension; dizziness, headache;\r\npenile pain, other localised pain (buttocks, leg, testicular, abdominal);\r\ninfluenza-like syndrome; urethral burning, urethral bleeding; injection\r\nsite reactions including penile fibrosis, penile oedema, penile rash,\r\nhaematoma, haemosiderin deposits;less commonlynausea,\r\ndry mouth, vasodilatation, syncope, supraventricular extrasystole,\r\nrapid pulse, asthenia, leg cramps, pelvic pain, scrotal or testicular\r\noedema, scrotal erythema, testicular thickening, micturation difficulties,\r\nhaematuria, mydriasis, and sweating; local reactions including penile\r\nwarmth, pruritus, irritation, penile numbness or sensitivity, balantitis,\r\nphimosis, priapism (see section 7.4.5and under Cautions), abnormal ejaculation;rarelyvertigo, urinary-tract infection, and hypersensitivity\r\nreactions (including rash, erythema, urticaria, and anaphylaxis)", "contra-indications": "predisposition to prolonged erection (as in sickle cell anaemia, multiple\r\nmyeloma or leukaemia); not for use with other agents for erectile dysfunction, in patients with penile implants or when sexual activity medically\r\ninadvisable; urethral application also contra-indicated in urethral\r\nstricture, severe hypospadia, severe curvature, balanitis, urethritis", "doses": ["by direct urethral application,adultover 18 years, erectile dysfunction, initially\r\n250\u00a0micrograms adjusted according to response (usual range 0.125\u20131\u00a0mg);\r\nmax. 2 doses in 24 hours and 7 doses in 7 days)", "During initiation of treatmentMUSE\u00ae should be used under medical supervision; self-administration may only be undertaken after proper training"]}, "MENINGOCOCCAL VACCINES": {"indications": "immunisation againstNeisseria\r\nmeningitidis", "name": "MENINGOCOCCAL VACCINES", "cautions": "seesection 14.1", "side-effects": "seesection 14.1; alsorarelysymptoms of meningitis reported (but no evidence\r\nthat the vaccine causes meningococcal C meningitis)", "contra-indications": "seesection 14.1", "doses": ["by intramuscular injection,adultandchildover\r\n1 year 0.5\u00a0mL as a single dose; for routine immunisation inchild2 months\u20131 year, 0.5\u00a0mL, see notes above and\r\nImmunisation schedule,section 14.1"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "ALLOPURINOL": {"indications": "prophylaxis of gout and of uric acid and calcium oxalate renal stones;\r\nprophylaxis of hyperuricaemia associated with cancer chemotherapy", "name": "ALLOPURINOL", "renal impairment": "max. 100\u00a0mg daily, increased only if response inadequate;\r\nin severe impairment, reduce daily dose below 100\u00a0mg, or increase\r\ndose interval; if facilities available, adjust dose to maintain plasma-oxipurinol\r\nconcentration below 100\u00a0micromol/litre", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of rash when  ampicillin given with allopurinol ", "name": "Allopurinol", "backrefs": ["Amoxicillin", "Didanosine", "Ampicillin", "Capecitabine", "Allopurinol"]}, "cautions": "administer prophylactic NSAID (notaspirinorsalicylates) orcolchicineuntil at least 1 month after hyperuricaemia\r\ncorrected (usually for first 3 months) to avoid precipitating an acute\r\nattack; ensure adequate fluid intake (2\u20133\u00a0litres/day); for hyperuricaemia associated with cancer therapy,allopurinoltreatment should be started before cancer therapy;interactions:Appendix 1 (allopurinol)", "side-effects": "rashes (withdrawtherapy; if\r\nrash mild re-introduce cautiously butdiscontinuepromptly if recurrence\u2014hypersensitivity reactions occur rarely and\r\ninclude exfoliation, fever, lymphadenopathy, arthralgia, and eosinophilia\r\nresembling Stevens-Johnson syndrome or toxic epidermal necrolysis,\r\nvasculitis, hepatitis, renal impairment, and very rarely seizures);\r\ngastro-intestinal disorders; rarely malaise, headache, vertigo, drowsiness,\r\nvisual and taste disturbances, hypertension, alopecia, hepatotoxicity,\r\nparaesthesia and neuropathy, gynaecomastia, blood disorders (including\r\nleucopenia, thrombocytopenia, haemolytic anaemia and aplastic anaemia)", "contra-indications": "not a treatment for acute gout but continue\r\nif attack develops when already receivingallopurinol, and treat attack separately (seenotes above)", "hepatic impairment": "reduce dose", "doses": ["Initially 100\u00a0mg daily, preferably after food, then adjusted\r\naccording to plasma or urinary uric acid concentration; usual maintenance\r\ndose in mild conditions 100\u2013200\u00a0mg daily, in moderately severe conditions\r\n300\u2013600\u00a0mg daily, in severe conditions 700\u2013900\u00a0mg daily; doses over\r\n300\u00a0mg daily given in divided doses;childunder 15 years, (in neoplastic conditions, enzyme disorders) 10\u201320\u00a0mg/kg\r\ndaily (max. 400\u00a0mg daily)"], "pregnancy": "toxicity not reported; manufacturer advises use only\r\nif no safer alternative and disease carries risk for mother or child", "breast-feeding": "present in milk\u2014not known to be harmful"}, "CASPOFUNGIN": {"indications": "invasive aspergillosis (seenotes above); invasive\r\ncandidiasis (seenotes above); empirical treatment of systemic fungal infections in patients\r\nwith neutropenia", "name": "CASPOFUNGIN", "interactions": {"extra": "", "bad": 0, "interaction": " nevirapine possibly reduces plasma concentration of caspofungin\u2014consider increasing dose of caspofungin", "name": "Caspofungin", "backrefs": ["Caspofungin"]}, "cautions": "interactions:Appendix 1 (caspofungin)", "side-effects": "nausea, diarrhoea, vomiting; dyspnoea; headache;\r\nhypokalaemia; arthralgia; rash, pruritus, sweating, injection-site\r\nreactions;less commonlyabdominal pain, dyspepsia,\r\ndry mouth, dysphagia, taste disturbances, anorexia, constipation,\r\nflatulence, cholestasis, hepatic dysfunction, ascites, palpitation,\r\narrhythmia, chest pain, heart failure, thrombophlebitis, flushing,\r\nhypotension, hypertension, bronchospasm, cough, dizziness, fatigue,\r\nparaesthesia, hypoaesthesia, sleep disturbances, tremor, anxiety,\r\ndisorientation, hyperglycaemia, renal failure, hypomagnesaemia, hypocalcaemia,\r\nmetabolic acidosis, anaemia, thrombocytopenia, leucopenia, myalgia,\r\nmuscular weakness, blurred vision, and erythema multiforme; also reported,\r\nadult respiratory distress syndrome and anaphylaxis", "hepatic impairment": "70\u00a0mg on first day then 35\u00a0mg once daily in moderate\r\nimpairment; no information available for severe impairment", "doses": ["By intravenous infusion, 70\u00a0mg on first\r\nday then 50\u00a0mg once daily (70\u00a0mg once daily if body-weight over 80\u00a0kg);childunder 18 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid unless essential\u2014toxicity\r\ninanimalstudies", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid"}, "MILRINONE": {"indications": "short-term treatment of severe congestive heart failure unresponsive\r\nto conventional maintenance therapy (not immediately after myocardial\r\ninfarction); acute heart failure, including low output states following\r\nheart surgery", "name": "MILRINONE", "renal impairment": "reduce dose and monitor response if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2\u2014consult product literature for details", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  anagrelide advises avoid concomitant use with milrinone ", "name": "Milrinone", "backrefs": ["Anagrelide", "Milrinone"]}, "cautions": "see underEnoximone; also correct hypokalaemia;interactions:Appendix 1 (phosphodiesterase type-3 inhibitors)", "side-effects": "ectopic beats, ventricular tachycardia, supraventricular\r\narrhythmias (more likely in patients with pre-existing arrhythmias),\r\nhypotension; headache;less commonlyventricular\r\nfibrillation, chest pain, tremor, hypokalaemia, thrombocytopenia;very rarelybronchospasm, anaphylaxis, and rash", "contra-indications": "severe hypovolaemia", "doses": ["By intravenous injectionover 10 minutes,\r\neither undiluted or diluted before use, 50\u00a0micrograms/kg followed\r\nbyintravenous infusionat a rate of 375\u2013750\u00a0nanograms/kg/minute,\r\nusually for up to 12\u00a0hours following surgery or for 48\u201372 hours in\r\ncongestive heart failure; max. daily dose 1.13\u00a0mg/kg"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PALIPERIDONE": {"indications": "maintenance in schizophrenia in patients\r\npreviously responsive to paliperidone or risperidone", "name": "PALIPERIDONE", "renal impairment": "initial dose 100\u00a0mg on day 1 and then 75\u00a0mg on day 8\r\nif eGFR 50\u201380\u00a0mL/minute/1.73\u00a0m2; recommended maintenance\r\ndose 50\u00a0mg (range 25\u2013100\u00a0mg) monthly if eGFR 50\u201380\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " carbamazepine reduces plasma concentration of paliperidone ", "name": "Paliperidone", "backrefs": ["Paliperidone"]}, "cautions": "seePaliperidone(section 4.2.1) andnotes above", "side-effects": "seePaliperidone(section 4.2.1) andnotes above", "hepatic impairment": "seePaliperidone(section 4.2.1)", "doses": ["By deep intramuscular injectioninto the\r\ndeltoid muscle, 150\u00a0mg on day 1, then 100\u00a0mg on day 8, then adjusted\r\nat monthly intervals according to response; recommended maintenance\r\ndose 75\u00a0mg (range 25\u2013150\u00a0mg) monthly", "Following the second dose, monthly maintenance\r\ndoses can be administered into either the deltoid or gluteal muscle;\r\nfor missed doses see product literature"], "pregnancy": "seePaliperidone(section 4.2.1)", "breast-feeding": "seePaliperidone(section 4.2.1)"}, "CLONIDINE HYDROCHLORIDE": {"indications": "prevention of recurrent migraine\r\n(but see notes above), vascular headache, menopausal flushing; hypertension\r\n(section 2.5.2)", "name": "CLONIDINE HYDROCHLORIDE", "renal impairment": "use with caution in severe impairment\u2014reduce initial\r\ndose and increase gradually", "cautions": "depressive illness; heart failure; Raynaud\u2019s syndrome; concurrent antihypertensive therapy; cerebrovascular disease; polyneuropathy; constipation;interactions:Appendix 1 (clonidine)", "side-effects": "constipation, dry mouth, nausea, vomiting; postural\r\nhypotension; depression, sleep disorder, dizziness, headache, drowsiness;\r\nerectile dysfunction;less commonlyRaynaud\u2019s syndrome,\r\nparaesthesia, hallucination, rash, and pruritus;rarelyAV block, gynaecomastia, and alopecia", "contra-indications": "severe bradyarrhythmia", "doses": ["adultover 18 years, 50\u00a0micrograms\r\ntwice daily, increased after 2 weeks to 75\u00a0micrograms twice daily\r\nif necessary"], "pregnancy": "avoid unless potential benefit outweighs risk", "breast-feeding": "avoid"}, "LACOSAMIDE": {"indications": "seenotes above", "name": "LACOSAMIDE", "renal impairment": "titrate dose with caution; max. 250\u00a0mg daily if eGFR\r\nless than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "risk of PR-interval prolongation (including conduction problems, severe cardiac disease, and concomitant\r\nuse of drugs that prolong PR interval), elderly;interactions:Appendix 1\r\n(lacosamide)", "side-effects": "nausea, vomiting, constipation, flatulence, dizziness,\r\nheadache, impaired coordination, cognitive disorder, drowsiness, tremor,\r\ndepression, fatigue, abnormal gait, blurred vision, nystagmus, pruritus;rarelymulti-organ hypersensitivity reaction (seeAntiepileptic Hypersensitivity\r\nSyndrome);also reporteddyspepsia, dry mouth, AV block, bradycardia,\r\nPR-interval prolongation, atrial fibrillation, atrial flutter, aggression,\r\nagitation, psychosis, euphoria, confusion, hypoesthesia, dysarthria,\r\nirritability, muscle spasm, tinnitus, rash; suicidal ideation", "contra-indications": "second- or third-degree AV block", "hepatic impairment": "caution in severe impairment\u2014no information available", "doses": ["By mouthorby\r\nintravenous infusionover 15\u201360 minutes (for up to 5 days),adultandchildover\r\n16 years, initially 50\u00a0mg twice daily, increased weekly by 50\u00a0mg twice\r\ndaily; max. 200\u00a0mg twice daily"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "OCTREOTIDE": {"indications": "see under Dose", "name": "OCTREOTIDE", "interactions": {"extra": "", "bad": 0, "interaction": "requirements for  insulin possibly reduced by octreotide ", "name": "Octreotide", "backrefs": ["Octreotide"]}, "cautions": "seenotes above; monitor thyroid function on long-term therapy;interactions:Appendix 1 (octreotide)", "side-effects": "seenotes above; also arrhythmias, bradycardia,\r\ndyspnoea, headache, dizziness, dehydration, alopecia,\r\nrash; hepatitis also reported", "hepatic impairment": "adjustment of maintenance dose of non-depot preparations\r\nmay be necessary in patients with liver cirrhosis", "doses": ["acromegaly (test doseby subcutaneous injection50\u2013100\u00a0micrograms if subcutaneous octreotide not previously given),\r\nneuroendocrine (particularly carcinoid) tumour adequately controlled\r\nby subcutaneous octreotide,by deep intramuscular injectioninto gluteal muscle, initially 20\u00a0mg every 4 weeks for 3 months\r\nthen adjusted according to response; max. 30\u00a0mg every 4 weeks"], "pregnancy": "possible effect on fetal growth; manufacturer advises\r\nuse only if potential benefit outweighs risk and effective contraception\r\nrequired during treatment", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "ROTIGOTINE": {"indications": "Parkinson\u2019s disease, either used alone or as adjunct to co-beneldopa\r\nor co-careldopa; moderate to severe restless legs syndrome", "name": "ROTIGOTINE", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  metoclopramide advised by manufacturer of rotigotine (antagonism of effect)", "name": "Rotigotine", "backrefs": ["Rotigotine"]}, "cautions": "seenotes above; ophthalmic testing recommended; avoid\r\nexposure of patch to heat; withdraw gradually;interactions:Appendix 1 (rotigotine)", "side-effects": "seenotes above; also\r\nconstipation, dry mouth, dyspepsia, nausea, vomiting, weight changes;\r\nhypertension, postural hypotension, palpitation, peripheral oedema;\r\nhiccup; asthenia, dizziness, drowsiness (includingsudden onset of sleep),\r\nsleep disturbances, dyskinesia, hallucinations, headache, syncope,\r\nsweating, rash, pruritus;less commonlyabdominal\r\npain, atrial fibrillation, hypotension, confusion, paranoia, compulsive\r\nbehaviour (seenotes above), erectile\r\ndysfunction, and visual disturbances;rarelytachycardia,\r\nseizures, irritability, obsessive compulsive disorder, and psychotic\r\ndisorder", "hepatic impairment": "caution in severe impairment\u2014no information available", "doses": ["Monotherapy in Parkinson\u2019s disease, initially apply \u20182\u00a0mg/24\r\nhours\u2019 patch, increased in steps of 2\u00a0mg/24 hours at weekly intervals\r\nif required; max. 8\u00a0mg/24 hours", "Adjunctive therapy with levodopa in Parkinson\u2019s disease, initially\r\napply \u20184\u00a0mg/24 hours\u2019 patch, increased in steps of 2\u00a0mg/24 hours at\r\nweekly intervals if required; max. 16\u00a0mg/24 hours", "Restless legs syndrome, initially apply \u20181\u00a0mg/24 hours\u2019 patch,\r\nincreased in steps of 1\u00a0mg/24 hours at weekly intervals if required;\r\nmax. 3\u00a0mg/24 hours", "Apply patch to dry, non-irritated skin on\r\ntorso, thigh, or upper arm, removing after 24 hours and siting replacement\r\npatch on a different area (avoid using the same area for 14 days)"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "may suppress lactation; avoid\u2014present in milk\r\ninanimalstudies"}, "BUMETANIDE": {"indications": "oedema (seenotes above)", "name": "BUMETANIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\ngynaecomastia, breast pain, musculoskeletal pain (associated with\r\nhigh doses in renal failure)", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, 1\u00a0mg in the morning, repeated\r\nafter 6\u20138 hours if necessary; severe cases, 5\u00a0mg daily increased by\r\n5\u00a0mg every 12\u201324 hours according to response;elderly, 500\u00a0micrograms daily may be sufficient", "By intravenous injection, 1\u20132\u00a0mg,\r\nrepeated after 20 minutes if necessary;elderly, 500\u00a0micrograms daily may be sufficient", "By intravenous infusion, 2\u20135\u00a0mg over\r\n30\u201360 minutes;elderly, 500\u00a0micrograms\r\ndaily may be sufficient", "By intramuscular injection, 1\u00a0mg\r\ninitially then adjusted according to response;elderly, 500\u00a0micrograms daily may be sufficient"], "pregnancy": "seenotes above", "breast-feeding": "no information available; may inhibit lactation"}, "PROPRANOLOL": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  muscle relaxants enhanced by propranolol ", "name": "Propranolol", "backrefs": ["Imipramine", "Propranolol", "Rizatriptan", "Chlorpromazine", "Pyridostigmine", "Bupivacaine"]}}, "EPOETIN ALFA, BETA, THETA, and ZETA": {"indications": "see under preparations, below", "name": "EPOETIN ALFA, BETA, THETA, and ZETA", "cautions": "seenotes above; alsoinadequately treated or poorly controlled blood pressure (monitor closely blood pressure,\r\nreticulocyte counts, haemoglobin, and electrolytes), interrupt treatment if blood pressure uncontrolled; sudden stabbing migraine-like pain\r\nis warning of a hypertensive crisis; sickle-cell\r\ndisease (lower target haemoglobin concentration may be appropriate); ischaemic vascular disease; thrombocytosis (monitor platelet count for first 8 weeks); epilepsy; malignant disease; increase in unfractionated or low molecular weightheparindose may be needed during dialysis; risk of thrombosis may be increased when used for\r\nanaemia in adults receiving cancer chemotherapy; risk of thrombosis may be increased when used for anaemia before\r\northopaedic surgery\u2014avoid in cardiovascular disease\r\nincluding recent myocardial infarction or cerebrovascular accident", "side-effects": "diarrhoea, nausea, vomiting; dose-dependent increase\r\nin blood pressure or aggravation of hypertension; in isolated patients\r\nwith normal or low blood pressure, hypertensive crisis with encephalopathy-like\r\nsymptoms and generalised tonic-clonic seizures requiring immediate\r\nmedical attention; headache; dose-dependent increase in platelet count\r\n(but thrombocytosis rare) regressing during treatment; influenza-like\r\nsymptoms (may be reduced if intravenous injection given over 5 minutes);\r\ncardiovascular events; shunt thrombosis especially if tendency to\r\nhypotension or arteriovenous shunt complications;very rarelysudden loss of efficacy because of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue erythropoietin therapy)\u2014see alsonotes above, hyperkalaemia,\r\nhypersensitivity reactions (including anaphylaxis and angioedema),\r\nskin reactions, injection-site reactions, and peripheral oedema also\r\nreported", "contra-indications": "pure red\r\ncell aplasia following erythropoietin therapy (see alsonotes above); uncontrolled hypertension; patients unable\r\nto receive thromboprophylaxis; avoid injections containing\r\nbenzyl alcohol in neonates(see under preparations,\r\nbelow)", "hepatic impairment": "manufacturers advise caution in chronic hepatic failure", "doses": ["symptomatic anaemia associated with chronic renal failure\r\n(see alsoMHRA/CHM advice),by subcutaneous injection,adultandchildover 3 years, initially\r\n20\u00a0units/kg 3 times weekly for 4 weeks, increased according to response\r\nat intervals of 4 weeks in steps of 20\u00a0units/kg 3 times weekly; total\r\nweekly dose may be divided into daily doses; maintenance dose, initially\r\nreduce dose by half then adjust according to response at intervals\r\nof 1\u20132 weeks; total weekly maintenance dose may be given as a single\r\ndose or in 3 or 7 divided doses; max. 720\u00a0units/kg weekly"], "pregnancy": "no evidence of harm; benefits probably outweigh risk\r\nof anaemia and of transfusion in pregnancy", "breast-feeding": "unlikely to be present in milk; minimal effect\r\non infant"}, "SODIUM CLODRONATE": {"indications": "see under Dose", "name": "SODIUM CLODRONATE", "renal impairment": "use half normal dose if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  estramustine increased by sodium clodronate ", "name": "Sodium Clodronate", "backrefs": ["Sodium Clodronate", "Estramustine"]}, "cautions": "monitor renal and hepatic function and white cell\r\ncount; also monitor serum calcium and phosphate periodically; renal dysfunction reported in patients receiving concomitant NSAIDs; maintain adequate fluid intake during treatment; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, seeMHRA/CHM advice;interactions:Appendix 1 (bisphosphonates)", "side-effects": "nausea, diarrhoea, skin reactions, bronchospasm;rarelyatypical femoral fractures (seeMHRA/CHM advice);very rarelyosteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw)", "contra-indications": "acute gastro-intestinal inflammatory\r\nconditions", "doses": ["2 tablets daily in single or two divided doses; may be\r\nincreased to max. 4 tablets daily"], "pregnancy": "avoid", "breast-feeding": "no information available"}, "ROPIVACAINE HYDROCHLORIDE": {"indications": "see under Dose", "name": "ROPIVACAINE HYDROCHLORIDE", "renal impairment": "caution in severe impairment; increased risk of systemic\r\ntoxicity in chronic renal failure", "cautions": "seeCautions of Local Anaesthetics;\r\nalso acute porphyria (section 9.8.2);interactions:Appendix 1 (ropivacaine)", "side-effects": "seeToxicity and Side-effects;\r\nalso hypertension, pyrexia;less commonlysyncope and hypothermia", "contra-indications": "seeContra-indications of Local\r\nAnaesthetics", "hepatic impairment": "use with caution in severe impairment", "doses": ["To avoid excessive dosage in obese patients, dose may\r\nneed to be calculated on the basis of ideal body-weight", "Doses should be adjusted according to patient\u2019s\r\nphysical status and nature of procedure\u2014importantsee also under Administration,section 15.2", "Surgical anaesthesia", "Lumbar epidural,adultandchildover 12 years, 15\u201320\u00a0mL\r\n(150\u2013200\u00a0mg) of 10\u00a0mg/mL solutionor15\u201325\u00a0mL (113\u2013188\u00a0mg)\r\nof 7.5\u00a0mg/mL solution; caesarean section, 15\u201320\u00a0mL (113\u2013150\u00a0mg) of\r\n7.5\u00a0mg/mL solution in incremental doses", "Thoracic epidural(to establish block for postoperative\r\npain),adultandchildover 12 years, 5\u201315\u00a0mL (38\u2013113\u00a0mg) of 7.5\u00a0mg/mL solution", "Major nerve block(brachial plexus block),adultandchildover\r\n12 years, 30\u201340\u00a0mL (225\u2013300\u00a0mg) of 7.5\u00a0mg/mL solution", "Field block,adultandchildover 12 years, 1\u201330\u00a0mL\r\n(7.5\u2013225\u00a0mg) of 7.5\u00a0mg/mL solution", "Acute pain using 2\u00a0mg/mL solution", "Lumbar epidural,adultandchildover 12 years, 10\u201320\u00a0mL\r\n(20\u201340\u00a0mg) followed by 10\u201315\u00a0mL (20\u201330\u00a0mg) at intervals of at least\r\n30 minutesor6\u201310\u00a0mL/hour (12\u201320\u00a0mg/hour) as acontinuous epidural infusionfor labour painor6\u201314\u00a0mL/hour (12\u201328\u00a0mg/hour) as acontinuous epidural infusionfor postoperative pain", "Thoracic epidural,adultandchildover 12 years, 6\u201314\u00a0mL/hour\r\n(12\u201328\u00a0mg/hour) as acontinuous infusion", "Field block,adultandchildover 12 years, 1\u2013100\u00a0mL\r\n(2\u2013200\u00a0mg)", "Peripheral nerve block,adultandchildover 12 years, 5\u201310\u00a0mL/hour\r\n(10\u201320\u00a0mg/hour) as acontinuous infusionorbyintermittent injection", "childunder 12 years, consult\r\nproduct literature"], "pregnancy": "not known to be harmful; do not use for paracervical\r\nblock in obstetrics", "breast-feeding": "not known to be harmful"}, "KETAMINE": {"indications": "induction and maintenance of anaesthesia (but rarely used)", "name": "KETAMINE", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of CNS toxicity when  memantine given with ketamine (manufacturer of memantine advises avoid concomitant use)", "name": "Ketamine", "backrefs": ["Atracurium", "Ketamine"]}, "cautions": "see underIntravenous Anaestheticsandnotes above; dehydration; hypertension; respiratory\r\ntract infection; increased cerebrospinal\r\nfluid pressure; predisposition to seizures, hallucinations, or nightmares; psychotic disorders; head injury or intracranial\r\nmass lesions; thyroid dysfunction; raised intra-ocular pressure;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above; also nausea,\r\nvomiting, tachycardia, hypertension, diplopia, nystagmus, rash;less commonlyarrhythmias, hypotension, bradycardia, respiratory\r\ndepression, laryngospasm;rarelyhypersalivation,\r\napnoea, insomnia, cystitis (including haemorrhagic); raised intra-ocular\r\npressure also reported", "contra-indications": "see underIntravenous Anaesthetics; hypertension, pre-eclampsia or eclampsia, severe cardiac disease, stroke; raised intracranial pressure; head trauma; acute porphyria (section 9.8.2)", "hepatic impairment": "consider dose reduction", "doses": ["By intramuscular injection, short\r\nprocedures, initially 6.5\u201313\u00a0mg/kg, adjusted according to response\r\n(10\u00a0mg/kg usually produces 12\u201325 minutes of surgical anaesthesia)", "Diagnostic manoeuvres and procedures not involving intense pain,\r\ninitially 4\u00a0mg/kg", "By intravenous injectionover at least 60 seconds,\r\nshort procedures, initially 1\u20134.5\u00a0mg/kg, adjusted according to response\r\n(2\u00a0mg/kg usually produces 5\u201310 minutes of surgical anaesthesia)", "By intravenous infusionof a solution containing\r\n1\u00a0mg/mL, longer procedures, induction, total dose of 0.5\u20132\u00a0mg/kg;\r\nmaintenance, 10\u201345\u00a0micrograms/kg/minute, rate adjusted according to\r\nresponse"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "avoid for at least 12 hours after last dose"}, "IVABRADINE": {"indications": "treatment of angina in patients in\r\nnormal sinus rhythm (see notes above)", "name": "IVABRADINE", "renal impairment": "manufacturer advises use with caution if eGFR less than\r\n15\u00a0mL/minute/1.73\u00a0m2\u2014no information available", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of ivabradine\u2014avoid concomitant use", "name": "Ivabradine", "backrefs": ["Ivabradine"]}, "cautions": "mild heart failure including asymptomatic left ventricular dysfunction; monitor\r\nfor atrial fibrillation or other arrhythmias (treatment\r\nineffective); hypotension (avoid if severe); retinitis pigmentosa; elderly;interactions: Appendix 1 (ivabradine)", "side-effects": "bradycardia, first-degree heart block, ventricular\r\nextrasystoles; headache, dizziness; visual disturbances including\r\nphosphenes and blurred vision;less commonlynausea,\r\nconstipation, diarrhoea, palpitations, supraventricular extrasystoles,\r\ndyspnoea, vertigo, muscle cramps, eosinophilia, hyperuricaemia, and\r\nraised plasma-creatinine concentration", "contra-indications": "severe bradycardia (not to be\r\ninitiated if heart rate below 60 beats per minute); cardiogenic shock; acute myocardial infarction; immediately after cerebrovascular accident; sick-sinus syndrome; sino-atrial\r\nblock; moderate to severe heart failure; patients with pacemaker; unstable\r\nangina; second- and third-degree heart block; congenital\r\nQT syndrome", "hepatic impairment": "manufacturer advises caution in moderate impairment;\r\navoid in severe impairment", "doses": ["Initially 5\u00a0mg  twice daily, increased if necessary after\r\n3\u20134 weeks to 7.5\u00a0mg twice daily (if not tolerated reduce dose to 2.5\u20135\u00a0mg\r\ntwice daily);elderlyinitially 2.5\u00a0mg\r\ntwice daily", "Ventricular rate at rest should not be allowed\r\nto fall below 50 beats per minute"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid"}, "METHYLNALTREXONE BROMIDE": {"indications": "opioid-induced constipation in terminally\r\nill patients, when response to other laxatives is inadequate", "name": "METHYLNALTREXONE BROMIDE", "renal impairment": "if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2, reduce\r\ndose as follows: body-weight under 62\u00a0kg, 75\u00a0micrograms/kg on alternate\r\ndays; body-weight 62\u2013114\u00a0kg, 8\u00a0mg on alternate days; body-weight over\r\n114\u00a0kg, 75\u00a0micrograms/kg on alternate days", "cautions": "diverticular disease; faecal impaction; patients with colostomy or peritoneal catheter", "side-effects": "abdominal pain, nausea, diarrhoea, flatulence;\r\ndizziness; injection site reactions, hyperhidrosis; also reported\r\ngastro-intestinal perforation", "contra-indications": "gastro-intestinal obstruction; acute surgical abdominal conditions", "hepatic impairment": "manufacturer advises avoid in severe hepatic impairment\u2014no\r\ninformation available", "doses": ["By subcutaneous injection,adultover 18 years, body-weight under 38\u00a0kg, 150\u00a0micrograms/kg\r\non alternate days; body-weight 38\u201362\u00a0kg, 8\u00a0mg on alternate days; body-weight\r\n62\u2013114\u00a0kg, 12\u00a0mg on alternate days; body-weight over 114\u00a0kg, 150\u00a0micrograms/kg\r\non alternate days; may be given less frequently depending on response;\r\n2 consecutive doses may be given 24 hours apart if no response to\r\ntreatment on the preceding day; rotate sites of injection; max. duration\r\nof treatment 4 months", "May act within 30\u201360 minutes"], "pregnancy": "toxicity at high doses inanimalstudies\u2014manufacturer advises avoid unless essential", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014present in milk inanimalstudies"}, "TRIAMCINOLONE": {"indications": "suppression of inflammatory and allergic\r\ndisorders; see also notes above; rheumatic disease (section 10.1.2); skin (section 13.4)", "name": "TRIAMCINOLONE", "renal impairment": "seenotes above", "cautions": "seenotes above; also high dosage may cause proximal myopathy, avoid in chronic therapy", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By deep intramuscular injection, into gluteal\r\nmuscle, 40\u00a0mg of acetonide for depot effect, repeated at intervals\r\naccording to the patient\u2019s response; max. single dose 100\u00a0mg"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "METHYLDOPA": {"indications": "hypertension", "name": "METHYLDOPA", "renal impairment": "start with small dose; increased sensitivity to hypotensive\r\nand sedative effect", "interactions": {"extra": "", "bad": 1, "interaction": "neurotoxicity may occur when  lithium given with methyldopa without increased plasma concentration of lithium", "name": "Methyldopa", "backrefs": ["Methyldopa"]}, "cautions": "monitor blood counts and liver-function\r\nbefore treatment and at intervals during first 6\u201312 weeks or if unexplained\r\nfever occurs; history of depression; positive direct Coombs\u2019 test in up to 20% of patients\r\n(may affect blood cross-matching); interference\r\nwith laboratory tests;interactions:Appendix 1 (methyldopa)", "side-effects": "gastro-intestinal disturbances, dry mouth, stomatitis,\r\nsialadenitis; bradycardia, exacerbation of angina, postural hypotension,\r\noedema; sedation, headache, dizziness, asthenia, myalgia, arthralgia,\r\nparaesthesia, nightmares, mild psychosis, depression, impaired mental\r\nacuity, parkinsonism, Bell\u2019s palsy; hepatitis, jaundice; pancreatitis;\r\nhaemolytic anaemia; bone-marrow depression, leucopenia, thrombocytopenia,\r\neosinophilia; hypersensitivity reactions including lupus erythematosus-like\r\nsyndrome, drug fever, myocarditis, pericarditis; rashes (including\r\ntoxic epidermal necrolysis); nasal congestion, failure of ejaculation,\r\nimpotence, decreased libido, gynaecomastia, hyperprolactinaemia, amenorrhoea", "contra-indications": "depression, phaeochromocytoma; acute porphyria (section 9.8.2)", "hepatic impairment": "manufacturer advises caution in history of liver disease;\r\navoid in active liver disease", "doses": ["Initially 250\u00a0mg 2\u20133 times daily, increased gradually\r\nat intervals of at least 2 days, max. 3\u00a0g daily;elderlyinitially 125\u00a0mg twice daily, increased gradually, max. 2\u00a0g daily"], "pregnancy": "not known to be harmful", "breast-feeding": "amount too small to be harmful"}, "MIFEPRISTONE": {"indications": "see under dose", "name": "MIFEPRISTONE", "renal impairment": "manufacturer advises avoid", "interactions": {"extra": "", "bad": 0, "interaction": "effect of  corticosteroids (including inhaled corticosteroids) may be reduced for 3\u20134 days after mifepristone ", "name": "Mifepristone", "backrefs": ["Mifepristone"]}, "cautions": "asthma (avoid if severe\r\nand uncontrolled); haemorrhagic disorders and anticoagulant therapy; prosthetic heart valve or history of endocarditis (seesection 5.1table 2); risk factors for or existing cardiovascular\r\ndisease; adrenal suppression (may require corticosteroid);interactions: Appendix\r\n1 (mifepristone)", "side-effects": "gastro-intestinal cramps; uterine contractions,\r\nvaginal bleeding (sometimes severe) may occur between administration\r\nofmifepristoneand surgery (and rarely abortion\r\nmay occur before surgery);less commonlyhypersensitivity\r\nreactions including rash and urticaria;rarelyhypotension,\r\nmalaise, headache, fever, hot flushes, dizziness, and chills; infections\r\n(including toxic shock syndrome) also reported", "contra-indications": "uncontrolled severe asthma; suspected ectopic pregnancy (use other specific\r\nmeans of termination); chronic adrenal failure; acute porphyria (section 9.8.2)", "hepatic impairment": "manufacturer advises avoid", "doses": ["Medical termination of intra-uterine pregnancy of\r\nup to 49 days gestation,by mouth, mifepristone 600\u00a0mg\r\nas a single dose under medical supervision followed 36\u201348 hours later\r\n(unless abortion already complete) by gemeprost 1\u00a0mgby vaginaormisoprostol 400\u00a0microgramsby mouth[unlicensed]; alternative regimen, mifepristone 200\u00a0mgby\r\nmouthas a single dose followed 36\u201348 hours later (unless\r\nabortion already complete) by gemeprost 1\u00a0mgby vagina; observe for at least 3 hours (or until bleeding or pain at acceptable\r\nlevel); follow-up visit within 2 weeks to verify complete expulsion\r\nand to assess vaginal bleeding", "Medical termination of intra-uterine pregnancy of\r\n50\u201363 days gestation,by mouth, mifepristone 600\u00a0mg\r\n(200\u00a0mg also effective) as a single dose under medical supervision,\r\nfollowed 36\u201348 hours later (unless abortion already complete) by gemeprost\r\n1\u00a0mgby vagina; observe for at least 3 hours (or until\r\nbleeding or pain at acceptable level); follow-up visit within 2 weeks\r\nto verify complete expulsion and to assess vaginal bleeding", "Cervical ripening before mechanical cervical dilatation\r\nfor termination of pregnancy of up to 84 days gestation,by\r\nmouth, mifepristone 200\u00a0mg as a single dose under medical\r\nsupervision 36\u201348 hours before procedure", "Termination of pregnancy of 13\u201324 weeks gestation\r\n(in combination with a prostaglandin),by mouth,mifepristone600\u00a0mg (200\u00a0mg may be effective) as a single\r\ndose under medical supervision followed 36\u201348 hours later bygemeprost1\u00a0mgby vaginaevery 3 hours up\r\nto max. 5\u00a0mgormisoprostol (seeabove[unlicensed]); if abortion does not occur,\r\n24 hours after start of treatment repeat course ofgemeprost1\u00a0mgby vaginaup to max. 5\u00a0mg; follow-up visit after\r\nappropriate interval to assess vaginal bleeding recommended", "Careful monitoring of blood pressure and\r\npulse essential for 3 hours after administration ofgemeprostpessary (risk of profound hypotension)", "Labour induction in fetal deathin uterowhere prostaglandin or oxytocin inappropriate,by mouth, mifepristone 600\u00a0mg daily as a single dose for 2 days under medical\r\nsupervision; if labour not started within 72 hours of first dose,\r\nanother method should be used"]}, "METHADONE HYDROCHLORIDE": {"indications": "adjunct in treatment of opioid dependence,\r\nsee notes above; analgesia (section 4.7.2); cough in terminal disease (section 3.9.1)", "name": "METHADONE HYDROCHLORIDE", "renal impairment": "see notes insection 4.7.2", "cautions": "see Methadone,section 4.7.2", "side-effects": "see Methadone,section 4.7.2;overdosage:seeEmergency Treatment of Poisoning", "contra-indications": "see Methadone,section 4.7.2", "hepatic impairment": "see notes insection 4.7.2", "doses": ["Initially 10\u201340\u00a0mg daily, increased by up to 10\u00a0mg daily\r\n(max. weekly increase 30\u00a0mg) until no signs of withdrawal or intoxication;\r\nusual dose range 60\u2013120\u00a0mg daily;childnot recommended (see also important note above)", "Methadone hydrochloride doses in the BNF\r\nmay differ from those in the product literature"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLUOROMETHOLONE": {"side-effects": "seenotes above", "indications": "local treatment of inflammation (short-term)", "name": "FLUOROMETHOLONE", "cautions": "seenotes above", "doses": ["adultandchildover 2 years, apply every hour for 24\u201348 hours\r\nthen reduce frequency to 2\u20134 times daily"]}, "ESTRAMUSTINE": {"interactions": {"extra": "", "bad": 1, "interaction": " sodium clodronate increases plasma concentration of estramustine ", "name": "Estramustine", "backrefs": ["Sodium Clodronate", "Estramustine"]}}, "Simeticone alone": {"name": "Simeticone alone", "doses": ["colic or wind pains,neonateandinfant2.5\u00a0mL with or after each\r\nfeed (max. 6 doses in 24 hours); may be added to bottle feed"]}, "INOSITOL NICOTINATE": {"indications": "peripheral vascular disease (but see notes above); hyperlipidaemia\r\n(section 2.12)", "name": "INOSITOL NICOTINATE", "cautions": "cerebrovascular insufficiency, unstable angina", "side-effects": "nausea, vomiting, hypotension, flushing, syncope,\r\noedema, headache, dizziness, paraesthesia, rash", "contra-indications": "recent myocardial infarction, acute phase of a cerebrovascular accident", "doses": ["3\u00a0g daily in 2\u20133 divided doses; max. 4\u00a0g daily"], "pregnancy": "no information available\u2014manufacturer advises avoid\r\nunless potential benefit outweighs risk"}, "THIOTEPA": {"indications": "seenotes aboveandsection 7.4.4", "name": "THIOTEPA", "interactions": {"extra": "", "bad": 0, "interaction": "effects of  suxamethonium enhanced by thiotepa ", "name": "Thiotepa", "backrefs": ["Thiotepa"]}, "cautions": "seesection 8.1; avoid in acute porphyria (but seesection 9.8.2);interactions:Appendix 1\r\n(thiotepa)", "side-effects": "seesection 8.1", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and embryotoxic inanimals); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ROFLUMILAST": {"indications": "seenotes above", "name": "ROFLUMILAST", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits the metabolism of roflumilast ", "name": "Roflumilast", "backrefs": ["Roflumilast"]}, "cautions": "monitor body-weight; latent infection (such as tuberculosis, viral hepatitis, herpes infection); moderate\r\nto severe cardiac failure; history of psychiatric\r\nillness, or concomitant use of drugs likely\r\nto cause psychiatric events;interactions:Appendix 1 (roflumilast)", "side-effects": "diarrhoea, nausea, abdominal pain, weight loss,\r\ndecreased appetite, headache, insomnia;less commonlygastritis, vomiting, gastro-oesophageal reflux, dyspepsia, palpitation,\r\nanxiety, tremor, vertigo, dizziness, malaise, muscle spasm, myalgia,\r\nback pain, rash;rarelytaste disturbances, haematochezia,\r\nconstipation, respiratory tract infections, depression, nervousness,\r\nsuicidal ideation, gynaecomastia, raised creatine kinase, urticaria", "contra-indications": "severe immunological disease; severe acute infectious disease; cancer (except basal cell carcinoma); concomitant treatment with immunosuppressive drugs (except\r\nshort-term systemic corticosteroids)", "hepatic impairment": "caution in mild impairment; avoid in moderate to severe\r\nimpairment", "doses": ["adultover 18 years, 500\u00a0micrograms\r\nonce daily"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies; women of child-bearing age should use effective contraception", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "MECASERMIN": {"indications": "seenotes above", "name": "MECASERMIN", "cautions": "correct hypothyroidism before initiating\r\ntreatment; diabetes mellitus (adjustment\r\nof antidiabetic therapy may be necessary), monitor ECG before and on termination of treatment (and during treatment\r\nif ECG abnormal), papilloedema (see under Side-effects), monitor for disorders of\r\nthe epiphysis of the hip (monitor for limping), monitor for signs of tonsillar hypertrophy (snoring, sleep apnoea,\r\nand chronic middle ear effusions)", "side-effects": "headache, funduscopy for papilloedema recommended\r\nif severe or recurrent headache, visual problems, nausea and vomiting\r\noccur\u2014if papilloedema confirmed consider benign intracranial hypertension\r\n(rare cases reported); cardiomegaly, ventricular hypertrophy, tachycardia;\r\nconvulsions, sleep apnoea, night terrors, dizziness, nervousness;\r\ntonsillar hypertrophy (see Cautions above); hypoglycaemia (especially\r\nin first month, and in younger children), hyperglycaemia, gynaecomastia;\r\narthralgia, myalgia; visual disturbance, impaired hearing; antibody\r\nformation; injection-site reactions (rotate site)", "contra-indications": "evidence of tumour activity (discontinue\r\ntreatment)", "doses": ["By subcutaneous injection,adolescentandchildover 2 years, initially 40\u00a0micrograms/kg twice daily for 1 week,\r\nif tolerated increase dose in steps of 40\u00a0micrograms/kg to max. 120\u00a0micrograms/kg\r\ntwice daily; discontinue if no response within 1 year", "Dose should be administered just before\r\nor after food; do not increase dose if a dose is missed", "Reduce dose if hypoglycaemia occurs despite\r\nadequate food intake; withhold injection if patient unable to eat"], "pregnancy": "avoid unless essential; contraception advised in\r\nwomen of child-bearing potential", "breast-feeding": "avoid"}, "FEXOFENADINE": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin possibly reduces effects of fexofenadine ", "name": "Fexofenadine", "backrefs": ["Fexofenadine"]}}, "STIRIPENTOL": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  clobazam increased by stiripentol ", "name": "Stiripentol", "backrefs": ["Stiripentol", "Clobazam"]}}, "JAPANESE ENCEPHALITIS VACCINE": {"indications": "immunisation against Japanese encephalitis", "name": "JAPANESE ENCEPHALITIS VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1; alsoless commonlymigraine, vertigo, pharyngolaryngeal pain", "contra-indications": "seesection 14.1; hypersensitivity reaction\r\nafter first dose\u2014do not give the second dose", "doses": ["by intramuscular injection in deltoid region,adultover 18 years 2 doses of 0.5\u00a0mL separated by\r\ninterval of 28 days; booster dose 1\u20132 years after completing primary\r\ncourse, but for those at continued risk the booster dose should be\r\ngiven 1 year after completing the primary course"], "pregnancy": "although manufacturer advises avoid because of limited\r\ninformation, miscarriage has been associated with Japanese encephalitis\r\nvirus infection acquired during the first 2 trimesters of pregnancy", "breast-feeding": "seesection 14.1"}, "QUINAGOLIDE": {"indications": "see notes above and under Dose", "name": "QUINAGOLIDE", "renal impairment": "avoid\u2014no information available", "cautions": "seenotes above; history\r\nof psychotic illness; advise non-hormonal contraception\r\nif pregnancy not desired;interactions:Appendix 1 (quinagolide)", "side-effects": "nausea, vomiting, anorexia, abdominal pain, constipation\r\nor diarrhoea; syncope, hypotension (see alsonotes above), oedema,\r\nflushing; nasal congestion; headache, dizziness, fatigue, insomnia;very rarelypsychosis", "contra-indications": "hypersensitivity toquinagolide(but not ergot alkaloids)", "hepatic impairment": "avoid\u2014no information available", "doses": ["Hyperprolactinaemia, 25\u00a0micrograms at bedtime for 3 days;\r\nincreased at intervals of 3 days in steps of 25\u00a0micrograms to usual\r\nmaintenance dose of 75\u2013150\u00a0micrograms daily; for doses higher than\r\n300\u00a0micrograms daily increase in steps of 75\u2013150\u00a0micrograms at intervals\r\nof not less than 4 weeks;childnot\r\nrecommended"], "pregnancy": "discontinue when pregnancy confirmed unless medical\r\nreason for continuing (specialist advice needed)", "breast-feeding": "suppresses lactation"}, "ATROPINE SULPHATE": {"indications": "premedication; intra-operative\r\nbradycardia; with anticholinesterases for reversal of non-depolarising\r\nneuromuscular block; antidote to organophosphorous poisoning (seeEmergency Treatment of Poisoning); symptomatic relief of gastro-intestinal\r\ndisorders characterised by smooth muscle spasm (section 1.2); bradycardia (section 2.3.1); cardiopulmonary\r\nresuscitation (section 2.7.3); cycloplegia,\r\nanterior uveitis (section 11.5)", "name": "ATROPINE SULPHATE", "cautions": "see notes insection 1.2", "side-effects": "see notes insection 1.2", "contra-indications": "see notes insection 1.2", "doses": ["Premedication,by intravenous injection, 300\u2013600\u00a0micrograms immediately before induction of anaesthesia;childunder 12 years seeBNF for Children", "By subcutaneousorintramuscular injection, 300\u2013600\u00a0micrograms 30\u201360 minutes before induction of anaesthesia;childunder 12 years seeBNF for Children", "Intra-operative bradycardia,by intravenous\r\ninjection, 300\u2013600\u00a0micrograms (larger doses in emergencies);childunder 12 years seeBNF for Children", "Control of muscarinic side-effects ofneostigminein reversal of competitive neuromuscular block,by intravenous\r\ninjection, 0.6\u20131.2\u00a0mg;childunder 12 years seeBNF for Children", "Control of muscarinic side-effects ofedrophoniumin reversal of competitive neuromuscular block [unlicensed indication],by intravenous injection, 600\u00a0micrograms;childunder 18 years seeBNF for Children", "Arrhythmias after myocardial infarction, see section2.3.1"], "pregnancy": "not known to be harmful; use with caution", "breast-feeding": "small amount present in milk\u2014use with caution"}, "ANTIMALARIALS": {"interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  artemether/lumefantrine advises avoid concomitant use with antimalarials ", "name": "Antimalarials", "backrefs": ["Typhoid Vaccine (oral)", "Antimalarials"]}}, "MACROLIDES": {"interactions": {"extra": "See also Telithromycin", "bad": 1, "interaction": "metabolism of  ciclosporin possibly inhibited by macrolides (increased plasma concentration)", "name": "Macrolides", "backrefs": ["Macrolides"]}}, "METFORMIN": {"interactions": {"extra": "", "bad": 0, "interaction": " lanreotide possibly reduces requirements for metformin ", "name": "Metformin", "backrefs": ["Ketotifen", "Metformin"]}}, "PENICILLAMINE": {"indications": "see notes above and under Dose", "name": "PENICILLAMINE", "renal impairment": "reduce dose and monitor renal function or avoid (consult\r\nproduct literature)", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  sodium aurothiomalate advised by manufacturer of penicillamine (increased risk of toxicity)", "name": "Penicillamine", "backrefs": ["Penicillamine", "Sodium Aurothiomalate"]}, "cautions": "seenotes above; concomitant nephrotoxic\r\ndrugs (increased risk of toxicity); gold\r\ntreatment (avoid concomitant use if adverse reactions to gold);interactions:Appendix 1 (penicillamine)", "side-effects": "(see alsonotes above) initially nausea, anorexia, fever,\r\nand skin reactions; taste loss (mineral supplements not recommended);\r\nblood disorders including thrombocytopenia, leucopenia, agranulocytosis\r\nand aplastic anaemia; proteinuria, rarely haematuria (withdraw immediately\r\nand seek specialist advice); haemolytic anaemia, pancreatitis, cholestatic\r\njaundice, nephrotic syndrome, lupus erythematosus-like syndrome, myasthenia\r\ngravis-like syndrome, neuropathy, polymyositis (rarely with cardiac\r\ninvolvement), dermatomyositis, mouth ulcers, stomatitis, alopecia,\r\nbronchiolitis and pneumonitis, pemphigus, Goodpasture\u2019s syndrome,\r\nand Stevens-Johnson syndrome also reported; male and female breast\r\nenlargement reported; in non-rheumatoid conditions rheumatoid arthritis-like\r\nsyndrome also reported; late rashes (consider withdrawing treatment)", "contra-indications": "lupus\r\nerythematosus", "doses": ["Severe active rheumatoid arthritis, administered on expert\r\nadvice,adultover 18 years, initially\r\n125\u2013250\u00a0mg daily for 1 month increased by similar amounts at intervals\r\nof not less than 4 weeks to usual maintenance of 500\u2013750\u00a0mg daily\r\nin divided doses; max. 1.5\u00a0g daily; if remission sustained for 6 months,\r\nreduction of daily dose by 125\u2013250\u00a0mg every 12 weeks may be attempted;elderlyinitially up to 125\u00a0mg daily for 1 month\r\nincreased by similar amounts at intervals of not less than 4 weeks;\r\nmax. 1\u00a0g daily", "Wilson\u2019s disease, autoimmune hepatitis, and cystinuria,section 9.8.1"], "pregnancy": "fetal abnormalities reported rarely; avoid if possible", "breast-feeding": "manufacturer advises avoid unless potential\r\nbenefit outweighs risk\u2014no information available"}, "Pain": {"name": "Pain"}, "FOSCARNET SODIUM": {"indications": "cytomegalovirus disease [licensed for cytomegalovirus retinitis in\r\nAIDS patients only]; mucocutaneous herpes simplex virus infections\r\nunresponsive toaciclovirin immunocompromised\r\npatients", "name": "FOSCARNET SODIUM", "renal impairment": "reduce dose; consult product literature", "cautions": "monitor electrolytes, particularly calcium\r\nand magnesium; monitor serum creatinine\r\nevery second day during induction and every week during maintenance; ensure adequate hydration; avoid rapid infusion;interactions:Appendix 1 (foscarnet)", "side-effects": "nausea, vomiting, diarrhoea (occasionally constipation\r\nand dyspepsia), abdominal pain, anorexia; changes in blood pressure\r\nand ECG; headache, fatigue, mood disturbances (including psychosis),\r\nasthenia, paraesthesia, convulsions, tremor, dizziness, and other\r\nneurological disorders; rash; impairment of renal function including\r\nacute renal failure; hypocalcaemia (sometimes symptomatic) and other\r\nelectrolyte disturbances; abnormal liver function tests; decreased\r\nhaemoglobin concentration, leucopenia, granulocytopenia, thrombocytopenia;\r\nthrombophlebitis if given undiluted by peripheral vein; genital irritation\r\nand ulceration (due to high concentrations excreted in urine); isolated\r\nreports of pancreatitis", "doses": ["CMV disease [licensed for CMV retinitis only],by intravenous infusion, initially (induction) 60\u00a0mg/kg every\r\n8 hoursor90\u00a0mg/kg every 12 hours, for 2\u20133 weeks;\r\nmaintenance 60\u00a0mg/kg daily, increased to 90\u2013120\u00a0mg/kg if tolerated;\r\nif disease progresses on maintenance dose, repeat induction regimen", "Mucocutaneous herpes simplex infection,by intravenous\r\ninfusion, 40\u00a0mg/kg every 8 hours for 2\u20133 weeks or until lesions\r\nheal", "Foscarnet doses in BNF may differ from those\r\nin product literature"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "DICLOFENAC SODIUM": {"indications": "pain and inflammation in rheumatic disease (including\r\njuvenile idiopathic arthritis) and other musculoskeletal disorders;\r\nacute gout; postoperative pain", "name": "DICLOFENAC SODIUM", "renal impairment": "avoid in severe impairment; avoid intravenous use if\r\nserum creatinine greater than 160\u00a0micromol/litre; see alsonotes above", "cautions": "seenotes above; avoid\r\nin acute porphyria (section 9.8.2)", "side-effects": "seenotes above; suppositories may cause rectal\r\nirritation; injection site reactions", "contra-indications": "seenotes above; avoid\r\nsuppositories in proctitis; avoid injections\r\ncontaining benzyl alcohol in neonates (see preparations\r\nbelow)", "hepatic impairment": "seenotes above", "doses": ["adultover 18 years, 1\r\ncapsule once daily;child12\u201318 years\r\nseeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "amount in milk too small to be harmful; see\r\nalsonotes above"}, "GLIPIZIDE": {"indications": "type 2 diabetes mellitus", "name": "GLIPIZIDE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 1, "interaction": " miconazole enhances hypoglycaemic effect of glipizide\u2014avoid concomitant use", "name": "Glipizide", "backrefs": ["Glipizide"]}, "cautions": "seenotes above;interactions:Appendix 1 (antidiabetics)", "side-effects": "see notes above; also dizziness, drowsiness", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially 2.5\u20135\u00a0mg daily shortly before breakfast or lunch,\r\nadjusted according to response; max. 20\u00a0mg daily; up to 15\u00a0mg may\r\nbe given as a single dose; higher doses divided"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ANTIEPILEPTICS": {"interactions": {"extra": "", "bad": 1, "interaction": " antipsychotics antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)", "name": "Antiepileptics", "backrefs": ["Antiepileptics"]}}, "TRASTUZUMAB": {"indications": "seenotes aboveand product literature", "name": "TRASTUZUMAB", "cautions": "seesection 8.1andnotes above; symptomatic heart\r\nfailure, history of hypertension, coronary artery disease, uncontrolled arrhythmias", "side-effects": "seesection 8.1; also\r\ninfusion-related side-effects (possibly delayed onset), including\r\nchills, fever, hypersensitivity reactions such as anaphylaxis, urticaria,\r\nand angioedema; gastro-intestinal symptoms, hepatitis; cardiotoxicity\r\n(see also above), chest pain, hypertension, hypotension; pulmonary\r\nevents (possibly delayed onset); headache, taste disturbance, anxiety,\r\nmalaise, depression, insomnia, drowsiness, dizziness, paraesthesia,\r\ntremor, asthenia, peripheral neuropathy, hypertonia, paresis; mastitis,\r\nurinary-tract infection; ecchymosis, oedema, weight loss; arthralgia,\r\nmyalgia, arthritis, bone pain, leg cramps; dry eye, increased lacrimation;\r\nrash, pruritus, sweating, dry skin, alopecia, acne, nail disorders", "contra-indications": "seesection 8.1andnotes above; severe dyspnoea at\r\nrest", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises avoid\u2014oligohydramnios reported;\r\neffective contraception must be used during treatment and for 6 months\r\nafter stopping", "breast-feeding": "avoid breast-feeding during treatment and for\r\nsix months afterwards"}, "DIGOXIN": {"indications": "heart failure (see alsosection 2.5.5), supraventricular arrhythmias (particularly\r\natrial fibrillation and atrial flutter; see alsosection 2.3.2)", "name": "DIGOXIN", "renal impairment": "reduce dose and monitor plasma-digoxin concentration;\r\ntoxicity increased by electrolyte disturbances", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of digoxin ", "name": "Digoxin", "backrefs": ["Sitagliptin", "Prazosin", "Cytarabine", "Bleomycin", "Lenalidomide", "Digoxin", "Salbutamol", "Procarbazine"]}, "cautions": "recent myocardial infarction; sick sinus syndrome; thyroid disease; reduce dose in the elderly; severe respiratory disease; hypokalaemia, hypomagnesaemia, hypercalcaemia, and hypoxia (risk of digitalis toxicity); monitor serum electrolytes and renal function; avoid rapid intravenous administration (risk of hypertension and\r\nreduced coronary flow);interactions:Appendix 1 (cardiac glycosides)", "side-effects": "seenotes above; also nausea, vomiting, diarrhoea;\r\narrhythmias, conduction disturbances; dizziness; blurred or yellow\r\nvision; rash, eosinophilia;less commonlydepression;very rarelyanorexia, intestinal ischaemia and necrosis,\r\npsychosis, apathy, confusion, headache, fatigue, weakness, gynaecomastia\r\non long-term use, and thrombocytopenia", "contra-indications": "intermittent complete\r\nheart block, second degree AV block; supraventricular arrhythmias associated with accessory\r\nconducting pathways e.g. Wolff-Parkinson-White\r\nsyndrome; ventricular tachycardia or fibrillation; hypertrophic cardiomyopathy\r\n(unless concomitant atrial fibrillation and heart failure\u2014but use\r\nwith caution); myocarditis; constrictive pericarditis (unless to control atrial fibrillation\r\nor improve systolic dysfunction\u2014but use with caution)", "doses": ["Rapid digitalisation, for atrial fibrillation or flutter,by mouth, 0.75\u20131.5\u00a0mg over 24 hours in divided doses", "Maintenance, for atrial fibrillation or flutter,by mouth, according to renal function and initial loading dose; usual range\r\n125\u2013250\u00a0micrograms daily", "Heart failure (for patients in sinus rhythm),by mouth, 62.5\u2013125\u00a0micrograms once daily", "Emergency loading dose, for atrial fibrillation or flutter,by intravenous infusion(but rarely necessary), 0.75\u20131\u00a0mg\r\nover at least 2 hours (see also Cautions) then maintenance doseby mouthon the following day", "The above doses may need to be reduced ifdigoxin(or another cardiac glycoside) has been given in\r\nthe preceding 2 weeks. Digoxin doses in the BNF may differ from those\r\nin product literature. For plasma concentration monitoring, blood\r\nshould be taken at least 6 hours after a dose"], "pregnancy": "may need dosage adjustment", "breast-feeding": "amount too small to be harmful"}, "AGOMELATINE": {"indications": "major depression", "name": "AGOMELATINE", "renal impairment": "caution in moderate to severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": " fluvoxamine inhibits metabolism of agomelatine (increased plasma concentration)", "name": "Agomelatine", "backrefs": ["Agomelatine"]}, "cautions": "elderly; mania or hypomania; concomitant\r\nuse of drugs associated with hepatic injury; excessive alcohol consumption; obesity; non-alcoholic\r\nfatty liver disease; monitor liver function before treatment\r\nand after 6, 12 and 24 weeks of treatment, then as appropriate\r\n(discontinue if serum transaminases exceed 3 times the\r\nupper limit of reference range);interactions: Appendix 1 (agomelatine)", "side-effects": "nausea, diarrhoea, constipation, abdominal pain,\r\nincreased serum transaminases (see Cautions); headache, dizziness,\r\ndrowsiness, agitation, sleep disturbances, fatigue, anxiety; back\r\npain; sweating;less commonlyparaesthesia, blurred\r\nvision, and eczema;rarelyhepatitis and rash; suicidal\r\nbehaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy)\r\nand pruritus also reported", "contra-indications": "dementia", "hepatic impairment": "avoid", "doses": ["adultover 18 years, 25\u00a0mg\r\nat bedtime, increased if necessary after 2 weeks to 50\u00a0mg at bedtime"], "pregnancy": "caution", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "PARECOXIB": {"indications": "short-term management of acute postoperative pain", "name": "PARECOXIB", "renal impairment": "section 10.1.1", "interactions": {"extra": "", "bad": 0, "interaction": " fluconazole increases plasma concentration of parecoxib (reduce dose of parecoxib)", "name": "Parecoxib", "backrefs": ["Parecoxib"]}, "cautions": "section 10.1.1; dehydration; following coronary artery\r\nbypass graft surgery;interactions:Appendix 1 (NSAIDs)", "side-effects": "section 10.1.1; also flatulence, hypotension,\r\nhypoaesthesia, alveolar osteitis, postoperative anaemia, hypokalaemia,\r\nsweating;less commonlybradycardia, cardiovascular\r\nevents, pulmonary embolism, anorexia, malaise, hyperglycaemia, increased\r\nblood urea nitrogen, arthralgia, ecchymosis;rarelytachycardia", "contra-indications": "section 10.1.1; also history of allergic drug reactions including sulfonamide hypersensitivity; inflammatory bowel disease", "hepatic impairment": "halve dose in moderate impairment (max. 40\u00a0mg daily);\r\nsee alsosection 10.1.1", "doses": ["By deep intramuscular injectionorby intravenous injection, initially 40\u00a0mg,\r\nthen 20\u201340\u00a0mg every 6\u201312 hours when required for up to 3 days; max.\r\n80\u00a0mg daily;elderlyweighing less\r\nthan 50\u00a0kg, initially 20\u00a0mg, then max. 40\u00a0mg daily;childunder 18 years, not recommended"], "pregnancy": "section 10.1.1", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "SAPROPTERIN DIHYDROCHLORIDE": {"indications": "see under Dose below", "name": "SAPROPTERIN DIHYDROCHLORIDE", "renal impairment": "manufacturer advises caution\u2014no information available", "cautions": "monitor blood-phenylalanine concentration\r\nbefore and after first week of treatment\u2014if unsatisfactory response\r\nincrease dose at weekly intervals to max. dose and monitor blood-phenylalanine\r\nconcentration weekly; discontinue treatment\r\nif unsatisfactory response after 1 month; monitor blood-phenylalanine and tyrosine concentrations 1\u20132 weeks\r\nafter dose adjustment and during treatment; history of convulsions", "side-effects": "diarrhoea, vomiting, abdominal pain; nasal congestion,\r\ncough, pharyngolaryngeal pain; headache", "hepatic impairment": "manufacturer advises caution\u2014no information available", "doses": ["Phenylketonuria (specialist use only),by mouth,adultandchildover 4 years, initially 10\u00a0mg/kg once daily, preferably in the morning,\r\nadjusted according to response; usual dose 5\u201320\u00a0mg/kg daily"], "pregnancy": "manufacturer advises caution\u2014consider only if strict\r\ndietary management inadequate", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "METHIONINE": {"side-effects": "nausea, vomiting, drowsiness, irritability", "indications": "paracetamoloverdosage, seenotes above", "hepatic impairment": "may precipitate coma", "name": "METHIONINE", "doses": ["adultandchildover 6 years initially 2.5\u00a0g, followed by 3\r\nfurther doses of 2.5\u00a0g every 4 hours,childunder 6 years initially 1\u00a0g, followed by 3 further doses of 1\u00a0g\r\nevery 4 hours"]}, "DORIPENEM": {"indications": "hospital-acquired pneumonia; complicated intra-abdominal infections;\r\ncomplicated urinary-tract infections", "name": "DORIPENEM", "renal impairment": "250\u00a0mg every 8 hours if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; 250\u00a0mg every 12 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of doripenem (manufacturers of doripenem advise avoid concomitant use)", "name": "Doripenem", "backrefs": ["Doripenem"]}, "cautions": "sensitivity to beta-lactam antibacterials (avoid if history of immediate hypersensitivity reaction, seeHypersensitivity Reactions);interactions:Appendix 1 (doripenem)", "side-effects": "nausea, diarrhoea; headache; phlebitis, pruritus,\r\nrash;less commonlyantibiotic-associated colitis,\r\nthrombocytopenia, neutropenia; also reported, toxic epidermal necrolysis,\r\nand Stevens-Johnson syndrome", "doses": ["By intravenous infusion,adultover 18 years, 500\u00a0mg every 8 hours; max. duration\r\nof treatment 14 days"], "pregnancy": "manufacturer advises avoid unless essential\u2014no information\r\navailable", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014present in milk inanimalstudies"}, "PRAVASTATIN": {"interactions": {"extra": "", "bad": 0, "interaction": " erythromycin increases plasma concentration of pravastatin ", "name": "Pravastatin", "backrefs": ["Pravastatin"]}}, "DIENOGEST": {"interactions": {"extra": "", "bad": 0, "interaction": " erythromycin increases plasma concentration of dienogest ", "name": "Dienogest", "backrefs": ["Dienogest"]}}, "ANAGRELIDE": {"indications": "seenotes above", "name": "ANAGRELIDE", "renal impairment": "manufacturer advises avoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  milrinone advised by manufacturer of anagrelide ", "name": "Anagrelide", "backrefs": ["Anagrelide", "Enoximone", "Milrinone"]}, "cautions": "cardiovascular disease\u2014assess cardiac\r\nfunction before and during treatment; concomitant\r\naspirin in patients at risk of haemorrhage; monitor full blood count (monitor platelet count every 2 days for\r\n1 week, then weekly until maintenance dose established), liver function,\r\nserum creatinine and urea;interactions:Appendix 1 (anagrelide)", "side-effects": "gastro-intestinal disturbances; palpitation, tachycardia,\r\nfluid retention; headache, dizziness, fatigue; anaemia; rash;less commonlypancreatitis, gastro-intestinal haemorrhage,\r\ncongestive heart failure, hypertension, arrhythmias, syncope, chest\r\npain, dyspnoea, sleep disturbances, paraesthesia, hypoaesthesia, depression,\r\nnervousness, confusion, amnesia, fever, weight changes, impotence,\r\nblood disorders, myalgia, arthralgia, epistaxis, dry mouth, alopecia,\r\nskin discoloration, and pruritus;rarelygastritis,\r\ncolitis, postural hypotension, angina, myocardial infarction, vasodilatation,\r\npulmonary hypotension, pulmonary infiltrates, migraine, drowsiness,\r\nimpaired coordination, dysarthria, asthenia, tinnitus, renal failure,\r\nnocturia, visual disturbances, and gingival bleeding; allergic alveolitis\r\nand hepatitis also reported", "hepatic impairment": "manufacturer advises caution in mild impairment; avoid\r\nin moderate to severe impairment", "doses": ["Initially 500\u00a0micrograms twice daily adjusted according\r\nto response in steps of 500\u00a0micrograms daily at weekly intervals to\r\nmax. 10\u00a0mg daily (max. single dose 2.5\u00a0mg); usual dose range 1\u20133\u00a0mg\r\ndaily in divided doses;childunder\r\n18 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid (toxicity inanimalstudies)", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PINDOLOL": {"indications": "see under Dose", "name": "PINDOLOL", "renal impairment": "may adversely affect renal function in severe impairment\u2014manufacturer\r\nadvises avoid", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "doses": ["hypertension, 1 tablet daily in the morning, increased\r\nif necessary after 2\u20133 weeks to 2 tablets once daily; max. 3 tablets\r\ndaily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FAMCICLOVIR": {"indications": "see under Dose", "name": "FAMCICLOVIR", "renal impairment": "reduce dose; consult product literature", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid possibly reduces excretion of famciclovir (increased plasma concentration)", "name": "Famciclovir", "backrefs": ["Famciclovir"]}, "cautions": "interactions:Appendix 1 (famciclovir)", "side-effects": "nausea, vomiting, abdominal pain, diarrhoea; headache,\r\nfatigue; sweating, pruritus;rarelyconfusion;very rarelyjaundice, dizziness, drowsiness, hallucinations,\r\nthrombocytopenia, rash (including Stevens-Johnson syndrome); also\r\nreported, constipation and fever", "hepatic impairment": "usual dose in well compensated liver disease (information\r\nnot available on decompensated)", "doses": ["Herpes zoster, treatment, 500\u00a0mg 3 times daily for 7 daysor750\u00a0mg 1\u20132 times daily for 7 days (in immunocompromised,\r\n500\u00a0mg 3 times daily for 10 days, continue for 2 days\r\nafter crusting of lesions)", "Genital herpes, treatment offirst episode,\r\n250\u00a0mg 3 times daily for 5 days, longer if new lesions appear during\r\ntreatment or if healing incomplete (500\u00a0mg twice daily for 10 days\r\nin immunocompromised or HIV-positive patients); treatment ofrecurrent infection, 125\u00a0mg twice daily for 5 daysor1\u00a0g twice daily for 1 day (500\u00a0mg twice daily for 5\u201310\r\ndays in immunocompromised or HIV-positive patients)", "Genital herpes, suppression, 250\u00a0mg twice daily (500\u00a0mg twice\r\ndaily in immunocompromised or HIV-positive patients); therapy interrupted\r\nevery 6\u201312 months to reassess recurrence frequency\u2014consider restarting\r\nafter two or more recurrences", "Non-genital herpes simplex, treatment in the immunocompromised,\r\n500\u00a0mg twice daily for 7 days", "childnot recommended", "Famciclovir doses in BNF may differ from\r\nthose in product literature"], "pregnancy": "manufacturers advise avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "no information available\u2014present in milk inanimalstudies"}, "URSODEOXYCHOLIC ACID": {"indications": "see under Dose and under preparations", "name": "URSODEOXYCHOLIC ACID", "interactions": {"extra": "", "bad": 1, "interaction": "absorption of  ciclosporin increased by ursodeoxycholic acid ", "name": "Ursodeoxycholic Acid", "backrefs": ["Ursodeoxycholic Acid"]}, "cautions": "seenotes above;interactions:Appendix 1 (bile acids)", "side-effects": "diarrhoea;very rarelyabdominal\r\npain, gallstone calcification, urticaria;also reportednausea, vomiting, pruritus", "contra-indications": "radio-opaque stones, non-functioning gall bladder, acute inflammation\r\nof the gall bladder, frequent episodes of biliary colic, inflammatory diseases and other conditions of the small intestine,\r\ncolon and liver which interfere with entero-hepatic circulation of\r\nbile salts", "hepatic impairment": "avoid in chronic liver disease (but used in primary\r\nbiliary cirrhosis)", "doses": ["Dissolution of gallstones, 8\u201312\u00a0mg/kg daily as a single\r\ndose at bedtimeorin two divided doses, for up to\r\n2 years; treatment is continued for 3\u20134 months after\r\nstones dissolve", "Primary biliary cirrhosis, see underUrsofalk\u00ae"], "pregnancy": "no evidence of harm but manufacturer advises avoid", "breast-feeding": "not known to be harmful but manufacturer advises\r\navoid"}, "KETOTIFEN": {"indications": "allergic rhinitis", "name": "KETOTIFEN", "interactions": {"extra": "", "bad": 0, "interaction": "thrombocyte count depressed when  metformin given with ketotifen (manufacturer of ketotifen advises avoid concomitant use)", "name": "Ketotifen", "backrefs": ["Ketotifen"]}, "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nexcitation, irritability, nervousness;less commonlycystitis;rarelyweight gain;very rarelyStevens-Johnson syndrome", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["1\u00a0mg twice daily with food increased if necessary to 2\u00a0mg\r\ntwice daily; initial treatment in readily sedated patients 0.5\u20131\u00a0mg\r\nat night;child3 years and over, 1\u00a0mg\r\ntwice daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DACARBAZINE": {"indications": "seenotes above", "name": "DACARBAZINE", "renal impairment": "dose reduction may be required in combined renal and\r\nhepatic impairment; avoid in severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  aldesleukin advises avoid concomitant use with dacarbazine ", "name": "Dacarbazine", "backrefs": ["Dacarbazine"]}, "cautions": "seesection 8.1; caution in handling;interactions: Appendix 1 (dacarbazine)", "side-effects": "seesection 8.1and notes above;rarelyliver necrosis due to hepatic vein thrombosis; irritant to skin\r\nand tissues", "hepatic impairment": "dose reduction may be required in combined renal and\r\nhepatic impairment; avoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (carcinogenic and teratogenic inanimalstudies); ensure effective contraception during and for at least\r\n6 months after treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "HUMAN MENOPAUSAL GONADOTROPHINS": {"indications": "see notes above", "name": "HUMAN MENOPAUSAL GONADOTROPHINS", "cautions": "acute porphyria (section 9.8.2)", "side-effects": "ovarian hyperstimulation, increased risk of multiple\r\npregnancy and miscarriage, hypersensitivity reactions, gastro-intestinal\r\ndisturbances, headache, joint pain, fever, injection site reactions,very rarelythromboembolism; gynaecomastia, acne, and weight\r\ngain reported in men", "contra-indications": "ovarian cysts (not caused by polycystic ovarian syndrome); tumours of pituitary, hypothalamus, breast,\r\nuterus, ovaries, testes or prostate; vaginal bleeding of unknown cause", "doses": ["By deep intramuscularorsubcutaneous injection, according to patient\u2019s response"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "LABETALOL HYDROCHLORIDE": {"indications": "hypertension (including hypertension in\r\npregnancy, hypertension with angina, and hypertension following acute\r\nmyocardial infarction); hypertensive crises (seesection 2.5); controlled\r\nhypotension in anaesthesia", "name": "LABETALOL HYDROCHLORIDE", "renal impairment": "dose reduction may be required", "cautions": "see underPropranolol Hydrochloride; interferes with laboratory tests for catecholamines; liver damage (see below)", "side-effects": "postural hypotension (avoid upright position during\r\nand for 3 hours after intravenous administration), tiredness, weakness,\r\nheadache, rashes, scalp tingling, difficulty in micturition, epigastric\r\npain, nausea, vomiting; liver damage (see above); rarely lichenoid\r\nrash", "contra-indications": "see underPropranolol Hydrochloride", "hepatic impairment": "avoid\u2014severe hepatocellular injury reported", "doses": ["By mouth, initially 100\u00a0mg (50\u00a0mg\r\nin elderly) twice daily with food, increased at intervals of 14 days\r\nto usual dose of 200\u00a0mg twice daily; up to 800\u00a0mg daily in 2 divided\r\ndoses (3\u20134 divided doses if higher); max. 2.4\u00a0g daily", "By intravenous injection, 50\u00a0mg over\r\nat least 1\u00a0minute, repeated after 5\u00a0minutes if necessary; max. total\r\ndose 200\u00a0mg", "Excessive bradycardia can be countered withintravenous injectionofatropine sulphate0.6\u20132.4\u00a0mg in divided doses of 600\u00a0micrograms; foroverdosageseeEmergency Treatment of Poisoning", "By intravenous infusion, 2\u00a0mg/minute\r\nuntil satisfactory response then discontinue; usual total dose 50\u2013200\u00a0mg,\r\n(notrecommended for phaeochromocytoma, see under\r\nPhaeochromocytoma,section 2.5.4)", "Hypertension of pregnancy, 20\u00a0mg/hour, doubled every 30 minutes;\r\nusual max. 160\u00a0mg/hour", "Hypertension following myocardial infarction, 15\u00a0mg/hour, gradually\r\nincreased to max. 120\u00a0mg/hour"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "NELFINAVIR": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "NELFINAVIR", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of inhaled and intranasal  fluticasone possibly increased by nelfinavir ", "name": "Nelfinavir", "backrefs": ["Nelfinavir"]}, "cautions": "seenotes above;interactions:Appendix 1 (nelfinavir)", "side-effects": "see notes above; also reported, fever", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\nmanufacturer advises caution", "doses": ["1.25\u00a0g twice dailyor750\u00a0mg 3 times\r\ndaily;child3\u201313 years, initially\r\n50\u201355\u00a0mg/kg twice daily (max. 1.25\u00a0g twice daily)or25\u201330\u00a0mg/kg 3 times daily (max. 750\u00a0mg 3 times daily)"], "pregnancy": "no information available\u2014manufacturer advises use\r\nonly if potential benefit outweighs risk", "breast-feeding": "seeBreast-feeding"}, "CARTEOLOL HYDROCHLORIDE": {"indications": "seenotes above", "name": "CARTEOLOL HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply twice daily"]}, "EPHEDRINE HYDROCHLORIDE": {"indications": "nasal congestion", "name": "EPHEDRINE HYDROCHLORIDE", "cautions": "seesection 3.1.1.2andnotes above; also avoid\r\nexcessive or prolonged use;interactions:Appendix\r\n1 (sympathomimetics)", "side-effects": "local irritation, nausea, headache; after excessive\r\nuse tolerance with diminished effect, rebound congestion; cardiovascular\r\neffects also reported", "doses": ["adultandchildover 12 years, 1\u20132 drops into each nostril\r\nup to 4 times daily when required, max. duration 7 days"], "pregnancy": "seesection 3.1.1.2", "breast-feeding": "seesection 3.1.1.2"}, "ROMIPLOSTIM": {"indications": "seenotes above", "name": "ROMIPLOSTIM", "renal impairment": "manufacturer advises caution\u2014no information available", "cautions": "monitor full blood count and peripheral\r\nblood smears for morphological abnormalities before and during treatment; monitor platelet count weekly until 50 \u00d7 109/litre or\r\nmore for at least 4 weeks without dose adjustment, then monthly thereafter", "side-effects": "gastro-intestinal disturbances; flushing, oedema;\r\ndizziness, migraine, insomnia, fatigue, asthenia, paraesthesia; influenza-like\r\nsymptoms; arthralgia, myalgia, bone pain, muscle spasm; increased\r\nbone marrow reticulin; ecchymosis, rash; injection-site reactions", "hepatic impairment": "avoid in moderate or severe impairment unless potential\r\nbenefit outweighs risk (e.g. of portal vein thrombosis)", "doses": ["By subcutaneous injection,adultover 18 years, initially 1\u00a0microgram/kg once\r\nweekly, adjusted in steps of 1\u00a0microgram/kg at weekly intervals until\r\na stable platelet count of 50 \u00d7 109/litre or more is reached\r\n(consult product literature for dose adjustments); max. 10\u00a0micrograms/kg\r\nonce weekly; discontinue if inadequate response after 4 weeks at maximum\r\ndose"], "pregnancy": "manufacturer advises use only if essential\u2014toxicity\r\ninanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "INSULIN ZINC SUSPENSION": {"indications": "diabetes mellitus", "name": "INSULIN ZINC SUSPENSION", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin(section 6.1.1.1)", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection, according to\r\nrequirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "NELARABINE": {"indications": "seenotes above", "name": "NELARABINE", "cautions": "seesection 8.1andnotes above; previous or concurrent intrathecal\r\nchemotherapy or craniospinal irradiation (increased risk of neurotoxicity)", "side-effects": "seesection 8.1; also abdominal pain, constipation,\r\ntaste disturbance, anorexia, diarrhoea; hypotension, oedema; pleural\r\neffusion, wheezing, dyspnoea, cough; confusion, seizures, amnesia,\r\ndrowsiness, peripheral neurological disorders, hypoaesthesia, paraesthesia,\r\nataxia, demyelination, tremor, dizziness, headache, asthenia, fatigue;\r\npyrexia; electrolyte disturbances; blurred vision; muscle weakness,\r\nmyalgia, arthralgia; benign and malignant tumours also reported", "doses": ["SeeDoses"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nmanufacturer advises effective contraception during and for at least\r\n3 months after treatment in men and women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "NORGESTREL": {"interactions": {"extra": "", "bad": 0, "interaction": " rosuvastatin increases plasma concentration of norgestrel ", "name": "Norgestrel", "backrefs": ["Norgestrel"]}}, "ADRENALINE (EPINEPHRINE)": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of arrhythmias when  volatile liquid general anaesthetics given with adrenaline (epinephrine) ", "name": "Adrenaline (epinephrine)", "backrefs": ["Dopexamine", "Adrenaline (epinephrine)", "Tolazoline"]}}, "ISOSORBIDE DINITRATE": {"indications": "prophylaxis and treatment of angina; left ventricular\r\nfailure", "name": "ISOSORBIDE DINITRATE", "renal impairment": "see underGlyceryl Trinitrate", "cautions": "see underGlyceryl Trinitrate", "side-effects": "see underGlyceryl Trinitrate", "contra-indications": "see underGlyceryl Trinitrate", "hepatic impairment": "see underGlyceryl Trinitrate", "doses": ["treatment or prophylaxis of angina, spray 1\u20133 doses under\r\ntongue whilst holding breath; allow 30 second interval between each\r\ndose"], "pregnancy": "may cross placenta\u2014manufacturers advise avoid unless\r\npotential benefit outweighs risk", "breast-feeding": "see underGlyceryl Trinitrate"}, "OMALIZUMAB": {"indications": "prophylaxis of allergic asthma (seenotes above)", "name": "OMALIZUMAB", "renal impairment": "manufacturer advises caution\u2014no information available", "cautions": "autoimmune disease; susceptibility to helminth infection\u2014discontinue if infection does\r\nnot respond to anthelmintic", "side-effects": "abdominal pain, headache, pyrexia;less\r\ncommonlydyspepsia, nausea, diarrhoea, weight increase, postural\r\nhypotension, flushing, pharyngitis, bronchospasm, cough, syncope,\r\nparaesthesia, dizziness, malaise, influenza-like illness, photosensitivity,\r\nurticaria, rash, pruritus;rarelylaryngoedema, parasitic\r\ninfection, antibody formation;also reportedarterial\r\nthromboembolic events, Churg-Strauss syndrome (seenotes above), thrombocytopenia, arthralgia, myalgia, joint swelling, alopecia,\r\nserum sickness (including fever and lymphadenopathy)", "hepatic impairment": "manufacturer advises caution\u2014no information available", "doses": ["By subcutaneous injection,adultandchildover\r\n6 years, according to immunoglobulin E concentration and body-weight,\r\nconsult product literature"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CO-CARELDOPA": {"indications": "Parkinson\u2019s\r\ndisease, seenotes above", "name": "CO-CARELDOPA", "cautions": "seenotes above", "side-effects": "seenotes above", "doses": ["patients not receiving levodopa/dopa-decarboxylase inhibitor\r\ntherapy, initially, 1Sinemet\u00aeCRtablet twice daily; both dose and interval then adjusted according\r\nto response at intervals of not less than 3 days", "Patients transferring from immediate-release levodopa/dopa-decarboxylase\r\ninhibitor preparations, 1Sinemet\u00aeCRtablet twice daily can be substituted for a daily dose oflevodopa300\u2013400\u00a0mg in immediate-releaseSinemet\u00ae tablets (substituteSinemet\u00aeCRto provide approx. 10% more levodopa per day and extend dosing interval\r\nby 30\u201350%); dose and interval then adjusted according to response\r\nat intervals of not less than 3 days"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CYCLOPENTHIAZIDE": {"indications": "oedema, hypertension (see also notes above); heart failure", "name": "CYCLOPENTHIAZIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; alsorarelydepression", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Heart failure, 250\u2013500\u00a0micrograms daily in the morning\r\nincreased if necessary to 1\u00a0mg daily (reduce to lowest effective dose\r\nfor maintenance)", "Hypertension, initially 250\u00a0micrograms daily in the morning,\r\nincreased if necessary to 500\u00a0micrograms daily (but see notes above)", "Oedema, up to 500\u00a0micrograms daily for a short period"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DOPAMINE HYDROCHLORIDE": {"indications": "cardiogenic shock in infarction or cardiac surgery", "name": "DOPAMINE HYDROCHLORIDE", "cautions": "correct hypovolaemia; low dose in shock due to acute myocardial infarction\u2014seenotes above; hyperthyroidism;interactions:Appendix\r\n1 (sympathomimetics)", "side-effects": "nausea, vomiting, chest pain, palpitation, tachycardia,\r\nvasoconstriction, hypotension, dyspnoea, headache;less commonlybradycardia, hypertension, gangrene, mydriasis;rarelyfatal ventricular arrhythmias", "contra-indications": "tachyarrhythmia, phaeochromocytoma", "doses": ["By intravenous infusion, 2\u20135\u00a0micrograms/kg/minute\r\ninitially (see notes above)"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk"}, "SELEGILINE HYDROCHLORIDE": {"indications": "Parkinson\u2019s disease, used alone or as adjunct to co-beneldopa or\r\nco-careldopa; symptomatic parkinsonism", "name": "SELEGILINE HYDROCHLORIDE", "renal impairment": "use with caution in severe impairment", "cautions": "avoid abrupt withdrawal; gastric and duodenal ulceration (avoid in active ulceration), uncontrolled hypertension (and avoid drugs that increase blood pressure), arrhythmias, angina, psychosis (and patients\r\npredisposed to confusion and psychosis), side-effects oflevodopamay be increased\u2014concurrentlevodopadosage can be\r\nreduced by 10\u201330% in steps of 10% every 3\u20134 days; history of hepatic dysfunction; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (selegiline)", "side-effects": "nausea, constipation, diarrhoea, dry mouth, stomatitis,\r\nmouth ulcers, bradycardia, hypertension, hypotension, depression,\r\ndizziness, psychosis, impaired balance, tremor, fatigue, movement\r\ndisorders, sleeping disorders, headache, confusion, arthralgia, myalgia,\r\nmuscle cramps, myopathy, nasal congestion, hair loss, sweating;less commonlyloss of appetite, angina, arrhythmias, palpitation,\r\npostural hypotension, supraventricular tachycardia, ankle oedema,\r\ndyspnoea, agitation, anxiety, micturition difficulties, leucocytopenia,\r\nthrombocytopenia, blurred vision; skin reactions;also reportedhypersexuality", "hepatic impairment": "use with caution in severe impairment", "doses": ["1.25\u00a0mg daily before breakfast"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "avoid\u2014no information available"}, "SEVOFLURANE": {"indications": "seenotes above", "name": "SEVOFLURANE", "renal impairment": "use with caution", "cautions": "seenotes above; susceptibility to QT-interval prolongation;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above; also urinary\r\nretention, leucopenia, agitation in children; cardiac arrest, torsade\r\nde pointes, dystonia and seizures also reported", "contra-indications": "seenotes above", "doses": ["Induction of anaesthesia,by inhalationusing a specifically calibrated vaporiser, in oxygen or nitrous\r\noxide\u2013oxygen, adjusted according to response,adultandchildover 1 month initially\r\n0.5\u20131% then increased gradually up to 8%", "Maintenance of anaesthesia,by inhalationusing a specifically calibrated vaporiser, in oxygen or nitrous\r\noxide\u2013oxygen, adjusted according to response,adultandchildover 1 month 0.5\u20133%"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "UNDECENOATES": {"side-effects": "see notes above", "indications": "see under preparations below", "name": "UNDECENOATES", "doses": ["treatment of athlete\u2019s foot, apply twice daily continuing\r\nfor 7 days after lesions have healed"]}, "AMSACRINE": {"indications": "seenotes above", "name": "AMSACRINE", "renal impairment": "manufacturer advises reduce initial dose by 20\u201330%", "cautions": "seesection 8.1andnotes above; also caution in handling\u2014irritant\r\nto skin and tissues", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "manufacturer advises reduce initial dose by 20\u201330%", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and toxic inanimalstudies); may reduce fertility; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "FLUOCINONIDE": {"indications": "severe inflammatory skin disorders such as eczemas unresponsive to\r\nless potentcorticosteroids; psoriasis, seenotes above", "name": "FLUOCINONIDE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily"]}, "NICOTINE": {"indications": "seenotes above", "name": "NICOTINE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "effects of  adenosine possibly enhanced by nicotine ", "name": "Nicotine", "backrefs": ["Nicotine", "Adenosine"]}, "cautions": "seenotes above;interactions:Appendix 1 (nicotine)", "side-effects": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Seenotes above"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DESFERRIOXAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  prochlorperazine advised by manufacturer of desferrioxamine ", "name": "Desferrioxamine", "backrefs": ["Levomepromazine", "Desferrioxamine", "Prochlorperazine"]}}, "BECLOMETASONE DIPROPIONATE": {"indications": "prophylaxis of asthma (see alsoManagement of Chronic Asthma\r\ntable)", "name": "BECLOMETASONE DIPROPIONATE", "cautions": "seenotes above", "side-effects": "seenotes above", "doses": ["by aerosol inhalation, prophylaxis of asthma,adultandchildover\r\n12 years, 50\u2013200\u00a0micrograms twice daily, increased if necessary to\r\nmax. 400\u00a0micrograms twice daily"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "ACECLOFENAC": {"indications": "pain and inflammation in rheumatoid arthritis, osteoarthritis and\r\nankylosing spondylitis", "name": "ACECLOFENAC", "renal impairment": "avoid in moderate to severe impairment; see alsonotes above", "cautions": "seenotes above; avoid\r\nin acute porphyria (section 9.8.2)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "initially 100\u00a0mg daily; see alsonotes above", "doses": ["100\u00a0mg twice daily;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid; see alsonotes above"}, "DIPYRIDAMOLE": {"indications": "see notes above and under Dose", "name": "DIPYRIDAMOLE", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  heparins enhanced by dipyridamole ", "name": "Dipyridamole", "backrefs": ["Fludarabine", "Dipyridamole"]}, "cautions": "rapidly worsening angina, aortic stenosis, recent\r\nmyocardial infarction, left ventricular\r\noutflow obstruction, heart failure; may exacerbate migraine; hypotension; myasthenia gravis (risk of\r\nexacerbation); coagulation disorders; concomitant use of drugs that increase risk of bleeding;interactions:Appendix 1 (dipyridamole)", "side-effects": "gastro-intestinal effects, dizziness, myalgia,\r\nthrobbing headache, hypotension, hot flushes and tachycardia; worsening\r\nsymptoms of coronary heart disease; hypersensitivity reactions such\r\nas rash, urticaria, severe bronchospasm and angioedema; increased\r\nbleeding during or after surgery; thrombocytopenia reported", "doses": ["secondary prevention of ischaemic stroke and transient\r\nischaemic attacks, 1 capsule twice daily"], "pregnancy": "not known to be harmful", "breast-feeding": "manufacturers advise use only if essential\u2014small\r\namount present in milk"}, "HYOSCINE HYDROBROMIDE": {"indications": "premedication, motion sickness, hypersalivation\r\nassociated with clozapine therapy (section 4.6); excessive respiratory secretions\r\n(seePrescribing in Palliative\r\nCare)", "name": "HYOSCINE HYDROBROMIDE", "renal impairment": "use with caution", "cautions": "see notes insection 1.2andnotes above; also epilepsy", "side-effects": "see notes insection 1.2", "contra-indications": "see notes insection 1.2", "hepatic impairment": "use with caution", "doses": ["Premedication,by subcutaneousorintramuscular injection, 200\u2013600\u00a0micrograms 30\u201360\u00a0minutes\r\nbefore induction of anaesthesia;child15\u00a0micrograms/kg"], "pregnancy": "use only if potential benefit outweighs risk; injection\r\nmay depress neonatal respiration", "breast-feeding": "amount too small to be harmful"}, "ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)": {"indications": "seenotes above", "name": "ANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)", "cautions": "seenotes above; monitor blood count", "side-effects": "nausea, vomiting, dysphagia, diarrhoea; hypotension;\r\ninfusion-related reactions (including cytokine release syndrome and\r\nanaphylaxis, seenotes above), serum\r\nsickness; fever, shivering, increased susceptibility to infection;\r\nincreased susceptibility to malignancy; lymphopenia, neutropenia,\r\nthrombocytopenia; myalgia; pruritus, rash", "contra-indications": "infection", "doses": ["Heart transplantation,by intravenous infusionover at least 6 hours, 1\u20132.5\u00a0mg/kg daily for 3\u20135 days", "Renal transplantation,by intravenous infusionover at least 6 hours, 1\u20131.5\u00a0mg/kg daily for 3\u20139 days", "Corticosteroid-resistant renal graft rejection,by intravenous\r\ninfusionover at least 6 hours, 1.5\u00a0mg/kg daily for 7\u201314 days"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "CLOFAZIMINE": {"indications": "leprosy", "name": "CLOFAZIMINE", "renal impairment": "use with caution", "cautions": "may discolour soft contact lenses; avoid if persistent abdominal pain and diarrhoea", "side-effects": "nausea, vomiting (hospitalise if persistent),\r\nabdominal pain; headache, tiredness; brownish-black discoloration\r\nof lesions and skin including areas exposed to light; reversible hair\r\ndiscoloration; dry skin; red discoloration of faeces, urine and other\r\nbody fluids; also rash, pruritus, photosensitivity, acne-like eruptions,\r\nanorexia, eosinophilic enteropathy, bowel obstruction, dry eyes, dimmed\r\nvision, macular and subepithelial corneal pigmentation; elevation\r\nof blood sugar, weight loss, splenic infarction, lymphadenopathy", "hepatic impairment": "use with caution", "doses": ["Leprosy, seenotes above", "Lepromatous lepra reactions, dosage increased to 300\u00a0mg daily\r\nfor max. of 3 months"], "pregnancy": "use with caution", "breast-feeding": "may alter colour of milk; skin discoloration\r\nof infant"}, "TERLIPRESSIN ACETATE": {"indications": "bleeding from oesophageal varices", "name": "TERLIPRESSIN ACETATE", "cautions": "see underVasopressin", "side-effects": "see underVasopressin, but\r\neffects milder", "contra-indications": "see underVasopressin", "doses": ["By intravenous injection, 2\u00a0mg followed\r\nby 1 or 2\u00a0mg every 4 to 6 hours until bleeding is controlled, for\r\nup to 72 hours"], "breast-feeding": "see underVasopressin"}, "OXYCODONE HYDROCHLORIDE": {"indications": "moderate to severe pain in patients with cancer;\r\npostoperative pain; severe pain", "name": "OXYCODONE HYDROCHLORIDE", "renal impairment": "initially 2.5\u00a0mg every 6 hours in patients not currently\r\ntreated with an opioid with mild to moderate impairment; avoid if\r\neGFR less than 10\u00a0mL/minute/1.73m2; see alsonotes above", "cautions": "seenotes above; alsotoxic psychosis; pancreatitis", "side-effects": "seenotes above; also\r\ndiarrhoea, abdominal pain, anorexia, dyspepsia; bronchospasm, dyspnoea,\r\nimpaired cough reflex; asthenia, anxiety; chills;less commonlyparalytic ileus, cholestasis, gastritis, flatulence, dysphagia,\r\ntaste disturbance, belching, hiccups, vasodilatation, supraventricular\r\ntachycardia, syncope, amnesia, hypoaesthesia, restlessness, seizures,\r\nhypotonia, paraesthesia, disorientation, malaise, agitation, speech\r\ndisorder, tremor, pyrexia, amenorrhoea, thirst, dehydration, muscle\r\nfasciculation, and dry skin", "contra-indications": "seenotes above; alsoacute abdomen; delayed gastric emptying; chronic\r\nconstipation; cor pulmonale; acute porphyria(section 9.8.2)", "hepatic impairment": "initially 2.5\u00a0mg every 6 hours in patients not currently\r\ntreated with an opioid with mild impairment; avoid in moderate to\r\nsevere impairment; see alsonotes above", "doses": ["initially, 10\u00a0mg every 12 hours, increased if necessary\r\naccording to severity of pain, usual max. 200\u00a0mg every 12 hours, but\r\nsome patients may require higher doses;childunder 18 years seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014avoid"}, "HYDROXYCARBAMIDE": {"indications": "sickle-cell disease (seenotes above); chronic\r\nmyeloid leukaemia, cancer of the cervix (section 8.1.5)", "name": "HYDROXYCARBAMIDE", "renal impairment": "reduce initial dose by 50% if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of toxicity when  didanosine given with hydroxycarbamide\u2014avoid concomitant use", "name": "Hydroxycarbamide", "backrefs": ["Hydroxycarbamide", "Stavudine"]}, "cautions": "seesection 8.1andnotes above; also monitor renal and hepatic function before and during treatment; monitor full blood count before treatment, then every\r\n2 weeks for the first 2 months and then every 2 months thereafter\r\n(or every 2 weeks if on max. dose); leg\r\nulcers (review treatment if cutaneous vasculitic\r\nulcerations develop);interactions:Appendix 1 (hydroxycarbamide)", "side-effects": "seesection 8.1andnotes above; also\r\nheadache;less commonlydizziness and rash;rarelyreduced sperm count and activity; fever, amenorrhoea,\r\nskin cancers (in elderly patients), bleeding and hypomagnesaemia also\r\nreported", "hepatic impairment": "manufacturer advises caution in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["By mouth, initially 15\u00a0mg/kg daily, increased\r\nevery 12 weeks in steps of 2.5\u20135\u00a0mg/kg daily according to response;\r\nusual dose 15\u201330\u00a0mg/kg daily (max. 35\u00a0mg/kg daily);childunder 18 years, seeBNF for Children"], "pregnancy": "section 8.1.5", "breast-feeding": "section 8.1.5"}, "NALTREXONE HYDROCHLORIDE": {"indications": "adjunct to prevent relapse in formerly\r\nopioid-dependent patients (who have remained opioid-free for at least\r\n7\u201310 days); adjunct to prevent relapse in formerly alcohol-dependent\r\npatients [unlicensed]", "name": "NALTREXONE HYDROCHLORIDE", "renal impairment": "avoid in severe impairment", "cautions": "liver function tests needed before and\r\nduring treatment; test for opioid dependence\r\nwith naloxone before treatment; avoid concomitant\r\nuse of opioids but increased dose of opioid analgesic may be required\r\nfor pain (monitor for opioid intoxication)", "side-effects": "nausea, vomiting, abdominal pain, diarrhoea, constipation,\r\nreduced appetite, increased thirst; chest pain; anxiety, sleep disorders,\r\nheadache, reduced energy, increased energy, irritability, emotional\r\nlability, dizziness; chills; urinary retention; delayed ejaculation,\r\ndecreased potency; arthralgia, myalgia; increased lacrimation; rash,\r\nand increased sweating;rarelyhepatic dysfunction,\r\nsuicidal ideation, and speech disorders;very rarelyhallucinations, tremor, and idiopathic thrombocytopenia", "contra-indications": "patients currently dependent\r\non opioids", "hepatic impairment": "avoid in acute hepatitis, hepatic failure, or severe\r\nimpairment", "doses": ["Relapse prevention in opioid dependence,adultover 18 years (initiate in specialist clinics\r\nonly), 25\u00a0mg initially then 50\u00a0mg daily; total weekly dose (350\u00a0mg)\r\nmay be divided and given on 3 days of the week for improved compliance\r\n(e.g. 100\u00a0mg on Monday and Wednesday, and 150\u00a0mg on Friday)", "Relapse prevention in alcohol dependence [unlicensed indication],adultandchildover\r\n16 years, 25\u00a0mg on first day, increased to 50\u00a0mg daily if tolerated"], "pregnancy": "use only if benefit outweighs risk", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "HYOSCINE": {"interactions": {"extra": "", "bad": 0, "interaction": "increased sedative effect when  alcohol given with hyoscine ", "name": "Hyoscine", "backrefs": ["Hyoscine"]}}, "RALOXIFENE HYDROCHLORIDE": {"indications": "treatment and prevention of postmenopausal osteoporosis", "name": "RALOXIFENE HYDROCHLORIDE", "renal impairment": "caution in mild to moderate impairment; avoid in severe\r\nimpairment", "cautions": "risk factors for venous thromboembolism\r\n(discontinue if prolonged immobilisation); risk factors for stroke; breast cancer (seenotes above); history of oestrogen-induced\r\nhypertriglyceridaemia (monitor serum triglycerides);\r\navoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (raloxifene)", "side-effects": "hot flushes, leg cramps, peripheral oedema, influenza-like\r\nsymptoms;less commonlyvenous thromboembolism, thrombophlebitis;rarelyrashes, gastro-intestinal disturbances, hypertension,\r\narterial thromboembolism, headache (including migraine), breast discomfort,\r\nthrombocytopenia", "contra-indications": "history of venous thromboembolism, undiagnosed uterine bleeding, endometrial cancer, cholestasis", "hepatic impairment": "avoid", "doses": ["60\u00a0mg once daily"]}, "OLANZAPINE": {"indications": "see under Dose", "name": "OLANZAPINE", "renal impairment": "consider initial dose of 5\u00a0mg daily", "interactions": {"extra": "", "bad": 0, "interaction": "possible risk of toxicity when  lithium given with olanzapine ", "name": "Olanzapine", "backrefs": ["Olanzapine"]}, "cautions": "seenotes above; also paralytic ileus, diabetes mellitus (risk of exacerbation or ketoacidosis), low leucocyte\r\nor neutrophil count, bone-marrow depression, hypereosinophilic disorders, myeloproliferative disease; dose adjustment\r\nmay be necessary if smoking started or stopped during treatment", "side-effects": "seenotes above; also\r\nmild, transient antimuscarinic effects (very rarelyprecipitation of angle-closure glaucoma); drowsiness, speech difficulty,\r\nexacerbation of Parkinson\u2019s disease, abnormal gait, hallucinations,\r\nakathisia, asthenia, fatigue, increased appetite, increased body temperature,\r\nraised triglyceride concentration, oedema, hyperprolactinaemia (but\r\nclinical manifestations uncommon); eosinophilia;less commonlyhypotension, bradycardia, QT-interval prolongation, urinary incontinence,\r\nand photosensitivity;rarelyseizures, leucopenia,\r\nand rash;very rarelyhepatitis, pancreatitis, hypercholesterolaemia,\r\nhypothermia, urinary retention, priapism, thrombocytopenia, neutropenia,\r\nrhabdomyolysis, and alopecia;with injection, sinus\r\npause and hypoventilation", "contra-indications": "for injection, acute myocardial\r\ninfarction, unstable angina, severe hypotension or bradycardia, sick sinus syndrome, recent heart surgery", "hepatic impairment": "consider initial dose of 5\u00a0mg daily", "doses": ["Schizophrenia, combination therapy for mania, preventing\r\nrecurrence in bipolar disorder,by mouth,adultover 18 years, 10\u00a0mg daily adjusted to usual\r\nrange of 5\u201320\u00a0mg daily; doses greater than 10\u00a0mg daily only after\r\nreassessment; max. 20\u00a0mg daily;child12\u201318 years seeBNF for Children", "Monotherapy for mania,by mouth,adultover 18 years, 15\u00a0mg daily adjusted to usual\r\nrange of 5\u201320\u00a0mg daily; doses greater than 15\u00a0mg only after reassessment;\r\nmax. 20\u00a0mg daily;child12\u201318 years\r\nseeBNF for Children", "Control of agitation and disturbed behaviour in schizophrenia\r\nor mania,by intramuscular injection,adultover 18 years, initially 5\u201310\u00a0mg  (usual dose\r\n10\u00a0mg) as a single dose followed by 5\u201310\u00a0mg after 2 hours if necessary;elderlyinitially 2.5\u20135\u00a0mg as a single dose followed\r\nby 2.5\u20135\u00a0mg after 2 hours if necessary; max. 3 injections daily for\r\n3 days; max. daily combined oral and parenteral dose 20\u00a0mg", "When one or more factors present\r\nthat might result in slower metabolism (e.g. female gender, elderly,\r\nnon-smoker) consider lower initial dose and more gradual dose increase"], "pregnancy": "seePregnancy notes; also use only if potential\r\nbenefit outweighs risk; neonatal lethargy, tremor, and hypertonia\r\nreported when used in third trimester", "breast-feeding": "avoid\u2014present in milk"}, "SODIUM PHENYLBUTYRATE": {"indications": "adjunct in long-term treatment\r\nof urea cycle disorders (under specialist supervision)", "name": "SODIUM PHENYLBUTYRATE", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid possibly reduces excretion of conjugate formed by sodium phenylbutyrate ", "name": "Sodium Phenylbutyrate", "backrefs": ["Sodium Phenylbutyrate"]}, "cautions": "congestive heart failure;interactions:Appendix 1 (sodium phenylbutyrate)", "side-effects": "gastro-intestinal disturbances, weight gain, taste\r\ndisturbance, decreased appetite; syncope, oedema; headache, depression,\r\nirritability; renal tubular acidosis, menstrual disorders; blood disorders,\r\nmetabolic acidosis, alkalosis; rash, body odour;less commonlyrectal bleeding, peptic ulcer, pancreatitis, and arrhythmias", "hepatic impairment": "manufacturer advises caution", "doses": ["adultandchildbody-weight over 20\u00a0kg, 9.9\u201313\u00a0g/m2daily in divided doses with meals (max. 20\u00a0g daily);childbody-weight less than 20\u00a0kg, 450\u2013600\u00a0mg/kg\r\ndaily in divided doses with meals"], "pregnancy": "avoid\u2014toxicity inanimalstudies;\r\nmanufacturer advises adequate contraception during administration", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "METHYLPREDNISOLONE": {"indications": "suppression of inflammatory and allergic\r\ndisorders; severe inflammatory bowel disease (section 1.5); cerebral oedema associated with\r\nmalignancy; see also notes above; rheumatic disease (section 10.1.2); skin (section 13.4)", "name": "METHYLPREDNISOLONE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " itraconazole possibly inhibits metabolism of methylprednisolone ", "name": "Methylprednisolone", "backrefs": ["Methylprednisolone"]}, "cautions": "seenotes above; also rapid intravenous administration of large doses associated with cardiovascular\r\ncollapse", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["by deep intramuscular injectioninto gluteal\r\nmuscle, 40\u2013120\u00a0mg, a second injection may be given after 2\u20133 weeks\r\nif required"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DIAZOXIDE": {"indications": "chronic intractable hypoglycaemia; hypertensive\r\nemergency\u2014but no longer recommended, seesection 2.5", "name": "DIAZOXIDE", "renal impairment": "dose reduction may be required", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with diazoxide ", "name": "Diazoxide", "backrefs": ["Diazoxide"]}, "cautions": "ischaemic heart disease; monitor blood pressure; during prolonged use monitor white cell and platelet count, and in children, regularly assess growth, bone, and psychological\r\ndevelopment;interactions:Appendix 1 (diazoxide)", "side-effects": "anorexia, nausea, vomiting, hyperuricaemia, hypotension,\r\noedema, tachycardia, arrhythmias, extrapyramidal effects; hypertrichosis\r\non prolonged treatment", "doses": ["By mouth,adult, initially 5\u00a0mg/kg daily in 2\u20133 divided doses, then adjusted according\r\nto response; usual maintenance dose 3\u20138\u00a0mg/kg daily in 2\u20133 divided\r\ndoses;child1 month\u201318 years seeBNF for Children"], "pregnancy": "prolonged use in second or third trimesters may produce\r\nalopecia and impaired glucose tolerance in neonate; inhibits uterine\r\nactivity during labour"}, "DOXYCYCLINE": {"indications": "see notes above; chronic prostatitis; sinusitis, syphilis, pelvic\r\ninflammatory disease (Table 1,section 5.1); treatment\r\nand prophylaxis of anthrax [unlicensed indication]; malaria treatment\r\nand prophylaxis (section\r\n5.4.1); recurrent aphthous ulceration, adjunct to gingival\r\nscaling and root planing for periodontitis (section 12.3.1); oral\r\nherpes simplex (section 12.3.2); rosacea, acne vulgaris (section 13.6)", "name": "DOXYCYCLINE", "renal impairment": "use with caution (avoid excessive doses)", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of  methotrexate toxicity when given with doxycycline ", "name": "Doxycycline", "backrefs": ["Dairy Products", "Doxycycline"]}, "cautions": "seenotes above;alcoholdependence; photosensitivity reported\r\n(avoid exposure to sunlight or sun lamps)", "side-effects": "seenotes above; also\r\nanorexia, dry mouth, flushing, anxiety, and tinnitus", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["200\u00a0mg on first day, then 100\u00a0mg daily; severe infections\r\n(including refractory urinary-tract infections), 200\u00a0mg daily", "Early syphilis, 100\u00a0mg twice daily for 14 days; late latent\r\nsyphilis, 100\u00a0mg twice daily for 28 days; neurosyphilis, 200\u00a0mg twice\r\ndaily for 28 days", "Uncomplicated genital chlamydia, non-gonococcal urethritis,\r\n100\u00a0mg twice daily for 7 days (14 days in pelvic inflammatory disease,\r\nsee also Table 1,section 5.1)", "Lyme disease (see alsosection 5.1.1.3), 100\u00a0mg twice daily for 10\u201314\r\ndays (28 days in Lyme arthritis)", "Anthrax (treatment or post-exposure prophylaxis; see alsosection 5.1.12), 100\u00a0mg twice daily;child(only if alternative antibacterial cannot be given) [unlicensed\r\ndose] 5\u00a0mg/kg daily in 2 divided doses (max. 200\u00a0mg daily)", "Capsules should be swallowed whole\r\nwith plenty of fluid during meals while sitting or standing", "Doxycyclinedoses in BNF\r\nmay differ from those in product literature"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "MEFENAMIC ACID": {"indications": "pain and inflammation in rheumatoid arthritis\r\nand osteoarthritis; postoperative pain; mild to moderate pain; dysmenorrhoea\r\nand menorrhagia", "name": "MEFENAMIC ACID", "renal impairment": "avoid in severe impairment; see alsonotes above", "cautions": "seenotes above; epilepsy; acute porphyria (section 9.8.2)", "side-effects": "seenotes above; also diarrhoea or rashes (withdraw\r\ntreatment), stomatitis;less commonlyparaesthesia\r\nand fatigue;rarelyhypotension, palpitation, glucose\r\nintolerance, thrombocytopenia, haemolytic anaemia (positive\r\nCoombs\u2019 test), and aplastic anaemia", "contra-indications": "seenotes above; inflammatory bowel disease", "hepatic impairment": "seenotes above", "doses": ["adultover 18 years, 500\u00a0mg\r\n3 times daily", "child12\u201318 years, acute pain\r\nincluding dysmenorrhoea, menorrhagia, 500\u00a0mg 3 times daily"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful but manufacturer\r\nadvises avoid; see alsonotes above"}, "DIURETICS, LOOP": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium reduced by loop diuretics (increased plasma concentration and risk of toxicity)\u2014loop diuretics safer than thiazides", "name": "Diuretics, Loop", "backrefs": []}}, "INFLIXIMAB": {"indications": "see notes above; inflammatory bowel\r\ndisease (section 1.5.3); ankylosing spondylitis, psoriatic\r\narthritis, rheumatoid arthritis (section 10.1.3)", "name": "INFLIXIMAB", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  anakinra with infliximab ", "name": "Infliximab", "backrefs": ["Infliximab"]}, "cautions": "section 10.1.3; monitor for non-melanoma skin cancer before and during treatment", "side-effects": "section 10.1.3", "contra-indications": "section 10.1.3", "doses": ["By intravenous infusion, plaque psoriasis,adultover 18 years, 5\u00a0mg/kg, repeated 2 weeks and\r\n6 weeks after initial infusion, then every 8 weeks; discontinue if\r\nno response within 14 weeks of initial infusion"], "pregnancy": "section\r\n10.1.3", "breast-feeding": "section\r\n10.1.3"}, "POLYSTYRENE SULPHONATE RESINS": {"indications": "hyperkalaemia associated with anuria\r\nor severe oliguria, and in dialysis patients", "name": "POLYSTYRENE SULPHONATE RESINS", "renal impairment": "usesodium-containing resinwith caution", "interactions": {"extra": "", "bad": 0, "interaction": "risk of intestinal obstruction when  aluminium hydroxide given with polystyrene sulphonate resins ", "name": "Polystyrene Sulphonate Resins", "backrefs": ["Aluminium Hydroxide", "Polystyrene Sulphonate Resins"]}, "cautions": "children (impaction of resin with excessive\r\ndosage or inadequate dilution); monitor\r\nfor electrolyte disturbances (stop if plasma-potassium\r\nconcentration below 5\u00a0mmol/litre);sodium-containing resinin congestive heart failure, hypertension, and oedema;interactions:Appendix 1 (polystyrene sulphonate\r\nresins)", "side-effects": "faecal impaction following rectal administration,\r\ngastro-intestinal concretions following oral administration, intestinal\r\nnecrosis reported with concomitant use of sorbitol, gastric irritation,\r\nanorexia, nausea, vomiting, constipation (discontinue treatment\u2014avoid\r\nmagnesium-containing laxatives), diarrhoea, hypomagnesaemia; gastro-intestinal\r\nobstruction, ulceration, necrosis, and ischaemic colitis also reported;\r\nwithcalcium-containing resin, hypercalcaemia (including\r\nin dialysed patients and occasionally in those with renal impairment);\r\nwithsodium-containing resin, sodium retention, hypocalcaemia", "contra-indications": "obstructive bowel disease; neonates with reduced gut motility;calcium-containing resinin hyperparathyroidism, multiple myeloma, sarcoidosis, or metastatic carcinoma", "doses": ["By mouth, 15\u00a0g 3\u20134 times daily in a small\r\namount of water or syrup (not fruit juice which has a high potassium\r\ncontent);child0.5\u20131\u00a0g/kg daily in\r\ndivided doses", "By rectum, as an enema, 30\u00a0g in 150\u00a0mL of water\r\nor 10% glucose, retained for 9 hours followed by irrigation to remove\r\nresin from colon;neonateandchild, 0.5\u20131\u00a0g/kg daily"], "pregnancy": "manufacturers advise use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturers advise use only if potential benefit\r\noutweighs risk\u2014no information available"}, "PYRIDOXINE HYDROCHLORIDE": {"side-effects": "sensory neuropathy reported with high doses given\r\nfor extended periods", "indications": "see under Dose", "name": "PYRIDOXINE HYDROCHLORIDE", "cautions": "interactions:Appendix 1 (vitamins)", "doses": ["Deficiency states, 20\u201350\u00a0mg up to 3 times daily", "Isoniazid-induced neuropathy, prophylaxis\r\n10\u00a0mg daily [or 20\u00a0mg daily if suitable product not available]; treatment,\r\n50\u00a0mg three times daily;childunder\r\n18 years seeBNF for Children", "Idiopathic sideroblastic anaemia, 100\u2013400\u00a0mg daily in divided\r\ndoses", "Penicillamine-induced neuropathy, prophylaxis in Wilson\u2019s disease\r\n[unlicensed use] (see alsonotes above), 20\u00a0mg daily;childunder 18 years seeBNF for Children", "Premenstrual syndrome [unlicensed use], 50\u2013100\u00a0mg daily (see\r\nnotes above)", "Prolonged use of pyridoxine in a dose of 10\u00a0mg daily\r\nis considered safe but the long-term use of pyridoxine in a dose of\r\n200\u00a0mg or more daily has been associated with neuropathy.  The safety\r\nof long-term pyridoxine supplementation with doses above 10\u00a0mg daily\r\nhas not been established."]}, "TAMSULOSIN HYDROCHLORIDE": {"indications": "benign prostatic hyperplasia", "name": "TAMSULOSIN HYDROCHLORIDE", "renal impairment": "use with caution if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["400\u00a0micrograms daily"]}, "BRIMONIDINE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  MAOIs advised by manufacturer of brimonidine ", "name": "Brimonidine", "backrefs": ["Antidepressants, Tricyclic (related)", "Brimonidine"]}}, "DOXORUBICIN": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of neurotoxicity when  ciclosporin given with doxorubicin ", "name": "Doxorubicin", "backrefs": ["Doxorubicin"]}}, "ETOMIDATE": {"indications": "induction of anaesthesia", "name": "ETOMIDATE", "interactions": {"extra": "", "bad": 0, "interaction": " fentanyl inhibits metabolism of etomidate (consider reducing dose of etomidate)", "name": "Etomidate", "backrefs": ["Etomidate"]}, "cautions": "see underIntravenous Anaestheticsandnotes above; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(anaesthetics, general)", "side-effects": "seenotes above; also nausea,\r\nvomiting; hypotension; apnoea, hyperventilation, stridor; rash;less commonlyhypersalivation, arrhythmias, hypertension,\r\nhiccups, cough, phlebitis; AV block, cardiac arrest, respiratory depression,\r\nseizures, shivering, and Stevens-Johnson syndrome also reported", "contra-indications": "see underIntravenous Anaestheticsandnotes above", "hepatic impairment": "reduce dose in liver cirrhosis", "doses": ["adultandchild,by slow intravenous injection, 300\u00a0micrograms/kg (max. total dose 60\u00a0mg);elderly150\u2013200\u00a0micrograms/kg (max. total dose 60\u00a0mg)"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "ETODOLAC": {"indications": "pain and inflammation in rheumatoid arthritis and osteoarthritis", "name": "ETODOLAC", "renal impairment": "avoid in severe impairment; see alsonotes above", "cautions": "seenotes above", "side-effects": "seenotes above; also stomatitis, vasculitis, palpitation,\r\ndyspnoea, confusion, fatigue, paraesthesia, tremor, urinary frequency,\r\ndysuria, pyrexia, and pruritus", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["1 tablet daily;childnot\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid; see alsonotes above"}, "MEROPENEM": {"indications": "aerobic and anaerobic Gram-positive and Gram-negative infections\r\n(seenotes above); hospital-acquired septicaemia\r\n(Table 1,section 5.1)", "name": "MEROPENEM", "renal impairment": "use normal dose every 12 hours if eGFR 26\u201350\u00a0mL/minute/1.73\u00a0m2; use half normal dose every 12 hours if eGFR 10\u201325\u00a0mL/minute/1.73\u00a0m2; use half normal dose every 24 hours if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of meropenem ", "name": "Meropenem", "backrefs": ["Meropenem"]}, "cautions": "sensitivity to beta-lactam antibacterials (avoid if history of immediate hypersensitivity reaction, seeHypersensitivity Reactions);interactions:Appendix 1 (meropenem)", "side-effects": "nausea, vomiting, diarrhoea (antibiotic-associated\r\ncolitis reported), abdominal pain, disturbances in liver function\r\ntests, headache, thrombocythaemia, rash, pruritus;less commonlyparaesthesia, eosinophilia, thrombocytopenia, leucopenia;rarelyconvulsions; also reported haemolytic anaemia, positive\r\nCoombs\u2019 test, Stevens-Johnson syndrome, toxic epidermal necrolysis", "hepatic impairment": "monitor liver function", "doses": ["By intravenous injectionover 5 minutesorby intravenous infusion, 0.5\u20131\u00a0g every\r\n8 hours;child3 months\u201312 years 10\u201320\u00a0mg/kg\r\nevery 8 hours, body-weight over 50\u00a0kg, adult dose", "Exacerbations of chronic lower respiratory-tract infection in\r\ncystic fibrosis, meningitis, 2\u00a0g every 8 hours;child3 months\u201312 years 40\u00a0mg/kg every 8 hours, body-weight over 50\u00a0kg,\r\nadult dose"], "pregnancy": "use only if potential benefit outweighs risk\u2014no information\r\navailable", "breast-feeding": "unlikely to be absorbed (however, manufacturer\r\nadvises avoid)"}, "PANITUMUMAB": {"indications": "seenotes above", "name": "PANITUMUMAB", "cautions": "monitor for dermatological reactions\r\n(may require temporary or permanent discontinuation\u2014consult product\r\nliterature); pulmonary disease\u2014discontinue\r\nif pneumonitis or lung infiltrates occur; monitor for hypomagnesaemia and hypocalcaemia; history\r\nof, or risk factors for keratitis, ulcerative keratitis (including\r\ncontact lens use), or severe dry eye", "side-effects": "seesection 8.1; also infusion-related reactions\r\nincluding hypertension, hypotension, tachycardia, and severe hypersensitivity\r\nreactions (possibly delayed onset); diarrhoea, abdominal pain, constipation,\r\ndry mouth and nose; dyspnoea, cough, embolism; fatigue, dizziness,\r\nheadache; hypomagnesaemia, hypocalcaemia, hypokalaemia, dehydration;\r\nocular disorders (including conjunctivitis, increased lacrimation,\r\ndry eyes, ocular hyperaemia and keratitis); skin reactions (including\r\nrash, erythema, pruritus, dry skin, acne, hand-foot syndrome and exfoliation),\r\nmucosal inflammation, hypertrichosis, and nail disorders", "contra-indications": "interstitial pulmonary disease", "doses": ["SeeDoses"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nmanufacturer advises effective contraception during and for 6 months\r\nafter treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid breast-feeding during\r\nand for 3 months after treatment"}, "LEVOTHYROXINE SODIUM": {"indications": "hypothyroidism; see also notes above", "name": "LEVOTHYROXINE SODIUM", "cautions": "panhypopituitarism or predisposition to adrenal\r\ninsufficiency (initiate corticosteroid therapy before starting levothyroxine), elderly, cardiovascular disorders (including hypertension, myocardial insufficiency or myocardial infarction, see Initial Dosage below), long-standing hypothyroidism, diabetes\r\ninsipidus, diabetes mellitus (dose of antidiabetic\r\ndrugs including insulin may need to be increased);interactions:Appendix 1 (thyroid hormones)", "side-effects": "usually at excessive dosage (see Initial Dosage\r\nabove) include diarrhoea, vomiting, anginal pain, arrhythmias, palpitation,\r\ntachycardia, tremor, restlessness, excitability, insomnia; headache,\r\nflushing, sweating, fever, heat intolerance, weight-loss, muscle cramp,\r\nand muscular weakness; transient hair loss in children; hypersensitivity\r\nreactions including rash, pruritus and oedema also reported", "contra-indications": "thyrotoxicosis", "doses": ["adultover 18 years, initially\r\n50\u2013100\u00a0micrograms once daily, preferably before breakfast, adjusted\r\nin steps of 25\u201350\u00a0micrograms every 3\u20134 weeks according to response\r\n(usual maintenance dose 100\u2013200\u00a0micrograms once daily); in cardiac\r\ndisease, severe hypothyroidism, and patients over 50 years, initially\r\n25\u00a0micrograms once daily, adjusted in steps of 25\u00a0micrograms every\r\n4 weeks according to response; usual maintenance dose 50\u2013200\u00a0micrograms\r\nonce daily;childunder 18\r\nyears seeBNF for Children(section 6.2.1)", "Congenital hypothyroidism and juvenile myxoedema, seeBNF for Children(section\r\n6.2.1)"], "pregnancy": "monitor maternal serum-thyrotrophin concentration\u2014levothyroxine\r\nmay cross the placenta and excessive maternal concentration can be\r\ndetrimental to fetus", "breast-feeding": "amount too small to affect tests for neonatal\r\nhypothyroidism"}, "VECURONIUM BROMIDE": {"indications": "neuromuscular blockade (intermediate duration) for surgery", "name": "VECURONIUM BROMIDE", "renal impairment": "use with caution in renal failure", "cautions": "seenotes above", "side-effects": "seenotes above", "hepatic impairment": "use with caution in significant impairment", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "adultandchildover 1 month,by intravenous injection, 80\u2013100\u00a0micrograms/kg;thenmaintenance,by intravenous injectioneither20\u201330\u00a0micrograms/kg, adjusted according\r\nto response (max. 100\u00a0micrograms/kg in caesarian section),orby intravenous infusion, 0.8\u20131.4\u00a0micrograms/kg/minute,\r\nadjusted according to response;neonateseeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CARMUSTINE": {"indications": "see notes above", "name": "CARMUSTINE", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine possibly enhances myelosuppressive effects of carmustine ", "name": "Carmustine", "backrefs": ["Carmustine"]}, "cautions": "seesection 8.1andnotes above;\r\navoid in acute porphyria (but seesection 9.8.2);interactions: Appendix 1 (carmustine)", "side-effects": "seesection 8.1andnotes above; irritant to tissues", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and embryotoxic inanimals); manufacturer advises effective contraception during treatment\r\nin men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "TRIFLUOPERAZINE": {"indications": "severe nausea and vomiting (see notes\r\nabove); other indications (section 4.2.1)", "name": "TRIFLUOPERAZINE", "renal impairment": "see notes insection 4.2.1", "cautions": "see notes insection 4.2.1", "side-effects": "see Trifluoperazine,section 4.2.1", "contra-indications": "see notes insection 4.2.1", "hepatic impairment": "see notes insection 4.2.1", "doses": ["2\u20134\u00a0mg daily in divided doses; max. 6\u00a0mg\r\ndaily;child3\u20135 years up to 1\u00a0mg daily,\r\n6\u201312 years up to 4\u00a0mg daily"], "pregnancy": "see notes insection 4.2.1", "breast-feeding": "see notes insection 4.2.1"}, "ALCLOMETASONE DIPROPIONATE": {"indications": "inflammatory skin disorders such as eczemas", "name": "ALCLOMETASONE DIPROPIONATE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily"]}, "ADEFOVIR DIPIVOXIL": {"indications": "chronic hepatitis B infection witheithercompensated\r\nliver disease with evidence of viral replication, and histologically\r\ndocumented active liver inflammation and fibrosisordecompensated liver disease", "name": "ADEFOVIR DIPIVOXIL", "renal impairment": "10\u00a0mg every 48 hours if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; 10\u00a0mg every 72 hours if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; no information available if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2; see also Cautions above", "cautions": "monitor liver function tests every 3\r\nmonths, and viral markers for hepatitis B every 3\u20136 months during\r\ntreatment (continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation); monitor renal function before treatment then every 3 months, more frequently in renal impairment or in patients receiving nephrotoxic\r\ndrugs; elderly; discontinue\r\nif deterioration in liver function, hepatic steatosis, progressive\r\nhepatomegaly or unexplained lactic acidosis", "side-effects": "nausea, vomiting, dyspepsia, abdominal pain, flatulence,\r\ndiarrhoea; asthenia, headache; renal failure; hypophosphataemia; rash\r\nand pruritus; also reported pancreatitis", "doses": ["adultover 18 years, 10\u00a0mg\r\nonce daily"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises use only if potential benefit outweighs risk; effective contraception\r\nrequired during treatment", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "BACILLUS CALMETTE-GU\u00c9RIN": {"indications": "seenotes above; BCG immunisation\r\n(section 14.4)", "name": "BACILLUS CALMETTE-GU\u00c9RIN", "cautions": "screen for active tuberculosis (contra-indicated if tuberculosis confirmed); traumatic\r\ncatheterisation or urethral or bladder\r\ninjury (delay administration until mucosal damage healed)", "side-effects": "cystitis, dysuria, urinary frequency, haematuria,\r\nmalaise, fever, influenza-like syndrome; also systemic BCG infection\r\n(with fatalities)\u2014consult product literature; rarely hypersensitivity\r\nreactions (such as arthralgia and rash), orchitis, transient urethral\r\nobstruction, bladder contracture, renal abscess; ocular symptoms reported", "contra-indications": "impaired immune response, HIV infection, urinary-tract\r\ninfection, severe haematuria, tuberculosis, fever of unknown origin", "doses": ["Consult product literature"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "PHOSPHATES (ORAL)": {"indications": "see preparations", "name": "PHOSPHATES (ORAL)", "renal impairment": "avoid if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above; also cardiac disease (avoid\r\nin congestive cardiac failure)", "side-effects": "seenotes above; also chest\r\npain, arrhythmias, asthenia, and renal failure", "contra-indications": "seenotes above; also ascites; congestive cardiac failure", "hepatic impairment": "use with caution in cirrhosis; avoid in ascites", "doses": ["bowel evacuation before colonic surgery, colonoscopy or\r\nradiological examination,adultover\r\n18 years, 45\u00a0mL diluted with half a glass (120\u00a0mL) of cold water,\r\nfollowed by one full glass (240\u00a0mL) of cold water"], "pregnancy": "caution", "breast-feeding": "caution"}, "HEPATITIS B IMMUNOGLOBULIN": {"side-effects": "injection site reactions; less frequently, buccal\r\nulceration, glossitis, abdominal pain, chest pain, dyspnoea, anaphylaxis,\r\ntremor, dizziness, headache, arthralgia; for side-effects associated\r\nwith intravenous immunoglobulin, seesection 14.5.1", "indications": "prophylaxis against hepatitis B infection", "name": "HEPATITIS B IMMUNOGLOBULIN", "cautions": "IgA deficiency; interference with live virus vaccines see underNormal Immunoglobulin.", "doses": ["by intramuscular injection(as soon as\r\npossible after exposure; ideally within 12\u201348 hours, but no later\r\nthan 7 days after exposure),adultandchildover 10 years 500\u00a0units;childunder 5 years 200\u00a0units, 5\u20139 years 300\u00a0units;neonate200\u00a0units", "Prevention of transmitted infection at birth,neonate200\u00a0units as soon as possible after birth;\r\nfor full details consultImmunisation against Infectious Disease(www.dh.gov.uk)"]}, "BUSERELIN": {"side-effects": "seenotes above; worsening\r\nhypertension, palpitation,glucoseintolerance,\r\naltered blood lipids, thrombocytopenia, leucopenia, nervousness, fatigue,\r\nmemory and concentration disturbances, anxiety, increased thirst,\r\nhearing disorders, musculoskeletal pain; nasal irritation, nose bleeds\r\nand altered sense of taste and smell (spray formulation only)", "indications": "advanced prostate cancer; other indications\r\n(section 6.7.2)", "name": "BUSERELIN", "cautions": "diabetes, hypertension, depression; see\r\nalsonotes above", "doses": ["By subcutaneous injection, 500\u00a0micrograms\r\nevery 8 hours for 7 days, thenintranasally, 1 spray\r\ninto each nostril 6 times daily (see also notes above)", "Avoid use of nasal decongestants\r\nbefore and for at least 30 minutes after treatment."]}, "CAPTOPRIL": {"indications": "mild to moderate essential hypertension alone\r\nor with thiazide therapy and severe hypertension resistant to other\r\ntreatment; congestive heart failure with left ventricular dysfunction\r\n(adjunct\u2014seesection 2.5.5); following\r\nmyocardial infarction, see dose; diabetic nephropathy (microalbuminuria\r\ngreater than 30\u00a0mg/day) in type 1 diabetes", "name": "CAPTOPRIL", "renal impairment": "seenotes above; reduce\r\ndose; max. initial dose 25\u00a0mg daily (do not exceed 100\u00a0mg daily) if\r\neGFR 20\u201340\u00a0mL/minute/1.73\u00a0m2; max. initial dose 12.5\u00a0mg\r\ndaily (do not exceed 75\u00a0mg daily) if eGFR 10\u201320\u00a0mL/minute/1.73\u00a0m2; max. initial dose 6.25\u00a0mg daily (do not exceed 37.5\u00a0mg daily)\r\nif eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of captopril ", "name": "Captopril", "backrefs": ["Captopril"]}, "cautions": "seenotes above", "side-effects": "see notes above; tachycardia, serum sickness,\r\nweight loss, stomatitis, maculopapular rash, photosensitivity, flushing\r\nand acidosis", "contra-indications": "seenotes above", "doses": ["Hypertension, used alone, initially 12.5\u00a0mg twice daily;\r\nif used in addition to diuretic (see notes above),\r\nor in elderly, initially 6.25\u00a0mg twice daily (first dose at bedtime);\r\nusual maintenance dose 25\u00a0mg twice daily; max. 50\u00a0mg twice daily (rarely\r\n3 times daily in severe hypertension)", "Heart failure (adjunct), initially 6.25\u201312.5\u00a0mg 2\u20133 times daily\r\nunder close medical supervision (see notes above),\r\nincreased gradually at intervals of at least 2 weeks up to max. 150\u00a0mg\r\ndaily in divided doses if tolerated", "Prophylaxis after infarction in clinically stable patients with\r\nasymptomatic or symptomatic left ventricular dysfunction (radionuclide\r\nventriculography or echocardiography undertaken before initiation),\r\ninitially 6.25\u00a0mg, starting as early as 3 days after infarction, then\r\nincreased over several weeks to 150\u00a0mg daily (if tolerated) in divided\r\ndoses", "Diabetic nephropathy, 75\u2013100\u00a0mg daily in divided doses; if further\r\nblood pressure reduction required, other antihypertensives may be\r\nused in conjunction withcaptopril; in severe renal\r\nimpairment, initially 12.5\u00a0mg twice daily (if concomitant diuretic\r\ntherapy required, loop diuretic rather than thiazide should be chosen)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "LITHIUM CARBONATE": {"indications": "treatment and prophylaxis of mania, bipolar disorder, and recurrent\r\ndepression (see also notes above); aggressive or self-mutilating behaviour", "name": "LITHIUM CARBONATE", "renal impairment": "avoid if possible or reduce dose and monitor serum-lithium\r\nconcentration carefully", "cautions": "seenotes above; also measure serum-lithium\r\nconcentration regularly (every 3 months on stabilised regimens), measure renal function and thyroid function every\r\n6 months on stabilised regimens and advise\r\npatient to seek attention if symptoms of hypothyroidism develop (women\r\nat greater risk) e.g. lethargy, feeling cold; maintain adequate sodium and fluid intake; test renal function before initiating and if evidence of toxicity; cardiac disease (monitor cardiac function\r\nbefore initiating); QT-interval prolongation; conditions with sodium imbalance such\r\nas Addison\u2019s disease; reduce\r\ndose or discontinue in diarrhoea, vomiting, and intercurrent infection (especially if sweating profusely);\r\nconcurrent ECT treatment (seizure threshold may be lowered); psoriasis (risk of exacerbation); elderly (reduce dose); diuretic treatment; myasthenia gravis; surgery (section 15.1); avoid abrupt withdrawal (see notes above);interactions:Appendix 1 (lithium)", "side-effects": "gastro-intestinal disturbances, fine tremor, renal\r\nimpairment (particularly impaired urinary concentration and polyuria),\r\npolydipsia, leucocytosis; also weight gain and oedema (may respond\r\nto dose reduction); hyperparathyroidism, hyperthyroidism, hyperglycaemia,\r\nhypermagnesaemia, and hypercalcaemia reported; signs of intoxication\r\nare blurred vision, increasing gastro-intestinal disturbances (anorexia,\r\nvomiting, diarrhoea), muscle weakness, arthralgia, myalgia, increased\r\nCNS disturbances (mild drowsiness and sluggishness increasing to giddiness\r\nwith ataxia, coarse tremor, lack of coordination, dysarthria), and\r\nrequire withdrawal of treatment; with severeoverdosage(serum-lithium concentration above 2\u00a0mmol/litre) hyperreflexia and\r\nhyperextension of limbs, convulsions, toxic psychoses, syncope, renal\r\nfailure, circulatory failure, coma, and occasionally, death; goitre,\r\nraised antidiuretic hormone concentration, hypothyroidism, hypokalaemia,\r\nECG changes, and kidney changes may also occur; see alsoEmergency Treatment of Poisoning", "contra-indications": "dehydration, untreated hypothyroidism", "doses": ["(see Dose above for advice on bioavailability and serum\r\nmonitoring):Treatment and prophylaxis, initially 0.4\u20131.2\u00a0g\r\ndaily as a single dose or in 2 divided doses (elderly or patients\r\nless than 50\u00a0kg, 400\u00a0mg daily);childnot recommended"], "pregnancy": "avoid if possible in the first trimester (risk of\r\nteratogenicity, including cardiac abnormalities); dose requirements\r\nincreased during the second and third trimesters (but on delivery\r\nreturn abruptly to normal); close monitoring of serum-lithium concentration\r\nadvised (risk of toxicity in neonate)", "breast-feeding": "present in milk and risk of toxicity in infant\u2014avoid"}, "ISRADIPINE": {"indications": "hypertension", "name": "ISRADIPINE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": " grapefruit juice increases plasma concentration of isradipine ", "name": "Isradipine", "backrefs": ["Isradipine"]}, "cautions": "sick sinus syndrome (if pacemaker not\r\nfitted); severe aortic stentosis; poor\r\ncardiac reserve; chronic heart failure;interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "abdominal discomfort; tachycardia, palpitation,\r\nflushing, peripheral oedema; dyspnoea; headache, fatigue, dizziness;\r\npolyuria; rash;less commonlyhypotension, weight\r\ngain;very rarelyvomiting, nausea, gum hyperplasia,\r\nanorexia, drowsiness, arrhythmia, bradycardia, heart failure, cough,\r\ndepression, paraesthesia, anxiety, erectile dysfunction, blood disorders\r\n(such as thrombocytopenia, leucopenia, anaemia), arthralgia, visual\r\ndisturbance, hypersensitivity reactions; hepatitis and gynaecomastia\r\nalso reported;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "cardiogenic shock; during or within 1 month of myocardial\r\ninfarction; unstable angina; acute porphyria (section 9.8.2)", "hepatic impairment": "1.25\u00a0mg twice daily, increased if necessary after 3\u20134\r\nweeks according to response; maintenance dose of 2.5\u00a0mg or 5\u00a0mg once\r\ndaily may be sufficient", "doses": ["2.5\u00a0mg twice daily, increased if necessary after 3\u20134 weeks\r\nto 5\u00a0mg twice daily (exceptionally up to 10\u00a0mg twice daily);elderly1.25\u00a0mg twice daily, increased if necessary\r\nafter 3\u20134 weeks according to response; maintenance dose of 2.5\u00a0mg\r\nor 5\u00a0mg once daily may be sufficient"], "pregnancy": "may inhibit labour; risk to fetus should be balanced\r\nagainst risk of uncontrolled maternal hypertension", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CHORIONIC GONADOTROPHIN": {"indications": "see notes above", "name": "CHORIONIC GONADOTROPHIN", "renal impairment": "use with caution", "cautions": "cardiac impairment, asthma, epilepsy, migraine; prepubertal boys (risk of premature\r\nepiphyseal closure or precocious puberty)", "side-effects": "oedema (particularly in males\u2014reduce dose), headache,\r\ntiredness, mood changes, gynaecomastia, local reactions; may aggravate\r\novarian hyperstimulation, multiple pregnancy", "contra-indications": "androgen-dependent tumours", "doses": ["By subcutaneousorintramuscular injection, according to patient\u2019s response"]}, "MAGNESIUM SALTS (ORAL)": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  nitrofurantoin reduced by oral magnesium salts (as magnesium trisilicate)", "name": "Magnesium Salts (oral)", "backrefs": []}}, "TETRACYCLINE": {"indications": "see notes above; acne vulgaris, rosacea\r\n(section 13.6)", "name": "TETRACYCLINE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of  methotrexate toxicity when given with tetracycline ", "name": "Tetracycline", "backrefs": ["Kaolin", "Quinapril", "Tetracyclines", "Retinoids", "Strontium Ranelate", "Tetracycline", "Dairy Products", "Tripotassium Dicitratobismuthate"]}, "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nacute renal failure, skin discoloration", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; max.\r\n1\u00a0g daily in divided doses", "doses": ["250\u00a0mg every 6 hours, increased in severe infections to\r\n500\u00a0mg every 6\u20138 hours", "Acne, seesection 13.6.2", "Non-gonococcal urethritis, 500\u00a0mg every 6 hours for 7\u201314 days\r\n(21 days if failure or relapse after first course)", "Tablets should be swallowed whole\r\nwith plenty of fluid while sitting or standing"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "HYDROXOCOBALAMIN": {"indications": "see under dose below; cyanide poisoning (seeEmergency Treatment of Poisoning)", "name": "HYDROXOCOBALAMIN", "interactions": {"extra": "", "bad": 0, "interaction": " chloramphenicol reduces response to hydroxocobalamin ", "name": "Hydroxocobalamin", "backrefs": ["Hydroxocobalamin"]}, "cautions": "should not be given before diagnosis\r\nfully established but see alsonotes above;interactions:Appendix 1 (hydroxocobalamin)", "side-effects": "nausea, headache, dizziness; fever, hypersensitivity\r\nreactions (including rash and pruritus); injection-site reactions;\r\nhypokalaemia and thrombocytosis during initial treatment; chromaturia", "doses": ["By intramuscular injection, pernicious\r\nanaemia and other macrocytic anaemias without neurological involvement,\r\ninitially 1\u00a0mg 3 times a week for 2 weeks then 1\u00a0mg every 3 months", "Pernicious anaemia and other macrocytic anaemias with neurological\r\ninvolvement, initially 1\u00a0mg on alternate days until no further improvement,\r\nthen 1\u00a0mg every 2 months", "Prophylaxis of macrocytic anaemias associated with vitamin B12deficiency, 1\u00a0mg every 2\u20133 months", "Tobacco amblyopia and Leber\u2019s optic atrophy, initially 1\u00a0mg\r\ndaily for 2 weeks, then 1\u00a0mg twice weekly until no further improvement,\r\nthereafter 1\u00a0mg every 1\u20133 months", "childseeBNF for Children"], "breast-feeding": "present in milk but not known to be harmful"}, "MELOXICAM": {"indications": "pain and inflammation in rheumatic disease; exacerbation of osteoarthritis\r\n(short-term); ankylosing spondylitis", "name": "MELOXICAM", "renal impairment": "avoid if eGFR less than 25\u00a0mL/minute/1.73m2; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": "excretion of  methotrexate reduced by meloxicam (increased risk of toxicity)\u2014but for concomitant use in rheumatic disease see Methotrexate, section 10.1.3", "name": "Meloxicam", "backrefs": ["Meloxicam"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, osteoarthritis,adultandchildover\r\n16 years, 7.5\u00a0mg once daily, increased if necessary to max. 15\u00a0mg\r\nonce daily", "Rheumatoid arthritis, ankylosing spondylitis,adultandchildover\r\n16 years, 15\u00a0mg once daily, may be reduced to 7.5\u00a0mg once daily;elderly7.5\u00a0mg daily", "childover 12 years,\r\nseeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid; see alsonotes above"}, "INFLUENZA VACCINE": {"interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  warfarin possibly enhanced by influenza vaccine ", "name": "Influenza Vaccine", "backrefs": ["Influenza Vaccine"]}}, "SULFONAMIDES": {"interactions": {"extra": "", "bad": 0, "interaction": " potassium aminobenzoate inhibits effects of sulfonamides ", "name": "Sulfonamides", "backrefs": ["Sulfonamides", "Potassium Aminobenzoate"]}}, "RANITIDINE": {"indications": "see under Dose, other conditions where reduction of gastric acidity\r\nis beneficial (see notes above andsection\r\n1.9.4)", "name": "RANITIDINE", "renal impairment": "use half normal dose if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  erlotinib reduced by ranitidine\u2014manufacturer of erlotinib advises give at least 2 hours before or 10 hours after ranitidine", "name": "Ranitidine", "backrefs": ["Ranitidine"]}, "cautions": "seenotes above;interactions:Appendix 1 (histamine H2-antagonists)\r\nand notes above", "side-effects": "see notes above;less commonlyblurred vision; also reported pancreatitis, involuntary movement\r\ndisorders, interstitial nephritis, alopecia", "doses": ["By mouth, benign gastric and duodenal\r\nulceration, chronic episodic dyspepsia,adultandchildover 12 years, 150\u00a0mg twice\r\ndailyor300\u00a0mg at night for 4\u20138 weeks in benign\r\ngastric and duodenal ulceration, up to 6 weeks in chronic episodic\r\ndyspepsia, and up to 8 weeks in NSAID-associated ulceration (in duodenal\r\nulcer 300\u00a0mg can be given twice daily for 4 weeks to achieve a higher\r\nhealing rate);child3\u201312 years, (benign\r\ngastric and duodenal ulceration) 2\u20134\u00a0mg/kg (max. 150\u00a0mg) twice daily\r\nfor 4\u20138 weeks", "Prophylaxis of NSAID-associated gastric or duodenal ulcer [unlicensed\r\ndose],adultandchildover 12 years, 300\u00a0mg twice daily", "Gastro-oesophageal reflux disease,adultandchildover 12 years, 150\u00a0mg twice\r\ndailyor300\u00a0mg at night for up to 8 weeks or if\r\nnecessary 12 weeks (moderate to severe, 600\u00a0mg daily in 2\u20134 divided\r\ndoses for up to 12 weeks); long-term treatment of healed gastro-oesophageal\r\nreflux disease, 150\u00a0mg twice daily;child3\u201312 years, 2.5\u20135\u00a0mg/kg (max. 300\u00a0mg) twice daily", "Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics,adultandchildover\r\n12 years,by mouth, 150\u00a0mg at onset of labour, then\r\nevery 6 hours; surgical procedures,by intramuscularorslow intravenous injection, 50\u00a0mg\r\n45\u201360 minutes before induction of anaesthesia (intravenous injection\r\ndiluted to 20\u00a0mL and given over at least 2 minutes), orby\r\nmouth, 150\u00a0mg 2 hours before induction of anaesthesia and\r\nalso when possible on the preceding evening", "By intramuscular injection, 50\u00a0mg\r\nevery 6\u20138 hours", "By slow intravenous injection,adultandchildover\r\n12 years, 50\u00a0mg diluted to 20\u00a0mL and given over at least 2 minutes;\r\nmay be repeated every 6\u20138 hours", "Prophylaxis of stress ulceration [unlicensed dose],adultandchildover\r\n12 years,by slow intravenous injectionover at least\r\n2 minutes, 50\u00a0mg diluted to 20\u00a0mL every 8 hours (may be changed to\r\n150\u00a0mg twice dailyby mouthwhen oral feeding commences)"], "pregnancy": "manufacturer advises avoid unless essential, but\r\nnot known to be harmful", "breast-feeding": "significant amount present in milk, but not\r\nknown to be harmful"}, "ABACAVIR": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "ABACAVIR", "renal impairment": "manufacturer advises avoid in end-stage renal disease;\r\navoidKivexa\u00ae orTrizivir\u00ae if\r\neGFR less than 50\u00a0mL/minute/1.73\u00a0m2(consult product literature)", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin possibly reduces plasma concentration of abacavir ", "name": "Abacavir", "backrefs": ["Abacavir", "Ribavirin"]}, "cautions": "seenotes above; also test for HLA-B*5701 allele before treatment or if restarting treatment\r\nand HLA-B*5701 status not known\u2014increased risk of hypersensitivity\r\nreaction in presence of HLA-B*5701 allele; HIV load greater than 100\u00a0000 copies/mL; patients at high risk of cardiovascular disease (especially\r\nif 10-year cardiovascular risk greater than 20%);interactions:Appendix 1 (abacavir)", "side-effects": "see notes above; also hypersensitivity reactions\r\n(see above);very rarelyStevens-Johnson syndrome\r\nand toxic epidermal necrolysis; rash and gastro-intestinal disturbances\r\nmore common in children", "hepatic impairment": "seenotes above; also\r\navoid in moderate impairment unless essential; avoid in severe impairment", "doses": ["600\u00a0mg daily in 1\u20132 divided doses;child3 months\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid (toxicity inanimalstudies); see alsoPregnancy", "breast-feeding": "seeBreast-feeding"}, "NEOSTIGMINE WITH GLYCOPYRRONIUM BROMIDE": {"indications": "see under Dose", "name": "NEOSTIGMINE WITH GLYCOPYRRONIUM BROMIDE", "renal impairment": "may need dose reduction", "cautions": "bronchospasm; severe bradycardia; coronary artery disease; congestive heart failure; arrhythmias; hyperthyroidism; hypertension; pyrexia; epilepsy; parkinsonism; susceptibility to angle-closure glaucoma;interactions:Appendix 1 (parasympathomimetics,\r\nantimuscarinics)", "side-effects": "nausea, vomiting, changes in salivation, diarrhoea;\r\ntransient bradycardia (followed by tachycardia, palpitation, and arrhythmias);\r\nchanges in bronchial secretions; urinary urgency and retention; dilatation\r\nof the pupils with loss of accommodation;very rarelyangle-closure glaucoma;signs of overdosage with neostigmineinclude bronchoconstriction, increased bronchial secretions, lacrimation,\r\nexcessive sweating, involuntary defaecation and micturition, miosis,\r\nnystagmus, bradycardia, heart block, arrhythmias, hypotension, agitation,\r\nexcessive dreaming, and weakness (leading to fasciculation and paralysis)", "contra-indications": "intestinal or urinary obstruction", "doses": ["reversal of non-depolarising neuromuscular blockade,by intravenous injectionover 10\u201330 seconds, 1\u20132\u00a0mLor0.02\u00a0mL/kg, dose may be repeated if required (total max.\r\n2\u00a0mL);child0.02\u00a0mL/kg (or 0.2\u00a0mL/kg\r\nof a 1 in 10 dilution using water for injections or sodium chloride\r\ninjection 0.9%), dose may be repeated if required (total max. 2\u00a0mL)"], "pregnancy": "safety not established\u2014limited information available", "breast-feeding": "no information available"}, "TADALAFIL": {"indications": "pulmonary arterial hypertension;\r\nerectile dysfunction (section 7.4.5)", "name": "TADALAFIL", "renal impairment": "initially 20\u00a0mg once daily in mild to moderate impairment,\r\nincreased to 40\u00a0mg once daily if tolerated; avoid in severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of tadalafil\u2014manufacturer of tadalafil advises avoid concomitant use", "name": "Tadalafil", "backrefs": ["Tadalafil", "Doxazosin"]}, "cautions": "hypotension (avoid if systolic blood pressure below 90\u00a0mmHg); aortic and mitral\r\nvalve disease; pericardial constriction; congestive cardiomyopathy; left ventricular dysfunction; life-threatening\r\narrhythmias; coronary artery disease; uncontrolled hypertension; pulmonary veno-occlusive disease; predisposition\r\nto priapism; anatomical deformation of\r\nthe penis; hereditary degenerative retinal\r\ndisorders;interactions:Appendix 1\r\n(tadalafil)", "side-effects": "nausea, vomiting, dyspepsia, gastro-oesophageal\r\nreflux, chest pain, palpitation, flushing, hypotension, nasopharyngitis,\r\nepistaxis, headache, myalgia, back and limb pain, increased uterine\r\nbleeding, blurred vision, facial oedema, rash;less commonlytachycardia, hypertension, seizures, amnesia, priapism, hyperhidrosis;also reportedunstable angina, arrhythmia, myocardial infarction,\r\nstroke, hearing loss, non-arteritic anterior ischaemic optic neuropathy,\r\nretinal vascular occlusion, visual field defect, Stevens-Johnson syndrome", "contra-indications": "acute myocardial infarction in\r\npast 90 days; history of non-arteritic anterior\r\nischaemic optic neuropathy; avoid concomitant\r\nuse of nitrates", "hepatic impairment": "initially 20\u00a0mg once daily in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["adultover 18 years, 40\u00a0mg\r\nonce daily"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "LACIDIPINE": {"indications": "hypertension", "name": "LACIDIPINE", "interactions": {"extra": "", "bad": 0, "interaction": " grapefruit juice increases plasma concentration of lacidipine ", "name": "Lacidipine", "backrefs": ["Lacidipine"]}, "cautions": "cardiac conduction abnormalities; poor cardiac reserve;interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "flushing, palpitation, oedema; headache, dizziness;rarelygastro-intestinal disturbances, gum hyperplasia,\r\naggravation of angina, mood disturbances, asthenia, polyuria, muscle\r\ncramps, skin rash (including pruritus and erythema);overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "cardiogenic shock, unstable angina, aortic stenosis; avoid within 1 month of myocardial infarction; acute porphyria (section 9.8.2)", "hepatic impairment": "antihypertensive effect possibly increased", "doses": ["Initially 2\u00a0mg as a single daily dose, preferably in the\r\nmorning; increased after 3\u20134 weeks to 4\u00a0mg daily, then if necessary\r\nto 6\u00a0mg daily"], "pregnancy": "manufacturer advises avoid; may inhibit labour", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "SILVER NITRATE": {"side-effects": "chemical burns on surrounding skin; stains skin\r\nand fabric", "indications": "warts, verrucas, umbilical granulomas, over-granulating tissue, cauterisation", "name": "SILVER NITRATE", "cautions": "protect surrounding skin and avoid broken skin; not\r\nsuitable for application to face, ano-genital region,\r\nor large areas", "doses": ["Common warts and verrucas, apply moistened caustic pencil\r\ntip for 1\u20132 minutes; repeat after 24 hours up to max. 3 applications\r\nfor wartsormax. 6 applications for verrucas", "Instructions in proprietary packs generally\r\nincorporate advice to remove dead skin before use by gentle filing\r\nand to cover with adhesive dressing after application", "Umbilical granulomas, apply moistened caustic pencil tip (usually\r\ncontaining silver nitrate 40%) for 1\u20132 minutes while protecting surrounding\r\nskin with soft paraffin"]}, "FOSINOPRIL SODIUM": {"indications": "hypertension; congestive heart failure (adjunct\u2014seesection 2.5.5)", "name": "FOSINOPRIL SODIUM", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "see notes above; chest pain; musculoskeletal pain", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Hypertension, initially 10\u00a0mg daily, increased if necessary\r\nafter 4 weeks; usual dose range 10\u201340\u00a0mg (doses over 40\u00a0mg not shown\r\nto increase efficacy); if used in addition to diureticsee notes above", "Heart failure (adjunct), initially 10\u00a0mg once daily under close\r\nmedical supervision (see notes above),\r\nincreased gradually to 40\u00a0mg once daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLUCLOXACILLIN": {"indications": "infections due to beta-lactamase-producing staphylococci including\r\notitis externa; adjunct in pneumonia, impetigo, cellulitis, osteomyelitis\r\nand in staphylococcal endocarditis (Table 1,section 5.1)", "name": "FLUCLOXACILLIN", "renal impairment": "reduce dose if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underBenzylpenicillin(section 5.1.1.1); risk of kernicterus in jaundiced neonates when high doses given parenterally;interactions:Appendix 1 (penicillins)", "side-effects": "see underBenzylpenicillin(section 5.1.1.1); also\r\ngastro-intestinal disturbances;very rarelyhepatitis\r\nand cholestatic jaundice (see also Hepatic disorders above)", "contra-indications": "see underBenzylpenicillin(section 5.1.1.1)", "hepatic impairment": "see Cautions and Hepatic Disorders above", "doses": ["By mouth, 250\u2013500\u00a0mg every 6 hours, at\r\nleast 30 minutes before food;neonateseeBNF for Children;child1 month\u20132 years, 62.5\u2013125\u00a0mg\r\nevery 6 hours, at least 30 minutes before food; 2\u201310 years, 125\u2013250\u00a0mg\r\nevery 6 hours, at least 30 minutes before food", "By intramuscular injection, 250\u2013500\u00a0mg every\r\n6 hours;child1 month\u201318 years seeBNF for Children", "By slow intravenous injectionorby intravenous infusion, 0.25\u20132\u00a0g every\r\n6 hours;childunder 18 years seeBNF for Children", "Endocarditis (in combination with another antibacterial, see\r\nTable 1,section 5.1), body-weight under 85\u00a0kg, 8\u00a0g\r\ndaily in 4 divided doses; body-weight over 85\u00a0kg, 12\u00a0g daily in 6\r\ndivided doses;child1 month\u201318 years\r\nseeBNF for Children", "Osteomyelitis (see Table 1,section 5.1), up to 8\u00a0g daily\r\nin 3\u20134 divided doses;childunder 18\r\nyears seeBNF for Children", "Surgical prophylaxis,by slow intravenous\r\ninjectionorby intravenous infusion, 1\u20132\u00a0g up to 30 minutes before the procedure; up to 4 further doses\r\nof 500\u00a0mg may be given every 6 hoursby mouth,orby intramuscular injection,orby slow intravenous injectionorby intravenous infusionfor high risk procedures", "Flucloxacillindoses in\r\nBNF may differ from those in product literature"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "DOXEPIN": {"indications": "depressive illness, particularly where\r\nsedation is required; pruritus in eczema (section 13.3)", "name": "DOXEPIN", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits metabolism of doxepin (increased plasma concentration)", "name": "Doxepin", "backrefs": ["Doxepin"]}, "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nabdominal pain, stomatitis, diarrhoea, flushing, and oedema", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["adultandchildover 12 years, initially 75\u00a0mg daily in divided\r\ndosesoras a single dose at bedtime, adjusted according\r\nto response; usual maintenance 25\u2013300\u00a0mg daily (doses above 100\u00a0mg\r\ngiven in 3 divided doses);elderlystart\r\nwith lower doses and adjust according to response"], "pregnancy": "use with caution\u2014limited information available", "breast-feeding": "seenotes above; accumulation\r\nof metabolite may cause sedation and respiratory depression in neonate"}, "LABETALOL": {"interactions": {"extra": "", "bad": 0, "interaction": " cimetidine increases plasma concentration of labetalol ", "name": "Labetalol", "backrefs": ["Labetalol"]}}, "PNEUMOCOCCAL VACCINE": {"indications": "immunisation against pneumococcal infection", "name": "PNEUMOCOCCAL VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1;alsoRevaccination,above", "contra-indications": "seesection 14.1", "doses": ["by intramuscular or subcutaneous injection,adultandchildover 2 years, 0.5\u00a0mL; revaccination, seenotes above"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "ERDOSTEINE": {"indications": "symptomatic treatment of acute exacerbations of chronic bronchitis", "name": "ERDOSTEINE", "renal impairment": "avoid if eGFR less than 25\u00a0mL/minute/1.73\u00a0m2\u2014no information available", "cautions": "seenotes above", "side-effects": "very rarelynausea, vomiting,\r\ndiarrhoea, abdominal pain, taste disturbance, headache, rash, and\r\nurticaria", "hepatic impairment": "manufacturer advises max. 300\u00a0mg daily in mild to moderate\r\nimpairment; avoid in severe impairment", "doses": ["adultover 18 years, 300\u00a0mg\r\ntwice daily for up to 10 days"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PYRIMETHAMINE WITH SULFADOXINE": {"indications": "adjunct toquininein treatment ofPlasmodium falciparummalaria;notrecommended for prophylaxis", "name": "PYRIMETHAMINE WITH SULFADOXINE", "cautions": "see underPyrimethamineand underCo-trimoxazole(section 5.1.8); not recommended\r\nfor prophylaxis (severe side-effects on long-term use);interactions:Appendix 1 (pyrimethamine, sulfonamides)", "side-effects": "see underPyrimethamineand\r\nunderCo-trimoxazole(section 5.1.8); pulmonary infiltrates (e.g.\r\neosinophilic or allergic alveolitis) reported\u2014discontinue if cough\r\nor shortness of breath", "contra-indications": "see underPyrimethamineand underCo-trimoxazole(section 5.1.8); sulfonamide\r\nallergy", "doses": ["Treatment of falciparum malaria, seenotes above", "Prophylaxis, not recommended by UK malaria experts"], "pregnancy": "possible teratogenic risk infirst trimester(pyrimethaminea folate antagonist); inthird trimester\u2014risk of neonatal haemolysis and methaemoglobinaemia;\r\nfear of increased risk of kernicterus in neonates appears to be unfounded;\r\nsee alsoFalciparum Malaria (treatment)", "breast-feeding": "small risk of kernicterus in jaundiced infants\r\nand of haemolysis in G6PD-deficient infants (due to sulfadoxine)"}, "BASILIXIMAB": {"indications": "see notes above", "name": "BASILIXIMAB", "side-effects": "severe hypersensitivity reactions and cytokine\r\nrelease syndrome have been reported", "doses": ["By intravenous injectionorby intravenous infusion, 20\u00a0mg within 2 hours before\r\ntransplant surgery and 20\u00a0mg 4 days after surgery; withhold second\r\ndose if severe hypersensitivity or graft loss occurs;childandadolescent1\u201317 years, body-weight under 35\u00a0kg, 10\u00a0mg within 2 hours before\r\ntransplant surgery and 10\u00a0mg 4 days after surgery; body-weight over\r\n35\u00a0kg, adult dose"], "pregnancy": "avoid\u2014no information available; adequate contraception\r\nmust be used during treatment and for 16 weeks after last dose", "breast-feeding": "avoid\u2014no information available"}, "ALUMINIUM SALTS": {"side-effects": "skin irritation", "indications": "see under Dose below", "name": "ALUMINIUM SALTS", "cautions": "avoid contact with eyes or mucous membranes; avoid use on broken or irritated skin; do not\r\nshave axillae or use depilatories within 12 hours of application; avoid contact with clothing", "doses": ["Hyperhidrosis affecting axillae, hands or feet, apply\r\nliquid formulation at night to dry skin, wash off the following morning,\r\ninitially daily then reduce frequency as condition improves\u2014do not\r\nbathe immediately before use", "Hyperhidrosis, bromidrosis, intertrigo, and prevention of tinea\r\npedis and related conditions, apply powder to dry skin"]}, "TRIMETHOPRIM": {"indications": "urinary-tract infections, acute and chronic bronchitis; pneumocystis\r\npneumonia (section 5.4.8)", "name": "TRIMETHOPRIM", "renal impairment": "use half normal dose after 3 days if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2; use half normal dose if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2(monitor plasma-trimethoprim concentration if eGFR less than\r\n10\u00a0mL/minute/1.73\u00a0m2)", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of hyperkalaemia when  spironolactone given with trimethoprim ", "name": "Trimethoprim", "backrefs": ["Pyrimethamine", "Lamivudine", "Trimethoprim"]}, "cautions": "predisposition to folate deficiency; elderly; manufacturer recommends\r\nblood counts on long-term therapy (but evidence of practical value\r\nunsatisfactory); neonates (specialist supervision\r\nrequired); acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(trimethoprim)", "side-effects": "gastro-intestinal disturbances including nausea\r\nand vomiting, pruritus, rashes, hyperkalaemia, depression of haematopoiesis;\r\nrarely erythema multiforme, toxic epidermal necrolysis, photosensitivity\r\nand other allergic reactions including angioedema and anaphylaxis;\r\naseptic meningitis and uveitis reported", "contra-indications": "blood dyscrasias", "doses": ["Acute infections, 200\u00a0mg every 12 hours;child1 month\u201312 years, 4\u00a0mg/kg (max. 200\u00a0mg) every\r\n12 hours;or6 weeks\u20136 months 25\u00a0mg every 12 hours,\r\n6 months\u20136 years 50\u00a0mg every 12 hours, 6\u201312 years 100\u00a0mg every 12\r\nhours", "Prophylaxis, 100\u00a0mg at night;childunder 12 years, 2\u00a0mg/kg (max.100\u00a0mg) at night;or[unlicensed dose] 6 weeks\u20136 months 12.5\u00a0mg at night, 6 months\u20136\r\nyears 25\u00a0mg at night, 6\u201312 years 50\u00a0mg at night"], "pregnancy": "teratogenic risk in first trimester (folate antagonist);\r\nmanufacturers advise avoid", "breast-feeding": "present in milk\u2014short-term use not known to\r\nbe harmful"}, "DIHYDROTACHYSTEROL": {"indications": "seenotes above", "name": "DIHYDROTACHYSTEROL", "cautions": "see underErgocalciferol", "side-effects": "see underErgocalciferol", "contra-indications": "see underErgocalciferol", "doses": ["acute, chronic, and latent forms of hypocalcaemic tetany\r\ndue to hypoparathyroidism, consult product literature"], "pregnancy": "see underErgocalciferol", "breast-feeding": "see underErgocalciferol"}, "TRAMADOL HYDROCHLORIDE": {"indications": "moderate to severe pain", "name": "TRAMADOL HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; impaired consciousness; excessive bronchial\r\nsecretions; not suitable as a substitute\r\nin opioid-dependent patients", "side-effects": "seenotes above; also\r\ndiarrhoea, retching, fatigue, paraesthesia;less commonlygastritis, and flatulence;rarelyanorexia, syncope,\r\nhypertension, bronchospasm, dyspnoea, wheezing, seizures, and muscle\r\nweakness; blood disorders also reported", "contra-indications": "seenotes above; uncontrolled epilepsy", "hepatic impairment": "seenotes above", "doses": ["adultandchildover 12 years, 150\u00a0mg once daily increased\r\nif necessary; usual max. 400\u00a0mg once daily"], "pregnancy": "embryotoxic in animal studies\u2014manufacturers advise\r\navoid; see alsonotes above", "breast-feeding": "amount probably too small to be harmful, but\r\nmanufacturer advises avoid"}, "KETOCONAZOLE": {"indications": "fungal skin infections; systemic or resistant fungal\r\ninfections (section 5.2.2); vulval candidiasis (section 7.2.2)", "name": "KETOCONAZOLE", "interactions": {"extra": "", "bad": 0, "interaction": "in vitro studies suggest a possible interaction between  docetaxel and ketoconazole (consult docetaxel product literature)", "name": "Ketoconazole", "backrefs": ["Temsirolimus", "Mometasone", "Darunavir", "Irinotecan", "Salmeterol", "Bortezomib", "Ciclesonide", "Loratadine", "Isoniazid", "Almotriptan", "Cinacalcet", "Fingolimod", "Antimuscarinics", "Alitretinoin", "Cilostazol", "Lanthanum", "Domperidone", "Rupatadine", "Ketoconazole", "Tolvaptan", "Boceprevir", "Mefloquine", "Galantamine", "Paricalcitol", "Dasatinib", "Sunitinib"]}, "cautions": "seenotes above", "side-effects": "see notes above", "doses": ["Tinea pedis, apply twice daily; other fungal infections,\r\napply 1\u20132 times daily"]}, "PROGUANIL": {"interactions": {"extra": "", "bad": 0, "interaction": "isolated reports that anticoagulant effect of  warfarin may be enhanced by proguanil ", "name": "Proguanil", "backrefs": ["Proguanil"]}}, "VINFLUNINE": {"indications": "seenotes above", "name": "VINFLUNINE", "renal impairment": "reduce dose if creatinine clearance less than 60\u00a0mL/minute\u2014consult\r\nproduct literature", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of vinflunine\u2014manufacturer of vinflunine advises avoid concomitant use", "name": "Vinflunine", "backrefs": ["Vinflunine"]}, "cautions": "seesection 8.1andnotes above; cardiovascular disease; QT-interval prolongation (avoid hypokalaemia or concomitant use of drugs that prolong QT-interval);interactions:Appendix 1 (vinflunine)", "side-effects": "seesection 8.1andnotes above; also anorexia,\r\ndiarrhoea, dyspepsia; tachycardia, hypertension, hypotension, thrombosis;\r\noedema; insomnia, fatigue; dehydration; cutaneous reactions, sweating;less commonlyincreased weight, myocardial infarction, renal\r\nfailure;also reportedQT-interval prolongation,\r\ninappropriate anti-diuretic hormone secretion, blurred vision", "contra-indications": "seenotes above", "hepatic impairment": "reduce dose\u2014consult product literature", "doses": ["SeeDoses"], "pregnancy": "avoid unless essential\u2014teratogenicity and embryotoxicity\r\ninanimalstudies; manufacturer advises effective\r\ncontraception during and for up to 3 months after treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CHLORAL HYDRATE": {"indications": "insomnia (short-term use)", "name": "CHLORAL HYDRATE", "renal impairment": "avoid in severe impairment", "cautions": "reduce dose in elderly and debilitated; avoid prolonged use (and abrupt withdrawal\r\nthereafter); avoid contact with skin and mucous membranes;interactions:Appendix 1 (anxiolytics and hypnotics)", "side-effects": "gastric irritation (nausea and vomiting reported),\r\nabdominal distention, flatulence, headache, tolerance, dependence,\r\nexcitement, delirium (especially on abrupt withdrawal), ketonuria,\r\nand rash", "contra-indications": "severe\r\ncardiac disease; gastritis; acute porphyria (section 9.8.2)", "hepatic impairment": "can precipitate coma; reduce dose in mild to moderate\r\nimpairment; avoid in severe impairment", "doses": ["15\u201345\u00a0mL (chloral hydrate0.4\u20131.3\u00a0g)\r\nwith water or milk, at bedtime, max. 70\u00a0mL (chloral hydrate2\u00a0g) daily;child2\u201312 years, 1\u20131.75\u00a0mL/kg\r\n(chloral hydrate30\u201350\u00a0mg/kg), max. 35\u00a0mL (chloral hydrate1\u00a0g) daily"], "pregnancy": "avoid", "breast-feeding": "risk of sedation in infant\u2014avoid"}, "MEPROBAMATE": {"indications": "short-term use in anxiety, but see notes above", "name": "MEPROBAMATE", "renal impairment": "start with small doses in severe impairment; increased\r\ncerebral sensitivity", "cautions": "respiratory disease, muscle weakness, epilepsy (may induce seizures), history of drug or alcohol abuse, marked personality disorder; elderly and debilitated; avoid prolonged\r\nuse, abrupt withdrawal (may precipitate\r\nconvulsions);interactions:Appendix\r\n1 (anxiolytics and hypnotics)", "side-effects": "see under Diazepam, but incidence greater and\r\ndrowsiness most common side-effect; also gastro-intestinal disturbances,\r\nhypotension, paraesthesia, weakness, CNS effects including headache,\r\nparadoxical excitement, disturbances of vision; rarely agranulocytosis\r\nand rashes", "contra-indications": "acute\r\npulmonary insufficiency; respiratory depression; acute porphyria (section 9.8.2)", "hepatic impairment": "can precipitate coma", "doses": ["400\u00a0mg 3\u20134 times daily;elderlyhalf adult dose or less;childnot\r\nrecommended", "Meprobamate treatment shouldnotbe initiated in new patients, seenotes above"], "pregnancy": "avoid if possible", "breast-feeding": "avoid; concentration in milk may exceed maternal\r\nplasma concentrations fourfold and may cause drowsiness in infant"}, "BEZAFIBRATE": {"indications": "hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nalso see notes above", "name": "BEZAFIBRATE", "renal impairment": "reduce dose to 400\u00a0mg daily if eGFR 40\u201360\u00a0mL/minute/1.73\u00a0m2; reduce dose to 200\u00a0mg every 1\u20132 days if eGFR 15\u201340\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2;\r\navoid modified-release preparations if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of renal impairment when  ciclosporin given with bezafibrate ", "name": "Bezafibrate", "backrefs": ["Bezafibrate"]}, "cautions": "correct hypothyroidism before initiating treatment (seeLipid-regulating drugs);interactions:Appendix 1 (fibrates)", "side-effects": "gastro-intestinal disturbances, anorexia;less commonlycholestasis, weight gain, dizziness, headache,\r\nfatigue, drowsiness, renal impairment, raised serum creatinine (unrelated\r\nto renal impairment), erectile dysfunction, myotoxicity (with myasthenia\r\nor myalgia)\u2014special risk in renal impairment (see Cautions), urticaria,\r\npruritus, photosensitivity reactions;very rarelygallstones, hypoglycaemia, anaemia, leucopenia, thrombocytopenia,\r\nincreased platelet count, alopecia, Stevens-Johnson syndrome, and\r\ntoxic epidermal necrolysis", "contra-indications": "hypoalbuminaemia, primary biliary\r\ncirrhosis, gall bladder disease, nephrotic syndrome", "hepatic impairment": "avoid in severe liver disease", "doses": ["See preparations below"], "pregnancy": "manufacturers advise avoid\u2014embryotoxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PROSTAGLANDINS": {"interactions": {"extra": "", "bad": 0, "interaction": "uterotonic effect of  oxytocin potentiated by prostaglandins ", "name": "Prostaglandins", "backrefs": ["Prostaglandins"]}}, "IMIGLUCERASE": {"indications": "(specialist use only) non-neurological manifestations\r\nof type I or type III Gaucher\u2019s disease", "name": "IMIGLUCERASE", "cautions": "monitor immunoglobulin G (IgG) antibody\r\nconcentration; when stabilised, monitor\r\nall parameters and response to treatment at intervals of 6\u201312 months", "side-effects": "hypersensitivity reactions (including urticaria,\r\nangioedema, cyanosis, hypotension, flushing, tachycardia, paraesthesia,\r\nbackache);less commonlynausea, vomiting, diarrhoea,\r\nabdominal cramps, headache, dizziness, fatigue, fever, arthralgia,\r\nand injection-site reactions", "doses": ["By intravenous infusion, initially 60\u00a0units/kg\r\nonce every 2 weeks (doses as low as 15\u00a0units/kg once every 2 weeks\r\nmay improve haematological parameters and organomegaly); maintenance,\r\nadjust dose according to response;childunder 18 years seeBNF for Children"], "pregnancy": "manufacturer advises use with caution\u2014limited information\r\navailable", "breast-feeding": "no information available"}, "LOCAL ANAESTHETICS": {"indications": "relief of pain in oral lesions", "name": "LOCAL ANAESTHETICS", "renal impairment": "see Lidocainesection 2.3.2", "cautions": "avoid prolonged use; hypersensitivity; avoid anaesthesia of\r\nthe pharynx before meals\u2014risk of choking", "hepatic impairment": "see Lidocainesection 2.3.2", "doses": ["apply thinly to the ulcer [unlicensed indication] using\r\na cotton bud"], "pregnancy": "see Lidocainesection 15.2", "breast-feeding": "see Lidocainesection 2.3.2"}, "CO-DYDRAMOL": {"indications": "mild to moderate pain", "name": "CO-DYDRAMOL", "renal impairment": "reduce dose or avoid dihydrocodeine; increased and prolonged\r\neffect: increased cerebral sensitivity", "cautions": "section 4.7.2; also alcohol dependence; severe cor pulmonale;interactions:Appendix 1 (opioid analgesics, paracetamol)", "side-effects": "section 4.7.2; also\r\nabdominal pain, paralytic ileus, pancreatitis, paraesthesia, blood\r\ndisorders (including thrombocytopenia, leucopenia, neutropenia);important: liver damage (and less frequently renal damage)\r\nfollowingoverdosagewith paracetamol; see Emergency\r\nTreatment of Poisoning forparacetamolandanalgesics (opioid); for reversal of opioid-induced respiratory depression, see section15.1.7", "contra-indications": "section 4.7.2", "hepatic impairment": "reduce dose or avoid dihydrocodeine\u2014may precipitate\r\ncoma; dose-related toxicity with paracetamol\u2014avoid large doses", "doses": ["severe pain, 1\u20132 tablets every 4\u20136 hours; max. 8 tablets\r\ndaily;childunder 12 years not recommended"], "pregnancy": "withdrawal effects in neonates of dependant mothers", "breast-feeding": "amount too small to be harmful but use only\r\nif potential benefit outweighs risk"}, "ARIPIPRAZOLE": {"indications": "see under Dose", "name": "ARIPIPRAZOLE", "interactions": {"extra": "", "bad": 1, "interaction": " nevirapine possibly reduces plasma concentration of aripiprazole\u2014increase dose of aripiprazole", "name": "Aripiprazole", "backrefs": ["Aripiprazole"]}, "cautions": "seenotes above; cerebrovascular disease; elderly (reduce initial dose)", "side-effects": "seenotes above; gastro-intestinal\r\ndisturbances; tachycardia; fatigue, insomnia, akathisia, drowsiness,\r\nrestlessness, tremor, headache, asthenia; blurred vision;less commonlydepression;very rarelyanorexia,\r\ndysphagia, oropharyngeal spasm, laryngospasm, hepatitis, jaundice,\r\nhypersalivation, pancreatitis, oedema, thromboembolism, arrhythmias,\r\nbradycardia, hypertension, chest pain, agitation, anxiety, speech\r\ndisorder, suicidal ideation, seizures, hyponatraemia, stiffness, myalgia,\r\nrhabdomyolysis, priapism, urinary retention and incontinence, blood\r\ndisorders, sweating, alopecia, photosensitivity reactions, rash, weight\r\nloss, and impaired temperature regulation;with injection, dry mouth", "contra-indications": "seenotes above", "hepatic impairment": "use with caution in severe impairment", "doses": ["Schizophrenia,by mouth,adultover 18 years, 10\u201315\u00a0mg once daily, usual maintenance\r\n15\u00a0mg once daily; max. 30\u00a0mg once daily;child15\u201318 years, initially 2\u00a0mg once daily for 2 days, then 5\u00a0mg once\r\ndaily for 2 days, then 10\u00a0mg daily; thereafter increased if necessary\r\nin steps of 5\u00a0mg to max. 30\u00a0mg daily", "Treatment and recurrence prevention of mania,by mouth,adultover 18 years, 15\u00a0mg once\r\ndaily, increased if necessary; max. 30\u00a0mg once daily", "Control of agitation and disturbed behaviour in schizophrenia,by intramuscular injection,adultover 18 years, initially 5.25\u201315\u00a0mg (usual dose 9.75\u00a0mg) as a single\r\ndose followed by 5.25\u201315\u00a0mg after 2 hours if necessary; max. 3 injections\r\ndaily; max. daily combined oral and parenteral dose 30\u00a0mg"], "pregnancy": "seePregnancy notes; also use only if potential\r\nbenefit outweighs risk", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "MENADIOL SODIUM PHOSPHATE": {"indications": "seenotes above", "name": "MENADIOL SODIUM PHOSPHATE", "cautions": "G6PD deficiency (section 9.1.5) and vitamin E deficiency (risk\r\nof haemolysis);interactions:Appendix\r\n1 (vitamins)", "contra-indications": "neonates and infants", "doses": ["10\u201340\u00a0mg daily, adjusted as necessary;childunder 18 years seeBNF for Children"], "pregnancy": "avoid in late pregnancy and labour unless benefit\r\noutweighs risk of neonatal haemolytic anaemia, hyperbilirubinaemia,\r\nand kernicterus in neonate"}, "RETIGABINE": {"indications": "seenotes above", "name": "RETIGABINE", "renal impairment": "reduce dose by 50% if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2; increase by 50\u00a0mg every week according to response up to\r\nmax. 600\u00a0mg daily (450\u00a0mg inelderly)", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin possibly reduces plasma concentration of retigabine ", "name": "Retigabine", "backrefs": ["Retigabine"]}, "cautions": "avoid abrupt withdrawal; risk of urinary retention; known QT-interval prolongation (see below);interactions:seeInteractionsin section\r\n4.8.1 and Appendix 1 (retigabine)", "side-effects": "increased appetite, weight gain, nausea, constipation,\r\ndyspepsia, dry mouth, peripheral oedema, malaise, drowsiness, dizziness,\r\nvertigo, amnesia, paraesthesia, tremor, impaired coordination, impaired\r\nspeech and attention, myoclonus, confusion, psychosis, anxiety, dysuria,\r\nhaematuria, diplopia, blurred vision;less commonlydysphagia, hypokinesia, urinary retention, nephrolithiasis, rash,\r\nsweating; suicidal ideation", "hepatic impairment": "reduce dose by 50% in moderate to severe impairment;\r\nincrease by 50\u00a0mg every week according to response up to max. 600\u00a0mg\r\ndaily (450\u00a0mg inelderly)", "doses": ["adultover 18 years, initially\r\nup to 300\u00a0mg daily in 3 divided doses, increased according to response\r\nby up to 150\u00a0mg every week up to maintenance dose of 0.6\u20131.2\u00a0g daily;elderlyover 65 years, initially 150\u00a0mg daily in\r\n3 divided doses, increased according to response by up to 150\u00a0mg every\r\nweek; max. 900\u00a0mg daily"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "DEXAMFETAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of dexamfetamine ", "name": "Dexamfetamine", "backrefs": ["Dexamfetamine", "Guanethidine"]}}, "PROTAMINE SULPHATE": {"side-effects": "nausea, vomiting, lassitude, flushing, hypotension,\r\nhypertension, bradycardia, dyspnoea, rebound bleeding, back pain;\r\nhypersensitivity reactions (including angioedema, anaphylaxis) and\r\npulmonary oedema reported", "indications": "see above", "name": "PROTAMINE SULPHATE", "cautions": "see above; also monitor activated partial thromboplastin\r\ntime or other appropriate blood clotting parameters; increased risk\r\nof allergic reaction to protamine (including previous treatment with\r\nprotamine or protamine insulin, allergy to fish, men who are infertile\r\nor who have had a vasectomy)", "doses": ["Overdosage with intravenous injection of unfractionated\r\nheparin,by intravenous injection(rate not exceeding\r\n5\u00a0mg/minute), 1\u00a0mg neutralises 80\u2013100\u00a0unitsheparinwhen given within 15 minutes ofheparin; if longer\r\nthan 15 minutes since heparin, less protamine required (consult product\r\nliterature for details) as heparin rapidly excreted; max. 50\u00a0mg", "Overdosage with intravenous infusion of unfractionated\r\nheparin,by intravenous injection(rate not exceeding\r\n5\u00a0mg/minute), 25\u201350\u00a0mg once heparin infusion stopped", "Overdosage with subcutaneous injection of unfractionated\r\nheparin, 1\u00a0mg neutralises 100\u00a0units heparin; give 25\u201350\u00a0mgby intravenous injection(rate not exceeding 5\u00a0mg/minute)\r\nthen any remaining dose givenby intravenous infusionover 8\u201316 hours; max. total dose 50\u00a0mg", "Overdosage with subcutaneous injection of low molecular\r\nweight heparin,by intermittent intravenous injection(rate not exceeding 5\u00a0mg/minute) orby continuous intravenous\r\ninfusion, 1\u00a0mg neutralises approx. 100\u00a0units low molecular\r\nweight heparin (consult product literature of low molecular weight\r\nheparin for details); max. 50\u00a0mg"]}, "DICYCLOVERINE HYDROCHLORIDE": {"indications": "symptomatic relief of gastro-intestinal disorders characterised by\r\nsmooth muscle spasm", "name": "DICYCLOVERINE HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "see notes above", "contra-indications": "seenotes above; also infants under 6 months", "doses": ["10\u201320\u00a0mg 3 times daily;infant6\u201324 months 5\u201310\u00a0mg 3\u20134 times daily, 15 minutes before feeds;child2\u201312 years 10\u00a0mg 3 times daily"], "pregnancy": "not known to be harmful; manufacturer advises use\r\nonly if essential", "breast-feeding": "avoid\u2014present in milk; apnoea reported in infant"}, "ADALIMUMAB": {"indications": "seenotes above; Crohn\u2019s\r\ndisease (section 1.5.3); ankylosing spondylitis, polyarticular\r\njuvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis\r\n(section 10.1.3)", "name": "ADALIMUMAB", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  anakinra with adalimumab ", "name": "Adalimumab", "backrefs": ["Adalimumab"]}, "cautions": "section 10.1.3", "side-effects": "section 10.1.3", "contra-indications": "section 10.1.3", "doses": ["By subcutaneous injection, plaque psoriasis,adultover 18 years, initially 80\u00a0mg, then 40\u00a0mg\r\non alternate weeks starting 1 week after initial dose; discontinue\r\ntreatment if no response within 16 weeks"], "pregnancy": "section 10.1.3", "breast-feeding": "section 10.1.3"}, "GEMFIBROZIL": {"indications": "hyperlipidaemias of types IIa, IIb, III, IV and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nprimary prevention of cardiovascular disease in men with hyperlipidaemias\r\nthat have not responded to diet and other appropriate measures; also\r\nsee notes above", "name": "GEMFIBROZIL", "renal impairment": "initially 900\u00a0mg daily if eGFR 30\u201380\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2;\r\nsee alsoMyotoxicityunder\r\nBezafibrate", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of myopathy when  statins given with gemfibrozil (preferably avoid concomitant use)", "name": "Gemfibrozil", "backrefs": ["Gemfibrozil", "Bexarotene"]}, "cautions": "lipid profile, blood counts, and liver-function tests\r\nbefore initiating long-term treatment; preferably avoid use with statins (high risk of rhabdomyolysis); correct hypothyroidism before initiating treatment (seeLipid-regulating Drugs); elderly;interactions:Appendix 1\r\n(fibrates)", "side-effects": "gastro-intestinal disturbances; headache, fatigue,\r\nvertigo; eczema, rash;less commonlyatrial fibrillation;rarelypancreatitis, appendicitis, disturbances in liver\r\nfunction including hepatitis and cholestatic jaundice, dizziness,\r\nparaesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia,\r\neosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia,\r\nmyositis accompanied by increase in creatine kinase (discontinue if\r\nraised significantly), blurred vision, exfoliative dermatitis, alopecia,\r\nand photosensitivity)", "contra-indications": "alcoholism, biliary-tract disease including gallstones; photosensitivity to fibrates", "hepatic impairment": "avoid in liver disease", "doses": ["1.2\u00a0g daily, usually in 2 divided doses; range 0.9\u20131.2\u00a0g\r\ndaily;childnot recommended"], "pregnancy": "manufacturers advise avoid\u2014embryotoxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "MESTEROLONE": {"indications": "see under Dose", "name": "MESTEROLONE", "renal impairment": "see underTestosterone and Esters", "cautions": "see underTestosterone and\r\nEsters", "side-effects": "see underTestosterone and Estersbut spermatogenesis unimpaired", "contra-indications": "see underTestosterone and\r\nEsters", "hepatic impairment": "see underTestosterone and Esters", "doses": ["Androgen deficiency and male infertility associated with\r\nhypogonadism, 25\u00a0mg 3\u20134 times daily for several months, reduced to\r\n50\u201375\u00a0mg daily in divided doses for maintenance;childnot recommended"], "pregnancy": "see underTestosterone and Esters", "breast-feeding": "see underTestosterone and Esters"}, "ALFUZOSIN HYDROCHLORIDE": {"indications": "benign prostatic hyperplasia", "name": "ALFUZOSIN HYDROCHLORIDE", "renal impairment": "initial dose 2.5\u00a0mg twice daily and adjust according\r\nto response; manufacturers advise avoid use of modified-release preparations\r\nif eGFR less than 30\u00a0mL/minute/1.73\u00a0m2as limited experience", "cautions": "seenotes above; discontinue if angina\r\nworsens; acute heart failure; history of QT-interval\r\nprolongation; concomitant use with other drugs known to prolong QT\r\ninterval", "side-effects": "seenotes above; alsoless commonlyflushes and chest pain;also reportedliver damage and cholestasis", "contra-indications": "seenotes above", "hepatic impairment": "initial dose 2.5\u00a0mg once daily, adjusted according\r\nto response to 2.5\u00a0mg twice daily in mild to moderate impairment\u2014avoid\r\nif severe; avoid modified-release preparations", "doses": ["benign prostatic hyperplasia 10\u00a0mg once daily"]}, "METOPROLOL": {"interactions": {"extra": "", "bad": 0, "interaction": " dronedarone possibly increases plasma concentration of metoprolol ", "name": "Metoprolol", "backrefs": ["Metoprolol"]}}, "ENALAPRIL MALEATE": {"indications": "hypertension; symptomatic heart failure (adjunct\u2014seesection 2.5.5); prevention\r\nof symptomatic heart failure in patients with asymptomatic left ventricular\r\ndysfunction", "name": "ENALAPRIL MALEATE", "renal impairment": "seenotes above; max.\r\ninitial dose 2.5\u00a0mg daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; also dyspnoea; depression, asthenia;\r\nblurred vision;less commonlydry mouth, peptic ulcer,\r\nanorexia, ileus; arrhythmias, palpitation, flushing; confusion, nervousness,\r\ndrowsiness, insomnia, vertigo; impotence; muscle cramps; tinnitus;\r\nalopecia, sweating; hyponatraemia;rarelystomatitis,\r\nglossitis, Raynaud\u2019s syndrome, pulmonary infiltrates, allergic alveolitis,\r\ndream abnormalities, gynaecomastia, Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis, exfoliative dermatitis, pemphigus;very\r\nrarelygastro-intestinal angioedema", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Hypertension, used alone, initially 5\u00a0mg once daily; if\r\nused in addition to diuretic (see notes above),\r\nor in renal impairment, lower initial doses may be required; usual\r\nmaintenance dose 20\u00a0mg once daily; max. 40\u00a0mg once daily", "Heart failure (adjunct), asymptomatic left ventricular dysfunction,\r\ninitially 2.5\u00a0mg once daily under close medical supervision (see notes above),\r\nincreased gradually over 2\u20134 weeks to 10\u201320\u00a0mg twice daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ENALAPRIL": {"interactions": {"extra": "", "bad": 0, "interaction": " antacids reduce absorption of enalapril ", "name": "Enalapril", "backrefs": ["Enalapril"]}}, "13.10.5 Preparations for minor cuts and abrasions": {"name": "13.10.5 Preparations for minor cuts and abrasions", "doses": ["apply under dressing"]}, "FLURBIPROFEN": {"indications": "relief of sore throat", "name": "FLURBIPROFEN", "renal impairment": "section 10.1.1", "interactions": {"extra": "", "bad": 0, "interaction": " fluconazole increases plasma concentration of flurbiprofen ", "name": "Flurbiprofen", "backrefs": ["Flurbiprofen"]}, "cautions": "section 10.1.1", "side-effects": "taste disturbance, mouth ulcers (move lozenge\r\naround mouth); see alsosection 10.1.1", "contra-indications": "section 10.1.1", "hepatic impairment": "section 10.1.1", "doses": ["adultandchildover 12 years, allow 1 lozenge to dissolve\r\nslowly in the mouth every 3\u20136 hours, max. 5 lozenges in 24 hours,\r\nfor max. 3 days"], "pregnancy": "section 10.1.1", "breast-feeding": "section 10.1.1"}, "METHADONE": {"interactions": {"extra": "", "bad": 0, "interaction": " nevirapine possibly reduces plasma concentration of methadone ", "name": "Methadone", "backrefs": ["Methadone"]}}, "TIAPROFENIC ACID": {"indications": "pain and inflammation in rheumatic disease and other\r\nmusculoskeletal disorders", "name": "TIAPROFENIC ACID", "renal impairment": "reduce dose in mild or moderate impairment; avoid in\r\nsevere impairment; see alsonotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above; also\r\nactive bladder or prostate disease (or symptoms) and history\r\nof recurrent urinary-tract disorders\u2014if urinary\r\nsymptoms develop discontinue immediately and perform urine tests and\r\nculture; see also CSM advice below", "hepatic impairment": "reduce dose in mild or moderate impairment; see alsonotes above", "doses": ["adultover 18 years, 300\u00a0mg\r\ntwice daily"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful; see alsonotes above"}, "GLATIRAMER ACETATE": {"indications": "seenotes above", "name": "GLATIRAMER ACETATE", "renal impairment": "no information available\u2014manufacturer advises caution", "cautions": "cardiac disorders", "side-effects": "hypersensitivity reactions; flushing, chest pain,\r\npalpitation, tachycardia, and dyspnoea may occur within minutes of\r\ninjection; nausea, constipation, dyspepsia; syncope, anxiety, asthenia,\r\ndepression, headache, tremor, sweating; oedema, lymphadenopathy; hypertonia,\r\nback pain, arthralgia, influenza-like symptoms; injection-site reactions,\r\nrash;rarelyseizures", "doses": ["By subcutaneous injection,adultover 18 years, 20\u00a0mg daily"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises caution\u2014no\r\ninformation available"}, "APREPITANT": {"indications": "adjunct to dexamethasone and a 5HT3-receptor antagonist\r\nin preventing nausea and vomiting associated with moderately and highly\r\nemetogenic chemotherapy", "name": "APREPITANT", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of aprepitant ", "name": "Aprepitant", "backrefs": ["Aprepitant"]}, "cautions": "interactions:Appendix 1 (aprepitant)", "side-effects": "hiccups, dyspepsia, diarrhoea, constipation, anorexia;\r\nasthenia, headache, dizziness;less commonlyweight\r\nchanges, dry mouth, colitis, flatulence, stomatitis, abdominal pain,\r\nduodenal ulcer, taste disturbance, oedema, bradycardia, palpitations,\r\ncough, euphoria, anxiety, confusion, drowsiness, thirst, abnormal\r\ndreams, chills, hyperglycaemia, polyuria, anaemia, dysuria, haematuria,\r\nhyponatraemia, neutropenia, myalgia, conjunctivitis, pharyngitis,\r\nsneezing, tinnitus, sweating, pruritus, rash, acne, photosensitivity,\r\nand flushing; dyspnoea, insomnia, visual disturbances, dysarthria,\r\nurticaria, and Stevens-Johnson syndrome also reported", "hepatic impairment": "caution in moderate to severe impairment", "doses": ["adultover 18 years 125\u00a0mg\r\n1 hour before chemotherapy, then 80\u00a0mg daily as a single dose for\r\nthe next 2 days; consult product literature for dose of concomitant\r\ncorticosteroid and 5HT3-receptor antagonist"], "pregnancy": "avoid unless potential benefit outweighs risk\u2014no\r\ninformation available", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "POTASSIUM SALTS": {"interactions": {"extra": "Includes salt substitutes", "bad": 1, "interaction": "increased risk of hyperkalaemia when  tacrolimus given with potassium salts ", "name": "Potassium Salts", "backrefs": ["Potassium Salts"]}}, "MINOXIDIL": {"indications": "androgenetic alopecia (men and women)", "name": "MINOXIDIL", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with minoxidil ", "name": "Minoxidil", "backrefs": ["Minoxidil"]}, "cautions": "flammable; wash hands after application", "side-effects": "section 2.5.1; also headache,  local irritation;less\r\ncommonlyhypotension, changes in hair colour or texture (discontinue\r\nif increased hair loss persists for more than 2 weeks)", "contra-indications": "section 2.5.1", "doses": ["apply half a capful twice daily to affected areas of scalp;\r\ndiscontinue if no improvement after 16 weeks"], "pregnancy": "section 2.5.1", "breast-feeding": "section 2.5.1"}, "HALOPERIDOL": {"indications": "maintenance in schizophrenia\r\nand other psychoses", "name": "HALOPERIDOL", "renal impairment": "seesection 4.2.1", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects and possibly neurotoxicity when  lithium given with haloperidol ", "name": "Haloperidol", "backrefs": ["Haloperidol"]}, "cautions": "seeHaloperidol(section 4.2.1) andnotes above", "side-effects": "seeHaloperidol(section 4.2.1) andnotes above", "contra-indications": "seeHaloperidol(section 4.2.1) andnotes above", "hepatic impairment": "seesection 4.2.1", "doses": ["By deep intramuscular injectioninto the\r\ngluteal muscle, initially 50\u00a0mg every 4 weeks, if necessary increasing\r\nby 50-mg increments to 300\u00a0mg every 4 weeks; higher doses may be needed\r\nin some patients;elderly, initially\r\n12.5\u201325\u00a0mg every 4 weeks;childnot\r\nrecommended", "If 2-weekly administration preferred, doses\r\nshould be halved"], "pregnancy": "seesection 4.2.1", "breast-feeding": "seesection 4.2.1"}, "TESTOSTERONE": {"interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  phenindione enhanced by testosterone ", "name": "Testosterone", "backrefs": ["Testosterone"]}}, "VINDESINE SULPHATE": {"indications": "seenotes above", "name": "VINDESINE SULPHATE", "cautions": "seesection 8.1andnotes above; neuromuscular disease; caution in handling", "side-effects": "seesection 8.1andnotes above; irritant to tissues", "contra-indications": "seesection 8.1andnotes above", "hepatic impairment": "dose reduction may be necessary", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "VARICELLA-ZOSTER VACCINE": {"indications": "immunisation against varicella infection\r\n(seenotes above)", "name": "VARICELLA-ZOSTER VACCINE", "interactions": {"extra": "", "bad": 0, "interaction": "possible risk of Reyes syndrome when  aspirin given with varicella-zoster vaccine\u2014manufacturers advise avoid aspirin for 6 weeks after giving varicella-zoster vaccine", "name": "Varicella-zoster Vaccine", "backrefs": ["Varicella-zoster Vaccine"]}, "cautions": "seesection 14.1;alsopost-vaccination close-contact with susceptible individuals (seenotes above);interactions:Appendix 1 (vaccines)", "side-effects": "seesection 14.1; also\r\nvaricella-like rash;rarelythrombocytopenia", "contra-indications": "seesection 14.1", "doses": ["See under preparations"], "pregnancy": "avoid pregnancy for 3 months after vaccination; see\r\nalsosection 14.1", "breast-feeding": "seesection 14.1"}, "SODIUM BICARBONATE": {"indications": "metabolic acidosis, see alsonotes above", "interactions": {"extra": "", "bad": 0, "interaction": "excretion of  lithium increased by sodium bicarbonate (reduced plasma concentration)", "name": "Sodium Bicarbonate", "backrefs": ["Sodium Bicarbonate"]}, "name": "SODIUM BICARBONATE", "doses": ["By slow intravenous injection, a strong\r\nsolution (up to 8.4%), orby continuous intravenous infusion, a weaker solution (usually 1.26%), an amount appropriate to the\r\nbody base deficit (see notes above)"]}, "SERTRALINE": {"indications": "see under Dose", "name": "SERTRALINE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of bleeding when  ticagrelor given with sertraline ", "name": "Sertraline", "backrefs": ["Sertraline"]}, "cautions": "seenotes above", "side-effects": "seenotes above; pancreatitis, hepatitis, jaundice,\r\nliver failure, stomatitis, palpitation, hypertension, hypercholesterolaemia,\r\ntachycardia, postural hypotension, bronchospasm, amnesia, paraesthesia,\r\naggression, hypoglycaemia, hypothyroidism, hyperprolactinaemia, urinary\r\nincontinence, menstrual irregularities, leucopenia, and tinnitus also\r\nreported", "contra-indications": "seenotes above", "hepatic impairment": "reduce dose or increase dose interval in mild or moderate\r\nimpairment; avoid in severe impairment", "doses": ["Depressive illness, initially 50\u00a0mg daily, increased if\r\nnecessary by increments of 50\u00a0mg at intervals of at least 1 week to\r\nmax. 200\u00a0mg daily; usual maintenance dose 50\u00a0mg daily;childunder 18 years seeBNF for ChildrenandDepressive Illness in Children\r\nand Adolescents", "Obsessive-compulsive disorder,adultandchildover 12 years initially\r\n50\u00a0mg daily, increased if necessary in steps of 50\u00a0mg at intervals\r\nof at least 1 week; max. 200\u00a0mg daily;child6\u201312 years initially 25\u00a0mg daily, increased to 50\u00a0mg daily after\r\n1 week, further increased if necessary in steps of 50\u00a0mg at intervals\r\nof at least 1 week; max. 200\u00a0mg daily", "Panic disorder, post-traumatic stress disorder, or social anxiety\r\ndisorder,adultover 18 years, initially\r\n25\u00a0mg daily, increased after 1 week to 50\u00a0mg daily; if response is\r\npartial and if drug tolerated, dose increased in steps of 50\u00a0mg at\r\nintervals of at least 1 week to max. 200\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "not known to be harmful but consider discontinuing\r\nbreast-feeding"}, "LOPERAMIDE HYDROCHLORIDE": {"indications": "symptomatic treatment of acute diarrhoea; adjunct to rehydration\r\nin acute diarrhoea in adults and children over 4 years (but see notes\r\nabove); chronic diarrhoea in adults only", "name": "LOPERAMIDE HYDROCHLORIDE", "cautions": "seenotes above;interactions:Appendix 1 (loperamide)", "side-effects": "abdominal cramps, dizziness, drowsiness, and skin\r\nreactions including urticaria; paralytic ileus and abdominal bloating\r\nalso reported", "contra-indications": "conditions where inhibition of\r\nperistalsis should be avoided, where abdominal\r\ndistension develops, or in conditions such\r\nas active ulcerative colitis or antibiotic-associated colitis", "hepatic impairment": "risk of accumulation\u2014manufacturer advises caution", "doses": ["Acute diarrhoea, 4\u00a0mg initially followed by 2\u00a0mg after\r\neach loose stool for up to 5 days; usual dose 6\u20138\u00a0mg daily; max. 16\u00a0mg\r\ndaily;childunder 4 years not recommended;\r\n4\u20138 years, 1\u00a0mg 3\u20134 times daily for up to3 days only; 8\u201312 years, 2\u00a0mg 4 times daily for up to 5 days", "Chronic diarrhoea in adults, initially, 4\u20138\u00a0mg daily in divided\r\ndoses, subsequently adjusted according to response and given in 2\r\ndivided doses for maintenance; max. 16\u00a0mg daily;childunder 18 years seeBNF for Children", "Faecal incontinence [unlicensed indication], initially 500\u00a0micrograms\r\ndaily, adjusted according to response; max. 16\u00a0mg daily in divided\r\ndoses"], "pregnancy": "manufacturers advise avoid\u2014no information available", "breast-feeding": "amount probably too small to be harmful"}, "CO-FLUAMPICIL": {"indications": "mixed infections involving beta-lactamase-producing\r\nstaphylococci", "name": "CO-FLUAMPICIL", "renal impairment": "see underAmpicillinandFlucloxacillin", "cautions": "see underAmpicillinandFlucloxacillin;interactions:Appendix 1 (penicillins)", "side-effects": "see underAmpicillinandFlucloxacillin", "contra-indications": "see underAmpicillinandFlucloxacillin", "hepatic impairment": "see underFlucloxacillin", "doses": ["By mouth,co-fluampicil, 250/250 every 6 hours, dose doubled in severe infections;childunder 10 years half adult dose, dose doubled\r\nin severe infections", "By intramuscularorslow\r\nintravenous injectionorby intravenous\r\ninfusion,co-fluampicil250/250 every 6\r\nhours, dose doubled in severe infections;childunder 2 years quarter adult dose, 2\u201310 years half adult dose, dose\r\ndoubled in severe infections"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "TENOFOVIR DISOPROXIL": {"indications": "HIV infection in combination with other antiretroviral\r\ndrugs; chronic hepatitis B infection witheithercompensated\r\nliver disease (with evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis)ordecompensated liver disease", "name": "TENOFOVIR DISOPROXIL", "renal impairment": "monitor renal function\u2014interrupt treatment if further\r\ndeterioration; 245\u00a0mg every 2 days if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; 245\u00a0mg every 3\u20134 days if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; avoidAtripla\u00ae if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2; use normal dose ofTruvuda\u00ae every 2 days\r\nif eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; avoidTruvada\u00ae if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above; also test renal function and serum phosphate before\r\ntreatment, then every 4 weeks (more frequently if at increased risk\r\nof renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate\r\ndecreases; concomitant or recent use of nephrotoxic\r\ndrugs;interactions:Appendix 1 (tenofovir)", "side-effects": "see notes above; also hypophosphataemia;rarelyrenal failure, proximal renal tubulopathy, nephrogenic\r\ndiabetes insipidus; also reported reduced bone density", "hepatic impairment": "seenotes aboveand Cautions\r\nabove; manufacturer ofAtripla\u00ae advises caution\r\nin mild impairment; avoidAtripla\u00ae in moderate\r\nto severe impairment", "doses": ["HIV infection stabilised on antiretroviral therapy for\r\nmore than 3 months,adultover 18 years,\r\n1 tablet once daily"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "FUSIDIC ACID": {"indications": "staphylococcal skin infections; penicillin-resistant\r\nstaphylococcal infections (section 5.1.7); staphylococcal eye infections\r\n(section 11.3.1)", "name": "FUSIDIC ACID", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of both drugs increased when  ritonavir given with fusidic acid\u2014avoid concomitant use", "name": "Fusidic Acid", "backrefs": ["Sugammadex", "Statins", "Fusidic Acid"]}, "cautions": "see notes above; avoid contact with eyes", "side-effects": "rarely hypersensitivity reactions", "doses": ["Apply 3\u20134 times daily"]}, "CEFTAZIDIME": {"indications": "see underCefaclor; see also notes above", "name": "CEFTAZIDIME", "renal impairment": "reduce dose if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2\u2014consult product literature", "cautions": "see underCefaclor;interactions:Appendix\r\n1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["By deep intramuscular injectionorintravenous injectionorinfusion, 1\u00a0g every 8 hoursor2\u00a0g\r\nevery 12 hours; 2\u00a0g every 8\u201312 hoursor3\u00a0g every\r\n12 hours in severe infections; single doses over 1\u00a0g intravenous route\r\nonly;elderlyusual max. 3\u00a0g daily;child, up to 2 months 25\u201360\u00a0mg/kg daily in 2 divided\r\ndoses, over 2 months 30\u2013100\u00a0mg/kg daily in 2\u20133 divided doses; up to\r\n150\u00a0mg/kg daily (max. 6\u00a0g daily) in 3 divided doses if immunocompromised\r\nor meningitis; intravenous route recommended for children", "Urinary-tract and less serious infections, 0.5\u20131\u00a0g every 12\r\nhours", "Pseudomonal lung infection in cystic fibrosis,adult100\u2013150\u00a0mg/kg daily in 3 divided doses;childup to 150\u00a0mg/kg daily (max. 6\u00a0g daily) in 3\r\ndivided doses; intravenous route recommended for children", "Surgical prophylaxis, prostatic surgery, 1\u00a0g up to 30 minutes\r\nbefore the procedure, repeated if necessary when catheter removed"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "THIOPENTAL": {"interactions": {"extra": "", "bad": 0, "interaction": " probenecid possibly enhances effects of thiopental ", "name": "Thiopental", "backrefs": ["Thiopental"]}}, "ASPIRIN (antiplatelet)": {"indications": "secondary prevention of thrombotic cerebrovascular\r\nor cardiovascular disease, and following by-pass surgery (see alsosection 2.10.1and notes above)", "name": "ASPIRIN (antiplatelet)", "renal impairment": "use with caution; avoid in severe impairment; sodium\r\nand water retention; deterioration in renal function; increased risk\r\nof gastro-intestinal bleeding", "cautions": "asthma; uncontrolled\r\nhypertension; previous peptic ulceration (but manufacturers may advise avoidance of low-doseaspirinin history of peptic ulceration); concomitant use of\r\ndrugs that increase risk of bleeding; G6PD\r\ndeficiency (section 9.1.5); dehydration; elderly;interactions:Appendix 1 (aspirin)", "side-effects": "bronchospasm; gastro-intestinal irritation, gastro-intestinal\r\nhaemorrhage (occasionally major), also other haemorrhage (e.g. subconjunctival)", "contra-indications": "use other\r\nthan as an antiplatelet in children and adolescents under 16 years\r\n(Reye\u2019s syndrome,section 4.7.1); active peptic ulceration; haemophilia and other bleeding\r\ndisorders", "hepatic impairment": "avoid in severe impairment\u2014increased risk of gastro-intestinal\r\nbleeding", "doses": ["See notes above"], "pregnancy": "use with caution during third trimester; impaired\r\nplatelet function and risk of haemorrhage; delayed onset and increased\r\nduration of labour with increased blood loss; avoid analgesic doses\r\nif possible in last few weeks (low doses probably not harmful); with\r\nhigh doses, closure of fetal ductus arteriosusin uteroand possibly persistent pulmonary hypertension of newborn; kernicterus\r\nin jaundiced neonates", "breast-feeding": "avoid\u2014possible risk of Reye\u2019s syndrome; regular\r\nuse of high doses could impair platelet function and produce hypoprothrombinaemia\r\nin infant if neonatal vitamin K stores low"}, "TEMAZEPAM": {"indications": "premedication before surgery or investigatory\r\nprocedures; conscious sedation for dental procedures [unlicensed];\r\nhypnotic (section 4.1.1)", "name": "TEMAZEPAM", "renal impairment": "see Benzodiazepines,section 4.1.1", "interactions": {"extra": "", "bad": 0, "interaction": " disulfiram increases risk of temazepam toxicity", "name": "Temazepam", "backrefs": ["Temazepam"]}, "cautions": "seenotes aboveandDiazepam,section 4.1.2;interactions:Appendix 1 (anxiolytics and hypnotics)", "side-effects": "see notes above andDiazepam,section 4.1.2", "contra-indications": "seeDiazepam,section 4.1.2", "hepatic impairment": "see Benzodiazepines,section 4.1.1", "doses": ["By mouth, premedication,adult, 10\u201320\u00a0mg (up to 30\u00a0mg in exceptional circumstances)\r\n1\u20132 hours before procedure;elderly10\u00a0mg (up to 20\u00a0mg in exceptional circumstances);child12\u201318 years seeBNF for Children", "By mouth, conscious sedation for dental procedures,adultover 18 years, 15\u201330\u00a0mg 30\u201360 minutes before\r\nprocedure", "Temazepam doses in BNF may differ from those\r\nin product literature"], "pregnancy": "see Benzodiazepines,section 4.1.1", "breast-feeding": "see Benzodiazepines,section 4.1.1"}, "Vitamin and mineral supplements and adjuncts to synthetic diets": {"name": "Vitamin and mineral supplements and adjuncts to synthetic diets", "doses": ["prevention of vitamin deficiency in disorders of carbohydrate\r\nor amino-acid metabolism and adjunct in restricted, specialised, or\r\nsynthetic diets, 5\u00a0mL daily; use withKetovite\u00aeTabletsfor complete vitamin supplementation"]}, "ASCORBIC ACID": {"indications": "prevention and treatment of scurvy", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  selenium possibly reduced by ascorbic acid (give at least 4 hours apart)", "name": "Ascorbic acid", "backrefs": ["Ascorbic acid", "Selenium"]}, "name": "ASCORBIC ACID", "cautions": "interactions:Appendix 1 (vitamins)", "doses": ["Prophylactic, 25\u201375\u00a0mg daily; therapeutic, not less than\r\n250\u00a0mg daily in divided doses"]}, "VARDENAFIL": {"indications": "erectile dysfunction", "name": "VARDENAFIL", "renal impairment": "initial dose 5\u00a0mg if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of vardenafil\u2014avoid concomitant use", "name": "Vardenafil", "backrefs": ["Nitrates", "Alpha-blockers", "Nicorandil", "Vardenafil", "Tipranavir", "Grapefruit Juice"]}, "cautions": "seenotes above; also elderly; bleeding disorders or active peptic ulceration; susceptibility to prolongation of QT interval (including concomitant use of drugs which prolong QT interval);interactions:Appendix 1 (vardenafil)", "side-effects": "seenotes above; alsoless commonlydrowsiness, dyspnoea, increased lacrimation,\r\nphotosensitivity;rarelyanxiety, transient amnesia,\r\nhypertonia, and raised intra-ocular pressure", "contra-indications": "seenotes above; also hereditary degenerative retinal disorders", "hepatic impairment": "initial dose 5\u00a0mg in mild to moderate impairment, increased\r\nsubsequently according to response (max. 10\u00a0mg in moderate impairment);\r\nmanufacturer advises avoid in severe impairment", "doses": ["adultover 18 years, 10\u00a0mg\r\napprox. 60 minutes before sexual activity; max. 10\u00a0mg in 24 hours\r\n(dose form not suitable for patients with moderate hepatic impairment,\r\nor for initiation of therapy in patients taking alpha-blockers, or\r\nif eGFR less than 30\u00a0mL/minute/1.73m2)"]}, "AZITHROMYCIN": {"indications": "respiratory-tract infections; otitis media; skin and soft-tissue\r\ninfections; uncomplicated gonorrhoea [unlicensed indication], uncomplicated\r\ngenital chlamydial infections and non-gonococcal urethritis (see also\r\nTable 1,section 5.1); mild or moderate typhoid due\r\nto multiple-antibacterial-resistant organisms [unlicensed indication];\r\nLyme disease (see also section5.1.1.3[unlicensed indication]); prophylaxis\r\nof group A streptococcal infection (Table 2,section 5.1)", "name": "AZITHROMYCIN", "renal impairment": "use with caution if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of azithromycin ", "name": "Azithromycin", "backrefs": ["Azithromycin"]}, "cautions": "seenotes above;interactions:Appendix 1 (macrolides)", "side-effects": "seenotes above; also\r\nanorexia, dyspepsia, flatulence, dizziness, headache, malaise, paraesthesia,\r\narthralgia, disturbances in taste and vision;less commonlyconstipation, gastritis, chest pain, oedema, anxiety, sleep disturbances,\r\nhypoaesthesia, leucopenia, photosensitivity;rarelyagitation; also reported syncope, convulsions, smell disturbances,\r\ninterstitial nephritis, acute renal failure, thrombocytopenia, haemolytic\r\nanaemia, tongue discoloration", "hepatic impairment": "manufacturers advise avoid in severe liver disease\u2014no\r\ninformation available", "doses": ["500\u00a0mg once daily for 3 daysor500\u00a0mg\r\non first day then 250\u00a0mg once daily for 4 days;childover 6 months 10\u00a0mg/kg once daily for 3 days;orbody-weight 15\u201325\u00a0kg, 200\u00a0mg once daily for 3 days; body-weight\r\n26\u201335\u00a0kg, 300\u00a0mg once daily for 3 days; body-weight 36\u201345\u00a0kg, 400\u00a0mg\r\nonce daily for 3 days", "Uncomplicated gonorrhoea [unlicensed indication] (see also Table\r\n1,section 5.1), uncomplicated genital chlamydial\r\ninfections and non-gonococcal urethritis, 1\u00a0g as a single dose", "Lyme disease (see also section5.1.1.3), typhoid [unlicensed indications],\r\n500\u00a0mg once daily for 7\u201310 days (7 days in typhoid)"], "pregnancy": "manufacturers advise use only if adequate alternatives\r\nnot available", "breast-feeding": "present in milk; use only if no suitable alternatives"}, "EPINASTINE HYDROCHLORIDE": {"side-effects": "burning;less commonlytaste\r\ndisturbance, headache, conjunctival hyperaemia, dry eye, eye pruritus,\r\nvisual disturbance, increased lacrimation, eye pain, nasal irritation,\r\nrhinitis", "indications": "seasonal allergic conjunctivitis", "name": "EPINASTINE HYDROCHLORIDE", "doses": ["adultandadolescentover 12 years, apply twice daily; max.\r\nduration of treatment 8 weeks"]}, "PLATINUM COMPOUNDS": {"interactions": {"extra": "", "bad": 0, "interaction": "increased risk of nephrotoxicity and ototoxicity when  diuretics given with platinum compounds ", "name": "Platinum Compounds", "backrefs": ["Platinum Compounds"]}}, "VINCRISTINE SULPHATE": {"indications": "seenotes above", "name": "VINCRISTINE SULPHATE", "cautions": "seesection 8.1andnotes above; neuromuscular disease; caution in handling;interactions:Appendix 1 (vincristine)", "side-effects": "seesection 8.1andnotes above; alsorarelyinappropriate secretion of antidiuretic\r\nhormone; diarrhoea, intestinal necrosis, paralytic ileus, seizures,\r\nurinary retention, muscle wasting, and eye disorders also reported;\r\nirritant to tissues", "contra-indications": "seesection 8.1andnotes above", "hepatic impairment": "dose reduction may be necessary", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenicity and fetal loss inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "SITAGLIPTIN": {"indications": "seenotes above", "name": "SITAGLIPTIN", "renal impairment": "avoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  digoxin increased by sitagliptin ", "name": "Sitagliptin", "backrefs": ["Sitagliptin"]}, "cautions": "discontinue if symptoms of acute pancreatitis\r\n(persistent, severe abdominal pain);interactions:Appendix 1 (antidiabetics)", "side-effects": "gastro-intestinal disturbances; peripheral oedema;\r\nupper respiratory tract infection, nasopharyngitis; pain;less commonlydry mouth, anorexia, headache, drowsiness,\r\ndizziness, hypoglycaemia, osteoarthritis;also reportedpancreatitis, rash, cutaneous vasculitis, and Stevens-Johnson syndrome", "contra-indications": "ketoacidosis", "doses": ["adultover 18 years, 100\u00a0mg\r\nonce daily", "Dose of concomitant sulfonylurea\r\nor insulin may need to be reduced"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "GRASS AND TREE POLLEN EXTRACTS": {"indications": "treatment of seasonal allergic hay\r\nfever due to grass or tree pollen in patients who have failed to respond\r\nto anti-allergy drugs (seenotes above)", "name": "GRASS AND TREE POLLEN EXTRACTS", "cautions": "seenotes aboveand consult product literature", "side-effects": "seenotes aboveand consult product literature", "contra-indications": "seenotes aboveand consult product literature", "doses": ["By subcutaneous injection, consult product\r\nliterature"], "pregnancy": "avoid"}, "MEFLOQUINE": {"indications": "chemoprophylaxis of malaria, treatment\r\nof malaria, see notes above", "name": "MEFLOQUINE", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of mefloquine ", "name": "Mefloquine", "backrefs": ["Mefloquine"]}, "cautions": "cardiac conduction disorders; epilepsy (avoid for prophylaxis); not recommended in infants under\r\n3 months (5\u00a0kg);interactions:Appendix\r\n1 (mefloquine)", "side-effects": "nausea, vomiting, dyspepsia, abdominal pain, diarrhoea;\r\nheadache, dizziness, sleep disturbances;less frequentlyanorexia, bradycardia, fatigue, abnormal dreams, fever, tinnitus,\r\nand neuropsychiatric reactions (including sensory and motor neuropathies,\r\ntremor, ataxia, anxiety, depression, panic attacks, agitation, hallucinations,\r\npsychosis, convulsions);rarelysuicidal ideation;very rarelypneumonitis; also reported, circulatory disorders\r\n(including hypotension and hypertension), chest pain, tachycardia,\r\npalpitation, cardiac conduction disorders, oedema, dyspnoea, encephalopathy,\r\nleucopenia, leucocytosis, thrombocytopenia, muscle weakness, myalgia,\r\narthralgia, visual disturbances, vestibular disorders, rash (including\r\nStevens-Johnson syndrome), pruritus, and alopecia", "contra-indications": "hypersensitivity toquinine; avoid for prophylaxis if\r\nhistory of psychiatric disorders (including depression) or convulsions", "hepatic impairment": "avoid for prophylaxis in severe liver disease", "doses": ["Prophylaxis of malaria, preferably started 2\u00bd weeks before\r\nentering endemic area and continued for 4 weeks after leaving (see\r\nnotes above),adultandchildbody-weight over 45\u00a0kg, 250\u00a0mg once weekly;\r\nbody-weight 6\u201316\u00a0kg, 62.5\u00a0mg once weekly; body-weight 16\u201325\u00a0kg, 125\u00a0mg\r\nonce weekly; body-weight 25\u201345\u00a0kg, 187.5\u00a0mg once weekly", "Treatment of malaria, see notes above", "Inform travellers about adverse reactions\r\nof mefloquine and, if they occur, to seek medical advice on alternative\r\nantimalarials before the next dose is due. Also warn travellers aboutimportanceof avoiding mosquito bites,importanceof taking prophylaxis regularly, andimportanceof immediate visit to doctor if ill within 1 year andespeciallywithin 3 months of return. For details, see notes above", "Mefloquine doses in BNF may differ from those\r\nin product literature"], "pregnancy": "manufacturer advises adequate contraception during\r\nprophylaxis and for 3 months after stopping (teratogenicity inanimalstudies), but see alsoProphylaxis Against Malaria", "breast-feeding": "present in milk but risk to infant minimal;\r\nsee alsoProphylaxis Against Malaria"}, "4.7.2 Opioid analgesics": {"name": "4.7.2 Opioid analgesics"}, "ALPHA TOCOPHERYL ACETATE": {"indications": "seenotes above", "name": "ALPHA TOCOPHERYL ACETATE", "cautions": "predisposition to thrombosis; increased risk of necrotising enterocolitis in neonate\r\nweighing less than 1.5\u00a0kg;interactions: Appendix 1 (vitamins)", "side-effects": "diarrhoea and abdominal pain with doses more than\r\n1\u00a0g daily", "doses": ["malabsorption in cystic fibrosis, 100\u2013200\u00a0mg daily;child1 month\u20131 year 50\u00a0mg daily; 1\u201312 years, 100\u00a0mg\r\ndaily"], "pregnancy": "no evidence of safety of high doses", "breast-feeding": "excreted in milk; minimal risk, although caution\r\nwith large doses"}, "OLANZAPINE EMBONATE": {"indications": "maintenance in schizophrenia in patients\r\ntolerant to olanzapine by mouth", "name": "OLANZAPINE EMBONATE", "renal impairment": "initially 150\u00a0mg every 4 weeks", "cautions": "see under Olanzapine (section 4.2.1) and notes above; observe patient for at least 3 hours after injection", "side-effects": "see under Olanzapine (section 4.2.1) andnotes above;\r\npost-injection reactions have been reported leading to signs and symptoms\r\nof overdose", "contra-indications": "see under Olanzapine (section 4.2.1) and notes above", "hepatic impairment": "initially 150\u00a0mg every 4 weeks; increase with caution\r\nin moderate impairment", "doses": ["By deep intramuscular injectioninto the\r\ngluteal muscle,adult18\u201375 years,patients taking oral olanzapine 10\u00a0mg daily, initially 210\u00a0mg\r\nevery 2 weeksor405\u00a0mg every 4 weeks, then maintenance\r\ndose after 2 months treatment, 150\u00a0mg every 2 weeksor300\u00a0mg every 4 weeks;patients taking oral olanzapine 15\u00a0mg\r\ndaily, initially 300\u00a0mg every 2 weeks, then maintenance dose\r\nafter 2 months treatment, 210\u00a0mg every 2 weeksor405\u00a0mg every 4 weeks;patients taking oral olanzapine 20\u00a0mg\r\ndaily, initially 300\u00a0mg every 2 weeks, then maintenance dose\r\nafter 2 months treatment 300\u00a0mg every 2 weeks; dose adjusted according\r\nto response; max. 300\u00a0mg every 2 weeks"], "pregnancy": "see under Olanzapine (section 4.2.1)", "breast-feeding": "see under Olanzapine (section 4.2.1)"}, "TRIENTINE DIHYDROCHLORIDE": {"indications": "Wilson\u2019s disease in patients intolerant ofpenicillamine", "name": "TRIENTINE DIHYDROCHLORIDE", "cautions": "seenotes above;interactions:Appendix 1 (trientine)", "side-effects": "nausea, rash;very rarelyanaemia;\r\nduodenitis and colitis also reported", "doses": ["adultandchildover 12 years, 1.2\u20132.4\u00a0g daily in 2\u20134 divided\r\ndoses before food;child2\u201312 years,\r\ninitially 0.6\u20131.5\u00a0g daily in 2\u20134 divided doses before food, adjusted\r\naccording to response"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk; monitor maternal and neonatal serum-copper concentration;\r\nteratogenic inanimalstudies"}, "ETOPOSIDE": {"indications": "seenotes above", "name": "ETOPOSIDE", "renal impairment": "consider dose reduction\u2014consult local treatment protocol\r\nfor details", "interactions": {"extra": "", "bad": 0, "interaction": " ciclosporin possibly increases plasma concentration of etoposide (increased risk of toxicity)", "name": "Etoposide", "backrefs": ["Etoposide"]}, "cautions": "seesection 8.1andnotes above;interactions:Appendix 1 (etoposide)", "side-effects": "seesection 8.1; irritant to tissues", "contra-indications": "seesection 8.1andnotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["By mouth, 120\u2013240\u00a0mg/m2daily\r\nfor 5 days", "By intravenous infusion, consult product literature"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "GLUTARALDEHYDE": {"side-effects": "rashes, skin irritation (discontinue if severe);\r\nstains skin brown", "indications": "warts, particularly plantar warts", "name": "GLUTARALDEHYDE", "cautions": "protect surrounding skin; not for application to face, mucosa,\r\nor anogenital areas", "doses": ["Apply twice daily (see also underSalicylic acid)"]}, "EPIRUBICIN HYDROCHLORIDE": {"indications": "seenotes aboveandsection 7.4.4", "name": "EPIRUBICIN HYDROCHLORIDE", "renal impairment": "dose reduction may be necessary in severe impairment", "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant\r\nto tissues;interactions:Appendix\r\n1 (epirubicin)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "severe myocardial insufficiency, recent myocardial infarction, severe arrhythmia, unstable angina, myocardiopathy; previous treatment\r\nwith maximum cumulative doses of epirubicin or other anthracycline", "hepatic impairment": "reduce dose according to bilirubin concentration; avoid\r\nin severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (carcinogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CERTOLIZUMAB PEGOL": {"indications": "see underCytokine Modulatorsabove", "name": "CERTOLIZUMAB PEGOL", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  anakinra with certolizumab pegol ", "name": "Certolizumab pegol", "backrefs": ["Certolizumab pegol"]}, "cautions": "predisposition to infection; monitor for infection before, during, and for 5 months\r\nafter treatment (see also Tuberculosis below); do not initiate until active infections are controlled; discontinue if new serious infection develops until\r\ninfection controlled; hepatitis B virus\u2014monitor\r\nfor active infection; mild heart failure\r\n(discontinue if symptoms develop or worsen\u2014avoid in moderate to severe heart failure); demyelinating\r\nCNS disorders (risk of exacerbation); history or development\r\nof malignancy;interactions: Appendix 1 (certolizumab\r\npegol)", "side-effects": "see underCytokine Modulatorsand Cautions above; hypertension; sensory abnormalities; rash;less commonlyascites, cholestasis, gastro-intestinal disorders\r\n(including perforation and ulcer), hepatic disorders, appetite disorders;\r\ncardiomyopathies (including heart failure), dyslipidaemia, syncope,\r\noedema, dizziness, ischaemic coronary artery disorders, arrhythmias;\r\nasthma, pleural effusion, cough; peripheral neuropathy, tremor, anxiety,\r\nmood disorders; influenza-like illness; menstrual disorders, renal\r\nimpairment, haematuria; malignancy (including solid tumours, lymphoma,\r\nand leukaemia), skin cancer, benign tumours; haemorrhage, electrolyte\r\ndisorders; muscle disorders; visual disturbance, ocular inflammation;\r\necchymosis, impaired healing, alopecia, photosensitivity, acne, skin\r\ndiscoloration, nail disorders, new onset or worsening psoriasis, dermatitis;rarelycholelithiasis, splenomegaly, atrioventricular block,\r\ncerebrovascular accident, Raynaud\u2019s phenomenon, interstitial lung\r\ndisease, impaired coordination, trigeminal neuralgia, seizures, thyroid disorders, sexual dysfunction, nephropathy, tinnitus;also reportedmultiple sclerosis", "contra-indications": "severe active infection (see also Cautions)", "doses": ["By subcutaneous injection,adultover 18 years, 400\u00a0mg, repeated 2 weeks and\r\n4 weeks after initial injection, then 200\u00a0mg every 2 weeks; review\r\ntreatment if no response within 12 weeks"], "pregnancy": "avoid; manufacturer advises adequate contraception\r\nduring treatment and for at least 5 months after last dose", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available"}, "HISTAMINE DIHYDROCHLORIDE": {"indications": "see notes above", "name": "HISTAMINE DIHYDROCHLORIDE", "renal impairment": "increased risk of hypotension in severe impairment", "cautions": "consult product literature;interactions: Appendix 1 (histamine)", "side-effects": "consult product literature", "contra-indications": "consult product literature", "hepatic impairment": "increased risk of tachycardia and hypotension in moderate\r\nto severe impairment", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises avoid\u2014no information available;\r\nensure effective contraception during treatment in men and women", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "METHYSERGIDE": {"indications": "prevention of severe recurrent migraine, cluster headache and other\r\nvascular headaches in patients who are refractory to other treatment\r\nand whose lives are seriously disrupted (important:hospital supervision only, see notes above); diarrhoea associated\r\nwith carcinoid syndrome", "name": "METHYSERGIDE", "renal impairment": "avoid", "cautions": "history of peptic ulceration; avoid abrupt withdrawal of treatment; after 6 months withdraw (gradually over 2 to 3 weeks) for reassessment\r\nfor at least 1 month (see alsonotes above);interactions:Appendix 1 (ergot alkaloids)", "side-effects": "nausea, vomiting, heartburn, abdominal discomfort,\r\ndrowsiness, and dizziness occur frequently in initial treatment; mental\r\nand behavioural disturbances, insomnia, oedema, weight gain, rashes,\r\nloss of scalp hair, cramps, arterial spasm (including coronary artery\r\nspasm with angina and possible myocardial infarction), paraesthesias\r\nof extremities, postural hypotension, and tachycardia also occur;\r\nretroperitoneal and other abnormal fibrotic reactions may occur on\r\nprolonged administration, requiring immediate withdrawal of treatment", "contra-indications": "pulmonary\r\nand cardiovascular disease, severe\r\nhypertension, collagen disease, cellulitis, urinary-tract disorders, cachectic or septic conditions", "hepatic impairment": "avoid", "doses": ["Initially 1\u00a0mg at bedtime, increased gradually over about\r\n2 weeks to 1\u20132\u00a0mg 3 times daily with food (see notes above);childnot recommended", "Diarrhoea associated with carcinoid syndrome, usual range, 12\u201320\u00a0mg\r\ndaily (hospital supervision);childnot recommended"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "Antacid preparations containing simeticone": {"name": "Antacid preparations containing simeticone", "doses": ["5\u201310\u00a0mL 4 times daily (after meals and at bedtime) or\r\nwhen required;childunder 12 years\r\nseeBNF for Children"]}, "CINACALCET": {"indications": "see under Dose andnotes above", "name": "CINACALCET", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole inhibits metabolism of cinacalcet (increased plasma concentration)", "name": "Cinacalcet", "backrefs": ["Cinacalcet"]}, "cautions": "measure serum-calcium concentration before\r\ninitiation of treatment and within 1 week after starting treatment\r\nor adjusting dose, then monthly for secondary hyperparathyroidism and every 2\u20133 months for primary hyperparathyroidism\r\nand parathyroid carcinoma; treatment should not be initiated\r\nin patients with hypocalcaemia; in secondary\r\nhyperparathyroidism measure parathyroid hormone concentration 1\u20134\r\nweeks after starting treatment or adjusting dose, then every 1\u20133 months; dose adjustment may be necessary if smoking started or stopped\r\nduring treatment;interactions:Appendix 1 (cinacalcet)", "side-effects": "nausea, vomiting, anorexia; dizziness, paraesthesia,\r\nasthenia; reduced testosterone concentrations; myalgia; rash;less commonlydyspepsia, diarrhoea, and seizures; hypotension,\r\nheart failure, and allergic reactions (including angioedema) also\r\nreported", "hepatic impairment": "manufacturer advises caution in moderate to severe\r\nimpairment\u2014monitor closely especially when increasing dose", "doses": ["Secondary hyperparathyroidism in patients with end-stage\r\nrenal disease on dialysis (but seenotes above),adultover 18 years, initially 30\u00a0mg once daily,\r\nadjusted every 2\u20134 weeks to max. 180\u00a0mg daily", "Hypercalcaemia of primary hyperparathyroidism or parathyroid\r\ncarcinoma,adultover 18 years, initially\r\n30\u00a0mg twice daily, adjusted every 2\u20134 weeks according to response\r\nup to max. 90\u00a0mg 4 times daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "13.9 Shampoos and other preparations for scalp and hair conditions": {"name": "13.9 Shampoos and other preparations for scalp and hair conditions", "doses": ["scalp psoriasis, seborrhoeic dermatitis, dandruff, apply\r\n2\u20133 times weekly"]}, "DITHRANOL": {"indications": "subacute and chronic psoriasis, see notes above", "name": "DITHRANOL", "cautions": "avoid use near eyes and\r\nsensitive areas of skin; see\r\nalso notes above", "side-effects": "local burning sensation and irritation; stains\r\nskin, hair, and fabrics", "contra-indications": "hypersensitivity;\r\nacute and pustular psoriasis", "doses": ["for application to scalp, initially apply on alternate\r\ndays for 10\u201320 minutes; may be increased to daily application for\r\nmax. 1 hour and then wash off"]}, "TIOCONAZOLE": {"indications": "fungal nail infections", "name": "TIOCONAZOLE", "cautions": "seenotes above", "side-effects": "see notes above; also local oedema, dry skin,\r\nnail discoloration, periungual inflammation, nail pain, rash, exfoliation", "doses": ["Apply to nails and surrounding skin twice daily usually\r\nfor up to 6 months (may be extended to 12 months)"], "pregnancy": "manufacturer advises avoid"}, "ANTIDEPRESSANTS": {"interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  artemether/lumefantrine advises avoid concomitant use with antidepressants ", "name": "Antidepressants", "backrefs": ["Antidepressants, Tricyclic (related)", "Antidepressants", "Antidepressants, SSRI (related)"]}}, "LAMOTRIGINE": {"indications": "monotherapy and adjunctive treatment of focal\r\nseizures and generalised seizures including tonic-clonic seizures;\r\nseizures associated with Lennox-Gastaut syndrome; monotherapy of typical\r\nabsence seizures in children; prevention of depressive episodes associated\r\nwith bipolar disorder", "name": "LAMOTRIGINE", "renal impairment": "caution in renal failure; metabolite may accumulate;\r\nconsider reducing maintenance dose in significant impairment", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly reduces plasma concentration of lamotrigine ", "name": "Lamotrigine", "backrefs": ["Desogestrel", "Lamotrigine"]}, "cautions": "closely monitor and consider withdrawal\r\nif rash, fever, or other signs of hypersensitivity syndrome develop; avoid abrupt withdrawal (taper off over 2 weeks or\r\nlonger) unless serious skin reaction occurs; myoclonic seizures (may be exacerbated); Parkinson\u2019s disease (may be exacerbated);interactions:seeInteractionsin section 4.8.1 and Appendix 1 (lamotrigine)", "side-effects": "nausea, vomiting, diarrhoea, dry mouth, aggression,\r\nagitation, headache, drowsiness, dizziness, tremor, insomnia, ataxia,\r\nback pain, arthralgia, nystagmus, diplopia, blurred vision, rash (see\r\nSkin Reactions, below);rarelyconjunctivitis;very rarelyhepatic failure, movement disorders, unsteadiness,\r\nincrease in seizure frequency, exacerbation of Parkinson\u2019s disease,\r\nconfusion, hallucination, blood disorders (including anaemia, leucopenia,\r\nthrombocytopenia, pancytopenia\u2014see Blood Disorders, above), hypersensitivity\r\nsyndrome (seeAntiepileptic Hypersensitivity\r\nSyndrome),\r\nlupus erythematosus-like reactions;also reportedsuicidal ideation, aspectic meningitis", "hepatic impairment": "halve dose in moderate impairment; quarter dose in\r\nsevere impairment", "doses": ["Do not confuse the different combinations\r\nor indications; see also notes above", "Dose titration should be repeated if restarting\r\nafter an interval of more than 5 days", "Monotherapy of seizures,adultandchildover 12 years, initially\r\n25\u00a0mg once daily for 14 days, increased to 50\u00a0mg once daily for further\r\n14 days, then increased by max. 100\u00a0mg every 7\u201314 days; usual maintenance\r\n100\u2013200\u00a0mg daily in 1\u20132 divided doses (up to 500\u00a0mg daily has been\r\nrequired)", "Monotherapy of typical absence seizures,child2\u201312 years seeBNF for Children", "Adjunctive therapy of seizureswith valproate,adultandchildover 12 years, initially 25\u00a0mg on alternate days for 14 days then\r\n25\u00a0mg once daily for further 14 days, thereafter increased by max.\r\n50\u00a0mg every 7\u201314 days; usual maintenance, 100\u2013200\u00a0mg daily in 1\u20132\r\ndivided doses;child2\u201312 years initially\r\n150\u00a0micrograms/kg once daily for 14 days (those weighing under 13\u00a0kg\r\nmay receive 2\u00a0mg on alternate days for first 14 days) then 300\u00a0micrograms/kg\r\nonce daily for further 14 days, thereafter increased by max. 300\u00a0micrograms/kg\r\nevery 7\u201314 days; usual maintenance 1\u20135\u00a0mg/kg daily in 1\u20132 divided\r\ndoses; max. 200\u00a0mg daily", "Adjunctive therapy of seizures (with enzyme inducing drugs)without valproate,adultandchildover 12 years, initially 50\u00a0mg once daily for\r\n14 days then 50\u00a0mg twice daily for further 14 days, thereafter increased\r\nby max. 100\u00a0mg every 7\u201314 days; usual maintenance 200\u2013400\u00a0mg daily\r\nin 2 divided doses (up to 700\u00a0mg daily has been required);child2\u201312 years initially 600\u00a0micrograms/kg daily\r\nin 2 divided doses for 14 days then 1.2\u00a0mg/kg daily in 2 divided doses\r\nfor further 14 days, thereafter increased by max. 1.2\u00a0mg/kg every\r\n7\u201314 days; usual maintenance 5\u201315\u00a0mg/kg daily in 1\u20132 divided doses;\r\nmax. 400\u00a0mg daily", "Adjunctive therapy of seizures (without enzyme inducing drugs)without valproate,adultandchildover 12 years, initially 25\u00a0mg once daily for\r\n14 days, increased to 50\u00a0mg once daily for further 14 days, then increased\r\nby max. 100\u00a0mg every 7\u201314 days; usual maintenance 100\u2013200\u00a0mg daily\r\nin 1\u20132 divided doses;child2\u201312 years\r\ninitially 300\u00a0micrograms/kg daily in 1\u20132 divided doses for 14 days\r\nthen 600\u00a0micrograms/kg daily in 1\u20132 divided doses for further 14 days,\r\nthereafter increased by max. 600\u00a0micrograms/kg every 7\u201314 days; usual\r\nmaintenance 1\u201310\u00a0mg/kg daily in 1\u20132 divided doses; max. 200\u00a0mg daily", "Monotherapyoradjunctive therapy of bipolar\r\ndisorder (without enzyme inducing drugs)without valproate,adultover 18 years, initially 25\u00a0mg\r\nonce daily for 14 days, then 50\u00a0mg daily in 1\u20132 divided doses for\r\nfurther 14 days, then 100\u00a0mg daily in 1\u20132 divided doses for further\r\n7 days; usual maintenance 200\u00a0mg daily in 1\u20132 divided doses; max.\r\n400\u00a0mg daily", "Adjunctive therapy of bipolar disorderwith valproate,adultover 18 years, initially 25\u00a0mg\r\non alternate days for 14 days, then 25\u00a0mg once daily for further 14\r\ndays, then 50\u00a0mg daily in 1\u20132 divided doses for further 7 days; usual\r\nmaintenance 100\u00a0mg daily in 1\u20132 divided doses; max. 200\u00a0mg daily", "Adjunctive therapy of bipolar disorder (with enzyme inducing\r\ndrugs)without valproate,adultover 18 years, initially 50\u00a0mg once daily for 14 days, then 50\u00a0mg\r\ntwice daily for further 14 days, then 100\u00a0mg twice daily for further\r\n7 days, then 150\u00a0mg twice daily for further 7 days; usual maintenance\r\n200\u00a0mg twice daily", "Patients stabilised on lamotrigine for bipolar\r\ndisorder may require dose adjustments if other drugs are added to\r\nor withdrawn from their treatment regimens\u2014consult product literature"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "METHYLCELLULOSE": {"indications": "see notes above", "name": "METHYLCELLULOSE", "cautions": "see underIspaghulaHusk", "side-effects": "see underIspaghulaHusk", "contra-indications": "see underIspaghulaHusk; also infective bowel disease", "doses": ["constipation and diarrhoea, 3\u20136 tablets twice daily; in\r\nconstipation the dose should be taken with at least 300\u00a0mL liquid;\r\nin diarrhoea, ileostomy, and colostomy control, avoid liquid intake\r\nfor 30 minutes before and after dose;child7\u201312 years seeBNF for Children"]}, "DINOPROSTONE": {"indications": "see\r\nnotes above and under preparations below", "name": "DINOPROSTONE", "renal impairment": "manufacturers advise avoid", "cautions": "history of asthma, glaucoma\r\nand raised intra-ocular pressure; hypertension; history of epilepsy; uterine\r\nscarring; monitor uterine activity and fetal status (particular care if history of uterine\r\nhypertony); uterine rupture; see alsonotes above; monitor for disseminated intravascular coagulation after parturition; risk factors for disseminated intravascular coagulation; effect ofoxytocinenhanced (care needed in monitoring uterine activity when used in sequence);interactions:Appendix 1 (prostaglandins)", "side-effects": "nausea, vomiting, diarrhoea; other side-effects\r\ninclude uterine hypertonus, severe uterine contractions, pulmonary\r\nor amniotic fluid embolism, abruptio placenta, fetal distress, maternal\r\nhypertension, bronchospasm, rapid cervical dilation, fever, backache;\r\nuterine hypercontractility with or without fetal bradycardia, low\r\nApgar scores; cardiac arrest, uterine rupture, stillbirth or neonatal\r\ndeath also reported; vaginal symptoms (warmth, irritation, pain);\r\nafter intravenous administration\u2014flushing, shivering, headache, dizziness,\r\ntemporary pyrexia and raised white blood cell count; disseminated\r\nintravascular coagulation reported; also local tissue reaction and\r\nerythema after intravenous administration and possibility of infection\r\nafter extra-amniotic administration", "contra-indications": "active cardiac, or pulmonary disease; placenta praevia or unexplained vaginal bleeding\r\nduring pregnancy, ruptured membranes, major cephalopelvic disproportion or fetal malpresentation, history of caesarean\r\nsection or major uterine surgery, untreated pelvic infection, fetal distress, grand multiparas and multiple pregnancy, history of difficult\r\nor traumatic delivery; avoid extra-amniotic route in cervicitis or vaginitis", "hepatic impairment": "manufacturers advise avoid", "doses": ["by vagina, induction of labour, inserted\r\nhigh into posterior fornix, 3\u00a0mg, followed after 6\u20138 hours by 3\u00a0mg\r\nif labour is not established; max. 6\u00a0mg [vaginal tablets]"]}, "MUSCLE RELAXANTS, NON-DEPOLARISING": {"interactions": {"extra": "", "bad": 0, "interaction": " parenteral magnesium enhances effects of non-depolarising muscle relaxants ", "name": "Muscle Relaxants, non-depolarising", "backrefs": []}}, "DESMOPRESSIN": {"indications": "see under Dose", "name": "DESMOPRESSIN", "renal impairment": "use with caution; antidiuretic effect may be reduced", "interactions": {"extra": "", "bad": 0, "interaction": " indometacin enhances effects of desmopressin ", "name": "Desmopressin", "backrefs": ["Desmopressin", "Loperamide"]}, "cautions": "see underVasopressin; less pressor\r\nactivity, but still considerable caution in cardiovascular\r\ndisease and in hypertension (not indicated for nocturnal enuresis or nocturia in these circumstances); elderly (avoid for nocturnal enuresis and nocturia\r\nin those over 65 years); also considerable caution in cystic fibrosis; in nocturia and nocturnal enuresis\r\nlimit fluid intake to minimum from 1 hour before dose until 8 hours\r\nafterwards; in nocturia periodic\r\nblood pressure and weight checks needed to monitor for fluid overload;interactions:Appendix 1 (desmopressin)", "side-effects": "fluid retention, and hyponatraemia (in more serious\r\ncases with convulsions) on administration without restricting fluid\r\nintake; stomach pain, headache, nausea, vomiting, allergic reactions,\r\nand emotional disturbance in children also reported; epistaxis, nasal\r\ncongestion, rhinitis with nasal spray", "contra-indications": "cardiac insufficiency and other conditions treated with diuretics; psychogenic polydipsia and polydipsia\r\nin alcohol dependence", "doses": ["By mouth(as desmopressin acetate)", "Diabetes insipidus, treatment,adultandchildinitially 300\u00a0micrograms\r\ndaily (in 3 divided doses); maintenance, 300\u2013600\u00a0micrograms daily\r\nin 3 divided doses; range 0.2\u20131.2\u00a0mg daily", "Primary nocturnal enuresis,adult(under\r\n65 years) andchildover 5 years 200\u00a0micrograms\r\nat bedtime, only increased to 400\u00a0micrograms if lower dose not effective\r\n(important:see also Cautions); withdraw for at least\r\n1 week for reassessment after 3 months", "Postoperative polyuria or polydipsia, adjust dose according\r\nto urine osmolality", "Sublingually(as desmopressin base)", "Diabetes insipidus, treatment,adultandchildinitially 180\u00a0micrograms\r\ndaily in 3 divided doses; range 120\u2013720\u00a0micrograms daily", "Primary nocturnal enuresis,adult(under 65 years) andchildover 5\r\nyears 120\u00a0micrograms at bedtime, only increased to 240\u00a0micrograms\r\nif lower dose not effective (important:see also\r\nCautions); withdraw for at least 1 week for reassessment after 3 months", "Polyuria or polydipsia after hypophysectomy, adjust dose according\r\nto urine osmolality", "Intranasally(as desmopressin acetate)", "Diabetes insipidus, diagnosis,adultandchild20\u00a0micrograms (limit fluid\r\nintake to 500\u00a0mL from 1 hour before to 8 hours after administration)", "Diabetes insipidus, treatment,adult10\u201340\u00a0micrograms daily (in 1\u20132 divided doses);child5\u201320\u00a0micrograms daily; infants may require lower doses", "Nocturia associated with multiple sclerosis (when other treatments\r\nhave failed),adult(under 65 years)\r\n10\u201320\u00a0micrograms at bedtime (important:see also\r\nCautions), dose not to be repeated within 24 hours", "Renal function testing (empty bladder at time of administration\r\nand limit fluid intake to 500\u00a0mL from 1 hour before until 8 hours\r\nafter administration),adult40\u00a0micrograms;infantunder 1 year 10\u00a0micrograms (restrict fluid\r\nintake to 50% at next 2 feeds to avoid fluid overload),child1\u201315\u00a0years 20\u00a0micrograms", "Mild to moderate haemophilia and von Willebrand\u2019s disease,adult300\u00a0micrograms (one 150-microgram spray into\r\neach nostril) 30 minutes before surgery or when bleeding; may be repeated\r\nat intervals of 12 hours (or at intervals of at least 3 days if self-administered)", "Fibrinolytic response testing,adult300\u00a0micrograms (one 150-microgram spray into each nostril); blood\r\nsampled after 1 hour for fibrinolytic activity", "By injection(as desmopressin acetate)", "Diabetes insipidus, diagnosis (subcutaneousorintramuscular),adultandchild2\u00a0micrograms (limit fluid\r\nintake to 500\u00a0mL from 1 hour before to 8 hours after administration)", "Diabetes insipidus, treatment (subcutaneous,intramuscularorintravenous),adult1\u20134\u00a0micrograms daily;infantandchild400\u00a0nanograms", "Renal function testing (empty bladder at time of administration\r\nand limit fluid intake to 500\u00a0mL from 1 hour before until 8 hours\r\nafter administration) (subcutaneousorintramuscular),adultandchild2\u00a0micrograms;infant400\u00a0nanograms (restrict fluid intake to 50%\r\nat next 2 feeds)", "Mild to moderate haemophilia and  von Willebrand\u2019s disease, (subcutaneousorintravenous),adultandchildover 1 month 300\u00a0nanograms/kg as a single dose immediately before\r\nsurgery or after trauma; may be repeated at intervals of 12 hours", "Fibrinolytic response testing, (subcutaneousorintravenous),adultandchild300\u00a0nanograms/kg; blood\r\nsampled after 20 minutes for fibrinolytic activity", "Lumbar-puncture-associated headache, consult product literature"], "pregnancy": "small oxytocic effect in third trimester; increased\r\nrisk of pre-eclampsia", "breast-feeding": "not known to be harmful"}, "LEVOBUPIVACAINE": {"indications": "see under Dose", "name": "LEVOBUPIVACAINE", "interactions": {"extra": "", "bad": 0, "interaction": "increased myocardial depression when  anti-arrhythmics given with levobupivacaine ", "name": "Levobupivacaine", "backrefs": ["Levobupivacaine"]}, "cautions": "seeCautions of Local Anaesthetics; cardiovascular disease;interactions:Appendix 1 (levobupivacaine)", "side-effects": "seeToxicity and Side-effects;\r\nalso sweating, pyrexia, anaemia", "contra-indications": "seeContra-indications of Local\r\nAnaesthetics", "hepatic impairment": "use with caution", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "Doses should be adjusted according to patient\u2019s\r\nphysical status and nature of procedure\u2014important:see also under Administration,section 15.2", "Surgical anaesthesia", "Lumbar epidural, 10\u201320\u00a0mL (50\u2013150\u00a0mg) of 5\u00a0mg/mL\r\nor 7.5\u00a0mg/mL solution over 5 minutes; caesarean section, 15\u201330\u00a0mL\r\n(75\u2013150\u00a0mg) of 5\u00a0mg/mL solution over 15\u201320 minutes", "Intrathecal, 3\u00a0mL (15\u00a0mg) of 5\u00a0mg/mL solution", "Peripheral nerve block, 1\u201340\u00a0mL of 2.5\u00a0mg/mL\r\nor 5\u00a0mg/mL solution (max. 150\u00a0mg);ilioinguinal/iliohypogastric\r\nblock,childunder 12 years\r\n0.25\u20130.5\u00a0mL/kg (0.625\u20132.5\u00a0mg/kg) of a 2.5\u00a0mg/mL or 5\u00a0mg/mL solution", "Peribulbar block, 5\u201315\u00a0mL (37.5\u2013112.5\u00a0mg) of\r\n7.5\u00a0mg/mL solution", "Local infiltration, 1\u201360\u00a0mL (max. 150\u00a0mg) of\r\n2.5\u00a0mg/mL solution", "Acute pain", "Lumbar epidural, labour pain, 6\u201310\u00a0mL (15\u201325\u00a0mg)\r\nof 2.5\u00a0mg/mL solution at intervals of at least 15 minutesor5\u201312.5\u00a0mg/hour as a continuous epidural infusion; postoperative\r\npain, 12.5\u201318.75\u00a0mg/hour as a continuous epidural infusion; max. 400\u00a0mg\r\nin 24 hours", "The licensed doses stated above may not be appropriate in some\r\nsettings and expert advice should be sought"], "pregnancy": "large doses during delivery can cause neonatal respiratory\r\ndepression, hypotonia, and bradycardia after epidural block; avoid\r\nif possible in the first trimester\u2014toxicity inanimalstudies; may cause fetal distress syndrome; do not use for paracervical\r\nblock in obstetrics; do not use 7.5\u00a0mg/mL strength in obstetrics", "breast-feeding": "amount too small to be harmful"}, "ESTRADIOL": {"interactions": {"extra": "", "bad": 0, "interaction": " erythromycin increases plasma concentration of estradiol ", "name": "Estradiol", "backrefs": ["Colesevelam", "Ethinylestradiol", "Etoricoxib", "Estradiol"]}}, "ERGOCALCIFEROL": {"indications": "seenotes above", "name": "ERGOCALCIFEROL", "cautions": "take care to ensure correct dose in infants; monitor plasma-calcium concentration in patients receiving\r\nhigh doses and in renal impairment (seenotes above);interactions: Appendix 1 (vitamins)", "side-effects": "symptoms of overdosage include\r\nanorexia, lassitude, nausea and vomiting, diarrhoea, constipation,\r\nweight loss, polyuria, sweating, headache, thirst, vertigo, and raised\r\nconcentrations of calcium and phosphate in plasma and urine", "contra-indications": "hypercalcaemia; metastatic calcification", "doses": ["Seenotes above"], "pregnancy": "high doses teratogenic inanimalsbut therapeutic doses unlikely to be harmful", "breast-feeding": "caution with high doses; may cause hypercalcaemia\r\nin infant\u2014monitor serum-calcium concentration"}, "POLYSACCHARIDE\u2013IRON COMPLEX": {"side-effects": "seenotes above", "indications": "iron-deficiency anaemia", "name": "POLYSACCHARIDE\u2013IRON COMPLEX", "cautions": "interactions:Appendix 1 (iron)", "doses": ["prophylactic, 2.5\u00a0mL daily; therapeutic, 5\u00a0mL 1\u20132 times\r\ndaily (once daily if required during second and third trimester of\r\npregnancy);preterm neonate,neonate, andinfant(from dropper bottle) 1 drop (approx. 500\u00a0micrograms iron) per 450\u00a0g\r\nbody-weight 3 times daily;child2\u20136\r\nyears 2.5\u00a0mL daily, 6\u201312 years 5\u00a0mL daily"]}, "RIFAMPICIN": {"indications": "see under Dose", "name": "RIFAMPICIN", "renal impairment": "use with caution if dose above 600\u00a0mg daily", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  nevirapine reduced by rifampicin\u2014avoid concomitant use", "name": "Rifampicin", "backrefs": ["Linezolid", "Zopiclone", "Oxycodone", "Rifampicin", "Linagliptin", "Nateglinide", "Celiprolol", "Imidapril", "Codeine", "Celecoxib", "Exemestane", "Fexofenadine", "Bisoprolol", "Losartan"]}, "cautions": "see Monitoring innotes above; alsoliver function tests and blood counts in hepatic disorders,alcoholdependence, and on prolonged\r\ntherapy, see also below); acute porphyria (section 9.8.2);important:effectiveness of hormonal contraceptives is reduced and alternative\r\nfamily planning advice should be offered (see alsosection 7.3.1); discolours soft\r\ncontact lenses; see also notes above;interactions:Appendix 1 (rifamycins)", "side-effects": "gastro-intestinal symptoms including anorexia,\r\nnausea, vomiting, diarrhoea (antibiotic-associated colitis reported);\r\nheadache, drowsiness; those occurring mainly on intermittent therapy\r\ninclude influenza-like symptoms (with chills, fever, dizziness, bone\r\npain), respiratory symptoms (including shortness of breath), collapse\r\nand shock, haemolytic anaemia, thrombocytopenic purpura, disseminated\r\nintravascular coagulation, and acute renal failure; alterations of\r\nliver function, jaundice; flushing, urticaria, and rashes; other side-effects\r\nreported include oedema, psychoses, adrenal insufficiency, muscular\r\nweakness and myopathy, exfoliative dermatitis, toxic epidermal necrolysis,\r\nStevens-Johnson syndrome, pemphigoid reactions, leucopenia, eosinophilia,\r\nmenstrual disturbances; urine, saliva, and other body secretions coloured\r\norange-red; thrombophlebitis reported if infusion used for prolonged\r\nperiod", "contra-indications": "jaundice; rifamycin hypersensitivity", "hepatic impairment": "impaired elimination; monitor liver function; avoid\r\nor do not exceed 8\u00a0mg/kg daily; see also Cautions above", "doses": ["initial treatment of pulmonary tuberculosis, patients\r\nup to 40\u00a0kg 3 tablets daily preferably before breakfast, 40\u201349\u00a0kg\r\n4 tablets daily, 50\u201364\u00a0kg 5 tablets daily, 65\u00a0kg or more, 6 tablets\r\ndaily; not suitable for use in children"], "pregnancy": "manufacturers advise very high doses teratogenic\r\ninanimalstudies in first trimester; risk of neonatal\r\nbleeding may be increased in third trimester; see alsoPregnancy", "breast-feeding": "amount too small to be harmful; see alsoBreast-feeding"}, "CEFOTAXIME": {"indications": "see underCefaclor; gonorrhoea; surgical prophylaxis; Haemophilus\r\nepiglottitis and meningitis (Table 1,section 5.1); see\r\nalso notes above", "name": "CEFOTAXIME", "renal impairment": "if eGFR less than 5\u00a0mL/minute/1.73\u00a0m2, initial\r\ndose of 1\u00a0g then use half normal dose", "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor; rarely arrhythmias following rapid injection\r\nreported", "contra-indications": "see underCefaclor", "doses": ["By intramuscularorintravenous injectionorby\r\nintravenous infusion, 1\u00a0g every 12 hours increased in severe\r\ninfections (e.g. meningitis) to 8\u00a0g daily in 4 divided doses; higher\r\ndoses (up to 12\u00a0g daily in 3\u20134 divided doses) may be required; intramuscular\r\ndoses over 1\u00a0g divided between more than one site;neonate50\u00a0mg/kg daily in 2\u20134 divided doses increased\r\nto 150\u2013200\u00a0mg/kg daily in severe infections;child100\u2013150\u00a0mg/kg daily in 2\u20134 divided doses increased up to 200\u00a0mg/kg\r\ndaily in very severe infections", "Uncomplicated gonorrhoea,by intramuscular\r\ninjection, 500\u00a0mg as a single dose", "Important. If meningococcal\r\ndisease (meningitis with non-blanching rash or meningococcal septicaemia)\r\nis suspected, and the patient cannot be givenbenzylpenicillin(e.g. because of an allergy), a single dose ofcefotaximecan be given (if available) before urgent transfer to hospital,\r\nso long as this does not delay the transfer. If a patient with suspected\r\nbacterial meningitis without non-blanching rash cannot be transferred\r\nto hospital urgently and cannot be given benzylpenicillin, a single\r\ndose of cefotaxime can be given before transfer. Suitable doses ofcefotaximeby intravenous injection (or by intramuscular\r\ninjection) areadultandchildover 12 years 1\u00a0g;childunder 12 years 50\u00a0mg/kg;chloramphenicol(section 5.1.7) may be used if there is a history\r\nof anaphylaxis to penicillins or cephalosporins"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "TRABECTEDIN": {"indications": "seenotes above", "name": "TRABECTEDIN", "renal impairment": "avoid monotherapy if creatinine clearance less than 30\u00a0mL/minute;\r\navoid combination regimens if creatinine clearance less than 60\u00a0mL/minute", "cautions": "seesection 8.1andnotes above; measure creatine\r\nkinase, renal function and hepatic function before starting (consult\r\nproduct literature); monitor haematological\r\nand hepatic parameters weekly during first 2 cycles and at least once\r\nbetween treatments in subsequent cycles; concomitant use with hepatotoxic drugs (avoid alcohol)", "side-effects": "seesection 8.1; also abdominal pain, constipation,\r\ndiarrhoea, dyspepsia, taste disturbance, hepatobiliary disorders;\r\nhypotension, oedema, flushing; dyspnoea, cough; headache, insomnia,\r\nperipheral neuropathy, paraesthesia, dizziness, anorexia, asthenia,\r\nfatigue; pyrexia; hypokalaemia, dehydration, increased blood creatine\r\nkinase; myalgia, arthralgia, back pain", "hepatic impairment": "manufacturer advises caution in impairment\u2014consider\r\ndose reduction; avoid in patients with raised bilirubin", "doses": ["SeeDoses"], "pregnancy": "effective contraception recommended during and for\r\nat least 3 months after treatment in women and at least 5 months after\r\ntreatment in men; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid breast-feeding during\r\nand for 3 months after treatment"}, "ABRASIVE AGENTS": {"indications": "acne vulgaris (but see notes above)", "contra-indications": "superficial venules, telangiectasia", "name": "ABRASIVE AGENTS", "cautions": "avoid contact with eyes; discontinue use temporarily if skin becomes irritated", "doses": ["use instead of soap 1\u20133 times daily"]}, "LOFEXIDINE": {"interactions": {"extra": "", "bad": 0, "interaction": "increased sedative effect when  alcohol given with lofexidine ", "name": "Lofexidine", "backrefs": ["Lofexidine"]}}, "CHLORPROMAZINE HYDROCHLORIDE": {"indications": "nausea and vomiting of terminal illness (where\r\nother drugs have failed or are not available); other indications (section 4.2.1)", "name": "CHLORPROMAZINE HYDROCHLORIDE", "renal impairment": "see notes insection 4.2.1", "cautions": "seeChlorpromazine Hydrochloride,section 4.2.1", "side-effects": "seeChlorpromazine Hydrochloride,section 4.2.1", "contra-indications": "see notes insection 4.2.1", "hepatic impairment": "see notes insection 4.2.1", "doses": ["By mouth, 10\u201325\u00a0mg every 4\u20136 hours;child500\u00a0micrograms/kg every 4\u20136 hours (1\u20135 years\r\nmax. 40\u00a0mg daily, 6\u201312 years max. 75\u00a0mg daily)", "By deep intramuscular injectioninitially 25\u00a0mg\r\nthen 25\u201350\u00a0mg every 3\u20134 hours until vomiting stops;child500\u00a0micrograms/kg every 6\u20138 hours (1\u20135 years\r\nmax. 40\u00a0mg daily, 6\u201312 years max. 75\u00a0mg daily)", "By rectumin suppositories, chlorpromazine 100\u00a0mg\r\nevery 6\u20138 hours [unlicensed]"], "pregnancy": "see notes insection 4.2.1", "breast-feeding": "see notes insection 4.2.1"}, "CELECOXIB": {"indications": "pain and inflammation in osteoarthritis, rheumatoid arthritis, and\r\nankylosing spondylitis", "name": "CELECOXIB", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; see alsonotes above", "interactions": {"extra": "", "bad": 0, "interaction": " rifampicin reduces plasma concentration of celecoxib ", "name": "Celecoxib", "backrefs": ["Celecoxib"]}, "cautions": "seenotes above; monitor blood pressure before and during treatment", "side-effects": "seenotes above; dyspnoea, influenza-like symptoms;less commonlystomatitis, palpitation, cerebral infarction,\r\nfatigue, paraesthesia, muscle cramps;rarelytaste\r\ndisturbance, alopecia;very rarelyseizures;also reportedchest pain", "contra-indications": "seenotes above; sulphonamide sensitivity; inflammatory bowel\r\ndisease", "hepatic impairment": "halve initial dose in moderate impairment; see alsonotes above", "doses": ["Osteoarthritis, 200\u00a0mg daily in 1\u20132 divided doses, increased\r\nif necessary to max. 200\u00a0mg twice daily;childnot recommended", "Rheumatoid arthritis, 100\u00a0mg twice daily, increased if necessary\r\nto 200\u00a0mg twice daily;childnot recommended", "Ankylosing spondylitis, 200\u00a0mg daily in 1\u20132 divided doses, increased\r\nif necessary to max. 400\u00a0mg daily in 1\u20132 divided doses;childnot recommended", "Discontinue if no improvement after 2 weeks\r\non max. dose"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsonotes above", "breast-feeding": "avoid\u2014present in milk inanimalstudies; see alsonotes above"}, "MAGNESIUM SALTS": {"indications": "see under preparations below", "name": "MAGNESIUM SALTS", "renal impairment": "avoid or reduce dose; increased risk of toxicity", "cautions": "elderly and debilitated; see alsonotes above;interactions:Appendix 1 (antacids)", "side-effects": "colic", "contra-indications": "acute gastro-intestinal conditions", "hepatic impairment": "avoid in hepatic coma if risk of renal failure", "doses": ["See preparations"]}, "PORACTANT ALFA": {"side-effects": "seenotes above; alsorarelyhypotension", "indications": "treatment of respiratory distress syndrome or hyaline membrane disease\r\nin neonates over 700\u00a0g; prophylaxis of respiratory distress syndrome\r\nin preterm neonates 24\u201332 weeks post-menstrual age", "name": "PORACTANT ALFA", "cautions": "seenotes aboveand consult product literature", "doses": ["By endotracheal tube,treatment, 100\u2013200\u00a0mg/kg; further doses of 100\u00a0mg/kg may be repeated at intervals\r\nof 12 hours; max. total dose 300\u2013400\u00a0mg/kg;prophylaxis, 100\u2013200\u00a0mg/kg soon after birth (preferably within 15 minutes);\r\nfurther doses of 100\u00a0mg/kg may be repeated 6\u201312 hours later and after\r\na further 12 hours if still intubated; max. total dose 300\u2013400\u00a0mg/kg"]}, "KETOROLAC": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium reduced by ketorolac (increased risk of toxicity)\u2014avoid concomitant use", "name": "Ketorolac", "backrefs": ["Pentoxifylline", "Anticoagulants", "Ketorolac"]}}, "MORPHINE HYDROCHLORIDE": {"indications": "cough in terminal disease (see alsoPrescribing in Palliative\r\nCare)", "name": "MORPHINE HYDROCHLORIDE", "renal impairment": "section 4.7.2", "cautions": "section 4.7.2", "side-effects": "section 4.7.2", "contra-indications": "section 4.7.2", "hepatic impairment": "section 4.7.2", "doses": ["Initially 5\u00a0mg every 4 hours"], "pregnancy": "section 4.7.2", "breast-feeding": "section 4.7.2"}, "LAPATINIB": {"indications": "seenotes above", "name": "LAPATINIB", "renal impairment": "caution in severe impairment\u2014no information available", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of neutropenia when  docetaxel given with lapatinib ", "name": "Lapatinib", "backrefs": ["Lapatinib"]}, "cautions": "seesection 8.1; low gastric pH (reduced absorption); susceptibility to QT-interval prolongation (including concomitant use of drugs that prolong QT-interval and electrolyte disturbances); monitor left ventricular function; monitor\r\nfor pulmonary toxicity; monitor liver function\r\nbefore treatment and at monthly intervals;interactions:Appendix 1 (lapatinib)", "side-effects": "seesection 8.1; anorexia, diarrhoea (treat promptly),\r\ndecreased left ventricular ejection fraction, cardiac failure (fatal\r\ncases reported), malaise, rash, nail disorders, hyperbilirubinaemia,\r\nhepatotoxicity (discontinue permanently if severe);less commonlyinterstitial lung disease; respiratory failure (including fatal\r\ncases) also reported", "hepatic impairment": "caution in moderate to severe impairment\u2014metabolism\r\nreduced", "doses": ["In combination with capecitabine,adultover 18 years, 1.25\u00a0g once daily", "In combination with an aromatase inhibitor,adultover 18 years, 1.5\u00a0g once daily", "Always take at the same time in relation\r\nto food: either one hour before or one hour after food. Patients should\r\nreport unexpected changes in bowel habit"], "pregnancy": "avoid unless potential benefit outweighs risk\u2014toxicity\r\ninanimalstudies; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "LUTROPIN ALFA": {"indications": "see notes above", "name": "LUTROPIN ALFA", "cautions": "acute porphyria (section 9.8.2)", "side-effects": "nausea, vomiting, abdominal and pelvic pain; headache,\r\nsomnolence; injection-site reactions; ovarian hyperstimulation syndrome,\r\novarian cyst, breast pain, ectopic pregnancy; thromboembolism, adnexal\r\ntorsion, and haemoperitoneum", "contra-indications": "ovarian enlargement or cyst (unless caused\r\nby polycystic ovarian disease); undiagnosed vaginal bleeding; tumours of hypothalamus and pituitary; ovarian, uterine or mammary carcinoma", "doses": ["By subcutaneous injection, in conjunction\r\nwith follicle-stimulating hormone, according to response"]}, "ALFACALCIDOL": {"indications": "seenotes above", "name": "ALFACALCIDOL", "cautions": "see underErgocalciferol; also nephrolithiasis", "side-effects": "see underErgocalciferol; alsorarelynephrocalcinosis, pruritus,\r\nrash, and urticaria", "contra-indications": "see underErgocalciferol", "doses": ["By mouthorby\r\nintravenous injectionover 30 seconds,adultandchildover 20\u00a0kg, initially 1\u00a0microgram\r\ndaily (elderly 500\u00a0nanograms), adjusted to avoid hypercalcaemia; maintenance,\r\nusually 0.25\u20131\u00a0microgram daily;neonateandpreterm neonateinitially 50\u2013100\u00a0nanograms/kg\r\ndaily,childunder 20\u00a0kg initially\r\n50\u00a0nanograms/kg daily"], "pregnancy": "see underErgocalciferol", "breast-feeding": "see underErgocalciferol"}, "MIVACURIUM": {"indications": "neuromuscular blockade (short duration) for surgery", "name": "MIVACURIUM", "renal impairment": "clinical effect prolonged in renal failure\u2014reduce dose\r\naccording to response", "cautions": "seenotes above; low plasma cholinesterase activity; elderly", "side-effects": "seenotes above", "hepatic impairment": "reduce dose in severe impairment", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "By intravenous injection, 70\u2013250\u00a0micrograms/kg;\r\nmaintenance 100\u00a0micrograms/kg every 15 minutes;child2\u20136 months initially 150\u00a0micrograms/kg, 7 months\u201312 years initially\r\n200\u00a0micrograms/kg; maintenance (child2 months\u201312 years) 100\u00a0micrograms/kg every 6\u20139 minutes", "Doses up to 150\u00a0micrograms/kg may be given\r\nover 5\u201315 seconds, higher doses should be given over 30 seconds. In\r\npatients with asthma, cardiovascular disease or those who are sensitive\r\nto falls in arterial blood pressure give over 60 seconds", "By intravenous infusionafter initial bolus intravenous\r\ndose, maintenance of block, 8\u201310\u00a0micrograms/kg/minute, adjusted if\r\nnecessary every 3 minutes by 1\u00a0microgram/kg/minute to usual dose of\r\n6\u20137\u00a0micrograms/kg/minute;child2 months\u201312\r\nyears, usual dose 11\u201314\u00a0micrograms/kg/minute"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CARVEDILOL": {"indications": "hypertension; angina; adjunct to diuretics,digoxin, or ACE inhibitors in symptomatic chronic heart\r\nfailure", "name": "CARVEDILOL", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  ciclosporin increased by carvedilol ", "name": "Carvedilol", "backrefs": ["Carvedilol"]}, "cautions": "see underPropranolol Hydrochloride; monitor renal function during dose titration in patients\r\nwith heart failure who also have renal impairment, low\r\nblood pressure, ischaemic heart disease, or diffuse vascular disease", "side-effects": "postural hypotension, dizziness, headache, fatigue,\r\ngastro-intestinal disturbances, bradycardia; occasionally diminished\r\nperipheral circulation, peripheral oedema and painful extremities,\r\ndry mouth, dry eyes, eye irritation or disturbed vision, impotence,\r\ndisturbances of micturition, influenza-like symptoms; rarely angina,\r\nAV block, exacerbation of intermittent claudication or Raynaud\u2019s phenomenon;\r\nallergic skin reactions, exacerbation of psoriasis, nasal stuffiness,\r\nwheezing, depressed mood, sleep disturbances, paraesthesia, heart\r\nfailure, changes in liver enzymes, thrombocytopenia, leucopenia also\r\nreported", "contra-indications": "see underPropranolol Hydrochloride; acute or decompensated heart failure requiring\r\nintravenous inotropes", "hepatic impairment": "avoid", "doses": ["Hypertension, initially 12.5\u00a0mg once daily, increased\r\nafter 2 days to usual dose of 25\u00a0mg once daily; if necessary may be\r\nfurther increased at intervals of at least 2 weeks to max. 50\u00a0mg daily\r\nin single or divided doses;elderlyinitial dose of 12.5\u00a0mg daily may provide satisfactory control", "Angina, initially 12.5\u00a0mg twice daily, increased after 2 days\r\nto 25\u00a0mg twice daily", "Adjunct in heart failure (section 2.5.5) initially 3.125\u00a0mg twice daily\r\n(with food), dose increased at intervals of at least 2 weeks to 6.25\u00a0mg\r\ntwice daily, then to 12.5\u00a0mg twice daily, then to 25\u00a0mg twice daily;\r\nincrease to highest dose tolerated, max. 25\u00a0mg twice daily in patients\r\nwith severe heart failure or body-weight less than 85\u00a0kg and 50\u00a0mg\r\ntwice daily in patients over 85\u00a0kg"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "INTERFERON ALFA": {"indications": "see under preparations", "name": "INTERFERON ALFA", "renal impairment": "close monitoring required; avoid in severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of peripheral neuropathy when  telbivudine given with interferon alfa ", "name": "Interferon Alfa", "backrefs": ["Telbivudine", "Interferon Alfa"]}, "cautions": "consult product literature;interactions:Appendix 1 (interferons)", "side-effects": "seenotes aboveand consult product literature", "contra-indications": "consult product literature; avoid injections containing benzyl alcohol in neonates (see under preparations below)", "hepatic impairment": "close monitoring in mild to moderate impairment; avoid\r\nif severe", "doses": ["Consult product literature"], "pregnancy": "avoid unless potential benefit outweighs risk (toxicity\r\ninanimalstudies); effective contraception required\r\nduring treatment\u2014consult product literature", "breast-feeding": "unlikely to be harmful"}, "HEPATITIS B VACCINE": {"indications": "immunisation against hepatitis B infection", "name": "HEPATITIS B VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1", "contra-indications": "seesection 14.1", "doses": ["by intramuscular injection(see note below),adultandchildover\r\n16 years, 3 doses of 20\u00a0micrograms, the second 1 month and the third\r\n6 months after the first dose;neonate(except if born to hepatitis B surface antigen positive mother,\r\nsee below) andchild1 month\u201316 years,\r\n3 doses of 10\u00a0micrograms"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "Topical NSAIDs": {"name": "Topical NSAIDs", "doses": ["apply up to 4 times daily; therapy should be reviewed\r\nafter 14 days"]}, "LETROZOLE": {"indications": "adjuvant treatment of oestrogen-receptor-positive early breast cancer\r\nin postmenopausal women; advanced breast cancer in postmenopausal\r\nwomen (including those in whom other anti-oestrogen therapy has failed);\r\nearly invasive breast cancer in postmenopausal women after standard\r\nadjuvant tamoxifen therapy; pre-operative treatment in postmenopausal\r\nwomen with localised hormone-receptor-positive breast cancer to allow\r\nsubsequent breast conserving surgery", "name": "LETROZOLE", "renal impairment": "manufacturer advises caution if creatinine\r\nclearance less than 10\u00a0mL/minute", "cautions": "susceptibility to osteoporosis (assess\r\nbone mineral density before treatment and at regular intervals)", "side-effects": "hot flushes, nausea, vomiting, fatigue, dizziness,\r\nheadache, dyspepsia, constipation, diarrhoea, depression, anorexia,\r\nappetite increase, hypercholesterolaemia, alopecia, increased sweating,\r\nrash, peripheral oedema, musculoskeletal pain, osteoporosis, bone\r\nfracture;less commonlyhypertension, palpitation,\r\ntachycardia, dyspnoea, cough, drowsiness, insomnia, anxiety, memory\r\nimpairment, dysaesthesia, taste disturbance, pruritus, dry skin, urticaria,\r\nthrombophlebitis, abdominal pain, urinary frequency, urinary-tract\r\ninfection, vaginal bleeding, vaginal discharge, breast pain, pyrexia,\r\nmucosal dryness, stomatitis, cataract, eye irritation, blurred vision,\r\ntumour pain, arthritis, leucopenia, general oedema;rarelypulmonary embolism, arterial thrombosis, cerebrovascular infarction", "contra-indications": "not indicated for premenopausal\r\nwomen", "hepatic impairment": "avoid in severe impairment", "doses": ["2.5\u00a0mg daily"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nmanufacturer advises effective contraception required until postmenopausal\r\nstatus fully established", "breast-feeding": "manufacturer advises avoid"}, "AZELASTINE HYDROCHLORIDE": {"side-effects": "mild transient irritation; bitter taste reported", "indications": "allergic conjunctivitis", "name": "AZELASTINE HYDROCHLORIDE", "doses": ["Seasonal allergic conjunctivitis,adultandchildover 4 years, apply twice\r\ndaily, increased if necessary to 4 times daily", "Perennial conjunctivitis,adultandchildover 12 years, apply twice\r\ndaily, increased if necessary to 4 times daily; max. duration of treatment\r\n6 weeks"]}, "MEBEVERINE HYDROCHLORIDE": {"indications": "adjunct in gastro-intestinal disorders characterised by smooth muscle\r\nspasm", "name": "MEBEVERINE HYDROCHLORIDE", "side-effects": "allergic reactions (including rash, urticaria,\r\nangioedema) reported", "contra-indications": "paralytic ileus", "doses": ["adultandchildover 10 years 135\u2013150\u00a0mg 3 times daily preferably\r\n20 minutes before meals;childunder\r\n10 years seeBNF for Children"], "pregnancy": "not known to be harmful; manufacturers advise caution"}, "ANTAZOLINE SULPHATE": {"indications": "allergic conjunctivitis", "name": "ANTAZOLINE SULPHATE", "doses": ["adultandchildover 12 years apply 2\u20133 times daily (max. 7\r\ndays)"]}, "ALISKIREN": {"indications": "essential hypertension", "name": "ALISKIREN", "renal impairment": "caution in renal artery stenosis or if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2\u2014no information available; monitor\r\nplasma-potassium concentration", "interactions": {"extra": "", "bad": 1, "interaction": " itraconazole increases plasma concentration of aliskiren\u2014avoid concomitant use", "name": "Aliskiren", "backrefs": ["Aliskiren", "Irbesartan"]}, "cautions": "patients taking concomitant diuretics, on a low-sodium\r\ndiet, or who are dehydrated (first doses may cause hypotension\u2014initiate\r\nwith care); renal artery\r\nstenosis; patients at risk of renal impairment; monitor plasma-potassium concentration and renal function\r\nin diabetes mellitus and heart failure; history of angioedema (avoid in hereditary or idiopathic\r\nangioedema);interactions:Appendix 1 (aliskiren)", "side-effects": "diarrhoea;less commonlyrash;rarelyangioedema; peripheral oedema, acute renal failure\r\n(reversible on discontinuation of treatment), anaemia, and hyperkalaemia\r\nalso reported", "doses": ["adultover 18 years, 150\u00a0mg\r\nonce daily, increased if necessary to 300\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid\u2014no information available;\r\nother drugs acting on the renin-angiotensin system have been associated\r\nwith fetal malformations and neonatal death", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises avoid"}, "VALGANCICLOVIR": {"indications": "induction and maintenance treatment\r\nof cytomegalovirus retinitis in AIDS patients; prevention of cytomegalovirus\r\ndisease following solid organ transplantation from a cytomegalovirus-positive\r\ndonor.", "name": "VALGANCICLOVIR", "renal impairment": "reduce dose; consult product literature", "cautions": "see underGanciclovir", "side-effects": "see underGanciclovir", "contra-indications": "see underGanciclovir", "doses": ["CMV retinitis, induction,adultover 18 years, 900\u00a0mg twice daily for 21 days then 900\u00a0mg once daily;\r\ninduction regimen may be repeated if retinitis progresses", "Prevention of cytomegalovirus disease following solid organ\r\ntransplantation (starting within 10 days of transplantation),adultover 18 years, 900\u00a0mg once daily for 100 days\r\n(for 100\u2013200 days following kidney transplantation)", "Oral valganciclovir 900\u00a0mg twice daily is\r\nequivalent to intravenous ganciclovir 5\u00a0mg/kg twice daily"], "pregnancy": "see underGanciclovir", "breast-feeding": "see underGanciclovir"}, "BETAMETHASONE": {"side-effects": "seenotes above", "indications": "local treatment of inflammation (short-term)", "name": "BETAMETHASONE", "cautions": "seenotes above", "doses": ["Apply eye drops every 1\u20132 hours until controlled then\r\nreduce frequency; apply eye ointment 2\u20134 times dailyorat night when used with eye drops"]}, "EXEMESTANE": {"indications": "adjuvant treatment of oestrogen-receptor-positive early breast cancer\r\nin postmenopausal women following 2\u20133 years of tamoxifen therapy;\r\nadvanced breast cancer in postmenopausal women in whom anti-oestrogen\r\ntherapy has failed", "name": "EXEMESTANE", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": " rifampicin possibly reduces plasma concentration of exemestane ", "name": "Exemestane", "backrefs": ["Exemestane"]}, "cautions": "interactions:Appendix 1 (exemestane)", "side-effects": "nausea, vomiting, abdominal pain, dyspepsia, constipation,\r\nanorexia; dizziness, fatigue, headache, depression, insomnia; hot\r\nflushes, sweating; alopecia, rash;less commonlydrowsiness,\r\nasthenia, and peripheral oedema;rarelythrombocytopenia,\r\nleucopenia", "contra-indications": "not indicated for premenopausal\r\nwomen", "hepatic impairment": "manufacturer advises caution", "doses": ["25\u00a0mg daily"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "TEICOPLANIN": {"indications": "seenotes aboveand under\r\nDose", "name": "TEICOPLANIN", "renal impairment": "from day 4, use normal dose every 48 hours if eGFR 40\u201360\u00a0mL/minute/1.73\u00a0m2and use normal dose every 72 hours if eGFR less than 40\u00a0mL/minute/1.73\u00a0m2; see also Cautions above", "cautions": "vancomycinsensitivity; blood counts and liver and kidney function tests required; monitor renal and auditory function during prolonged\r\ntreatment in renal impairment or if other nephrotoxic or neurotoxic\r\ndrugs given; monitor plasma-teicoplanin concentration during parenteral\r\ntreatment if severe sepsis or burns, deep-seated staphylococcal infection\r\n(including bone and joint infection), endocarditis, renal impairment,\r\nin elderly, and in intravenous drug abusers;interactions:Appendix 1 (teicoplanin)", "side-effects": "rash, pruritus;less commonlynausea, vomiting, diarrhoea, bronchospasm, dizziness, headache,\r\nfever, leucopenia, thrombocytopenia, eosinophilia, tinnitus, mild\r\nhearing loss, vestibular disorders, thrombophlebitis;also\r\nreportedrenal failure, exfoliative dermatitis, Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis", "doses": ["By mouth,Clostridium difficileinfection, 200\u00a0mg twice daily for 10 days", "By intravenous injectionorinfusion,adultbody-weight\r\nunder 70\u00a0kg, initially 400\u00a0mg every 12 hours for 3 doses, subsequently\r\n400\u00a0mg once daily (subsequent doses can alternatively be givenby intramuscular injection); body-weight over 70\u00a0kg, initially\r\n6\u00a0mg/kg every 12 hours for 3 doses, then 6\u00a0mg/kg once daily; higher\r\ndoses may be required in severe infection (including burns, septicaemia,\r\nseptic arthritis, and osteomyelitis), consult product literature", "Streptococcal endocarditis (in combination with another antibacterial\r\nif necessary, seeTable 1, section 5.1),by intravenous\r\ninjectionorinfusion,adultinitially 6\u00a0mg/kg every 12 hours for 3 doses,\r\nthen 6\u00a0mg/kg once daily", "Enterococcal endocarditis (in combination with another antibacterial,\r\nseeTable 1, section 5.1),by intravenous\r\ninjectionorinfusion,adultinitially 10\u00a0mg/kg every 12 hours for 3 doses,\r\nthen 10\u00a0mg/kg once daily", "Surgical prophylaxis,adult,by intravenous injection, 400\u00a0mg up to 30 minutes before\r\nthe procedure; open fractures,by intravenous infusion, 800\u00a0mg up to 30 minutes before skeletal stabilisation and definitive\r\nsoft-tissue closure", "childunder 18 years seeBNF for Children", "Plasma-teicoplanin concentration is not measured\r\nroutinely because a relationship between plasma concentration and\r\ntoxicity has not been established. However, the plasma-teicoplanin\r\nconcentration can be used to optimise parenteral treatment in some\r\npatients (see Cautions). Pre-dose (\u2018trough\u2019) concentrations should\r\nbe greater than 10\u00a0mg/litre (greater than 15\u201320\u00a0mg/litre in endocarditis;\r\ngreater than 20\u00a0mg/litre in deep-seated infection such as bone and\r\njoint infection), but less than 60\u00a0mg/litre. Teicoplanin doses in\r\nBNF may differ from those in product literature"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "no information available"}, "PYRIMETHAMINE": {"indications": "malaria (but used only in combined preparations\r\nincorporating sulfadoxine); toxoplasmosis\u2014section 5.4.7", "name": "PYRIMETHAMINE", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 1, "interaction": "increased antifolate effect when  trimethoprim given with pyrimethamine ", "name": "Pyrimethamine", "backrefs": ["Pyrimethamine", "Pemetrexed"]}, "cautions": "blood counts required with prolonged\r\ntreatment;history of seizures\u2014avoid\r\nlarge loading doses;interactions:Appendix\r\n1 (pyrimethamine)", "side-effects": "depression of haematopoiesis with high doses,\r\nrashes, insomnia", "hepatic impairment": "manufacturer advises caution", "doses": ["Malaria, no dose stated because not recommended alone,\r\nseePyrimethamine with Sulfadoxinebelow", "Toxoplasmosis,section 5.4.7"], "pregnancy": "theoretical teratogenic risk infirst trimester(folate antagonist); adequate folate supplements should be given\r\nto mother", "breast-feeding": "significant amount in milk\u2014avoid administration\r\nof other folate antagonists to infant; avoid breast-feeding during\r\ntoxoplasmosis treatment"}, "PIPERACILLIN WITH TAZOBACTAM": {"indications": "see under Dose", "name": "PIPERACILLIN WITH TAZOBACTAM", "renal impairment": "max. 4.5\u00a0g every 8 hours if eGFR 20\u201340\u00a0mL/minute/1.73\u00a0m2; max. 4.5\u00a0g every 12 hours if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underBenzylpenicillin(section 5.1.1.1);interactions:Appendix 1 (penicillins)", "side-effects": "see underBenzylpenicillin(section 5.1.1.1); also\r\nnausea, vomiting, diarrhoea;less commonlystomatitis,\r\ndyspepsia, constipation, jaundice, hypotension, headache, insomnia,\r\ninjection-site reactions;rarelyabdominal pain,\r\nhepatitis, eosinophilia;very rarelyhypoglycaemia,\r\nhypokalaemia, pancytopenia, Stevens-Johnson syndrome, toxic epidermal\r\nnecrolysis", "contra-indications": "see underBenzylpenicillin(section 5.1.1.1)", "doses": ["Expressed as a combination of piperacillin\r\nand tazobactam (both as sodium salts) in a ratio of 8:1", "Hospital-acquired pneumonia, septicaemia, complicated\r\nintra-abdominal infections, complicated infections involving the urinary\r\ntract or skin and soft tissues,adultandchildover 12 years,by\r\nintravenous infusion, 4.5\u00a0g every 8 hours, increased to 4.5\u00a0g\r\nevery 6 hours in severe infections", "Complicated intra-abdominal infections,by\r\nintravenous infusion,child2\u201312 years, 112.5\u00a0mg/kg (max. 4.5\u00a0g) every 8 hours", "Infections in neutropenic patients,by intravenous\r\ninfusion,adultandchildover 12 years, 4.5\u00a0g every 6 hours;child2\u201312 years, 90\u00a0mg/kg (max. 4.5\u00a0g) every 6 hours"], "pregnancy": "manufacturers advise use only if potential benefit\r\noutweighs risk", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "LEVETIRACETAM": {"indications": "seenotes above", "name": "LEVETIRACETAM", "renal impairment": "max. 2\u00a0g daily if eGFR 50\u201380\u00a0mL/minute/1.73\u00a0m2; max. 1.5\u00a0g daily if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; max.\r\n1\u00a0g daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of  carbamazepine toxicity when given with levetiracetam ", "name": "Levetiracetam", "backrefs": ["Levetiracetam"]}, "cautions": "avoid abrupt withdrawal;interactions:Appendix 1 (levetiracetam)", "side-effects": "anorexia, weight changes, abdominal pain, nausea,\r\nvomiting, dyspepsia, diarrhoea, cough, drowsiness, amnesia, ataxia,\r\nconvulsion, dizziness, headache, tremor, hyperkinesia, malaise, impaired\r\nattention, aggression, agitation, depression, insomnia, anxiety, irritability,\r\npersonality disorder, thrombocytopenia, myalgia, diplopia, blurred\r\nvision, rash;also reportedpancreatitis, hepatic\r\nfailure, paraesthesia, confusion, psychosis, suicidal ideation, leucopenia,\r\nneutropenia, pancytopenia, alopecia, toxic epidermal necrolysis, Stevens-Johnson\r\nsyndrome", "hepatic impairment": "halve dose in severe hepatic impairment if eGFR less\r\nthan 60\u00a0mL/minute/1.73\u00a0m2", "doses": ["Monotherapy of focal seizures,by mouthorby intravenous infusion,adultandchildover\r\n16 years, initially 250\u00a0mg once daily increased after 1\u20132 weeks to\r\n250\u00a0mg twice daily; thereafter, increased according to response in\r\nsteps of 250\u00a0mg twice daily every 2 weeks; max. 1.5\u00a0g twice daily", "Adjunctive therapy of focal seizures,by\r\nmouth,adultandchildover 12 years, body-weight over 50\u00a0kg, initially\r\n250\u00a0mg twice daily, increased by 500\u00a0mg twice daily every 2\u20134 weeks;\r\nmax. 1.5\u00a0g twice daily;childover\r\n6 months, body-weight under 50\u00a0kg, initially 10\u00a0mg/kg once daily,\r\nincreased by max. 10\u00a0mg/kg twice daily every 2 weeks; max. 30\u00a0mg/kg\r\ntwice daily;child1\u20136 months, initially\r\n7\u00a0mg/kg once daily, increased by max. 7\u00a0mg/kg twice daily every 2\r\nweeks; max. 21\u00a0mg/kg twice daily", "By intravenous infusion,adultandchildover 12 years, body-weight\r\nover 50\u00a0kg, initially 250\u00a0mg twice daily, increased by 500\u00a0mg twice\r\ndaily every 2\u20134 weeks; max. 1.5\u00a0g twice daily;childover 4 years, body-weight under 50\u00a0kg, initially 10\u00a0mg/kg once daily,\r\nincreased by max. 10\u00a0mg/kg twice daily every 2 weeks; max. 30\u00a0mg/kg\r\ntwice daily", "Adjunctive therapy of myoclonic seizures and tonic-clonic seizures,by mouthorby intravenous infusion,adultandchildover 12 years, body-weight over 50\u00a0kg, initially 250\u00a0mg twice daily,\r\nincreased by 500\u00a0mg twice daily every 2\u20134 weeks; max. 1.5\u00a0g twice\r\ndaily;child12\u201318 years, body-weight\r\nunder 50\u00a0kg, initially 10\u00a0mg/kg once daily, increased by max. 10\u00a0mg/kg\r\ntwice daily every 2 weeks; max. 30\u00a0mg/kg twice daily", "If switching between oral therapy and intravenous therapy (because\r\noral route temporarily unavailable),by intravenous infusion, same as established oral dose", "Levetiracetam doses in BNF may differ from\r\nthose in product literature"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "CAPREOMYCIN": {"indications": "in combination with other drugs, tuberculosis resistant to first-line\r\ndrugs", "name": "CAPREOMYCIN", "renal impairment": "reduce dose\u2014consult product literature; nephrotoxic;\r\nototoxic", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of nephrotoxicity and ototoxicity when  vancomycin given with capreomycin ", "name": "Capreomycin", "backrefs": ["Capreomycin"]}, "cautions": "auditory impairment; monitor renal, hepatic, auditory, and vestibular function\r\nand electrolytes;interactions:Appendix\r\n1 (capreomycin)", "side-effects": "hypersensitivity reactions including urticaria\r\nand rashes; leucocytosis or leucopenia, rarely thrombocytopenia; changes\r\nin liver function tests; nephrotoxicity, electrolyte disturbances;\r\nhearing loss with tinnitus and vertigo; neuromuscular block after\r\nlarge doses, pain and induration at injection site", "hepatic impairment": "use with caution", "doses": ["By deep intramuscular injection, 1\u00a0g daily\r\n(not more than 20\u00a0mg/kg) for 2\u20134 months, then 1\u00a0g 2\u20133 times each week"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014teratogenic inanimalstudies", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "SULPIRIDE": {"indications": "schizophrenia", "name": "SULPIRIDE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects when  lithium given with sulpiride ", "name": "Sulpiride", "backrefs": ["Droperidol", "Sulpiride"]}, "cautions": "seenotes above; also excited, agitated, or aggressive patients (even low doses may aggravate symptoms)", "side-effects": "seenotes above; also\r\nhepatitis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["adultandchildover 14 years, 200\u2013400\u00a0mg twice daily; max.\r\n800\u00a0mg daily in predominantly negative symptoms, and 2.4\u00a0g daily in\r\nmainly positive symptoms;elderly,\r\nlower initial dose, increased gradually according to response"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FEXOFENADINE HYDROCHLORIDE": {"indications": "see under Dose", "name": "FEXOFENADINE HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Seasonal allergic rhinitis, 120\u00a0mg once daily;child6\u201312 years, 30\u00a0mg twice daily", "Chronic idiopathic urticaria,adultandchildover 12 years, 180\u00a0mg once\r\ndaily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ANTIDIABETICS": {"interactions": {"extra": "", "bad": 0, "interaction": " corticosteroids antagonise hypoglycaemic effect of antidiabetics ", "name": "Antidiabetics", "backrefs": ["Antidiabetics"]}}, "KETOPROFEN": {"indications": "pain and mild inflammation in rheumatic disease and\r\nother musculoskeletal disorders, and after orthopaedic surgery; acute\r\ngout; dysmenorrhoea", "name": "KETOPROFEN", "renal impairment": "avoid in severe impairment; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": " probenecid reduces excretion of ketoprofen (increased plasma concentration)", "name": "Ketoprofen", "backrefs": ["Dexketoprofen", "Ketoprofen"]}, "cautions": "seenotes above", "side-effects": "seenotes above; suppositories may cause rectal\r\nirritation", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, rheumatic disease, 100\u2013200\u00a0mg\r\ndaily in 2\u20134 divided doses;childnot\r\nrecommended", "Pain and dysmenorrhoea, 50\u00a0mg up to 3 times daily;childnot recommended", "By rectumin suppositories, rheumatic\r\ndisease, 100\u00a0mg at bedtime;childnot\r\nrecommended", "Combined oral and rectal treatment, max. total daily dose 200\u00a0mg"], "pregnancy": "seenotes above", "breast-feeding": "amount probably too small to be harmful but\r\nmanufacturers advise avoid; see alsonotes above"}, "NORTRIPTYLINE": {"indications": "depressive illness; neuropathic pain [unlicensed]\r\n(section 4.7.3)", "name": "NORTRIPTYLINE", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits metabolism of nortriptyline (increased plasma concentration)", "name": "Nortriptyline", "backrefs": ["Nortriptyline"]}, "cautions": "seenotes above; manufacturer advises plasma-nortriptylineconcentration\r\nmonitoring if dose above 100\u00a0mg daily, but evidence of practical value\r\nuncertain", "side-effects": "seenotes above; also\r\nabdominal pain, stomatitis, diarrhoea, hypertension, oedema, flushing,\r\nrestlessness, fatigue, and mydriasis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Depression, low dose initially increased as necessary\r\nto 75\u2013100\u00a0mg daily in divided dosesoras a single\r\ndose (max. 150\u00a0mg daily);adolescentandelderly30\u201350\u00a0mg daily in divided\r\ndoses;childnot recommended for depression", "Neuropathic pain [unlicensed], initially 10\u00a0mg\r\ndaily at night, gradually increased if necessary to 75\u00a0mg daily; higher\r\ndoses under specialist supervision"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "seenotes above"}, "IPILIMUMAB": {"indications": "seenotes above", "name": "IPILIMUMAB", "cautions": "seenotes above\u2014for full details consult product\r\nliterature", "side-effects": "seenotes above\u2014for full details (including monitoring\r\nand management of side-effects) consult product literature", "hepatic impairment": "use with caution if plasma-bilirubin concentration\r\ngreater than 3 times upper limit of normal rangeorif plasma-transaminase concentration 5 times or greater than the\r\nupper limit of normal range", "doses": ["Consult product literature"], "pregnancy": "avoid unless potential benefit outweighs risk; use\r\neffective contraception", "breast-feeding": "discontinue breast-feeding\u2014no information available"}, "PILOCARPINE HYDROCHLORIDE": {"indications": "xerostomia following irradiation for head\r\nand neck cancer (see alsonotes above); dry mouth and dry eyes in Sj\u00f6gren\u2019s\r\nsyndrome", "name": "PILOCARPINE HYDROCHLORIDE", "renal impairment": "manufacturer advises caution with tablets", "cautions": "asthma and chronic obstructive pulmonary disease (avoid if uncontrolled,\r\nsee Contra-indications), cardiovascular disease (avoid if uncontrolled); cholelithiasis or biliary-tract disease, peptic ulcer, risk of increased urethral\r\nsmooth muscle tone and renal colic; maintain adequate fluid intake to avoid dehydration\r\nassociated with excessive sweating; cognitive or psychiatric disturbances; susceptibility to angle-closure glaucoma;interactions:Appendix 1 (parasympathomimetics)", "side-effects": "dyspepsia, diarrhoea, abdominal pain, nausea,\r\nvomiting, constipation; flushing, hypertension, palpitation, headache,\r\ndizziness, asthenia, influenza-like symptoms, sweating; increased\r\nurinary frequency; visual disturbances, lacrimation, ocular pain,\r\nconjunctivitis; rhinitis; rash, pruritus;less commonlyflatulence, urinary urgency", "contra-indications": "uncontrolled asthma and chronic obstructive\r\npulmonary disease (increased bronchial secretions and increased airways\r\nresistance); uncontrolled cardiorenal\r\ndisease; acute iritis", "hepatic impairment": "reduce initial oral dose in moderate or severe cirrhosis", "doses": ["Xerostomia following irradiation for head and neck cancer,\r\n5\u00a0mg 3 times daily with or immediately after meals (last dose always\r\nwith evening meal); if tolerated but response insufficient after 4\r\nweeks, may be increased to max. 30\u00a0mg daily in divided doses; max.\r\ntherapeutic effect normally within 4\u20138 weeks; discontinue if no improvement\r\nafter 2\u20133 months;childnot recommended", "Dry mouth and dry eyes in Sj\u00f6gren\u2019s syndrome, 5\u00a0mg 4 times daily\r\n(with meals and at bedtime); if tolerated but response insufficient,\r\nmay be increased to max. 30\u00a0mg daily in divided doses; discontinue\r\nif no improvement after 2\u20133 months;childnot recommended"], "pregnancy": "avoid\u2014smooth muscle stimulant; toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "RALOXIFENE": {"interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  coumarins antagonised by raloxifene ", "name": "Raloxifene", "backrefs": ["Raloxifene"]}}, "LINAGLIPTIN": {"indications": "seenotes above", "name": "LINAGLIPTIN", "interactions": {"extra": "", "bad": 0, "interaction": " rifampicin possibly reduces effects of linagliptin ", "name": "Linagliptin", "backrefs": ["Linagliptin"]}, "cautions": "interactions:Appendix 1 (antidiabetics)", "side-effects": "cough, nasopharyngitis;also reportedpancreatitis", "doses": ["adultover 18 years, 5\u00a0mg\r\nonce daily", "Dose of concomitant sulfonylurea\r\nmay need to be reduced"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "ZUCLOPENTHIXOL DECANOATE": {"indications": "maintenance in schizophrenia and paranoid psychoses", "name": "ZUCLOPENTHIXOL DECANOATE", "renal impairment": "seesection 4.2.1", "cautions": "seesection 4.2.1and\r\nnotes above; QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval); avoid\r\nin acute porphyria (section 9.8.2)", "side-effects": "seesection 4.2.1andnotes above", "contra-indications": "seesection 4.2.1", "hepatic impairment": "seesection 4.2.1", "doses": ["By deep intramuscular injectioninto the\r\nupper outer buttock or lateral thigh, test dose 100\u00a0mg, followed after\r\nat least 7 days by 200\u2013500\u00a0mg or more, repeated at intervals of 1\u20134\r\nweeks, adjusted according to response; max. 600\u00a0mg weekly;elderlyquarter to half usual starting dose;childnot recommended"], "pregnancy": "seesection 4.2.1", "breast-feeding": "seesection 4.2.1"}, "CEFTRIAXONE": {"indications": "see underCefaclorand notes above; surgical prophylaxis;\r\nprophylaxis of meningococcal meningitis [unlicensed indication] (Table\r\n2,section 5.1)", "name": "CEFTRIAXONE", "renal impairment": "reduce dose if eGFR less than 10\u00a0mL/minute/1.73m2(max. 2\u00a0g daily); monitor plasma concentration if both hepatic\r\nand severe renal impairment", "cautions": "see underCefaclor; may displace bilirubin\r\nfrom serum albumin, administer over 60 minutes in neonates (see also Contra-indications); treatment longer than 14 days, renal failure, dehydration\u2014risk of\r\nceftriaxone precipitation in gall bladder;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor; calciumceftriaxoneprecipitates in urine (particularly in very young, dehydrated or\r\nthose who are immobilised) or in gall bladder\u2014consider discontinuation\r\nif symptomatic; rarely prolongation of prothrombin time, pancreatitis", "contra-indications": "see underCefaclor; neonates less than\r\n41 weeks postmenstrual age; neonates over 41\r\nweeks postmenstrual age with jaundice, hypoalbuminaemia,\r\nor acidosis; concomitant treatment with intravenous calcium\r\n(including total parenteral nutrition containing calcium) in neonates\r\nover 41 weeks postmenstrual age\u2014risk of precipitation in urine and\r\nlungs", "hepatic impairment": "reduce dose and monitor plasma concentration if both\r\nhepatic and severe renal impairment", "doses": ["By deep intramuscular injection,orby intravenous injectionover at least\r\n2\u20134 minutes,orby intravenous infusion, 1\u00a0g daily; 2\u20134\u00a0g daily in severe infections; intramuscular doses\r\nover 1\u00a0g divided between more than one site; single intravenous doses\r\nabove 1\u00a0g by intravenous infusion only", "neonate,by intravenous\r\ninfusionover 60 minutes, 20\u201350\u00a0mg/kg daily (max. 50\u00a0mg/kg\r\ndaily);infantandchildunder 50\u00a0kg,by deep intramuscular injection,orby intravenous injectionover 2\u20134 minutes,orby intravenous infusion, 20\u201350\u00a0mg/kg\r\ndaily; up to 80\u00a0mg/kg daily in severe infections; doses of 50\u00a0mg/kg\r\nand over by intravenous infusion only; 50\u00a0kg and over, adult dose", "Endocarditis caused by haemophilus, actinobacillus,\r\ncardiobacterium, eikenella, and kingella species (\u2018HACEK organisms\u2019)\r\n(in combination with another antibacterial, see Table 1,section 5.1; [unlicensed indication]),by intravenous infusion, 2\u20134\u00a0g daily", "Early syphilis [unlicensed indication],by\r\ndeep intramuscular injection, 500\u00a0mg daily for 10 days", "Uncomplicated gonorrhoea, pelvic inflammatory disease\r\n(see also Table 1,section 5.1),by deep intramuscular\r\ninjection, 500\u00a0mg as a single dose [unlicensed dose]", "Surgical prophylaxis,by deep intramuscular\r\ninjectionorby intravenous injectionover at least 2\u20134 minutes, 1\u00a0g up to 30 minutes before the procedure;\r\ncolorectal surgery,by deep intramuscular injectionorby intravenous infusion, 2\u00a0g\r\nup to 30 minutes before the procedure; intramuscular doses over 1\u00a0g\r\ndivided between more than one site"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "13.13 Topical circulatory preparations": {"name": "13.13 Topical circulatory preparations", "doses": ["apply up to 4 times daily in superficial soft-tissue injuries\r\nand superficial thrombophlebitis"]}, "LEUPRORELIN ACETATE": {"side-effects": "seenotes aboveandsection 6.7.2; also fatigue, muscle weakness,\r\nparaesthesia, hypertension, palpitation, alteration ofglucosetolerance and of blood lipids; hypotension, jaundice, thrombocytopenia\r\nand leucopenia reported", "indications": "locally advanced prostate cancer as an\r\nalternative to surgical castration; adjuvant treatment to radiotherapy\r\nor radical prostatectomy in patients with high-risk localised or locally\r\nadvanced prostate cancer; metastatic prostate cancer; endometriosis,\r\nendometrial thinning, uterine fibroids (section 6.7.2)", "name": "LEUPRORELIN ACETATE", "cautions": "seenotes aboveandsection 6.7.2; risk of ureteric\r\nobstruction and spinal cord compression in men", "doses": ["prostate cancer (see indications),by subcutaneous\r\ninjection, 11.25\u00a0mg every three months"]}, "LIQUID PARAFFIN": {"side-effects": "anal seepage of paraffin and consequent anal irritation\r\nafter prolonged use, granulomatous reactions caused by absorption\r\nof small quantities ofliquid paraffin(especially\r\nfrom the emulsion), lipoid pneumonia, and interference with the absorption\r\nof fat-soluble vitamins", "indications": "constipation", "name": "LIQUID PARAFFIN", "cautions": "avoid prolonged use; contra-indicated\r\nin children under 3 years", "doses": ["adultover 18 years, 10\u201330\u00a0mL\r\nat night when required"]}, "RIFAMYCINS": {"interactions": {"extra": "Interactions do not apply to rifaximin", "bad": 1, "interaction": "metabolism of  phenytoin accelerated by rifamycins (reduced plasma concentration)", "name": "Rifamycins", "backrefs": ["Rifamycins"]}}, "TINZAPARIN SODIUM": {"indications": "see notes above and under preparations", "name": "TINZAPARIN SODIUM", "renal impairment": "risk of bleeding may be increased; monitoring of anti-Factor\r\nXa may be required if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; dose reduction may be required if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2; unfractionated heparin may be preferable", "cautions": "see underHeparinand notes above", "side-effects": "see underHeparin; alsoless commonlyheadache", "contra-indications": "see underHeparin", "hepatic impairment": "manufacturer advises avoid in severe impairment", "doses": ["treatment of deep-vein thrombosis and of pulmonary embolism,by subcutaneous injection, 175\u00a0units/kg once daily until\r\nadequate oral anticoagulation established"], "pregnancy": "not known to be harmful; vials contain benzyl alcohol\u2014manufacturer\r\nadvises avoid; see alsoPregnancy", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "OXALIPLATIN": {"indications": "metastatic colorectal cancer in combination withfluorouraciland folinic acid; colon cancer\u2014see notes above", "name": "OXALIPLATIN", "renal impairment": "manufacturer advises avoid if creatinine clearance less\r\nthan 30\u00a0mL/minute", "cautions": "seesection 8.1andnotes\r\nabove;interactions:Appendix 1 (platinum\r\ncompounds)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "seesection 8.1; peripheral neuropathy with functional\r\nimpairment", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies; effective contraception required during and for 4 months\r\nafter treatment in women and 6 months after treatment in men; see\r\nalsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "FLURAZEPAM": {"indications": "insomnia (short-term use; seenotes above)", "name": "FLURAZEPAM", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of flurazepam (risk of extreme sedation and respiratory depression\u2014avoid concomitant use)", "name": "Flurazepam", "backrefs": ["Flurazepam"]}, "cautions": "see underNitrazepam", "side-effects": "see underNitrazepam", "contra-indications": "see underNitrazepam", "hepatic impairment": "seenotes above", "doses": ["15\u201330\u00a0mg at bedtime;elderly(or debilitated) 15\u00a0mg;childnot\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "TICK-BORNE ENCEPHALITIS VACCINE, INACTIVATED": {"indications": "immunisation against tick-borne encephalitis", "name": "TICK-BORNE ENCEPHALITIS VACCINE, INACTIVATED", "cautions": "seesection 14.1", "side-effects": "seesection 14.1", "contra-indications": "seesection 14.1", "doses": ["Initial immunisation,by intramuscular injectionin deltoid region or anterolateral thigh in infants,adultandchildover\r\n16 years, 3 doses each of 0.5\u00a0mL, second dose after 1\u20133 months and\r\nthird dose after further 5\u201312 months;child1\u201316 years 3 doses of 0.25\u00a0mL, second dose after 1\u20133 months and\r\nthird dose after further 5\u201312 months;elderlyover 60 years and immunocompromised (including those receiving immunosuppressants),\r\nantibody concentration may be measured 4 weeks after second dose and\r\ndose repeated if protective levels not achieved", "To achieve more rapid protection, second\r\ndose may be given 14 days after first dose", "Booster doses, give first dose within 3 years after initial\r\ncourse completed, then every 3\u20135 years"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "OFATUMUMAB": {"indications": "seenotes above", "name": "OFATUMUMAB", "renal impairment": "no information available for creatinine clearance less\r\nthan 30\u00a0mL/minute", "cautions": "seenotes above\u2014for full details consult\r\nproduct literature", "side-effects": "seenotes above\u2014for full details (including monitoring\r\nand management of side-effects) consult product literature", "contra-indications": "consult product literature", "doses": ["SeeDoses"], "pregnancy": "avoid unless potential benefit outweighs risk; use\r\neffective contraception during and for 12 months after treatment", "breast-feeding": "discontinue breast-feeding during and for 12\r\nmonths after treatment\u2014no information available"}, "PARASYMPATHOMIMETICS": {"interactions": {"extra": "", "bad": 0, "interaction": " antimuscarinics antagonise effects of parasympathomimetics ", "name": "Parasympathomimetics", "backrefs": ["Parasympathomimetics"]}}, "INTRA-UTERINE PROGESTOGEN-ONLY SYSTEM": {"indications": "see under preparation", "name": "INTRA-UTERINE PROGESTOGEN-ONLY SYSTEM", "cautions": "seenotes above; history of depression; advanced uterine\r\natrophy; systemic lupus erythematosus with\r\npositive (or unknown) antiphospholipid antibodies;interactions:see notes above and Appendix 1 (progestogens)", "side-effects": "seenotes above; also\r\nabdominal pain, expulsion, peripheral oedema, depression (sometimes\r\nsevere), nervousness, salpingitis, pelvic inflammatory disease, pelvic\r\npain, back pain;rarelyuterine perforation, hirsutism,\r\nhair loss, pruritus, migraine, rash", "contra-indications": "seenotes above; not suitable for emergency contraception", "hepatic impairment": "see Oral Progestogen-only Contraceptives,section 7.3.2.1", "doses": ["contraception and menorrhagia, insert into uterine\r\ncavity within 7 days of onset of menstruation, or any time if replacement,\r\nor any time if reasonably certain woman is not pregnant and there\r\nis no risk of conception (additional precautions (e.g. barrier methods)\r\nnecessary for next 7 days), or immediately after first-trimester termination\r\nby curettage; postpartum insertions should be delayed until at least\r\n4 weeks after delivery; effective for 5 years.", "Prevention of endometrial hyperplasia during oestrogen replacement\r\ntherapy, insert during last days of menstruation or withdrawal bleeding\r\nor any time if amenorrhoeic; effective for 4 years", "When system is removed (and not immediately\r\nreplaced) and pregnancy is not desired, remove during the first few\r\ndays of menstruation, otherwise additional precautions (e.g. barrier\r\nmethods) should be used for at least 7 days before removal"], "pregnancy": "avoid; if pregnancy occurs remove system", "breast-feeding": "progestogen-only contraceptives do not affect\r\nlactation"}, "FOLINIC ACID": {"indications": "seenotes above", "name": "FOLINIC ACID", "cautions": "avoid simultaneous administration ofmethotrexate;notindicated for pernicious anaemia\r\nor other megaloblastic anaemias caused by vitamin B12deficiency;interactions:Appendix 1 (folates)", "side-effects": "rarelypyrexia after parenteral use; insomnia, agitation, and depression\r\nafter high doses", "contra-indications": "intrathecal\r\ninjection", "doses": ["as an antidote tomethotrexate,by intravenous injectionorinfusion, consult product literature", "Adjunct tofluorouracilin colorectal cancer,\r\nconsult product literature"], "pregnancy": "not known to be harmful; benefit outweighs risk", "breast-feeding": "presence in milk unknown but benefit outweighs\r\nrisk"}, "AMBRISENTAN": {"indications": "pulmonary arterial hypertension", "name": "AMBRISENTAN", "renal impairment": "use with caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "not to be initiated in significant anaemia; monitor haemoglobin concentration or haematocrit after\r\n1 month and 3 months of starting treatment, and periodically thereafter (reduce dose or discontinue treatment if significant\r\ndecrease in haemoglobin concentration or haematocrit observed); monitor liver function before treatment, and monthly\r\nthereafter\u2014discontinue if liver enzymes raised significantly\r\nor if symptoms of liver impairment develop", "side-effects": "abdominal pain, constipation; palpitation, flushing,\r\nperipheral oedema; upper respiratory-tract disorders; headache; anaemia;less commonlyhypersensitivity reactions (including angioedema\r\nand rash)", "hepatic impairment": "avoid in severe impairment", "doses": ["adultover 18 years, 5\u00a0mg\r\nonce daily, increased if necessary to 10\u00a0mg once daily"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nexclude pregnancy before treatment and ensure effective contraception\r\nduring treatment; monthly pregnancy tests advised", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "MIGLUSTAT": {"indications": "mild to moderate type I Gaucher\u2019s disease\r\n(specialist supervision only); Niemann-Pick type C disease (specialist\r\nsupervision only)", "name": "MIGLUSTAT", "renal impairment": "for Gaucher\u2019s disease initially 100\u00a0mg twice daily if\r\neGFR 50\u201370\u00a0mL/minute/1.73\u00a0m2; initially 100\u00a0mg once daily\r\nif eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; for Niemann-Pick type\r\nC disease, initially 200\u00a0mg twice daily if eGFR 50\u201370\u00a0mL/minute/1.73\u00a0m2; initially 100\u00a0mg twice daily if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; child under 12 years\u2014consult product literature; avoid if\r\neGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "monitor cognitive and neurological function; monitor growth and platelet count in Niemann-Pick\r\ntype C disease", "side-effects": "diarrhoea, flatulence, abdominal pain, dyspepsia,\r\nconstipation, nausea, vomiting, anorexia, weight changes; tremor,\r\ndizziness, headache, peripheral neuropathy, ataxia, hypoaesthesia,\r\nparaesthesia, insomnia, fatigue, asthenia; decreased libido; thrombocytopenia;\r\nmuscle spasm", "hepatic impairment": "no information available\u2014manufacturer advises caution", "doses": ["Gaucher\u2019s disease,adultover 18 years, 100\u00a0mg 3 times daily; reduced if not tolerated to\r\n100\u00a0mg 1\u20132 times daily", "Niemann-Pick type C disease,adultandchildover 12 years, 200\u00a0mg 3\r\ntimes daily;child4\u201312 years, body\r\nsurface area less than 0.47\u00a0m2, 100\u00a0mg once daily; body\r\nsurface area 0.47\u20130.73\u00a0m2, 100\u00a0mg twice daily; body surface\r\narea 0.73\u20130.88\u00a0m2, 100\u00a0mg three times daily; body surface\r\narea 0.88\u20131.25\u00a0m2, 200\u00a0mg twice daily; body surface area\r\ngreater than 1.25\u00a0m2, adult dose"], "pregnancy": "manufacturer advises avoid (toxicity inanimalstudies)\u2014effective contraception must be used during treatment;\r\nalso men should avoid fathering a child during and for 3 months after\r\ntreatment", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "NALIDIXIC ACID": {"indications": "urinary-tract infections", "name": "NALIDIXIC ACID", "renal impairment": "use with caution; avoid if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " nitrofurantoin possibly antagonises effects of nalidixic acid ", "name": "Nalidixic Acid", "backrefs": ["Nalidixic Acid", "Melphalan"]}, "cautions": "seenotes above; avoid in acute porphyria (section 9.8.2); false positive urinaryglucose(if tested for reducing substances); monitor\r\nblood counts, renal and liver function if treatment exceeds 2 weeks;interactions:Appendix 1 (quinolones)", "side-effects": "seenotes above; also reported toxic psychosis, increased intracranial pressure,\r\ncranial nerve palsy, peripheral neuropathy, and metabolic acidosis", "contra-indications": "seenotes above", "hepatic impairment": "manufacturer advises caution in liver disease", "doses": ["900\u00a0mg every 6 hours for 7 days, reduced in chronic infections\r\nto 600\u00a0mg every 6 hours;child3 months\u201318\r\nyears seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "risk to infant very small but one case of haemolytic\r\nanaemia reported"}, "TRAZODONE HYDROCHLORIDE": {"indications": "depressive illness, particularly where sedation is required; anxiety", "name": "TRAZODONE HYDROCHLORIDE", "renal impairment": "use with caution in severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\ndyspepsia, hypersalivation, hypertension, palpitation, dyspnoea, priapism\r\n(discontinue immediately), myalgia, arthralgia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Depression, initially 150\u00a0mg (elderly 100\u00a0mg) daily in\r\ndivided doses after foodoras a single dose at bedtime;\r\nmay be increased to 300\u00a0mg daily; hospital patients up to max. 600\u00a0mg\r\ndaily in divided doses;childnot recommended", "Anxiety, 75\u00a0mg daily, increasing if necessary to 300\u00a0mg daily;childnot recommended"], "pregnancy": "avoid during first trimester\u2014limited information\r\navailable; monitor infant for signs of withdrawal if used until delivery", "breast-feeding": "seenotes above"}, "METHYLPHENIDATE": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of hypertension when  volatile liquid general anaesthetics given with methylphenidate ", "name": "Methylphenidate", "backrefs": ["Methylphenidate"]}}, "OXPRENOLOL HYDROCHLORIDE": {"indications": "see under Dose", "name": "OXPRENOLOL HYDROCHLORIDE", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "hepatic impairment": "reduce dose", "doses": ["hypertension, 1 tablet daily, increased if necessary to\r\n2 daily as a single dose"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ACITRETIN": {"indications": "severe extensive psoriasis resistant to other forms of therapy; palmoplantar\r\npustular psoriasis; severe congenital ichthyosis; severe Darier\u2019s\r\ndisease (keratosis follicularis)", "name": "ACITRETIN", "renal impairment": "avoid in severe impairment; increased risk of toxicity", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  methotrexate increased by acitretin (also increased risk of hepatotoxicity)\u2014avoid concomitant use", "name": "Acitretin", "backrefs": ["Acitretin"]}, "cautions": "exclude pregnancy before starting (test\r\nfor pregnancy within 2 weeks before treatment and monthly thereafter;\r\nstart treatment on day 2 or 3 of menstrual cycle)\u2014women (including those with history of infertility) should avoid\r\npregnancy and use effective contraception (ideally 2 methods of contraception,\r\none of which is a combined hormonal contraceptive or an intra-uterine\r\ndevice) for at least 1 month before, during, and for at least 3 years\r\nafter treatment (oral progestogen-only contraceptives not considered\r\neffective); avoid concomitant use of keratolytics; do not donate blood during and for 2 years after\r\nstopping therapy (teratogenic risk); check liver function at start, then every 2\u20134 weeks for first 2 months\r\nand then every 3 months; monitor serum-triglyceride\r\nand serum-cholesterol concentrations before treatment, 1 month after\r\nstarting, then every 3 months; diabetes\r\n(can alterglucosetolerance\u2014initial frequent bloodglucosechecks); investigate\r\natypical musculoskeletal symptoms; in children\r\nuse only in exceptional circumstances and monitor growth parameters\r\nand bone development (premature epiphyseal closure reported); avoid excessive exposure to sunlight and unsupervised use of sunlamps;interactions:Appendix 1 (retinoids)", "side-effects": "abdominal pain, diarrhoea, nausea, vomiting, dryness\r\nand inflammation of mucous membranes, peripheral oedema, reversible\r\nincrease in serum-cholesterol and serum-triglyceride concentrations\r\n(with high doses), headache, arthralgia, myalgia, dryness of conjunctiva\r\n(causing conjunctivitis and decreased tolerance to contact lenses),\r\nalopecia (reversible on withdrawal), abnormal hair texture, skin exfoliation,\r\npruritus, epidermal fragility, sticky skin, dermatitis, erythema,\r\nbrittle nails, paronychia;less commonlyhepatitis,\r\ndizziness, visual disturbances, photosensitivity;rarelyperipheral neuropathy;very rarelybenign intracranial\r\nhypertension (discontinue if severe headache, nausea, vomiting, or\r\nvisual disturbances occur), bone pain, exostosis (skeletal hyperostosis\r\nand extra-osseous calcification reported following long-term treatment\r\nwith etretinate, and premature epiphyseal closure in children, see\r\nCautions above), night blindness, ulcerative keratitis;also\r\nreportedtaste disturbance, rectal haemorrhage, flushing,\r\nmalaise, drowsiness, granulomatous lesions, impaired hearing, tinnitus,\r\ninitial worsening of psoriasis, dry skin, sweating", "contra-indications": "hyperlipidaemia", "hepatic impairment": "avoid in severe impairment\u2014risk of further impairment", "doses": ["adultover 18 years (under\r\nexpert supervision), initially 25\u201330\u00a0mg daily (Darier\u2019s disease 10\u00a0mg\r\ndaily) for 2\u20134 weeks, then adjusted according to response, usual range\r\n25\u201350\u00a0mg daily; up to 75\u00a0mg daily for short periods in psoriasis and\r\nichthyosis (seenotes above);childunder 18 years seeBNF for Children"], "pregnancy": "avoid\u2014teratogenic; effective contraception must be\r\nused\u2014see Cautions above", "breast-feeding": "avoid"}, "MEMANTINE": {"interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  warfarin possibly enhanced by memantine ", "name": "Memantine", "backrefs": ["Memantine", "Dantrolene", "Dopaminergics", "Ketamine"]}}, "CARNITINE": {"indications": "primary and secondarycarnitinedeficiency", "name": "CARNITINE", "renal impairment": "accumulation of metabolites may occur with chronic oral\r\nadministration in severe impairment", "cautions": "diabetes mellitus; monitoring of free and acylcarnitinein blood\r\nand urine recommended", "side-effects": "nausea, vomiting, abdominal pain, diarrhoea, body\r\nodour; side-effects may be dose-related\u2014monitor tolerance during first\r\nweek and after any dose increase", "doses": ["Primary deficiency,by mouth, up to 200\u00a0mg/kg\r\ndaily in 2\u20134 divided doses; usual max. 3\u00a0g daily;by intravenous\r\ninjectionover 2\u20133 minutes, up to 100\u00a0mg/kg daily in 2\u20134 divided doses", "Secondary deficiency,by intravenous injectionover 2\u20133 minutes, 20\u00a0mg/kg after each dialysis session (dosage adjusted\r\naccording to plasma-carnitineconcentration); maintenance\r\n(if benefit gained from first intravenous course),by mouth, 1\u00a0g daily"], "pregnancy": "appropriate to use; no evidence of teratogenicity\r\ninanimalstudies"}, "RALTITREXED": {"indications": "seenotes above", "name": "RALTITREXED", "renal impairment": "reduce dose and increase dosing interval if creatinine\r\nclearance less than 65\u00a0mL/minute (consult product literature); avoid\r\nif creatinine clearance less than 25\u00a0mL/minute", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  folates advised by manufacturer of raltitrexed ", "name": "Raltitrexed", "backrefs": ["Raltitrexed", "Folates"]}, "cautions": "seesection 8.1andnotes above;interactions: Appendix 1 (raltitrexed)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "caution in mild to moderate impairment; avoid if severe", "doses": ["SeeDoses"], "pregnancy": "pregnancy must be excluded before treatment; ensure\r\neffective contraception during and for at least 6 months after treatment\r\nin men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "AMIODARONE": {"interactions": {"extra": "Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped", "bad": 0, "interaction": "possible increased risk of ventricular arrhythmias when  sulfamethoxazole (as co-trimoxazole) given with amiodarone\u2014manufacturer of amiodarone advises avoid concomitant use of co-trimoxazole", "name": "Amiodarone", "backrefs": ["Amiodarone"]}}, "DICLOFENAC": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  methotrexate reduced by diclofenac (increased risk of toxicity)\u2014but for concomitant use in rheumatic disease see Methotrexate, section 10.1.3", "name": "Diclofenac", "backrefs": ["Diclofenac"]}}, "CARBIMAZOLE": {"indications": "hyperthyroidism", "name": "CARBIMAZOLE", "side-effects": "nausea, mild gastro-intestinal disturbances, taste\r\ndisturbance, headache, fever, malaise, rash, pruritus, arthralgia;rarelymyopathy, alopecia, bone marrow suppression (including\r\npancytopenia and agranulocytosis, see Neutropenia and Agranulocytosis\r\nabove), and jaundice", "contra-indications": "severe blood disorders", "hepatic impairment": "use with caution in mild to moderate impairment; avoid\r\nin severe impairment", "doses": ["See notes above"], "pregnancy": "neonatal goitre and hypothyroidism; has been associated\r\nwith congenital defects including aplasia cutis of the neonate; see\r\nalsonotes above", "breast-feeding": "amount in milk may be sufficient to affect neonatal\r\nthyroid function therefore lowest effective dose should be used; see\r\nalsonotes above"}, "PEMETREXED": {"indications": "seenotes above", "name": "PEMETREXED", "renal impairment": "manufacturer advises avoid if creatinine clearance less\r\nthan 45\u00a0mL/minute\u2014no information available", "interactions": {"extra": "", "bad": 1, "interaction": " pyrimethamine increases antifolate effect of pemetrexed ", "name": "Pemetrexed", "backrefs": ["Pemetrexed"]}, "cautions": "seesection 8.1andnotes above; history of cardiovascular disease; diabetes; prophylactic folic acid and\r\nvitamin B12supplementation required (consult product literature); concomitant nephrotoxic drugs including non-steroidal\r\nanti-inflammatory drugs (consult product literature);interactions:Appendix 1 (pemetrexed)", "side-effects": "seesection 8.1; also gastro-intestinal disturbances;\r\noedema; neuropathy; dehydration; conjunctivitis, increased lacrimation;\r\nskin disorders;less commonlycolitis, arrhythmias,\r\nand interstitial pneumonitis;rarelyhepatitis; peripheral\r\nischaemia, acute renal failure, Stevens-Johnson syndrome and toxic\r\nepidermal necrolysis also reported", "doses": ["SeeDoses"], "pregnancy": "avoid (toxicity inanimalstudies);\r\nmanufacturer advises effective contraception during treatment; men\r\nmust avoid fathering a child during and for 6 months after treatment;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CHLORAL": {"interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  coumarins may transiently be enhanced by chloral ", "name": "Chloral", "backrefs": ["Chloral"]}}, "DICLOFENAC POTASSIUM": {"indications": "pain and inflammation in rheumatic\r\ndisease and other musculoskeletal disorders; acute gout; postoperative\r\npain; migraine; fever in ear, nose, or throat infection in children", "name": "DICLOFENAC POTASSIUM", "renal impairment": "avoid in severe impairment; see alsonotes above", "cautions": "seenotes above; avoid in acute porphyria (section 9.8.2)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Rheumatic disease, musculoskeletal disorders, acute gout,\r\n75\u2013150\u00a0mg daily in 2\u20133 divided doses;childover 14 years, 75\u2013100\u00a0mg daily in 2\u20133 divided doses", "Postoperative pain, 75\u2013150\u00a0mg daily in 2\u20133 divided doses;child9\u201314 years (body-weight 35\u00a0kg and over), up\r\nto 2\u00a0mg/kg (max. 100\u00a0mg) daily in 3 divided doses;childover 14 years, 75\u2013100\u00a0mg daily in 2\u20133 divided\r\ndoses", "Migraine, 50\u00a0mg at onset, repeated after 2 hours if necessary\r\nthen after 4\u20136 hours; max. 200\u00a0mg in 24 hours;childnot recommended", "Fever in ear, nose, or throat infection,childover 9 years (body-weight 35\u00a0kg and over), up to 2\u00a0mg/kg (max. 100\u00a0mg)\r\ndaily in 3 divided doses"], "pregnancy": "seenotes above", "breast-feeding": "amount in milk too small to be harmful; see\r\nalsonotes above"}, "HYDROXYCHLOROQUINE SULPHATE": {"indications": "active rheumatoid arthritis (including juvenile idiopathic arthritis),\r\nsystemic and discoid lupus erythematosus; dermatological conditions\r\ncaused or aggravated by sunlight", "name": "HYDROXYCHLOROQUINE SULPHATE", "renal impairment": "manufacturer advises caution and monitoring of plasma-hydroxychloroquine\r\nconcentration in severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nreported bronchospasm", "hepatic impairment": "seenotes above", "doses": ["Administered on expert advice, 200\u2013400\u00a0mg daily (but not\r\nexceeding 6.5\u00a0mg/kg daily based on ideal body-weight, see also recommendations\r\nabove);child1 month\u201318 years seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "avoid\u2014risk of toxicity in infant; see alsonotes above"}, "CLOBAZAM": {"indications": "adjunct in\r\nepilepsy; anxiety (short-term use)", "name": "CLOBAZAM", "renal impairment": "see Benzodiazepines,section 4.1.2", "interactions": {"extra": "", "bad": 0, "interaction": " stiripentol increases plasma concentration of clobazam ", "name": "Clobazam", "backrefs": ["Valproate", "Stiripentol", "Clobazam"]}, "cautions": "seeDiazepam,section\r\n4.1.2", "side-effects": "seeDiazepam,section\r\n4.1.2", "contra-indications": "seeDiazepam,section\r\n4.1.2", "hepatic impairment": "see Benzodiazepines,section 4.1.2", "doses": ["Epilepsy, 20\u201330\u00a0mg daily, increased if necessary to max.\r\n60\u00a0mg daily;childover 3 years, not\r\nmore than half adult dose", "Anxiety, 20\u201330\u00a0mg daily in divided doses or as a single dose\r\nat bedtime, increased in severe anxiety (in hospital patients) to\r\na max. of 60\u00a0mg daily in divided doses;elderly(or debilitated) 10\u201320\u00a0mg daily"], "pregnancy": "seePregnancy;\r\nin late pregnancy may cause neonatal hypothermia, hypotonia, respiratory\r\ndepression, and withdrawal", "breast-feeding": "see Benzodiazepines,section 4.1.2"}, "MOEXIPRIL HYDROCHLORIDE": {"indications": "essential hypertension", "name": "MOEXIPRIL HYDROCHLORIDE", "renal impairment": "seenotes above; if eGFR\r\nless than 40\u00a0mL/minute/1.73\u00a0m2, initial dose 3.75\u00a0mg once\r\ndaily titrated to max. 15\u00a0mg once daily", "cautions": "seenotes above", "side-effects": "see notes above; arrhythmias, angina, chest pain,\r\nsyncope, cerebrovascular accident, myocardial infarction; appetite\r\nand weight changes; dry mouth, photosensitivity, flushing, nervousness,\r\nmood changes, anxiety, drowsiness, sleep disturbance, tinnitus, influenza-like\r\nsyndrome, sweating and dyspnoea", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; initial\r\ndose 3.75\u00a0mg once daily in hepatic cirrhosis", "doses": ["Monotherapy, initially 7.5\u00a0mg once daily adjusted according\r\nto response; usual range 7.5\u201315\u00a0mg once daily (max. 30\u00a0mg once daily);\r\nif used in addition to diuretic (see notes above),\r\nwithnifedipineor other antihypertensive drug,\r\nor in elderly, initially 3.75\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "SYMPATHOMIMETICS, BETA2": {"interactions": {"extra": "", "bad": 0, "interaction": "increased risk of hypokalaemia when  corticosteroids given with high doses of beta2 sympathomimetics\u2014see Hypokalaemia, section 3.1.1.1", "name": "Sympathomimetics, Beta2", "backrefs": []}}, "THIOPENTAL SODIUM": {"indications": "induction of general anaesthesia; anaesthesia of short duration;\r\nreduction of raised intracranial pressure if ventilation controlled;\r\nstatus epilepticus (see alsosection 4.8.2)", "name": "THIOPENTAL SODIUM", "renal impairment": "caution in severe impairment", "cautions": "seenotes above; cardiovascular disease; reconstituted\r\nsolution is highly alkaline\u2014extravasation causes tissue necrosis and\r\nsevere pain; avoid intra-arterial injection;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "hypotension, arrhythmias, myocardial depression,\r\nlaryngeal spasm, cough, headache, sneezing, hypersensitivity reactions,\r\nrash", "contra-indications": "seenotes above; acute porphyria (section 9.8.2); myotonic dystrophy", "hepatic impairment": "use with caution\u2014reduce dose", "doses": ["Induction of general anaesthesia,by slow intravenous\r\ninjectionusually as a 2.5% (25\u00a0mg/mL) solution,adultover 18 years, fit and premedicated, initially\r\n100\u2013150\u00a0mg (reduced in elderly or debilitated) over 10\u201315 seconds\r\n(longer in elderly or debilitated), followed by further quantity if\r\nnecessary according to response after 30\u201360 seconds;orup to 4\u00a0mg/kg (max. 500\u00a0mg);child1 month\u201318 years, initially up to 4\u00a0mg/kg,then1\u00a0mg/kg repeated as necessary (max. total dose 7\u00a0mg/kg)", "Raised intracranial pressure,by slow intravenous injection, 1.5\u20133\u00a0mg/kg, repeated as required", "Status epilepticus (only if other measures fail, seesection 4.8.2),by slow intravenous injectionas a 2.5% (25\u00a0mg/mL) solution,adultover 18 years, 75\u2013125\u00a0mg as a single dose;child1 month\u201318 years, initially up to 4\u00a0mg/kgby slow intravenous injection,thenup to\r\n8\u00a0mg/kg/hourby continuous intravenous infusion, adjusted\r\naccording to response"], "pregnancy": "may depress neonatal respiration if used during delivery;\r\ndose should not exceed 250\u00a0mg", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "POTASSIUM CANRENOATE": {"interactions": {"extra": "", "bad": 0, "interaction": " NSAIDs possibly antagonise diuretic effect of potassium canrenoate ", "name": "Potassium Canrenoate", "backrefs": ["Potassium Canrenoate"]}}, "VERAPAMIL": {"interactions": {"extra": "", "bad": 0, "interaction": "neurotoxicity may occur when  lithium given with verapamil without increased plasma concentration of lithium", "name": "Verapamil", "backrefs": ["Verapamil"]}}, "ERGOT ALKALOIDS": {"interactions": {"extra": "", "bad": 1, "interaction": " ticagrelor possibly increases plasma concentration of ergot alkaloids ", "name": "Ergot Alkaloids", "backrefs": ["Ergot Alkaloids"]}}, "ESMOLOL HYDROCHLORIDE": {"indications": "short-term treatment of supraventricular\r\narrhythmias (including atrial fibrillation, atrial flutter, sinus\r\ntachycardia); tachycardia and hypertension in peri-operative period", "name": "ESMOLOL HYDROCHLORIDE", "renal impairment": "manufacturer advises caution", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride; also on infusion venous irritation and thrombophlebitis", "contra-indications": "see underPropranolol Hydrochloride", "doses": ["By intravenous infusion, usually within\r\nrange 50\u2013200\u00a0micrograms/kg/minute (consult product literature for\r\ndetails of dose titration and doses during peri-operative period)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PHENOL": {"side-effects": "irritation, tissue necrosis", "indications": "see notes above", "name": "PHENOL", "doses": ["2\u20133\u00a0mL into the submucosal layer at the base of the pile;\r\nseveral injections may be given at different sites, max. total injected\r\n10\u00a0mL at any one time"]}, "ITRACONAZOLE": {"indications": "see under Dose", "name": "ITRACONAZOLE", "renal impairment": "risk of congestive heart failure; bioavailability of\r\noral formulations possibly reduced; use intravenous infusion with\r\ncaution if eGFR 30\u201380\u00a0mL/minute/1.73\u00a0m2; avoid intravenous\r\ninfusion if eGFR less than 30\u00a0mL/minute/1.73m2", "interactions": {"extra": "", "bad": 0, "interaction": " nevirapine possibly reduces plasma concentration of itraconazole\u2014consider increasing dose of itraconazole", "name": "Itraconazole", "backrefs": ["Cyclophosphamide", "Aliskiren", "Mizolastine", "Histamine H2-antagonists", "Methylprednisolone", "Proton Pump Inhibitors", "Vinorelbine", "Busulfan", "Itraconazole", "Sirolimus", "Felodipine", "Calcium-channel Blockers (dihydropyridines)", "Vincristine", "Micafungin"]}, "cautions": "absorption\r\nreduced in HIV-infection and neutropenia (monitor plasma-itraconazoleconcentration and increase dose if necessary); susceptibility to congestive heart failure (see also\r\nHeart Failure, below);interactions:Appendix 1 (antifungals,\r\ntriazole)", "side-effects": "nausea, abdominal pain, rash;less commonlyvomiting, dyspepsia, taste disturbances, flatulence, diarrhoea,\r\nconstipation, oedema, headache, dizziness, paraesthesia (discontinue\r\ntreatment if neuropathy), menstrual disorder, and alopecia;rarelypancreatitis, dyspnoea, hypoaesthesia, urinary frequency,\r\nleucopenia, visual disturbances, and tinnitus; also reported, heart\r\nfailure (see Cautions above), hypertriglyceridaemia, hepatitis (see\r\nHepatotoxicity above), erectile dysfunction, thrombocytopenia,\r\nhypokalaemia, myalgia, arthralgia, photosensitivity, toxic epidermal\r\nnecrolysis, and Stevens\u2013Johnson syndrome;with intravenous\r\ninjectionhypertension and hyperglycaemia", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "use only if potential benefit outweighs risk of hepatotoxicity\r\n(see Hepatotoxicity above); dose reduction may be necessary", "doses": ["oral or oesophageal candidiasis in HIV-positive or other\r\nimmunocompromised patients, 20\u00a0mL (2 measuring cups) daily in 1\u20132\r\ndivided doses for 1 week (continue for another week if no response)"], "pregnancy": "manufacturer advises use only in life-threatening\r\nsituations (toxicity at high doses inanimalstudies);\r\nensure effective contraception during treatment and until the next\r\nmenstrual period following end of treatment", "breast-feeding": "small amounts present in milk\u2014may accumulate;\r\nmanufacturer advises avoid"}, "NEBIVOLOL": {"indications": "essential hypertension; adjunct in stable\r\nmild to moderate heart failure in patients over 70 years", "name": "NEBIVOLOL", "renal impairment": "forhypertension, initially 2.5\u00a0mg once\r\ndaily, increased to 5\u00a0mg once daily if required; forheart\r\nfailure, manufacturer advises avoid if serum creatinine greater\r\nthan 250\u00a0micromol/litre", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride; also oedema and depression", "contra-indications": "see underPropranolol Hydrochloride; also acute or decompensated heart failure requiring intravenous inotropes", "hepatic impairment": "no information available\u2014manufacturer advises avoid", "doses": ["Hypertension, 5\u00a0mg daily;elderlyinitially 2.5\u00a0mg daily, increased if necessary to 5\u00a0mg daily", "Adjunct in heart failure (section 2.5.5), initially 1.25\u00a0mg once daily, then if tolerated increased\r\nat intervals of 1\u20132 weeks to 2.5\u00a0mg once daily, then to 5\u00a0mg once\r\ndaily, then to max. 10\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ULIPRISTAL ACETATE": {"indications": "emergency contraception", "name": "ULIPRISTAL ACETATE", "cautions": "seenotes above; uncontrolled severe\r\nasthma; effectiveness of combined hormonal and progestogen-only\r\ncontraceptives may be reduced\u2014additional precautions (barrier methods)\r\nrequired for 14 days for combined and parenteral progestogen-only\r\nhormonal contraceptives and 9 days for oral progestogen-only contraceptives\r\n(16 days forQlaira\u00ae);interactions:seenotes aboveand\r\nAppendix 1 (ulipristal)", "side-effects": "gastro-intestinal disturbances (including nausea,\r\nvomiting, diarrhoea, and abdominal pain); dizziness, fatigue, headache;\r\nmenstrual irregularities (seenotes above); back\r\npain, muscle spasms;less commonlytremor, hot flushes,\r\nuterine spasm, breast tenderness, dry mouth, blurred vision, pruritus,\r\nand rash", "contra-indications": "repeated use within a menstrual cycle", "hepatic impairment": "manufacturer advises avoid in severe impairment\u2014no\r\ninformation available", "doses": ["30\u00a0mg as a single dose as soon as possible after coitus,\r\nbut no later than after 120 hours"], "pregnancy": "limited information available", "breast-feeding": "manufacturer advises avoid for at least 36 hours\u2014no\r\ninformation available"}, "MOMETASONE FUROATE": {"side-effects": "seenotes above", "indications": "see preparations", "name": "MOMETASONE FUROATE", "cautions": "seenotes above", "doses": ["prophylaxis and treatment of allergic rhinitis,adultandchildover\r\n12 years, 100\u00a0micrograms (2 sprays) into each nostril once daily,\r\nincreased if necessary to max. 200\u00a0micrograms (4 sprays) into each\r\nnostril once daily; when control achieved reduce to 50\u00a0micrograms\r\n(1 spray) into each nostril once daily;child6\u201312 years, 50\u00a0micrograms (1 spray) into each nostril\r\nonce daily"]}, "NEOSTIGMINE METILSULFATE": {"indications": "see under Dose", "name": "NEOSTIGMINE METILSULFATE", "renal impairment": "section 10.2.1", "cautions": "section 10.2.1andnotes above; glycopyrronium or\r\natropine should also be given", "side-effects": "section 10.2.1and notes above", "contra-indications": "section 10.2.1and notes above", "doses": ["Reversal of non-depolarising neuromuscular blockade,by intravenous injectionover 1 minute,adultover 18 years, 2.5\u00a0mg repeated if necessary (max. 5\u00a0mg) after or\r\nwithglycopyrroniumoratropine;childunder 18 years seeBNF for Children", "Myasthenia gravis, seesection 10.2.1"], "pregnancy": "section 10.2.1", "breast-feeding": "section 10.2.1"}, "TIZANIDINE": {"indications": "spasticity associated with multiple sclerosis\r\nor spinal cord injury or disease", "name": "TIZANIDINE", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with tizanidine ", "name": "Tizanidine", "backrefs": ["Tizanidine"]}, "cautions": "elderly; monitor\r\nliver function monthly for first 4 months and in those who develop\r\nunexplained nausea, anorexia or fatigue; concomitant administration of drugs that prolong QT interval; avoid abrupt withdrawal (risk of rebound\r\nhypertension and tachycardia, see under Withdrawal, below);interactions:Appendix 1 (muscle relaxants)", "side-effects": "drowsiness, fatigue, dizziness, dry mouth, nausea,\r\ngastro-intestinal disturbances, hypotension; also reported, bradycardia,\r\ninsomnia, hallucinations and altered liver enzymes (discontinue if\r\npersistently raised\u2014consult product literature); rarely acute hepatitis", "hepatic impairment": "avoid in severe impairment", "doses": ["adultover 18 years, initially\r\n2\u00a0mg daily as a single dose increased according to response at intervals\r\nof at least 3\u20134 days in steps of 2\u00a0mg daily (and given in divided\r\ndoses) usually up to 24\u00a0mg daily in 3\u20134 divided doses; max. 36\u00a0mg\r\ndaily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available"}, "DISULFIRAM": {"indications": "seenotes above", "name": "DISULFIRAM", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 1, "interaction": "metabolism of  phenytoin inhibited by disulfiram (increased risk of toxicity)", "name": "Disulfiram", "backrefs": ["Disulfiram", "Tinidazole", "Paraldehyde", "Temazepam"]}, "cautions": "ensure thatalcoholnot consumed for at least 24 hours before initiating treatment; see alsonotes above;alcoholchallengenotrecommended on routine basis (if considered essential\u2014specialist units only with resuscitation\r\nfacilities); respiratory disease, diabetes mellitus, epilepsy; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (disulfiram)", "side-effects": "initially drowsiness and fatigue; nausea, vomiting,\r\nhalitosis, reduced libido;rarelypsychotic reactions\r\n(depression, paranoia, schizophrenia, mania), allergic dermatitis,\r\nperipheral neuritis, hepatic cell damage", "contra-indications": "cardiac failure, coronary artery disease, history of cerebrovascular\r\naccident, hypertension, psychosis, severe personality disorder, suicide risk", "hepatic impairment": "use with caution", "doses": ["200\u00a0mg daily increased if necessary; usual max. 500\u00a0mg\r\ndaily;childnot recommended"], "pregnancy": "high concentrations of acetaldehyde which occur in\r\npresence ofalcoholmay be teratogenic; avoid in\r\nfirst trimester", "breast-feeding": "avoid\u2014no information available"}, "ADRENALINE/EPINEPHRINE": {"indications": "see notes\r\nabove", "name": "ADRENALINE/EPINEPHRINE", "renal impairment": "manufacturers advise use with caution in severe impairment", "cautions": "ischaemic heart disease, severe angina, obstructive\r\ncardiomyopathy, hypertension, arrhythmias, cerebrovascular\r\ndisease, occlusive vascular disease, arteriosclerosis, monitor\r\nblood pressure and ECG; cor pulmonale; organic brain damage, psychoneurosis; diabetes mellitus, hyperthyroidism, phaeochromocytoma; prostate\r\ndisorders; hypokalaemia, hypercalcaemia; susceptibility to angle-closure\r\nglaucoma; elderly;interactions:Appendix 1 (sympathomimetics)", "side-effects": "nausea, vomiting, dry mouth, hypersalavation;\r\narrhythmias, syncope, angina, pallor, palpitation, cold extremities,\r\nhypertension (risk of cerebral haemorrhage); dyspnoea, pulmonary oedema\r\n(on excessive dosage or extreme sensitivity); anxiety, tremor, restlessness,\r\nheadache, weakness, dizziness, hallucinations; hyperglycaemia; urinary\r\nretention, difficulty in micturition; metabolic acidosis; hypokalaemia;\r\ntissue necrosis at injection site and of extremities, liver and kidneys;\r\nmydriasis, angle-closure glaucoma, and sweating", "doses": ["See notes above"], "pregnancy": "may reduce placental perfusion and can delay second\r\nstage of labour; manufacturers advise use only if benefit outweighs\r\nrisk", "breast-feeding": "present in milk but unlikely to be harmful as\r\npoor oral bioavailability"}, "ACIPIMOX": {"indications": "hyperlipidaemias of types IIb and IV in patients who have not responded\r\nadequately to diet and other appropriate measures", "name": "ACIPIMOX", "renal impairment": "reduce dose if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "side-effects": "vasodilatation, flushing, itching, rashes, urticaria,\r\nerythema; heartburn, epigastric pain, nausea, diarrhoea, headache,\r\nmalaise, dry eyes; rarely angioedema, bronchospasm, anaphylaxis", "contra-indications": "peptic ulcer", "doses": ["Usually 500\u2013750\u00a0mg daily in divided doses"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "manufacturer advises avoid"}, "LOTEPREDNOL ETABONATE": {"side-effects": "seenotes above", "indications": "treatment of post-operative inflammation\r\nfollowing ocular surgery", "name": "LOTEPREDNOL ETABONATE", "cautions": "seenotes above", "doses": ["Apply 4 times daily starting 24 hours after surgery; max.\r\nduration of treatment 14 days"]}, "PHENINDIONE": {"indications": "prophylaxis of embolisation in rheumatic heart disease and atrial\r\nfibrillation; prophylaxis after insertion of prosthetic heart valve;\r\nprophylaxis and treatment of venous thrombosis and pulmonary embolism", "name": "PHENINDIONE", "renal impairment": "seenotes above", "interactions": {"extra": "Change in patient\u2019s clinical condition particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control  ", "bad": 1, "interaction": " ritonavir possibly enhances anticoagulant effect of phenindione ", "name": "Phenindione", "backrefs": ["Testosterone", "Vitamin K (Phytomenadione)", "Anabolic Steroids", "Phenindione", "Testolactone"]}, "cautions": "see underWarfarin Sodium;interactions:Appendix 1 (phenindione)", "side-effects": "see underWarfarin Sodium;\r\nalso hypersensitivity reactions including exfoliative dermatitis,\r\nexanthema, fever, leucopenia, agranulocytosis, eosinophilia, and renal\r\ndamage; micro-adenopathy and urine coloured pink or orange", "contra-indications": "see underWarfarin Sodium", "hepatic impairment": "seenotes above", "doses": ["200\u00a0mg on day 1; 100\u00a0mg on day 2, then adjusted according\r\nto response; maintenance dose usually 50\u2013150\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "LATANOPROST": {"indications": "raised intra-ocular pressure in open-angle glaucoma; ocular hypertension", "name": "LATANOPROST", "cautions": "seenotes above; also history of herpetic keratitis (avoid in\r\nactive herpes simplex keratitis); cataract\r\nsurgery", "side-effects": "seenotes above;also reportedherpetic keratitis, iris cyst", "doses": ["Apply once daily, preferably in the evening"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "may be present in milk\u2014manufacturer advises\r\navoid"}, "ATOVAQUONE": {"indications": "treatment of mild to moderatePneumocystis jirovecii (Pneumocystis carinii)pneumonia\r\nin patients intolerant ofco-trimoxazole", "name": "ATOVAQUONE", "renal impairment": "manufacturer advises caution\u2014monitor more closely", "interactions": {"extra": "", "bad": 0, "interaction": "metabolism of  zidovudine possibly inhibited by atovaquone (increased plasma concentration)", "name": "Atovaquone", "backrefs": ["Atovaquone"]}, "cautions": "initial diarrhoea and difficulty in taking with food may reduce absorption\r\n(and require alternative therapy); other causes of pulmonary\r\ndisease should be sought and treated; elderly;interactions:Appendix 1 (atovaquone)", "side-effects": "nausea, diarrhoea, vomiting; headache, insomnia;\r\nfever; anaemia, neutropenia, hyponatraemia; rash, pruritus; also reported,\r\nStevens-Johnson syndrome", "hepatic impairment": "manufacturer advises caution\u2014monitor more closely", "doses": ["750\u00a0mg twice daily with food (particularly high fat) for\r\n21 days;childnot recommended"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid"}, "LIDOCAINE": {"interactions": {"extra": "Interactions less likely when lidocaine used topically", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  saquinavir given with lidocaine\u2014avoid concomitant use", "name": "Lidocaine", "backrefs": ["Lidocaine"]}}, "IMIQUIMOD": {"indications": "see under Dose", "name": "IMIQUIMOD", "cautions": "avoid normal or broken skin, and open wounds; not suitable for internal genital\r\nwarts; uncircumcised males (risk of phimosis\r\nor stricture of foreskin); autoimmune disease; immunosuppressed patients", "side-effects": "local reactions (including itching, burning sensation,\r\nerythema, erosion, oedema, excoriation, and scabbing); headache; influenza-like\r\nsymptoms; myalgia;less commonlylocal ulceration\r\nand alopecia;rarelyStevens-Johnson syndrome and\r\ncutaneous lupus erythematosus-like effect;very rarelydysuria in women; permanent hypopigmentation or hyperpigmentation\r\nreported", "doses": ["Warts (external genital and perianal), apply thinly 3\r\ntimes a week at night until lesions resolve (max. 16 weeks)", "Superficial basal cell carcinoma, apply to lesion (and 1\u00a0cm\r\nbeyond it) on 5 days each week for 6 weeks; assess response 12 weeks\r\nafter completing treatment", "Actinic keratosis, apply to lesion 3 times a week for 4 weeks;\r\nassess response after a 4 week treatment-free interval; repeat 4-week\r\ncourse if lesions persist; max. 2 courses", "childunder 18 years\r\nseeBNF for Children", "Should be rubbed in and allowed to stay\r\non the treated area for 6\u201310 hours for warts or for 8 hours for basal\r\ncell carcinoma and actinic keratosis, then washed off with mild soap\r\nand water (uncircumcised males treating warts under foreskin should\r\nwash the area daily). The cream should be washed off before sexual\r\ncontact"], "pregnancy": "no evidence of teratogenicity or toxicity inanimalstudies; manufacturer advises caution", "breast-feeding": "no information available"}, "PREDNISONE": {"indications": "moderate to severe rheumatoid arthritis\r\n(section 10.1.2.1)", "name": "PREDNISONE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["adultover 18 years, initially\r\n10\u201320\u00a0mg at bedtime, adjusted according to response"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "TIOGUANINE": {"indications": "seenotes above", "name": "TIOGUANINE", "renal impairment": "reduce dose", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of hepatotoxicity when  busulfan given with tioguanine ", "name": "Tioguanine", "backrefs": ["Tioguanine"]}, "cautions": "seesection 8.1andnotes above; thiopurine methyltransferase status\r\n(seesection 8.2.1); monitor liver\r\nfunction weekly\u2014discontinue if liver toxicity develops;interactions:Appendix 1 (tioguanine)", "side-effects": "seesection 8.1; also stomatitis and hepatotoxicity;rarelyintestinal necrosis and perforation", "hepatic impairment": "reduce dose", "doses": ["100\u2013200\u00a0mg/m2daily"], "pregnancy": "avoid (teratogenicity reported when men receivingtioguaninehave fathered children); ensure effective contraception\r\nduring treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ZINC": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  ofloxacin reduced by zinc ", "name": "Zinc", "backrefs": ["Zinc"]}}, "PHENYTOIN SODIUM": {"indications": "status epilepticus; acute\r\nsymptomatic seizures associated with head trauma or neurosurgery", "name": "PHENYTOIN SODIUM", "cautions": "seenotes above;respiratory\r\ndepression; hypotension and heart failure; resuscitation facilities\r\nmust be available; injection solutions\r\nalkaline (irritant to tissues);see alsosection 4.8.1;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (phenytoin)", "side-effects": "intravenous injection may cause cardiovascular\r\nand CNS depression (particularly if injection too rapid) with arrhythmias,\r\nhypotension, and cardiovascular collapse; alterations in respiratory\r\nfunction (including respiratory arrest);also reportedtonic seizures, purple glove syndrome; see alsosection 4.8.1", "contra-indications": "sinus\r\nbradycardia, sino-atrial block,\r\nand second- and third-degree\r\nheart block; Stokes-Adams syndrome; acute porphyria (section 9.8.2)", "hepatic impairment": "see Phenytoin,section 4.8.1", "doses": ["By slow intravenous injectionorinfusion(with blood pressure and ECG\r\nmonitoring), 20\u00a0mg/kg (max. 2\u00a0g) at a rate not exceeding 1\u00a0mg/kg/minute\r\n(max. 50\u00a0mg per minute), as a loading dose (see alsonotes above); maintenance\r\ndoses of about 100\u00a0mg,by mouthorby intravenous\r\nadministration, should be given thereafter every 6\u20138 hours,\r\nadjusted according to plasma-phenytoin concentration;child1 month\u201312 years, 20\u00a0mg/kg at a rate not exceeding\r\n1\u00a0mg/kg/minute (max. 50\u00a0mg per minute) as a loading dose; maintenance\r\ndose of 5\u201310\u00a0mg/kg daily (max. 300\u00a0mg daily) in 2 divided doses;neonate20\u00a0mg/kg at a rate not exceeding 1\u00a0mg/kg/minute,\r\nas a loading dose; maintenance dose of 5\u201310\u00a0mg/kg daily in 2 divided\r\ndoses", "To avoid local venous irritation each injection\r\nor infusion should be preceded and followed by an injection of sterile\r\nphysiological saline through the same needle or catheter", "Phenytoin sodium doses in BNF may differ\r\nfrom those in product literature"], "pregnancy": "see Phenytoin,section 4.8.1, andPregnancy", "breast-feeding": "seeBreast-feeding"}, "CLOMIPRAMINE HYDROCHLORIDE": {"indications": "depressive illness, phobic and obsessional states; adjunctive treatment\r\nof cataplexy associated with narcolepsy", "name": "CLOMIPRAMINE HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nabdominal pain, diarrhoea, hypertension, flushing, restlessness, fatigue,\r\naggression, impaired memory, muscle weakness, muscle hypertonia, myoclonus,\r\nmydriasis, and yawning;very rarelyallergic alveolitis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["seeabove; to be taken once\r\ndaily"], "pregnancy": "neonatal withdrawal symptoms reported if used during\r\nthird trimester", "breast-feeding": "seenotes above"}, "ORPHENADRINE HYDROCHLORIDE": {"indications": "parkinsonism; drug-induced extrapyramidal\r\nsymptoms (but not tardive dyskinesia, seenotes above)", "name": "ORPHENADRINE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above;less commonlyseizures, drowsiness, insomnia, and impaired\r\ncoordination", "contra-indications": "seenotes above; also acute porphyria (section 9.8.2)", "hepatic impairment": "seenotes above", "doses": ["Initially 150\u00a0mg daily in divided doses, increased gradually\r\nin steps of 50\u00a0mg every 2\u20133 days according to response; usual dose\r\nrange 150\u2013300\u00a0mg daily in divided doses; max. 400\u00a0mg daily;elderlypreferably lower end of range"], "pregnancy": "caution", "breast-feeding": "caution"}, "TRIMIPRAMINE": {"indications": "depressive illness, particularly where sedation required", "name": "TRIMIPRAMINE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially 50\u201375\u00a0mg daily in divided dosesoras a single dose at bedtime, increased as necessary to 150\u2013300\u00a0mg\r\ndaily;elderlyinitially 10\u201325\u00a0mg 3\r\ntimes daily, maintenance half adult dose may be sufficient;childnot recommended"], "pregnancy": "use only if potential benefit outweighs\r\nrisk", "breast-feeding": "seenotes above"}, "APRACLONIDINE": {"indications": "control of intra-ocular pressure", "name": "APRACLONIDINE", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  MAOIs advised by manufacturer of apraclonidine ", "name": "Apraclonidine", "backrefs": ["Apraclonidine"]}, "cautions": "history of angina, severe coronary insufficiency, recent\r\nmyocardial infarction, heart failure, cerebrovascular disease, vasovagal attack, chronic renal failure; depression; monitor intra-ocular\r\npressure and visual fields; loss of effect\r\nmay occur over time; suspend treatment\r\nif reduction in vision occurs in end-stage glaucoma; monitor for excessive reduction in intra-ocular pressure following\r\nperi-operative use;interactions:Appendix\r\n1 (apraclonidine)", "side-effects": "dry mouth, taste disturbance; hyperaemia, ocular\r\npruritus, discomfort and lacrimation (withdraw if ocular intolerance\r\nincluding oedema of lids and conjunctiva); headache, asthenia, dry\r\nnose; lid retraction, conjunctival blanching and mydriasis reported\r\nafter peri-operative use; since absorption may follow topical application\r\nsystemic effects (seeClonidine,section 2.5.2) may occur", "contra-indications": "history of severe or unstable and uncontrolled\r\ncardiovascular disease", "doses": ["short-term adjunctive treatment of chronic glaucoma in\r\npatients not adequately controlled by another drug (see note below),\r\napply 1 drop 3 times daily usually for max. 1 month;childnot recommended"], "pregnancy": "manufacturer advises caution\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "DIURETICS, POTASSIUM-SPARING AND ALDOSTERONE ANTAGONISTS": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium reduced by potassium-sparing diuretics and aldosterone antagonists (increased plasma concentration and risk of toxicity)", "name": "Diuretics, Potassium-sparing and Aldosterone Antagonists", "backrefs": []}}, "CARBOPROST": {"indications": "postpartum\r\nhaemorrhage due to uterine atony in patients unresponsive to ergometrine\r\nandoxytocin", "name": "CARBOPROST", "renal impairment": "manufacturer advises avoid", "cautions": "history of glaucoma or\r\nraised intra-ocular pressure, asthma, hypertension, hypotension, anaemia, jaundice, diabetes, epilepsy; uterine scars; excessive dosage may cause uterine rupture;interactions:Appendix 1 (prostaglandins)", "side-effects": "nausea, vomiting and diarrhoea, hyperthermia and\r\nflushing, bronchospasm; less frequent effects include raised blood\r\npressure, dyspnoea, and pulmonary oedema; chills, headache, diaphoresis,\r\ndizziness; cardiovascular collapse also reported; erythema and pain\r\nat injection site reported", "contra-indications": "untreated pelvic infection; cardiac or pulmonary disease", "hepatic impairment": "manufacturer advises avoid", "doses": ["By deep intramuscular injection, 250\u00a0micrograms\r\nrepeated if necessary at intervals of not less than 15 minutes; total dose should not exceed 2\u00a0mg (8 doses)"]}, "PROPRANOLOL HYDROCHLORIDE": {"indications": "see under Dose", "name": "PROPRANOLOL HYDROCHLORIDE", "renal impairment": "manufacturer advises caution\u2014dose reduction may be required", "cautions": "seenotes above; also avoid abrupt\r\nwithdrawal especially in ischaemic heart disease; first-degree AV block; portal hypertension\r\n(risk of deterioration in liver function); diabetes; history of\r\nobstructive airways disease (introduce cautiously and monitor lung\r\nfunction\u2014seenotes above); myasthenia gravis; symptoms of hypoglycaemia and thyrotoxicosis may be masked (also see notes above); psoriasis; history of hypersensitivity\u2014may increase sensitivity\r\nto allergens and result in more serious hypersensitivity response, also may reduce response to adrenaline (epinephrine) (see alsosection 3.4.3);interactions:Appendix 1\r\n(beta-blockers),important:verapamil\r\ninteraction, see also  VERAPAMILsection 2.6.2", "side-effects": "see notes above; also gastro-intestinal disturbances;\r\nbradycardia, heart failure, hypotension, conduction disorders, peripheral\r\nvasoconstriction (including exacerbation of intermittent claudication\r\nand Raynaud\u2019s phenomenon); bronchospasm (see above), dyspnoea; headache,\r\nfatigue, sleep disturbances, paraesthesia, dizziness, vertigo, psychoses;\r\nsexual dysfunction; purpura, thrombocytopenia; visual disturbances;\r\nexacerbation of psoriasis, alopecia;rarelyrashes\r\nand dry eyes (reversible on withdrawal);overdosage:seeEmergency Treatment of Poisoning", "contra-indications": "asthma (but seenotes above), uncontrolled heart failure, Prinzmetal\u2019s angina, marked bradycardia, hypotension, sick sinus syndrome, second- or third- degree AV block, cardiogenic shock, metabolic acidosis, severe peripheral\r\narterial disease; phaeochromocytoma (apart from specific\r\nuse with alpha-blockers, see alsonotes above)", "hepatic impairment": "reduce oral dose", "doses": ["By mouth, hypertension, initially\r\n80\u00a0mg twice daily, increased at weekly intervals as required; maintenance\r\n160\u2013320\u00a0mg daily", "Prophylaxis of variceal bleeding in portal hypertension, initially\r\n40\u00a0mg twice daily, increased to 80\u00a0mg twice daily according to heart\r\nrate; max. 160\u00a0mg twice daily", "Phaeochromocytoma (only with an alpha-blocker), 60\u00a0mg daily\r\nfor 3\u00a0days before surgeryor30\u00a0mg daily in patients\r\nunsuitable for surgery", "Angina, initially 40\u00a0mg 2\u20133\u00a0times daily; maintenance 120\u2013240\u00a0mg\r\ndaily", "Arrhythmias, hypertrophic cardiomyopathy, anxiety tachycardia,\r\nand thyrotoxicosis (adjunct), 10\u201340\u00a0mg 3\u20134\u00a0times daily", "Anxiety with symptoms such as palpitation, sweating, tremor,\r\n40\u00a0mg once daily, increased to 40\u00a0mg 3 times daily if necessary", "Prophylaxis after myocardial infarction, 40\u00a0mg 4 times daily\r\nfor 2\u20133 days, then 80\u00a0mg twice daily, beginning 5 to 21 days after\r\ninfarction", "Essential tremor, initially 40\u00a0mg 2\u20133\u00a0times daily; maintenance\r\n80\u2013160\u00a0mg daily", "Migraine prophylaxis, 80\u2013240\u00a0mg daily in divided doses", "By intravenous injection, arrhythmias\r\nand thyrotoxic crisis, 1\u00a0mg over 1 minute; if necessary repeat at\r\n2-minute intervals; max. total dose 10\u00a0mg (5\u00a0mg in anaesthesia)", "Excessive bradycardia can be countered withintravenous injectionofatropine sulphate0.6\u20132.4\u00a0mg in divided doses of 600\u00a0micrograms; foroverdosageseeEmergency Treatment of Poisoning"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "FLECAINIDE": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of flecainide (increased risk of ventricular arrhythmias\u2014avoid concomitant use)", "name": "Flecainide", "backrefs": ["Flecainide"]}}, "ADAPALENE": {"indications": "mild to moderate acne", "name": "ADAPALENE", "cautions": "seenotes above", "side-effects": "see notes above", "doses": ["adultandchildover 12 years, apply thinly once daily in the\r\nevening"], "pregnancy": "seenotes above", "breast-feeding": "amount of drug in milk probably too small to\r\nbe harmful; ensure infant does not come in contact with treated areas"}, "PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES": {"indications": "contraception, see also notes above and under\r\npreparations (roles vary according to preparation)", "name": "PARENTERAL PROGESTOGEN-ONLY CONTRACEPTIVES", "cautions": "seenotes aboveand under\r\npreparations; possible risk of breast cancer, seeoral progestogen-only contraceptives(section 7.3.2.1); history during pregnancy\r\nof pruritus or of deterioration of otosclerosis, disturbances\r\nof lipid metabolism;interactions:seenotes aboveand Appendix\r\n1 (progestogens)", "side-effects": "seenotes above; injection-site\r\nreactions", "contra-indications": "seenotes above; history of breast cancer but can be used after 5 years if no evidence\r\nof disease and non-hormonal contraceptive methods unacceptable", "hepatic impairment": "see Oral Progestogen-only Contraceptives,section 7.3.2.1", "doses": ["See under preparations"], "pregnancy": "not known to be harmful; forImplanon\u00ae orNexplanon\u00ae if pregnancy occurs remove implant", "breast-feeding": "progestogen-only contraceptives do not affect\r\nlactation; see alsonotes aboveand under\r\npreparations"}, "MAGNESIUM SULPHATE": {"indications": "see notes above; constipation (section 1.6.4); severe acute asthma (section 3.1); paste for boils (section 13.10.5)", "name": "MAGNESIUM SULPHATE", "renal impairment": "avoid or reduce dose; increased risk of toxicity", "cautions": "seenotes above; in severe hypomagnesaemia\r\nadminister initially via controlled infusion device (preferably syringe\r\npump); monitor blood pressure, respiratory\r\nrate, urinary output and for signs of overdosage (loss\r\nof patellar reflexes, weakness, nausea, sensation of warmth, flushing,\r\ndrowsiness, double vision, and slurred speech);interactions:Appendix 1 (magnesium,\r\nparenteral)", "side-effects": "generally associated with hypermagnesaemia, nausea,\r\nvomiting, thirst, flushing of skin, hypotension, arrhythmias, coma,\r\nrespiratory depression, drowsiness, confusion, loss of tendon reflexes,\r\nmuscle weakness; colic and diarrhoea following oral administration", "hepatic impairment": "avoid in hepatic coma if risk of renal failure", "doses": ["Hypomagnesaemia, seenotes above", "Arrhythmias, seenotes above", "Prevention of seizures in pre-eclampsia [unlicensed indication],\r\ninitiallyby intravenous injectionover 5\u201315 minutes,\r\n4\u00a0g followedby intravenous infusion, 1\u00a0g/hour for\r\n24 hours; if seizure occurs, additional doseby intravenous\r\ninjection, 2\u00a0g", "Treatment of seizures and prevention of seizure recurrence in\r\neclampsia, initiallyby intravenous injectionover\r\n5\u201315 minutes, 4\u00a0g, followedby intravenous infusion, 1\u00a0g/hour for 24 hours after seizure or delivery, whichever is later;\r\nif seizure recurs, increase the infusion rate to 1.5\u20132\u00a0g/hour or give\r\nan additional doseby intravenous injection, 2\u00a0g", "For intravenous injection,\r\nconcentration of magnesium sulphate heptahydrate should not exceed\r\n20% (dilute 1 part of magnesium sulphate injection 50% with at least\r\n1.5 parts of water for injections)", "Magnesium sulphate heptahydrate 1\u00a0g equivalent\r\nto Mg2+approx. 4\u00a0mmol"], "pregnancy": "not known to be harmful for short-term intravenous\r\nadministration in eclampsia, but excessive doses in third trimester\r\ncause neonatal respiratory depression"}, "RITUXIMAB": {"indications": "see notes above; severe active rheumatoid arthritis\r\n(section 10.1.3)", "name": "RITUXIMAB", "cautions": "see notes above\u2014for full details consult product literature", "side-effects": "see notes above\u2014but for full details (including\r\nmonitoring and management of side-effects) consult product literature", "doses": ["SeeDoses"], "pregnancy": "avoid unless potential benefit to mother outweighs\r\nrisk of B-lymphocyte depletion in fetus\u2014effective contraception required\r\nduring and for 12 months after treatment", "breast-feeding": "avoid breast-feeding during and for 12 months\r\nafter treatment"}, "SODIUM FEREDETATE": {"side-effects": "seenotes above", "indications": "iron-deficiency anaemia", "name": "SODIUM FEREDETATE", "cautions": "interactions:Appendix 1 (iron)", "doses": ["therapeutic, 5\u00a0mL increasing gradually to 10\u00a0mL 3 times\r\ndaily;childunder 1 year, seeBNF for Children;child1\u20135 years, therapeutic, 2.5\u00a0mL 3 times daily,\r\n6\u201312 years, therapeutic, 5\u00a0mL 3 times daily"]}, "SITAGLIPTIN WITH METFORMIN": {"indications": "type 2 diabetes mellitus not controlled\r\nby metformin aloneorby metformin in combination\r\nwith either a sulfonylureaorpioglitazoneorinsulin", "name": "SITAGLIPTIN WITH METFORMIN", "renal impairment": "see under Cautions", "cautions": "determine renal function before treatment\r\nand at least annually (at least twice a year in patients with additional\r\nrisk factors for renal impairment, or if deterioration suspected); discontinue if symptoms of acute pancreatitis (persistent,\r\nsevere abdominal pain);interactions:Appendix 1 (antidiabetics)", "side-effects": "gastro-intestinal disturbances (including nausea,\r\nvomiting, abdominal pain, flatulence, diarrhoea (usually transient),\r\nconstipation), taste disturbance, anorexia; peripheral oedema, upper\r\nrespiratory tract infection, nasopharyngitis; pain;less commonlydry mouth, headache, drowsiness, dizziness, hypoglycaemia, osteoarthritis;very rarelylactic acidosis (withdraw treatment), decreased\r\nvitamin-B12absorption, erythema, pruritus, and urticaria;also reportedpancreatitis, hepatitis, rash, cutaneous vasculitis,\r\nand Stevens-Johnson syndrome", "contra-indications": "ketoacidosis, see\r\nalso Lactic Acidosis above; use of general anaesthesia\r\n(suspend treatment on the morning of surgery and restart when renal\r\nfunction returns to baseline)", "hepatic impairment": "withdraw if tissue hypoxia likely", "doses": ["adultover 18 years, 1\r\ntablet twice daily", "Dose of concomitant sulfonylurea or insulin\r\nmay need to be reduced"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "STATINS": {"interactions": {"extra": "", "bad": 1, "interaction": "risk of myopathy and rhabdomyolysis when  fusidic acid given with statins\u2014avoid concomitant use and for 7 days after last fusidic acid dose", "name": "Statins", "backrefs": ["Gemfibrozil", "Daptomycin", "Statins", "Nicotinic Acid"]}}, "OXYTOCIN": {"indications": "see under Dose and notes above", "name": "OXYTOCIN", "interactions": {"extra": "", "bad": 0, "interaction": "oxytocic effect possibly reduced, also enhanced hypotensive effect and risk of arrhythmias when  volatile liquid general anaesthetics given with oxytocin ", "name": "Oxytocin", "backrefs": ["Prostaglandins", "Oxytocin"]}, "cautions": "induction or enhancement of labour\u2014presence of borderline\r\ncephalopelvic disproportion (avoid if significant), secondary\r\nuterine inertia, mild or moderate pregnancy-induced\r\nhypertension or cardiac disease, women over 35 years or with history\r\nof lower-uterine segment caesarean section (see also under Contra-indications\r\nbelow); risk factors for disseminated intravascular coagulation; monitor for disseminated intravascular coagulation\r\nafter parturition; avoid large infusion volumes and\r\nrestrict fluid intake by mouth (risk of hyponatraemia and water-intoxication\u2014see\r\nalsoAppendix 4); effects\r\nenhanced by concomitant prostaglandins (very careful\r\nmonitoring of uterine activity); caudal block anaesthesia\r\n(may enhance hypertensive effects of sympathomimetic vasopressors); see alsointeractions:Appendix 1 (oxytocin)", "side-effects": "nausea, vomiting; arrhythmia; headache;rarelydisseminated intravascular coagulation, rash, and\r\nanaphylactoid reactions (with dyspnoea, hypotension, or shock); uterine\r\nspasm (may occur at low doses), uterine hyperstimulation (usually\r\nwith excessive doses\u2014may cause fetal distress, asphyxia, and death,\r\nor may lead to hypertonicity, tetanic contractions, soft-tissue damage\r\nor uterine rupture); water intoxication and hyponatraemia associated\r\nwith high doses with large infusion volumes of electrolyte-free fluid\r\n(see also under Dose below); placental abruption and amniotic fluid\r\nembolism also reported on overdose", "contra-indications": "hypertonic uterine contractions, fetal distress; any condition where spontaneous\r\nlabour or vaginal delivery inadvisable; avoid prolonged administration inoxytocin-resistant uterine inertia, severe pre-eclamptic toxaemia, or severe\r\ncardiovascular disease", "doses": ["Induction of labour for medical reasons or stimulation\r\nof labour in hypotonic uterine inertia,by intravenous infusion(not to be started for at least 6 hours after administration of\r\nvaginal prostaglandin), initially 0.001\u20130.004\u00a0units/minute, increased\r\nat intervals of at least 30 minutes until a maximum of 3\u20134 contractions\r\noccur every 10 minutes (0.01\u00a0units/minute is often adequate) up to\r\nmax. 0.02\u00a0units/minute; if regular contractions not established after\r\ntotal of 5\u00a0units stop induction attempt (may be repeated next day\r\nstarting again at 0.001\u20130.004\u00a0units/minute)", "Careful monitoring of fetal heart rate\r\nand uterine motility essential for dose titration (avoidintravenous injection during labour);\r\ndiscontinue immediately in uterine hyperactivity or fetal distress", "Caesarean section,by slow intravenous injectionimmediately after delivery, 5\u00a0units", "Prevention of postpartum haemorrhage, after delivery\r\nof placenta,by slow intravenous injection, 5\u00a0units\r\n(if infusion used for induction or enhancement of labour, increase\r\nrate during third stage and for next few hours).", "Avoid rapid intravenous injection (may\r\ntransiently reduce blood pressure)", "Can be given in a dose of 10\u00a0unitsby intramuscular injection[unlicensed route] instead ofoxytocinwith ergometrine (Syntometrine\u00ae), see notes above", "Treatment of postpartum haemorrhage,by slow\r\nintravenous injection, 5\u00a0units (dose may be repeated), followed\r\nin severe casesby intravenous infusionof 40\u00a0units\r\nin 500\u00a0mL infusion fluid at a rate sufficient to control uterine atony", "Avoid rapid intravenous injection (may\r\ntransiently reduce blood pressure); prolonged administration, see\r\nwarning below", "Incomplete, inevitable, or missed miscarriage,by slow intravenous injection, 5\u00a0units followed if necessaryby intravenous infusion, 0.02\u20130.04\u00a0units/minute or faster", "Prolonged intravenous administration\r\nat high doses with large volume of fluid (which is possible in inevitable\r\nor missed miscarriage or postpartum haemorrhage) may cause water intoxication\r\nwith hyponatraemia. To avoid: use electrolyte-containing\r\ndiluent (i.e. notglucose), increaseoxytocinconcentration to reduce fluid, restrict fluid intake by mouth; monitor\r\nfluid and electrolytes.", "Oxytocin doses in the BNF may differ from\r\nthose in the product literature"]}, "PHENELZINE": {"indications": "depressive illness", "name": "PHENELZINE", "interactions": {"extra": "", "bad": 0, "interaction": "effects of  suxamethonium enhanced by phenelzine ", "name": "Phenelzine", "backrefs": ["Phenelzine"]}, "cautions": "diabetes mellitus, cardiovascular\r\ndisease, epilepsy, blood disorders, concurrent electroconvulsive\r\ntherapy; elderly (great caution); monitor blood pressure (risk of postural hypotension\r\nand hypertensive responses\u2014discontinue if palpitations or frequent headaches); if possible avoid abrupt withdrawal; severe\r\nhypertensive reactions to certain drugs and foods\u2014seenotes above; avoid in agitated patients; acute porphyria (section 9.8.2); surgery (section 15.1);interactions:seenotes aboveand Appendix\r\n1 (MAOIs)", "side-effects": "commonly postural hypotension (especially in elderly)\r\nand dizziness; less common side-effects include drowsiness, insomnia,\r\nheadache, weakness and fatigue, dry mouth, constipation and other\r\ngastro-intestinal disturbances, oedema, myoclonic movement, hyperreflexia,\r\nelevated liver enzymes; agitation and tremors, nervousness, euphoria,\r\narrhythmias, blurred vision, nystagmus, difficulty in micturition,\r\nsweating, convulsions, rashes, purpura, leucopenia, sexual disturbances,\r\nand weight gain with inappropriate appetite may also occur; psychotic\r\nepisodes with hypomanic behaviour, confusion, and hallucinations may\r\nbe induced in susceptible persons; suicidal behaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy);\r\njaundice has been reported and, on rare occasions, fatal progressive\r\nhepatocellular necrosis; paraesthesia, peripheral neuritis, peripheral\r\nneuropathy may be due to pyridoxine deficiency; hyponatraemia (see\r\nHyponatraemia and Antidepressant Therapy,section 4.3)", "contra-indications": "cerebrovascular\r\ndisease, phaeochromocytoma; not indicated in manic phase", "hepatic impairment": "avoid in hepatic impairment or if abnormal liver function\r\ntests; see alsonotes above", "doses": ["15\u00a0mg 3 times daily, increased if necessary to 4 times\r\ndaily after 2 weeks (hospital patients, max. 30\u00a0mg 3 times daily),\r\nthen reduced gradually to lowest possible maintenance dose (15\u00a0mg\r\non alternate days may be adequate);childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "avoid\u2014no information available"}, "VASOPRESSIN": {"indications": "pituitary diabetes insipidus; bleeding from oesophageal varices", "name": "VASOPRESSIN", "renal impairment": "see Contra-indications", "cautions": "heart failure, hypertension, asthma, epilepsy, migraine or other conditions\r\nwhich might be aggravated by water retention; avoid fluid overload", "side-effects": "fluid retention, pallor, tremor, sweating, vertigo,\r\nheadache, nausea, vomiting, belching, abdominal cramps, desire to\r\ndefaecate, hypersensitivity reactions (including anaphylaxis), constriction\r\nof coronary arteries (may cause anginal attacks and myocardial ischaemia),\r\nperipheral ischaemia and rarely gangrene", "contra-indications": "vascular disease (especially\r\ndisease of coronary arteries) unless extreme caution, chronic nephritis (until reasonable\r\nblood nitrogen concentrations attained)", "doses": ["By subcutaneousorintramuscular injection, diabetes insipidus, 5\u201320\u00a0units every\r\nfour hours", "By intravenous infusion, initial control of variceal\r\nbleeding, 20\u00a0units over 15 minutes"], "pregnancy": "oxytocic effect in third trimester", "breast-feeding": "not known to be harmful"}, "TERAZOSIN": {"indications": "benign prostatic hyperplasia; hypertension\r\n(section 2.5.4)", "name": "TERAZOSIN", "cautions": "seenotes aboveandsection 2.5.4", "side-effects": "seenotes aboveandsection 2.5.4", "contra-indications": "seenotes above", "doses": ["Initially 1\u00a0mg at bedtime; if necessary dose may be doubled\r\nat intervals of 1\u20132 weeks according to response, up to max. 10\u00a0mg\r\nonce daily; usual maintenance 5\u201310\u00a0mg daily", "First dose may\r\ncause collapse due to hypotensive effect (therefore should be taken\r\non retiring to bed). Patient should be\r\nwarned to lie down if symptoms such as dizziness, fatigue or sweating\r\ndevelop, and to remain lying down until they abate completely"]}, "MICAFUNGIN": {"indications": "see under Dose", "name": "MICAFUNGIN", "renal impairment": "use with caution; renal function may deteriorate", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  itraconazole increased by micafungin (consider reducing dose of itraconazole)", "name": "Micafungin", "backrefs": ["Micafungin"]}, "cautions": "monitor renal function;interactions:Appendix 1 (micafungin)", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain; headache,\r\nfever; hypokalaemia, hypomagnesaemia, hypocalcaemia, leucopenia, anaemia;\r\nrash, phlebitis;less commonlydyspepsia, constipation,\r\nhepatomegaly, hepatitis and cholestasis (see also Hepatotoxicity above),\r\ntaste disturbances, anorexia, tachycardia, palpitation, bradycardia,\r\nblood pressure changes, flushing, dyspnoea, sleep disturbances, anxiety,\r\nconfusion, dizziness, tremor, pancytopenia, thrombocytopenia, eosinophilia,\r\nhyponatraemia, hypophosphataemia, hyperkalaemia, hyperhidrosis, and\r\npruritus;rarelyhaemolytic anaemia; also reported\r\nrenal failure (more frequent in children)", "hepatic impairment": "use with caution in mild to moderate impairment; avoid\r\nin severe impairment; see also Hepatotoxicity above", "doses": ["By intravenous infusion, invasive\r\ncandidiasis,adultbody-weight over\r\n40\u00a0kg, 100\u00a0mg once daily (increased to 200\u00a0mg daily if inadequate\r\nresponse) for at least 14 days; body-weight under 40\u00a0kg, 2\u00a0mg/kg once\r\ndaily (increased to 4\u00a0mg/kg daily if inadequate response) for at least\r\n14 days;childunder 18 years seeBNF for Children", "Oesophageal candidiasis,adultbody-weight over 40\u00a0kg, 150\u00a0mg once daily; body-weight under 40\u00a0kg,\r\n3\u00a0mg/kg once daily;child16\u201318 years\r\nseeBNF for Children", "Prophylaxis of candidiasis in patients undergoing bone-marrow\r\ntransplantation or who are expected to become neutropenic for over\r\n10 days,adultbody-weight over 40\u00a0kg,\r\n50\u00a0mg once daily; body-weight under 40\u00a0kg, 1\u00a0mg/kg once daily; continue\r\nfor at least 7 days after neutrophil count in desirable range;childunder 18 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid unless essential\u2014toxicity\r\ninanimalstudies", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014present in milk inanimalstudies"}, "DOPEXAMINE": {"interactions": {"extra": "", "bad": 1, "interaction": "effects of  adrenaline (epinephrine) possibly enhanced by dopexamine ", "name": "Dopexamine", "backrefs": ["Dopexamine"]}}, "PROPAFENONE": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of propafenone (increased risk of ventricular arrhythmias\u2014avoid concomitant use)", "name": "Propafenone", "backrefs": ["Propafenone"]}}, "HEXETIDINE": {"side-effects": "local irritation;very rarelytaste disturbance and transient anaesthesia", "indications": "oral hygiene", "name": "HEXETIDINE", "doses": ["adultandchildover 6 years, use 15\u00a0mL undiluted 2\u20133 times\r\ndaily"]}, "FLUVOXAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  lansoprazole possibly increased by fluvoxamine ", "name": "Fluvoxamine", "backrefs": ["Frovatriptan", "Fluvoxamine", "Agomelatine"]}}, "FLUTAMIDE": {"indications": "advanced prostate cancer, see alsonotes above", "name": "FLUTAMIDE", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  coumarins enhanced by flutamide ", "name": "Flutamide", "backrefs": ["Flutamide"]}, "cautions": "cardiac disease (oedema\r\nreported); also liver function tests, monthly for first\r\n4 months, periodically thereafter and at the first sign\r\nor symptom of liver disorder (e.g. pruritus, dark urine, persistent\r\nanorexia, jaundice, abdominal pain, unexplained influenza-like symptoms); avoid excessive alcohol consumption; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (flutamide)", "side-effects": "gynaecomastia (sometimes with galactorrhoea);\r\nnausea, vomiting, diarrhoea, increased appetite, insomnia, tiredness;\r\nother side-effects reported include decreased libido, reduced sperm\r\ncount, gastric and chest pain, hypertension, headache, dizziness,\r\noedema, blurred vision, thirst, rash, pruritus, haemolytic anaemia,\r\nsystemic lupus erythematosus-like syndrome, and lymphoedema; hepatic\r\ninjury (with transaminase abnormalities, cholestatic jaundice, hepatic\r\nnecrosis, hepatic encephalopathy and occasional fatality) reported", "hepatic impairment": "use with caution (hepatotoxic)", "doses": ["250\u00a0mg 3 times daily (see also notes above)"]}, "ZOLMITRIPTAN": {"indications": "treatment of acute migraine; cluster headache\r\n(nasal route only) [unlicensed use]", "name": "ZOLMITRIPTAN", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits metabolism of zolmitriptan (reduce dose of zolmitriptan)", "name": "Zolmitriptan", "backrefs": ["Quinolones", "Zolmitriptan"]}, "cautions": "see under5HT1-receptor agonistsabove; should not be taken within 24 hours of any other 5HT1-receptor\r\nagonist;interactions:Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; also abdominal pain, dry mouth; palpitation;\r\ndrowsiness, paraesthesia, headache; myalgia, muscle weakness;less commonlytachycardia, transient increase in blood pressure,\r\npolyuria;rarelyurticaria;very rarelygastro-intestinal and splenic infarction, ischaemic colitis, angina,\r\nmyocardial infarction;with nasal spray, taste disturbance,\r\nand epistaxis", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; Wolff-Parkinson-White syndrome or arrhythmias associated with accessory cardiac conduction\r\npathways; previous cerebrovascular accident or transient\r\nischaemic attack", "hepatic impairment": "max. 5\u00a0mg in 24 hours in moderate or severe impairment", "doses": ["By mouth, migraine,adultover 18 years, 2.5\u00a0mg repeated after not less than 2 hours if migraine\r\nrecurs (increase to 5\u00a0mg for subsequent attacks in patients not achieving\r\nsatisfactory relief with 2.5-mg dose); max. 10\u00a0mg in 24 hours;child12\u201318 years seeBNF for Children", "Intranasally, cluster headache [unlicensed] or\r\nmigraine,adultover 18 years, 5\u00a0mg\r\n(1 spray) into one nostril as soon as possible after onset, repeated\r\nafter not less than 2 hours if headache recurs; max. 10\u00a0mg in 24 hours;child12\u201318 years seeBNF for Children", "Max. 5\u00a0mg in 24 hours with concomitant cimetidine,\r\nfluvoxamine, moclobemide, or quinolone antibiotics"], "pregnancy": "seenotes above", "breast-feeding": "use with caution\u2014present in milk inanimalstudies"}, "THYROTROPIN ALFA": {"indications": "see notes above and product literature", "name": "THYROTROPIN ALFA", "cautions": "presence of thyroglobulin autoantibodies\r\nmay give false negative results", "side-effects": "nausea, vomiting; headache, dizziness, fatigue;less commonlyasthenia, paraesthesia, back pain, influenza-like\r\nsymptoms, rash, urticaria;rarelydiarrhoea;very rarelypalpitation, flushing, dyspnoea, pain at site\r\nof metastases, tremor, arthralgia, myalgia, hyperhidrosis, and injection-site\r\nreactions including pain, pruritus, and rash", "contra-indications": "hypersensitivity to bovine or human thyrotrophin", "doses": ["By intramuscular injectioninto the gluteal\r\nmuscle, 900\u00a0micrograms every 24 hours for 2 doses, consult product\r\nliterature"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "TRETINOIN": {"indications": "seenotes above; acne (section 13.6.1); photodamage (section 13.8.1)", "name": "TRETINOIN", "renal impairment": "reduce dose to 25\u00a0mg/m2", "cautions": "exclude pregnancy before starting treatment; monitor haematological and coagulation profile, liver\r\nfunction, serum calcium and plasma lipids before and during treatment; increased risk of thromboembolism during first month\r\nof treatment;interactions:Appendix\r\n1 (retinoids)", "side-effects": "retinoic acid syndrome (fever, dyspnoea, acute\r\nrespiratory distress, pulmonary infiltrates, pleural effusion, hyperleucocytosis,\r\nhypotension, oedema, weight gain, hepatic, renal and multi-organ failure)\r\nrequires immediate treatment\u2014consult product literature; gastro-intestinal\r\ndisturbances, pancreatitis; arrhythmias, flushing, oedema; headache,\r\nbenign intracranial hypertension (mainly in children\u2014consider dose\r\nreduction if intractable headache in children), shivering, dizziness,\r\nconfusion, anxiety, depression, insomnia, paraesthesia, visual and\r\nhearing disturbances; raised liver enzymes, serum creatinine and lipids;\r\nbone and chest pain, alopecia, erythema, rash, pruritus, sweating,\r\ndry skin and mucous membranes, cheilitis; thromboembolism,\r\nhypercalcaemia, and genital ulceration reported", "hepatic impairment": "reduce dose to 25\u00a0mg/m2", "doses": ["adultandchild45\u00a0mg/m2daily in 2 divided doses,\r\nmax. duration of treatment 90 days (consult product literature for\r\ndetails of concomitant chemotherapy)"], "pregnancy": "teratogenic; effective contraception must be used\r\nfor at least 1 month before oral treatment, during treatment and for\r\nat least 1 month after stopping (oral progestogen-only contraceptives\r\nnot considered effective)", "breast-feeding": "avoid"}, "TENOXICAM": {"indications": "pain and inflammation in rheumatic disease and other musculoskeletal\r\ndisorders", "name": "TENOXICAM", "renal impairment": "avoid in severe impairment; see alsonotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, rheumatic disease,adultover 18 years, 20\u00a0mg daily", "Acute musculoskeletal disorders,adultover 18 years, 20\u00a0mg daily for 7 days; max. duration of treatment\r\n14 days (including treatment by intravenous or intramuscular injection)", "By intravenousorintramuscular injection,adultover 18 years, initial treatment for 1\u20132 days if oral administration\r\nnot possible, 20\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "present in milk inanimalstudies;\r\nsee alsonotes above"}, "DILTIAZEM": {"interactions": {"extra": "", "bad": 0, "interaction": "neurotoxicity may occur when  lithium given with diltiazem without increased plasma concentration of lithium", "name": "Diltiazem", "backrefs": ["Dutasteride", "Diltiazem"]}}, "PRAMIPEXOLE": {"indications": "Parkinson\u2019s disease, used alone or\r\nas an adjunct to co-beneldopa\r\nor co-careldopa; moderate to severe restless legs syndrome", "name": "PRAMIPEXOLE", "renal impairment": "forimmediate-releasetablets in Parkinson\u2019s\r\ndisease, initially 88\u00a0micrograms twice daily (max. 1.57\u00a0mg daily in\r\n2 divided doses) if eGFR 20\u201350\u00a0mL/minute/1.73m2; initially\r\n88\u00a0micrograms once daily (max. 1.1\u00a0mg once daily) if eGFR less than\r\n20\u00a0mL/minute/1.73 m2; if renal function declines during\r\ntreatment, reduce dose by the same percentage as the decline in eGFR", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  antipsychotics advised by manufacturer of pramipexole (antagonism of effect)", "name": "Pramipexole", "backrefs": ["Pramipexole"]}, "cautions": "seenotes above; psychotic disorders; ophthalmological\r\ntesting recommended (risk of visual disorders); severe cardiovascular disease; risk of\r\npostural hypotension (especially on initiation)\u2014monitor blood pressure;interactions:Appendix 1 (pramipexole)", "side-effects": "seenotes above; also\r\nnausea, constipation, vomiting, weight changes, decreased appetite,\r\nhypotension (including postural hypotension), peripheral oedema, dizziness,\r\ndyskinesia, hyperkinesia, drowsiness (includingsudden onset of sleep),\r\nheadache, sleep disturbances, confusion, hallucinations, restlessness,\r\nvisual disturbances;less commonlyhiccups, cardiac\r\nfailure, syncope, pneumonia, dyspnoea, binge eating, compulsive behaviour\r\n(seenotes above), amnesia,\r\ndelusion, paranoia, pruritus, rash;also reportedparadoxical worsening of restless legs syndrome", "doses": ["Doses and strengths are stated in terms\r\nofpramipexole(base); equivalent strengths in\r\nterms ofpramipexoledihydrochloride monohydrate\r\n(salt) are as follows:88\u00a0micrograms base \u2261 125\u00a0micrograms\r\nsalt;180\u00a0micrograms base \u2261 250\u00a0micrograms salt;350\u00a0micrograms base \u2261 500\u00a0micrograms salt;700\u00a0micrograms\r\nbase \u2261 1\u00a0mg salt", "Parkinson\u2019s disease,adultover\r\n18 years, initially 88\u00a0micrograms 3 times daily, dose doubled every\r\n5\u20137 days if tolerated to 350\u00a0micrograms 3 times daily; further increased\r\nif necessary by 180\u00a0micrograms 3 times daily at weekly intervals;\r\nmax. 3.3\u00a0mg daily in 3 divided doses", "During dose titration and maintenance,levodopadose may be reduced", "Restless legs syndrome,adultover 18 years, initially 88\u00a0micrograms once daily 2\u20133 hours before\r\nbedtime, dose doubled every 4\u20137 days if necessary; max. 540\u00a0micrograms\r\ndaily"], "pregnancy": "use only if potential benefit outweighs risk\u2014no information\r\navailable", "breast-feeding": "may suppress lactation; avoid\u2014present in milk\r\ninanimalstudies"}, "TIOTROPIUM": {"indications": "maintenance treatment of chronic obstructive pulmonary disease", "name": "TIOTROPIUM", "renal impairment": "plasma-tiotropium concentration raised; use with caution\r\nif eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above; also cardiac rhythm disorders (withSpiriva\u00aeRespimat\u00ae)", "side-effects": "seenotes above;less commonlytaste disturbance, gastro-oesophageal reflux\r\ndisease, pharyngitis, dysphonia, dysphagia, dysuria, epistaxis, oropharyngeal\r\ncandidiasis;rarelyintestinal obstruction (including\r\nparalytic ileus), laryngitis, insomnia, urinary-tract infection, skin\r\ninfection, sinusitis, dental caries, gingivitis, glossitis, skin ulcer;also reporteddehydration, joint swelling, dry skin", "doses": ["by inhalation,adultover 18 years, 5\u00a0micrograms (2 puffs) once daily"]}, "PALIFERMIN": {"indications": "seenotes above", "name": "PALIFERMIN", "side-effects": "oral paraesthesia, taste disturbance, thickening\r\nand discoloration of tongue; fever; oedema; arthralgia; rash, pruritus,\r\nerythema, skin hyperpigmentation", "doses": ["By intravenous injection, 60\u00a0micrograms/kg\r\nonce daily for 3 doses (third dose given 24\u201348 hours before myeloablative\r\ntherapy) then 3 further doses at least 24 hours after myeloablative\r\ntherapy, and more than 4 days after most recent palifermin\r\ninjection, starting on same day as (but after) stem-cell infusion;childnot recommended"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PRAVASTATIN SODIUM": {"indications": "adjunct to diet for primary hypercholesterolaemia or combined (mixed)\r\nhyperlipidaemias in patients who have not responded adequately to\r\ndietary control; adjunct to diet to prevent cardiovascular events\r\nin patients with hypercholesterolaemia; prevention of cardiovascular\r\nevents in patients with previous myocardial infarction or unstable\r\nangina; reduction of hyperlipidaemia in patients receiving immunosuppressive\r\ntherapy following solid-organ transplantation", "name": "PRAVASTATIN SODIUM", "renal impairment": "manufacturer advises initial dose of 10\u00a0mg once daily\r\nin moderate to severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above;less commonlyabnormal urination (including dysuria, nocturia and frequency);very rarelyfulminant hepatic necrosis", "hepatic impairment": "seenotes above", "doses": ["Hypercholesterolaemia or combined hyperlipidaemias, 10\u201340\u00a0mg\r\nonce daily at night, adjusted at intervals of at least 4 weeks;childunder 18 years seeBNF for Children", "Familial hypercholesterolaemia,childunder 18 years seeBNF for Children", "Prevention of cardiovascular events, 40\u00a0mg once daily at night", "Post-transplantation hyperlipidaemia, initially 20\u00a0mg once daily\r\nat night, increased if necessary (under close medical supervision)\r\nto max. 40\u00a0mg once daily at night"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "METFORMIN HYDROCHLORIDE": {"indications": "diabetes\r\nmellitus (see notes above); polycystic ovary syndrome [unlicensed\r\nindication]", "name": "METFORMIN HYDROCHLORIDE", "renal impairment": "see under Cautions", "cautions": "seenotes above; determine renal function before treatment and at least annually (at\r\nleast twice a year in patients with additional risk factors for renal\r\nimpairment, or if deterioration suspected);interactions:Appendix 1 (antidiabetics)", "side-effects": "anorexia, nausea, vomiting, diarrhoea (usually\r\ntransient), abdominal pain, taste disturbance,rarelylactic acidosis (withdraw treatment), decreased vitamin-B12absorption, erythema, pruritus and urticaria; hepatitis also reported", "contra-indications": "ketoacidosis, see\r\nalso Lactic Acidosis above; use of general anaesthesia\r\n(suspend metformin on the morning of surgery and restart when renal\r\nfunction returns to baseline)", "hepatic impairment": "withdraw if tissue hypoxia likely", "doses": ["Diabetes mellitus,adultandchildover 10 years initially\r\n500\u00a0mg with breakfast for at least 1 week then 500\u00a0mg with breakfast\r\nand evening meal for at least 1 week then 500\u00a0mg with breakfast, lunch\r\nand evening meal; usual max. 2\u00a0g daily in divided doses", "Polycystic ovary syndrome [unlicensed], initially 500\u00a0mg with\r\nbreakfast for 1 week, then 500\u00a0mg with breakfast and evening meal\r\nfor 1 week, then 1.5\u20131.7\u00a0g daily in 2\u20133 divided doses", "Metformin doses in the BNF may differ from\r\nthose in the product literature"], "pregnancy": "used in pregnancy for both pre-existing and gestational\r\ndiabetes\u2014see alsosection 6.1.2", "breast-feeding": "may be used during breast-feeding\u2014seesection 6.1.2"}, "Selecting the dose": {"name": "Selecting the dose"}, "INSULIN DETEMIR": {"indications": "diabetes mellitus", "name": "INSULIN DETEMIR", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see under Insulin (section 6.1.1.1)", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection,adultandchildover\r\n2 years, according to requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "PHYTOMENADIONE": {"indications": "seenotes above", "name": "PHYTOMENADIONE", "cautions": "intravenous injections should be given\r\nvery slowly (see also below);interactions:Appendix 1 (vitamins)", "doses": ["Seenotes aboveandsection 2.8.2"], "pregnancy": "use if potential benefit outweighs risk", "breast-feeding": "present in milk, but seenotes above"}, "PIVMECILLINAM": {"interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  valproate advised by manufacturer of pivmecillinam ", "name": "Pivmecillinam", "backrefs": ["Pivmecillinam"]}}, "CARGLUMIC ACID": {"indications": "hyperammonaemia due toN-acetylglutamate synthase\r\ndeficiency and organic acidaemia under specialist supervision", "name": "CARGLUMIC ACID", "side-effects": "sweating;less commonlydiarrhoea,\r\nvomiting, bradycardia, pyrexia", "doses": ["Hyperammonaemia due toN-acetylglutamate\r\nsynthase deficiency,adultandchildinitially 100\u2013250\u00a0mg/kg daily in 2\u20134 divided\r\ndoses immediately before food, adjusted according to plasma\u2013ammonia\r\nconcentration; maintenance 10\u2013100\u00a0mg/kg daily in 2\u20134 divided doses", "Hyperammonaemia due to organic acidaemia,adultandchildinitially 100\u2013250\u00a0mg/kg\r\ndaily in 2\u20134 divided doses immediately before food, adjusted according\r\nto plasma-ammonia concentration"], "pregnancy": "manufacturer advises avoid unless essential\u2014no information\r\navailable", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "PIRACETAM": {"indications": "adjunctive treatment of cortical myoclonus", "name": "PIRACETAM", "renal impairment": "use two-thirds of normal dose if eGFR 50\u201380\u00a0mL/minute/1.73\u00a0m2; use one-third of normal dose in 2 divided doses if eGFR\r\n30\u201350\u00a0mL/minute/1.73\u00a0m2; use one-sixth normal dose as a\r\nsingle dose if eGFR 20\u201330\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR\r\nless than 20\u00a0mL/minute/1.73\u00a0m2", "cautions": "avoid abrupt withdrawal; increased risk of bleeding (gastric ulcer, history of haemorrhagic\r\nstroke, concomitant drugs that increase\r\nbleeding), underlying disorders of haemostasis, major surgery", "side-effects": "weight gain, nervousness, hyperkinesia;less commonlydrowsiness, depression, asthenia;also reportedabdominal pain, nausea, vomiting, diarrhoea,\r\nheadache, anxiety, confusion, hallucination, vertigo, ataxia, insomnia,\r\nhaemorrhagic disorder, dermatitis, pruritus, urticaria", "contra-indications": "cerebral haemorrhage; Huntington\u2019s chorea", "hepatic impairment": "adjust dose if both hepatic and renal impairment (see\r\nunder Renal impairment, below)", "doses": ["Initially 7.2\u00a0g daily in 2\u20133 divided doses, increased\r\naccording to response by 4.8\u00a0g every 3\u20134 days to max. 24\u00a0g daily (subsequently,\r\nattempts should be made to reduce dose of concurrent therapy);childunder 16 years not recommended", "Follow the oral solution with a\r\nglass of water (or soft drink) to reduce bitter taste."], "pregnancy": "avoid", "breast-feeding": "avoid"}, "TELMISARTAN": {"indications": "hypertension (see also notes above); prevention of cardiovascular\r\nevents in patients with established atherosclerotic cardiovascular\r\ndisease, or type 2 diabetes mellitus with target-organ damage", "name": "TELMISARTAN", "renal impairment": "manufacturer advises initial dose of 20\u00a0mg once daily\r\nin severe impairment", "cautions": "seenotes above", "side-effects": "see notes above; also gastro-intestinal disturbances;\r\nchest pain; influenza-like symptoms including pharyngitis and sinusitis;\r\nurinary-tract infection; arthralgia, myalgia, back pain, leg cramps;\r\neczema;less commonlydry mouth, flatulence, anxiety,\r\nvertigo, tendinitis-like symptoms, abnormal vision, increased sweating;rarelybradycardia, tachycardia, dyspnoea, insomnia, depression,\r\nblood disorders, increase in uric acid, eosinophilia, rash, and pruritus;\r\nsyncope and asthenia also reported", "hepatic impairment": "20\u201340\u00a0mg once daily in mild or moderate impairment;\r\navoid in severe impairment or biliary obstruction", "doses": ["Hypertension, usually 40\u00a0mg once daily (but 20\u00a0mg may\r\nbe sufficient), increased if necessary after at least 4 weeks, to\r\nmax. 80\u00a0mg once daily", "Prevention of cardiovascular events, 80\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ATRACURIUM": {"interactions": {"extra": "", "bad": 0, "interaction": " ketamine enhances effects of atracurium ", "name": "Atracurium", "backrefs": ["Atracurium"]}}, "GALSULFASE": {"indications": "(specialist use only) mucopolysaccharidosis\r\nVI", "name": "GALSULFASE", "cautions": "respiratory disease; acute\r\nfebrile or respiratory illness (consider delaying treatment)", "side-effects": "abdominal pain, umbilical hernia, gastroenteritis;\r\nchest pain, hypertension; dyspnoea, apnoea, nasal congestion; rigors,\r\nmalaise, areflexia; pharyngitis; conjunctivitis, corneal opacity;\r\near pain; facial oedema", "doses": ["By intravenous infusion,adultandchildover\r\n5 years, 1\u00a0mg/kg once weekly"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "MUSCLE RELAXANTS": {"interactions": {"extra": "", "bad": 0, "interaction": " lithium enhances effects of muscle relaxants ", "name": "Muscle Relaxants", "backrefs": ["Clindamycin", "Muscle Relaxants, non-depolarising", "Edrophonium", "Propranolol", "Rivastigmine", "Magnesium (parenteral)", "Piperacillin", "Muscle Relaxants", "Lithium", "Donepezil"]}}, "DISOPYRAMIDE": {"indications": "prevention and treatment of ventricular and supraventricular arrhythmias,\r\nincluding after myocardial infarction; maintenance of sinus rhythm\r\nafter cardioversion", "name": "DISOPYRAMIDE", "renal impairment": "reduce dose by increasing dose interval; adjust according\r\nto response; avoid modified-release preparation", "interactions": {"extra": "", "bad": 0, "interaction": "hypoglycaemic effect of  insulin possibly enhanced by disopyramide ", "name": "Disopyramide", "backrefs": ["Gliclazide", "Disopyramide"]}, "cautions": "monitor for hypotension, hypoglycaemia, ventricular\r\ntachycardia, ventricular fibrillation or torsade de pointes (discontinue if occur); monitor serum potassium; atrial flutter\r\nor atrial tachycardia with partial block, structural\r\nheart disease, heart failure (avoid if severe); prostatic enlargement; susceptibility to angle-closure glaucoma; myasthenia gravis; elderly; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (disopyramide)", "side-effects": "ventricular tachycardia, ventricular fibrillation\r\nor torsade de pointes (usually associated with prolongation of QRS\r\ncomplex or QT interval\u2014see Cautions above), myocardial depression,\r\nhypotension, AV block; antimuscarinic effects include dry mouth, blurred\r\nvision, urinary retention, and very rarely angle-closure glaucoma;\r\ngastro-intestinal irritation; psychosis, cholestatic jaundice, hypoglycaemia\r\nalso reported (see Cautions above)", "contra-indications": "second-\r\nand third-degree AV block or bifascicular block (unless pacemaker\r\nfitted), bundle-branch block associated with first-degree AV block; severe sinus node dysfunction; severe heart\r\nfailure (unless secondary to arrhythmia)", "hepatic impairment": "half-life prolonged\u2014may need dose reduction;\r\navoid modified-release preparation", "doses": ["250\u2013375\u00a0mg every 12 hours"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk; may induce labour if used in third trimester", "breast-feeding": "present in milk\u2014use only if essential and monitor\r\ninfant for antimuscarinic effects"}, "SODIUM OXYBATE": {"indications": "narcolepsy with\r\ncataplexy (under specialist supervision)", "name": "SODIUM OXYBATE", "renal impairment": "caution\u2014contains 3.96\u00a0mmol Na+/mL", "interactions": {"extra": "", "bad": 0, "interaction": " antipsychotics possibly enhance effects of sodium oxybate ", "name": "Sodium Oxybate", "backrefs": ["Sodium Oxybate"]}, "cautions": "history of drug abuse or depression; epilepsy; body mass index\r\nof 40\u00a0kg/m2or greater (higher risk of sleep apnoea); elderly; respiratory disorders; heart failure and hypertension (high sodium content); risk of discontinuation effects\r\nincluding rebound cataplexy and withdrawal symptoms;interactions:Appendix 1 (sodium oxybate)", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain, taste\r\ndisturbance, anorexia; hypertension, palpitation, peripheral oedema;\r\ndyspnoea; sleep disorders, confusion, disorientation, paraesthesia,\r\nhypoaesthesia, impaired attention, depression, drowsiness, anxiety,\r\ndizziness, headache, tremor, asthenia, fatigue; urinary incontinence,\r\nnocturnal enuresis; arthralgia, back pain, muscle cramps; blurred\r\nvision; nasal congestion, vertigo; sweating, rash;less commonlyfaecal incontinence, myoclonus, psychosis, paranoia, hallucination,\r\nagitation, and amnesia; respiratory depression, dependence, seizures,\r\nsuicidal ideation, sleep apnoea, and urticaria also reported", "hepatic impairment": "halve initial dose", "doses": ["adultover 18 years, initially\r\n2.25\u00a0g on retiring and repeated 2.5\u20134 hours later, increased according\r\nto response in steps of 1.5\u00a0g daily in 2 divided doses at intervals\r\nof 1\u20132 weeks; max. 9\u00a0g daily in two divided doses", "Dose titration should be repeated if restarting\r\nafter interval of more than 14 days", "Dilute each dose with 60\u00a0mL water;\r\nprepare both doses before retiring. Observe the same time interval\r\n(2\u20133 hours) each night between the last meal and the first dose"], "pregnancy": "avoid", "breast-feeding": "no information available"}, "MERCAPTAMINE": {"indications": "(specialist use only) nephropathic cystinosis", "name": "MERCAPTAMINE", "cautions": "leucocyte-cystine concentration and haematological\r\nmonitoring required\u2014consult product literature; dose of phosphate supplement may need to be adjusted if transferring\r\nfrom phosphocysteamine to mercaptamine", "side-effects": "breath and body odour, nausea, vomiting, diarrhoea,\r\nanorexia, abdominal pain, gastroenteritis, dyspepsia, encephalopathy,\r\nheadache, malaise, fever, rash;less commonlygastro-intestinal\r\nulcer, seizures, hallucinations, somnolence, nervousness, leucopenia,\r\nnephrotic syndrome", "contra-indications": "hypersensitivity\r\nto penicillamine", "doses": ["Initial doses should be one-sixth to one-quarter of the\r\nexpected maintenance dose, increased gradually over 4\u20136 weeks", "Maintenance,adultandchildover 50\u00a0kg body-weight,\r\n2\u00a0g daily in 4 divided doses", "childup to 12 years, 1.3\u00a0g/m2(approx. 50\u00a0mg/kg) daily in 4 divided doses"], "pregnancy": "avoid\u2014teratogenic and toxic inanimalstudies", "breast-feeding": "avoid"}, "HYDRALAZINE": {"interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with hydralazine ", "name": "Hydralazine", "backrefs": ["Hydralazine"]}}, "SULFONYLUREAS": {"interactions": {"extra": "", "bad": 1, "interaction": " sulfinpyrazone enhances effects of sulfonylureas ", "name": "Sulfonylureas", "backrefs": ["Sulfonylureas"]}}, "NITROFURANTOIN": {"indications": "urinary-tract infections", "name": "NITROFURANTOIN", "renal impairment": "avoid if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2; risk of peripheral neuropathy; ineffective because of inadequate\r\nurine concentrations", "interactions": {"extra": "", "bad": 0, "interaction": " sulfinpyrazone reduces excretion of nitrofurantoin (increased risk of toxicity)", "name": "Nitrofurantoin", "backrefs": ["Nitrofurantoin", "Nalidixic Acid", "Sulfinpyrazone", "Probenecid", "Magnesium Salts (oral)"]}, "cautions": "anaemia; diabetes\r\nmellitus; electrolyte imbalance; vitamin B and folate deficiency; pulmonary disease; on long-term therapy, monitor liver function and monitor for pulmonary symptoms, especially\r\nin the elderly (discontinue if deterioration\r\nin lung function); susceptibility to peripheral\r\nneuropathy; false positive urinaryglucose(if tested for reducing substances); urine may be coloured yellow or brown;interactions:Appendix 1 (nitrofurantoin)", "side-effects": "anorexia, nausea, vomiting, and diarrhoea; acute\r\nand chronic pulmonary reactions (pulmonary fibrosis reported; possible\r\nassociation with lupus erythematosus-like syndrome); peripheral neuropathy;\r\nalso reported, hypersensitivity reactions (including angioedema, anaphylaxis,\r\nsialadenitis, urticaria, rash and pruritus); rarely, cholestatic jaundice,\r\nhepatitis, exfoliative dermatitis, erythema multiforme, pancreatitis,\r\narthralgia, blood disorders (including agranulocytosis, thrombocytopenia,\r\nand aplastic anaemia), benign intracranial hypertension, and transient\r\nalopecia", "contra-indications": "infants less than 3 months old, G6PD deficiency (section 9.1.5); acute porphyria (section 9.8.2)", "hepatic impairment": "use with caution; cholestatic jaundice and chronic\r\nactive hepatitis reported", "doses": ["Acute uncomplicated infection, 50\u00a0mg every 6 hours with\r\nfood for 7 days (3 days usually adequate in women);childover 3 months, 750\u00a0micrograms/kg every 6 hours", "Severe chronic recurrent infection, 100\u00a0mg every 6 hours with\r\nfood for 7 days (dose reduced or discontinued if severe nausea)", "Prophylaxis (but see Cautions), 50\u2013100\u00a0mg at night;childover 3 months, 1\u00a0mg/kg at night"], "pregnancy": "avoid at term\u2014may produce neonatal haemolysis", "breast-feeding": "avoid; only small amounts in milk but could\r\nbe enough to produce haemolysis in G6PD-deficient infants (section 9.1.5)"}, "SIMVASTATIN": {"indications": "primary hypercholesterolaemia, homozygous familial hypercholesterolaemia\r\nor combined (mixed) hyperlipidaemia in patients who have not responded\r\nadequately to diet and other appropriate measures; prevention of cardiovascular\r\nevents in patients with atherosclerotic cardiovascular disease or\r\ndiabetes mellitus", "name": "SIMVASTATIN", "renal impairment": "doses above 10\u00a0mg daily should be used with caution if\r\neGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of myopathy when  ritonavir given with simvastatin (avoid concomitant use)", "name": "Simvastatin", "backrefs": ["Miconazole", "Amlodipine", "Posaconazole", "Danazol", "Simvastatin"]}, "cautions": "seenotes above; also 80-mg dose only\r\nfor those with severe hypercholesterolaemia and at high risk of cardiovascular\r\ncomplications", "side-effects": "seenotes above; alsorarelyanaemia", "hepatic impairment": "seenotes above", "doses": ["Primary hypercholesterolaemia, combined hyperlipidaemia,\r\n10\u201320\u00a0mg daily at night, adjusted at intervals of at least 4 weeks;\r\nusual range 10\u201380\u00a0mg once daily at night;childunder 18 years seeBNF for Children", "Homozygous familial hypercholesterolaemia, 40\u00a0mg daily at nightor80\u00a0mg daily in 3 divided doses (with largest dose at\r\nnight)", "Heterozygous familial hypercholesterolaemia,childunder 18 years seeBNF for Children", "Prevention of cardiovascular events, initially 20\u201340\u00a0mg once\r\ndaily at night, adjusted at intervals of at least 4 weeks; max. 80\u00a0mg\r\nonce daily at night", "Max. 10\u00a0mg daily with concomitantciclosporin,danazol, or fibrate (except\r\nfenofibrate). Max. 20\u00a0mg daily with concomitantamiodaroneorverapamil. Max. 40\u00a0mg daily withdiltiazemor amlodipine"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PENTAMIDINE ISETIONATE": {"indications": "see under Dose (should only be given by specialists)", "name": "PENTAMIDINE ISETIONATE", "renal impairment": "reduce intravenous dose for pneumocystis pneumonia if\r\ncreatinine clearance less than 10\u00a0mL/minute: inlife-threatening\r\ninfection, use 4\u00a0mg/kg once daily for 7\u201310 days, then 4\u00a0mg/kg\r\non alternate days to complete course of at least 14 doses; inless severe infection, use 4\u00a0mg/kg on alternate days for\r\nat least 14 doses", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  saquinavir given with pentamidine isetionate\u2014avoid concomitant use", "name": "Pentamidine Isetionate", "backrefs": ["Foscarnet", "Pentamidine Isetionate"]}, "cautions": "risk of severe hypotension following\r\nadministration (monitor blood pressure\r\nbefore starting treatment, during administration, and at regular intervals,\r\nuntil treatment concluded; patient should\r\nbe lying down when receiving drug parenterally); hypokalaemia, hypomagnesaemia, coronary heart disease, bradycardia, history of\r\nventricular arrhythmias, concomitant use\r\nwith other drugs which prolong QT-interval; hypertension or hypotension; hyperglycaemia or hypoglycaemia; leucopenia, thrombocytopenia, or anaemia; carry out laboratory\r\nmonitoring according to product literature; care required to protect personnel during handling and administration;interactions:Appendix 1 (pentamidine isetionate)", "side-effects": "severe reactions, sometimes fatal, due to hypotension,\r\nhypoglycaemia, pancreatitis, and arrhythmias; also leucopenia, thrombocytopenia,\r\nacute renal failure, hypocalcaemia; also reported: azotaemia, abnormal\r\nliver-function tests, anaemia, hyperkalaemia, nausea and vomiting,\r\ndizziness, syncope, flushing, hyperglycaemia, rash, and taste disturbances;\r\nStevens-Johnson syndrome reported; on inhalation, bronchoconstriction\r\n(may be prevented by prior use of bronchodilators), cough, and shortness\r\nof breath; discomfort, pain, induration, abscess formation, and muscle\r\nnecrosis at injection site", "hepatic impairment": "manufacturer advises caution", "doses": ["Treatment ofPneumocystis jirovecii (Pneumocystis\r\ncarinii)pneumonia,by intravenous infusion, 4\u00a0mg/kg once daily for at least 14 days", "Prophylaxis ofPneumocystis jirovecii (Pneumocystis\r\ncarinii)pneumonia,by inhalation of nebulised solution(using suitable equipment\u2014consult product literature), 300\u00a0mg every\r\n4 weeksor150\u00a0mg every 2 weeks [unlicensed for primary\r\nprevention]", "Visceral leishmaniasis (kala-azar,section 5.4.5),by deep intramuscular injection, 3\u20134\u00a0mg/kg on alternate days to max. total of 10 injections; course\r\nmay be repeated if necessary", "Cutaneous leishmaniasis,by deep intramuscular injection, 3\u20134\u00a0mg/kg once or twice weekly until condition resolves (but see\r\nalsosection 5.4.5)", "Trypanosomiasis,by deep intramuscular injectionorintravenous infusion, 4\u00a0mg/kg\r\ndaily or on alternate days to total of 7\u201310 injections", "Direct intravenous injection should be avoided\r\nwhenever possible andnevergiven rapidly; intramuscular\r\ninjections should be deep and preferably given into the buttock"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "manufacturer advises avoid unless essential\u2014no\r\ninformation available"}, "IMIPRAMINE HYDROCHLORIDE": {"indications": "depressive illness; nocturnal enuresis in children\r\n(section 7.4.2)", "name": "IMIPRAMINE HYDROCHLORIDE", "renal impairment": "use with caution in severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\npalpitation, flushing, restlessness, headache, fatigue;very\r\nrarelyabdominal pain, stomatitis, hypertension, oedema,\r\ncardiac decompensation, allergic alveolitis, aggression, myoclonus,\r\nperipheral vasospasm, and mydriasis", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Depression, initially up to 75\u00a0mg daily in divided doses\r\nincreased gradually to 150\u2013200\u00a0mg (up to 300\u00a0mg in hospital patients);\r\nup to 150\u00a0mg may be given as a single dose at bedtime;elderlyinitially 10\u00a0mg daily, increased gradually\r\nto 30\u201350\u00a0mg daily;childnot recommended\r\nfor depression", "Nocturnal enuresis,child6\u20138 years 25\u00a0mg, 8\u201311 years 25\u201350\u00a0mg, over 11 years 50\u201375\u00a0mg\r\nat bedtime; max. period of treatment (including gradual withdrawal)\r\n3 months\u2014full physical examination before further course"], "pregnancy": "colic, tachycardia, dyspnoea, irritability, muscle\r\nspasms, respiratory depression, and withdrawal symptoms reported in\r\nneonates when used in the third trimester", "breast-feeding": "seenotes above"}, "BUPIVACAINE HYDROCHLORIDE": {"indications": "see under Dose", "name": "BUPIVACAINE HYDROCHLORIDE", "renal impairment": "use with caution in severe impairment", "cautions": "seeCautions of Local Anaesthetics; myocardial depression may be more severe and more resistant to treatment; cardiovascular disease; hypertension; hypotension; cerebral atheroma;interactions:Appendix 1 (bupivacaine)", "side-effects": "seeToxicity and Side-effects", "contra-indications": "seeContra-indications of Local\r\nAnaesthetics", "hepatic impairment": "use with caution in severe impairment", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "Doses should be adjusted according to patient\u2019s\r\nphysical status and nature of procedure\u2014important: see also under Administration,section 15.2", "Local infiltration, max. 60\u00a0mL, using a 2.5\u00a0mg/mL\r\n(0.25%) solution", "Peripheral nerve block, max. 60\u00a0mL (150\u00a0mg),\r\nusing a 2.5\u00a0mg/mL (0.25%) solution; max. 30\u00a0mL, using a 5\u00a0mg/mL (0.5%)\r\nsolution", "Epidural block", "Surgery,lumbar, 10\u201320\u00a0mL (50\u2013100\u00a0mg), using\r\na 5\u00a0mg/mL (0.5%) solution", "Surgery,caudal, 15\u201330\u00a0mL (75\u2013150\u00a0mg), using\r\na 5\u00a0mg/mL (0.5%) solution", "Labour,lumbar, 6\u201312\u00a0mL (15\u201330\u00a0mg) using a\r\n2.5\u00a0mg/mL (0.25%) or 6\u201312\u00a0mL (30\u201360\u00a0mg) using a 5\u00a0mg/mL (0.5%) solution", "Sympathetic block, 20\u201350\u00a0mL (50\u2013125\u00a0mg), using\r\na 2.5\u00a0mg/mL (0.25%) solution", "Intrathecal anaesthesia, see under preparations", "The licensed doses stated above may not be appropriate in some\r\nsettings and expert advice should be sought"], "pregnancy": "large doses during delivery can cause neonatal respiratory\r\ndepression, hypotonia, and bradycardia after paracervical or epidural\r\nblock; use lower doses for intrathecal use during late pregnancy", "breast-feeding": "amount too small to be harmful"}, "ETHERIFIED STARCH": {"indications": "low blood volume", "name": "ETHERIFIED STARCH", "renal impairment": "use with caution in mild to moderate impairment; avoid\r\nin severe impairment", "cautions": "see notes above", "side-effects": "seenotes above; also\r\npruritus, raised serum amylase", "hepatic impairment": "use with caution in severe impairment", "doses": ["by intravenous infusion, pentastarch 6%,\r\nup to 2500\u00a0mL daily; pentastarch 10\u00a0%, up to 1500\u00a0mL daily (seenotes above)"]}, "Hypertonic sodium chloride": {"name": "Hypertonic sodium chloride", "doses": ["by inhalation of nebulised solution, 4\u00a0mL\r\n2\u20134 times daily"]}, "PROPANTHELINE BROMIDE": {"indications": "adult enuresis", "name": "PROPANTHELINE BROMIDE", "renal impairment": "manufacturer advises caution", "cautions": "seenotes above; ulcerative colitis", "side-effects": "seenotes above; also\r\nfacial flushing", "contra-indications": "seenotes above", "hepatic impairment": "manufacturer advises caution", "doses": ["Initially 15\u00a0mg 3 times daily at least one hour before\r\nfood and 30\u00a0mg at bedtime, subsequently adjusted according to response\r\n(max. 120\u00a0mg daily)"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "may suppress lactation"}, "ANAESTHETICS, GENERAL": {"interactions": {"extra": "See also Surgery and Long-term Medication, \r\nsection 15.1\r\n\r\n\r\n\r\n", "bad": 1, "interaction": "enhanced hypotensive effect when  alpha-blockers given with general anaesthetics ", "name": "Anaesthetics, General", "backrefs": []}}, "LOSARTAN": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin reduces plasma concentration of losartan and its active metabolite", "name": "Losartan", "backrefs": ["Losartan"]}}, "MOXISYLYTE": {"indications": "primary Raynaud\u2019s syndrome (short-term treatment)", "name": "MOXISYLYTE", "interactions": {"extra": "", "bad": 1, "interaction": "possible severe postural hypotension when  alpha-blockers given with moxisylyte ", "name": "Moxisylyte", "backrefs": ["Moxisylyte"]}, "cautions": "diabetes mellitus", "side-effects": "nausea, diarrhoea, flushing, headache, dizziness;\r\nhepatic reactions including cholestatic jaundice and hepatitis reported\r\nto CSM", "contra-indications": "active liver disease", "doses": ["Initially 40\u00a0mg 4 times daily, increased to 80\u00a0mg 4 times\r\ndaily if poor initial response; discontinue after 2 weeks if no response"], "pregnancy": "manufacturer advises avoid"}, "METHENAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoid concomitant use of  potassium citrate with methenamine ", "name": "Methenamine", "backrefs": ["Potassium Citrate", "Sodium Citrate", "Methenamine"]}}, "MOMETASONE": {"interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of inhaled mometasone ", "name": "Mometasone", "backrefs": ["Mometasone"]}}, "LITHIUM": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  muscle relaxants enhanced by lithium ", "name": "Lithium", "backrefs": ["Acetazolamide", "Olanzapine", "Baclofen", "Haloperidol", "Verapamil", "Theophylline", "Carbamazepine", "Angiotensin-II Receptor Antagonists", "Diuretics, Loop", "NSAIDs", "Metronidazole", "Methyldopa", "Topiramate", "Sodium Bicarbonate", "ACE Inhibitors", "Diuretics, Potassium-sparing and Aldosterone Antagonists", "Diltiazem", "Clonazepam", "Diuretics, Thiazide and related", "Arsenic Trioxide", "Antidepressants, SSRI", "Antidepressants, Tricyclic", "Sulpiride", "Phenytoin", "Flupentixol", "Neostigmine", "Ketorolac", "Zuclopenthixol", "Phenothiazines", "Clozapine", "Muscle Relaxants", "Sumatriptan", "Lithium"]}}, "LISINOPRIL": {"indications": "hypertension (but see notes above); symptomatic\r\nheart failure (adjunct\u2014seesection 2.5.5); short-term\r\ntreatment following myocardial infarction in haemodynamically stable\r\npatients; renal complications of diabetes mellitus", "name": "LISINOPRIL", "renal impairment": "seenotes above; max.\r\ninitial doses 5\u201310\u00a0mg daily if eGFR 30\u201380\u00a0mL/minute/1.73\u00a0m2(max. 40\u00a0mg daily); 2.5\u20135\u00a0mg daily if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2(max. 40\u00a0mg daily); 2.5\u00a0mg daily if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "see notes above; alsoless commonlytachycardia, palpitation, cerebrovascular accident, myocardial infarction,\r\nRaynaud\u2019s syndrome, confusion, mood changes, vertigo, sleep disturbances,\r\nasthenia, impotence;rarelydry mouth, gynaecomastia,\r\nalopecia, psoriasis;very rarelyallergic alveolitis,\r\npulmonary infiltrates, profuse sweating, pemphigus, Stevens-Johnson\r\nsyndrome, and toxic epidermal necrolysis", "contra-indications": "seenotes above", "doses": ["Hypertension, initially 10\u00a0mg once daily; if used in addition\r\nto diuretic (see notes above) or\r\nin cardiac decompensation or in volume depletion, initially 2.5\u20135\u00a0mg\r\nonce daily; usual maintenance dose 20\u00a0mg once daily; max. 80\u00a0mg once\r\ndaily", "Heart failure (adjunct), initially 2.5\u00a0mg once daily under close\r\nmedical supervision (see notes above);\r\nincreased in steps no greater than 10\u00a0mg at intervals of at least\r\n2 weeks up to max. 35\u00a0mg once daily if tolerated", "Prophylaxis after myocardial infarction, systolic blood pressure\r\nover 120\u00a0mmHg, 5\u00a0mg within 24 hours, followed by further 5\u00a0mg 24 hours\r\nlater, then 10\u00a0mg after a further 24 hours, and continuing with 10\u00a0mg\r\nonce daily for 6 weeks (or continued if heart failure); systolic blood\r\npressure 100\u2013120\u00a0mmHg, initially 2.5\u00a0mg once daily, increased to maintenance\r\ndose of 5\u00a0mg once daily", "Should not be started after\r\nmyocardial infarction if systolic blood pressure less than 100\u00a0mmHg; temporarily reduce maintenance dose to 5\u00a0mg and if necessary 2.5\u00a0mg\r\ndaily if systolic blood pressure 100\u00a0mmHg or less during treatment;\r\nwithdraw if prolonged hypotension occurs (systolic blood pressure\r\nless than 90\u00a0mmHg for more than 1 hour)", "Renal complications of diabetes mellitus, initially 2.5\u20135\u00a0mg\r\nonce daily adjusted according to response; usual dose range 10\u201320\u00a0mg\r\nonce daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "Coumarins and phenindione": {"name": "Coumarins and phenindione"}, "PROPOFOL": {"indications": "see under Dose", "name": "PROPOFOL", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of myocardial depression and bradycardia when  suxamethonium given with propofol ", "name": "Propofol", "backrefs": ["Propofol"]}, "cautions": "see underIntravenous Anaestheticsandnotes above; cardiac impairment; respiratory impairment; elderly; hypovolaemia; epilepsy; hypotension; raised intracranial pressure; monitor blood-lipid concentration if risk of fat overload or if sedation longer than 3 days;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above; also hypotension,\r\ntachycardia, flushing; transient apnoea, hyperventilation, coughing,\r\nand hiccup during induction; headache;less commonlythrombosis, phlebitis;rarelyarrhythmia, headache,\r\nvertigo, shivering, euphoria;very rarelypancreatitis,\r\npulmonary oedema, sexual disinhibition, and discoloration of urine;\r\nserious and sometimes fatal side-effects reported with prolonged infusion\r\nof doses exceeding 5\u00a0mg/kg/hour, including metabolic acidosis, rhabdomyolysis,\r\nhyperkalaemia, and cardiac failure, dystonia and dyskinesia also reported", "contra-indications": "seenotes above", "hepatic impairment": "use with caution", "doses": ["Induction of anaesthesia using 0.5%or1% injection,by slow intravenous injectionorinfusion,adultunder 55 years, 1.5\u20132.5\u00a0mg/kg at a rate of 20\u201340\u00a0mg every 10 seconds\r\nuntil response;adultover 55 years\r\nor debilitated, 1\u20131.5\u00a0mg/kg at a rate of 20\u00a0mg every 10 seconds until\r\nresponse;child1 month\u201318 years seeBNF for Children", "Induction of anaesthesia using 2% injection,by intravenous\r\ninfusion,adultunder 55 years,\r\n1.5\u20132.5\u00a0mg/kg at a rate of 20\u201340\u00a0mg every 10 seconds;adultover 55 years or debilitated, 1\u20131.5\u00a0mg/kg at\r\na rate of 20\u00a0mg every 10 seconds until response;child3\u201318 years seeBNF for Children", "Maintenance of anaesthesia using 1% injection,by intravenous\r\ninfusion, 4\u201312\u00a0mg/kg/hour (3\u20136\u00a0mg/kg/hour inelderlyor debilitated)orby slow intravenous injection, 25\u201350\u00a0mg repeated according\r\nto response;child1 month\u201318 years\r\nseeBNF for Children", "Maintenance of anaesthesia using 2% injection,by intravenous\r\ninfusion, 4\u201312\u00a0mg/kg/hour (3\u20136\u00a0mg/kg/hour inelderlyor debilitated);child3\u201318 years seeBNF for Children", "Sedation of ventilated patients in intensive care using 1%or2% injection,by intravenous infusion,adultandchildover\r\n16 years, 0.3\u20134\u00a0mg/kg/hour", "Induction of sedation for surgical and diagnostic procedures\r\nusing 0.5%or1% injection,adult, initiallyby slow intravenous injectionover 1\u20135\r\nminutes, 0.5\u20131\u00a0mg/kg, dose and rate of administration adjusted according\r\nto desired level of sedation and response;child1 month\u201318 years seeBNF for Children", "Maintenance of sedation for surgical and diagnostic procedures\r\nusing 0.5% injection,by intravenous infusion,adult, 1.5\u20134.5\u00a0mg/kg/hour, dose and rate of administration\r\nadjusted according to desired level of sedation and response (additionally,\r\nif rapid increase in sedation required,by slow intravenous\r\ninjection, 10\u201320\u00a0mg); patients over 55 years or debilitated\r\nmay require lower dose and rate of administration;child17\u201318 years seeBNF for Children", "Maintenance of sedation for surgical and diagnostic procedures\r\nusing 1% injection,by intravenous infusion,adult, 1.5\u20134.5\u00a0mg/kg/hour, dose and rate of administration\r\nadjusted according to desired level of sedation and response (additionally,\r\nif rapid increase in sedation required,by slow intravenous\r\ninjection, 10\u201320\u00a0mg); patients over 55 years or debilitated\r\nmay require lower dose and rate of administration;child1 month\u201318 years seeBNF for Children", "Maintenance of sedation for surgical and diagnostic procedures\r\nusing 2% injection,by intravenous infusion,adult, 1.5\u20134.5\u00a0mg/kg/hour, dose and rate of administration\r\nadjusted according to desired level of sedation and response (additionally,\r\nif rapid increase in sedation required,by slow intravenous\r\ninjectionusing 0.5%or1% injection, 10\u201320\u00a0mg);\r\npatients over 55 years or debilitated may require lower dose and rate\r\nof administration;child3\u201318 years\r\nseeBNF for Children"], "pregnancy": "may depress neonatal respiration if used during delivery;\r\nmax. dose for maintenance of anaesthesia 6\u00a0mg/kg/hour", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "EZETIMIBE": {"indications": "adjunct to dietary measures and statin treatment in primary hypercholesterolaemia\r\nand homozygous familial hypercholesterolaemia (ezetimibe alone in\r\nprimary hypercholesterolaemia if statin inappropriate or not tolerated);\r\nadjunct to dietary measures in homozygous sitosterolaemia", "name": "EZETIMIBE", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of both drugs may increase when  ciclosporin given with ezetimibe ", "name": "Ezetimibe", "backrefs": ["Ezetimibe"]}, "cautions": "interactions:Appendix 1 (ezetimibe)", "side-effects": "gastro-intestinal disturbances; headache, fatigue;\r\nmyalgia;rarelyarthralgia, hypersensitivity reactions\r\n(including rash, angioedema, and anaphylaxis), hepatitis;very\r\nrarelypancreatitis, cholelithiasis, cholecystitis, thrombocytopenia,\r\nraised creatine kinase, myopathy, and rhabdomyolysis", "hepatic impairment": "avoid in moderate and severe impairment\u2014may accumulate", "doses": ["adultandchildover 10 years, 10\u00a0mg once daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "ANTIBACTERIALS": {"indications": "acne vulgaris", "interactions": {"extra": "", "bad": 0, "interaction": " oral typhoid vaccine inactivated by antibacterials\u2014see under Typhoid vaccines, section 14.4", "name": "Antibacterials", "backrefs": ["Antibacterials"]}, "name": "ANTIBACTERIALS", "cautions": "some manufacturers advise preparations\r\ncontainingalcoholare not suitable for use withbenzoyl peroxide", "doses": ["apply twice daily"]}, "HYDROMORPHONE HYDROCHLORIDE": {"indications": "severe pain in cancer", "name": "HYDROMORPHONE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; also pancreatitis; toxic psychosis", "side-effects": "seenotes above; also\r\nparalytic ileus, peripheral oedema, seizures, asthenia, dyskinesia,\r\nagitation, and tremor", "contra-indications": "seenotes above; also acute abdomen", "hepatic impairment": "seenotes above", "doses": ["See under preparations below"], "pregnancy": "seenotes above", "breast-feeding": "avoid\u2014no information available"}, "PROMAZINE": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  suxamethonium possibly enhanced by promazine ", "name": "Promazine", "backrefs": ["Promazine", "Levomepromazine", "Chlorpromazine"]}}, "BENZYDAMINE HYDROCHLORIDE": {"side-effects": "occasional numbness or stinging; rarely hypersensitivity\r\nreactions", "indications": "painful inflammatory conditions of oropharynx", "name": "BENZYDAMINE HYDROCHLORIDE", "doses": ["adult, 4\u20138\u00a0sprays onto\r\naffected area every 1\u00bd\u20133 hours;childunder 6 years 1\u00a0spray per 4\u00a0kg body-weight to max. 4\u00a0sprays every\r\n1\u00bd\u20133 hours; 6\u201312 years 4\u00a0sprays every 1\u00bd\u20133 hours"]}, "DROSPIRENONE": {"interactions": {"extra": "", "bad": 0, "interaction": " boceprevir increases plasma concentration of drospirenone (increased risk of toxicity)", "name": "Drospirenone", "backrefs": ["Drospirenone"]}}, "MITOMYCIN": {"indications": "seenotes aboveandsection 7.4.4", "name": "MITOMYCIN", "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant\r\nto tissues", "side-effects": "seesection 8.1andnotes above", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "APOMORPHINE": {"interactions": {"extra": "", "bad": 0, "interaction": " antipsychotics antagonise effects of apomorphine ", "name": "Apomorphine", "backrefs": ["Apomorphine"]}}, "TEMOZOLOMIDE": {"indications": "seenotes above", "name": "TEMOZOLOMIDE", "renal impairment": "manufacturer advises caution\u2014no information available", "interactions": {"extra": "", "bad": 0, "interaction": " valproate increases plasma concentration of temozolomide ", "name": "Temozolomide", "backrefs": ["Temozolomide"]}, "cautions": "seesection 8.1;interactions:Appendix 1 (temozolomide)", "side-effects": "seesection 8.1", "hepatic impairment": "use with caution in severe impairment\u2014no information\r\navailable", "doses": ["Consult product literature;childunder 3 years not recommended"], "pregnancy": "avoid (teratogenic and embryotoxic inanimalstudies); manufacturer advises adequate contraception during treatment;\r\nmen should avoid fathering a child during and for at least 6 months\r\nafter treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "PROPIVERINE HYDROCHLORIDE": {"indications": "urinary frequency, urgency and incontinence; neurogenic bladder instability", "name": "PROPIVERINE HYDROCHLORIDE", "renal impairment": "doses above 30\u00a0mg daily should be used with caution if\r\neGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "avoid in moderate to severe impairment", "doses": ["adultover\r\n18 years, 15\u00a0mg 1\u20133 times daily, increased if necessary to max. 15\u00a0mg\r\n4 times daily"], "pregnancy": "manufacturer advises avoid (restriction of skeletal\r\ndevelopment inanimals)", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "CO-AMILOZIDE": {"indications": "potassium conservation in the treatment\r\nof hypertension, congestive heart failure, or hepatic cirrhosis with\r\nascites and oedema", "name": "CO-AMILOZIDE", "renal impairment": "see Amiloride (section 2.2.3), and Thiazides and related diuretics\r\n(section 2.2.1)", "cautions": "see Amiloride (section 2.2.3), and\r\nThiazides and related diuretics (section 2.2.1)", "side-effects": "see Amiloride (section 2.2.3), and Thiazides and related diuretics\r\n(section 2.2.1); also\r\nfever, flushing, respiratory distress, restlessness, sweating", "contra-indications": "see Amiloride (section 2.2.3), and\r\nThiazides and related diuretics (section 2.2.1)", "hepatic impairment": "see Thiazides and related diuretics (section 2.2.1)", "doses": ["hypertension, initially \u00bd tablet daily, increased if necessary\r\nto max. 1 tablet daily", "Congestive heart failure, initially \u00bd tablet daily, increased\r\nif necessary to max. 2 tablets daily; reduce for maintenance if possible", "Oedema and ascites in cirrhosis of the liver, initially 1 tablet\r\ndaily, increased if necessary to max. 2 tablets daily; reduce for\r\nmaintenance if possible"], "pregnancy": "see Amiloride (section 2.2.3), and Thiazides and related diuretics\r\n(section 2.2.1)", "breast-feeding": "avoid\u2014no information regarding amiloride component\r\navailable; amount of hydrochlorothiazide in milk probably too small\r\nto be harmful; large doses of hydrochlorothiazide may suppress lactation"}, "Local treatment": {"name": "Local treatment", "doses": ["symptomatic treatment of dry mouth in patients with impaired\r\nsalivary gland function and patent salivary ducts, allow 1 tablet\r\nto dissolve slowly in the mouth when required"]}, "LAMIVUDINE": {"indications": "see preparations below", "name": "LAMIVUDINE", "renal impairment": "reduce dose if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2; consult product literature", "interactions": {"extra": "", "bad": 0, "interaction": " trimethoprim (as co-trimoxazole) increases plasma concentration of lamivudine\u2014avoid concomitant use of high-dose co-trimoxazole", "name": "Lamivudine", "backrefs": ["Emtricitabine", "Lamivudine"]}, "cautions": "seenotes above;interactions:Appendix 1 (lamivudine)", "side-effects": "see notes above; also peripheral neuropathy, muscle\r\ndisorders including rhabdomyolysis, nasal symptoms, alopecia", "hepatic impairment": "seenotes aboveand Cautions\r\nabove", "doses": ["chronic hepatitis B infectioneitherwith\r\ncompensated liver disease (with evidence of viral replication and\r\nhistology of active liver inflammation or fibrosis) when first-line\r\ntreatments cannot be used,or(in combination with\r\nanother antiviral drug without cross-resistance to lamivudine) with\r\ndecompensated liver disease, 100\u00a0mg daily;child[unlicensed indication] 2\u201311 years, 3\u00a0mg/kg once daily (max. 100\u00a0mg\r\ndaily); 12\u201317 years, adult dose", "Patients receivinglamivudinefor concomitant HIV infection should continue to receivelamivudinein a dose appropriate for HIV infection"], "pregnancy": "seePregnancy", "breast-feeding": "can be used with caution in women infected with\r\nchronic hepatitis B alone, providing that adequate measures are taken\r\nto prevent hepatitis B infection in infants; for women infected with\r\nHIV, seeBreast-feeding"}, "CRANBERRY JUICE": {"interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  coumarins possibly enhanced by cranberry juice\u2014avoid concomitant use", "name": "Cranberry Juice", "backrefs": ["Cranberry Juice"]}}, "FLUPENTIXOL DECANOATE": {"indications": "maintenance in schizophrenia and other psychoses", "name": "FLUPENTIXOL DECANOATE", "renal impairment": "seesection 4.2.1", "cautions": "seeFlupentixol(section 4.2.1) and notes above; an alternative antipsychotic may be necessary if symptoms such as\r\naggression or agitation appear", "side-effects": "seeFlupentixol(section 4.2.1) andnotes above,\r\nbut may have a mood elevating effect", "contra-indications": "seeFlupentixol(section 4.2.1) and notes above", "hepatic impairment": "seesection 4.2.1", "doses": ["By deep intramuscular injectioninto the\r\nupper outer buttock or lateral thigh, test dose 20\u00a0mg, then after\r\nat least 7 days 20\u201340\u00a0mg repeated at intervals of 2\u20134 weeks, adjusted\r\naccording to response; max. 400\u00a0mg weekly; usual maintenance dose\r\n50\u00a0mg every 4 weeks to 300\u00a0mg every 2 weeks;elderlyinitially quarter to half adult dose;childnot recommended"], "pregnancy": "seesection 4.2.1", "breast-feeding": "seesection 4.2.1"}, "BUPROPION HYDROCHLORIDE": {"indications": "seenotes above", "name": "BUPROPION HYDROCHLORIDE", "renal impairment": "reduce dose to 150\u00a0mg daily", "cautions": "elderly; predisposition\r\nto seizures (prescribe only if benefit clearly outweighs risk) including concomitant use of drugs that lower seizure\r\nthreshold, alcohol abuse, history of head trauma, and diabetes; measure blood pressure before and during treatment;interactions: Appendix 1 (bupropion)", "side-effects": "dry mouth, gastro-intestinal disturbances, taste\r\ndisturbance; agitation, anxiety, dizziness, depression, headache,\r\nimpaired concentration, insomnia (reduced by avoiding dose at bedtime),\r\ntremor; fever; pruritus, rash, sweating;less commonlychest pain, flushing, hypertension, tachycardia, anorexia, asthenia,\r\nconfusion, tinnitus, and visual disturbances;rarelyhepatitis, jaundice, palpitation, postural hypotension, vasodilatation,\r\nabnormal dreams, ataxia, dystonia, depersonalisation, hallucinations,\r\nhostility, incoordination, irritability, impaired memory, paraesthesia,\r\nseizures, twitching, blood-glucose changes, urinary frequency, urinary\r\nretention, exacerbation of psoriasis, and Stevens-Johnson syndrome;very rarelyaggression, delusions, paranoid ideation, and\r\nrestlessness;also reportedsuicidal ideation", "contra-indications": "acute alcohol or benzodiazepine withdrawal; severe hepatic cirrhosis; CNS tumour; history of seizures, eating disorders, or bipolar disorder", "hepatic impairment": "reduce dose to 150\u00a0mg daily; avoid in severe hepatic\r\ncirrhosis", "doses": ["adultover 18 years, start\r\n1\u20132 weeks before target stop date, initially 150\u00a0mg daily for 6 days\r\nthen 150\u00a0mg twice daily (max. single dose 150\u00a0mg, max. daily dose\r\n300\u00a0mg; minimum 8 hours between doses); period of treatment 7\u20139 weeks;\r\ndiscontinue if abstinence not achieved at 7 weeks; consider max. 150\u00a0mg\r\ndaily in patients with risk factors for seizures;elderlymax. 150\u00a0mg daily"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "present in milk\u2014avoid"}, "BILE ACIDS": {"interactions": {"extra": "", "bad": 0, "interaction": " antacids possibly reduce absorption of bile acids ", "name": "Bile Acids", "backrefs": ["Bile Acids"]}}, "NEOSTIGMINE": {"indications": "myasthenia gravis; other indications\r\n(section 15.1.6)", "name": "NEOSTIGMINE", "renal impairment": "may need dose reduction", "interactions": {"extra": "", "bad": 0, "interaction": " lithium antagonises effects of neostigmine ", "name": "Neostigmine", "backrefs": ["Neostigmine"]}, "cautions": "asthma (extremecaution), bradycardia, arrhythmias, recent myocardial infarction, epilepsy, hypotension, parkinsonism, vagotonia, peptic ulceration, hyperthyroidism; atropine or other antidote to muscarinic effects may be necessary\r\n(particularly whenneostigmineis given by injection),\r\nbut not given routinely because it may mask signs of overdosage;interactions:Appendix 1 (parasympathomimetics)", "side-effects": "nausea, vomiting, increased salivation, diarrhoea,\r\nabdominal cramps (more marked with higher doses); signs of overdosage\r\ninclude bronchoconstriction, increased bronchial secretions, lacrimation,\r\nexcessive sweating, involuntary defaecation and micturition, miosis,\r\nnystagmus, bradycardia, heart block, arrhythmias, hypotension, agitation,\r\nexcessive dreaming, and weakness eventually leading to fasciculation\r\nand paralysis", "contra-indications": "intestinal or urinary obstruction", "doses": ["By mouth,neostigminebromide 15\u201330\u00a0mg at suitable intervals throughout day, total daily\r\ndose 75\u2013300\u00a0mg (but see also notes above);neonate1\u20135\u00a0mg every 4 hours, half an hour before feeds;childup to 6 years initially 7.5\u00a0mg, 6\u201312 years\r\ninitially 15\u00a0mg, usual total daily dose 15\u201390\u00a0mg", "By subcutaneousorintramuscular\r\ninjection,adultandchildover 12 years,neostigminemetilsulfate 1\u20132.5\u00a0mg at suitable intervals throughout day (usual\r\ntotal daily dose 5\u201320\u00a0mg);neonate150\u00a0micrograms/kg\r\nevery 6\u20138 hours 30 minutes before feeds, increased to max. 300\u00a0micrograms/kg\r\nevery 4 hours, if necessary [unlicensed];child1 month\u201312 years 200\u2013500\u00a0micrograms as required"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "amount probably too small to be harmful"}, "DUTASTERIDE": {"indications": "benign prostatic hyperplasia", "name": "DUTASTERIDE", "interactions": {"extra": "", "bad": 0, "interaction": " diltiazem increases plasma concentration of dutasteride ", "name": "Dutasteride", "backrefs": ["Dutasteride"]}, "cautions": "seenotes above;interactions:Appendix 1 (dutasteride)", "side-effects": "see notes above", "hepatic impairment": "avoid in severe impairment\u2014no information available", "doses": ["500\u00a0micrograms daily, review treatment at 3\u20136 months and\r\nthen every 6\u201312 months (may require several months treatment before\r\nbenefit is obtained)"]}, "LEPIRUDIN": {"indications": "thromboembolic disease requiring parenteral anticoagulation in patients\r\nwith heparin-induced thrombocytopenia type II", "name": "LEPIRUDIN", "renal impairment": "reduce initial intravenous injection dose to 200\u00a0micrograms/kg\r\nand reduce subsequent infusion dose by 50\u201385% if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2, but avoid or stop infusion if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2(consult product literature)", "cautions": "recent bleeding or risk of bleeding including recent active peptic ulcer, recent puncture of large vessels, organ\r\nbiopsy, recent major surgery, stroke, bleeding disorders, severe hypertension, bacterial\r\nendocarditis, elderly; concomitant use\r\nof drugs that increase risk of bleeding; determine activated partial thromboplastin time 4 hours after start\r\nof treatment (or after infusion rate altered) and at least once daily\r\nthereafter", "side-effects": "bleeding, reduced haemoglobin concentration without\r\nobvious source of bleeding;rarelyhot flushes, shock,\r\ncough, stridor, dyspnea, fever, chills", "hepatic impairment": "no information\u2014manufacturer advises that cirrhosis\r\nmay affect renal excretion", "doses": ["Initiallyby slow intravenous injection(of 5\u00a0mg/mL solution), 400\u00a0micrograms/kg followed bycontinuous\r\nintravenous infusionof 150\u00a0micrograms/kg/hour (max. 16.5\u00a0mg/hour),\r\nadjusted according to activated partial thromboplastin time, for 2\u201310\r\ndays (longer if necessary)"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "CEFUROXIME": {"indications": "see underCefaclor; surgical prophylaxis; more active againstHaemophilus influenzae; Lyme disease", "name": "CEFUROXIME", "renal impairment": "use parenteral dose of 750\u00a0mg twice daily if eGFR 10\u201320\u00a0mL/minute/1.73\u00a0m2; use parenteral dose of 750\u00a0mg once daily if eGFR less than\r\n10\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["By mouth(ascefuroximeaxetil),\r\n250\u00a0mg twice daily in most infections including mild to moderate lower\r\nrespiratory-tract infections (e.g. bronchitis); doubled for more severe\r\nlower respiratory-tract infections or if pneumonia suspected", "Urinary-tract infection, 125\u00a0mg twice daily, doubled in pyelonephritis", "childover 3 months, 125\u00a0mg twice\r\ndaily, if necessary doubled in child over 2 years with otitis media", "Lyme disease (see alsosection 5.1.1.3),adultandchildover 12 years, 500\u00a0mg twice\r\ndaily for 14\u201321 days (for 28 days in Lyme arthritis) [unlicensed duration]", "By intramuscular injectionorintravenous injectionorinfusion, 750\u00a0mg every 6\u20138 hours; 1.5\u00a0g every 6\u20138\r\nhours in severe infections; single doses over 750\u00a0mg intravenous route\r\nonly", "childusual dose 60\u00a0mg/kg daily\r\n(range 30\u2013100\u00a0mg/kg daily) in 3\u20134 divided doses (2\u20133 divided doses\r\nin neonates)", "Surgical prophylaxis, 1.5\u00a0gby intravenous injectionup to 30 minutes before the procedure; up to 3 further doses of\r\n750\u00a0mg may be givenby intramuscularorintravenous injectionevery 8 hours for high-risk\r\nprocedures", "Open fractures, prophylaxis (see also Table 2,section 5.1),by intravenous injectionorinfusion, 1.5\u00a0g every 8 hours until soft-tissue closure (max. duration 72\r\nhours)"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "Capsaicin": {"side-effects": "transient burning sensation during initial treatment\r\n(particularly if too much used or if administered less than 4 times\r\ndaily);rarelycough, sneezing, eye irritation; dyspnoea\r\nand exacerbation of asthma also reported", "cautions": "avoid contact with eyes, inflamed or broken skin;\r\nwash hands immediately after use (or wash hands 30 minutes after application\r\nif hands treated); not to be used under tight bandages; avoid hot\r\nshower or bath just before or after application (burning sensation\r\nenhanced); avoid inhalation of vapours", "name": "Capsaicin", "doses": ["symptomatic relief in osteoarthritis, apply sparingly\r\n4 times daily (not more often than every 4 hours)"]}, "CEFADROXIL": {"indications": "see underCefaclor; see also notes above", "name": "CEFADROXIL", "renal impairment": "1\u00a0g initially, then 500\u00a0mg every 12 hours if eGFR 26\u201350\u00a0mL/minute/1.73\u00a0m2; 1\u00a0g initially, then 500\u00a0mg every 24 hours if eGFR 11\u201326\u00a0mL/minute/1.73\u00a0m2; 1\u00a0g initially, then 500\u00a0mg every 36 hours if eGFR less than\r\n11\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["0.5\u20131\u00a0g twice daily; skin, soft-tissue, and uncomplicated\r\nurinary-tract infections, 1\u00a0g daily;child6\u201318 years, body-weight under 40\u00a0kg, 500\u00a0mg twice daily; body-weight\r\nover 40\u00a0kg, adult dose"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "DEXAMFETAMINE SULPHATE": {"indications": "narcolepsy; refractory attention deficit hyperactivity disorder (under\r\nspecialist supervision)", "name": "DEXAMFETAMINE SULPHATE", "renal impairment": "use with caution", "cautions": "seenotes above; also anorexia; mild hypertension (contra-indicated if moderate or severe); psychosis or bipolar disorder; monitor\r\nfor aggressive behaviour or hostility during initial treatment; history of epilepsy (discontinue if\r\nseizures occur); tics and Tourette syndrome (use with caution)\u2014discontinue if\r\ntics occur; monitor growth in children (see\r\nalso below); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal; data on safety and efficacy of long-term use not complete; acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(sympathomimetics)", "side-effects": "nausea, diarrhoea, dry mouth, abdominal cramps,\r\nanorexia (increased appetite also reported), weight loss, taste disturbance,\r\nischaemic colitis, palpitations, tachycardia, chest pain, hypertension,\r\nhypotension, cardiomyopathy, myocardial infarction, cardiovascular\r\ncollapse, cerebral vasculitis, stroke, headache, restlessness, depression,\r\nhyperreflexia, hyperactivity, impaired concentration, ataxia, anxiety,\r\naggression, dizziness, confusion, sleep disturbances, dysphoria, euphoria,\r\nirritability, nervousness, malaise, obsessive-compulsive behaviour,\r\nparanoia, psychosis, panic attack, tremor, seizures (see also Cautions),\r\nneuroleptic malignant syndrome, anhedonia, growth restriction in children\r\n(see also under Cautions andnotes above), pyrexia,\r\nrenal impairment, sexual dysfunction, acidosis, rhabdomyolysis, mydriasis,\r\nvisual disturbances, alopecia, rash, sweating, urticaria; central\r\nstimulants have provoked choreoathetoid movements and dyskinesia,\r\ntics and Tourette syndrome in predisposed individuals (see also Cautions);very rarelyangle-closure glaucoma;overdosage:seeEmergency Treatment of Poisoning", "contra-indications": "cardiovascular disease including moderate to severe hypertension, structural cardiac abnormalities, advanced arteriosclerosis, hyperexcitability or agitated states, hyperthyroidism, history of drug oralcoholabuse", "doses": ["Narcolepsy, initially 10\u00a0mg (elderly5\u00a0mg) daily in divided doses increased at weekly intervals by 10\u00a0mg\r\n(elderly5\u00a0mg) daily to a max. of 60\u00a0mg\r\ndaily", "Refractory attention deficit hyperactivity disorder,adultover 18 years [unlicensed use], initially 5\u00a0mg\r\ntwice daily, increased at weekly intervals according to response;\r\nmax. 60\u00a0mg daily;child6\u201318 years,\r\ninitially 2.5\u00a0mg 2\u20133 times daily, increased if necessary at weekly\r\nintervals by 5\u00a0mg daily, usual max. 1\u00a0mg/kg (up to 20\u00a0mg) daily (40\u00a0mg\r\ndaily has been required in some children)", "Maintenance dose given in 2\u20134 divided doses"], "pregnancy": "avoid (retrospective evidence of uncertain significance\r\nsuggesting possible embryotoxicity)", "breast-feeding": "significant amount in milk\u2014avoid"}, "FLUVOXAMINE MALEATE": {"indications": "depressive illness, obsessive-compulsive disorder", "name": "FLUVOXAMINE MALEATE", "renal impairment": "start with low dose", "cautions": "seenotes above", "side-effects": "seenotes above; palpitation, tachycardia, malaise;less commonlypostural hypotension, confusion, ataxia;rarelyabnormal liver function, usually symptomatic (discontinue\r\ntreatment);also reportedparaesthesia, taste disturbance,\r\nneuroleptic malignant syndrome-like event", "contra-indications": "seenotes above", "hepatic impairment": "start with low dose", "doses": ["Depression,adultover\r\n18 years, initially 50\u2013100\u00a0mg daily in the evening, increased gradually\r\nif necessary to max. 300\u00a0mg daily (over 150\u00a0mg in divided doses);\r\nusual maintenance dose 100\u00a0mg daily", "Obsessive-compulsive disorder, initially 50\u00a0mg in the evening\r\nincreased gradually if necessary after some weeks to max. 300\u00a0mg daily\r\n(over 150\u00a0mg in divided doses); usual maintenance dose 100\u2013300\u00a0mg\r\ndaily;childover 8 years initially\r\n25\u00a0mg daily increased if necessary in steps of 25\u00a0mg every 4\u20137 days\r\nto max. 200\u00a0mg daily (over 50\u00a0mg in 2 divided doses)", "If no improvement in obsessive-compulsive\r\ndisorder within 10 weeks, treatment should be reconsidered"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014avoid"}, "NIFEDIPINE": {"indications": "prophylaxis of angina; hypertension; Raynaud\u2019s phenomenon; premature\r\nlabour (section 7.1.3)", "name": "NIFEDIPINE", "interactions": {"extra": "", "bad": 1, "interaction": "profound hypotension reported with concomitant use of  parenteral magnesium and nifedipine in pre-eclampsia", "name": "Nifedipine", "backrefs": ["Nifedipine"]}, "cautions": "seenotes above; also withdraw if ischaemic pain\r\noccurs or existing pain worsens shortly after initiating treatment; poor cardiac reserve; heart failure or significantly impaired left ventricular function\r\n(heart failure deterioration observed); severe hypotension; elderly; diabetes mellitus; acute\r\nporphyria (but seesection 9.8.2);interactions:Appendix 1\r\n(calcium-channel blockers)", "side-effects": "gastro-intestinal disturbance; hypotension, oedema,\r\nvasodilatation, palpitation; headache, dizziness, lethargy, asthenia;less commonlytachycardia, syncope, chills, nasal congestion,\r\ndyspnoea, anxiety, sleep disturbance, vertigo, migraine, paraesthesia,\r\ntremor, polyuria, dysuria, nocturia, erectile dysfunction, epistaxis,\r\nmyalgia, joint swelling, visual disturbance, sweating, hypersensitivity\r\nreactions (including angioedema, jaundice, pruritus, urticaria, and\r\nrash);rarelyanorexia, gum hyperplasia, mood disturbances,\r\nhyperglycaemia, male infertility, purpura, and photosensitivity reactions;\r\nalso reported dysphagia, intestinal obstruction, intestinal ulcer,\r\nbezoar formation (with some modified-release preparations), gynaecomastia,\r\nagranulocytosis, and anaphylaxis;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "cardiogenic shock; advanced aortic stenosis; within\r\n1 month of myocardial infarction; unstable or acute attacks of angina", "hepatic impairment": "dose reduction may be required in severe liver disease", "doses": ["hypertension and angina prophylaxis, 30\u00a0mg once daily,\r\nincreased if necessary; max. 90\u00a0mg once daily"], "pregnancy": "may inhibit labour; manufacturer advises avoid before\r\nweek 20; risk to fetus should be balanced against risk of uncontrolled\r\nmaternal hypertension; use only if other treatment options are not\r\nindicated or have failed", "breast-feeding": "amount too small to be harmful but manufacturers\r\nadvise avoid"}, "ANTIHISTAMINES, SEDATING": {"interactions": {"extra": "", "bad": 1, "interaction": "sedative effects possibly increased when  opioid analgesics given with sedating antihistamines ", "name": "Antihistamines, Sedating", "backrefs": []}}, "BEE AND WASP ALLERGEN EXTRACTS": {"indications": "hypersensitivity to wasp or bee venom\r\n(see notes above)", "name": "BEE AND WASP ALLERGEN EXTRACTS", "cautions": "seenotes aboveand consult product literature", "side-effects": "consult product literature", "contra-indications": "seenotes aboveand consult product literature", "doses": ["By subcutaneous injection, consult product\r\nliterature"], "pregnancy": "avoid"}, "DARBEPOETIN ALFA": {"indications": "see under Dose below", "name": "DARBEPOETIN ALFA", "cautions": "seeEpoetin", "side-effects": "seeEpoetin; also, oedema,\r\ninjection-site pain; isolated reports of pure red cell aplasia, particularly\r\nfollowing subcutaneous administration in patients with chronic renal\r\nfailure (discontinue therapy)\u2014see alsonotes above", "contra-indications": "seeEpoetin", "hepatic impairment": "manufacturer advises caution", "doses": ["Symptomatic anaemia associated with chronic renal failure\r\nin patients on dialysis (see alsoMHRA/CHM advice),adultandchildover\r\n11 years,by subcutaneousorintravenous injection, initially 450\u00a0nanograms/kg once weekly,\r\nadjusted according to response by approx. 25% at intervals of at least\r\n4 weeks; maintenance dose, given once weeklyoronce\r\nevery 2 weeks"], "pregnancy": "no evidence of harm inanimalstudies\u2014manufacturer\r\nadvises caution", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "GUANETHIDINE MONOSULPHATE": {"indications": "hypertensive crisis (but no longer recommended\u2014seesection 2.5)", "name": "GUANETHIDINE MONOSULPHATE", "renal impairment": "reduce dose if eGFR 40\u201365\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 40\u00a0mL/minute/1.73\u00a0m2", "cautions": "coronary or cerebral arteriosclerosis, asthma, history of peptic ulceration;interactions:Appendix 1 (adrenergic neurone blockers)", "side-effects": "postural hypotension, failure of ejaculation,\r\nfluid retention, nasal congestion, headache, diarrhoea, drowsiness", "contra-indications": "phaeochromocytoma, heart failure", "doses": ["By intramuscular injection, 10\u201320\u00a0mg, repeated\r\nafter 3 hours if required"], "pregnancy": "postural hypotension and reduced uteroplacental perfusion;\r\nshould not be used to treat hypertension in pregnancy"}, "BETAMETHASONE ESTERS": {"indications": "severe inflammatory skin disorders such as eczemas\r\nunresponsive to less potentcorticosteroids; psoriasis,\r\nseenotes above", "name": "BETAMETHASONE ESTERS", "cautions": "seenotes above; use of more than 100\u00a0g per week\r\nof 0.1% preparation likely to cause adrenal suppression", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily"]}, "DALTEPARIN SODIUM": {"indications": "see notes above and under preparations", "name": "DALTEPARIN SODIUM", "renal impairment": "risk of bleeding may be increased\u2014dose reduction, and\r\nmonitoring of anti-Factor Xa, may be required; use of unfractionated\r\nheparin may be preferable", "cautions": "see underHeparinand notes above", "side-effects": "see underHeparin", "contra-indications": "see underHeparin", "hepatic impairment": "dose reduction may be required in severe impairment", "doses": ["unstable coronary artery disease (including non-ST-segment-elevation\r\nmyocardial infarction),by subcutaneous injection,\r\n120\u00a0units/kg every 12 hours (max. 10\u00a0000\u00a0units twice daily) for up\r\nto 8 days; beyond 8 days (if awaiting angiography or revascularisation)\r\nwomen body-weight less than 80\u00a0kg and men less than 70\u00a0kg, 5000 units\r\nevery 12 hours, women body-weight greater than 80\u00a0kg and men greater\r\nthan 70\u00a0kg, 7500\u00a0units every 12 hours, until day of procedure (max.\r\n45 days)"], "pregnancy": "not known to be harmful; multidose vial contains\r\nbenzyl alcohol\u2014manufacturer advises avoid; see alsoPregnancy", "breast-feeding": "no information available"}, "CLOMETHIAZOLE": {"indications": "see under Dose;alcoholwithdrawal (section 4.10.1)", "name": "CLOMETHIAZOLE", "renal impairment": "start with small doses in severe impairment; increased\r\ncerebral sensitivity", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits metabolism of clomethiazole (increased plasma concentration)", "name": "Clomethiazole", "backrefs": ["Clomethiazole"]}, "cautions": "cardiac and respiratory\r\ndisease (confusional state may indicate hypoxia), chronic pulmonary insufficiency, sleep\r\napnoea syndrome; history of drug abuse; avoid prolonged use (and abrupt withdrawal thereafter); marked personality disorder; elderly; excessive sedation may occur (particularly with higher\r\ndoses);interactions:Appendix 1 (anxiolytics\r\nand hypnotics)", "side-effects": "nasal congestion and irritation (increased nasopharyngeal\r\nand bronchial secretions), conjunctival irritation, headache;rarelygastro-intestinal disturbances, paradoxical excitement,\r\nconfusion, dependence, rash, urticaria, bullous eruption, anaphylaxis,\r\nalterations in liver enzymes", "contra-indications": "acute pulmonary insufficiency;alcohol-dependent patients who continue\r\nto drink", "hepatic impairment": "can precipitate coma; reduce dose", "doses": ["Severe insomnia in the elderly (short-term use), 1\u20132 capsules\r\nat bedtime;childnot recommended", "Restlessness and agitation in the elderly, 1 capsule 3 times\r\ndaily", "Alcoholwithdrawal (but seesection 4.10.1), initially 2\u20134 capsules, if\r\nnecessary repeated after some hours; day 1 (first 24 hours), 9\u201312\r\ncapsules in 3\u20134 divided doses; day 2, 6\u20138 capsules in 3\u20134 divided\r\ndoses; day 3, 4\u20136 capsules in 3\u20134 divided doses; then gradually reduced\r\nover days 4\u20136; total treatment for not more than 9 days"], "pregnancy": "avoid if possible\u2014especially during first and third\r\ntrimesters", "breast-feeding": "use only if benefit outweighs risk\u2014present in\r\nbreast milk but effects unknown"}, "GEMCITABINE": {"indications": "seenotes above", "name": "GEMCITABINE", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  warfarin possibly enhanced by gemcitabine ", "name": "Gemcitabine", "backrefs": ["Gemcitabine"]}, "cautions": "seesection 8.1andnotes above;interactions: Appendix 1 (gemcitabine)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "manufacturer advises caution", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nmanufacturer advises effective contraception during treatment; men\r\nmust avoid fathering a child during and for 6 months after treatment;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "DOCETAXEL": {"indications": "adjuvant treatment of operable node-positive and operable node-negative\r\nbreast cancer, in combination with doxorubicin and cyclophosphamide;\r\nwith doxorubicin for initial chemotherapy of locally advanced or metastatic\r\nbreast cancer; monotherapy for locally advanced or metastatic breast\r\ncancer where cytotoxic chemotherapy with an anthracycline or an alkylating\r\ndrug has failed; with capecitabine for locally advanced or metastatic\r\nbreast cancer where cytotoxic chemotherapy with an anthracycline has\r\nfailed; with trastuzumab for initial chemotherapy of metastatic breast\r\ncancer which overexpresses human epidermal growth factor-2; locally\r\nadvanced or metastatic non-small cell lung cancer where first-line\r\nchemotherapy has failed; with cisplatin for unresectable, locally\r\nadvanced or metastatic non-small cell lung cancer; with prednisolone\r\nfor hormone-refractory metastatic prostate cancer; with cisplatin\r\nand fluorouracil for initial treatment of metastatic gastric adenocarcinoma,\r\nincluding adenocarcinoma of the gastro-oesophageal junction; with\r\ncisplatin and fluorouracil for induction treatment of locally advanced\r\nsquamous cell carcinoma of the head and neck", "name": "DOCETAXEL", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of docetaxel (increased risk of toxicity)", "name": "Docetaxel", "backrefs": ["Ritonavir", "Docetaxel", "Lapatinib", "Sorafenib", "Erythromycin", "Ciclosporin", "Ketoconazole"]}, "cautions": "seesection 8.1andnotes\r\nabove; avoid in acute porphyria (but\r\nseesection 9.8.2);interactions:Appendix 1\r\n(docetaxel)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "monitor liver function\u2014reduce dose according to liver\r\nenzymes; avoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (toxicity and reduced fertility inanimalstudies); manufacturer advises effective contraception\r\nduring and for at least 3 months after treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "RIFABUTIN": {"indications": "see under Dose", "name": "RIFABUTIN", "renal impairment": "use half normal dose if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " nevirapine possibly increases plasma concentration of rifabutin ", "name": "Rifabutin", "backrefs": ["Rifabutin"]}, "cautions": "see underRifampicin; acute porphyria (section 9.8.2)", "side-effects": "nausea, vomiting; leucopenia, thrombocytopenia,\r\nanaemia, rarely haemolysis; raised liver enzymes, jaundice, rarely\r\nhepatitis; uveitis following high doses or administration with drugs\r\nwhich raise plasma concentration\u2014see alsointeractions:Appendix 1 (rifamycins); arthralgia, myalgia, influenza-like syndrome,\r\ndyspnoea; also hypersensitivity reactions including fever, rash, eosinophilia,\r\nbronchospasm, shock; skin, urine, saliva and other body secretions\r\ncoloured orange-red; asymptomatic corneal opacities reported with\r\nlong-term use", "contra-indications": "rifamycin hypersensitivity", "hepatic impairment": "reduce dose in severe impairment", "doses": ["Prophylaxis ofMycobacterium\r\naviumcomplex infections in immunosuppressed patients with\r\nlow CD4 count (see product literature), 300\u00a0mg daily as a single dose", "Treatment of non-tuberculous mycobacterial disease, in combination\r\nwith other drugs, 450\u2013600\u00a0mg daily as a single dose for up to 6 months\r\nafter cultures negative", "Treatment of pulmonary tuberculosis, in combination with other\r\ndrugs, 150\u2013450\u00a0mg daily as a single dose for at least 6 months", "childnot recommended"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "CIPROFLOXACIN": {"indications": "see notes above and under Dose; eye infections (section\r\n11.3.1)", "name": "CIPROFLOXACIN", "renal impairment": "by mouth, 250\u2013500\u00a0mg every 12 hours if\r\neGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2(every 24 hours if eGFR less\r\nthan 30\u00a0mL/minute/1.73\u00a0m2); by intravenous infusion (200\u00a0mg over 30 minutes), 200\u2013400\u00a0mg every 12 hours if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2(every 24 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2)", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of ciprofloxacin (increased plasma concentration)", "name": "Ciprofloxacin", "backrefs": ["Ciprofloxacin"]}, "cautions": "seenotes above; avoid excessive alkalinity of urine and ensure adequate fluid intake (risk of crystalluria);interactions:Appendix 1 (quinolones)", "side-effects": "seenotes above;\r\nalso flatulence, pain and phlebitis at injection site;rarelydysphagia, pancreatitis, chest pain, tachycardia, syncope, oedema,\r\nhot flushes, abnormal dreams, sweating, hyperglycaemia, and erythema\r\nnodosum;very rarelymovement disorders, tinnitus,\r\nand tenosynovitis", "contra-indications": "seenotes above", "doses": ["By mouth, respiratory-tract infections,\r\n500\u2013750\u00a0mg twice daily (750\u00a0mg twice daily in pseudomonal lower respiratory-tract\r\ninfection in cystic fibrosis)", "Urinary-tract infections, 250\u2013750\u00a0mg twice daily (250\u00a0mg twice\r\ndaily for 3 days usually adequate for acute uncomplicated cystitis\r\nin women)", "Acute or chronic prostatitis, 500\u00a0mg twice daily for 28 days", "Gonorrhoea (see also Table 1,section 5.1), 500\u00a0mg as a single dose", "Most other infections, 500\u00a0mg twice daily (increased to 750\u00a0mg\r\ntwice daily in severe or deep-seated infection)", "Surgical prophylaxis [unlicensed], 750\u00a0mg 60 minutes before\r\nprocedure", "Prophylaxis of meningococcal meningitis, Table 2,section 5.1", "By intravenous infusionover 60 minutes,\r\n400\u00a0mg every 8\u201312 hours", "Anthrax (treatment and post-exposure prophylaxis,\r\nseenotes above),by mouth, 500\u00a0mg\r\ntwice daily", "By intravenous infusionover 60 minutes, 400\u00a0mg\r\nevery 12 hours", "childunder 18 years\r\nseeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful but manufacturer\r\nadvises avoid"}, "XYLOMETAZOLINE HYDROCHLORIDE": {"indications": "nasal congestion", "name": "XYLOMETAZOLINE HYDROCHLORIDE", "cautions": "see underEphedrine Hydrochloridesection 3.1.1.2andnotes above; also\r\navoid excessive or prolonged use", "side-effects": "see underEphedrine Hydrochlorideandnotes above; in small\r\nchildren, also restlessness, sleep disturbances, and hallucinations\r\n(discontinue treatment)", "doses": ["1 spray into each nostril 1\u20133 times daily when required;\r\nmax. duration 7 days; not recommended for children under 12 years"], "pregnancy": "manufacturer advises avoid"}, "TRAMADOL": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  mirtazapine given with tramadol ", "name": "Tramadol", "backrefs": ["Tramadol"]}}, "TOPIRAMATE": {"indications": "seenotes above", "name": "TOPIRAMATE", "renal impairment": "use with caution if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2\u2014reduced clearance and longer time to steady-state plasma\r\nconcentration", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  lithium possibly affected by topiramate ", "name": "Topiramate", "backrefs": ["Topiramate"]}, "cautions": "avoid abrupt withdrawal; risk of metabolic acidosis; risk of nephrolithiasis\u2014ensure adequate hydration (especially\r\nin strenuous activity or warm environment); avoid in acute\r\nporphyria (section 9.8.2);interactions:seeInteractionsin section 4.8.1 and Appendix 1 (topiramate)", "side-effects": "nausea, diarrhoea, vomiting, constipation, dyspepsia,\r\nabdominal pain, dry mouth, taste disturbance, gastritis, appetite\r\nchanges, dyspnoea, impaired attention, cognitive impairment, movement\r\ndisorders, seizures, tremor, malaise, impaired coordination, speech\r\ndisorder, drowsiness, dizziness, sleep disturbance, anxiety, confusion,\r\nparaesthesia, aggression, mood changes, depression, agitation, irritability,\r\nnephrolithiasis, urinary disorders, anaemia, arthralgia, muscle spasm,\r\nmyalgia, muscular weakness, visual disturbances, nystagmus, tinnitus,\r\nepistaxis, alopecia, rash, pruritus;less commonlypancreatitis, flatulence, abdominal distension, gingival bleeding,\r\nsalivation, halitosis, thirst, glossodynia, bradycardia, palpitation,\r\nhypotension, postural hypotension, flushing, altered sense of smell,\r\nperipheral neuropathy, suicidal ideation, psychosis, panic attack,\r\ninfluenza-like symptoms, sexual dysfunction, urinary calculus, haematuria,\r\nblood disorders (including leucopenia, neutropenia, and thrombocytopenia),\r\nhypokalaemia, metabolic acidosis, dry eye, photophobia, blepharospasm,\r\nincreased lacrimation, mydriasis, hearing loss, reduced sweating,\r\nskin discoloration;rarelyRaynaud\u2019s syndrome, periorbital\r\noedema, unilateral blindness, Stevens-Johnson syndrome, abnormal skin\r\nodour, calcinosis;very rarelyangle-closure glaucoma;also reportedencephalopathy, hyperammonaemia, maculopathy,\r\ntoxic epidermal necrolysis", "hepatic impairment": "use with caution in moderate to severe impairment\u2014clearance\r\nmay be reduced", "doses": ["Monotherapy in epilepsy, initially 25\u00a0mg at night for\r\n1 weekthenincreased in steps of 25\u201350\u00a0mg taken\r\nin 2 divided doses at intervals of 1\u20132 weeks; usual dose 100\u2013200\u00a0mg\r\ndaily in 2 divided doses, adjusted according to response; max. 500\u00a0mg\r\ndaily (doses of 1\u00a0g daily have been used in refractory epilepsy);child6\u201318 years, initially 0.5\u20131\u00a0mg/kg (max. 25\u00a0mg)\r\nat night for 1 weekthenincreased in steps of 0.5\u20131\u00a0mg/kg\r\n(max. 50\u00a0mg) taken in 2 divided doses at intervals of 1\u20132 weeks; initial\r\ntarget dose 100\u00a0mg daily in 2 divided doses; max. 15\u00a0mg/kg (max. 500\u00a0mg)\r\ndaily", "Adjunctive therapy in epilepsy, initially 25\u201350\u00a0mg at night\r\nfor 1 weekthenincreased in steps of 25\u201350\u00a0mg taken\r\nin 2 divided doses at intervals of 1\u20132 weeks; usual dose 200\u2013400\u00a0mg\r\ndaily in 2 divided doses; max. 400\u00a0mg daily;child2\u201318 years, initially 1\u20133\u00a0mg/kg (max. 25\u00a0mg) at night for 1 weekthenincreased in steps of 1\u20133\u00a0mg/kg (max. 50\u00a0mg) taken\r\nin 2 divided doses at intervals of 1\u20132 weeks; usual dose 5\u20139\u00a0mg/kg\r\ndaily in 2 divided doses; max. 15\u00a0mg/kg (max. 400\u00a0mg) daily", "Migraine prophylaxis,adultover\r\n18 years, initially 25\u00a0mg at night for 1 weekthenincreased in steps of 25\u00a0mg at weekly intervals; usual dose 50\u2013100\u00a0mg\r\ndaily in 2 divided doses; max. 200\u00a0mg daily;child16\u201318 years seeBNF for Children"], "pregnancy": "seePregnancy", "breast-feeding": "manufacturer advises avoid\u2014present in milk;\r\nsee alsoBreast-feeding"}, "IMATINIB": {"indications": "seenotes above", "name": "IMATINIB", "renal impairment": "max. starting dose 400\u00a0mg daily if creatinine clearance\r\nless than 60\u00a0mL/minute; reduce dose further if not tolerated", "interactions": {"extra": "", "bad": 0, "interaction": "replacement of  warfarin with a heparin advised by manufacturer of imatinib (possibility of enhanced warfarin effect)", "name": "Imatinib", "backrefs": ["Imatinib", "Oxcarbazepine"]}, "cautions": "seesection 8.1; cardiac disease; monitor for fluid retention; monitor liver\r\nfunction;interactions:Appendix 1\r\n(imatinib)", "side-effects": "seesection 8.1; also abdominal pain, appetite\r\nchanges, constipation, diarrhoea, flatulence, gastro-oesophageal reflux,\r\ntaste disturbance, weight changes, dry mouth; oedema (including pulmonary\r\noedema, pleural effusion, and ascites), flushing, haemorrhage; cough,\r\ndyspnoea; dizziness, headache, insomnia, hypoaesthesia, paraesthesia,\r\nfatigue; influenza-like symptoms; cramps, arthralgia; visual disturbances,\r\nincreased lacrimation, conjunctivitis, dry eyes; epistaxis; dry skin,\r\nsweating, rash, pruritus, photosensitivity;less commonlygastric ulceration, pancreatitis, hepatic dysfunction (rarely hepatic\r\nfailure, hepatic necrosis), dysphagia, heart failure, tachycardia,\r\npalpitation, syncope, hypertension, hypotension, cold extremities,\r\ncough, acute respiratory failure, depression, drowsiness, anxiety,\r\nperipheral neuropathy, tremor, migraine, impaired memory, vertigo,\r\ngynaecomastia, menorrhagia, irregular menstruation, sexual dysfunction,\r\nelectrolyte disturbances, renal failure, urinary frequency, gout,\r\ntinnitus, hearing loss; skin hyperpigmentation;rarelyintestinal obstruction, gastro-intestinal perforation, inflammatory\r\nbowel disease, arrhythmia, atrial fibrillation, myocardial infarction,\r\nangina, pulmonary fibrosis, pulmonary hypertension, increased intracranial\r\npressure, convulsions, confusion, haemolytic anaemia, rhabdomyolysis,\r\nmyopathy, aseptic necrosis of bone, cataract, glaucoma, angioedema,\r\nexfoliative dermatitis, and Stevens-Johnson syndrome", "hepatic impairment": "max. 400\u00a0mg daily; reduce dose further if not tolerated", "doses": ["Chronic phase chronic myeloid leukaemia,adult400\u00a0mg once daily, increased if necessary to\r\nmax. 800\u00a0mg daily (in 2 divided doses);child(chronic and advanced phase) 2\u201318 years 340\u00a0mg/m2(max.\r\n800\u00a0mg) daily (in 1\u20132 divided doses), increased to 570\u00a0mg/m2(max. 800\u00a0mg) daily if necessary (consult product literature)", "Accelerated phase and blast crisis chronic myeloid leukaemia,adult600\u00a0mg once daily, increased if necessary to\r\nmax. 800\u00a0mg daily (in 2 divided doses)", "Acute lymphoblastic leukaemia,adult600\u00a0mg once daily", "Gastro-intestinal stromal tumours,adult400\u00a0mg once daily", "Dermatofibrosarcoma protuberans,adult800\u00a0mg daily in 2 divided doses", "Myelodysplastic/myeloproliferative diseases,adult400\u00a0mg once daily", "Advanced hypereosinophilic syndrome and chronic eosinophilic\r\nleukaemia,adult100\u2013400\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk; effective contraception required during treatment;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "DOXAPRAM HYDROCHLORIDE": {"indications": "see under Dose", "name": "DOXAPRAM HYDROCHLORIDE", "cautions": "give with\r\noxygen in severe irreversible airways obstruction or severely decreased\r\nlung compliance (because of increased work load of breathing); give with beta2agonist in bronchoconstriction; hypertension (avoid if severe), impaired cardiac reserve; phaeochromocytoma;interactions:Appendix 1 (doxapram)", "side-effects": "nausea, vomiting; hypertension, tachycardia, bradycardia,\r\nextrasystoles, arrhythmias, chest pain, flushing; dyspnoea, cough,\r\nbronchospasm, laryngospasm; pyrexia, headache, dizziness, hyperactivity,\r\nconfusion, hallucination, convulsions; urinary retention, incontinence,\r\nperineal warmth; muscle spasms", "contra-indications": "severe hypertension; status asthmaticus; coronary\r\nartery disease; hyperthyroidism; epilepsy and other convulsive\r\ndisorders; physical obstruction of respiratory\r\ntract; cerebral oedema, cerebrovascular accident", "hepatic impairment": "use with caution", "doses": ["Postoperative respiratory depression,by\r\nintravenous injectionover at least 30 seconds, 1\u20131.5\u00a0mg/kg\r\nrepeated if necessary after intervals of 1 houroralternativelyby intravenous infusion, 2\u20133\u00a0mg/minute\r\nadjusted according to response;childnot recommended", "Acute respiratory failure,by intravenous\r\ninfusion, 1.5\u20134\u00a0mg/minute adjusted according to response (given\r\nconcurrently with oxygen and whenever possible monitor with frequent\r\nmeasurement of blood gas tensions);childnot recommended"], "pregnancy": "no evidence of harm, but manufacturer advises avoid\r\nunless benefit outweighs risk"}, "CO-CODAMOL": {"indications": "mild to moderate pain", "name": "CO-CODAMOL", "renal impairment": "reduce dose or avoid codeine; increased and prolonged\r\neffect; increased cerebral sensitivity; note also sodium content of\r\neffervescent tablets (see under relevant preparation entry)", "cautions": "hypotension, asthma (avoid during attack) and impaired respiratory function (avoid in chronic obstructive pulmonary disease), prostatic hypertrophy; shock; myasthenia gravis; obstructive or inflammatory bowel disorders; diseases\r\nof the biliary tract; reduced dose recommended in elderly and debilitated patients, in hypothyroidism, and in adrenocortical\r\ninsufficiency; convulsive disorders; cardiac arrhythmias; acute abdomen; gallstones; alcohol dependence;interactions:Appendix 1 (opioid analgesics, paracetamol)", "side-effects": "nausea and vomiting (particularly in initial stages),\r\nconstipation, dry mouth, and biliary spasm; larger doses produce respiratory\r\ndepression, hypotension, and muscle rigidity; other side-effects include\r\nabdominal pain, anorexia, bradycardia, tachycardia, palpitation, oedema,\r\npostural hypotension, seizures, malaise, hypothermia; hallucinations,\r\nvertigo, euphoria, dysphoria, mood changes, dependence, dizziness,\r\nconfusion, drowsiness, sleep disturbances, headache; sexual dysfunction,\r\ndifficulty with micturition, urinary retention, ureteric spasm, muscle\r\nfasciculation; blood disorders (including thrombocytopenia, leucopenia,\r\nneutropenia), miosis, visual disturbances, flushing, sweating, rashes,\r\nurticaria and pruritus; pancreatitis also reported;important:liver damage (and less frequently renal damage) followingoverdosagewith paracetamol; see Emergency Treatment of\r\nPoisoning forparacetamolandanalgesics (opioid); for reversal of opioid-induced\r\nrespiratory depression, seesection 15.1.7", "contra-indications": "avoid in acute respiratory depression, in comatose patients, and where risk of paralytic ileus; also avoid in raised\r\nintracranial pressure or head injury (affects pupillary responses vital for neurological assessment)", "hepatic impairment": "reduce dose or avoid codeine\u2014may precipitate coma;\r\ndose-related toxicity with paracetamol\u2014avoid large doses", "doses": ["adultover 16 years 2 tablets\r\nevery 4 hours; max. 8 tablets daily;child12\u201316 years 1 tablet every 4 hours; max. 4 tablets daily;childunder 12 years not recommended"], "pregnancy": "codeine may depress neonatal respiration; withdrawal\r\neffects in neonates of dependent mothers; gastric stasis and risk\r\nof inhalation pneumonia in mother during labour", "breast-feeding": "amount of codeine usually too small to be harmful;\r\nhowever, mothers vary considerably in their capacity to metabolise\r\ncodeine\u2014risk of morphine overdose in infant"}, "BOTULINUM TOXIN TYPE B": {"indications": "spasmodic torticollis (cervical dystonia)\u2014specialist\r\nuse only", "name": "BOTULINUM TOXIN TYPE B", "cautions": "history of dysphagia or\r\naspiration; tolerance\r\nmay occur", "side-effects": "increased electrophysiologic jitter in some distant\r\nmuscles; dry mouth, dyspepsia, dysphagia, worsening torticollis, neck\r\npain, myasthenia, voice changes, taste disturbances, headache, blurred\r\nvision;also reportedexaggerated muscle weakness\r\nand aspiration (seek medical attention if swallowing, speech, or respiratory\r\ndisorders)", "contra-indications": "neuromuscular\r\nor neuromuscular junctional disorders", "doses": ["By intramuscular injection, initially 5000\u201310\u00a0000\u00a0units\r\ndivided between 2\u20134 most affected muscles; adjust dose and frequency\r\naccording to response;important: notinterchangeable\r\nwith other botulinum toxin preparations"], "pregnancy": "low risk of systemic absorption but avoid unless\r\nessential", "breast-feeding": "low risk of systemic absorption but avoid unless\r\nessential"}, "BOTULINUM TOXIN TYPE A": {"indications": "seenotes above; preparations\r\narenotinterchangeable and should be used under\r\nspecialist supervision", "name": "BOTULINUM TOXIN TYPE A", "cautions": "history of dysphagia or\r\naspiration; chronic\r\nrespiratory disorder; neurological disorders\r\n(can lead to increased sensitivity and exaggerated muscle weakness); excessive weakness or atrophy in target muscle", "side-effects": "increased electrophysiologic jitter in some distant\r\nmuscles; misplaced injections may paralyse nearby muscle groups and\r\nexcessive doses may paralyse distant muscles; influenza-like symptoms;rarelyarrhythmias, myocardial infarction, seizures, and\r\nantibody formation (substantial deterioration in response);very rarelyexaggerated muscle weakness, dysphagia, and\r\naspiration (seek medical attention if swallowing, speech, or respiratory\r\ndisorders)", "contra-indications": "generalised disorders of muscle\r\nactivity (e.g. myasthenia gravis); infection at injection site", "doses": ["Consult product literature (important:specific toeach individual preparationandnot interchangeable)"], "pregnancy": "low risk of systemic absorption but avoid unless\r\nessential", "breast-feeding": "low risk of systemic absorption but avoid unless\r\nessential"}, "ALITRETINOIN": {"indications": "severe chronic hand eczema refractory\r\nto potent topical corticosteroids", "name": "ALITRETINOIN", "renal impairment": "manufacturer advises avoid in severe impairment\u2014no information\r\navailable", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of alitretinoin ", "name": "Alitretinoin", "backrefs": ["Alitretinoin"]}, "cautions": "avoid blood donation during treatment\r\nand for at least 1 month after stopping treatment; monitor serum lipids (more frequently in those with\r\ndiabetes, history of hyperlipidaemia, or risk factors for cardiovascular\r\ndisease)\u2014discontinue if uncontrolled hyperlipidaemia; history of depression; dry eye syndrome;interactions:Appendix 1 (retinoids)", "side-effects": "raised serum concentration of triglycerides and\r\nof cholesterol (risk of pancreatitis if triglycerides above 9\u00a0mmol/litre),\r\nflushing; headache; changes in thyroid function tests; anaemia; myalgia,\r\nraised creatine kinase, arthralgia; conjunctivitis, dry eyes (may\r\nrespond to lubricating eye ointment or tear replacement therapy)\u2014sometimes\r\ndecreased tolerance to contact lenses, eye irritation; dryness of\r\nskin and lips, cheilitis, erythema, alopecia;less commonlyepistaxis, hyperostosis, ankylosing spondylitis, blurred vision,\r\ncataracts, pruritus, and asteototic eczema;rarelybenign intracranial hypertension (discontinue if severe headache,\r\nnausea, vomiting, papilloedema, or visual disturbances occur) and\r\nvasculitis; also reported keratitis and impaired night vision", "contra-indications": "uncontrolled hyperlipidaemia; uncontrolled hypothyroidism; hypervitaminosis A", "hepatic impairment": "manufacturer advises avoid\u2014no information available", "doses": ["adultover 18 years, 30\u00a0mg\r\nonce daily, reduced to 10\u00a0mg once daily if not tolerated; patients\r\nwith diabetes, history of hyperlipidaemia, or risk factors for cardiovascular\r\ndisease, initially 10\u00a0mg once daily, increased if necessary up to\r\nmax. 30\u00a0mg daily", "Duration of treatment 12\u201324 weeks; discontinue\r\nif no response after 12 weeks. Course may be repeated in those who\r\nrelapse. See also Pregnancy Prevention,above"], "pregnancy": "avoid\u2014teratogenic; effective contraception must be\r\nused\u2014see Pregnancy Preventionabove", "breast-feeding": "manufacturer advises avoid"}, "RIBAVIRIN": {"indications": "severe respiratory syncytial virus bronchiolitis in infants and children;\r\nin combination with peginterferon alfa orinterferon alfafor chronic hepatitis C in patients without liver decompensation\r\n(see alsosection 5.3.3.2)", "name": "RIBAVIRIN", "renal impairment": "plasma-ribavirin concentration increased; avoid oral\r\nribavirin unless essential if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2\u2014monitor haemoglobin concentration closely", "interactions": {"extra": "", "bad": 1, "interaction": " abacavir possibly reduces effects of ribavirin ", "name": "Ribavirin", "backrefs": ["Ribavirin"]}, "cautions": "Maintain standard supportive respiratory and fluid management therapy; monitor electrolytes closely; monitor equipment for precipitation; pregnant\r\nwomen (and those planning pregnancy) should avoid exposure to aerosol", "side-effects": "Worsening\r\nrespiration, bacterial pneumonia, and pneumothorax reported; rarely\r\nnon-specific anaemia and haemolysis", "contra-indications": "Severe cardiac\r\ndisease, including unstable or uncontrolled cardiac disease in previous\r\n6 months; haemoglobinopathies; severe\r\ndebilitating medical conditions; autoimmune\r\ndisease (including autoimmune hepatitis); uncontrolled severe psychiatric condition; history of severe psychiatric condition in children", "hepatic impairment": "no dosage adjustment required; use oral ribavirin with\r\ncaution in severe hepatic dysfunction or decompensated cirrhosis", "doses": ["chronic hepatitis C (in combination with interferon alfa\r\nor peginterferon alfa),adultover\r\n18 years, body-weight under 65\u00a0kg, 400\u00a0mg twice daily; body-weight\r\n65\u201381\u00a0kg, 400\u00a0mg in the morning and 600\u00a0mg in the evening; body-weight\r\n81\u2013105\u00a0kg, 600\u00a0mg twice daily; body-weight over 105\u00a0kg, 600\u00a0mg in\r\nthe morning and 800\u00a0mg in the evening;child3\u201318 years, body-weight under 47\u00a0kg, 15\u00a0mg/kg daily in 2 divided\r\ndoses; body-weight 47\u201350\u00a0kg, 200\u00a0mg in the morning and 400\u00a0mg in the\r\nevening; body-weight 50\u201365\u00a0kg, 400\u00a0mg twice daily; body-weight over\r\n65\u00a0kg, as adult"], "pregnancy": "avoid; teratogenicity inanimalstudies;\r\nsee also Cautions above", "breast-feeding": "avoid\u2014no information available"}, "DONEPEZIL HYDROCHLORIDE": {"indications": "mild to moderate dementia in Alzheimer\u2019s disease", "name": "DONEPEZIL HYDROCHLORIDE", "cautions": "sick sinus syndrome or\r\nother supraventricular conduction abnormalities; susceptibility to peptic ulcers; asthma, chronic obstructive pulmonary\r\ndisease;interactions:Appendix 1 (parasympathomimetics)", "side-effects": "nausea, vomiting, anorexia, diarrhoea; fatigue,\r\ninsomnia, headache, dizziness, syncope, abnormal dreams, hallucinations,\r\nagitation, aggression; muscle cramps; urinary incontinence; rash,\r\npruritus;less commonlygastric and duodenal ulcers,\r\ngastro-intestinal haemorrhage, bradycardia, seizures;rarelysino-atrial block, AV block, hepatitis, extrapyramidal symptoms;\r\npotential for bladder outflow obstruction", "hepatic impairment": "caution in mild to moderate impairment, no information\r\navailable for severe impairment", "doses": ["Initially 5\u00a0mg once daily at bedtime, increased if necessary\r\nafter one month to max. 10\u00a0mg daily"]}, "MIANSERIN HYDROCHLORIDE": {"indications": "depressive illness, particularly where sedation is required", "name": "MIANSERIN HYDROCHLORIDE", "renal impairment": "caution in renal impairment", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\njaundice, oedema, blood dyscrasias, arthritis, and arthralgia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["adultover 18 years, initially\r\n30\u201340\u00a0mg (elderly 30\u00a0mg) daily in divided dosesoras a single dose at bedtime, increased gradually as necessary; usual\r\ndose range 30\u201390\u00a0mg"], "pregnancy": "avoid", "breast-feeding": "seenotes above"}, "ACETAZOLAMIDE": {"indications": "reduction of intra-ocular pressure in open-angle glaucoma, secondary\r\nglaucoma, and peri-operatively in angle-closure glaucoma; diuresis\r\n(section 2.2.7); epilepsy", "name": "ACETAZOLAMIDE", "renal impairment": "avoid\u2014risk of metabolic acidosis", "interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium increased by acetazolamide ", "name": "Acetazolamide", "backrefs": ["Acetazolamide"]}, "cautions": "not generally recommended for prolonged\r\nuse but if given monitor blood count and plasma-electrolyte\r\nconcentration; pulmonary obstruction and impaired alveolar ventilation (risk of acidosis); elderly; diabetes mellitus; renal calculi; avoid extravasation\r\nat injection site (risk of necrosis);interactions:Appendix 1 (diuretics)", "side-effects": "seenotes above; also nausea,\r\nvomiting, diarrhoea, taste disturbance, loss of appetite, paraesthesia,\r\nflushing, headache, dizziness, fatigue, irritability, excitement,\r\nataxia, depression, thirst, polyuria, reduced libido;less\r\ncommonlymelaena, drowsiness, confusion, hearing disturbances,\r\nfever, glycosuria, metabolic acidosis and electrolyte disturbances\r\non long-term therapy, haematuria, crystalluria, renal and ureteric\r\ncolic, renal lesions or calculi, renal failure, blood disorders, bone\r\nmarrow suppression, rash (including Stevens-Johnson syndrome and toxic\r\nepidermal necrosis);rarelyfulminant hepatic necrosis,\r\nhepatitis, cholestatic jaundice, flaccid paralysis, convulsions, photosensitivity;also reportedtransient myopia", "contra-indications": "hypokalaemia, hyponatraemia, hyperchloraemic acidosis; adrenocortical insufficiency; long-term administration in chronic angle-closure glaucoma; sulfonamide hypersensitivity", "hepatic impairment": "manufacturer advises avoid", "doses": ["glaucoma, 1\u20132 capsules daily"], "pregnancy": "manufacturer advises avoid, especially in first trimester\r\n(toxicity inanimalstudies)", "breast-feeding": "amount too small to be harmful"}, "FESOTERODINE": {"interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of fesoterodine advises dose reduction when  ritonavir given with fesoterodine\u2014consult fesoterodine product literature", "name": "Fesoterodine", "backrefs": ["Fesoterodine"]}}, "BAMBUTEROL": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  suxamethonium enhanced by bambuterol ", "name": "Bambuterol", "backrefs": ["Bambuterol"]}}, "FERROUS SULPHATE WITH ASCORBIC ACID": {"side-effects": "seenotes above", "indications": "prophylaxis and treatment of iron deficiency\r\nanaemia and treatment of concurrent vitamin C deficiency", "name": "FERROUS SULPHATE WITH ASCORBIC ACID", "cautions": "interactions: Appendix 1 (iron, vitamins)", "doses": ["adultandchildover 12 years, 1 tablet daily before food"]}, "BENDAMUSTINE HYDROCHLORIDE": {"indications": "seenotes above", "name": "BENDAMUSTINE HYDROCHLORIDE", "renal impairment": "no information available on use in patients with creatinine\r\nclearance less than 10\u00a0mL/minute", "cautions": "seesection 8.1; cardiac disorders\u2014monitor\r\nserum potassium and ECG; avoid in acute porphyria (but seesection 9.8.2);interactions: see Appendix 1 (bendamustine)", "side-effects": "seesection 8.1; also\r\nanorexia, diarrhoea, constipation, haemorrhage, hypotension, hypertension,\r\npalpitation, angina, arrhythmias, respiratory dysfunction, insomnia,\r\npain, chills, malaise, infection, pyrexia, amenorrhoea, dehydration,\r\nelectrolyte disturbances (including hypokalaemia);less commonlypericardial effusion;rarelyacute circulatory\r\nfailure, drowsiness, voice changes, sweating;very rarelytaste disturbance, tachycardia, myocardial infarction, cardiac failure,\r\npulmonary fibrosis, paraesthesia, peripheral neuropathy, neurological\r\ndisorders, ataxia, anticholinergic syndrome, encephalitis, phlebitis,\r\nmultiple organ failure, haemolysis;also reportedsecondary tumours, Stevens-Johnson syndrome, toxic epidermal necrolysis", "contra-indications": "jaundice; severe bone marrow suppression, low leucocyte or platelet\r\ncount; major surgery less than 30 days before start of treatment", "hepatic impairment": "consider a 30\u00a0% dose reduction in moderate impairment;\r\navoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and mutagenic inanimalstudies); effective contraception required during treatment in men\r\nor women, and for 6 months after treatment in men; see alsoPregnancy and Reproductive\r\nfunction", "breast-feeding": "discontinue breast-feeding"}, "DARIFENACIN": {"indications": "urinary frequency, urgency, and incontinence", "name": "DARIFENACIN", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  ritonavir advised by manufacturer of darifenacin ", "name": "Darifenacin", "backrefs": ["Darifenacin"]}, "cautions": "seenotes above", "side-effects": "seenotes above; alsoless commonlyulcerative stomatitis, oedema, hypertension,\r\ndyspnoea, cough, rhinitis, weakness, insomnia, impotence, and vaginitis", "contra-indications": "seenotes above", "hepatic impairment": "max. 7.5\u00a0mg daily in moderate impairment; avoid in\r\nsevere impairment", "doses": ["adultover 18 years, 7.5\u00a0mg\r\nonce daily, increased if necessary after 2 weeks to 15\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises caution"}, "CO-AMILOFRUSE": {"indications": "oedema", "name": "CO-AMILOFRUSE", "renal impairment": "monitor plasma-potassium concentration; risk of hyperkalaemia\r\nin renal impairment but may need higher doses; avoid if eGFR less\r\nthan 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "monitor electrolytes; hepatorenal syndrome; hypotension; correct hypovolaemia before using in oliguria; hypoproteinaemia; diabetes\r\nmellitus; gout; impaired micturition; prostatic enlargement; elderly;interactions:Appendix 1 (diuretics)", "side-effects": "include gastro-intestinal disturbances, dry mouth,\r\npancreatitis, intrahepatic cholestasis, hepatic encephalopathy; hypotension,\r\ntemporary increase in serum cholesterol and triglyceride concentrations;\r\nconfusion, paraesthesia; hyperglycaemia; metabolic alkalosis or acidosis;\r\nhyponatraemia, hypokalaemia (due to furosemide\u2014may be followed by\r\nhyperkalaemia due to amiloride; see alsosection 2.2), hypomagnesaemia,\r\nhypocalcaemia, bone marrow depression (withdraw treatment), blood\r\ndisorders (including thrombocytopenia, leucopenia, agranulocytosis,\r\naplastic anaemia, and haemolytic anaemia); hyperuricaemia, gout; tinnitus\r\nand deafness (usually in renal impairment or in hypoproteinaemia);\r\nhypersensitivity reactions (including rashes, photosensitivity, eosinophilia,\r\nexfoliative dermatitis, purpura, anaphylaxis, Stevens-Johnson syndrome,\r\ntoxic epidermal necrolysis)", "contra-indications": "hyperkalaemia; comatose\r\nor precomatose states associated with liver cirrhosis; renal\r\nfailure; anuria; hypovolaemia; dehydration; severe hypokalaemia; severe hyponatraemia; Addison\u2019s\r\ndisease", "hepatic impairment": "increased risk of hypomagnesaemia in alcoholic cirrhosis", "doses": ["1 tablet in the morning"], "pregnancy": "not used to treat hypertension in pregnancy", "breast-feeding": "manufacturers advise avoid\u2014no information regarding\r\namiloride component available; amount of furosemide in milk too small\r\nto be harmful; furosemide may inhibit lactation"}, "GENTAMICIN": {"indications": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " indometacin possibly increases plasma concentration of gentamicin in neonates", "name": "Gentamicin", "backrefs": ["Gentamicin"]}, "name": "GENTAMICIN", "doses": ["SeeAdministrationin\r\nnotes above"]}, "DOPAMINERGICS": {"interactions": {"extra": "", "bad": 0, "interaction": " memantine possibly enhances effects of dopaminergics ", "name": "Dopaminergics", "backrefs": ["Dopaminergics"]}}, "NORMAL IMMUNOGLOBULIN": {"indications": "seenotes above", "name": "NORMAL IMMUNOGLOBULIN", "renal impairment": "monitor for acute renal failure; consider discontinuation\r\nif renal function deteriorates. Intravenous preparations with added\r\nsucrose have been associated with cases of renal dysfunction and acute\r\nrenal failure", "cautions": "hypo- or agammaglobulinaemia with or\r\nwithout IgA deficiency; interference with live virus vaccines\u2014seenotes above", "side-effects": "nausea, diarrhoea, chills, fever, headache, dizziness,\r\narthralgia, myalgia, muscle spasms, low back pain;rarelyhypotension, anaphylaxis, cutaneous skin reactions, aseptic meningitis,\r\nacute renal failure; also reported withintravenous use, injection site reactions, abdominal pain and distension, blood\r\npressure fluctuations, haemolytic anaemia, thromboembolic events including\r\nmyocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis", "contra-indications": "patients with selective IgA deficiency\r\nwho have known antibody against IgA", "doses": ["See under preparations", "Antibody titres can vary widely between normal\r\nimmunoglobulin preparations from different manufacturers\u2014formulations\r\narenot interchangeable; patients should be maintained\r\non the same formulation throughout long-term treatment to avoid adverse\r\neffects"]}, "PHENOXYMETHYLPENICILLIN": {"indications": "oral infections (see notes above); tonsillitis, otitis media, erysipelas,\r\ncellulitis; group A streptococcal infection, rheumatic fever and pneumococcal\r\ninfection prophylaxis (Table 2,section 5.1)", "name": "PHENOXYMETHYLPENICILLIN", "interactions": {"extra": "", "bad": 0, "interaction": " neomycin reduces absorption of phenoxymethylpenicillin ", "name": "Phenoxymethylpenicillin", "backrefs": ["Phenoxymethylpenicillin"]}, "cautions": "see underBenzylpenicillin;interactions:Appendix 1 (penicillins)", "side-effects": "see underBenzylpenicillin", "contra-indications": "see underBenzylpenicillin", "doses": ["500\u00a0mg every 6 hours increased up to 1\u00a0g every 6 hours\r\nin severe infections;childup to 1\r\nyear 62.5\u00a0mg every 6 hours, increased up to 12.5\u00a0mg/kg every 6 hours\r\nin severe infections; 1\u20136 years, 125\u00a0mg every 6 hours, increased up\r\nto 12.5\u00a0mg/kg every 6 hours in severe infections; 6\u201312 years, 250\u00a0mg\r\nevery 6 hours, increased up to 12.5\u00a0mg/kg every 6 hours in severe\r\ninfections", "Phenoxymethylpenicillindoses in the BNF may differ from those in product literature"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "HYDROXYPROPYL GUAR": {"indications": "dry eye conditions", "name": "HYDROXYPROPYL GUAR", "doses": ["Apply as required"]}, "Nasal staphylococci": {"name": "Nasal staphylococci", "doses": ["for eradication of nasal carriage of staphylococci, apply\r\nto nostrils 4 times daily for 10 days; for preventing nasal carriage\r\nof staphylococci, apply to nostrils twice daily"]}, "TAFLUPROST": {"indications": "raised intra-ocular pressure in open-angle\r\nglaucoma; ocular hypertension", "name": "TAFLUPROST", "renal impairment": "use with caution\u2014no information available", "cautions": "seenotes above", "side-effects": "seenotes above", "hepatic impairment": "use with caution\u2014no information available", "doses": ["Apply once daily, preferably in the evening;childunder 18 years, not recommended"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "VILDAGLIPTIN": {"indications": "type 2 diabetes mellitus (in combination\r\nwith metforminorwith a sulfonylureaorwith pioglitazone\u2014see alsonotes above)", "name": "VILDAGLIPTIN", "renal impairment": "avoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "cautions": "monitor liver function (see\r\nbelow); heart failure (avoid if moderate\r\nor severe);interactions:Appendix 1 (antidiabetics)", "side-effects": "nausea, peripheral oedema, headache, tremor, asthenia,\r\ndizziness;less commonlyconstipation, hypoglycaemia,\r\narthralgia;rarelyhepatic dysfunction (see also\r\nLiver Toxicity above);very rarelynasopharyngitis,\r\nupper respiratory tract infection; pancreatitisalso reported", "contra-indications": "ketoacidosis", "hepatic impairment": "avoid; see also Cautions above", "doses": ["adultover 18 years, in\r\ncombination with metformin or pioglitazone, 50\u00a0mg twice daily; in\r\ncombination with a sulfonylurea, 50\u00a0mg daily in the morning"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "PRALIDOXIME CHLORIDE": {"indications": "adjunct to atropine in the treatment\r\nof poisoning by organophosphorus insecticide or nerve agent", "name": "PRALIDOXIME CHLORIDE", "renal impairment": "use with caution", "cautions": "myasthenia gravis", "side-effects": "drowsiness, dizziness, disturbances of vision,\r\nnausea, tachycardia, headache, hyperventilation, and muscular weakness", "contra-indications": "poisoning with carbamates or with organophosphorus compounds without anticholinesterase\r\nactivity", "doses": ["By intravenous infusion,adultandchildinitially\r\n30\u00a0mg/kg over 20 minutes, followed by 8\u00a0mg/kg/hour; usual max. 12\u00a0g\r\nin 24 hours", "The loading dose may be administeredby intravenous injection(diluted to a concentration of 50\u00a0mg/mL\r\nwith water for injections) over at least 5 minutes if pulmonary oedema\r\nis present or if it is not practical to administer an intravenous\r\ninfusion;pralidoxime chloridedoses in BNF may\r\ndiffer from those in product literature"]}, "Other preparations for biliary disorders": {"name": "Other preparations for biliary disorders", "doses": ["1\u20132 capsules 3 times daily before food (but see notes\r\nabove)"]}, "METHOTREXATE": {"indications": "severe psoriasis unresponsive to conventional\r\ntherapy (specialist use only); Crohn\u2019s disease (section 1.5.3); malignant disease (section 8.1.3); rheumatoid arthritis (section 10.1.3)", "name": "METHOTREXATE", "renal impairment": "section 10.1.3", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of haematological toxicity when  sulfamethoxazole (as co-trimoxazole) given with methotrexate ", "name": "Methotrexate", "backrefs": ["Neomycin", "Nitrous Oxide", "Meloxicam", "Cisplatin", "Acitretin", "Diclofenac", "Sulfamethoxazole", "Ibuprofen", "Tetracycline", "Doxycycline", "Methotrexate"]}, "cautions": "section 10.1.3; also photosensitivity\u2014psoriasis\r\nlesions aggravated by UV radiation (skin ulceration reported)", "side-effects": "section 10.1.3", "contra-indications": "section 10.1.3", "hepatic impairment": "avoid\u2014dose-related toxicity", "doses": ["By mouthorby\r\nintramuscularorintravenousorsubcutaneous injection, 2.5\u201310\u00a0mg\r\nonce weekly, increased according to response in steps of 2.5\u20135\u00a0mg\r\nat intervals of at least 1 week; usual dose 7.5\u201315\u00a0mg once weekly;\r\nmax. weekly dose 30\u00a0mg;child2\u201318\r\nyears seeBNF for Children", "Note that the above dose is aweeklydose.\r\nTo avoid error with low dose methotrexate, it is recommended that:", "the patient is carefully advised of thedoseandfrequencyand the reason for taking methotrexate\r\nand any other prescribed medicine (e.g. folic acid);", "only onestrengthofmethotrexatetablet (usually 2.5\u00a0mg) is prescribed and dispensed;", "the prescription and the dispensing label clearly show\r\nthe dose and frequency of methotrexate administration;", "the patient is warned to report immediately the onset\r\nof any feature of blood disorders (e.g. sore throat, bruising, and\r\nmouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort\r\nand dark urine), and respiratory effects (e.g. shortness of breath)."], "pregnancy": "section 10.1.3", "breast-feeding": "section 10.1.3"}, "SODIUM TETRADECYL SULPHATE": {"indications": "sclerotherapy of varicose veins", "name": "SODIUM TETRADECYL SULPHATE", "cautions": "see underEthanolamine Oleate", "side-effects": "see underEthanolamine Oleate", "contra-indications": "see underEthanolamine Oleate", "doses": ["by slow injection into empty isolated segment of vein,\r\n0.1\u20131\u00a0mL according to site and condition being treated (consult product\r\nliterature)"]}, "C1-ESTERASE INHIBITOR": {"indications": "acute attacks of hereditary angioedema;\r\nprophylaxis prior to surgery or major dental procedures [unlicensed]", "name": "C1-ESTERASE INHIBITOR", "cautions": "vaccination againsthepatitis Aandhepatitis Bmay be required", "side-effects": "rarelyinjection-site reactions,\r\nhypersensitivity reactions (including anaphylaxis)", "doses": ["By slow intravenous injection or intravenous infusion,adultandchild20\u00a0units/kg"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available"}, "PALONOSETRON": {"indications": "prevention of nausea and vomiting induced\r\nby moderately and severely emetogenic chemotherapy", "name": "PALONOSETRON", "cautions": "history of constipation; intestinal obstruction; concomitant\r\nuse of drugs that prolong QT interval", "side-effects": "diarrhoea, constipation; headache, dizziness;less commonlydyspepsia, abdominal pain, dry mouth, flatulence,\r\nchanges in blood pressure, tachycardia, bradycardia, arrhythmia, myocardial\r\nischaemia, hiccups, drowsiness, asthenia, insomnia, anxiety, euphoria,\r\nparaesthesia, peripheral neuropathy, anorexia, motion sickness, influenza-like\r\nsymptoms, urinary retention, glycosuria, hyperglycaemia, electrolyte\r\ndisturbance, arthralgia, eye irritation, amblyopia, tinnitus, rash,\r\npruritus", "doses": ["By intravenous injection(over 30 seconds),\r\n250\u00a0micrograms as a single dose 30 minutes before treatment;childandadolescentunder 18 years not recommended"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "avoid\u2014no information available"}, "GALANTAMINE": {"indications": "mild to moderate dementia in Alzheimer\u2019s disease", "name": "GALANTAMINE", "renal impairment": "avoid if eGFR less than 9\u00a0mL/minute/1.73m2", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of galantamine ", "name": "Galantamine", "backrefs": ["Galantamine"]}, "cautions": "cardiac disease (including sick sinus syndrome or other supraventricular\r\nconduction abnormalities, unstable angina, congestive heart failure); electrolyte disturbances; susceptibility\r\nto peptic ulcers; asthma, chronic obstructive pulmonary disease, pulmonary infection; avoid in urinary\r\nretention, gastro-intestinal obstruction, and while recovering\r\nfrom bladder or gastro-intestinal surgery; history of seizures;interactions:Appendix 1 (parasympathomimetics)", "side-effects": "vomiting, nausea, abdominal pain, diarrhoea, dyspepsia,\r\nanorexia, weight loss, bradycardia, hypertension, syncope, hallucination,\r\ndepression, dizziness, tremor, headache, drowsiness, malaise, muscle\r\nspasm, sweating;less commonlytaste disturbance,\r\npalpitation, arrhythmias, first-degree AV block, hypotension, flushing,\r\nparaesthesia, dehydration, muscular weakness, blurred vision, tinnitus;rarelyhepatitis, exacerbation of Parkinson\u2019s disease, seizures", "hepatic impairment": "forimmediate-releasepreparations in\r\nmoderate impairment, initially 4\u00a0mg once daily (preferably in the\r\nmorning) for at least 7 days, then 4\u00a0mg twice daily for at least 4\r\nweeks; max. 8\u00a0mg twice daily; avoid in severe impairment", "doses": ["Initially 4\u00a0mg twice daily for 4 weeks increased to 8\u00a0mg\r\ntwice daily for 4 weeks; maintenance 8\u201312\u00a0mg twice daily"]}, "GANIRELIX": {"indications": "adjunct in the treatment of female infertility (under specialist\r\nsupervision)", "name": "GANIRELIX", "renal impairment": "avoid in moderate to severe renal impairment", "side-effects": "nausea, headache, malaise, injection-site reactions;very rarelyhypersensitivity reactions including rash, facial\r\noedema, and dyspnoea also reported", "hepatic impairment": "avoid in moderate or severe hepatic impairment", "doses": ["By subcutaneous injectionpreferably into\r\nthe upper leg (rotate injection sites to prevent lipoatrophy), 250\u00a0micrograms\r\nin the morning (or each afternoon) starting on day 5 or day 6 of ovarian\r\nstimulation with gonadotrophins; continue throughout administration\r\nof gonadotrophins including day of ovulation induction (if administering\r\nin afternoon, give last dose in afternoonbeforeovulation\r\ninduction)"], "pregnancy": "avoid in confirmed pregnancy\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014no information available"}, "ETAMSYLATE": {"indications": "short-term blood loss in menorrhagia", "name": "ETAMSYLATE", "cautions": "exclude structural or histological causes of menorrhagia,\r\nor fibroids causing distortion of the uterine cavity, before initiating\r\ntreatment", "side-effects": "nausea, vomiting, diarrhoea, fever (discontinue\r\ntreatment), headache, rashes", "contra-indications": "acute porphyria (seesection 9.8.2)", "doses": ["500\u00a0mg 4 times daily during menstruation"], "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "FOSAMPRENAVIR": {"indications": "HIV infection in combination with other\r\nantiretroviral drugs", "name": "FOSAMPRENAVIR", "interactions": {"extra": "Fosamprenavir is a prodrug of amprenavir", "bad": 0, "interaction": " nevirapine possibly reduces plasma concentration of fosamprenavir ", "name": "Fosamprenavir", "backrefs": ["Fosamprenavir"]}, "cautions": "seenotes above;interactions:Appendix 1 (fosamprenavir)", "side-effects": "see notes above; also reported, rash including\r\nrarely Stevens-Johnson syndrome (see also Rash above)", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\nmanufacturer advises caution in mild impairment; reduce dose to 450\u00a0mg\r\ntwice daily in moderate impairment; reduce dose to 300\u00a0mg twice daily\r\nin severe impairment", "doses": ["With low-dose ritonavir, 700\u00a0mg twice daily;child6\u201318 years seeBNF for Children", "700\u00a0mg fosamprenavir is equivalent to approx.\r\n600\u00a0mg amprenavir"], "pregnancy": "toxicity inanimalstudies; manufacturer\r\nadvises use only if potential benefit outweighs risk", "breast-feeding": "seeBreast-feeding"}, "CIPROFIBRATE": {"indications": "hyperlipidaemias of types IIa, IIb, III, and IV in patients who have\r\nnot responded adequately to diet; also see notes above", "name": "CIPROFIBRATE", "renal impairment": "manufacturer advises reduce dose to 100\u00a0mg on alternate\r\ndays in moderate impairment; avoid in severe impairment; see alsoMyotoxicityunder\r\nBezafibrate", "cautions": "see underBezafibrate", "side-effects": "see underBezafibrate", "contra-indications": "see underBezafibrate", "hepatic impairment": "avoid in severe liver disease", "doses": ["100\u00a0mg daily"], "pregnancy": "manufacturers advise avoid\u2014embryotoxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "GLIBENCLAMIDE": {"indications": "type 2 diabetes mellitus", "name": "GLIBENCLAMIDE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": " colesevelam reduces absorption of glibenclamide ", "name": "Glibenclamide", "backrefs": ["Glibenclamide"]}, "cautions": "seenotes above;interactions:Appendix 1 (antidiabetics)", "side-effects": "see notes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially 5\u00a0mg daily with or immediately after breakfast,\r\ndose adjusted according to response (elderlyavoid, see notes above); max. 15\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CLONAZEPAM": {"indications": "status epilepticus; other\r\nforms of epilepsy, and myoclonus (section 4.8.1)", "name": "CLONAZEPAM", "renal impairment": "see Benzodiazepines,section 4.1.2", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of neurotoxicity when  lithium given with clonazepam ", "name": "Clonazepam", "backrefs": ["Clonazepam"]}, "cautions": "see Clonazepam,section 4.8.1; facilities for\r\nreversing respiratory depression with mechanical ventilation must\r\nbe at hand (but see alsonotes above)", "side-effects": "see Clonazepam,section 4.8.1; hypotension\r\nand apnoea", "contra-indications": "see Clonazepam,section 4.8.1; avoid injections containing benzyl alcohol in neonates (see under preparations below)", "hepatic impairment": "see Benzodiazepines,section 4.1.2", "doses": ["By intravenous injectioninto a large vein\r\n(over at least 2 minutes), 1\u00a0mg, repeated if necessary;childall ages, 500\u00a0micrograms"], "pregnancy": "see Benzodiazepines,section 4.1.2, andPregnancy", "breast-feeding": "see Benzodiazepines,section 4.1.2"}, "DYDROGESTERONE": {"indications": "HRT (section 6.4.1.1)", "name": "DYDROGESTERONE", "renal impairment": "use with caution", "cautions": "see notes above", "side-effects": "see notes above", "contra-indications": "see notes above", "hepatic impairment": "avoid; see also Combined Hormonal Contraceptives,section 7.3.1", "doses": ["See under combined preparations (section 6.4.1.1)"], "pregnancy": "not known to be harmful", "breast-feeding": "present in milk\u2014no adverse effects reported"}, "VITAMIN A": {"indications": "seenotes above", "name": "VITAMIN A", "interactions": {"extra": "", "bad": 0, "interaction": " neomycin possibly reduces absorption of vitamin A ", "name": "Vitamin A", "backrefs": ["Vitamin A"]}, "cautions": "seenotes above;interactions:Appendix 1 (vitamins)", "side-effects": "seenotes above", "doses": ["Seenotes aboveand under preparations"], "pregnancy": "excessive doses may be teratogenic; see alsonotes above", "breast-feeding": "theoretical risk of toxicity in infants of mothers\r\ntaking large doses"}, "METHYLPHENIDATE HYDROCHLORIDE": {"indications": "attention deficit hyperactivity disorder (under specialist supervision);\r\nnarcolepsy [unlicensed indication]", "name": "METHYLPHENIDATE HYDROCHLORIDE", "cautions": "seenotes above; also monitor for psychiatric disorders; anxiety or agitation; tics or a family history of Tourette syndrome; drug or alcohol dependence; epilepsy (discontinue if increased seizure frequency); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal;interactions:Appendix 1 (sympathomimetics)", "side-effects": "abdominal pain, nausea, vomiting, diarrhoea, dyspepsia,\r\ndry mouth, anorexia, reduced weight gain; tachycardia, palpitation,\r\narrhythmias, changes in blood pressure; cough, nasopharyngitis; tics\r\n(very rarelyTourette syndrome), insomnia, nervousness,\r\nasthenia, depression, irritability, aggression, headache, drowsiness,\r\ndizziness, movement disorders; fever; arthralgia; rash, pruritus,\r\nalopecia; growth restriction;less commonlyconstipation,\r\ndyspnoea, abnormal dreams, confusion, suicidal ideation, urinary frequency,\r\nhaematuria, muscle cramps, epistaxis;rarelyangina,\r\nsweating, and visual disturbances;very rarelyhepatic\r\ndysfunction, myocardial infarction, cerebral arteritis, psychosis,\r\nneuroleptic malignant syndrome, tolerance and dependence, blood disorders\r\nincluding leucopenia and thrombocytopenia, angle-closure glaucoma,\r\nexfoliative dermatitis, and erythema multiforme; supraventricular\r\ntachycardia, bradycardia, and convulsionsalso reported", "contra-indications": "severe depression, suicidal ideation; anorexia nervosa; psychosis; uncontrolled bipolar\r\ndisorder; hyperthyroidism; cardiovascular disease (including heart failure, cardiomyopathy, severe hypertension, and arrhythmias), structural\r\ncardiac abnormalities; phaeochromocytoma; vasculitis; cerebrovascular disorders", "doses": ["Attention deficit hyperactivity disorder,adultover 18 years [unlicensed use], 5\u00a0mg 2\u20133 times\r\ndaily increased if necessary at weekly intervals according to response,\r\nmax. 100\u00a0mg daily in 2\u20133 divided doses;child6\u201318 years, initially 5\u00a0mg 1\u20132 times daily, increased if necessary\r\nat weekly intervals by 5\u201310\u00a0mg daily; usual max. 60\u00a0mg daily in 2\u20133\r\ndivided doses but may be increased to 2.1\u00a0mg/kg daily in 2\u20133 divided\r\ndoses (max. 90\u00a0mg daily) under the direction of a specialist; discontinue\r\nif no response after 1 month;child4\u20136 years seeBNF for Children", "If effect wears off in evening (with\r\nrebound hyperactivity) a dose at bedtime may be appropriate (establish\r\nneed with trial bedtime dose)", "Treatment may be started using a modified-release\r\npreparation", "Narcolepsy [unlicensed indication], 10\u201360\u00a0mg (usually 20\u201330\u00a0mg)\r\ndaily in divided doses before meals"], "pregnancy": "limited experience\u2014avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "limited information available\u2014avoid"}, "VITAMIN D": {"interactions": {"extra": "", "bad": 0, "interaction": " phenytoin possibly increases requirements for vitamin D ", "name": "Vitamin D", "backrefs": ["Vitamin D"]}}, "SODIUM CITRATE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoid concomitant use of  methenamine with sodium citrate ", "name": "Sodium Citrate", "backrefs": ["Sodium Citrate"]}}, "ESMOLOL": {"interactions": {"extra": "", "bad": 0, "interaction": " morphine possibly increases plasma concentration of esmolol ", "name": "Esmolol", "backrefs": ["Esmolol"]}}, "VALPROATE": {"interactions": {"extra": "", "bad": 0, "interaction": " clobazam possibly increases plasma concentration of valproate ", "name": "Valproate", "backrefs": ["Temozolomide", "Carbapenems", "Valproate", "Pivmecillinam"]}}, "CABERGOLINE": {"indications": "see notes above and under Dose", "name": "CABERGOLINE", "interactions": {"extra": "", "bad": 0, "interaction": " domperidone possibly antagonises hypoprolactinaemic effects of cabergoline ", "name": "Cabergoline", "backrefs": ["Cabergoline"]}, "cautions": "seenotes above; also monthly pregnancy tests during the amenorrhoeic period; advise non-hormonal contraception if pregnancy not\r\ndesired (see also Pregnancy, below);interactions:Appendix 1 (cabergoline)", "side-effects": "seenotes above; also\r\ncardiac valvulopathy, dyspepsia, gastritis, epigastric and abdominal\r\npain, angina, syncope, depression, confusion, hallucinations, breast\r\npain;rarelyvomiting, palpitation, epistaxis, digital\r\nvasospasm, hot flushes, transient hemianopia, muscle weakness;also reportederythromelalgia", "contra-indications": "seenotes above; history of puerperal psychosis; history of pulmonary, pericardial, or retroperitoneal fibrotic\r\ndisorders (seeFibrotic Reactionsin notes above); cardiac valvulopathy", "hepatic impairment": "reduce dose in severe hepatic impairment", "doses": ["Prevention of lactation (but see notes above and under\r\nContra-indications), during first day postpartum, 1\u00a0mg as a single\r\ndose; suppression of established lactation (but see notes above) 250\u00a0micrograms\r\nevery 12\u00a0hours for 2 days;childunder\r\n16 years, not recommended", "Hyperprolactinaemic disorders, 500\u00a0micrograms weekly (as a single\r\ndoseoras 2 divided doses on separate days) increased\r\nat monthly intervals in steps of 500\u00a0micrograms until optimal therapeutic\r\nresponse (usually 1\u00a0mg weekly, range 0.25\u20132\u00a0mg weekly) with monthly\r\nmonitoring of serum prolactin levels; reduce initial dose and increase\r\nmore gradually if patient intolerant; over 1\u00a0mg weekly give as divided\r\ndoses; up to 4.5\u00a0mg weekly has been used in hyperprolactinaemic patients;childunder 16 years, not recommended", "Parkinson\u2019s disease,section 4.9.1"], "pregnancy": "exclude pregnancy before starting and discontinue\r\n1 month before intended conception (ovulatory cycles persist for 6\r\nmonths)\u2014discontinue if pregnancy occurs during treatment (specialist\r\nadvice needed)", "breast-feeding": "suppresses lactation; avoid breast-feeding if\r\nlactation prevention fails"}, "SILVER SULFADIAZINE": {"indications": "prophylaxis and treatment of infection in burn\r\nwounds; as an adjunct to short-term treatment of infection in leg\r\nulcers and pressure sores; as an adjunct to prophylaxis of infection\r\nin skin graft donor sites and extensive abrasions; for conservative\r\nmanagement of finger-tip injuries", "name": "SILVER SULFADIAZINE", "renal impairment": "manufacturer advises caution if significant impairment;\r\nsee also Large Areas, above", "cautions": "G6PD deficiency; may inactivate enzymatic debriding agents\u2014concomitant use may be\r\ninappropriate; for large amounts see alsointeractions:Appendix 1 (sulfonamides)", "side-effects": "allergic reactions including burning, itching\r\nand rashes; argyria reported following prolonged use; leucopenia reported\r\n(monitor blood levels)", "contra-indications": "sensitivity to sulfonamides; not recommended for neonates", "hepatic impairment": "manufacturer advises caution if significant impairment;\r\nsee also Large Areas, above", "doses": ["burns, apply daily or more frequently if very exudative;\r\nleg ulcers or pressure sores, apply daily or on alternate days (not\r\nrecommended if ulcer very exudative); finger-tip injuries, apply every\r\n2\u20133 days; consult product literature for details"], "pregnancy": "risk of neonatal haemolysis and methaemoglobinaemia\r\nin third trimester", "breast-feeding": "small risk of kernicterus in jaundiced infants\r\nand of haemolysis in G6PD-deficient infants"}, "BACLOFEN": {"indications": "chronic severe spasticity resulting\r\nfrom disorders such as multiple sclerosis or traumatic partial section\r\nof spinal cord", "name": "BACLOFEN", "renal impairment": "risk of toxicity\u2014use smaller doses (e.g. 5\u00a0mg daily by\r\nmouth) and if necessary increase dosage interval; if eGFR less than\r\n15\u00a0mL/minute/1.73m2manufacturer advises use by mouth only\r\nif potential benefit outweighs risk; excreted by kidney", "interactions": {"extra": "", "bad": 0, "interaction": "hyperkinesis caused by  lithium possibly aggravated by baclofen ", "name": "Baclofen", "backrefs": ["Baclofen"]}, "cautions": "psychiatric illness, Parkinson\u2019s disease, cerebrovascular disease, elderly; respiratory impairment; epilepsy; history of peptic\r\nulcer (avoid oral route in active peptic\r\nulceration); diabetes; hypertonic bladder sphincter; avoid abrupt\r\nwithdrawal (risk of hyperactive state, may exacerbate\r\nspasticity, and precipitate autonomic dysfunction including hyperthermia,\r\npsychiatric reactions and convulsions, see also under Withdrawal below);interactions:Appendix 1 (muscle relaxants)", "side-effects": "gastro-intestinal disturbances, dry mouth; hypotension,\r\nrespiratory or cardiovascular depression; sedation, drowsiness, confusion,\r\ndizziness, ataxia, hallucinations, nightmares, headache, euphoria,\r\ninsomnia, depression, anxiety, agitation, tremor; seizure; urinary\r\ndisturbances; myalgia; visual disorders; rash, hyperhidrosis;rarelytaste disturbances, abdominal pain, changes in hepatic\r\nfunction, paraesthesia, erectile dysfunction, dysarthria;very rarelyhypothermia", "hepatic impairment": "manufacturer advises use by mouth with caution", "doses": ["By mouth,adultandchildover 10 years, initially\r\n5\u00a0mg 3 times daily, gradually increased; usual maintenance dose up\r\nto 60\u00a0mg daily in divided doses (max. 100\u00a0mg daily);child1\u20132 years, initially 300\u00a0micrograms/kg daily\r\nin 4 divided doses, increased gradually to usual maintenance dose\r\n0.75\u20132\u00a0mg/kg (max. 40\u00a0mg) daily in divided doses (or10\u201320\u00a0mg daily in divided doses);child2\u20136 years, initially 300\u00a0micrograms/kg daily in 4 divided doses,\r\nincreased gradually to usual maintenance dose of 0.75\u20132\u00a0mg/kg (max.\r\n40\u00a0mg) daily in divided doses (or20\u201330\u00a0mg daily\r\nin divided doses);child6\u20138 years,\r\ninitially 300\u00a0micrograms/kg daily in 4 divided doses, increased gradually\r\nto usual maintenance dose of 0.75\u20132\u00a0mg/kg (max. 40\u00a0mg) daily in divided\r\ndoses (or30\u201340\u00a0mg daily in divided doses);child8\u201310 years, initially 300\u00a0micrograms/kg daily\r\nin 4 divided doses, increased gradually to usual maintenance dose\r\nof 0.75\u20132\u00a0mg/kg (max. 60\u00a0mg) daily in divided doses", "Review treatment if no benefit within 6 weeks\r\nof achieving maximum dose", "By intrathecal injection, specialist\r\nuse only, severe chronic spasticity unresponsive to oral antispastic\r\ndrugs (or where side-effects of oral therapy unacceptable)oras alternative to ablative neurosurgical procedures,adultover 18 years, initialtest dose25\u201350\u00a0micrograms over at least 1 minute via catheter or lumbar puncture,\r\nincreased in 25-microgram steps (not more often than every 24 hours)\r\nto max. 100\u00a0micrograms to determine appropriate dose,then\r\ndose-titration phase, most often using infusion pump (implanted\r\ninto chest wall or abdominal wall tissues) to establishmaintenance\r\ndose(ranging from 12\u00a0micrograms to 2\u00a0mg daily for spasticity\r\nof spinal originor22\u00a0micrograms to 1.4\u00a0mg daily\r\nfor spasticity of cerebral origin) retaining some spasticity to avoid\r\nsensation of paralysis;child4\u201318\r\nyears (spasticity of cerebral or spinal origin only), initialtest dose25\u201350\u00a0micrograms then titrated as foradult, initialmaintenance dose25\u2013200\u00a0micrograms\r\ndaily, adjusted according to response", "Consult product literature\r\nfor details on test dose and titration\u2014important to monitor patients closely in appropriately equipped and staffed environment\r\nduring screening and immediately after pump implantation. Resuscitation equipment must be available for immediate\r\nuse"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk (toxicity inanimalstudies)", "breast-feeding": "present in milk\u2014amount probably too small to\r\nbe harmful"}, "AMANTADINE": {"interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects when  antipsychotics given with amantadine ", "name": "Amantadine", "backrefs": ["Amantadine"]}}, "NAFTIDROFURYL OXALATE": {"side-effects": "nausea, epigastric pain, rash, hepatitis, hepatic\r\nfailure", "indications": "see under Dose", "name": "NAFTIDROFURYL OXALATE", "doses": ["Peripheral vascular disease (see notes above), 100\u2013200\u00a0mg\r\n3 times daily", "Cerebral vascular disease, 100\u00a0mg 3 times daily"]}, "OXAZEPAM": {"indications": "anxiety (short-term use; seesection 4.1)", "name": "OXAZEPAM", "renal impairment": "seenotes above", "cautions": "see underDiazepam; short\r\nacting", "side-effects": "see underDiazepam", "contra-indications": "see underDiazepam", "hepatic impairment": "seenotes above", "doses": ["Anxiety, 15\u201330\u00a0mg (elderly or debilitated 10\u201320\u00a0mg) 3\u20134\r\ntimes daily;childnot recommended", "Insomnia associated with anxiety, 15\u201325\u00a0mg (max. 50\u00a0mg) at bedtime;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CEFACLOR": {"indications": "infections due to sensitive Gram-positive and Gram-negative bacteria,\r\nbut seenotes above", "name": "CEFACLOR", "renal impairment": "no dose adjustment required\u2014manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": " antacids reduce absorption of cefaclor ", "name": "Cefaclor", "backrefs": ["Cefaclor"]}, "cautions": "sensitivity to beta-lactam antibacterials (avoid if history of immediate hypersensitivity reaction, see alsonotes aboveandHypersensitivity Reactions);false positive urinaryglucose(if\r\ntested for reducing substances) and false\r\npositive Coombs\u2019 test;interactions:Appendix 1 (cephalosporins)", "side-effects": "diarrhoea (rarely antibiotic-associated colitis),\r\nnausea and vomiting, abdominal discomfort, headache; allergic reactions\r\nincluding rashes, pruritus, urticaria, serum sickness-like reactions\r\nwith rashes, fever and arthralgia, and anaphylaxis; Stevens-Johnson\r\nsyndrome, toxic epidermal necrolysis reported; disturbances in liver\r\nenzymes, transient hepatitis and cholestatic jaundice; other side-effects\r\nreported include eosinophilia and blood disorders (including thrombocytopenia,\r\nleucopenia, agranulocytosis, aplastic anaemia and haemolytic anaemia);\r\nreversible interstitial nephritis, hyperactivity, nervousness, sleep\r\ndisturbances, hallucinations, confusion, hypertonia, and dizziness", "contra-indications": "cephalosporin\r\nhypersensitivity", "doses": ["250\u00a0mg every 8 hours, doubled for severe infections; max.\r\n4\u00a0g daily;childover 1 month, 20\u00a0mg/kg\r\ndaily in 3 divided doses, doubled for severe infections,\r\nmax. 1\u00a0g daily;or1 month\u20131 year, 62.5\u00a0mg every\r\n8 hours; 1\u20135 years, 125\u00a0mg; over 5 years, 250\u00a0mg; doses doubled for\r\nsevere infections"], "pregnancy": "not known to be harmful", "breast-feeding": "present in milk in low concentration, but appropriate\r\nto use"}, "ETHINYLESTRADIOL": {"indications": "seenotes above; other indications (section 6.4.1.1)", "name": "ETHINYLESTRADIOL", "interactions": {"extra": "", "bad": 0, "interaction": " colesevelam reduces absorption of ethinylestradiol ", "name": "Ethinylestradiol", "backrefs": ["Colesevelam", "Ethinylestradiol", "Etoricoxib"]}, "cautions": "seesection 6.4.1.1;interactions:Appendix 1 (oestrogens)", "side-effects": "seesection 6.4.1.1", "contra-indications": "seesection 6.4.1.1", "hepatic impairment": "avoid; see also Combined Hormonal Contraceptives (section 7.3.1)", "doses": ["Prostate cancer (palliative), 0.15\u20131.5\u00a0mg daily"]}, "DOPEXAMINE HYDROCHLORIDE": {"indications": "inotropic support and vasodilator in exacerbations of chronic heart\r\nfailure and in heart failure associated with cardiac surgery", "name": "DOPEXAMINE HYDROCHLORIDE", "cautions": "myocardial infarction, recent angina, hypokalaemia, hyperglycaemia; correct\r\nhypovolaemia before starting and during treatment, monitor blood pressure, pulse, plasma potassium, and bloodglucose; hyperthyroidism; avoid abrupt withdrawal;interactions:Appendix 1 (sympathomimetics)", "side-effects": "nausea, vomiting; tachycardia, bradycardia, arrhythmias,\r\nangina, myocardial infarction; tremor, headache; dyspnoea; reversible\r\nthrombocytopenia; sweating", "contra-indications": "left ventricular outlet obstruction such as hypertrophic cardiomyopathy or aortic stenosis; phaeochromocytoma, thrombocytopenia", "doses": ["By intravenous infusioninto central or\r\nlarge peripheral vein, 500\u00a0nanograms/kg/minute, may be increased to\r\n1\u00a0microgram/kg/minute and further increased up to 6\u00a0micrograms/kg/minute\r\nin increments of 0.5\u20131\u00a0microgram/kg/minute at intervals of not less\r\nthan 15 minutes"], "pregnancy": "no information available\u2014manufacturer advises avoid"}, "GONADORELIN": {"indications": "see preparations below", "name": "GONADORELIN", "cautions": "pituitary adenoma", "side-effects": "rarely, nausea, headache, abdominal pain, increased\r\nmenstrual bleeding; rarely, hypersensitivity reaction on repeated\r\nadministration of large doses; irritation at injection site", "doses": ["for assessment of pituitary function (adults),by subcutaneousorintravenous injection, 100\u00a0micrograms"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "NITISINONE": {"indications": "hereditary tyrosinaemia type I (specialist\r\nuse only)", "name": "NITISINONE", "cautions": "slit-lamp examination of eyes recommended\r\nbefore treatment; monitor liver function\r\nregularly; monitor platelet and white blood\r\ncell count every 6 months", "side-effects": "thrombocytopenia, leucopenia, granulocytopenia;\r\nconjunctivitis, photophobia, corneal opacity, keratitis, eye pain;less commonlyleucocytosis, blepharitis, pruritus, exfoliative\r\ndermatitis, and erythematous rash", "doses": ["adultandchildinitially 500\u00a0micrograms/kg twice daily, adjusted\r\naccording to response; max. 2\u00a0mg/kg daily", "Capsules can be opened and the contents suspended\r\nin a small amount of water or formula diet and taken immediately"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014adverse effects inanimalstudies"}, "BEXAROTENE": {"indications": "skin manifestations of cutaneous T-cell lymphoma refractory to previous\r\nsystemic treatment", "name": "BEXAROTENE", "interactions": {"extra": "", "bad": 1, "interaction": " gemfibrozil increases plasma concentration of bexarotene\u2014avoid concomitant use", "name": "Bexarotene", "backrefs": ["Bexarotene"]}, "cautions": "seesection 8.1andnotes above; hyperlipidaemia (avoid if uncontrolled), hypothyroidism (avoid if uncontrolled); hypersensitivity to retinoids; avoid in acute porphyria (section 9.8.2);interactions:Appendix 1 (bexarotene)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "seesection 8.1andnotes above; history of pancreatitis, hypervitaminosis A", "hepatic impairment": "avoid", "doses": ["Initially 300\u00a0mg/m2daily as a single dose\r\nwith a meal; adjust dose according to response"], "pregnancy": "avoid; manufacturer advises effective contraception\r\nduring and for at least 1 month after treatment in men or women; see\r\nalsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "RISPERIDONE": {"indications": "acute and chronic psychoses, mania; short-term treatment (up to 6\r\nweeks) of persistent aggression in patients with moderate to severe\r\nAlzheimer\u2019s dementia unresponsive to non-pharmacological interventions\r\nand when there is a risk of harm to self or others; short-term treatment\r\n(up to 6 weeks) of persistent aggression in conduct disorder (under\r\nspecialist supervision)", "name": "RISPERIDONE", "renal impairment": "initial and subsequent oral doses should be halved", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  clozapine with depot formulation of risperidone as cannot be withdrawn quickly if neutropenia occurs", "name": "Risperidone", "backrefs": ["Risperidone"]}, "cautions": "seenotes above;dementia with\r\nLewy bodies; dehydration;\r\navoid in acute porphyria (section 9.8.2)", "side-effects": "seenotes above; also\r\ngastro-intestinal disturbances (including diarrhoea, constipation,\r\nnausea and vomiting, dyspepsia, abdominal pain), dry mouth; dyspnoea;\r\ndrowsiness, asthenia, tremor, sleep disturbances, agitation, anxiety,\r\nheadache; urinary incontinence; arthralgia, myalgia; abnormal vision;\r\nepistaxis; rash;less commonlyanorexia, ECG changes,\r\nhypoaesthesia, impaired concentration, hyperprolactinaemia (with galactorrhoea,\r\nmenstrual disturbances, gynaecomastia), sexual dysfunction, blood\r\ndisorders, tinnitus, angioedema;rarelyintestinal\r\nobstruction, pancreatitis, jaundice, seizures, hyponatraemia, abnormal\r\ntemperature regulation; oedema and priapism also reported", "hepatic impairment": "initial and subsequent oral doses should be halved", "doses": ["Psychosis, 2\u00a0mg in 1\u20132 divided doses on first daythen4\u00a0mg in 1\u20132 divided doses on second day (slower titration\r\nappropriate in some patients); usual dose range 4\u20136\u00a0mg daily; doses\r\nabove 10\u00a0mg daily only if benefit considered to outweigh risk (max.\r\n16\u00a0mg daily);elderlyinitially 500\u00a0micrograms\r\ntwice daily increased in steps of 500\u00a0micrograms twice daily to 1\u20132\u00a0mg\r\ntwice daily;child12\u201318 years seeBNF for Children", "Mania, initially 2\u00a0mg once daily, increased if necessary in\r\nsteps of 1\u00a0mg daily; usual dose range 1\u20136\u00a0mg daily;elderlyinitially 500\u00a0micrograms twice daily increased\r\nin steps of 500\u00a0micrograms twice daily to 1\u20132\u00a0mg twice daily;child12\u201318 years seeBNF for Children", "Persistent aggression in Alzheimer\u2019s dementia, initially 250\u00a0micrograms\r\ntwice daily, increased according to response in steps of 250\u00a0micrograms\r\ntwice daily on alternate days; usual dose 500\u00a0micrograms twice daily\r\n(up to 1\u00a0mg twice daily has been required)", "Persistent aggression in conduct disorder,childover 5 years, body-weight under 50\u00a0kg, initially 250\u00a0micrograms\r\nonce daily, increased according to response in steps of 250\u00a0micrograms\r\non alternate days; usual dose 500\u00a0micrograms daily (up to 750\u00a0micrograms\r\nonce daily has been required);childover 5 years, body-weight over 50\u00a0kg, initially 500\u00a0micrograms once\r\ndaily, increased according to response in steps of 500\u00a0micrograms\r\non alternate days; usual dose 1\u00a0mg daily (up to 1.5\u00a0mg once daily\r\nhas been required)"], "pregnancy": "seePregnancy notes;\r\nalso use only if potential benefit outweighs risk", "breast-feeding": "use only if potential benefit outweighs risk\u2014small\r\namount present in milk"}, "ERTAPENEM": {"indications": "abdominal infections; acute gynaecological infections; community-acquired\r\npneumonia; diabetic foot infections of the skin and soft-tissue; prophylaxis\r\nfor colorectal surgery", "name": "ERTAPENEM", "renal impairment": "risk of seizures; max. 500\u00a0mg daily if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2", "cautions": "sensitivity to beta-lactam antibacterials (avoid if history of immediate hypersensitivity reaction, seeHypersensitivity Reactions); elderly, CNS disorders\u2014risk of seizures;interactions:Appendix 1 (ertapenem)", "side-effects": "diarrhoea, nausea, vomiting, headache, injection-site\r\nreactions, rash (also reported with eosinophilia and systemic symptoms),\r\npruritus, raised platelet count;less commonlydry\r\nmouth, taste disturbances, dyspepsia, abdominal pain, anorexia, constipation,\r\nmelaena, antibiotic-associated colitis, bradycardia, hypotension,\r\nchest pain, oedema, pharyngeal discomfort, dyspnoea, dizziness, sleep\r\ndisturbances, confusion, asthenia, seizures, raised glucose, petechiae;rarelydysphagia, cholecystitis, liver disorder (including\r\njaundice), arrhythmia, increase in blood pressure, syncope, nasal\r\ncongestion, cough, wheezing, anxiety, depression, agitation, tremor,\r\npelvic peritonitis, renal impairment, muscle cramp, scleral disorder,\r\nblood disorders (including neutropenia, thrombocytopenia, haemorrhage),\r\nhypoglycaemia, electrolyte disturbances; also reported hallucinations,\r\ndyskinesia", "doses": ["By intravenous infusion,adultandadolescentover 13 years, 1\u00a0g once daily;child3 months\u201313 years, 15\u00a0mg/kg every 12 hours (max. 1\u00a0g daily)", "Surgical prophylaxis, colorectal surgery,adultover 18 years, 1\u00a0g completed within 1 hour before surgery"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "ROPIVACAINE": {"interactions": {"extra": "", "bad": 0, "interaction": "increased myocardial depression when  anti-arrhythmics given with ropivacaine ", "name": "Ropivacaine", "backrefs": ["Ropivacaine"]}}, "ANAKINRA": {"indications": "see underCytokine Modulatorsabove", "name": "ANAKINRA", "renal impairment": "caution if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; avoid\r\nif eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of live  vaccines with anakinra (see under Active Immunity, section 14.1)", "name": "Anakinra", "backrefs": ["Etanercept", "Golimumab", "Certolizumab pegol", "Infliximab", "Vaccines", "Adalimumab", "Anakinra"]}, "cautions": "predisposition to infection; history of asthma (risk of serious infection);interactions:Appendix 1 (anakinra)", "side-effects": "injection-site reactions; headache; infections,\r\nneutropenia (see also Cautions), and antibody formation;also\r\nreportedmalignancy", "contra-indications": "neutropenia", "doses": ["By subcutaneous injection,adultover 18 years, 100\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid; effective contraception\r\nmust be used during treatment", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "ERGOTAMINE AND METHYSERGIDE": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ergotism when  ritonavir given with ergotamine and methysergide\u2014avoid concomitant use", "name": "Ergotamine and Methysergide", "backrefs": ["Ergotamine and Methysergide"]}}, "ARACHIS OIL": {"indications": "see notes above", "name": "ARACHIS OIL", "doses": ["See below"]}, "ZINC SULPHATE": {"indications": "zincdeficiency or supplementation in zinc-losing\r\nconditions", "name": "ZINC SULPHATE", "renal impairment": "accumulation may occur in acute renal failure", "cautions": "interactions:Appendix 1 (zinc)", "side-effects": "abdominal pain, dyspepsia, nausea, vomiting, diarrhoea,\r\ngastric irritation; irritability, headache, lethargy", "doses": ["adultandchildover 30\u00a0kg, 1 tablet in water 1\u20133 times daily\r\nafter food;childunder 10\u00a0kg, \u00bd tablet\r\ndaily; 10\u201330\u00a0kg, \u00bd tablet 1\u20133 times daily"], "pregnancy": "crosses placenta; risk theoretically minimal, but\r\nno information available", "breast-feeding": "present in milk; risk theoretically minimal,\r\nbut no information available"}, "ANTIDEPRESSANTS, SSRI": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of CNS effects when  lithium given with SSRIs (lithium toxicity reported)", "name": "Antidepressants, SSRI", "backrefs": []}}, "TESTOSTERONE AND ESTERS": {"indications": "see under preparations", "name": "TESTOSTERONE AND ESTERS", "renal impairment": "caution\u2014potential for fluid retention", "cautions": "cardiac impairment, elderly, ischaemic heart\r\ndisease, hypertension, epilepsy, migraine, diabetes mellitus, skeletal metastases\r\n(risk of hypercalcaemia), undertake regular examination\r\nof the prostate and breast during treatment; monitor\r\nfull blood count, lipid profile and liver function; pre-pubertal boys (seenotes aboveand under Side-effects);interactions:Appendix 1 (testosterone)", "side-effects": "prostate abnormalities and prostate cancer, headache,\r\ndepression, gastro-intestinal bleeding, nausea, vomiting, cholestatic\r\njaundice, changes in libido, gynaecomastia, polycythaemia, anxiety,\r\nirritability, nervousness, asthenia, paraesthesia, hypertension, electrolyte\r\ndisturbances including sodium retention with oedema and hypercalcaemia,\r\nweight gain; increased bone growth, muscle cramps, arthralgia; androgenic\r\neffects such as hirsutism, male-pattern baldness, seborrhoea, acne,\r\npruritus, excessive frequency and duration of penile erection, precocious\r\nsexual development and premature closure of epiphyses in pre-pubertal\r\nmales, suppression of spermatogenesis in men and virilism in women;rarelyliver tumours; sleep apnoea also reported;with patches, buccal tablets,andgel, local irritation and allergic reactions (including\r\nburn-like lesions withpatches), and taste disturbances", "contra-indications": "breast\r\ncancer in men, prostate cancer, history of primary liver tumours, hypercalcaemia, nephrotic syndrome", "hepatic impairment": "avoid if possible\u2014fluid retention and dose-related\r\ntoxicity", "doses": ["See under preparations"], "pregnancy": "avoid; causes masculinisation of female fetus", "breast-feeding": "avoid; may cause masculinisation in the female\r\ninfant or precocious development in the male infant; high doses suppress\r\nlactation"}, "MACROGOLS": {"indications": "see\r\npreparations below", "name": "MACROGOLS", "cautions": "patients with cardiovascular impairment\r\nshould not take more than 2 sachets in any 1 hour", "side-effects": "abdominal distension and pain, nausea, flatulence", "contra-indications": "intestinal perforation or obstruction, paralytic ileus, severe inflammatory conditions of the intestinal tract (such as Crohn\u2019s disease, ulcerative\r\ncolitis, and toxic megacolon),\r\nsee also preparations below", "doses": ["chronic constipation,adultandchildover 12 years, 25\u00a0mL 1\u20133\r\ntimes daily usually for up to 2 weeks; maintenance, 25\u00a0mL 1\u20132 times\r\ndaily"], "pregnancy": "manufacturers advise use only if essential\u2014no information\r\navailable", "breast-feeding": "manufacturer ofMovicol\u00ae\r\noral concentrate advises avoid\u2014no information available"}, "PHENTOLAMINE MESILATE": {"indications": "hypertensive episodes due to phaeochromocytoma\r\ne.g. during surgery; diagnosis of phaeochromocytoma (but seenotes above)", "name": "PHENTOLAMINE MESILATE", "renal impairment": "manufacturer advises caution\u2014no information available", "cautions": "monitor blood pressure (avoid\r\nin hypotension), heart rate; gastritis, peptic ulcer; elderly;interactions:Appendix 1\r\n(alpha-blockers)", "side-effects": "postural hypotension, tachycardia, dizziness,\r\nflushing; nausea and vomiting, diarrhoea, nasal congestion; also acute\r\nor prolonged hypotension, angina, chest pain, arrhythmias", "contra-indications": "hypotension; history of myocardial infarction; coronary\r\ninsufficiency, angina, or other evidence of coronary artery disease", "doses": ["Hypertensive episodes,by intravenous injection, 2\u20135\u00a0mg repeated if necessary", "Diagnosis of phaeochromocytoma, consult product literature"], "pregnancy": "use with caution\u2014may cause marked decrease in maternal\r\nblood pressure with resulting fetal anoxia", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "MICONAZOLE NITRATE": {"side-effects": "see notes above", "indications": "fungal skin infections; oral and intestinal fungal\r\ninfections (section 12.3.2); vaginal candidiasis (section 7.2.2)", "name": "MICONAZOLE NITRATE", "cautions": "seenotes above;interactions:\r\nAppendix 1 (miconazole)", "doses": ["Apply twice daily continuing for 10 days after lesions\r\nhave healed; nail infections, apply 1\u20132 times daily"]}, "MITOXANTRONE": {"indications": "seenotes above", "name": "MITOXANTRONE", "interactions": {"extra": "", "bad": 0, "interaction": " ciclosporin reduces excretion of mitoxantrone (increased plasma concentration)", "name": "Mitoxantrone", "backrefs": ["Mitoxantrone"]}, "cautions": "seesection 8.1andnotes above; intrathecal administration not recommended;interactions:Appendix 1 (mitoxantrone)", "side-effects": "seesection 8.1andnotes above, anorexia, diarrhoea, abdominal pain, gastro-intestinal bleeding,\r\nconstipation, dyspnoea, drowsiness, confusion, paraesthesia, anxiety,\r\namenorrhoea, and transient blue-green discoloration of urine and blue\r\ndiscoloration of skin and nails also reported", "hepatic impairment": "use with caution\u2014consult local treatment protocol", "doses": ["SeeDoses"], "pregnancy": "avoid; manufacturer advises effective contraception\r\nduring and for at least 6 months after treatment in men or women;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "IRINOTECAN": {"interactions": {"extra": "", "bad": 1, "interaction": " ketoconazole reduces plasma concentration of  irinotecan (but concentration of active metabolite of irinotecan increased)\u2014avoid concomitant use", "name": "Irinotecan", "backrefs": ["Irinotecan"]}}, "SULFADIAZINE": {"indications": "prevention of rheumatic fever recurrence, toxoplasmosis [unlicensed]\u2014seesection 5.4.7", "name": "SULFADIAZINE", "renal impairment": "use with caution in mild to moderate impairment; avoid\r\nin severe impairment; high risk of crystalluria", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  ciclosporin possibly reduced by sulfadiazine ", "name": "Sulfadiazine", "backrefs": ["Sulfadiazine"]}, "cautions": "see underCo-trimoxazole;interactions:Appendix 1 (sulfonamides)", "side-effects": "see underCo-trimoxazole; also\r\nhypothyroidism, benign intracranial hypertension, optic neuropathy", "contra-indications": "see underCo-trimoxazole", "hepatic impairment": "use with caution in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["Prevention of rheumatic fever,by mouth, 1\u00a0g daily (500\u00a0mg daily for patients less than 30\u00a0kg)"], "pregnancy": "neonatal haemolysis and methaemoglobinaemia in third\r\ntrimester; fear of increased risk of kernicterus in neonates appears\r\nto be unfounded", "breast-feeding": "small risk of kernicterus in jaundiced infants\r\nand of haemolysis in G6PD-deficient infants"}, "TRANYLCYPROMINE": {"indications": "depressive illness", "name": "TRANYLCYPROMINE", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  buspirone for 10 days after stopping tranylcypromine advised by manufacturer of tranylcypromine", "name": "Tranylcypromine", "backrefs": ["Tranylcypromine"]}, "cautions": "see underPhenelzine", "side-effects": "see underPhenelzine; insomnia; hypertensive\r\ncrises with throbbing headache requiring discontinuation of treatment\r\nmore frequent than with other MAOIs; liver damage less frequent than\r\nwith phenelzine; blood dyscrasias also reported", "contra-indications": "see underPhenelzine; hyperthyroidism", "hepatic impairment": "seenotes above", "doses": ["Initially 10\u00a0mg twice daily not later than 3\u00a0p.m., increasing\r\nthe second daily dose to 20\u00a0mg after 1 week if necessary; doses above\r\n30\u00a0mg daily under close supervision only; usual maintenance dose 10\u00a0mg\r\ndaily;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "present in milk inanimalstudies"}, "QUETIAPINE": {"indications": "schizophrenia; mania, either alone or with mood stabilisers; depression\r\nin bipolar disorder; adjunctive treatment in major depressive disorder", "name": "QUETIAPINE", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of quetiapine\u2014manufacturer of quetiapine advises avoid concomitant use", "name": "Quetiapine", "backrefs": ["Quetiapine"]}, "cautions": "seenotes above; also cerebrovascular disease; patients at risk\r\nof aspiration pneumonia; treatment of depression\r\nin patients under 25 years (increased risk of suicide)", "side-effects": "seenotes above; also\r\ndry mouth, constipation, dyspepsia; tachycardia, hypertension, elevated\r\nplasma-triglyceride and -cholesterol concentrations, peripheral oedema;\r\ndrowsiness, headache, irritability, dysarthria, asthenia; leucopenia,\r\nneutropenia; blurred vision; rhinitis;less commonlydysphagia, seizures, restless legs syndrome, hyponatraemia, and\r\neosinophilia;rarelyjaundice and priapism;very rarelyhepatitis, angioedema, Stevens-Johnson syndrome,\r\nand rhabdomyolysis; suicidal behaviour (particularly on initiation)\r\nalso reported", "hepatic impairment": "forimmediate-release tablets, initially\r\n25\u00a0mg daily, increased daily in steps of 25\u201350\u00a0mg; formodified-release\r\ntablets, initially 50\u00a0mg daily, increased daily in steps\r\nof 50\u00a0mg", "doses": ["Schizophrenia,adultover\r\n18 years, 25\u00a0mg twice daily on day 1, 50\u00a0mg twice daily on day 2,\r\n100\u00a0mg twice daily on day 3, 150\u00a0mg twice daily on day 4, then adjusted\r\naccording to response, usual range 300\u2013450\u00a0mg daily in 2 divided doses;\r\nmax. 750\u00a0mg daily;elderlyinitially\r\n25\u00a0mg daily as a single dose, increased in steps of 25\u201350\u00a0mg daily\r\nin 2 divided doses;child12\u201318 years\r\nseeBNF for Children", "Treatment of mania in bipolar disorder,adultover 18 years, 50\u00a0mg twice daily on day 1, 100\u00a0mg twice daily on\r\nday 2, 150\u00a0mg twice daily on day 3, 200\u00a0mg twice daily on day 4, then\r\nadjusted according to response in steps of up to 200\u00a0mg daily to max.\r\n800\u00a0mg daily; usual range 400\u2013800\u00a0mg daily in 2 divided doses;elderlyinitially 25\u00a0mg daily as a single dose, increased\r\nin steps of 25\u201350\u00a0mg daily in 2 divided doses;child12\u201318 years seeBNF for Children", "Treatment of depression in bipolar disorder,adultover 18 years, 50\u00a0mg once daily (at bedtime)\r\non day 1, 100\u00a0mg once daily on day 2, 200\u00a0mg once daily on day 3,\r\n300\u00a0mg once daily on day 4; adjust according to response, usual dose\r\n300\u00a0mg once daily, max. 600\u00a0mg daily", "Prevention of mania and depression in bipolar disorder,adultover 18 years, continue at the dose effective\r\nfor treatment of bipolar disorder and adjust to lowest effective dose;\r\nusual range 300\u2013800\u00a0mg in 2 divided doses"], "pregnancy": "seePregnancy notes; also use only if potential\r\nbenefit outweighs risk", "breast-feeding": "avoid\u2014no information available"}, "9.5.2.1 Phosphate supplements": {"name": "9.5.2.1 Phosphate supplements", "doses": ["vitamin D-resistant hypophosphataemic osteomalacia, 4\u20136\r\ntablets daily;childunder 5 years\r\n2\u20133 tablets daily"]}, "PEGINTERFERON ALFA": {"indications": "see under preparations", "name": "PEGINTERFERON ALFA", "renal impairment": "close monitoring required\u2014reduce dose in moderate to\r\nsevere impairment; consult product literature", "cautions": "consult product literature;interactions:Appendix 1 (interferons)", "side-effects": "seenotes aboveand consult product literature", "contra-indications": "consult product literature", "hepatic impairment": "avoid in severe impairment", "doses": ["Consult product literature"], "pregnancy": "manufacturers recommend avoid unless potential benefit\r\noutweighs risk (toxicity inanimalstudies); effective\r\ncontraception required during treatment\u2014consult product literature", "breast-feeding": "manufacturers advise avoid\u2014no information available"}, "CARBONIC ANHYDRASE INHIBITORS": {"interactions": {"extra": "", "bad": 0, "interaction": "increased risk of osteomalacia when  phenytoin given with carbonic anhydrase inhibitors ", "name": "Carbonic Anhydrase Inhibitors", "backrefs": ["Carbonic Anhydrase Inhibitors"]}}, "NALOXONE HYDROCHLORIDE": {"indications": "see under Dose", "name": "NALOXONE HYDROCHLORIDE", "cautions": "cardiovascular disease or\r\nthose receiving cardiotoxic drugs (serious adverse cardiovascular\r\neffects reported); physical dependence\r\non opioids (precipitates withdrawal); pain (see also under Titration of Dose, below); has short\r\nduration of action (repeated doses or infusion may be necessary to\r\nreverse effects of opioids with longer duration of action)", "side-effects": "nausea, vomiting; hypotension, hypertension, ventricular\r\ntachycardia and fibrillation, cardiac arrest; hyperventilation, dyspnoea,\r\npulmonary oedema; headache, dizziness;less commonlydiarrhoea, dry mouth, agitation, excitement, paraesthesia, tremor,\r\nsweating;very rarelyseizures, erythema multiforme,\r\nand hypersensitivity reactions including anaphylaxis", "doses": ["Reversal of postoperative respiratory depression,adultandchildover\r\n12 years,by intravenous injection, 100\u2013200\u00a0micrograms\r\n(1.5\u20133\u00a0micrograms/kg); if response inadequate, give subsequent dose\r\nof 100\u00a0micrograms every 2 minutes; alternatively, subsequent doses\r\ncan be givenby intramuscular injectionevery 1\u20132 hours;child1 month\u201312 years seeBNF for Children", "Reversal of respiratory and CNS depression resulting from opioid\r\nadministration to mother during labour,neonate,by intramuscular injection, 200\u00a0micrograms (60\u00a0micrograms/kg)\r\nas a single dose at birth; alternativelyby subcutaneousorintravenous injection, 10\u00a0micrograms/kg,\r\nrepeated every 2\u20133 minutes", "Opioid overdose, seeEmergency Treatment of Poisoning", "Naloxone doses in BNF may differ from those\r\nin product literature"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "not orally bioavailable"}, "DIAZEPAM": {"indications": "status epilepticus; febrile convulsions (section 4.8.3); convulsions due to poisoning\r\n(seeEmergency Treatment of Poisoning); other indications (section 4.1.2,section 10.2.2, andsection 15.1.4.1)", "name": "DIAZEPAM", "renal impairment": "see Benzodiazepines,section 4.1.2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of diazepam (risk of extreme sedation and respiratory depression\u2014avoid concomitant use)", "name": "Diazepam", "backrefs": ["Diazepam"]}, "cautions": "see Diazepam,section 4.1.2; when given intravenously\r\nfacilities for reversing respiratory depression with mechanical ventilation\r\nmust be immediately available (but see alsonotes above)", "side-effects": "see Diazepam,section 4.1.2; hypotension\r\nand apnoea", "contra-indications": "see Diazepam,section 4.1.2", "hepatic impairment": "see Benzodiazepines,section 4.1.2", "doses": ["Status epilepticus (but seenotes above), febrile\r\nconvulsions, and convulsions due to poisoning,by intravenous\r\ninjection, 10\u00a0mg at a rate of 1\u00a0mL (5\u00a0mg) per minute, repeated\r\nonce after 10 minutes if necessary;childunder 12 years, 300\u2013400\u00a0micrograms/kg (max. 10\u00a0mg) [unlicensed dose],\r\nrepeated once after 10 minutes if necessary", "By rectumas rectal solution,adultandchildover\r\n12 years, 10\u201320\u00a0mg, repeated once after 10\u201315 minutes if necessary;elderly10\u00a0mg;neonate[unlicensed] 1.25\u20132.5\u00a0mg;child1\r\nmonth\u20131 year [unlicensed] 5\u00a0mg; 1\u20132 years 5\u00a0mg; 2\u201312 years 5\u201310\u00a0mg"], "pregnancy": "see Benzodiazepines,section 4.1.2, andPregnancy", "breast-feeding": "see Benzodiazepines,section 4.1.2"}, "ALIMEMAZINE TARTRATE": {"indications": "urticaria and pruritus, premedication", "name": "ALIMEMAZINE TARTRATE", "renal impairment": "avoid", "cautions": "seenotes above; see alsosection 4.2.1", "side-effects": "seenotes above; see alsosection 4.2.1", "contra-indications": "seenotes above; see\r\nalsosection 4.2.1", "hepatic impairment": "seenotes above", "doses": ["Urticaria and pruritus, 10\u00a0mg 2\u20133 times daily, in severe\r\ncases up to max. 100\u00a0mg daily has been used;elderly10\u00a0mg 1\u20132 times daily;childunder\r\n2 years, seeBNF for Children, 2\u20135 years 2.5\u00a0mg 3\u20134 times daily, 5\u201312 years 5\u00a0mg 3\u20134 times\r\ndaily", "Premedication,child2\u20137 years\r\nup to 2\u00a0mg/kg 1\u20132 hours before operation"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "RETAPAMULIN": {"side-effects": "local reactions including irritation, erythema,\r\npain, contact dermatitis, and pruritus", "indications": "superficial bacterial skin infections\r\n(see alsonotes above)", "contra-indications": "contact with eyes and mucous membranes", "name": "RETAPAMULIN", "doses": ["adultover 18 years, apply\r\nthinly twice daily for 5 days; max. area of skin treated 100\u00a0cm2or lesion length 10\u00a0cm;child9 months\u201318 years, apply thinly twice daily for 5 days; max. area\r\nof skin treated 2% of body surface area", "Review treatment if no response within 2\u20133\r\ndays"]}, "DESOGESTREL": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  lamotrigine possibly increased by desogestrel ", "name": "Desogestrel", "backrefs": ["Desogestrel"]}}, "DAPTOMYCIN": {"indications": "see under Dose", "name": "DAPTOMYCIN", "renal impairment": "seeMuscle Effects; also monitor renal function\r\nif eGFR less than 80\u00a0mL/minute/1.73\u00a0m2; use normal dose\r\nevery 48 hours if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of myopathy when  statins given with daptomycin (preferably avoid concomitant use)", "name": "Daptomycin", "backrefs": ["Daptomycin"]}, "cautions": "interference with assay for prothrombin time and INR\u2014take\r\nblood sample immediately before daptomycin dose;interactions:Appendix 1 (daptomycin)", "side-effects": "nausea, vomiting, abdominal pain, flatulence,\r\ndiarrhoea (antibiotic-associated colitis reported), constipation,\r\nhypertension, hypotension, headache, anxiety, insomnia, dizziness,\r\nasthenia, anaemia, arthralgia, rash, pruritus, injection-site reactions;less commonlydyspepsia, anorexia, taste disturbance, glossitis,\r\nflushing, arrhythmias, tremor, paraesthesia, hyperglycaemia, renal\r\nfailure, eosinophilia, thrombocythaemia, electrolyte disturbances,\r\nmuscle effects (seeCautions);rarelyjaundice; also reported syncope, wheezing, eosinophilic\r\npneumonia, peripheral neuropathy", "hepatic impairment": "manufacturer advises caution in severe hepatic impairment\u2014no\r\ninformation available", "doses": ["By slow intravenous injectionover\r\n2 minutesorby intravenous infusion, complicated skin and soft-tissue infections caused by Gram-positive\r\nbacteria,adultover 18 years, 4\u00a0mg/kg\r\nonce daily; increased to 6\u00a0mg/kg once daily if associated withStaphylococcus aureusbacteraemia", "Right-sided endocarditis caused byStaphylococcus\r\naureus,adultover 18 years,\r\n6\u00a0mg/kg once daily"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "present in milk in small amounts, but absorption\r\nfrom gastro-intestinal tract negligible"}, "OXYTETRACYCLINE": {"indications": "see notes above; acne vulgaris, rosacea (section 13.6)", "name": "OXYTETRACYCLINE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["250\u2013500\u00a0mg every 6 hours", "Acne, seesection 13.6.2"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "SULFINPYRAZONE": {"indications": "gout prophylaxis, hyperuricaemia", "name": "SULFINPYRAZONE", "renal impairment": "reduce dose; avoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "excretion of  nitrofurantoin reduced by sulfinpyrazone (increased risk of toxicity)", "name": "Sulfinpyrazone", "backrefs": ["Nitrofurantoin", "Penicillins", "Sulfinpyrazone", "Pyrazinamide", "Dabigatran Etexilate", "Sulfonylureas"]}, "cautions": "see underProbenecid; regular blood counts advisable; cardiac disease (may cause salt and\r\nwater retention);interactions:Appendix 1 (sulfinpyrazone)", "side-effects": "gastro-intestinal disturbances, occasionally allergic\r\nskin reactions, salt and water retention; rarely blood disorders,\r\ngastro-intestinal ulceration and bleeding, acute renal failure, raised\r\nliver enzymes, jaundice and hepatitis", "contra-indications": "see underProbenecid; avoid in hypersensitivity to NSAIDs", "hepatic impairment": "avoid in severe impairment", "doses": ["Initially 100\u2013200\u00a0mg daily with food (or milk) increasing\r\nover 2\u20133 weeks to 600\u00a0mg daily (rarely 800\u00a0mg daily), continued until\r\nserum uric acid concentration normal then reduced for maintenance\r\n(maintenance dose may be as low as 200\u00a0mg daily)"], "pregnancy": "manufacturer advises caution\u2014no information available", "breast-feeding": "no information available"}, "BENZOYL PEROXIDE": {"side-effects": "skin irritation (reduce frequency or suspend use\r\nuntil irritation subsides and re-introduce at reduced frequency)", "indications": "acne vulgaris", "name": "BENZOYL PEROXIDE", "cautions": "avoid contact with eyes, mouth, and mucous membranes; may bleach fabrics and hair; avoid excessive exposure to sunlight", "doses": ["Apply 1\u20132 times daily preferably after washing with soap\r\nand water, start treatment with lower-strength preparations", "May bleach clothing"]}, "LORAZEPAM": {"indications": "conscious sedation for procedures; premedication;\r\nshort-term use in anxiety or insomnia (section 4.1.2); status epilepticus (section 4.8.2)", "name": "LORAZEPAM", "renal impairment": "see Benzodiazepines,section 4.1.2", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of lorazepam (increased plasma concentration)", "name": "Lorazepam", "backrefs": ["Lorazepam"]}, "cautions": "seenotes aboveandsection 4.1.2;interactions:Appendix 1 (anxiolytics\r\nand hypnotics)", "side-effects": "see notes above andDiazepam,section 4.1.2", "contra-indications": "seeDiazepam,section 4.1.2", "hepatic impairment": "see Benzodiazepines,section 4.1.2", "doses": ["By mouth, 2\u20133\u00a0mg the night before operation;\r\n2\u20134\u00a0mg 1\u20132 hours before operation", "By slow intravenous injection, preferably diluted\r\nwith an equal volume ofsodium chlorideintravenous\r\ninfusion 0.9% or water for injections, 50\u00a0micrograms/kg 30\u201345 minutes\r\nbefore operation", "By intramuscular injection, diluted as above,\r\n50\u00a0micrograms/kg 60\u201390 minutes before operation"], "pregnancy": "see Benzodiazepines,section 4.1.2", "breast-feeding": "see Benzodiazepines,section 4.1.2"}, "ANTIFUNGALS, TRIAZOLE": {"interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  fentanyl possibly increased by triazoles ", "name": "Antifungals, Triazole", "backrefs": []}}, "TEGAFUR WITH URACIL": {"indications": "seenotes above", "name": "TEGAFUR WITH URACIL", "renal impairment": "use with caution", "cautions": "seesection 8.1; cardiac disease;interactions:Appendix 1 (fluorouracil)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "manufacturer advises monitor liver function in mild\r\nto moderate impairment and avoid in severe impairment", "doses": ["adult, tegafur 300\u00a0mg/m2(with uracil 672\u00a0mg/m2) daily in 3 divided doses\r\nfor 28 days; subsequent courses repeated after 7-day interval; for\r\ndose adjustment due to toxicity, consult product literature"], "pregnancy": "avoid; manufacturer advises effective contraception\r\nduring and for 3 months after treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "NICOTINAMIDE": {"side-effects": "dryness of skin; also pruritus, erythema, burning\r\nand irritation", "indications": "see under preparation", "name": "NICOTINAMIDE", "cautions": "avoid contact with eyes and mucous membranes (including nose and mouth); reduce frequency\r\nof application if excessive dryness, irritation or peeling", "doses": ["inflammatory acne vulgaris, apply twice daily; reduce\r\nto once daily or on alternate days if irritation occurs"]}, "PEGFILGRASTIM": {"indications": "(specialist use only) reduction in duration of neutropenia and incidence\r\nof febrile neutropenia in cytotoxic chemotherapy for malignancy (except\r\nchronic myeloid leukaemia and myelodysplastic syndromes)", "name": "PEGFILGRASTIM", "cautions": "seenotes above; also acute leukaemia and myelosuppressive chemotherapy;interactions:Appendix 1 (filgrastim)", "side-effects": "seenotes above; alsovery rarelysplenic rupture", "doses": ["Dose expressed as\r\nfilgrastim", "By subcutaneous injection,adultover 18 years, 6\u00a0mg (0.6\u00a0mL) for each chemotherapy cycle, starting\r\n24 hours after chemotherapy"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "TOLTERODINE": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  ritonavir advised by manufacturer of tolterodine ", "name": "Tolterodine", "backrefs": ["Tolterodine"]}}, "ATAZANAVIR": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "ATAZANAVIR", "interactions": {"extra": "", "bad": 1, "interaction": " nevirapine possibly reduces plasma concentration of atazanavir\u2014avoid concomitant use", "name": "Atazanavir", "backrefs": ["Norethisterone", "Atazanavir"]}, "cautions": "seenotes above; also concomitant use with drugs that prolong PR interval; cardiac conduction disorders; predisposition to QT interval prolongation (including electrolyte disturbances, concomitant\r\nuse of drugs that prolong QT interval);interactions:Appendix 1 (atazanavir)", "side-effects": "see notes above; also AV block (in children);less commonlymouth ulcers, dry mouth, hypertension, syncope,\r\nchest pain, dyspnoea, peripheral neuropathy, abnormal dreams, amnesia,\r\ndisorientation, depression, anxiety, weight changes, increased appetite,\r\ngynaecomastia, nephrolithiasis, urinary frequency, haematuria, proteinuria,\r\narthralgia, and alopecia;rarelyhepatosplenomegaly,\r\noedema, palpitation, and abnormal gait; also reported, cholelithiasis,\r\ncholecystitis, and torsade de pointes", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\nmanufacturer advises caution in mild impairment; avoid in moderate\r\nto severe impairment", "doses": ["With low-dose ritonavir, 300\u00a0mg once daily;child6\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk; theoretical risk of hyperbilirubinaemia in neonate\r\nif used at term", "breast-feeding": "seeBreast-feeding"}, "PROMAZINE HYDROCHLORIDE": {"indications": "see under Dose", "name": "PROMAZINE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; also cerebral arteriosclerosis", "side-effects": "seenotes above; also\r\nhaemolytic anaemia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Short-term adjunctive management of psychomotor agitation,\r\n100\u2013200\u00a0mg 4 times daily;childnot\r\nrecommended", "Agitation and restlessness in elderly, 25\u201350\u00a0mg 4 times daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CITALOPRAM": {"indications": "depressive illness, panic disorder", "name": "CITALOPRAM", "renal impairment": "no information available for eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of CNS toxicity when  5HT1 agonists given with citalopram (manufacturer of citalopram advises avoid concomitant use)", "name": "Citalopram", "backrefs": ["Citalopram", "Escitalopram"]}, "cautions": "seenotes above; susceptibility to QT-interval prolongation", "side-effects": "seenotes above; also hepatitis, palpitation, tachycardia,\r\noedema, bradycardia, postural hypotension, haemorrhage, QT-interval\r\nprolongation, coughing, yawning, confusion, impaired concentration,\r\naggression, malaise, amnesia, migraine, paraesthesia, abnormal dreams,\r\neuphoria, mydriasis, taste disturbance, increased salivation, rhinitis,\r\ntinnitus, polyuria, micturition disorders, hypokalaemia, pruritus;\r\nparadoxical increased anxiety during initial treatment of panic disorder\r\n(reduce dose)", "contra-indications": "seenotes above; QT-interval prolongation (avoid\r\nconcomitant administration of drugs that prolong QT interval)", "hepatic impairment": "use doses at lower end of range; fortabletsup to max. 20\u00a0mg; fororal solutionup to max.\r\n16\u00a0mg", "doses": ["By mouth as tablets, depressive illness,\r\n20\u00a0mg once daily increased if necessary in steps of 20\u00a0mg daily at\r\nintervals of 3\u20134 weeks; max. 40\u00a0mg daily (elderlyover 65 years, max. 20\u00a0mg daily);childunder 18 years seeBNF for ChildrenandDepressive Illness in Children\r\nand Adolescents", "Panic disorder,adultover 18\r\nyears, initially 10\u00a0mg daily increased gradually if necessary in steps\r\nof 10\u00a0mg daily, usual dose 20\u201330\u00a0mg daily; max. 40\u00a0mg daily (elderlyover 65 years, max. 20\u00a0mg daily)", "By mouth as oral drops, depressive\r\nillness, 16\u00a0mg daily as a single dose increased if necessary in steps\r\nof 16\u00a0mg daily at intervals of 3\u20134 weeks; max. 32\u00a0mg daily (elderlyover 65 years, max. 16\u00a0mg daily);childunder 18 years seeBNF for ChildrenandDepressive Illness in Children\r\nand Adolescents", "Panic disorder,adultover 18\r\nyears, initially 8\u00a0mg daily as a single dose increased gradually if\r\nnecessary in steps of 8\u00a0mg, usual dose 16\u201324\u00a0mg daily; max. 32\u00a0mg\r\ndaily (elderlyover 65 years, max.\r\n16\u00a0mg daily)"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014use with caution"}, "CANDESARTAN CILEXETIL": {"indications": "hypertension; heart failure with impaired left ventricular systolic\r\nfunction in conjunction with an ACE inhibitor, or when ACE inhibitors\r\nare not tolerated (see alsosection 2.5.5)", "name": "CANDESARTAN CILEXETIL", "renal impairment": "initially 4\u00a0mg daily", "cautions": "seenotes above", "side-effects": "see notes above; also vertigo, headache;very rarelynausea, hepatitis, blood disorders, hyponatraemia,\r\nback pain, arthralgia, myalgia, rash, urticaria, pruritus", "contra-indications": "cholestasis", "hepatic impairment": "initially 4\u00a0mg once daily in mild or moderate impairment;\r\navoid in severe impairment", "doses": ["Hypertension, initially 8\u00a0mg (intravascular volume depletion\r\n4\u00a0mg) once daily, increased if necessary at intervals of 4 weeks to\r\nmax. 32\u00a0mg once daily; usual maintenance dose 8\u00a0mg once daily", "Heart failure, initially 4\u00a0mg once daily, increased at intervals\r\nof at least 2 weeks to \u2018target\u2019 dose of 32\u00a0mg once daily or to max.\r\ntolerated dose"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DESLORATADINE": {"indications": "symptomatic relief of allergic rhinitis and urticaria", "name": "DESLORATADINE", "renal impairment": "use with caution in severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above;rarelymyalgia;very rarelyhallucinations", "contra-indications": "seenotes above; also hypersensitivity to loratadine", "doses": ["5\u00a0mg once daily;child1\u20136\r\nyears 1.25\u00a0mg once daily, 6\u201312 years 2.5\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "DOXORUBICIN HYDROCHLORIDE": {"indications": "seenotes aboveandsection 7.4.4", "name": "DOXORUBICIN HYDROCHLORIDE", "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant to tissues;interactions:Appendix 1 (doxorubicin)", "side-effects": "seesection 8.1andnotes above", "contra-indications": "seenotes above; severe myocardial insufficiency, recent myocardial infarction, severe arrhythmia; previous treatment with maximum cumulative doses of\r\ndoxorubicin or other anthracycline; intravesical\r\nuse in urinary tract infections, bladder inflammation,\r\nand in urethral stenosis with catheterisation difficulties", "hepatic impairment": "reduce dose according to bilirubin concentration; avoid\r\nin severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and toxic inanimalstudies); manufacturer of liposomal product advises effective contraception\r\nduring and for at least 6 months after treatment in men or women;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ACRIVASTINE": {"indications": "symptomatic relief of allergy such\r\nas hay fever, chronic idiopathic urticaria", "name": "ACRIVASTINE", "renal impairment": "avoid in severe impairment", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above; also hypersensitivity to triprolidine; elderly", "doses": ["adultandchildover 12 years, 8\u00a0mg 3 times daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ANAESTHETICS, GENERAL (INTRAVENOUS)": {"interactions": {"extra": "", "bad": 0, "interaction": " opioid analgesics possibly enhance effects of intravenous general anaesthetics ", "name": "Anaesthetics, General (intravenous)", "backrefs": []}}, "POLIOMYELITIS VACCINES": {"indications": "immunisation against poliomyelitis", "name": "POLIOMYELITIS VACCINES", "cautions": "seesection 14.1;also for live vaccine,interactions:Appendix 1 (vaccines)", "side-effects": "seenotes aboveandsection 14.1", "contra-indications": "seenotes aboveandsection 14.1", "doses": ["See under preparations"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "MORPHINE SALTS": {"indications": "see notes above and under Dose; acute diarrhoea (section 1.4.2); cough in terminal care (section 3.9.1)", "name": "MORPHINE SALTS", "renal impairment": "seenotes above", "cautions": "seenotes above; also pancreatitis, cardiac arrhythmias, severe cor pulmonale", "side-effects": "seenotes above; also\r\nparalytic ileus, abdominal pain, anorexia, dyspepsia, exacerbation\r\nof pancreatitis, taste disturbance; hypertension, hypothermia, syncope;\r\nbronchospasm, inhibition of cough reflex; restlessness, seizures,\r\nparaesthesia, asthenia, malaise, disorientation, excitation, agitation,\r\ndelirium, raised intracranial pressure; amenorrhoea; myoclonus, muscle\r\nfasciculation, rhabdomyolysis, and nystagmus", "contra-indications": "seenotes above; also delayed gastric emptying, acute abdomen; heart failure secondary to chronic lung disease; phaeochromocytoma", "hepatic impairment": "seenotes above", "doses": ["The patient should be closely monitored\r\nfor pain relief as well as for side-effects especially respiratory\r\ndepression. See also notes above.", "Acute pain,by subcutaneous injection(not suitable for oedematous patients)orby intramuscular injection, initially 10\u00a0mg (elderlyor frail 5\u00a0mg) every 4 hours (or more frequently\r\nduring titration), adjusted according to response;neonateinitially 100\u00a0micrograms/kg every 6 hours,\r\nadjusted according to response;child1\u20136 months initially 100\u2013200\u00a0micrograms/kg every 6 hours, adjusted\r\naccording to response;child6 months\u20132\r\nyears initially 100\u2013200\u00a0micrograms/kg every 4 hours, adjusted according\r\nto response;child2\u201312 years initially\r\n200\u00a0micrograms/kg every 4 hours, adjusted according to response;child12\u201318 years initially 2.5\u201310\u00a0mg every 4 hours,\r\nadjusted according to response", "By slow intravenous injection, initially 5\u00a0mg\r\n(reduce dose inelderlyor frail) every\r\n4 hours (or more frequently during titration), adjusted according\r\nto response;neonateinitially 50\u00a0micrograms/kg\r\nevery 6 hours, adjusted according to response;child1\u20136 months initially 100\u00a0micrograms/kg every 6 hours, adjusted according\r\nto response;child6 months\u201312 years\r\ninitially 100\u00a0micrograms/kg every 4 hours, adjusted according to response", "Premedication,by subcutaneousorintramuscular injection, up to 10\u00a0mg 60\u201390 minutes\r\nbefore operation;child,by\r\nintramuscular injection, 150\u00a0micrograms/kg", "Patient controlled analgesia (PCA), consult hospital protocols", "Myocardial infarction,by slow intravenous injection(1\u20132\u00a0mg/minute), 5\u201310\u00a0mg followed by a further 5\u201310\u00a0mg if necessary;elderlyor frail patients, reduce dose by half", "Acute pulmonary oedema,by slow intravenous injection(2\u00a0mg/minute) 5\u201310\u00a0mg;elderlyor\r\nfrail patients, reduce dose by half", "Chronic pain,by mouthorby subcutaneous injection(not suitable for oedematous\r\npatients)orby intramuscular injection, initially 5\u201310\u00a0mg every 4 hours, adjusted according to response;\r\nsee alsoPrescribing in Palliative\r\nCare", "By rectum, initially 15\u201330\u00a0mg every 4 hours,\r\nadjusted according to response", "The doses stated above refer equally tomorphinehydrochloride and sulphate"], "pregnancy": "seenotes above", "breast-feeding": "therapeutic doses unlikely to affect infant"}, "GEFITINIB": {"indications": "seenotes above", "name": "GEFITINIB", "renal impairment": "manufacturer advises caution if creatinine clearance\r\nless than 20\u00a0mL/minute", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  warfarin possibly enhanced by gefitinib ", "name": "Gefitinib", "backrefs": ["Gefitinib"]}, "cautions": "monitor liver function\u2014consider discontinuing\r\nif severe changes in liver function occur; monitor for worsening of dyspnoea, cough and fever\u2014discontinue if\r\ninterstitial lung disease confirmed; patients\r\nshould seek immediate medical advice if they experience any ocular\r\nsymptoms;interactions:Appendix 1\r\n(gefitinib)", "side-effects": "seesection 8.1; also\r\nanorexia, diarrhoea, dry mouth; epistaxis, interstitial lung disease\u2014discontinue\r\nif confirmed; asthenia; pyrexia; haematuria, proteinuria; dry eye,\r\nconjunctivitis, blepharitis; nail disorder, skin reactions (including\r\ndry skin, rash, acne, and pruritus);less commonlypancreatitis, corneal erosion;rarelyhepatitis,\r\ntoxic epidermal necrolysis", "hepatic impairment": "manufacturer advises caution in moderate to severe\r\nimpairment due to cirrhosis", "doses": ["adultover 18 years, 250\u00a0mg\r\nonce daily"], "pregnancy": "manufacturer advises avoid unless essential\u2014toxicity\r\ninanimalstudies; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "BUSPIRONE": {"interactions": {"extra": "", "bad": 0, "interaction": " ritonavir increases plasma concentration of buspirone (increased risk of toxicity)", "name": "Buspirone", "backrefs": ["Tranylcypromine", "Buspirone"]}}, "MINOCYCLINE": {"indications": "see notes above; meningococcal carrier state; acne vulgaris (section 13.6.2)", "name": "MINOCYCLINE", "renal impairment": "use with caution (avoid excessive doses)", "cautions": "seenotes above; if treatment continued for longer\r\nthan 6 months, monitor every 3 months for hepatotoxicity, pigmentation\r\nand for systemic lupus erythematosus\u2014discontinue if these develop\r\nor if pre-existing systemic lupus erythematosus worsens", "side-effects": "seenotes above; also\r\ndizziness and vertigo (more common in women);rarelyanorexia, tinnitus, impaired hearing, hyperaesthesia, paraesthesia,\r\nacute renal failure, pigmentation (sometimes irreversible), and alopecia;very rarelysystemic lupus erythematosus, discoloration\r\nof conjunctiva, tears, and sweat", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["100\u00a0mg twice daily", "Acne, seesection 13.6.2and under preparations, below", "Prophylaxis of asymptomatic meningococcal carrier state (but\r\nno longer recommended, see notes above), 100\u00a0mg twice daily for 5\r\ndays usually followed byrifampicin", "Tablets or capsules should be swallowed\r\nwhole with plenty of fluid while sitting or standing"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "SODIUM PICOSULFATE WITH MAGNESIUM CITRATE": {"indications": "see preparations", "name": "SODIUM PICOSULFATE WITH MAGNESIUM CITRATE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2\u2014risk of hypermagnesaemia", "cautions": "seenotes above; also recent gastro-intestinal surgery; cardiac\r\ndisease (avoid\r\nin congestive cardiac failure)", "side-effects": "seenotes above; also anal\r\ndiscomfort, sleep disturbances, fatigue, and rash", "contra-indications": "seenotes above; also gastro-intestinal ulceration; ascites; congestive cardiac failure", "hepatic impairment": "avoid in hepatic coma if risk of renal failure", "doses": ["bowel evacuation on day before radiological procedure,\r\nendoscopy, or surgery,adultandchildover 9 years, 1 sachet before 8\u00a0a.m. then 1\r\nsachet 6\u20138 hours later;child1\u20132 years,\r\nquarter sachet before 8 a.m. then quarter sachet 6\u20138 hours later;\r\n2\u20134 years, half sachet before 8 a.m. then half sachet 6\u20138 hours later;\r\n4\u20139 years, 1 sachet before 8 a.m. then half sachet 6\u20138 hours later", "Acts within 3 hours of first dose"], "pregnancy": "caution", "breast-feeding": "caution"}, "FLUORIDES": {"indications": "prophylaxis of dental caries\u2014seenotes above", "name": "FLUORIDES", "interactions": {"extra": "", "bad": 0, "interaction": " calcium salts reduce absorption of fluorides ", "name": "Fluorides", "backrefs": ["Fluorides"]}, "side-effects": "occasional white flecks on teeth with recommended\r\ndoses;rarelyyellowish-brown discoloration if recommended\r\ndoses are exceeded", "contra-indications": "not for areas where drinking\r\nwater is fluoridated", "doses": ["child6 years and over,\r\nfordailyuse, rinse with 10\u00a0mL"]}, "AMOROLFINE": {"indications": "fungal nail infections", "name": "AMOROLFINE", "cautions": "seenotes above; also avoid contact\r\nwith ears", "side-effects": "see notes above", "doses": ["Apply to infected nails 1\u20132 times weekly after filing\r\nand cleansing; allow to dry (approx. 3 minutes); treat finger nails\r\nfor 6 months, toe nails for 9\u201312 months (review at intervals of 3\r\nmonths); avoid nail varnish or artificial nails during treatment"], "pregnancy": "systemic absorption very low, but manufacturer advises\r\navoid\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "CETIRIZINE HYDROCHLORIDE": {"indications": "symptomatic relief of allergy such as hay fever, chronic idiopathic\r\nurticaria", "name": "CETIRIZINE HYDROCHLORIDE", "renal impairment": "use half normal dose if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; use half normal dose and reduce dose frequency to alternate\r\ndays if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less\r\nthan 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["adultandchildover 12 years, 10\u00a0mg once daily;child1\u20132 years seeBNF for Children, 2\u20136 years\r\n2.5\u00a0mg twice daily, 6\u201312 years 5\u00a0mg twice daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "BENZOIC ACID": {"indications": "ringworm (tinea), but see notes above", "name": "BENZOIC ACID", "doses": ["apply twice daily"]}, "VALSARTAN": {"indications": "hypertension; heart failure when ACE inhibitors cannot be used, or\r\nin conjunction with an ACE inhibitor when a beta-blocker cannot be\r\nused (see alsosection 2.5.5); myocardial infarction with\r\nleft ventricular failure or left ventricular systolic dysfunction\r\n(adjunct\u2014seesection 2.5.5andsection 2.10.1)", "name": "VALSARTAN", "renal impairment": "use with caution if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2\u2014no information available", "cautions": "seenotes above", "side-effects": "see notes above; renal impairment;less\r\ncommonlygastro-intestinal disturbance, syncope, fatigue,\r\ncough, headache, acute renal failure; neutropenia, thrombocytopenia,\r\nmyalgia, and hypersensitivity reactions (including rash, pruritus,\r\nvasculitis, and serum sickness) also reported", "contra-indications": "biliary cirrhosis, cholestasis", "hepatic impairment": "max. dose 80\u00a0mg daily in mild to moderate impairment;\r\navoid if severe", "doses": ["Hypertension, usually 80\u00a0mg once daily (initially 40\u00a0mg\r\nonce daily in intravascular volume depletion); if necessary increased\r\nat intervals of 4 weeks up to max. 320\u00a0mg daily", "Heart failure, initially 40\u00a0mg twice daily increased at intervals\r\nof at least 2 weeks up to max. 160\u00a0mg twice daily", "Myocardial infarction, initially 20\u00a0mg twice daily increased\r\nover several weeks to 160\u00a0mg twice daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "LEVODOPA": {"interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with levodopa ", "name": "Levodopa", "backrefs": ["Levodopa", "Amisulpride", "Benzodiazepines", "Pyridoxine"]}}, "PYRIDOXINE": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  levodopa reduced by pyridoxine when given without dopa-decarboxylase inhibitor", "name": "Pyridoxine", "backrefs": ["Pyridoxine"]}}, "CHLOROQUINE AND HYDROXYCHLOROQUINE": {"interactions": {"extra": "", "bad": 0, "interaction": " kaolin reduces absorption of chloroquine and hydroxychloroquine ", "name": "Chloroquine and Hydroxychloroquine", "backrefs": ["Agalsidase Alfa and Beta", "Laronidase", "Chloroquine and Hydroxychloroquine"]}}, "PANTOPRAZOLE": {"indications": "see under Dose", "name": "PANTOPRAZOLE", "renal impairment": "max. oral dose 40\u00a0mg daily", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  saquinavir possibly increased by pantoprazole\u2014manufacturer of saquinavir advises avoid concomitant use", "name": "Pantoprazole", "backrefs": ["Pantoprazole"]}, "cautions": "seenotes above;interactions:Appendix 1 (proton pump inhibitors)", "side-effects": "seenotes above; also hyperlipidaemia, weight changes", "hepatic impairment": "max. 20\u00a0mg daily in severe impairment and cirrhosis\u2014monitor\r\nliver function (discontinue if deterioration)", "doses": ["By mouth,benign gastric ulcer,adultover 18 years, 40\u00a0mg daily for 8 weeks; in\r\nsevere cases increase up to 80\u00a0mg daily", "Duodenal ulcer,adultover 18\r\nyears, 40\u00a0mg daily for 4 weeks; in severe cases increase up to 80\u00a0mg\r\ndaily", "Duodenal or benign gastric ulcer associated withHelicobacter\r\npylori, seeRecommended Regimens forHelicobacter pyloriEradication", "Prophylaxis of NSAID-associated gastric or duodenal ulcer in\r\npatients with an increased risk of gastroduodenal complications who\r\nrequire continued NSAID treatment,adultover 18 years, 20\u00a0mg daily", "Gastro-oesophageal reflux disease,adultandchildover 12 years, 20\u201380\u00a0mg\r\ndaily in the morning for 4 weeks, continued for further 4 weeks if\r\nnot fully healed; maintenance 20\u00a0mg daily, increased to 40\u00a0mg daily\r\nif symptoms return", "Zollinger\u2013Ellison syndrome (and other hypersecretory conditions),adultover 18 years, initially 80\u00a0mg once daily adjusted\r\naccording to response (elderlymax.\r\n40\u00a0mg daily); daily doses above 80\u00a0mg given in 2 divided doses", "By intravenous injectionover at\r\nleast 2 minutesorby intravenous infusion,adultover 18 years, duodenal ulcer,\r\ngastric ulcer, and gastro-oesophageal reflux, 40\u00a0mg daily until oral\r\nadministration can be resumed", "Zollinger\u2013Ellison syndrome (and other hypersecretory conditions),adultover 18 years, initially 80\u00a0mg (160\u00a0mg if rapid\r\nacid control required) then 80\u00a0mg once daily adjusted according to\r\nresponse; daily doses above 80\u00a0mg given in 2 divided doses"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014fetotoxic inanimals", "breast-feeding": "manufacturer advises avoid unless potential\r\nbenefit outweighs risk\u2014small amount present in milk"}, "DISODIUM ETIDRONATE": {"indications": "see under Dose", "name": "DISODIUM ETIDRONATE", "renal impairment": "reduce dose in mild impairment; avoid in moderate to\r\nsevere renal impairment", "cautions": "consider dental check-up before initiating\r\nbisphosphonate (risk of osteonecrosis of\r\nthe jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, seeMHRA/CHM advice;interactions:Appendix 1 (bisphosphonates)", "side-effects": "nausea, diarrhoea or constipation, abdominal pain,\r\nincreased bone pain in Paget\u2019s disease, also increased risk of fractures\r\nwith high doses in Paget\u2019s disease (discontinue if fractures occur);rarelyexacerbation of asthma, skin reactions (including\r\nangioedema, rash, urticaria and pruritus), transient hyperphosphataemia,\r\nheadache, paraesthesia, peripheral neuropathy, atypical femoral fractures\r\n(seeMHRA/CHM advice);very rarelyosteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw);\r\nblood disorders (including leucopenia, agranulocytosis and pancytopenia)\r\nalso reported", "contra-indications": "not indicated for osteoporosis\r\nin presence of hypercalcaemia or hypercalciuria or for osteomalacia", "doses": ["treatment of osteoporosis, prevention of bone loss in\r\npostmenopausal women (particularly if hormone replacement therapy\r\ninappropriate), and prevention and treatment of corticosteroid-induced\r\nosteoporosis, given in 90-day cycles, 1Didronel\u00ae tablet daily for 14 days, then 1Cacit\u00ae tablet\r\ndaily for 76 days"], "pregnancy": "avoid", "breast-feeding": "no information available"}, "DESFLURANE": {"indications": "seenotes above", "name": "DESFLURANE", "cautions": "seenotes above;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Induction of anaesthesia (but not recommended\u2014seenotes above),by inhalationthrough\r\nspecifically calibrated vaporiser,adult4\u201311%", "Maintenance of anaesthesia,by inhalationthrough\r\nspecifically calibrated vaporiser,adult2\u20136% in nitrous oxide\u2013oxygen; 2.5\u20138.5% in oxygen or oxygen-enriched\r\nair;child1 month\u201318 years seeBNF for Children"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "SAQUINAVIR": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "SAQUINAVIR", "renal impairment": "use with caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of saquinavir ", "name": "Saquinavir", "backrefs": ["Pentamidine Isetionate", "Saquinavir", "Lidocaine", "Lansoprazole", "Antifungals, Imidazole", "Rabeprazole", "Esomeprazole", "Sotalol", "Omeprazole", "Pantoprazole"]}, "cautions": "seenotes above; monitor ECG before starting treatment and then on day 3 or 4 of treatment\u2014discontinue if QT interval over 480\u00a0milliseconds, if\r\nQT interval more than 20\u00a0milliseconds above baseline, or if prolongation\r\nof PR interval; concomitant use of garlic (avoid garlic capsules\u2014reduces plasma-saquinavir concentration);interactions:Appendix 1 (saquinavir)", "side-effects": "see notes above; also dyspnoea, increased appetite,\r\nperipheral neuropathy, convulsions, changes in libido, renal impairment,\r\ndry mouth, and alopecia", "contra-indications": "seenotes above; predisposition to cardiac arrhythmias (including congenital QT prolongation, bradycardia, history of symptomatic arrhythmias, heart failure with reduced left ventricular ejection fraction, electrolyte disturbances, concomitant\r\nuse of drugs that prolong QT or PR interval); concomitant use of drugs that increase plasma-saquinavir concentration\r\n(avoid unless no alternative treatment available)", "hepatic impairment": "seenotes above; also\r\nmanufacturer advises caution in moderate impairment; avoid in decompensated\r\nliver disease", "doses": ["With low-dose ritonavir,adultpreviously treated with antiretroviral therapy, 1\u00a0g every 12 hours;child16\u201318 years seeBNF for Children", "With low-dose ritonavir,adultnot previously treated with antiretroviral therapy, 500\u00a0mg every\r\n12 hours for 7 days then 1\u00a0g every 12 hours;child16\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "seeBreast-feeding"}, "METHOCARBAMOL": {"indications": "short-term symptomatic relief of muscle spasm (but see notes above)", "name": "METHOCARBAMOL", "renal impairment": "manufacturer advises caution", "interactions": {"extra": "", "bad": 0, "interaction": "increased sedative effect when  alcohol given with methocarbamol ", "name": "Methocarbamol", "backrefs": ["Methocarbamol"]}, "cautions": "interactions:Appendix 1 (muscle\r\nrelaxants)", "side-effects": "nausea, vomiting, dyspepsia; hypersensitivity\r\nreactions (including urticaria, angioedema, anaphylaxis); fever, headache,\r\ndrowsiness, dizziness, hypotension, bradycardia, confusion,\r\namnesia, restlessness, anxiety, tremor, seizures; blurred vision,\r\nnasal congestion; rash, pruritus; leucopenia, cholestatic jaundice", "contra-indications": "coma or pre-coma, brain damage, epilepsy, myasthenia gravis", "hepatic impairment": "manufacturer advises caution; half-life may be prolonged", "doses": ["1.5\u00a0g 4 times daily; may be reduced to 750\u00a0mg 3 times\r\ndaily;elderlyup to 750\u00a0mg 4 times\r\ndaily may be sufficient;childnot\r\nrecommended"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "present in milk inanimalstudies\u2014manufacturer\r\nadvises caution"}, "ZOLEDRONIC ACID": {"indications": "see under preparations", "name": "ZOLEDRONIC ACID", "renal impairment": "avoid if serum creatinine above 400\u00a0micromol/litre in\r\ntumour-induced hypercalcaemia; in advanced malignancies involving\r\nbone, if eGFR 50\u201360\u00a0mL/minute/1.73\u00a0m2reduce dose to 3.5\u00a0mg\r\nevery 3\u20134 weeks, if eGFR 40\u201350\u00a0mL/minute/1.73\u00a0m2reduce\r\ndose to 3.3\u00a0mg every 3\u20134 weeks, if eGFR 30\u201340\u00a0mL/minute/1.73\u00a0m2reduce dose to 3\u00a0mg every 3\u20134 weeks, avoid if eGFR less than\r\n30\u00a0mL/minute/1.73\u00a0m2(or if serum creatinine greater than\r\n265\u00a0micromol/litre); if renal function deteriorates in patients with\r\nbone metastases, withhold dose until serum creatinine returns to within\r\n10% of baseline value; avoid in Paget\u2019s disease, treatment of postmenopausal\r\nosteoporosis and osteoporosis in men if eGFR less than 35\u00a0mL/minute/1.73\u00a0m2; see also Cautions above", "cautions": "correct disturbances of calcium metabolism\r\n(e.g. vitamin D deficiency, hypocalcaemia) before starting; monitor serum electrolytes, calcium,\r\nphosphate and magnesium; cardiac disease\r\n(avoid fluid overload); consider dental\r\ncheck-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, seeMHRA/CHM advice;interactions:Appendix 1 (bisphosphonates)", "side-effects": "hypophosphataemia, anaemia, influenza-like symptoms\r\nincluding bone pain, myalgia, arthralgia, fever and rigors; gastro-intestinal\r\ndisturbances; atrial fibrillation; headache, dizziness, conjunctivitis,\r\nrenal impairment (rarely acute renal failure);less commonlyanorexia, taste disturbance, dry mouth, stomatitis, chest pain,\r\nhypertension, hypotension, dyspnoea, cough, paraesthesia, tremor,\r\nanxiety, lethargy, sleep disturbance, blurred vision, weight gain,\r\npruritus, rash, sweating, muscle cramps, haematuria, proteinuria,\r\nurinary frequency, hypersensitivity reactions (including angioedema),\r\nasthenia, peripheral oedema, thrombocytopenia, leucopenia, hypomagnesaemia,\r\nhypokalaemia, also injection-site reactions;rarelybradycardia, confusion, hyperkalaemia, hypernatraemia, pancytopenia,\r\nosteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw),\r\natypical femoral fractures (seeMHRA/CHM advice);very rarelyuveitis and episcleritis", "contra-indications": "women of child-bearing potential", "hepatic impairment": "caution in severe hepatic impairment\u2014limited information\r\navailable", "doses": ["treatment of Paget\u2019s disease of bone,by\r\nintravenous infusion, 5\u00a0mg as a single dose over at least\r\n15\u00a0minutes", "At least 500\u00a0mg elemental calcium twice daily\r\n(with vitamin D,section 9.6.4) for at least 10 days is recommended following\r\ninfusion", "Treatment of postmenopausal osteoporosis and osteoporosis in\r\nmen (including corticosteroid-induced osteoporosis),by intravenous\r\ninfusion, 5\u00a0mg over at least 15 minutes once a year", "In patients with a recent low-trauma hip\r\nfracture, the dose should be given 2 or more weeks following hip fracture\r\nrepair; before first infusion give 50\u00a0000\u2013125\u00a0000\u00a0units of vitamin\r\nD (section 9.6.4)", "TheScottish Medicines\r\nConsortiumhas advised (February 2008) that in postmenopausal womenAclasta\u00ae is accepted for restricted use within the NHS\r\nScotland for the treatment of osteoporosis in those for whom oral\r\ntreatment options for osteoporosis are inappropriate and when initiated\r\nby a specialist"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014no information available"}, "CISPLATIN": {"indications": "seenotes above", "name": "CISPLATIN", "renal impairment": "avoid if possible; nephrotoxic", "interactions": {"extra": "", "bad": 1, "interaction": "increased pulmonary toxicity when  methotrexate given with cisplatin ", "name": "Cisplatin", "backrefs": ["Cisplatin"]}, "cautions": "seesection 8.1andnotes\r\nabove;interactions:Appendix 1 (platinum\r\ncompounds)", "side-effects": "seesection 8.1andnotes above", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and toxic inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "CARMELLOSE SODIUM": {"indications": "dry eye conditions", "name": "CARMELLOSE SODIUM", "doses": ["Apply as required"]}, "FLUCYTOSINE": {"indications": "systemic yeast and fungal infections; adjunct toamphotericinin cryptococcal meningitis (seeCryptococcosis), adjunct toamphotericinin severe systemic candidiasis and in other severe or long-standing\r\ninfections", "name": "FLUCYTOSINE", "renal impairment": "liver- and kidney-function tests and blood counts required\r\nweekly; use 50\u00a0mg/kg every 12 hours if creatinine clearance 20\u201340\u00a0mL/minute;\r\nuse 50\u00a0mg/kg every 24 hours if creatinine clearance 10\u201320\u00a0mL/minute;\r\nuse initial dose of 50\u00a0mg/kg if creatinine clearance less than 10\u00a0mL/minute\r\nand then adjust dose according to plasma-flucytosine concentration", "interactions": {"extra": "", "bad": 0, "interaction": " amphotericin reduces renal excretion and increases cellular uptake of flucytosine (toxicity possibly increased)", "name": "Flucytosine", "backrefs": ["Flucytosine"]}, "cautions": "elderly; blood\r\ndisorders; liver- and kidney-function tests\r\nand blood counts required (weekly in blood disorders);interactions:Appendix 1 (flucytosine)", "side-effects": "nausea, vomiting, diarrhoea, rashes; less frequently\r\ncardiotoxicity, confusion, hallucinations, convulsions, headache,\r\nsedation, vertigo, alterations in liver function tests (hepatitis\r\nand hepatic necrosis reported), and toxic epidermal necrolysis; blood\r\ndisorders including thrombocytopenia, leucopenia, and aplastic anaemia\r\nreported", "doses": ["By intravenous infusionover 20\u201340\r\nminutes, 200\u00a0mg/kg daily in 4 divided doses usually for not more than\r\n7 days; extremely sensitive organisms, 100\u2013150\u00a0mg/kg daily may be\r\nsufficient;childunder 18 years seeBNF for Children", "Cryptococcal meningitis (adjunct to amphotericin, seeCryptococcosis) 100\u00a0mg/kg daily in 4 divided\r\ndoses for 2 weeks [unlicensed duration];childunder 18 years seeBNF for Children", "For plasma concentration monitoring, blood\r\nshould be taken shortly before starting the next infusion; plasma\r\nconcentration for optimum response 25\u201350\u00a0mg/litre (200\u2013400\u00a0micromol/litre)\u2014should\r\nnot be allowed to exceed 80\u00a0mg/litre (620\u00a0micromol/litre)"], "pregnancy": "teratogenic inanimalstudies; manufacturer\r\nadvises use only if potential benefit outweighs risk", "breast-feeding": "manufacturer advises avoid"}, "INSULIN ASPART": {"indications": "diabetes mellitus", "name": "INSULIN ASPART", "renal impairment": "section 6.1.1", "cautions": "section 6.1.1;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection,adultandchildover\r\n2 years, immediately before meals or when necessary shortly after\r\nmeals, according to requirements", "By subcutaneous infusion,orintravenous injection,orintravenous infusion,adultandchildover 2 years, according\r\nto requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "COLESTYRAMINE": {"indications": "pruritus associated with partial biliary obstruction\r\nand primary biliary cirrhosis; diarrhoea associated with Crohn\u2019s disease,\r\nileal resection, vagotomy, diabetic vagal neuropathy, and radiation;\r\nhypercholesterolaemia (section 2.12)", "name": "COLESTYRAMINE", "interactions": {"extra": "Other drugs should be taken at least 1 hour before or 4\u20136 hours after colestyramine to reduce possible interference with absorption", "bad": 0, "interaction": "absorption of  paracetamol reduced by colestyramine ", "name": "Colestyramine", "backrefs": ["Colestyramine"]}, "cautions": "section 2.12", "side-effects": "section 2.12", "contra-indications": "section 2.12", "doses": ["Pruritus, 4\u20138\u00a0g daily in a suitable liquid;child1\u201318 years seeBNF for Children", "Diarrhoea, initially 4\u00a0g daily increased by 4\u00a0g at weekly intervals\r\nto 12\u201324\u00a0g daily in a suitable liquid in 1\u20134 divided doses, then adjusted\r\nas required; max. 36\u00a0g daily;child1\u201318 years seeBNF for Children", "Other drugs should be taken at least\r\n1 hour before or 4\u20136 hours aftercolestyramineto\r\nreduce possible interference with absorption", "The contents of each sachet should be mixed\r\nwith at least 150\u00a0mL of water or other suitable liquid such as fruit\r\njuice, skimmed milk, thin soups, and pulpy fruits with a high moisture\r\ncontent"], "pregnancy": "section 2.12", "breast-feeding": "section 2.12"}, "EPHEDRINE": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by ephedrine ", "name": "Ephedrine", "backrefs": ["Ephedrine", "Pseudoephedrine"]}}, "BROMOCRIPTINE": {"indications": "see notes above\r\nand under Dose; Parkinson\u2019s disease (section 4.9.1)", "name": "BROMOCRIPTINE", "interactions": {"extra": "", "bad": 1, "interaction": "risk of toxicity when  isometheptene given with bromocriptine ", "name": "Bromocriptine", "backrefs": ["Bromocriptine"]}, "cautions": "seenotes above; alsospecialist evaluation\u2014monitor\r\nfor pituitary enlargement, particularly during pregnancy; monitor visual field to detect secondary field loss\r\nin macroprolactinoma; contraceptive advice\r\nif appropriate (oral contraceptives may increase prolactin concentration);interactions:Appendix 1 (bromocriptine)", "side-effects": "seenotes above; also\r\nnasal congestion;less commonlyvomiting, postural\r\nhypotension, fatigue, dizziness, dry mouth; also, particularly withhigh doses, confusion, psychomotor excitation, hallucinations;rarelydiarrhoea, gastro-intestinal bleeding, gastric ulcer,\r\nabdominal pain, tachycardia, bradycardia, arrhythmia, insomnia, psychosis,\r\nvisual disturbances, tinnitus;very rarelyvasospasm\r\nof fingers and toes particularly in patients with Raynaud\u2019s syndrome,\r\nand effects like neuroleptic malignant syndrome on withdrawal; urinary\r\nincontinence, leucopenia, thrombocytopenia, hyponatraemia, reversible\r\nhearing loss, increased libido, and hypersexuality also reported", "contra-indications": "seenotes above; alsohypertension\r\nin postpartum women or in puerperium(see also below)", "hepatic impairment": "dose reduction may be necessary", "doses": ["Prevention or suppression of lactation (but see notes\r\nabove and under Cautions), 2.5\u00a0mg on day 1 (prevention) or daily for\r\n2\u20133 days (suppression); then 2.5\u00a0mg twice daily for 14 days", "Hypogonadism,\r\ngalactorrhoea, infertility, initially 1\u20131.25\u00a0mg at bedtime, increased\r\ngradually; usual dose 7.5\u00a0mg daily in divided doses, increased if\r\nnecessary to max. 30\u00a0mg daily, usual dose in infertility without hyperprolactinaemia,\r\n2.5\u00a0mg twice daily", "Acromegaly, initially 1\u20131.25\u00a0mg at bedtime, increase gradually\r\nto 5\u00a0mg every 6 hours", "Prolactinoma, initially 1\u20131.25\u00a0mg at bedtime; increased gradually\r\nto 5\u00a0mg every 6 hours (occasional patients may require up to 30\u00a0mg\r\ndaily)", "childunder 15 years, not recommended"], "pregnancy": "see Cautions above", "breast-feeding": "suppresses lactation; avoid breast feeding for\r\nabout 5 days if lactation prevention fails"}, "DANTRON": {"indications": "only for constipation in terminally ill patients of all ages", "name": "DANTRON", "cautions": "seenotes above;rodentstudies indicate potential carcinogenic risk; avoid prolonged contact with skin (as in incontinent patients or\r\ninfants wearing nappies)\u2014risk of irritation and excoriation", "side-effects": "seenotes above; urine may be coloured red", "contra-indications": "Seenotes above", "doses": ["See under preparations"], "pregnancy": "manufacturers of co-danthramer and co-danthrusate\r\nadvise avoid\u2014no information available", "breast-feeding": "manufacturers of co-danthramer and co-danthrusate\r\nadvise avoid\u2014limited information available"}, "ROTAVIRUS VACCINE": {"indications": "immunisation against gastro-enteritis\r\ncaused by rotavirus", "name": "ROTAVIRUS VACCINE", "cautions": "seesection 14.1;alsodiarrhoea\r\nor vomiting (postpone vaccination); immunosuppressed close contacts (see notes above);interactions:Appendix 1 (vaccines)", "side-effects": "seesection 14.1", "contra-indications": "seesection 14.1;alsopredisposition\r\nto, or history of, intussusception", "doses": ["By mouth,childover 6 weeks, 2 doses of 1.5\u00a0mL, separated by an interval of at\r\nleast 4 weeks; course should be completed before 24 weeks of age (preferably\r\nbefore 16 weeks)"]}, "PIMOZIDE": {"indications": "see under Dose", "name": "PIMOZIDE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of pimozide (increased risk of ventricular arrhythmias\u2014avoid concomitant use)", "name": "Pimozide", "backrefs": ["Pimozide"]}, "cautions": "seenotes above", "side-effects": "seenotes above; less\r\nsedating; serious arrhythmias reported; glycosuria and, rarely, hyponatraemia\r\nreported", "contra-indications": "seenotes above; history\r\nor family history of congenital QT prolongation; history of arrhythmias", "hepatic impairment": "seenotes above", "doses": ["Schizophrenia,adultandchildover 12 years, initially 2\u00a0mg daily, increased\r\naccording to response in steps of 2\u20134\u00a0mg at intervals of not less\r\nthan 1 week; usual dose range 2\u201320\u00a0mg daily;elderlyhalf usual starting dose", "Monosymptomatic hypochondriacal psychosis, paranoid psychosis,adultandchildover\r\n12 years, initially 4\u00a0mg daily, increased according to response in\r\nsteps of 2\u20134\u00a0mg at intervals of not less than 1 week; max. 16\u00a0mg daily;elderlyhalf usual starting dose"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "AGALSIDASE ALFA AND BETA": {"interactions": {"extra": "", "bad": 0, "interaction": " chloroquine and hydroxychloroquine possibly inhibit effects of agalsidase alfa and beta (manufacturers of agalsidase alfa and beta advise avoid concomitant use)", "name": "Agalsidase Alfa and Beta", "backrefs": ["Agalsidase Alfa and Beta"]}}, "CODEINE": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin accelerates metabolism of codeine (reduced effect)", "name": "Codeine", "backrefs": ["Codeine"]}}, "SORAFENIB": {"indications": "seenotes above", "name": "SORAFENIB", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  docetaxel increased by sorafenib ", "name": "Sorafenib", "backrefs": ["Sorafenib"]}, "cautions": "major surgical procedures; cardiac ischaemia; susceptibility\r\nto QT-interval prolongation;interactions:Appendix 1 (sorafenib)", "side-effects": "seesection 8.1; also diarrhoea, constipation,\r\ndyspepsia, dysphagia, anorexia, hypertension, haemorrhage, flushing,\r\nhoarseness, fatigue, asthenia, depression, peripheral neuropathy,\r\nfever, erectile dysfunction, renal failure, hypophosphataemia, arthralgia,\r\nmyalgia, tinnitus, rash, pruritus, erythema, dry skin, desquamation,\r\nacne, hand-foot skin reaction;less commonlygastro-intestinal perforations, myocardial infarction, congestive heart failure,\r\nhypertensive crisis, interstitial lung disease-like events, reversible\r\nposterior leucoencephalopathy, thyroid dysfunction, and Stevens-Johnson\r\nsyndrome;rarelyhepatitis", "hepatic impairment": "manufacturer advises caution in severe impairment\u2014no\r\ninformation available", "doses": ["adultover 18 years, 400\u00a0mg\r\ntwice daily"], "pregnancy": "manufacturer advises avoid unless essential\u2014toxicity\r\ninanimalstudies; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ICHTHAMMOL": {"side-effects": "skin irritation", "indications": "chronic lichenified eczema", "name": "ICHTHAMMOL", "doses": ["Apply 1\u20133 times daily"]}, "VIGABATRIN": {"indications": "seenotes above", "name": "VIGABATRIN", "renal impairment": "consider reduced dose or increased dose interval if eGFR\r\nless than 60\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  phenytoin reduced by vigabatrin ", "name": "Vigabatrin", "backrefs": ["Vigabatrin"]}, "cautions": "elderly; closely\r\nmonitor neurological function; avoid sudden\r\nwithdrawal; history of psychosis, depression, or behavioural problems; absence seizures (may be exacerbated);interactions:seeInteractionsin section 4.8.1 and Appendix 1 (vigabatrin)", "side-effects": "nausea, abdominal pain; oedema; drowsiness (rarelyencephalopathic symptoms including marked sedation,\r\nstupor, and confusion with non-specific slow wave EEG\u2014reduce dose\r\nor withdraw), fatigue, excitation (in children), agitation, dizziness,\r\nheadache, nervousness, depression, aggression, irritability, paranoia,\r\nimpaired concentration, impaired memory, tremor, paraesthesia, speech\r\ndisorder, weight gain; visual field defects (see under Cautions),\r\nblurred vision, nystagmus, diplopia;less commonlyataxia, psychosis, mania, and rash; occasional increase in seizure\r\nfrequency (especially if myoclonic);rarelysuicidal\r\nideation and retinal disorders (including peripheral retinal neuropathy);very rarelyhepatitis, optic neuritis, and optic atrophy;also reportedmovement disorders in infantile spasms", "contra-indications": "visual field defects", "doses": ["With current antiepileptic therapy, initially 1\u00a0g daily\r\nin single or 2 divided doses then increased according to response\r\nin steps of 500\u00a0mg at weekly intervals; usual range 2\u20133\u00a0g daily (max.\r\n3\u00a0g daily);childinitially 40\u00a0mg/kg\r\n(body-weight over 25\u00a0kg, max. 1\u00a0g) daily in single or 2 divided doses,\r\nthen adjusted according to response; usual maintenance dose, body-weight\r\n10\u201315\u00a0kg, 0.5\u20131\u00a0g daily; body-weight 15\u201330\u00a0kg, 1\u20131.5\u00a0g daily; body-weight\r\n30\u201350\u00a0kg, 1.5\u20133\u00a0g daily; body-weight over 50\u00a0kg, 2\u20133\u00a0g daily", "Infantile spasms (West\u2019s syndrome),monotherapy, 50\u00a0mg/kg daily, adjusted according to response over 7 days; up\r\nto 150\u00a0mg/kg daily used with good tolerability"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "PERPHENAZINE": {"indications": "severe nausea, vomiting (see notes above); other\r\nindications (section 4.2.1)", "name": "PERPHENAZINE", "renal impairment": "see notes insection 4.2.1", "interactions": {"extra": "", "bad": 0, "interaction": " paroxetine inhibits metabolism of perphenazine (reduce dose of perphenazine)", "name": "Perphenazine", "backrefs": ["Perphenazine"]}, "cautions": "see notes insection 4.2.1", "side-effects": "seePerphenazine,section 4.2.1", "contra-indications": "seePerphenazine,section 4.2.1", "hepatic impairment": "see notes insection 4.2.1", "doses": ["4\u00a0mg 3 times daily, adjusted according to response; max.\r\n24\u00a0mg daily (chemotherapy-induced);elderlyquarter to half adult dose;childunder 14 years not recommended"], "pregnancy": "see notes insection 4.2.1", "breast-feeding": "see notes insection 4.2.1"}, "TAMOXIFEN": {"indications": "see under Dose andnotes above; mastalgia [unlicensed indication]\r\n(section 6.7.2)", "name": "TAMOXIFEN", "interactions": {"extra": "", "bad": 1, "interaction": " paroxetine possibly inhibits metabolism of tamoxifen to active metabolite (avoid concomitant use)", "name": "Tamoxifen", "backrefs": ["Tamoxifen"]}, "cautions": "occasional cystic ovarian swellings in\r\npremenopausal women; increased risk of thromboembolic\r\nevents, especially when used with cytotoxics (see also below); endometrial changes (important:see below); porphyria,interactions:Appendix 1 (tamoxifen)", "side-effects": "hot flushes, vaginal bleeding and vaginal discharge\r\n(important:see also Endometrial Changes under Cautions),\r\nsuppression of menstruation in some premenopausal women, pruritus\r\nvulvae, gastro-intestinal disturbances, headache, light-headedness,\r\ntumour flare, decreased platelet counts; occasionally oedema, rarely\r\nhypercalcaemia if bony metastases, alopecia, rashes, uterine fibroids;\r\nalso visual disturbances (including corneal changes, cataracts, retinopathy);\r\nleucopenia (sometimes with anaemia and thrombocytopenia), rarely neutropenia;\r\nhypertriglyceridaemia reported rarely (sometimes with pancreatitis);\r\nthromboembolic events reported (see below); liver enzyme changes (rarely\r\nfatty liver, cholestasis, hepatitis); rarely interstitial pneumonitis,\r\nhypersensitivity reactions including angioedema, Stevens-Johnson syndrome,\r\nbullous pemphigoid; see also notes above", "contra-indications": "treatment of infertility contra-indicated\r\nif personal or family history of idiopathic venous thromboembolism\r\nor genetic predisposition to thromboembolism", "doses": ["Breast cancer, 20\u00a0mg daily", "Anovulatory infertility, 20\u00a0mg daily on days 2, 3, 4 and 5 of\r\ncycle; if necessary the daily dose may be increased to 40\u00a0mg then\r\n80\u00a0mg for subsequent courses; if cycles irregular, start initial course\r\non any day, with subsequent course starting 45 days lateroron day 2 of cycle if menstruation occurs"], "pregnancy": "avoid\u2014possible effects on fetal development; effective\r\ncontraception must be used during treatment and for 2 months after\r\nstopping", "breast-feeding": "suppresses lactation; avoid unless potential\r\nbenefit outweighs risk"}, "COLLAGENASE": {"indications": "Dupuytren\u2019s contracture in patients\r\nwith a palpable cord", "name": "COLLAGENASE", "cautions": "coagulation disorders or use of anticoagulants", "side-effects": "paraesthesia, hypoaesthesia, burning sensation,\r\nlymphadenopathy, arthralgia, myalgia, joint swelling, injection site\r\nreactions, ecchymosis, hyperhidrosis;less commonlycomplex regional pain syndrome, monoplegia, tremor, crepitus, muscle\r\nspasm and weakness, tendon rupture, ligament injury, wound dehiscence", "contra-indications": "avoid injecting into other structures\r\ncontaining collagen (e.g. tendons, nerves, and blood vessels)\u2014risk of tendon rupture or ligament damage", "doses": ["By intralesional injectioninto palpable\r\ncord,adultover 18 years, 580\u00a0micrograms;\r\nif necessary repeat at intervals of approx. 4 weeks; max. 3 injections\r\nper cord; max. 8 injections in total; only one cord may be treated\r\nat a time", "reconstitution and injected volumes vary\r\nwith site of injection\u2014consult product literature"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "systemic absorption by mother negligible"}, "SELEGILINE": {"interactions": {"extra": "Selegiline is a MAO-B inhibitor", "bad": 0, "interaction": "avoidance of  5HT1 agonists advised by manufacturer of selegiline ", "name": "Selegiline", "backrefs": ["Selegiline", "Dopamine"]}}, "COLECALCIFEROL": {"indications": "see notes above", "name": "COLECALCIFEROL", "cautions": "see underErgocalciferol", "side-effects": "see underErgocalciferol", "contra-indications": "see underErgocalciferol", "doses": ["Seenotes above"], "pregnancy": "see underErgocalciferol", "breast-feeding": "see underErgocalciferol"}, "SODIUM CITRATE (RECTAL)": {"indications": "rectal use in constipation", "contra-indications": "acute gastro-intestinal conditions", "name": "SODIUM CITRATE (RECTAL)", "cautions": "elderly and debilitated; see alsonotes above", "doses": ["adultandchild(but seesection 1.6) 5\u00a0mL (insert only half nozzle\r\nlength in child under 3 years)"]}, "REMIFENTANIL": {"indications": "supplementation of general anaesthesia during induction and analgesia\r\nduring maintenance of anaesthesia (consult product literature for\r\nuse in patients undergoing cardiac surgery); analgesia and sedation\r\nin ventilated, intensive care patients", "name": "REMIFENTANIL", "cautions": "section 4.7.2(but\r\nno dose adjustment necessary in renal impairment) andnotes above", "side-effects": "section 4.7.2andnotes above; also hypertension;less\r\ncommonlyhypoxia;rarelyasystole; AV block\r\nand convulsions also reported", "contra-indications": "section 4.7.2andnotes above; left ventricular dysfunction; analgesia in conscious patients", "hepatic impairment": "section 4.7.2", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "Induction of anaesthesia,adultandchildover 12 years,by\r\nintravenous infusion, 0.5\u20131\u00a0micrograms/kg/minute,with or withoutan initial doseby intravenous injectionof 0.25\u20131\u00a0microgram/kg over at least 30 seconds", "If patient to be intubated more than 8 minutes\r\nafter start of intravenous infusion, initial intravenous injection\r\ndose is not necessary", "Maintenance of anaesthesia in ventilated patients,adultandchildover\r\n12 years,by intravenous infusion, 0.05\u20132\u00a0micrograms/kg/minute\r\n(with or withoutan initial doseby intravenous\r\ninjectionof 0.25\u20131\u00a0micrograms/kg over at least 30 seconds)\r\naccording to anaesthetic technique and adjusted according to response;\r\nin light anaesthesia supplemental dosesby intravenous injectionevery 2\u20135 minutes;child1\u201312 years,\r\n0.05\u20131.3\u00a0micrograms/kg/minute (with or withoutan\r\ninitial doseby intravenous injectionof 0.1\u20131\u00a0microgram/kg\r\nover at least 30 seconds) according to anaesthetic technique and adjusted\r\naccording to response", "Maintenance of anaesthesia with spontaneous respiration,adultandchildover\r\n12 years,by intravenous infusion, initially 40\u00a0nanograms/kg/minute\r\nadjusted according to response, usual range 25\u2013100\u00a0nanograms/kg/minute", "Analgesia and sedation in ventilated, intensive-care patients\r\nfor max. 3 days,by intravenous infusion,adultover 18 years, initially 100\u2013150\u00a0nanograms/kg/minute\r\nadjusted according to response in steps of 25\u00a0nanograms/kg/minute\r\n(allow at least 5 minutes between dose adjustments); usual range 6\u2013740\u00a0nanograms/kg/minute;\r\nif an infusion rate of 200\u00a0nanograms/kg/minute does not produce adequate\r\nsedation add another sedative (consult product literature for details)", "Additional analgesia during stimulating or painful procedures\r\nin ventilated, intensive-care patients,by intravenous infusion,adultover 18 years, maintain infusion\r\nrate of at least 100\u00a0nanograms/kg/minute for at least 5 minutes before\r\nprocedure and adjust every 2\u20135 minutes according to requirements,\r\nusual range 250\u2013750\u00a0nanograms/kg/minute", "Cardiac surgery, consult product literature", "Remifentanil doses in BNF may differ from\r\nthose in product literature"], "pregnancy": "no information available: see alsosection 4.7.2", "breast-feeding": "avoid breast-feeding for 24 hours after administration\u2014present\r\nin milk inanimalstudies"}, "DOXEPIN HYDROCHLORIDE": {"indications": "pruritus in eczema; depressive illness\r\n(section 4.3.1)", "name": "DOXEPIN HYDROCHLORIDE", "cautions": "susceptibility to angle-closure glaucoma; urinary retention; mania; cardiac arrhythmias; severe\r\nheart disease; avoid application to large\r\nareas;interactions:Appendix 1 (antidepressants,\r\ntricyclic)", "side-effects": "drowsiness; local burning, stinging, irritation,\r\ntingling and rash; systemic side-effects such as antimuscarinic effects,\r\nheadache, fever, dizziness, gastro-intestinal disturbances also reported", "hepatic impairment": "manufacturer advises caution in severe liver disease", "doses": ["adultandchildover 12 years, apply thinly 3\u20134 times daily;\r\nusual max. 3\u00a0g per application; usual total max. 12\u00a0g daily; coverage\r\nshould be less than 10% of body surface area"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk"}, "PAZOPANIB": {"indications": "seenotes above", "name": "PAZOPANIB", "renal impairment": "use with caution if creatinine clearance less than 30\u00a0mL/minute\u2014no\r\ninformation available", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  ritonavir advised by manufacturer of pazopanib ", "name": "Pazopanib", "backrefs": ["Pazopanib"]}, "cautions": "seesection 8.1; monitor liver function\r\nbefore treatment and at least monthly for the first 4 months\u2014consult\r\nproduct literature; control blood pressure\r\nbefore initiating and monitor blood pressure\r\nthroughout treatment (consider dose reduction or interruption if hypertension\r\nuncontrolled despite anti-hypertensive therapy); susceptibility to QT-interval prolongation (including electrolyte\r\ndisturbances, concomitant use of drugs that prolong QT-interval); patients at risk of myocardial\r\ninfarction, ischaemic stroke or\r\ntransient ischaemic attack, cardiac disease; increased\r\nrisk of haemorrhage; increased risk of\r\ngastro-intestinal perforation or fistulas; discontinue treatment 7 days before elective surgery and restart\r\nonly if adequate wound healing; monitor\r\nthyroid function; monitor for proteinuria;interactions:Appendix 1 (pazopanib)", "side-effects": "seesection 8.1; also\r\nabdominal pain, dyspepsia, diarrhoea, weight loss, anorexia, taste\r\ndisturbance, flatulence, hepatic dysfunction, hyperbilirubinaemia,\r\nhypertension, flushing, chest pain, oedema, epistaxis, voice changes,\r\nheadache, dizziness, malaise, paraesthesia, hypothyroidism, proteinuria\r\n(discontinue if grade 4), blood disorders (including thrombocytopenia),\r\nmuscle spasm, myalgia, sweating, skin reactions, dry skin, hair and\r\nskin discoloration;less commonlyhepatic failure,\r\ngastro-intestinal perforation, peritonitis, pancreatitis, fistula,\r\ncardiac dysfunction, transient ischaemic attack, stroke, myocardial\r\ninfarction, myocardial ischaemia, bradycardia, haemorrhage, hypertensive\r\ncrisis, QT-interval prolongation, pulmonary embolism, peripheral neuropathy,\r\nmenstrual disturbances", "contra-indications": "cerebral or clinically significant gastro-intestinal\r\nhaemorrhage or haemoptysis in the past 6 months", "hepatic impairment": "use with caution in mild impairment; reduce dose to\r\n200\u00a0mg once daily in moderate impairment; avoid in severe impairment", "doses": ["adultover 18 years, 800\u00a0mg\r\nonce daily; adjust dose in steps of 200\u00a0mg according to tolerability\r\n(max. 800\u00a0mg daily)"], "pregnancy": "avoid unless potential benefit outweighs risk\u2014toxicity inanimalstudies; effective contraception\r\nadvised during treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "LEVOTHYROXINE": {"interactions": {"extra": "", "bad": 0, "interaction": " colesevelam reduces absorption of levothyroxine ", "name": "Levothyroxine", "backrefs": ["Levothyroxine"]}}, "CLONIDINE": {"interactions": {"extra": "", "bad": 0, "interaction": " mirtazapine possibly antagonises hypotensive effect of clonidine ", "name": "Clonidine", "backrefs": ["Apraclonidine", "Clonidine"]}}, "ISOSORBIDE MONONITRATE": {"indications": "prophylaxis of angina; adjunct in congestive\r\nheart failure", "name": "ISOSORBIDE MONONITRATE", "renal impairment": "see underGlyceryl Trinitrate", "cautions": "see underGlyceryl Trinitrate", "side-effects": "see underGlyceryl Trinitrate", "contra-indications": "see underGlyceryl Trinitrate", "hepatic impairment": "see underGlyceryl Trinitrate", "doses": ["prophylaxis of angina, 25\u201350\u00a0mg daily in the morning,\r\nincreased if necessary to 50\u2013100\u00a0mg once daily"], "pregnancy": "manufacturers advise avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "see underGlyceryl Trinitrate"}, "TINIDAZOLE": {"indications": "see under Dose below; anaerobic infections,section 5.1.11", "name": "TINIDAZOLE", "interactions": {"extra": "", "bad": 0, "interaction": "possibility of disulfiram-like reaction when  alcohol given with tinidazole ", "name": "Tinidazole", "backrefs": ["Tinidazole"]}, "cautions": "section 5.1.11", "side-effects": "section 5.1.11", "doses": ["Intestinal amoebiasis, 2\u00a0g daily for 2\u20133 days;child50\u201360\u00a0mg/kg daily for 3 days", "Amoebic involvement of liver, 1.5\u20132\u00a0g daily for 3\u20136 days;child50\u201360\u00a0mg/kg daily for 5 days", "Urogenital trichomoniasis and giardiasis, single 2\u00a0g dose;childsingle dose of 50\u201375\u00a0mg/kg (repeated once if\r\nnecessary)"], "pregnancy": "section 5.1.11", "breast-feeding": "section 5.1.11"}, "FENTANYL": {"indications": "analgesia during operation, enhancement\r\nof anaesthesia; respiratory depressant in assisted respiration; analgesia\r\nin other situations (section 4.7.2)", "name": "FENTANYL", "renal impairment": "see notes insection 4.7.2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of fentanyl ", "name": "Fentanyl", "backrefs": ["Antifungals, Triazole", "Fentanyl", "Etomidate"]}, "cautions": "see Fentanyl,section 4.7.2andnotes above", "side-effects": "see Fentanyl,section 4.7.2andnotes above; also myoclonic movements;less commonlylaryngospasm;rarelyasystole\r\nand insomnia", "contra-indications": "see notes insection 4.7.2", "hepatic impairment": "see notes insection 4.7.2", "doses": ["To avoid excessive dosage in obese patients,\r\ndose may need to be calculated on the basis of ideal body-weight", "By slow intravenous injection, with\r\nspontaneous respiration,adultandchildover 12 years, initially 50\u2013100\u00a0micrograms\r\n(max. 200\u00a0micrograms on specialist advice), then 25\u201350\u00a0micrograms\r\nas required;child1 month\u201312 years\r\nseeBNF for Children", "With assisted ventilation,adultandchildover 12 years, initially\r\n0.3\u20133.5\u00a0mg, then 100\u2013200\u00a0micrograms as required;child1 month\u201312 years seeBNF for Children", "By intravenous infusion, with spontaneous\r\nrespiration,adult, 3\u20134.8\u00a0micrograms/kg/hour\r\nadjusted according to response", "With assisted ventilation,adult, initially 10\u00a0micrograms/kg over 10 minutes then 6\u00a0micrograms/kg/hour\r\nadjusted according to response; may require up to 180\u00a0micrograms/kg/hour\r\nduring cardiac surgery;child1 month\u201318\r\nyears seeBNF for Children"], "pregnancy": "see notes insection 4.7.2", "breast-feeding": "see Fentanyl,section 4.7.2"}, "TACROLIMUS": {"indications": "prophylaxis of organ rejection in liver,\r\nkidney, and heart allograft recipients and allograft rejection resistant\r\nto conventional immunosuppressive regimens, see also notes above;\r\nmoderate to severe atopic eczema (section 13.5.3)", "name": "TACROLIMUS", "interactions": {"extra": "Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (see section 13.5.3) does not apply to tacrolimus taken systemically", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of tacrolimus ", "name": "Tacrolimus", "backrefs": ["Sevelamer", "Tacrolimus", "Mifamurtide", "Potassium Salts", "Chloramphenicol"]}, "cautions": "monitor blood pressure, ECG (important:see Cardiomyopathy below), fasting blood-glucose\r\nconcentration, haematological and neurological (including visual)\r\nparameters, electrolytes, hepatic and renal function; monitor whole blood-tacrolimus trough concentration\r\n(especially during episodes of diarrhoea)\u2014consult local treatment\r\nprotocol for details; QT-interval prolongation; neurotoxicity; increased\r\nrisk of infections, malignancies, and lymphoproliferative disorders; avoid excessive exposure to UV light including sunlight;interactions:Appendix 1 (tacrolimus)", "side-effects": "nausea, vomiting, diarrhoea, constipation, dyspepsia,\r\nflatulence, bloating, weight changes, anorexia, gastro-intestinal\r\ninflammation, ulceration, and perforation, hepatic dysfunction, jaundice,\r\ncholestasis, ascites, bile-duct abnormalities, oedema, tachycardia,\r\nhypertension, haemorrhage, thromboembolic and ischaemic events, dyspnoea,\r\npleural effusion, parenchymal lung disorders, sleep disturbances,\r\ntremor, headache, peripheral neuropathy, mood changes, depression,\r\nconfusion, anxiety, psychosis, seizures, paraesthesia, dizziness,\r\nrenal impairment, renal failure, renal tubular necrosis, urinary abnormalities,\r\nhyperglycaemia, electrolyte disturbances (including hyperkalaemia,\r\nhypokalaemia, and hyperuricaemia), blood disorders (including anaemia,\r\nleucopenia, pancytopenia, and thrombocytopenia), arthralgia, muscle\r\ncramp, visual disturbances, photophobia, tinnitus, impaired hearing,\r\nalopecia, sweating, acne;less commonlyparalytic\r\nileus, gastro-intestinal reflux disease, peritonitis, pancreatitis,\r\nheart failure, arrhythmia, cardiac arrest, cerebrovascular accident,\r\ncardiomyopathy (important: see Cardiomyopathy below),\r\npalpitation, respiratory failure, coma, speech disorder, amnesia,\r\nparalysis, influenza-like symptoms, encephalopathy, coagulation disorders,\r\nphotosensitivity, cataract, hypoglycaemia, dysmenorrhoea, hypertonia,\r\ndermatitis;rarelypericardial effusion, respiratory\r\ndistress syndrome, posterior reversible encephalopathy syndrome, dehydration,\r\nthrombotic thrombocytopenic purpura, blindness, toxic epidermal necrolysis,\r\nhirsutism;very rarelymyasthenia, haemorrhagic cystitis,\r\nStevens-Johnson syndrome", "contra-indications": "hypersensitivity to macrolides; avoid concurrent administration withciclosporin(care if patient has previously receivedciclosporin)", "hepatic impairment": "dose reduction may be necessary in severe impairment", "doses": ["liver transplantation, starting 12 hours after transplantation,by mouth, 100\u2013200\u00a0micrograms/kg daily in 2 divided dosesorby intravenous infusionover 24 hours,\r\n10\u201350\u00a0micrograms/kg daily for up to 7 days (then transfer to oral\r\ntherapy);childby mouth, 300\u00a0micrograms/kg daily in 2 divided dosesorby intravenous infusionover 24 hours, 50\u00a0micrograms/kg\r\ndaily for up to 7 days (then transfer to oral therapy)", "Renal transplantation, starting within 24 hours of transplantation,by mouth, 200\u2013300\u00a0micrograms/kg daily in 2 divided dosesorby intravenous infusionover 24 hours,\r\n50\u2013100\u00a0micrograms/kg daily for up to 7 days (then transfer to oral\r\ntherapy);childby mouth, 300\u00a0micrograms/kg daily in 2 divided dosesorby intravenous infusionover 24 hours, 75\u2013100\u00a0micrograms/kg\r\ndaily for up to 7 days (then transfer to oral therapy)", "Heart transplantation with antibody induction (starting within\r\n5 days of transplantation) or without antibody induction (starting\r\nwithin 12 hours of transplantation),by mouth, 75\u00a0micrograms/kg\r\ndaily in 2 divided dosesorby intravenous\r\ninfusionover 24 hours, 10\u201320\u00a0micrograms/kg daily for up to\r\n7 days (then transfer to oral therapy);child, with antibody induction (starting within 5 days of transplantation),by mouth, 100\u2013300\u00a0micrograms/kg daily in 2 divided doses;\r\nwithout antibody induction (starting within 12 hours of transplantation),\r\ninitiallyby intravenous infusionover 24 hours, 30\u201350\u00a0micrograms/kg\r\ndaily, thenby mouth, 300\u00a0micrograms/kg daily in 2\r\ndivided doses as soon as clinically possible (8\u201312 hours after discontinuing\r\nintravenous infusion)", "Maintenance treatment, dose adjusted according to response and\r\nwhole blood concentration", "Rejection therapy, seek specialist advice"], "pregnancy": "exclude before treatment; avoid unless potential\r\nbenefit outweighs risk\u2014risk of premature delivery, intra-uterine growth\r\nrestriction, and hyperkalaemia; toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in breast milk"}, "13.2.1 Emollients": {"name": "13.2.1 Emollients", "doses": ["for dry, scaling, and itching skin, apply twice daily"]}, "FLUDARABINE": {"interactions": {"extra": "", "bad": 0, "interaction": " dipyridamole possibly reduces effects of fludarabine ", "name": "Fludarabine", "backrefs": ["Fludarabine", "Pentostatin"]}}, "COLESEVELAM": {"interactions": {"extra": "Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption ", "bad": 0, "interaction": "absorption of  ethinylestradiol reduced by colesevelam ", "name": "Colesevelam", "backrefs": ["Levothyroxine", "Colesevelam", "Ethinylestradiol", "Glibenclamide"]}}, "DOSULEPIN HYDROCHLORIDE": {"indications": "depressive illness, particularly where sedation is required", "name": "DOSULEPIN HYDROCHLORIDE", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nincreased intra-ocular pressure; high rate of fatality in overdose\u2014seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially 75\u00a0mg (elderly50\u201375\u00a0mg) daily in divided dosesoras a single\r\ndose at bedtime, increased gradually as necessary to 150\u00a0mg daily\r\n(elderly75\u00a0mg may be sufficient);\r\nup to 225\u00a0mg daily in some circumstances (e.g. hospital use);childnot recommended", "A maximum prescription equivalent to 2 weeks\u2019\r\nsupply of 75\u00a0mg daily should be considered in patients with increased\r\nrisk factors for suicide at initiation of treatment, during any dose\r\nadjustment, and until improvement occurs"], "pregnancy": "use only if potential benefit outweighs risk", "breast-feeding": "seenotes above"}, "IBUPROFEN": {"indications": "pain and inflammation in rheumatic disease (including juvenile idiopathic\r\narthritis) and other musculoskeletal disorders; mild to moderate pain\r\nincluding dysmenorrhoea; postoperative analgesia; migraine; dental\r\npain; fever with discomfort and pain in children; post-immunisation\r\npyrexia (section\r\n14.1)", "name": "IBUPROFEN", "renal impairment": "avoid in severe impairment; see alsonotes above", "interactions": {"extra": "", "bad": 1, "interaction": "excretion of  methotrexate reduced by ibuprofen (increased risk of toxicity)\u2014but for concomitant use in rheumatic disease see Methotrexate, section 10.1.3", "name": "Ibuprofen", "backrefs": ["Ibuprofen"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["adultandchildover 12 years, initially 2 capsules twice daily,\r\nincreased in severe cases to 3 capsules twice daily; then 1\u20132 capsules\r\ntwice daily"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful but some manufacturers\r\nadvise avoid (including topical use); see alsonotes above"}, "SUGAMMADEX": {"indications": "reversal of neuromuscular blockade\r\ninduced by rocuronium or vecuronium", "name": "SUGAMMADEX", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " fusidic acid possibly reduces response to sugammadex ", "name": "Sugammadex", "backrefs": ["Sugammadex"]}, "cautions": "recurrence of neuromuscular blockade\u2014monitor\r\nrespiratory function until fully recovered; recovery may be delayed in cardiovascular disease and\r\nelderly; pre-existing coagulation disorders or use of anticoagulants (unrelated\r\nto surgery); wait 24 hours before re-administering rocuronium\r\nor vecuronium;interactions:Appendix\r\n1 (sugammadex)", "side-effects": "taste disturbances;less commonlyallergic reactions; bronchospasm also reported", "doses": ["Routine reversal of neuromuscular blockade induced by\r\nrocuronium or vecuronium,by intravenous injection,adultover 18 years, 2\u20134\u00a0mg/kg (consult product literature);\r\na further dose of 4\u00a0mg/kg may be required if recurrence of neuromuscular\r\nblockade occurs", "Routine reversal of neuromuscular blockade induced by rocuronium,by intravenous injection,child2\u201318 years, 2\u00a0mg/kg (consult product literature)", "Immediate reversal of neuromuscular blockade induced by rocuronium,by intravenous injection,adultover 18 years, 16\u00a0mg/kg (consult product literature)"], "pregnancy": "use with caution\u2014no information available"}, "GLIMEPIRIDE": {"indications": "type 2 diabetes mellitus", "name": "GLIMEPIRIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; manufacturer recommends\r\nregular hepatic and haematological monitoring but limited evidence\r\nof clinical value;interactions: Appendix\r\n1 (antidiabetics)", "side-effects": "see notes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Initially 1\u00a0mg daily, adjusted according to response in\r\n1-mg steps at 1\u20132 week intervals; usual max. 4\u00a0mg daily (exceptionally,\r\nup to 6\u00a0mg daily may be used); taken shortly before or with first\r\nmain meal"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "SULFASALAZINE": {"indications": "active rheumatoid arthritis;\r\ninflammatory bowel disease, seesection 1.5.1and notes above", "name": "SULFASALAZINE", "renal impairment": "section 1.5.1", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  folic acid possibly reduced by sulfasalazine ", "name": "Sulfasalazine", "backrefs": ["Sulfasalazine", "Folic Acid"]}, "cautions": "seesection 1.5.1andnotes above", "side-effects": "seesection 1.5.1andnotes above", "contra-indications": "seesection 1.5.1andnotes above", "hepatic impairment": "section 1.5.1", "doses": ["By mouth, administered on expert advice,\r\nas enteric-coated tablets, initially 500\u00a0mg daily, increased by 500\u00a0mg\r\nat intervals of 1 week to a max. of 2\u20133\u00a0g daily in divided doses"], "pregnancy": "section 1.5.1", "breast-feeding": "section 1.5.1"}, "TIBOLONE": {"indications": "short-term treatment of symptoms of oestrogen deficiency (including\r\nwomen being treated with gonadotrophin releasing hormone analogues);\r\nosteoporosis prophylaxis in women at risk of fractures (second-line)", "name": "TIBOLONE", "renal impairment": "risk of fluid retention\u2014patients with renal impairment\r\nshould be closely monitored", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin accelerates metabolism of tibolone ", "name": "Tibolone", "backrefs": ["Tibolone"]}, "cautions": "seeHormone Replacement Therapyand underOestrogens for HRT; vaginal bleeding\r\n(investigate for endometrial cancer if bleeding continues beyond 6\r\nmonths or after stopping treatment); history\r\nof liver disease, epilepsy, migraine, diabetes mellitus, hypercholesterolaemia; withdraw if signs of thromboembolic disease, abnormal\r\nliver function tests or cholestatic jaundice; see also Note below;interactions:Appendix 1\r\n(tibolone)", "side-effects": "see notes above; also abdominal pain, weight changes,\r\nvaginal bleeding, leucorrhoea, facial hair, andrarelyamnesia; gastro-intestinal disturbances, oedema, dizziness, headache,\r\nmigraine, depression, breast cancer (see notes above andsection 6.4.1.1), arthralgia, myalgia, visual\r\ndisturbances, seborrhoeic dermatitis, rash and pruritus also reported", "contra-indications": "seenotes aboveand underOestrogens for HRT; hormone-dependent tumours, history of cardiovascular\r\nor cerebrovascular disease (e.g. thrombophlebitis, thromboembolism), uninvestigated vaginal bleeding", "hepatic impairment": "avoid in severe impairment", "doses": ["2.5\u00a0mg daily", "Unsuitable for use in the premenopause (unless\r\nbeing treated with gonadotrophin-releasing hormone analogue) and as\r\n(or with) an oral contraceptive; also unsuitable for use within 12\r\nmonths of last menstrual period (may cause irregular bleeding); induce\r\nwithdrawal bleed with progestogen if transferring from another form\r\nof HRT"], "pregnancy": "avoid; toxicity inanimalstudies", "breast-feeding": "avoid"}, "ANTIDEPRESSANTS, TRICYCLIC": {"interactions": {"extra": "", "bad": 0, "interaction": "risk of toxicity when  lithium given with tricyclics ", "name": "Antidepressants, Tricyclic", "backrefs": []}}, "FLUOROURACIL": {"indications": "seenotes above; pre-malignant and malignant skin lesions (section 13.8.1)", "name": "FLUOROURACIL", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine inhibits metabolism of fluorouracil (increased plasma concentration)", "name": "Fluorouracil", "backrefs": ["Filgrastim", "Temoporfin", "Fluorouracil"]}, "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant to tissues;interactions:Appendix 1 (fluorouracil)", "side-effects": "seesection 8.1andnotes above; also local irritation with topical preparation", "hepatic impairment": "manufacturer advises caution", "doses": ["By intravenous injectionorinfusionorby intra-arterial\r\ninfusion, consult product literature"], "pregnancy": "avoid (teratogenic); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "SODIUM HYALURONATE": {"indications": "dry eye conditions", "name": "SODIUM HYALURONATE", "doses": ["Apply as required"]}, "HYALURONIDASE": {"indications": "enhance permeation of subcutaneous or intramuscular injections,local anaestheticsand subcutaneous infusions; promote\r\nresorption of excess fluids and blood", "name": "HYALURONIDASE", "cautions": "infants or elderly (control speed and total volume\r\nand avoid overhydration especially in renal impairment)", "side-effects": "oedema;rarelylocal irritation,\r\ninfection, bleeding, bruising; occasional severe allergy (including\r\nanaphylaxis)", "contra-indications": "do not apply direct to cornea; avoid sites where infection or malignancy; not for anaesthesia\r\nin unexplained premature labour; not to be used to reduce swelling\r\nof bites or stings; not for intravenous administration", "doses": ["With subcutaneous or intramuscular injection, 1500\u00a0units dissolved directly in solution to be injected (ensure\r\ncompatibility)", "Withlocal anaesthetics, 1500\u00a0units mixed\r\nwith local anaesthetic solution (ophthalmology, 15\u00a0units/mL)", "Hypodermoclysis, 1500\u00a0units dissolved in 1\u00a0mL water for injections\r\nor 0.9%sodium chlorideinjection, administered\r\nbefore start of 500\u20131000\u00a0mL infusion fluid", "Extravasation (see notes above) or haematoma, 1500\u00a0units dissolved in 1\u00a0mL\r\nwater for injections or 0.9%sodium chlorideinjection,\r\ninfiltrated into affected area (as soon as possible after extravasation)"]}, "POTASSIUM CHLORIDE": {"indications": "electrolyte imbalance; see also oral potassium supplements,section\r\n9.2.1.1", "name": "POTASSIUM CHLORIDE", "renal impairment": "close monitoring required\u2014high risk of hyperkalaemia;\r\navoid in severe impairment", "cautions": "for intravenous infusion the concentration\r\nof solution should not usually exceed 3\u00a0g (40\u00a0mmol)/litre; specialist advice and ECG monitoring (seenotes above);interactions:Appendix 1 (potassium salts)", "side-effects": "rapid infusion toxic to heart", "contra-indications": "plasma-potassium concentration\r\nabove 5\u00a0mmol/litre", "doses": ["By slow intravenous infusion, depending\r\non the deficit or the daily maintenance requirements, see also notes\r\nabove"]}, "ALUMINIUM ACETATE": {"indications": "inflammation in otitis externa (seenotes above)", "name": "ALUMINIUM ACETATE", "doses": ["Insert into meatus or apply on a ribbon gauze dressing\r\nor sponge wick which should be kept saturated with the ear drops"]}, "ALPHA-BLOCKERS": {"interactions": {"extra": "", "bad": 1, "interaction": "enhanced hypotensive effect when  vardenafil given with alpha-blockers (excludes tamsulosin)\u2014separate doses by 6 hours\u2014see also under Phosphodiesterase type-5 inhibitors, section 7.4.5", "name": "Alpha-blockers", "backrefs": ["Levodopa", "Aldesleukin", "Minoxidil", "Alpha-blockers", "Anaesthetics, General", "Moxisylyte", "Hydralazine", "Sodium Nitroprusside", "Diazoxide", "Moxonidine", "Tizanidine", "Alprostadil"]}}, "ERGOMETRINE MALEATE": {"indications": "see notes above", "name": "ERGOMETRINE MALEATE", "renal impairment": "manufacturer advises caution in mild or moderate impairment\r\nand avoid in severe impairment", "cautions": "cardiac disease; hypertension; multiple pregnancy; acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(ergot alkaloids)", "side-effects": "nausea, vomiting, abdominal pain; chest pain,\r\narrhythmias (including bradycardia), palpitation, hypertension, vasoconstriction;\r\ndyspnoea, pulmonary oedema; headache, dizziness; tinnitus; rash;very rarelymyocardial infarction", "contra-indications": "induction of labour, first and second stages of labour, vascular disease, severe cardiac disease, sepsis, severe hypertension, eclampsia", "hepatic impairment": "manufacturer advises caution in mild or moderate impairment\r\nand avoid in severe impairment", "doses": ["by intramuscular injection, 1\u00a0mL;by intravenous injection, no longer recommended"]}, "DABIGATRAN ETEXILATE": {"indications": "seenotes above", "name": "DABIGATRAN ETEXILATE", "renal impairment": "forprophylaxis of venous thromboembolism following\r\nknee or hip replacement surgery, reduce initial dose to 75\u00a0mg\r\nand subsequent doses to 150\u00a0mg once daily if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; reduce dose to 75\u00a0mg once daily if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2and patient receiving concomitant treatment with verapamil;\r\navoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; forprophylaxis of stroke and systemic embolismin atrial fibrillation,\r\navoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; monitor renal\r\nfunction at least annually", "interactions": {"extra": "", "bad": 1, "interaction": "possible increased risk of bleeding when  sulfinpyrazone given with dabigatran etexilate ", "name": "Dabigatran Etexilate", "backrefs": ["Dabigatran Etexilate"]}, "cautions": "seenotes above; also elderly; body-weight less than 50\u00a0kg; recent surgery; anaesthesia with postoperative\r\nindwelling epidural catheter (risk of paralysis\u2014give initial dose\r\nat least 2 hours after catheter removal and monitor neurological signs); bacterial endocarditis (increased risk of bleeding); bleeding disorders; active\r\ngastro-intestinal ulceration; assess renal function\r\nbefore treatment in all patients and at least annually in elderly\r\nand patients with renal impairment; concomitant use of\r\ndrugs that increase risk of bleeding;interactions: Appendix 1 (dabigatran etexilate)", "side-effects": "nausea, dyspepsia, diarrhoea, abdominal pain,\r\nanaemia, haemorrhage\u2014seenotes above;less commonlyhepatobiliary disorders, vomiting, dysphagia,\r\ngastro-intestinal ulcer, gastro-oesophageal reflux, oesophagitis,\r\nthrombocytopenia", "contra-indications": "active bleeding; impaired haemostasis", "hepatic impairment": "avoid in severe liver disease, especially if prothrombin\r\ntime already prolonged", "doses": ["Prophylaxis of venous thromboembolism following total\r\nknee replacement surgery,adultover\r\n18 years, 110\u00a0mg (elderlyover 75 years,\r\n75\u00a0mg) 1\u20134 hours after surgery,then220\u00a0mg (elderlyover 75 years or patient receiving concomitant\r\ntreatment with amiodarone or verapamil, 150\u00a0mg) once daily for 9 days", "Prophylaxis of venous thromboembolism following total hip replacement\r\nsurgery,adultover 18 years, 110\u00a0mg\r\n(elderlyover 75 years, 75\u00a0mg) 1\u20134\r\nhours after surgery,then220\u00a0mg (elderlyover 75 years or patient receiving concomitant\r\ntreatment with amiodarone or verapamil, 150\u00a0mg) once daily for 27\u201334\r\ndays", "Prophylaxis of stroke and systemic embolism in non-valvular\r\natrial fibrillation (seenotes above),adultover 18 years, 150\u00a0mg (elderlyover 80 years, patients at high risk of bleeding, or receiving concomitant\r\ntreatment with verapamil, 110\u00a0mg) twice daily"], "pregnancy": "manufacturer advises avoid unless essential\u2014toxicity\r\ninanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "RUFINAMIDE": {"indications": "seenotes above", "name": "RUFINAMIDE", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin possibly reduces plasma concentration of rufinamide , also plasma concentration of phenytoin possibly increased", "name": "Rufinamide", "backrefs": ["Rufinamide"]}, "cautions": "closely monitor and consider withdrawal\r\nif rash, fever, or other signs of hypersensitivity syndrome develop (see alsoAntiepileptic Hypersensitivity\r\nSyndrome); avoid abrupt withdrawal;interactions:seeInteractionsin section 4.8.1 and Appendix 1 (rufinamide)", "side-effects": "nausea, vomiting, constipation, diarrhoea, dyspepsia,\r\nabdominal pain, weight loss, anorexia; rhinitis, epistaxis; dizziness,\r\nheadache, drowsiness, insomnia, anxiety, fatigue, increase in seizure\r\nfrequency, impaired coordination, hyperactivity, tremor, gait disturbances;\r\ninfluenza-like symptoms; oligomenorrhoea; back pain; nystagmus, diplopia,\r\nblurred vision; rash and acne; hypersensitivity syndrome (seeAntiepileptic Hypersensitivity\r\nSyndrome)\r\nalso reported", "hepatic impairment": "caution and careful dose titration in mild to moderate\r\nimpairment; avoid in severe impairment", "doses": ["adultandchildover 4 years body-weight over 30\u00a0kg, initially\r\n200\u00a0mg twice daily increased according to response in steps of 200\u00a0mg\r\ntwice daily at intervals of not less than 2 days; body-weight 30\u201350\u00a0kg\r\nmax. 900\u00a0mg twice daily; body-weight 50\u201370\u00a0kg max. 1.2\u00a0g twice daily;\r\nbody-weight over 70\u00a0kg max. 1.6\u00a0g twice daily;childover 4 years body-weight less than 30\u00a0kg, initially 100\u00a0mg twice\r\ndaily increased according to response in steps of 100\u00a0mg twice daily\r\nat intervals of not less than 2 days; max. 500\u00a0mg twice daily (max.\r\n300\u00a0mg twice daily if adjunctive therapywith valproate)"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "MEPACRINE HYDROCHLORIDE": {"side-effects": "gastro-intestinal disturbances; dizziness, headache;\r\nwith large doses nausea, vomiting and occasionally transient acute\r\ntoxic psychosis and CNS stimulation; on prolonged treatment yellow\r\ndiscoloration of skin and urine, chronic dermatoses (including severe\r\nexfoliative dermatitis), hepatitis, aplastic anaemia; also reported\r\nblue/black discoloration of palate and nails and corneal deposits\r\nwith visual disturbances", "indications": "giardiasis; discoid lupus erythematosus (Antimalarials, section 10.1.3)", "name": "MEPACRINE HYDROCHLORIDE", "cautions": "hepatic impairment, elderly, history of psychosis; avoid in psoriasis;interactions:Appendix 1 (mepacrine)", "doses": ["Giardiasis [unlicensed], 100\u00a0mg every 8 hours for 5\u20137\r\ndays"]}, "DORNASE ALFA": {"indications": "management of cystic fibrosis patients with a forced vital capacity\r\n(FVC) of greater than 40% of predicted to improve pulmonary function", "name": "DORNASE ALFA", "side-effects": "rarelydyspepsia, chest pain,\r\ndysphonia, dyspnoea, pharyngitis, laryngitis, pyrexia, conjunctivitis,\r\nrhinitis, rash, urticaria", "doses": ["adultandchildover 5 years,by inhalation of nebulised\r\nsolution(by jet nebuliser), 2500\u00a0units (2.5\u00a0mg) once daily\r\n(patients over 21 years may benefit from twice daily dosage)"], "pregnancy": "no evidence of teratogenicity; manufacturer advises\r\nuse only if potential benefit outweighs risk", "breast-feeding": "amount probably too small to be harmful\u2014manufacturer\r\nadvises caution"}, "ARSENIC TRIOXIDE": {"indications": "seenotes above", "name": "ARSENIC TRIOXIDE", "renal impairment": "manufacturer advises caution\u2014limited information available", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  lithium given with arsenic trioxide ", "name": "Arsenic Trioxide", "backrefs": ["Arsenic Trioxide"]}, "cautions": "seesection 8.1; correct electrolyte abnormalities\r\nbefore treatment; ECG required before and\r\nduring treatment\u2014consult product literature; avoid concomitant administration with drugs causing QT interval prolongation, hypokalaemia, and hypomagnesaemia; previous treatment with anthracyclines (increased risk of QT interval prolongation);interactions: Appendix 1 (arsenic trioxide)", "side-effects": "seesection 8.1; diarrhoea, leucocyte activation\r\nsyndrome (unexplained fever, dyspnoea, weight gain, pulmonary infiltrates,\r\npleural or pericardial effusions, with or without leucocytosis\u2014treat\r\nwith high dose corticosteroids, consult product literature); hyperglycaemia,\r\nhypokalaemia, QT interval prolongation, atrial fibrillation, atrial\r\nflutter, haemorrhage, pleuritic pain, musculoskeletal pain, paraesthesia,\r\nfatigue;less commonlyabdominal pain, tachycardia,\r\nvasculitis, hypotension, oedema, pneumonitis, seizures, renal failure,\r\nblurred vision, and rash", "hepatic impairment": "manufacturer advises caution\u2014limited information available", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and embryotoxic inanimalstudies); manufacturer advises effective contraception during treatment\r\nin men and women; see alsoPregnancy and Reproductive\r\nfunction", "breast-feeding": "discontinue breast-feeding"}, "AGALSIDASE ALFA and BETA": {"indications": "Fabry\u2019s disease (specialist\r\nuse only)", "name": "AGALSIDASE ALFA and BETA", "cautions": "interactions:Appendix 1 (agalsidase\r\nalfa and beta)", "side-effects": "gastro-intestinal disturbances, taste disturbances;\r\ntachycardia, bradycardia, palpitation, hypertension, hypotension,\r\nchest pain, oedema, flushing; dyspnoea, cough, rhinorrhoea; headache,\r\nfatigue, dizziness, asthenia, paraesthesia, syncope, neuropathic pain,\r\ntremor, sleep disturbances; influenza-like symptoms, nasopharyngitis;\r\nmuscle spasms, myalgia, arthralgia; eye irritation; tinnitus; hypersensitivity\r\nreactions, angioedema, pruritus, urticaria, rash, acne;less\r\ncommonlycold extremities, parosmia, ear pain and swelling,\r\nskin discoloration, and injection-site reactions", "doses": ["By intravenous infusion,adultandchildover\r\n7 years 200\u00a0micrograms/kg every 2 weeks"], "pregnancy": "use with caution", "breast-feeding": "use with caution\u2014no information available"}, "ALPRAZOLAM": {"indications": "short-term use in anxiety (seesection 4.1)", "name": "ALPRAZOLAM", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of alprazolam (risk of extreme sedation and respiratory depression\u2014avoid concomitant use)", "name": "Alprazolam", "backrefs": ["Alprazolam"]}, "cautions": "see underDiazepam", "side-effects": "see underDiazepam", "contra-indications": "see underDiazepam", "hepatic impairment": "seenotes above", "doses": ["250\u2013500\u00a0micrograms 3 times daily (elderlyor debilitated 250\u00a0micrograms 2\u20133 times daily), increased if necessary\r\nto a total of 3\u00a0mg daily;childnot\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ECULIZUMAB": {"indications": "paroxysmal nocturnal haemoglobinuria,\r\nin those with a history of blood transfusions (specialist use only)", "name": "ECULIZUMAB", "cautions": "active systemic infection; monitor for intravascular haemolysis (including serum-lactate\r\ndehydrogenase concentration) for at least 8 weeks after discontinuation", "side-effects": "gastro-intestinal disturbances; oedema; cough,\r\nnasopharyngitis; headache, dizziness, fatigue, dysgeusia, paraesthesia;\r\ninfection (including meningococcal infection); spontaneous erection,\r\ndysuria; arthralgia, myalgia; blood disorders (including thrombocytopenia);\r\nalopecia, pruritus, rash; influenza-like symptoms; infusion-related\r\nreactions;less commonlyanorexia, gingival pain,\r\njaundice, palpitation, haematoma, hypotension, chest pain, syncope,\r\nhot flushing, epistaxis, anxiety, depression, mood changes, sleep\r\ndisturbances, Graves\u2019 disease, menstrual disorders, renal impairment,\r\nmalignant melanoma, muscle spasms, myelodysplastic syndrome, visual\r\ndisturbances, tinnitus, hyperhidrosis, petechiae, and skin depigmentation", "contra-indications": "unresolvedNeisseria\r\nmeningitidisinfection; patients\r\nunvaccinated againstNeisseria meningitidis(see Cautions above); known or suspected hereditary complement\r\ndeficiencies", "doses": ["By intravenous infusion,adultover 18 years, initially 600\u00a0mg once a week\r\nfor 4 weeks, then 900\u00a0mg on week 5; maintenance, 900\u00a0mg once every\r\n12\u201316 days"], "pregnancy": "no information available\u2014use only if potential benefit\r\noutweighs risk; human IgG antibodies known to cross placenta; manufacturer\r\nadvises effective contraception during and for 5 months after treatment", "breast-feeding": "no information available\u2014manufacturer advises\r\navoid breast-feeding during and for 5 months after treatment"}, "TYPHOID VACCINE (ORAL)": {"interactions": {"extra": "", "bad": 0, "interaction": " antimalarials inactivate oral typhoid vaccine\u2014see under Typhoid vaccines, section 14.4", "name": "Typhoid Vaccine (oral)", "backrefs": []}}, "UBIDECARENONE": {"interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  warfarin may be enhanced or reduced by ubidecarenone ", "name": "Ubidecarenone", "backrefs": ["Ubidecarenone"]}}, "RIZATRIPTAN": {"indications": "treatment of acute migraine", "name": "RIZATRIPTAN", "renal impairment": "reduce dose to 5\u00a0mg in mild to moderate impairment; avoid\r\nin severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": " propranolol increases plasma concentration of rizatriptan (manufacturer of rizatriptan advises halve dose and avoid within 2 hours of propranolol)", "name": "Rizatriptan", "backrefs": ["Moclobemide", "Rizatriptan"]}, "cautions": "see under5HT1-receptor agonistsabove;interactions:Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; drowsiness, palpitation, tachycardia, dry mouth,\r\ndiarrhoea, dyspepsia, thirst, pharyngeal discomfort, dyspnoea, headache,\r\nparaesthesia, decreased alertness, insomnia, tremor, ataxia, nervousness,\r\nvertigo, confusion, myalgia and muscle weakness, sweating, urticaria,\r\npruritus, blurred vision;rarelysyncope, hypertension,\r\ntoxic epidermal necrolysis; seizures and taste disturbance reported", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; previous cerebrovascular accident or transient\r\nischaemic attack; peripheral vascular disease", "hepatic impairment": "reduce dose to 5\u00a0mg in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["10\u00a0mg as soon as possible after onset repeated after 2\r\nhours if migraine recurs (patient not responding should not take second\r\ndose for same attack); max. 20\u00a0mg in 24 hours;childandadolescentunder 18 years not\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "present in milk inanimalstudies\u2014withhold\r\nbreast-feeding for 24 hours"}, "CARBAPENEMS": {"interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  valproate reduced by carbapenems\u2014avoid concomitant use", "name": "Carbapenems", "backrefs": ["Carbapenems"]}}, "LOPERAMIDE": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of oral  desmopressin increased by loperamide ", "name": "Loperamide", "backrefs": ["Loperamide"]}}, "LEVAMISOLE": {"interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  warfarin possibly enhanced by levamisole ", "name": "Levamisole", "backrefs": ["Levamisole"]}}, "ISOTRETINOIN": {"indications": "seenotes above; oral treatment\r\n(seesection 13.6.2)", "name": "ISOTRETINOIN", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  carbamazepine possibly reduced by isotretinoin ", "name": "Isotretinoin", "backrefs": ["Isotretinoin"]}, "cautions": "(topical applicationonly) seenotes above;\r\nalso personal or familial history of non-melanoma skin\r\ncancer", "side-effects": "(topical applicationonly) seenotes above", "contra-indications": "(topical applicationonly) rosacea, perioral\r\ndermatitis", "doses": ["Apply thinly 1\u20132 times daily"], "pregnancy": "(topical applicationonly) seenotes above", "breast-feeding": "avoid"}, "FLUPENTIXOL": {"indications": "depressive illness; psychoses (section 4.2.1)", "name": "FLUPENTIXOL", "renal impairment": "increased cerebral sensitivity in severe impairment;\r\nmanufacturer advises caution in renal failure", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects and possibly neurotoxicity when  lithium given with flupentixol ", "name": "Flupentixol", "backrefs": ["Flupentixol"]}, "cautions": "cardiovascular disease (including cardiac disorders and cerebral arteriosclerosis), QT-interval\r\nprolongation (avoid concomitant administration\r\nof drugs that prolong QT interval); diabetes; senile confusional states, parkinsonism; elderly; acute porphyria (section 9.8.2); see alsosection 4.2.1;interactions: Appendix 1 (antipsychotics)", "side-effects": "section 4.2.1; also hypersalivation, dyspnoea,\r\nasthenia, hyperglycaemia, myalgia; torsade de pointes and sudden death\r\nalso reported", "contra-indications": "excitable and overactive patients; impaired consciousness; circulatory collapse; coma", "hepatic impairment": "can precipitate coma; consider serum-flupentixol concentration\r\nmonitoring", "doses": ["adultover 18 years, initially\r\n1\u00a0mg (elderly500\u00a0micrograms) in the\r\nmorning, increased after 1 week to 2\u00a0mg (elderly1\u00a0mg) if necessary; max. 3\u00a0mg (elderly1.5\u00a0mg) daily, doses above 2\u00a0mg (elderly1\u00a0mg) in divided doses, last dose before 4\u00a0pm; discontinue if no\r\nresponse after 1 week at max. dosage", "Although drowsiness may occur, can\r\nalso have an alerting effect so should not be taken in the evening"], "pregnancy": "avoid unless potential benefit outweighs risk", "breast-feeding": "present in milk\u2014avoid"}, "SEVELAMER": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  tacrolimus possibly reduced by sevelamer ", "name": "Sevelamer", "backrefs": ["Sevelamer"]}}, "DEXTROMETHORPHAN": {"interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  rasagiline with dextromethorphan ", "name": "Dextromethorphan", "backrefs": ["Dextromethorphan"]}}, "PRUCALOPRIDE": {"indications": "chronic constipation in women when\r\nother laxatives fail to provide an adequate response", "name": "PRUCALOPRIDE", "renal impairment": "max. 1\u00a0mg daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "history of arrhythmias or\r\nischaemic heart disease; concomitant use with drugs that prolong QT interval; severe, unstable chronic illness", "side-effects": "nausea, vomiting, abdominal pain, dyspepsia, flatulence,\r\ndiarrhoea, rectal bleeding; headache, dizziness, fatigue; polyuria;less commonlyanorexia, palpitation, tremor, and fever", "contra-indications": "intestinal perforation or obstruction; severe inflammatory conditions of the\r\nintestinal tract (such as Crohn\u2019s disease, ulcerative colitis, and\r\ntoxic megacolon)", "hepatic impairment": "max. 1\u00a0mg daily in severe impairment", "doses": ["adultover 18 years, 2\u00a0mg\r\nonce daily;elderlyover 65 years,\r\ninitially 1\u00a0mg once daily, increased if necessary to 2\u00a0mg once daily", "Review treatment if no response after 4 weeks"], "pregnancy": "manufacturer advises avoid and recommends effective\r\ncontraception during treatment", "breast-feeding": "manufacturer advises avoid\u2014present in milk"}, "LACTULOSE": {"indications": "constipation (may take up to 48 hours to act), hepatic encephalopathy\r\n(portal systemic encephalopathy)", "name": "LACTULOSE", "interactions": {"extra": "", "bad": 0, "interaction": "anticoagulant effect of  coumarins possibly enhanced by lactulose ", "name": "Lactulose", "backrefs": ["Lactulose"]}, "cautions": "lactose intolerance;interactions:Appendix 1 (lactulose)", "side-effects": "nausea (can be reduced by administration with\r\nwater, fruit juice or with meals), vomiting, flatulence, cramps, and\r\nabdominal discomfort", "contra-indications": "galactosaemia, intestinal obstruction", "doses": ["constipation, initially 15\u00a0mL twice daily, adjusted according\r\nto response;child(but seesection\r\n1.6) under 1 year 2.5\u00a0mL twice daily, adjusted according to\r\nresponse; 1\u20135 years 2.5\u201310\u00a0mL twice daily, adjusted according to response;\r\n5\u201318 years 5\u201320\u00a0mL twice daily, adjusted according to response", "Hepatic encephalopathy, 30\u201350\u00a0mL 3 times daily, subsequently\r\nadjusted to produce 2\u20133 soft stools daily;child12\u201318 years seeBNF for Children", "Lactulose doses in BNF may differ from those\r\nin product literature"], "pregnancy": "not known to be harmful; see alsoPregnancy"}, "NYSTATIN": {"side-effects": "see notes above", "indications": "skin infections due toCandidaspp.; oral\r\nfungal infections (section 12.3.2)", "name": "NYSTATIN", "cautions": "seenotes above", "doses": ["apply 2\u20133 times daily continuing for 7 days after lesions\r\nhave healed."]}, "HYDRALAZINE HYDROCHLORIDE": {"indications": "moderate to severe hypertension (adjunct); heart failure (with long-acting\r\nnitrate, but seesection 2.5.5);hypertensive emergencies(including duringpregnancy) (seesection 2.5)", "name": "HYDRALAZINE HYDROCHLORIDE", "renal impairment": "reduce dose if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "coronary artery disease (may provoke angina, avoid after myocardial infarction\r\nuntil stabilised), cerebrovascular disease; occasionally blood pressure reduction too rapid even\r\nwith low parenteral doses; manufacturer\r\nadvises test for antinuclear factor and for proteinuria every 6 months\r\nand check acetylator status before increasing dose above 100\u00a0mg daily, but evidence of clinical value unsatisfactory;interactions:Appendix 1 (hydralazine)", "side-effects": "tachycardia, palpitation, flushing, hypotension,\r\nfluid retention, gastro-intestinal disturbances; headache, dizziness;\r\nsystemic lupus erythematosus-like syndrome after long-term therapy\r\nwith over 100\u00a0mg daily (or less in women and in slow acetylator individuals)\r\n(see also notes above); rarely rashes, fever, peripheral neuritis,\r\npolyneuritis, paraesthesia, arthralgia, myalgia, increased lacrimation,\r\nnasal congestion, dyspnoea, agitation, anxiety, anorexia; blood disorders\r\n(including leucopenia, thrombocytopenia, haemolytic anaemia), abnormal\r\nliver function, jaundice, raised plasma creatinine, proteinuria and\r\nhaematuria reported", "contra-indications": "idiopathic systemic lupus erythematosus, severe tachycardia, high output\r\nheart failure, myocardial insufficiency due\r\nto mechanical obstruction, cor pulmonale, dissecting aortic aneurysm; acute\r\nporphyria (section 9.8.2)", "hepatic impairment": "reduce dose", "doses": ["By mouth, hypertension, 25\u00a0mg twice\r\ndaily, increased to usual max. 50\u00a0mg twice daily (see notes above)", "Heart failure (initiated in hospital) 25\u00a0mg 3\u20134 times daily,\r\nincreased every 2 days if necessary; usual maintenance dose 50\u201375\u00a0mg\r\n4 times daily", "By slow intravenous injection, hypertensive\r\nemergencies and hypertension with renal complications, 5\u201310\u00a0mg diluted\r\nwith 10\u00a0mLsodium chloride0.9%; may be repeated\r\nafter 20\u201330 minutes (see Cautions)", "By intravenous infusion, hypertensive\r\nemergencies and hypertension with renal complications, initially 200\u2013300\u00a0micrograms/minute;\r\nmaintenance usually 50\u2013150\u00a0micrograms/minute"], "pregnancy": "neonatal thrombocytopenia reported, but risk should\r\nbe balanced against risk of uncontrolled maternal hypertension; manufacturer\r\nadvises avoid before third trimester", "breast-feeding": "present in milk but not known to be harmful;\r\nmonitor infant"}, "CISATRACURIUM": {"indications": "neuromuscular blockade (intermediate duration) for surgery or during\r\nintensive care", "name": "CISATRACURIUM", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nbradycardia", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "Intubation and surgery,by intravenous injection,adultandchildover 1 month, initially 150\u00a0micrograms/kg; maintenance,by\r\nintravenous injection,adultandchildover 12 years, 30\u00a0micrograms/kg\r\napprox. every 20 minutes;child2\u201312\r\nyears, 20\u00a0micrograms/kg approx. every 10 minutes;ormaintenance,by intravenous infusion,adultandchildover\r\n2 years, initially 180\u00a0micrograms/kg/hour,then after stabilisation, 60\u2013120\u00a0micrograms/kg/hour", "Lower doses can be used for children over\r\n2 years whennotfor intubation", "Intensive care,adultinitially\r\n150\u00a0micrograms/kg (optional)by intravenous injection, thenby intravenous infusion180\u00a0micrograms/kg/hour\r\nadjusted according to response (usual range 30\u2013600\u00a0micrograms/kg/hour)"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "GRISEOFULVIN": {"indications": "dermatophyte infections of the skin, scalp, hair and nails where\r\ntopical therapy has failed or is inappropriate", "name": "GRISEOFULVIN", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  ciclosporin possibly reduced by griseofulvin ", "name": "Griseofulvin", "backrefs": ["Griseofulvin"]}, "cautions": "interactions:Appendix 1 (griseofulvin)", "side-effects": "nausea, vomiting, diarrhoea; headache; also reported,\r\nabdominal pain, dyspepsia, hepatotoxicity, glossitis, taste disturbances,\r\nsleep disturbances, dizziness, fatigue, confusion, agitation, depression,\r\nimpaired coordination and hearing, peripheral neuropathy,\r\nmenstrual disturbances, renal failure, leucopenia, systemic lupus\r\nerythematosus, rash (including rarely erythema multiforme, toxic epidermal\r\nnecrolysis), and photosensitivity", "contra-indications": "severe liver disease; systemic lupus erythematosus (risk of exacerbation); acute porphyria (section 9.8.2)", "hepatic impairment": "avoid in severe liver disease", "doses": ["Dermatophyte infections, 500\u00a0mg once daily or in\r\ndivided doses; in severe infection dose may be doubled, reducing when\r\nresponse occurs;childunder 50\u00a0kg,\r\n10\u00a0mg/kg once daily or in divided doses", "Tinea capitis caused byTrichophyton tonsurans, 1\u00a0g once daily or in divided doses;childunder 50\u00a0kg, 15\u201320\u00a0mg/kg once daily or in divided doses", "Griseofulvin doses in BNF may differ from\r\nthose in product literature"], "pregnancy": "avoid (fetotoxicity and teratogenicity inanimals); effective contraception required during and for\r\nat least 1 month after administration to women (important:effectiveness of oral contraceptives may be reduced, additional\r\ncontraceptive precautions e.g. barrier method, required); also men\r\nshould avoid fathering a child during and for at least 6 months after\r\nadministration", "breast-feeding": "avoid\u2014no information available"}, "IDURSULFASE": {"indications": "(specialist use only) mucopolysaccharidosis\r\nII", "name": "IDURSULFASE", "cautions": "severe respiratory disease; acute febrile respiratory illness (consider delaying\r\ntreatment)", "side-effects": "gastro-intestinal disturbances, swollen tongue;\r\narrhythmia, tachycardia, chest pain, cyanosis, peripheral oedema,\r\nhypertension, hypotension, flushing; bronchospasm, hypoxia, cough,\r\nwheezing, tachypnoea, dyspnoea; headache, dizziness, tremor; pyrexia;\r\narthralgia; facial oedema, urticaria, pruritus, rash, infusion-site\r\nswelling, erythema; pulmonary embolism and anaphylaxis also reported", "contra-indications": "women of child-bearing potential", "doses": ["By intravenous infusion,adultandchildover\r\n5 years, 500\u00a0micrograms/kg once weekly"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "PROMETHAZINE HYDROCHLORIDE": {"indications": "nausea, vomiting, vertigo, labyrinthine\r\ndisorders, motion sickness; allergy and urticaria (section\r\n3.4.1); sedation (section\r\n4.1.1)", "name": "PROMETHAZINE HYDROCHLORIDE", "renal impairment": "see Promethazine Hydrochloride,section 3.4.1", "cautions": "see Promethazine Hydrochloride,section 3.4.1", "side-effects": "see Promethazine Hydrochloride,section 3.4.1", "contra-indications": "see notes insection 3.4.1", "hepatic impairment": "see notes insection 3.4.1", "doses": ["By mouth, 20\u201325\u00a0mg at bedtime on night\r\nbefore travel, repeat following morning if necessary;child2\u20135 years 5\u00a0mg at night, and following morning\r\nif necessary, 5\u201310 years 10\u00a0mg at night, and following morning if\r\nnecessary"], "pregnancy": "see notes insection 3.4.1", "breast-feeding": "see notes insection 3.4.1"}, "RETEPLASE": {"indications": "acute myocardial infarction (see notes above andsection 2.10.1)", "name": "RETEPLASE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By intravenous injection(initiated within\r\n12 hours of symptom onset), 10\u00a0units over not more than 2 minutes,\r\nfollowed after 30 minutes by a further 10\u00a0units"], "pregnancy": "seenotes above", "breast-feeding": "manufacturer advises avoid breast-feeding for\r\n24 hours after dose (express and discard milk during this time)"}, "SOLIFENACIN": {"interactions": {"extra": "", "bad": 0, "interaction": " ritonavir increases plasma concentration of solifenacin ", "name": "Solifenacin", "backrefs": ["Solifenacin"]}}, "NEFOPAM": {"interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  MAOIs advised by manufacturer of nefopam ", "name": "Nefopam", "backrefs": ["Nefopam"]}}, "CONESTAT ALFA": {"indications": "acute attacks of hereditary angioedema\r\nin patients with C1-esterase inhibitor deficiency", "name": "CONESTAT ALFA", "cautions": "test for immunoglobulin E (IgE) antibodies against\r\nrabbit allergens before starting treatment, repeat antibody testing\r\nannually or after 10 treatments\u2014consult product literature", "side-effects": "headache;less commonlynausea,\r\ndiarrhoea, abdominal discomfort, throat irritation, vertigo, paraesthesia,\r\nurticaria", "contra-indications": "rabbit allergy", "doses": ["By slow intravenous injectionover 5 minutes,adultover 18 years, body-weight under 84\u00a0kg, 50\u00a0units/kg\r\nas a single dose; body-weight over 84\u00a0kg, 4200\u00a0units as a single dose;\r\ndose may be repeated if necessary (max. 2 doses in 24 hours)"], "pregnancy": "use only if potential benefit outweighs risk\u2014toxicity\r\ninanimalstudies", "breast-feeding": "use only if potential benefit outweighs risk\u2014no\r\ninformation available"}, "CEFALEXIN": {"indications": "see underCefaclor", "name": "CEFALEXIN", "renal impairment": "max. 3\u00a0g daily if eGFR 40\u201350\u00a0mL/minute/1.73\u00a0m2; max. 1.5\u00a0g daily if eGFR 10\u201340\u00a0mL/minute/1.73\u00a0m2; max.\r\n750\u00a0mg daily if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["250\u00a0mg every 6 hoursor500\u00a0mg every\r\n8\u201312 hours increased to 1\u20131.5\u00a0g every 6\u20138 hours for severe infections;child25\u00a0mg/kg daily in divided doses, doubled for\r\nsevere infections, max. 100\u00a0mg/kg daily;orunder\r\n1 year 125\u00a0mg every 12 hours, 1\u20135 years 125\u00a0mg every 8 hours, 5\u201312\r\nyears 250\u00a0mg every 8 hours", "Prophylaxis of recurrent urinary-tract infection,adult125\u00a0mg at night"], "pregnancy": "see underCefaclor", "breast-feeding": "see underCefaclor"}, "TOLAZOLINE": {"interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  adrenaline (epinephrine) with tolazoline ", "name": "Tolazoline", "backrefs": ["Tolazoline"]}}, "ETHANOLAMINE OLEATE": {"indications": "sclerotherapy of varicose\r\nveins", "name": "ETHANOLAMINE OLEATE", "cautions": "extravasation may cause necrosis of tissues", "side-effects": "allergic reactions (including anaphylaxis)", "contra-indications": "inability\r\nto walk, acute phlebitis, oral contraceptive use, obese legs", "doses": ["by slow injection into empty isolated segment of vein,\r\n2\u20135\u00a0mL divided between 3\u20134 sites; repeated at weekly intervals"]}, "EPLERENONE": {"indications": "adjunct in stable patients with left\r\nventricular dysfunction with evidence of heart failure, following\r\nmyocardial infarction (start therapy within 3\u201314 days of event)", "name": "EPLERENONE", "renal impairment": "increased risk of hyperkalaemia\u2014close monitoring required;\r\navoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of eplerenone\u2014avoid concomitant use", "name": "Eplerenone", "backrefs": ["Eplerenone"]}, "cautions": "measure plasma-potassium concentration\r\nbefore treatment, during initiation, and when dose changed; elderly;interactions:Appendix 1 (diuretics)", "side-effects": "diarrhoea, nausea; hypotension; dizziness; hyperkalaemia;\r\nrash;less commonlyflatulence, vomiting, atrial\r\nfibrillation, postural hypotension, arterial thrombosis, dyslipidaemia,\r\npharyngitis, headache, insomnia, gynaecomastia, pyelonephritis, hyponatraemia,\r\ndehydration, eosinophilia, asthenia, malaise, back pain, leg cramps,\r\nimpaired renal function, azotaemia, sweating and pruritus", "contra-indications": "hyperkalaemia; concomitant use of potassium-sparing diuretics or potassium supplements", "hepatic impairment": "avoid in severe liver disease", "doses": ["Initially 25\u00a0mg once daily, increased within 4 weeks to\r\n50\u00a0mg once daily;childnot recommended"], "pregnancy": "manufacturer advises caution\u2014no information available", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk"}, "RISEDRONATE SODIUM": {"indications": "see under Dose", "name": "RISEDRONATE SODIUM", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "oesophageal abnormalities and other factors\r\nwhich delay transit or emptying (e.g. stricture or achalasia\u2014see also under Side-effects); correct hypocalcaemia before starting, correct other disturbances of bone and mineral metabolism (e.g.\r\nvitamin-D deficiency) at onset of treatment; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, seeMHRA/CHM advice;interactions:Appendix 1 (bisphosphonates)", "side-effects": "abdominal pain, dyspepsia, nausea, diarrhoea,\r\nconstipation, headache, musculoskeletal pain;less commonlyoesophagitis, oesophageal ulcer, dysphagia, gastritis, duodenitis,\r\nuveitis;rarelyglossitis, oesophageal stricture,\r\natypical femoral fractures (seeMHRA/CHM advice);also reportedgastroduodenal ulceration, hepatic disorders,\r\nStevens-Johnson syndrome, toxic epidermal necrolysis, hair loss, cutaneous\r\nvasculitis, osteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw)", "contra-indications": "hypocalcaemia (see\r\nCautions above)", "doses": ["Paget\u2019s disease of bone, 30\u00a0mg daily for 2 months; may\r\nbe repeated if necessary after at least 2 months", "Treatment of postmenopausal osteoporosis to reduce risk of vertebral\r\nor hip fractures, 5\u00a0mg dailyor35\u00a0mg once weekly", "Prevention of osteoporosis (including corticosteroid-induced\r\nosteoporosis) in postmenopausal women, 5\u00a0mg daily", "Treatment of osteoporosis in men at high risk of fractures,\r\n35\u00a0mg once weekly", "childseeBNF for Children", "Swallow tablets whole with full glass\r\nof water; on rising, take on an empty stomach at least 30 minutes\r\nbefore first food or drink of the dayor, if taking\r\nat any other time of the day, avoid food and drink for at least 2\r\nhours before or after risedronate (particularly avoid calcium-containing\r\nproducts e.g. milk; also avoid iron and mineral supplements and antacids);\r\nstand or sit upright for at least 30 minutes; do not take tablets\r\nat bedtime or before rising"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "LENOGRASTIM": {"indications": "(specialist use only) reduction in the duration of neutropenia and\r\nassociated complications following peripheral stem cells or bone-marrow\r\ntransplantation for non-myeloid malignancy, or following treatment\r\nwith cytotoxic chemotherapy associated with a significant incidence\r\nof febrile neutropenia; mobilisation of peripheral blood progenitor\r\ncells for harvesting and subsequent infusion", "name": "LENOGRASTIM", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\nmucositis, splenic rupture, and toxic epidermal necrolysis", "doses": ["Following bone-marrow transplantation,by intravenous\r\ninfusionorsubcutaneous injection,adultandchildover\r\n2 years 19.2\u00a0million\u00a0units/m2daily started the day after\r\ntransplantation, continued until neutrophil count stable in acceptable\r\nrange (max. 28 days)", "Following peripheral stem cells transplantation,by intravenous\r\ninfusionorsubcutaneous injection,adult19.2\u00a0million units/m2daily started\r\nthe day after transplantation, continued until neutrophil count stable\r\nin acceptable range (max. 28 days);childseeBNF for Children", "Cytotoxic-induced neutropenia,by subcutaneous injection,adult19.2\u00a0million\u00a0units/m2daily started the day after completion of chemotherapy, continued\r\nuntil neutrophil count stable in acceptable range (max. 28 days);childseeBNF for Children", "Mobilisation of peripheral blood progenitor cells, used alone,by subcutaneous injection,adult1.28\u00a0million\u00a0units/kg daily for 4\u20136 days (5\u20136 days in healthy donors);\r\nused following adjunctive myelosuppressive chemotherapy (to improve\r\nyield),by subcutaneous injection, 19.2\u00a0million\u00a0units/m2daily, started 1\u20135 days after completion of chemotherapy\r\nand continued until neutrophil count in acceptable range; for timing\r\nof leucopheresis consult product literature;childseeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "LOCAL CORTICOSTEROID INJECTIONS": {"indications": "local inflammation of joints and soft\r\ntissues (for details, consult product literature)", "name": "LOCAL CORTICOSTEROID INJECTIONS", "cautions": "seenotes aboveand consult product literature; see alsosection 6.3.2", "side-effects": "see notes above and consult product literature", "contra-indications": "seenotes aboveand consult product\r\nliterature; avoid injections containing benzyl\r\nalcohol in neonates (see preparations below)", "doses": ["by intra-articular injection(for details\r\nconsult product literature), 5\u201350\u00a0mg according to size; where appropriate\r\nmay be repeated at intervals of 21 days; not more than 3 joints should\r\nbe treated on any one day;child5\u201330\u00a0mg\r\n(divided)"]}, "XIPAMIDE": {"indications": "oedema, hypertension (see also notes above)", "name": "XIPAMIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; also acute porphyria (section 9.8.2)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Oedema, initially 40\u00a0mg daily in the morning, increased\r\nto 80\u00a0mg in resistant cases; maintenance 20\u00a0mg in the morning", "Hypertension, 20\u00a0mg daily in the morning"], "pregnancy": "seenotes above", "breast-feeding": "no information available"}, "LEVOMEPROMAZINE": {"indications": "see under Dose", "name": "LEVOMEPROMAZINE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  desferrioxamine advised by manufacturer of levomepromazine ", "name": "Levomepromazine", "backrefs": ["Levomepromazine"]}, "cautions": "seenotes above; diabetes; patients receiving large initial\r\ndoses should remain supine", "side-effects": "seenotes above; occasionally\r\nraised erythrocyte sedimentation rate occurs; hyperglycaemia also\r\nreported", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Schizophrenia,by mouthinitially 25\u201350\u00a0mg daily in\r\ndivided doses increased as necessary; bedpatients initially 100\u2013200\u00a0mg\r\ndaily usually in 3 divided doses, increased if necessary to 1\u00a0g daily;elderly, see Cautions", "Pain in palliative care", "Restlessness and confusion\r\nin palliative care;child1\u201318 years seeBNF for Children", "Nausea and vomiting in palliative care,by mouth,\r\norby subcutaneous infusion;child1 month\u201318 years seeBNF for Children"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PROCYCLIDINE": {"interactions": {"extra": "", "bad": 0, "interaction": " paroxetine increases plasma concentration of procyclidine ", "name": "Procyclidine", "backrefs": ["Procyclidine"]}}, "PHENOBARBITAL SODIUM": {"indications": "status epilepticus; other forms of\r\nepilepsy except absence seizures (section 4.8.1)", "name": "PHENOBARBITAL SODIUM", "renal impairment": "see Phenobarbital,section 4.8.1", "cautions": "see Phenobarbital,section 4.8.1;interactions:seeInteractionsin section\r\n4.8.1 and Appendix 1 (phenobarbital)", "side-effects": "see Phenobarbital,section 4.8.1", "hepatic impairment": "see Phenobarbital,section 4.8.1", "doses": ["Status epilepticus,by intravenous injection(dilute injection 1 in 10 with water for injections), 10\u00a0mg/kg at\r\na rate of not more than 100\u00a0mg/minute; max. 1\u00a0g", "For therapeutic purposes phenobarbital and\r\nphenobarbital sodium may be considered equivalent in effect"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "FOLLITROPIN ALFA and BETA": {"indications": "see notes above", "name": "FOLLITROPIN ALFA and BETA", "cautions": "acute porphyria (section 9.8.2)", "side-effects": "see underHuman Menopausal Gonadotrophins", "contra-indications": "see underHuman Menopausal\r\nGonadotrophins", "doses": ["By subcutaneousorintramuscular injection, according to patient\u2019s response"], "pregnancy": "avoid", "breast-feeding": "avoid"}, "CEFIXIME": {"indications": "see underCefaclor(acute infections only); gonorrhoea [unlicensed\r\nindication] (see also Table 1,section 5.1)", "name": "CEFIXIME", "renal impairment": "reduce dose if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2(max. 200\u00a0mg once daily)", "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["adultandchildover 10 years, 200\u2013400\u00a0mg daily in 1\u20132 divided\r\ndoses;childover 6 months 8\u00a0mg/kg\r\ndaily in 1\u20132 divided dosesor6 months\u20131 year 75\u00a0mg\r\ndaily; 1\u20134 years 100\u00a0mg daily; 5\u201310 years 200\u00a0mg daily", "Uncomplicated gonorrhoea [unlicensed indication] (see also Table\r\n1,section 5.1), 400\u00a0mg as a single dose"], "pregnancy": "see underCefaclor", "breast-feeding": "manufacturer advises avoid unless essential\u2014no\r\ninformation available"}, "BISPHOSPHONATES": {"interactions": {"extra": "", "bad": 0, "interaction": "oral  iron reduces absorption of bisphosphonates ", "name": "Bisphosphonates", "backrefs": ["Bisphosphonates"]}}, "VARICELLA\u2013ZOSTER IMMUNOGLOBULIN": {"side-effects": "injection site swelling and pain;rarelyanaphylaxis", "indications": "prophylaxis against varicella infection", "name": "VARICELLA\u2013ZOSTER IMMUNOGLOBULIN", "cautions": "IgA deficiency; interference with live virus vaccines\u2014see underNormal Immunoglobulins", "doses": ["By intramuscular injection, prophylaxis\r\n(as soon as possible\u2014not later than 10 days after exposure),adultandchildover\r\n14 years, 1\u00a0g;neonate,infantandchildup\r\nto 5 years 250\u00a0mg, 5\u201310 years 500\u00a0mg, 10\u201314 years 750\u00a0mg; give second\r\ndose if further exposure occurs more than 3 weeks after first dose"]}, "BETHANECHOL CHLORIDE": {"indications": "urinary retention, but see notes above", "name": "BETHANECHOL CHLORIDE", "cautions": "autonomic neuropathy (use lower initial\r\ndose);interactions:Appendix 1 (parasympathomimetics)", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain, increased\r\nsalivation, eructation; flushing, hypotension, bradycardia; bronchoconstriction,\r\nrhinorrhoea; headache; increased lacrimation; increased sweating", "contra-indications": "peptic ulcer; intestinal\r\nor urinary obstruction; conditions where increased motility of the urinary\r\nor gastro-intestinal tract could be harmful; cardiovascular\r\ndisorders (including recent myocardial infarction, bradycardia, and heart block); hypotension; obstructive airways\r\ndisease; epilepsy; parkinsonism; hyperthyroidism", "doses": ["10\u201325\u00a0mg 3\u20134 times daily half an hour before food"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "manufacturer advises avoid; gastro-intestinal\r\ndisturbances in infant reported"}, "CYANOCOBALAMIN": {"indications": "see notes above", "name": "CYANOCOBALAMIN", "doses": ["By mouth, vitamin B12deficiency\r\nof dietary origin, 50\u2013150\u00a0micrograms daily taken between meals;child50\u2013105\u00a0micrograms daily in 1\u20133 divided doses", "By intramuscular injection, initially 1\u00a0mg repeated\r\n10 times at intervals of 2\u20133 days, maintenance 1\u00a0mg every month, but\r\nsee notes above"]}, "PHENOTHIAZINES": {"interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects and possibly neurotoxicity when  lithium given with phenothiazines ", "name": "Phenothiazines", "backrefs": ["Phenothiazines"]}}, "FLECAINIDE ACETATE": {"indications": "capsules, tablets, and injection:AV nodal reciprocating\r\ntachycardia, arrhythmias associated with accessory conducting pathways\r\n(e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal\r\natrial fibrillation in patients without left ventricular dysfunction\r\n(arrhythmias of recent onset will respond more readily)", "name": "FLECAINIDE ACETATE", "renal impairment": "reduce initial oral dose to max. 100\u00a0mg daily or reduce\r\nintravenous dose by 50%, if eGFR less than 35\u00a0mL/minute/1.73\u00a0m2", "cautions": "patients with pacemakers (especially\r\nthose who may be pacemaker dependent because stimulation threshold\r\nmay rise appreciably); atrial fibrillation\r\nfollowing heart surgery; elderly (accumulation may occur); ECG monitoring and resuscitation\r\nfacilities must be available during intravenous use;interactions:Appendix 1 (flecainide)", "side-effects": "oedema, pro-arrhythmic effects; dyspnoea; dizziness,\r\nasthenia, fatigue, fever; visual disturbances;rarelypneumonitis, hallucinations, depression, confusion, amnesia, dyskinesia,\r\nconvulsions, peripheral neuropathy;also reportedgastro-intestinal disturbances, anorexia, hepatic dysfunction, flushing,\r\nsyncope, drowsiness, tremor, vertigo, headache, anxiety, insomnia,\r\nataxia, paraesthesia, anaemia, leucopenia, thrombocytopenia, corneal\r\ndeposits, tinnitus, increased antinuclear antibodies, hypersensitivity\r\nreactions (including rash, urticaria, and photosensitivity), increased\r\nsweating", "contra-indications": "heart failure; abnormal left ventricular function; history of myocardial infarction and either asymptomatic\r\nventricular ectopics or asymptomatic non-sustained ventricular tachycardia; long-standing atrial fibrillation where conversion to sinus rhythm\r\nnot attempted; haemodynamically significant\r\nvalvular heart disease; avoid in sinus node dysfunction,\r\natrial conduction defects, second-degree or greater AV block, bundle\r\nbranch block or distal block unless pacing rescue available", "hepatic impairment": "avoid (or reduce dose) in severe liver disease", "doses": ["By mouth(initiated under direction\r\nof hospital consultant), ventricular arrhythmias, initially 100\u00a0mg\r\ntwice daily (max. 400\u00a0mg daily usually reserved for rapid control\r\nor in heavily built patients), reduced after 3\u20135 days to the lowest\r\ndose that controls arrhythmia", "Supraventricular arrhythmias, 50\u00a0mg twice daily, increased if\r\nrequired to max. 300\u00a0mg daily", "By slow intravenous injection(in\r\nhospital), 2\u00a0mg/kg over 10\u201330 minutes, max. 150\u00a0mg, with ECG monitoring;\r\nfollowed if required byinfusionat a rate of 1.5\u00a0mg/kg/hour\r\nfor 1\u00a0hour, subsequently reduced to 100\u2013250\u00a0micrograms/kg/hour for\r\nup to 24 hours; max. cumulative dose in first 24 hours, 600\u00a0mg; transfer\r\ntooraltreatment, as above"], "pregnancy": "used in pregnancy to treat maternal and fetal arrhythmias\r\nin specialist centres; toxicity reported inanimalstudies; infant hyperbilirubinaemia also reported", "breast-feeding": "significant amount present in milk but not known\r\nto be harmful"}, "HAEM ARGINATE": {"indications": "acute porphyrias (acute intermittent\r\nporphyria, porphyria variegata, hereditary coproporphyria)", "name": "HAEM ARGINATE", "side-effects": "rarelyhypersensitivity reactions\r\nand fever; pain and thrombophlebitis at injection site", "doses": ["By intravenous infusion,adultandchild3\u00a0mg/kg\r\nonce daily (max. 250\u00a0mg daily) for 4 days; if response inadequate,\r\nrepeat 4-day course with close biochemical monitoring"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "manufacturer advises avoid unless essential\u2014no\r\ninformation available"}, "ALENDRONIC ACID": {"indications": "see under Dose", "name": "ALENDRONIC ACID", "renal impairment": "avoid if eGFR less than 35\u00a0mL/minute/1.73\u00a0m2", "cautions": "upper gastro-intestinal disorders (dysphagia, symptomatic\r\noesophageal disease, gastritis, duodenitis, or ulcers\u2014see also under\r\nContra-indications and Side-effects); history (within 1 year) of ulcers,\r\nactive gastro-intestinal bleeding, or surgery of the upper gastro-intestinal\r\ntract; correct disturbances of calcium\r\nand mineral metabolism (e.g. vitamin-D deficiency, hypocalcaemia)\r\nbefore starting and monitor serum-calcium concentration\r\nduring treatment; consider dental check-up before\r\ninitiating bisphosphonate (risk of osteonecrosis\r\nof the jaw, seeBisphosphonates: Osteonecrosis\r\nof the Jaw); exclude other causes of osteoporosis; atypical femoral fractures, seeMHRA/CHM advice;interactions:Appendix 1 (bisphosphonates)", "side-effects": "oesophageal reactions (see below), abdominal pain\r\nand distension, dyspepsia, regurgitation, melaena, diarrhoea or constipation,\r\nflatulence, musculoskeletal pain, headache;rarelyrash, pruritus, erythema, photosensitivity, uveitis, scleritis,\r\ntransient decrease in serum calcium and phosphate; nausea, vomiting,\r\ngastritis, peptic ulceration, hypersensitivity reactions (including\r\nurticaria and angioedema), atypical femoral fractures with long-term\r\nuse (seeMHRA/CHM advice);\r\nmyalgia, malaise, and fever at initiation of treatment;very\r\nrarelysevere skin reactions (including Stevens-Johnson syndrome),\r\nosteonecrosis of the jaw (seeBisphosphonates: Osteonecrosis\r\nof the Jaw)", "contra-indications": "abnormalities of oesophagus and other factors\r\nwhich delay emptying (e.g. stricture or achalasia), hypocalcaemia", "doses": ["Treatment of postmenopausal osteoporosis, 10\u00a0mg dailyor70\u00a0mg once weekly", "Treatment of osteoporosis in men, 10\u00a0mg daily", "Prevention and treatment of corticosteroid-induced osteoporosis\r\nin postmenopausal women not receiving hormone replacement therapy,\r\n10\u00a0mg daily", "Tablets should be swallowed whole\r\nwith plenty of water while sitting or standing; to be taken on an\r\nempty stomach at least 30 minutes before breakfast (or another oral\r\nmedicine); patient should stand or sit upright for at least 30 minutes\r\nafter taking tablet"], "pregnancy": "avoid", "breast-feeding": "no information available"}, "BETAXOLOL": {"indications": "seenotes above", "name": "BETAXOLOL", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply twice daily"]}, "GOLIMUMAB": {"indications": "see underCytokine Modulatorsabove", "name": "GOLIMUMAB", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  anakinra with golimumab ", "name": "Golimumab", "backrefs": ["Golimumab"]}, "cautions": "predisposition to infection; monitor for infection before, during, and for 5 months\r\nafter treatment (see also Tuberculosis below); do not initiate until active infections are controlled; discontinue if new serious infection develops until\r\ninfection controlled; hepatitis B virus\u2014monitor\r\nfor active infection; mild heart failure\r\n(discontinue if symptoms develop or worsen); demyelinating disorders (risk of exacerbation); history\r\nor development of malignancy;interactions: Appendix 1 (golimumab)", "side-effects": "see underCytokine Modulatorsand under Cautions above; also constipation, dyspepsia, hypertension,\r\ninsomnia, dizziness, paraesthesia, asthenia, alopecia, dermatitis;less commonlytaste disturbance, gastritis, colitis, stomatitis,\r\ngastro-oesophageal reflux disease, cholelithiasis, hepatic disorders,\r\nhyperlipidaemia, arrhythmia, ischaemic coronary artery disorders,\r\nRaynaud\u2019s syndrome, heart failure, thrombosis, flushing, bronchospasm,\r\ndemyelinating disorders, hyperglycaemia, thyroid disorders, menstrual\r\ndisorders, malignancy, bone fractures, visual disturbance, eye irritation,\r\nnew onset or worsening psoriasis;rarelyinterstitial\r\nlung disease, renal impairment", "contra-indications": "severe active infection (see also Cautions); moderate or severe heart failure", "hepatic impairment": "manufacturer advises caution\u2014no information available", "doses": ["By subcutaneous injection,adultover 18 years, 50\u00a0mg once a month on the same\r\ndate each month, review treatment if no response after 3\u20134 doses;\r\nbody-weight over 100\u00a0kg, if inadequate response to 3\u20134 doses of 50\u00a0mg\r\nonce a month, dose can be increased to 100\u00a0mg once a month, review\r\ntreatment if inadequate response to this higher dose after 3\u20134 doses", "If dose administered more than 2 weeks late,\r\nsubsequent doses should be administered on the new monthly due date"], "pregnancy": "use only if essential; manufacturer advises adequate\r\ncontraception during treatment and for at least 6 months after last\r\ndose", "breast-feeding": "manufacturer advises avoid during and for at\r\nleast 6 months after treatment\u2014present in milk inanimalstudies"}, "PREDNISOLONE": {"indications": "local treatment of inflammation (short-term)", "name": "PREDNISOLONE", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of prednisolone ", "name": "Prednisolone", "backrefs": ["Prednisolone", "Methylprednisolone"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "doses": ["Apply every 1\u20132 hours until controlled then reduce frequency"]}, "LATANOPROST WITH TIMOLOL": {"indications": "see under preparation", "name": "LATANOPROST WITH TIMOLOL", "cautions": "before initiating treatment, advise patients\r\nof possible change in eye colour; monitor\r\nfor eye colour change (see alsonotes above); history of herpetic keratitis (avoid in\r\nactive herpes simplex keratitis); aphakia, or pseudophakia with torn posterior lens capsule or anterior chamber lenses; risk factors for iritis, uveitis, and cystoid macular\r\noedema; not to be used within 5 minutes\r\nof use of thiomersal-containing preparations; consider\r\nalso other cautions of beta-blockers (section 2.4)", "side-effects": "brown pigmentation particularly in those with\r\nmixed-colour irides; ocular irritation and pain; darkening, thickening\r\nand lengthening of eye lashes; transient punctate epithelial erosion;less commonlyblepharitis, conjunctival hyperaemia, corneal\r\ndisorders, eyelid oedema and rash, skin rash;rarelydyspnoea, exacerbation of asthma, iritis, uveitis, local oedema,\r\ndarkening of palpebral skin;very rarelychest pain,\r\nexacerbation of angina; local side-effects of eye drops also include\r\nerythema, dry eyes and allergic reactions including anaphylaxis and\r\nblepharoconjunctivitis; consider also other side-effects of beta-blockers\r\n(section 2.4)", "contra-indications": "bradycardia, heart block, uncontrolled heart failure, cardiogenic shock; asthma (see CSM advice, below); consider also other contra-indications\r\nof beta-blockers (section 2.4)", "doses": ["for raised intra-ocular pressure in patients with open-angle\r\nglaucoma and ocular hypertension when beta-blocker alone not adequate;\r\napply once daily"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "latanoprost may be present in milk; timolol\r\npresent in small amounts\u2014manufacturer advises avoid"}, "NADOLOL": {"indications": "see under Dose", "name": "NADOLOL", "renal impairment": "increase dosage interval if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "hepatic impairment": "manufacturer advises caution", "doses": ["Hypertension, initially 80\u00a0mg once daily, increased in\r\nincrements of up to 80\u00a0mg at weekly intervals if required; max. 240\u00a0mg\r\ndaily (higher doses rarely necessary)", "Angina, initially 40\u00a0mg once daily, increased at weekly intervals\r\nif required; usual max. 160\u00a0mg daily (rarely up to 240\u00a0mg may be required)", "Arrhythmias, initially 40\u00a0mg once daily, increased at weekly\r\nintervals up to 160\u00a0mg if required; reduce to 40\u00a0mg if bradycardia\r\noccurs", "Migraine prophylaxis, initially 40\u00a0mg once daily, increased\r\nin 40\u00a0mg increments at weekly intervals according to response; usual\r\nmaintenance dose 80\u2013160\u00a0mg once daily", "Thyrotoxicosis (adjunct), 80\u2013160\u00a0mg once daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ERGOTAMINE TARTRATE": {"indications": "treatment of acute migraine and migraine variants unresponsive toanalgesics", "name": "ERGOTAMINE TARTRATE", "renal impairment": "avoid; risk of renal vasoconstriction", "cautions": "risk of peripheral vasospasm (see below); elderly; dependence (seeErgot Alkaloidsabove); cardiac\r\ndisease; anaemia;interactions:Appendix 1 (ergot alkaloids)", "side-effects": "abdominal pain, nausea, vomiting; dizziness;less commonlydiarrhoea, pain and weakness in extremities,\r\ncyanosis, peripheral vasoconstriction, paraesthesia, and hypoaesthesia;rarelyintestinal ischaemia, arrhythmias, increased blood\r\npressure, bradycardia, tachycardia, dyspnoea, ergotism (including\r\nabsence of pulse and numbness in extremities), myalgia, rash, and\r\nurticaria;very rarelymyocardial ischaemia, myocardial\r\ninfarction, heart-valve fibrosis, and gangrene; constipation, dry\r\nmouth, cerebral ischaemia, thrombosis, drowsiness, sleep disturbances,\r\ntremor, seizures, extrapyramidal effects, anxiety, depression, confusion,\r\nhallucinations, renal artery spasm, urinary retention, blood disorders,\r\nblurred vision, and arthralgia also reported", "contra-indications": "peripheral vascular disease, coronary heart disease, obliterative\r\nvascular disease and Raynaud\u2019s syndrome, temporal arteritis, sepsis, severe or inadequately controlled hypertension, hyperthyroidism, acute porphyria (section 9.8.2)", "hepatic impairment": "avoid in severe impairment\u2014risk of toxicity increased", "doses": ["1 tablet at onset, followed after 30 minutes by \u00bd\u20131 tablet,\r\nrepeated every 30 minutes if necessary; max. 3 tablets in 24 hours,\r\n4 tablets per attack, 6 tablets in one week (but see alsonotesabove);childnot recommended"], "pregnancy": "avoid; oxytocic effect on the uterus", "breast-feeding": "avoid; ergotism may occur in infant; repeated\r\ndoses may inhibit lactation"}, "PIPERAZINE": {"indications": "threadworm and roundworm infections", "name": "PIPERAZINE", "renal impairment": "use with caution; avoid in severe renal impairment; risk\r\nof neurotoxicity", "cautions": "epilepsy; packs on sale to the general public carry a warning to avoid in epilepsy,\r\nor in liver or kidney disease, and to seek medical advice in pregnancy", "side-effects": "nausea, vomiting, colic, diarrhoea, allergic reactions\r\nincluding urticaria, bronchospasm, and rare reports of arthralgia,\r\nfever, Stevens-Johnson syndrome and angioedema; rarely dizziness,\r\nmuscular incoordination (\u2018worm wobble\u2019); drowsiness, nystagmus, vertigo,\r\nblurred vision, confusion and clonic contractions in patients with\r\nneurological or renal abnormalities", "hepatic impairment": "manufacturer advises avoid", "doses": ["threadworms, stirred into milk or water,adultandchildover\r\n6 years, content of 1 sachet as a single dose (bedtime in adults or\r\nmorning in children), repeated after 14 days;infant3 months\u20131 year, 1 level 2.5-mL spoonful in the morning, repeated\r\nafter 14 days;child1\u20136 years, 1 level\r\n5-mL spoonful in the morning, repeated after 14 days"], "pregnancy": "not known to be harmful but manufacturer advises\r\navoid in first trimester", "breast-feeding": "present in milk\u2014manufacturer advises avoid breast-feeding\r\nfor 8 hours after dose (express and discard milk during this time)"}, "ANTIPSYCHOTICS": {"interactions": {"extra": "Increased risk of toxicity with myelosuppressive drugs", "bad": 0, "interaction": "effects of  pergolide antagonised by antipsychotics ", "name": "Antipsychotics", "backrefs": ["Apomorphine", "Atomoxetine", "Pramipexole", "Antiepileptics", "Antipsychotics", "Amantadine", "Anti-arrhythmics", "Sodium Oxybate"]}}, "MUPIROCIN": {"indications": "bacterial skin infections (see alsonotes above)", "name": "MUPIROCIN", "renal impairment": "manufacturer advises caution whenBactroban\u00ae ointment used in moderate or severe impairment because it contains\r\nmacrogols (polyethylene glycol)", "side-effects": "local reactions including urticaria, pruritus,\r\nburning sensation, rash", "doses": ["adultandchildover 1 year, apply up to 3 times daily for\r\nup to 10 days;childunder 1 year seeBNF for Children"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "no information available"}, "RITONAVIR": {"indications": "HIV infection in combination with other antiretroviral drugs; low\r\ndoses used to increase effect of some protease inhibitors", "name": "RITONAVIR", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  docetaxel possibly increased by ritonavir (increased risk of toxicity)", "name": "Ritonavir", "backrefs": ["Ritonavir", "Docetaxel", "Ulipristal", "Bosentan", "Tadalafil", "Zolpidem", "Solifenacin", "Prednisolone", "Pimozide", "Apixaban", "Propafenone", "Dronedarone", "Quinine", "Atorvastatin", "Diazepam", "Tacrolimus", "Quetiapine", "Alprazolam", "Buprenorphine", "Eplerenone", "Fesoterodine", "Corticosteroids", "Colchicine", "Fluticasone", "Rosuvastatin", "Dextropropoxyphene", "Paroxetine", "Pethidine", "Lamotrigine", "Dexamfetamine", "Eletriptan", "Saquinavir", "Vinflunine", "Vardenafil", "Morphine", "Azithromycin", "Piroxicam", "Buspirone", "Ivabradine", "Flecainide", "Alfentanil", "Ranolazine", "Telithromycin", "Voriconazole", "Artemether with Lumefantrine", "Midazolam", "Flurazepam", "Pazopanib", "Ergotamine and Methysergide", "Nilotinib", "Tolbutamide", "Alfuzosin", "Rivaroxaban", "Maraviroc", "Trazodone", "Budesonide", "Calcium-channel Blockers", "Phenindione", "Anxiolytics and Hypnotics", "Aprepitant", "Fentanyl", "Digoxin", "Antihistamines, Non-sedating", "Dexamethasone", "Sildenafil", "Fusidic Acid", "Tolterodine", "Lercanidipine", "Cabazitaxel", "Everolimus", "Vinblastine", "Simvastatin", "Darifenacin", "Coumarins", "Ticagrelor", "Paclitaxel", "Bupropion"]}, "cautions": "seenotes above; concomitant use with drugs that prolong PR interval; cardiac conduction disorders, structural heart disease; pancreatitis (see below);interactions:Appendix 1 (ritonavir)", "side-effects": "see notes and Cautions above; also diarrhoea (may\r\nimpair absorption\u2014close monitoring required), vasodilatation, cough,\r\nthroat irritation, anxiety, perioral and peripheral paraesthesia,\r\nhyperaesthesia, fever, decreased blood thyroxine concentration, electrolyte\r\ndisturbances, raised uric acid, dry mouth, mouth ulcers, and sweating;less commonlyincreased prothrombin time and dehydration;\r\nsyncope, postural hypotension, seizures, menorrhagia, and renal failure\r\nalso reported", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\navoid in decompensated liver disease; in severe impairment without\r\ndecompensation, use \u2018booster\u2019 doses with caution (avoid treatment\r\ndoses)", "doses": ["Initially 300\u00a0mg every 12 hours for 3 days, increased\r\nin steps of 100\u00a0mg every 12 hours over not longer than 14 days to\r\n600\u00a0mg every 12 hours;childover 2\r\nyears initially 250\u00a0mg/m2every 12 hours, increased by\r\n50\u00a0mg/m2at intervals of 2\u20133 days to 350\u00a0mg/m2every 12 hours (max. 600\u00a0mg every 12 hours)"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "seeBreast-feeding"}, "INDINAVIR": {"indications": "HIV infection in combination with nucleoside reverse transcriptase\r\ninhibitors", "name": "INDINAVIR", "renal impairment": "use with caution; monitor for nephrolithiasis", "interactions": {"extra": "", "bad": 0, "interaction": " nevirapine reduces plasma concentration of indinavir ", "name": "Indinavir", "backrefs": ["Indinavir"]}, "cautions": "seenotes above; also ensure adequate hydration (risk of nephrolithiasis especially in\r\nchildren); patients at risk of nephrolithiasis\r\n(monitor for nephrolithiasis); patients\r\nat high risk of cardiovascular disease (especially if 10-year cardiovascular\r\nrisk greater than 20%);interactions:Appendix 1 (indinavir)", "side-effects": "see notes above; also reported, dry mouth, hypoaesthesia,\r\ndry skin, hyperpigmentation, alopecia, paronychia, interstitial nephritis\r\n(with medullary calcification and cortical atrophy in asymptomatic\r\nsevere leucocyturia), nephrolithiasis (may require interruption or\r\ndiscontinuation; more frequent in children), dysuria, haematuria,\r\ncrystalluria, proteinuria, pyuria (in children), pyelonephritis; haemolytic\r\nanaemia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\nincreased risk of nephrolithiasis; reduce dose in mild to moderate\r\nimpairment; not studied in severe impairment", "doses": ["adultover 18 years, seek\r\nspecialist advice"], "pregnancy": "toxicity inanimalstudies; manufacturer\r\nadvises use only if potential benefit outweighs risk; theoretical\r\nrisk of hyperbilirubinaemia and renal stones in neonate if used at\r\nterm", "breast-feeding": "seeBreast-feeding"}, "CYCLIZINE": {"indications": "nausea, vomiting, vertigo, motion sickness, labyrinthine\r\ndisorders", "name": "CYCLIZINE", "cautions": "section 3.4.1; severe heart failure; may counteract haemodynamic\r\nbenefits of opioids;interactions:Appendix 1 (antihistamines)", "side-effects": "section 3.4.1; also\r\nhypertension, paraesthesia, and twitching", "contra-indications": "section 3.4.1", "hepatic impairment": "section 3.4.1", "doses": ["By mouth,cyclizinehydrochloride\r\n50\u00a0mg up to 3 times daily;child6\u201312\r\nyears 25\u00a0mg up to 3 times daily", "For motion sickness, take 1\u20132 hours before\r\ndeparture", "By intramuscularorintravenous\r\ninjection,cyclizinelactate 50\u00a0mg 3 times\r\ndaily"], "pregnancy": "section 3.4.1", "breast-feeding": "no information available"}, "OXCARBAZEPINE": {"indications": "seenotes above", "name": "OXCARBAZEPINE", "renal impairment": "halve initial dose if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; increase according to response at intervals of at least\r\n1 week", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  imatinib reduced by oxcarbazepine\u2014avoid concomitant use", "name": "Oxcarbazepine", "backrefs": ["Oxcarbazepine"]}, "cautions": "hypersensitivity tocarbamazepine(see alsoAntiepileptic Hypersensitivity\r\nSyndrome); avoid abrupt withdrawal; hyponatraemia (monitor plasma-sodium concentration in patients at risk), heart failure (monitor body-weight), cardiac conduction disorders; avoid in acute\r\nporphyria (section 9.8.2);interactions:seeInteractionsin section\r\n4.8.1 and Appendix 1 (oxcarbazepine)", "side-effects": "nausea, vomiting, constipation, diarrhoea, abdominal\r\npain; dizziness, headache, drowsiness, agitation, amnesia, asthenia,\r\nataxia, confusion, impaired concentration, depression, tremor; hyponatraemia;\r\nacne, alopecia, rash, nystagmus, visual disorders including diplopia;less commonlyurticaria, leucopenia;very rarelyhepatitis, pancreatitis, arrhythmias, blood disorders, multi-organ\r\nhypersensitivity  (see alsoAntiepileptic Hypersensitivity\r\nSyndrome),\r\nsystemic lupus erythematosus, Stevens-Johnson syndrome, and toxic\r\nepidermal necrolysis; hypertension and hypothyroidism also reported;\r\nsuicidal ideation", "hepatic impairment": "caution in severe impairment\u2014no information available", "doses": ["Initially 300\u00a0mg twice daily increased according to response\r\nin steps of up to 600\u00a0mg daily at weekly intervals; usual dose range\r\n0.6\u20132.4\u00a0g daily in divided doses;child6\u201318 years, 8\u201310\u00a0mg/kg daily in 2 divided doses increased according\r\nto response in steps of up to 10\u00a0mg/kg daily at weekly intervals (in\r\nadjunctive therapy, maintenance dose approx. 30\u00a0mg/kg daily); max.\r\n46\u00a0mg/kg daily in divided doses", "In adjunctive therapy, the dose\r\nof concomitant antiepileptics may need to be reduced when using high\r\ndoses ofoxcarbazepine"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "CIDOFOVIR": {"indications": "cytomegalovirus retinitis in AIDS patients for whom other drugs are\r\ninappropriate", "name": "CIDOFOVIR", "renal impairment": "avoid if creatinine clearance less than 55\u00a0mL/minute;\r\nnephrotoxic", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturers advise avoid concomitant use of  tenofovir with cidofovir ", "name": "Cidofovir", "backrefs": ["Cidofovir"]}, "cautions": "monitor renal function (serum creatinine\r\nand urinary protein) and neutrophil count within 24 hours before each\r\ndose; co-treatment withprobenecidand prior hydration with intravenous fluids necessary to minimise\r\npotential nephrotoxicity (see below); diabetes\r\nmellitus (increased risk of ocular hypotony);interactions:Appendix 1 (cidofovir)", "side-effects": "nephrotoxicity (see Cautions above); nausea, vomiting,\r\ndiarrhoea; dyspnoea; headache, fever, asthenia; neutropenia;\r\ndecreased intra-ocular pressure, iritis, uveitis (see Cautions above);\r\nalopecia, rash;less commonlyFanconi syndrome; also\r\nreported, hearing impairment and pancreatitis", "contra-indications": "concomitant administration of\r\npotentially nephrotoxic drugs (discontinue\r\npotentially nephrotoxic drugs at least 7 days before startingcidofovir)", "doses": ["Initial (induction) treatment,adultover 18 years,by intravenous infusionover 1 hour,\r\n5\u00a0mg/kg once weekly for 2 weeks (giveprobenecidand intravenous fluids with each dose, see below)", "Maintenance treatment, beginning 2 weeks after completion of\r\ninduction,adultover 18 years,by intravenous infusionover 1 hour, 5\u00a0mg/kg once every 2\r\nweeks (giveprobenecidand intravenous fluids with\r\neach dose, see below)", "By mouth(preferably after food),probenecid2\u00a0g 3 hours beforecidofovirinfusion followed\r\nbyprobenecid1\u00a0g at 2 hours and 1\u00a0g at 8 hours\r\nafter the end ofcidofovirinfusion (totalprobenecid4\u00a0g); for cautions, contra-indications and side-effects\r\nofprobenecidseesection 10.1.4", "Sodium chloride0.9%,by intravenous infusion, 1\u00a0litre over 1 hour\r\nimmediately beforecidofovirinfusion (if tolerated\r\nan additional 1\u00a0litre may be given over 1\u20133 hours, starting at the\r\nsame time as thecidofovirinfusion or immediately\r\nafterwards)"], "pregnancy": "avoid (toxicity inanimalstudies);\r\neffective contraception required during and for 1 month after treatment;\r\nalso men should avoid fathering a child during and for 3 months after\r\ntreatment", "breast-feeding": "manufacturer advises avoid"}, "GUANETHIDINE": {"interactions": {"extra": "", "bad": 1, "interaction": " dexamfetamine antagonises hypotensive effect of guanethidine ", "name": "Guanethidine", "backrefs": ["Guanethidine"]}}, "TETRACAINE": {"indications": "see under preparation; eye (section 11.7)", "name": "TETRACAINE", "cautions": "seeCautions of Local Anaesthetics", "side-effects": "seeToxicity and Side-effects", "contra-indications": "seeContra-indications of Local\r\nAnaesthetics", "doses": ["adultandchildover 1 month, apply contents of tube to site\r\nof venepuncture or venous cannulation and cover with occlusive dressing;\r\nremove gel and dressing after 30 minutes for venepuncture and after\r\n45 minutes for venous cannulation;neonateseeBNF for Children", "adultandchildover 5 years, contents of max. 5\u00a0tubes applied\r\nat separate sites at a single time;child1 month\u20135 years, contents of max. 1\u00a0tube applied at separate sites\r\nat a single time"], "breast-feeding": "not known to be harmful"}, "CLEMASTINE": {"indications": "symptomatic relief of allergy such as hay fever, urticaria", "name": "CLEMASTINE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["1\u00a0mg twice daily, increased up to 6\u00a0mg daily if required;child1\u20133 years 250\u2013500\u00a0micrograms twice daily; 3\u20136\r\nyears 500\u00a0micrograms twice daily; 6\u201312 years 0.5\u20131\u00a0mg twice daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "SOMATROPIN": {"indications": "see under Dose", "name": "SOMATROPIN", "interactions": {"extra": "", "bad": 0, "interaction": " corticosteroids may inhibit growth-promoting effect of somatropin ", "name": "Somatropin", "backrefs": ["Somatropin"]}, "cautions": "diabetes mellitus (adjustment of antidiabetic\r\ntherapy may be necessary), papilloedema (see under Side-effects), relative deficiencies of\r\nother pituitary hormones (notably hypothyroidism\u2014manufacturers recommend periodic thyroid function tests but limited\r\nevidence of clinical value), history of malignant disease, disorders of the epiphysis of the hip (monitor for\r\nlimping), resolved intracranial hypertension\r\n(monitor closely), initiation of treatment\r\nclose to puberty not recommended in child born small for gestational\r\nage; Silver-Russell syndrome; rotate subcutaneous injection sites to prevent lipoatrophy;interactions:Appendix 1 (somatropin)", "side-effects": "headache, funduscopy for papilloedema recommended\r\nif severe or recurrent  headache, visual problems, nausea and vomiting\r\noccur\u2014if papilloedema confirmed consider benign intracranial hypertension\r\n(rare cases reported); fluid retention (peripheral oedema), arthralgia,\r\nmyalgia, carpal tunnel syndrome, paraesthesia, antibody formation,\r\nhypothyroidism, insulin resistance, hyperglycaemia, hypoglycaemia,\r\nreactions at injection site; leukaemia in children with growth hormone\r\ndeficiency also reported", "contra-indications": "evidence of tumour activity (complete\r\nantitumour therapy and ensure intracranial lesions inactive before\r\nstarting); not to be used after renal transplantation or for growth promotion in children with closed epiphyses (or near\r\nclosure in Prader-Willi syndrome); severe obesity or severe\r\nrespiratory impairment in Prader-Willi syndrome", "doses": ["Gonadal dysgenesis (Turner syndrome),by subcutaneous\r\ninjection, 45\u201350\u00a0micrograms/kg dailyor1.4\u00a0mg/m2daily", "Deficiency of growth hormone in children,by subcutaneousorintramuscular injection, 23\u201339\u00a0micrograms/kg\r\ndailyor0.7\u20131\u00a0mg/m2daily", "Growth disturbance in short children born small for gestational\r\nage whose growth has not caught up by 4 years or later,by\r\nsubcutaneous injection, 35\u00a0micrograms/kg daily or 1\u00a0mg/m2daily", "Prader-Willi syndrome,by subcutaneous injectionin children with growth velocity greater than 1\u00a0cm/year, in combination\r\nwith energy-restricted diet, 35\u00a0micrograms/kg dailyor1\u00a0mg/m2daily; max. 2.7\u00a0mg daily", "Chronic renal insufficiency in children (renal function decreased\r\nto less than 50%),by subcutaneous injection, 45\u201350\u00a0micrograms/kg\r\ndailyor1.4\u00a0mg/m2daily (higher doses\r\nmay be needed) adjusted if necessary after 6 months", "Adult growth hormone deficiency,by subcutaneous injection, initially 150\u2013300\u00a0micrograms daily, gradually increased if required\r\nto max. 1\u00a0mg daily; use minimum effective dose (requirements may decrease\r\nwith age)", "SHOX deficiency in children,by subcutaneous injection, 45\u201350\u00a0micrograms/kg daily", "Dose formerly expressed in units;somatropin1\u00a0mg \u2261 3\u00a0units"], "pregnancy": "discontinue if pregnancy occurs\u2014no information available", "breast-feeding": "no information available"}, "SEVELAMER CARBONATE": {"indications": "hyperphosphataemia in patients on haemodialysis\r\nor peritoneal dialysis, and patients with chronic kidney disease not\r\non dialysis who have a serum-phosphate concentration of 1.78\u00a0mmol/litre\r\nor more", "name": "SEVELAMER CARBONATE", "cautions": "gastro-intestinal disorders;interactions:Appendix 1 (sevelamer)", "side-effects": "nausea, vomiting, abdominal pain, constipation,\r\ndiarrhoea, dyspepsia, flatulence;also reportedintestinal\r\nobstruction and perforation, ileus, pruritus, rash", "contra-indications": "bowel obstruction", "doses": ["adultover 18 years, initially\r\n2.4\u20134.8\u00a0g daily in 3 divided doses with meals, adjusted according\r\nto serum-phosphate concentration every 2\u20134 weeks (usual dose approx.\r\n6\u00a0g daily in 3 divided doses)"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "unlikely to be present in milk (however, manufacturer\r\nadvises avoid)"}, "BUDESONIDE": {"indications": "prophylaxis and treatment of allergic\r\nand vasomotor rhinitis; nasal polyps", "name": "BUDESONIDE", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir increases plasma concentration of inhaled and intranasal budesonide ", "name": "Budesonide", "backrefs": ["Budesonide"]}, "cautions": "seenotes above;interactions:Appendix 1 (corticosteroids)", "side-effects": "seenotes above", "doses": ["rhinitis,adultandchildover 12 years, 200\u00a0micrograms (2 sprays) into\r\neach nostril once daily in the morningor100\u00a0micrograms\r\n(1 spray) into each nostril twice daily; when control achieved reduce\r\nto 100\u00a0micrograms (1 spray) into each nostril once daily"]}, "DAUNORUBICIN": {"indications": "seenotes above", "name": "DAUNORUBICIN", "renal impairment": "reduce dose by 25% if serum creatinine 105\u2013265\u00a0micromol/litre\r\nand by 50% if serum creatinine greater than 265\u00a0micromol/litre; avoid\r\nin severe impairment", "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant to tissues", "side-effects": "seesection 8.1andnotes above", "contra-indications": "myocardial insufficiency, recent myocardial infarction, severe arrhythmia; previous treatment with\r\nmaximum cumulative doses of daunorubicin or other anthracycline", "hepatic impairment": "reduce dose according to serum bilirubin concentration\u2014consult\r\nlocal protocol for details; avoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and carcinogenic inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "MEPTAZINOL": {"indications": "moderate to severe pain, including postoperative and obstetric pain\r\nand renal colic; peri-operative analgesia,section 15.1.4.3", "name": "MEPTAZINOL", "renal impairment": "seenotes above", "cautions": "seenotes above; effects only partially reversed by naloxone", "side-effects": "seenotes above; can induce\r\nwithdrawal symptoms in patients dependent on opioids; also diarrhoea,\r\nabdominal pain, dyspepsia, and hypothermia", "contra-indications": "seenotes above; also myocardial infarction; phaeochromocytoma", "hepatic impairment": "seenotes above", "doses": ["By mouth, 200\u00a0mg every 3\u20136 hours as required;childnot recommended", "By intramuscular injection, 75\u2013100\u00a0mg every 2\u20134\r\nhours if necessary; obstetric analgesia, 100\u2013150\u00a0mg according to patient\u2019s\r\nweight (2\u00a0mg/kg);childnot recommended", "By slow intravenous injection, 50\u2013100\u00a0mg every\r\n2\u20134 hours if necessary;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "use only if potential benefit outweighs risk"}, "SODIUM CROMOGLICATE": {"side-effects": "local irritation;rarelytransient\r\nbronchospasm", "indications": "prophylaxis of allergic rhinitis", "name": "SODIUM CROMOGLICATE", "doses": ["adultandchild, 1 spray into each nostril 2\u20134 times daily"]}, "CORIFOLLITROPIN ALFA": {"indications": "controlled ovarian stimulation in combination\r\nwith a gonadotrophin-releasing hormone antagonist", "name": "CORIFOLLITROPIN ALFA", "renal impairment": "avoid", "cautions": "risk factors for thromboembolism; risk of ovarian hyperstimulation syndrome; acute porphyria (section 9.8.2)", "side-effects": "nausea; headache, fatigue; ovarian hyperstimulation,\r\npelvic pain, breast pain;less commonlyvomiting,\r\nabdominal distension and pain, diarrhoea, constipation, dizziness,\r\novarian torsion;also reportedectopic pregnancy,\r\nmiscarriage, and multiple pregnancies", "contra-indications": "ovarian enlargement or cyst; polycystic ovarian syndrome; tumours of hypothalamus, pituitary,\r\novaries, uterus, or breast; vaginal bleeding of unknown\r\ncause; history of ovarian hyperstimulation\r\nsyndrome", "doses": ["By subcutaneous injection, body-weight\r\nunder 60\u00a0kg, 100\u00a0micrograms; body-weight over 60\u00a0kg, 150\u00a0micrograms"], "breast-feeding": "avoid"}, "ENTECAVIR": {"indications": "chronic hepatitis B infectioneitherwith compensated\r\nliver disease (with evidence of viral replication, and histologically\r\ndocumented active liver inflammation or fibrosis)ordecompensated liver disease", "name": "ENTECAVIR", "renal impairment": "reduce dose if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2; consult product literature", "cautions": "monitor liver function tests every 3\r\nmonths, and viral markers for hepatitis B every 3\u20136 months during\r\ntreatment (continue monitoring for at least 1 year after discontinuation\u2014recurrent\r\nhepatitis may occur on discontinuation); HIV infection\u2014risk of HIV resistance in patients not receiving \u2018highly\r\nactive antiretroviral therapy\u2019; lamivudine-resistant\r\nchronic hepatitis B\u2014risk of entecavir resistance; discontinue if deterioration in liver function, hepatic steatosis,\r\nprogressive hepatomegaly or unexplained lactic acidosis", "side-effects": "nausea, vomiting, dyspepsia, diarrhoea, raised\r\nserum amylase and lipase, headache, fatigue, dizziness, sleep disturbances;less commonlythrombocytopenia, rash, alopecia", "doses": ["Compensated liver disease not previously treated with\r\nnucleoside analogues,adultover 18\r\nyears, 500\u00a0micrograms once daily", "Compensated liver disease with lamivudine-resistant chronic\r\nhepatitis B (but see notes above),adultover 18 years, 1\u00a0mg once daily; consider other treatment if inadequate\r\nresponse after 6 months", "To be taken at least 2 hours before\r\nor 2 hours after food", "Decompensated liver disease,adultover 18 years, 1\u00a0mg once daily", "To be taken at least 2 hours before\r\nor 2 hours after food"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises use only if potential benefit outweighs risk; effective contraception\r\nrequired during treatment", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "ZIDOVUDINE": {"indications": "HIV infection in combination with other antiretroviral drugs; prevention\r\nof maternal-fetal HIV transmission (see notes above under Pregnancy\r\nand Breast-feeding)", "name": "ZIDOVUDINE", "renal impairment": "reduce oral dose to 300\u2013400\u00a0mg daily in divided doses\r\nor intravenous dose to 1\u00a0mg/kg 3\u20134 times daily if eGFR is less than\r\n10\u00a0mL/minute/1.73\u00a0m2; avoidCombivir\u00ae if eGFR less than 50\u00a0mL/minute/1.73m2(consult product\r\nliterature)", "interactions": {"extra": "Increased risk of toxicity with nephrotoxic and myelosuppressive drugs\u2014for further details consult product literature", "bad": 1, "interaction": " probenecid reduces excretion of zidovudine (increased plasma concentration and risk of toxicity)", "name": "Zidovudine", "backrefs": ["Zidovudine", "Atovaquone"]}, "cautions": "seenotes above; also haematological toxicity particularly with high dose and advanced\r\ndisease\u2014monitor full blood count after 4 weeks of treatment, then\r\nevery 3 months; vitamin B12deficiency\r\n(increased risk of neutropenia); if anaemia or myelosuppression\r\noccur, reduce dose or interrupt treatment according to product literature,\r\nor consider other treatment; elderly;interactions:Appendix 1 (zidovudine)", "side-effects": "see notes above; also anaemia (may require transfusion),\r\ntaste disturbance, chest pain, influenza-like symptoms, paraesthesia,\r\nneuropathy, convulsions, dizziness, drowsiness, anxiety, depression,\r\nloss of mental acuity, myopathy, gynaecomastia, urinary frequency,\r\nsweating, pruritus, pigmentation of nails, skin and oral mucosa", "contra-indications": "abnormally low neutrophil\r\ncounts or haemoglobin concentration (consult product literature); neonates with hyperbilirubinaemia requiring treatment\r\nother than phototherapy, or with raised transaminase (consult product\r\nliterature); acute porphyria (section 9.8.2)", "hepatic impairment": "seenotes above; also\r\naccumulation may occur", "doses": ["1 tablet twice daily;childbody-weight over 14\u00a0kg seeBNF for\r\nChildren"], "pregnancy": "limited information available; manufacturer advises\r\nuse only if clearly indicated; see alsoPregnancy", "breast-feeding": "seeBreast-feeding"}, "SYMPATHOMIMETICS": {"interactions": {"extra": "", "bad": 0, "interaction": "increased risk of hypertension when  doxapram given with sympathomimetics ", "name": "Sympathomimetics", "backrefs": ["Parasympathomimetics", "Sympathomimetics, Beta2", "Sympathomimetics"]}}, "TIMOLOL MALEATE": {"indications": "see under Dose; glaucoma (section 11.6)", "name": "TIMOLOL MALEATE", "renal impairment": "manufacturer advises caution\u2014dose reduction may be required", "cautions": "see underPropranolol Hydrochloride", "side-effects": "see underPropranolol Hydrochloride", "contra-indications": "see underPropranolol Hydrochloride", "hepatic impairment": "dose reduction may be necessary", "doses": ["hypertension, 1\u20132 tablets daily; max. 4 daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CORTICOSTEROIDS": {"indications": "oral and perioral lesions", "name": "CORTICOSTEROIDS", "interactions": {"extra": "Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of corticosteroids ", "name": "Corticosteroids", "backrefs": ["Vecuronium", "Corticosteroids", "Somatropin", "Mifepristone", "Antidiabetics", "Sympathomimetics, Beta2", "Pancuronium", "Calcium Salts"]}, "side-effects": "occasional exacerbation of local infection; thrush\r\nor other candidal infections", "contra-indications": "untreated oral infection", "doses": ["adultandchildover 12 years, 1 lozenge 4 times daily, allowed\r\nto dissolve slowly in the mouth in contact with the ulcer;childunder 12 years, only on medical advice"]}, "DARUNAVIR": {"indications": "HIV infection in combination with other\r\nantiretroviral drugs", "name": "DARUNAVIR", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of both drugs increased when  ketoconazole given with darunavir ", "name": "Darunavir", "backrefs": ["Darunavir"]}, "cautions": "seenotes above; also sulfonamide\r\nsensitivity; monitor liver function before\r\nand during treatment;interactions:Appendix 1 (darunavir)", "side-effects": "seenotes above; also haematemesis, myocardial\r\ninfarction, angina, QT interval prolongation, syncope, bradycardia,\r\ntachycardia, palpitation, hypertension, flushing, peripheral oedema,\r\ndyspnoea, cough, peripheral neuropathy, anxiety, confusion, memory\r\nimpairment, depression, abnormal dreams, convulsions, increased appetite,\r\nweight changes, pyrexia, hypothyroidism, osteoporosis, gynaecomastia,\r\nerectile dysfunction, reduced libido, dysuria, polyuria, nephrolithiasis,\r\nrenal failure, arthralgia, visual disturbances, dry eyes, conjunctival\r\nhyperaemia, rhinorrheoa, throat irritation, dry mouth, stomatisis,\r\nnail discoloration, acne, seborrhoeic dermatitis, eczema, increased\r\nsweating, alopecia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\nmanufacturer advises caution in mild to moderate impairment; avoid\r\nin severe impairment\u2014no information available", "doses": ["With low-dose ritonavir,adultover 18 years previously treated with antiretroviral therapy, 600\u00a0mg\r\ntwice dailyor(if no resistance to darunavir, if\r\nplasma HIV-RNA concentration less than 100 000 copies/mL, and if CD4\r\ncell count greater than 100 cells \u00d7106/litre)\r\n800\u00a0mg once daily;child6\u201318 years\r\nseeBNF for Children", "With low-dose ritonavir,adultover 18 years not previously treated with antiretroviral therapy,\r\n800\u00a0mg once daily", "If a dose is more than\r\n6 hours late on the twice daily regimen (or more than 12 hours late\r\non the once daily regimen), the missed dose should not be taken and\r\nthe next dose should be taken at the normal time"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "seeBreast-feeding"}, "SODIUM NITROPRUSSIDE": {"indications": "hypertensive emergencies (seesection 2.5); controlled\r\nhypotension in anaesthesia; acute or chronic heart failure", "name": "SODIUM NITROPRUSSIDE", "renal impairment": "avoid prolonged use\u2014cyanide or thiocyanate metabolites\r\nmay accumulate", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  alpha-blockers given with sodium nitroprusside ", "name": "Sodium Nitroprusside", "backrefs": ["Sodium Nitroprusside"]}, "cautions": "hypothyroidism, hyponatraemia, ischaemic heart disease, impaired cerebral circulation, elderly; hypothermia; monitor\r\nblood pressure (including intra-arterial blood pressure) and blood-cyanide concentration, and if treatment exceeds 3 days,\r\nalso blood-thiocyanate concentration; avoid sudden withdrawal\u2014terminate\r\ninfusion over 15\u201330 minutes; protect infusion\r\nfrom light;interactions:Appendix\r\n1 (sodium nitroprusside)", "side-effects": "associated with over rapid reduction in blood\r\npressure (reduce infusion rate): headache, dizziness, nausea, retching,\r\nabdominal pain, perspiration, palpitation, anxiety, retrosternal discomfort;\r\noccasionally reduced platelet count, acute transient phlebitis", "contra-indications": "severe vitamin B12deficiency; Leber\u2019s optic atrophy; compensatory hypertension", "hepatic impairment": "use with caution; avoid in hepatic failure\u2014cyanide\r\nor thiocyanate metabolites may accumulate", "doses": ["Hypertensive emergencies,by intravenous infusion, initially 0.5\u20131.5\u00a0micrograms/kg/minute, then increased in steps\r\nof 500\u00a0nanograms/kg/minute every 5 minutes within range 0.5\u20138\u00a0micrograms/kg/minute\r\n(lower doses if already receiving other antihypertensives); stop if\r\nresponse unsatisfactory with max. dose in 10 minutes", "Lower initial dose of 300\u00a0nanograms/kg/minute\r\nhas been used", "Maintenance of blood pressure at 30\u201340% lower than pretreatment\r\ndiastolic blood pressure, 20\u2013400\u00a0micrograms/minute (lower doses for\r\npatients being treated with other antihypertensives)", "Controlled hypotension in surgery,by intravenous infusion, max. 1.5\u00a0micrograms/kg/minute", "Heart failure,by intravenous infusion, initially\r\n10\u201315\u00a0micrograms/minute, increased every 5\u201310 minutes as necessary;\r\nusual range 10\u2013200\u00a0micrograms/minute normally for max. 3 days"], "pregnancy": "avoid prolonged use\u2014potential for accumulation of\r\ncyanide in fetus", "breast-feeding": "no information available; caution advised due\r\nto thiocyanate metabolite"}, "MEBENDAZOLE": {"indications": "threadworm, roundworm, whipworm, and hookworm infections", "name": "MEBENDAZOLE", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine possibly inhibits metabolism of mebendazole (increased plasma concentration)", "name": "Mebendazole", "backrefs": ["Mebendazole"]}, "cautions": "interactions:Appendix 1 (mebendazole)", "side-effects": "abdominal pain;less commonlydiarrhoea, flatulence;rarelyhepatitis,\r\nconvulsions, dizziness, neutropenia, urticaria, alopecia, rash (including\r\nStevens-Johnson syndrome and toxic epidermal necrolysis)", "doses": ["Threadworms,adultandchildover 2 years, 100\u00a0mg as a single dose; if reinfection\r\noccurs second dose may be needed after 2 weeks;childunder 2 years, seeBNF for Children", "Whipworms,adultandchildover 2 years, 100\u00a0mg twice daily for 3 days;childunder 2 years, seeBNF for Children", "Roundworms\u2014section\r\n5.5.2", "Hookworms\u2014section 5.5.4"], "pregnancy": "manufacturer advises toxicity inanimalstudies", "breast-feeding": "amount too small to be harmful but manufacturer\r\nadvises avoid"}, "CIMETIDINE": {"indications": "benign gastric and duodenal ulceration, stomal ulcer, reflux oesophagitis,\r\nother conditions where gastric acid reduction is beneficial (see notes\r\nabove andsection\r\n1.9.4)", "name": "CIMETIDINE", "renal impairment": "reduce dose; 200\u00a0mg 4 times daily if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; 200\u00a0mg 3 times daily if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2; 200\u00a0mg twice daily if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2; occasional risk of confusion", "interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  loratadine advises plasma concentration possibly increased by cimetidine ", "name": "Cimetidine", "backrefs": ["Nortriptyline", "Mebendazole", "Melatonin", "Labetalol", "Zaleplon", "Clomethiazole", "Carmustine", "Fampridine", "Cimetidine", "Fluorouracil", "Roflumilast", "Lomustine", "Zolmitriptan", "Doxepin"]}, "cautions": "seenotes above;interactions:Appendix 1 (histamine H2-antagonists)\r\nand notes above", "side-effects": "see notes above; also malaise;less commonlytachycardia;rarelyinterstitial nephritis;very rarelypancreatitis, galactorrhoea, vasculitis, alopecia", "hepatic impairment": "increased risk of confusion; reduce dose", "doses": ["400\u00a0mg twice daily (with breakfast and at night)or800\u00a0mg at night (benign gastric and duodenal ulceration)\r\nfor at least 4 weeks (6 weeks in gastric ulceration, 8 weeks in NSAID-associated\r\nulceration); when necessary the dose may be increased to 400\u00a0mg 4\r\ntimes daily;infantunder 1 year 20\u00a0mg/kg\r\ndaily in divided doses has been used;child1\u201312 years, 25\u201330\u00a0mg/kg daily in divided doses; max. 400\u00a0mg 4 times\r\ndaily", "Maintenance, 400\u00a0mg at nightor400\u00a0mg morning\r\nand night", "Reflux oesophagitis, 400\u00a0mg 4 times daily for 4\u20138 weeks", "Prophylaxis of stress ulceration, 200\u2013400\u00a0mg every 4\u20136 hours", "Gastric acid reduction (prophylaxis of acid aspiration; do not\r\nuse syrup), obstetrics 400\u00a0mg at start of labour, then up to 400\u00a0mg\r\nevery 4 hours if required (max. 2.4\u00a0g daily); surgical procedures\r\n400\u00a0mg 90\u2013120 minutes before induction of general anaesthesia", "Short-bowel syndrome, 400\u00a0mg twice daily (with breakfast and\r\nat bedtime) adjusted according to response", "To reduce degradation of pancreatic enzyme supplements, 0.8\u20131.6\u00a0g\r\ndaily in 4 divided doses 1\u20131\u00bd hours before meals"], "pregnancy": "manufacturer advises avoid unless essential", "breast-feeding": "significant amount present in milk\u2014not known\r\nto be harmful but manufacturer advises avoid"}, "TRYPTOPHAN": {"indications": "see notes above", "name": "TRYPTOPHAN", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  duloxetine given with tryptophan ", "name": "Tryptophan", "backrefs": ["Tryptophan"]}, "cautions": "eosinophilia-myalgia syndrome has been\r\nreported (withhold treatment if increased eosinophil\r\ncount, myalgia, arthralgia, fever, dyspnoea, neuropathy, oedema or\r\nskin lesions develop until possibility of eosinophilia-myalgia syndrome\r\nexcluded);interactions:Appendix 1 (tryptophan)", "side-effects": "drowsiness, nausea, headache, light-headedness,\r\nsuicidal behaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy);\r\neosinophilia-myalgia syndrome, see Cautions", "contra-indications": "history of eosinophilia-myalgia\r\nsyndrome following use oftryptophan", "doses": ["1\u00a0g 3 times daily; max. 6\u00a0g daily;elderlylower dose may be appropriate especially in renal or hepatic impairment;childnot recommended"], "pregnancy": "no information available", "breast-feeding": "no information available"}, "PRAZOSIN": {"indications": "benign prostatic hyperplasia; hypertension, congestive\r\nheart failure and Raynaud\u2019s syndrome (section 2.5.4)", "name": "PRAZOSIN", "renal impairment": "section 2.5.4", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  digoxin increased by prazosin ", "name": "Prazosin", "backrefs": ["Prazosin"]}, "cautions": "seenotes aboveandsection 2.5.4", "side-effects": "seenotes aboveandsection 2.5.4", "contra-indications": "seenotes aboveandsection 2.5.4", "hepatic impairment": "section 2.5.4", "doses": ["Initially 500\u00a0micrograms twice daily for 3\u20137 days, subsequently\r\nadjusted according to response; usual maintenance (and max.) 2\u00a0mg\r\ntwice daily;elderlyinitiate with\r\nlowest possible dose", "First dose may\r\ncause collapse due to hypotensive effect (therefore should be taken\r\non retiring to bed). Patient should be\r\nwarned to lie down if symptoms such as dizziness, fatigue or sweating\r\ndevelop, and to remain lying down until they abate completely"]}, "REPAGLINIDE": {"indications": "type 2 diabetes mellitus (as monotherapy or in combination with metformin\r\nwhen metformin alone inadequate)", "name": "REPAGLINIDE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": " lanreotide possibly reduces requirements for repaglinide ", "name": "Repaglinide", "backrefs": ["Deferasirox", "Repaglinide"]}, "cautions": "substitute insulin during intercurrent\r\nillness (such as myocardial infarction, coma, infection,\r\nand trauma) and during surgery (omit repaglinide on morning of surgery\r\nand recommence when eating and drinking normally); debilitated\r\nand malnourished patients;interactions:Appendix 1 (antidiabetics)", "side-effects": "abdominal pain, diarrhoea, constipation, nausea,\r\nvomiting;rarelyhypoglycaemia, hypersensitivity\r\nreactions including pruritus, rashes, vasculitis, urticaria, and visual\r\ndisturbances", "contra-indications": "ketoacidosis", "hepatic impairment": "avoid in severe liver disease", "doses": ["adultover 18 years, initially\r\n500\u00a0micrograms within 30 minutes before main meals (1\u00a0mg if transferring\r\nfrom another oral hypoglycaemic), adjusted according to response at\r\nintervals of 1\u20132 weeks; up to 4\u00a0mg may be given as a single dose,\r\nmax. 16\u00a0mg daily;elderlyover 75 years,\r\nnot recommended"], "pregnancy": "avoid", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "GELATIN": {"indications": "low blood volume (but seenotes above)", "name": "GELATIN", "cautions": "seenotes above", "side-effects": "seenotes above", "hepatic impairment": "use with caution in severe impairment", "doses": ["By intravenous infusion, initially 500\u20131000\u00a0mL\r\nof a 3.5\u20134% solution (see notes above)"], "pregnancy": "manufacturer ofGeloplasma\u00ae advises\r\navoid at the end of pregnancy"}, "ABCIXIMAB": {"indications": "prevention of ischaemic cardiac complications in patients undergoing\r\npercutaneous coronary intervention; short-term prevention of myocardial\r\ninfarction in patients with unstable angina not responding to conventional\r\ntreatment and who are scheduled for percutaneous coronary intervention\r\n(use under specialist supervision)", "name": "ABCIXIMAB", "renal impairment": "caution in severe impairment\u2014increased risk of bleeding", "cautions": "measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time,\r\nplatelet count, haemoglobin and haematocrit; monitor haemoglobin and haematocrit 12 hours and 24 hours after start\r\nof treatment and platelet count 2\u20134 hours and 24 hours after start\r\nof treatment; concomitant use of drugs that increase\r\nrisk of bleeding; discontinue if uncontrollable\r\nserious bleeding occurs or emergency cardiac surgery needed; consult product literature for details of procedures to minimise\r\nbleeding; elderly", "side-effects": "bleeding manifestations; nausea, vomiting, hypotension,\r\nbradycardia, chest pain, back pain, headache, fever, puncture site\r\npain, thrombocytopenia;rarelycardiac tamponade,\r\nadult respiratory distress, hypersensitivity reactions", "contra-indications": "active internal bleeding; major surgery, intracranial\r\nor intraspinal surgery or trauma within last 2 months; stroke within last 2 years; intracranial neoplasm, arteriovenous malformation or aneurysm, severe hypertension, haemorrhagic diathesis, thrombocytopenia, vasculitis, hypertensive retinopathy", "hepatic impairment": "avoid in severe liver disease\u2014increased risk of bleeding", "doses": ["adultinitiallyby intravenous injectionover 1 minute, 250\u00a0micrograms/kg,\r\nthenby intravenous infusion, 125\u00a0nanograms/kg/minute\r\n(max. 10\u00a0micrograms/minute); for prevention of ischaemic complications\r\nstart 10\u201360 minutes before percutaneous coronary intervention and\r\ncontinue infusion for 12 hours; for unstable angina start up to 24\r\nhours before possible percutaneous coronary intervention and continue\r\ninfusion for 12 hours after intervention"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "LEVOFOLINIC ACID": {"indications": "seenotes above", "name": "LEVOFOLINIC ACID", "cautions": "seeFolinic acid", "side-effects": "seeFolinic acid", "contra-indications": "seeFolinic acid", "doses": ["Doses expressed as levofolinic acid", "Prevention ofmethotrexate-induced adverse\r\neffects, (usually started 12\u201324 hours after beginning ofmethotrexateinfusion),by intramuscular injection, orby intravenous injectionorby intravenous infusion, usually 7.5\u00a0mg\r\nevery 6 hours for 10 doses", "Suspectedmethotrexateoverdosage,by intravenous injectionorby intravenous\r\ninfusion(at a max. rate of 160\u00a0mg/minute), initial dose at\r\nleast 50% of the dose ofmethotrexate; consultpoisons information centresfor advice on continuing management", "Adjunct tofluorouracilin colorectal cancer,\r\nconsult product literature"], "pregnancy": "seeFolinic acid", "breast-feeding": "seeFolinic acid"}, "TRIENTINE": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of oral  iron reduced by trientine ", "name": "Trientine", "backrefs": ["Trientine"]}}, "RIVAROXABAN": {"indications": "seenotes above", "name": "RIVAROXABAN", "renal impairment": "use with caution if eGFR 15\u201329\u00a0mL/minute/1.73\u00a0m2or if eGFR 30\u201349\u00a0mL/minute/1.73\u00a0m2and concomitant use\r\nof drugs that increase plasma-rivaroxaban concentration (consult product\r\nliterature); avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of rivaroxaban\u2014manufacturer of rivaroxaban advises avoid concomitant use", "name": "Rivaroxaban", "backrefs": ["Rivaroxaban"]}, "cautions": "seenotes above; also bleeding disorders; concomitant use of drugs that increase risk of bleeding; severe hypertension; active or recent gastro-intestinal ulceration; vascular retinopathy; anaesthesia with postoperative indwelling epidural\r\ncatheter (risk of paralysis\u2014monitor neurological signs and wait at\r\nleast 18 hours after rivaroxaban dose before removing catheter and\r\ndo not give next dose until at least 6 hours after catheter removal); recent surgery;interactions: Appendix 1 (rivaroxaban)", "side-effects": "nausea; haemorrhage (seenotes above);less commonlyconstipation, diarrhoea, dyspepsia, dry mouth, vomiting, hypotension,\r\noedema, tachycardia, thrombocythaemia, syncope, dizziness, headache,\r\nrenal impairment, pain in extremities, pruritus, and rash; jaundice\r\nalso reported", "contra-indications": "active bleeding", "hepatic impairment": "manufacturer advises caution in cirrhotic patients\r\nwith moderate hepatic impairment; avoid in liver disease with coagulopathy", "doses": ["Prophylaxis of venous thromboembolism following knee replacement\r\nsurgery,adultover 18 years, 10\u00a0mg\r\nonce daily for 2 weeks starting 6\u201310 hours after surgery", "Prophylaxis of venous thromboembolism following hip replacement\r\nsurgery,adultover 18 years, 10\u00a0mg\r\nonce daily for 5 weeks starting 6\u201310 hours after surgery"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "AMISULPRIDE": {"indications": "schizophrenia", "name": "AMISULPRIDE", "renal impairment": "halve dose if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; use one-third dose if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2;\r\nno information available if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  levodopa advised by manufacturer of amisulpride (antagonism of effect)", "name": "Amisulpride", "backrefs": ["Amisulpride"]}, "cautions": "seenotes above", "side-effects": "seenotes above; also\r\ninsomnia, anxiety, agitation, drowsiness, gastro-intestinal disorders\r\nsuch as constipation, nausea, vomiting, and dry mouth;less\r\ncommonlybradycardia;rarelyseizures; urticaria\r\nalso reported", "contra-indications": "seenotes above; also prolactin-dependent tumours; pre-pubertal children", "doses": ["Acute psychotic episode, 400\u2013800\u00a0mg daily in 2 divided\r\ndoses, adjusted according to response; max. 1.2\u00a0g daily;childunder 18 years not recommended", "Predominantly negative symptoms, 50\u2013300\u00a0mg daily;childunder 18 years not recommended"], "pregnancy": "avoid", "breast-feeding": "avoid\u2014no information available"}, "BIPHASIC INSULIN LISPRO": {"indications": "diabetes mellitus", "name": "BIPHASIC INSULIN LISPRO", "renal impairment": "section 6.1.1", "cautions": "seesection 6.1.1.1andInsulin Lispro;interactions:Appendix 1 (antidiabetics)", "side-effects": "see underInsulin(section 6.1.1.1);\r\nprotamine may cause allergic reactions", "hepatic impairment": "section 6.1.1", "doses": ["By subcutaneous injection, up to 15 minutes\r\nbefore or soon after a meal, according to requirements"], "pregnancy": "section 6.1.1", "breast-feeding": "section 6.1.1"}, "TOLVAPTAN": {"indications": "see notes above", "name": "TOLVAPTAN", "renal impairment": "no information available in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole increases plasma concentration of tolvaptan ", "name": "Tolvaptan", "backrefs": ["Tolvaptan"]}, "cautions": "ensure adequate fluid intake (monitor\r\nfor dehydration in patients who are fluid-restricted); discontinue if rapid rise in serum sodium (greater\r\nthan 12\u00a0mmol/litre in 24 hours); diabetes\r\nmellitus; pseudohyponatraemia associated\r\nwith diabetes mellitus (exclude before treatment);interactions:Appendix 1 (tolvaptan)", "side-effects": "nausea, constipation, dry mouth; postural hypotension;\r\nthirst, decreased appetite, fever, asthenia; hyperglycaemia; urinary\r\nfrequency; hyperkalaemia, dehydration, ecchymosis, increased blood\r\ncreatinine; pruritus;less commonlytaste disturbance;also reportedhypernatraemia, hyperuricaemia, hypoglycaemia,\r\nsyncope, and dizziness", "contra-indications": "anuria; volume depletion; hypovolaemic hyponatraemia; hypernatraemia; impaired\r\nperception of thirst", "hepatic impairment": "use with caution in severe impairment\u2014no information\r\navailable", "doses": ["adultover 18 years, 15\u00a0mg\r\nonce daily, increased as required to max. 60\u00a0mg daily"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "CLOFARABINE": {"indications": "seenotes above", "name": "CLOFARABINE", "renal impairment": "manufacturer advises caution in mild to moderate impairment;\r\navoid in severe impairment", "cautions": "seesection 8.1andnotes above; cardiac disease", "side-effects": "seesection 8.1; also\r\ndiarrhoea, abdominal pain, jaundice; tachycardia, flushing, hypotension,\r\npericardial effusion, oedema, haematoma; dyspnoea, cough; anxiety,\r\nagitation, dizziness, drowsiness, headache, paraesthesia, peripheral\r\nneuropathy, restlessness; haematuria; arthralgia, myalgia; rash, pruritus,\r\nhand-foot (desquamative) syndrome, sweating; pancreatitis also reported", "hepatic impairment": "manufacturer advises caution in mild to moderate impairment;\r\navoid in severe impairment", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises avoid (teratogenic inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ZUCLOPENTHIXOL ACETATE": {"indications": "short-term management of acute psychosis, mania,\r\nor exacerbations of chronic psychosis", "name": "ZUCLOPENTHIXOL ACETATE", "renal impairment": "seenotes above", "cautions": "seenotes above; avoid\r\nin acute porphyria (section 9.8.2)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By deep intramuscular injectioninto the\r\ngluteal muscle or lateral thigh, 50\u2013150\u00a0mg (elderly50\u2013100\u00a0mg), repeated if necessary after 2\u20133 days (1\r\nadditional dose may be needed 1\u20132 days after the first injection);\r\nmax. cumulative dose 400\u00a0mg in 2 weeks and max. 4 injections; max.\r\nduration of treatment 2 weeks\u2014if maintenance treatment necessary change\r\nto an oral antipsychotic 2\u20133 days after last injection,orto a longer acting antipsychotic depot injection given concomitantly\r\nwith last injection ofzuclopenthixol acetate;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "PROCHLORPERAZINE": {"indications": "severe nausea, vomiting, vertigo, labyrinthine\r\ndisorders (see notes above); other indicationssection 4.2.1", "name": "PROCHLORPERAZINE", "renal impairment": "see notes insection 4.2.1", "interactions": {"extra": "", "bad": 0, "interaction": "manufacturer of  desferrioxamine advises avoid concomitant use with prochlorperazine ", "name": "Prochlorperazine", "backrefs": ["Desferrioxamine", "Prochlorperazine"]}, "cautions": "seeProchlorperazine,section 4.2.1; elderly (see notes above)", "side-effects": "seeProchlorperazine,section 4.2.1", "contra-indications": "seeProchlorperazine,section 4.2.1; avoid oral route\r\nin child under 10\u00a0kg", "hepatic impairment": "see notes insection 4.2.1", "doses": ["adultandchildover 12 years, 1\u20132 tablets twice daily; tablets\r\nare placed high between upper lip and gum and left to dissolve"], "pregnancy": "see notes insection 4.2.1", "breast-feeding": "see notes insection 4.2.1"}, "NABILONE": {"indications": "nausea and vomiting caused by cytotoxic chemotherapy, unresponsive\r\nto conventional antiemetics (under close observation, preferably in\r\nhospital setting)", "name": "NABILONE", "cautions": "history of psychiatric disorder; elderly; hypertension; heart disease; adverse\r\neffects on mental state can persist for 48\u201372 hours after stopping", "side-effects": "drowsiness, vertigo, euphoria, dry mouth, ataxia,\r\nvisual disturbance, concentration difficulties, sleep disturbance,\r\ndysphoria, hypotension, headache and nausea; also confusion, disorientation,\r\nhallucinations, psychosis, depression, decreased coordination, tremors,\r\ntachycardia, decreased appetite, and abdominal pain", "hepatic impairment": "avoid in severe impairment", "doses": ["Initially 1\u00a0mg twice daily, increased if necessary to\r\n2\u00a0mg twice daily, throughout each cycle of cytotoxic therapy and,\r\nif necessary, for 48 hours after the last dose of each cycle; max.\r\n6\u00a0mg daily given in 3 divided doses. The first dose should be taken\r\nthe night before initiation of cytotoxic treatment and the second\r\ndose 1\u20133 hours before the first dose of cytotoxic drug;adolescentandchildunder 18 years consult local treatment protocol [unlicensed use]"], "pregnancy": "avoid unless essential", "breast-feeding": "avoid\u2014no information available"}, "LORMETAZEPAM": {"indications": "insomnia (short-term use; seenotes above)", "name": "LORMETAZEPAM", "renal impairment": "seenotes above", "cautions": "see underNitrazepam", "side-effects": "see underNitrazepam; shorter\r\nacting", "contra-indications": "see underNitrazepam", "hepatic impairment": "seenotes above", "doses": ["0.5\u20131.5\u00a0mg at bedtime;elderly(or debilitated) 500\u00a0micrograms;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "KETOROLAC TROMETAMOL": {"indications": "short-term management of moderate to severe\r\nacute postoperative pain only", "name": "KETOROLAC TROMETAMOL", "renal impairment": "max. 60\u00a0mg daily by intramuscular or intravenous injection;\r\navoid if serum creatinine greater than 160\u00a0micromol/litre; see alsosection 10.1.1", "cautions": "section 10.1.1; avoid\r\nin  acute porphyria (section 9.8.2);interactions:Appendix 1 (NSAIDs)", "side-effects": "section 10.1.1; also gastro-intestinal disturbances,\r\ntaste disturbances, dry mouth; flushing, bradycardia, palpitation,\r\nchest pain, hypertension, pallor; dyspnoea, asthma; malaise, euphoria,\r\npsychosis, paraesthesia, convulsions, abnormal dreams, hyperkinesia,\r\nconfusion, hallucinations; urinary frequency, thirst, sweating; hyponatraemia,\r\nhyperkalaemia, myalgia; visual disturbances (including optic neuritis);\r\npurpura, pain at injection site", "contra-indications": "section 10.1.1; also complete or partial syndrome of nasal polyps; haemorrhagic diatheses (including coagulation disorders) and following operations with high risk of haemorrhage\r\nor incomplete haemostasis; confirmed or suspected\r\ncerebrovascular bleeding; hypovolaemia or dehydration", "hepatic impairment": "section 10.1.1", "doses": ["adultandchildover 16 years,by mouth, 10\u00a0mg\r\nevery 4\u20136 hours (elderlyevery 6\u20138\r\nhours) as required; max. 40\u00a0mg daily; max. duration of treatment 7\r\ndays", "adultandchildover 16 years,by intramuscular injectionorby intravenous injectionover at least\r\n15 seconds, initially 10\u00a0mg, then 10\u201330\u00a0mg every 4\u20136 hours as required\r\n(up to every 2 hours during initial postoperative period); max. 90\u00a0mg\r\ndaily (elderlyand patients weighing\r\nless than 50\u00a0kg max. 60\u00a0mg daily); max. duration of treatment 2 days;child6 months\u201316 years seeBNF for Children", "When converting from parenteral to oral administration,\r\ntotal combined dose on the day of converting should not exceed 90\u00a0mg\r\n(60\u00a0mg in the elderly and patients weighing less than 50\u00a0kg) of which\r\nthe oral component should not exceed 40\u00a0mg"], "pregnancy": "section 10.1.1", "breast-feeding": "amount too small to be harmful"}, "FLUMAZENIL": {"indications": "reversal of sedative effects of benzodiazepines in anaesthetic, intensive\r\ncare, and clinical procedures; overdosage with benzodiazepines (seeEmergency Treatment of Poisoning)", "name": "FLUMAZENIL", "cautions": "short-acting (repeat doses may be necessary\u2014benzodiazepine\r\neffects may persist for at least 24 hours); benzodiazepine dependence (may precipitate withdrawal symptoms); prolonged benzodiazepine therapy for epilepsy (risk\r\nof convulsions); history of panic disorders\r\n(risk of recurrence); ensure neuromuscular\r\nblockade cleared before giving; avoid rapid injection\r\nin high-risk or anxious patients and following major surgery; head injury (rapid reversal of benzodiazepine sedation\r\nmay cause convulsions); elderly; children", "side-effects": "nausea and vomiting;less commonlypalpitation, anxiety, fear;also reportedtransient\r\nhypertension, tachycardia, flushing, agitation, convulsions (particularly\r\nin those with epilepsy), dizziness, sensory disturbance, chills, sweating", "contra-indications": "life-threatening condition (e.g.\r\nraised intracranial pressure, status epilepticus) controlled by benzodiazepines", "hepatic impairment": "carefully titrate dose", "doses": ["Anaesthesia and clinical procedures,by intravenous\r\ninjection, 200\u00a0micrograms over 15 seconds, then 100\u00a0micrograms\r\nat 60-second intervals if required; usual dose range, 300\u2013600\u00a0micrograms;\r\nmax. total dose 1\u00a0mg;child1 month\u201318\r\nyears seeBNF for Children", "Intensive care,by intravenous injection, 300\u00a0micrograms\r\nover 15 seconds, then 100\u00a0micrograms at 60-second intervals if required;\r\nmax. total dose 2\u00a0mg; then if drowsiness recurseither,by intravenous injection, 300\u00a0micrograms,orby intravenous infusion, 100\u2013400\u00a0micrograms/hour,\r\nadjusted according to response;child1 month\u201318 years seeBNF for Children"], "pregnancy": "not known to be harmful", "breast-feeding": "avoid breast-feeding for 24 hours"}, "ESLICARBAZEPINE": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  warfarin reduced by eslicarbazepine ", "name": "Eslicarbazepine", "backrefs": ["Eslicarbazepine"]}}, "POTASSIUM CITRATE": {"indications": "relief of discomfort in mild urinary-tract\r\ninfections; alkalinisation of urine", "name": "POTASSIUM CITRATE", "renal impairment": "close monitoring required\u2014high risk of hyperkalaemia;\r\navoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "avoid concomitant use of  methenamine with potassium citrate ", "name": "Potassium Citrate", "backrefs": ["Potassium Citrate", "Methenamine"]}, "cautions": "cardiac disease; elderly;interactions:Appendix 1\r\n(potassium salts)", "side-effects": "hyperkalaemia on prolonged high dosage, mild diuresis", "doses": ["10\u00a0mL 3 times daily well diluted with water"]}, "ASPIRIN": {"indications": "mild to moderate pain, pyrexia; antiplatelet (section 2.9)", "name": "ASPIRIN", "renal impairment": "use with caution; avoid in severe impairment; sodium\r\nand water retention; deterioration in renal function; increased risk\r\nof gastro-intestinal bleeding", "interactions": {"extra": "", "bad": 0, "interaction": "diuretic effect of  spironolactone antagonised by aspirin ", "name": "Aspirin", "backrefs": ["Varicella-zoster Vaccine", "Aspirin"]}, "cautions": "asthma, allergic\r\ndisease, dehydration; preferably avoid during fever or viral infection\r\nin children (risk of Reye\u2019s syndrome, see below); elderly; G6PD-deficiency (section 9.1.5); concomitant use of drugs that\r\nincrease risk of bleeding; anaemia; thyrotoxicosis;interactions:Appendix 1 (aspirin)", "side-effects": "generally mild and infrequent but high incidence\r\nof gastro-intestinal irritation with slight asymptomatic blood loss,\r\nblood disorders have occurred (including increased bleeding time),\r\nconfusion, tinnitus, bronchospasm and skin reactions in hypersensitive\r\npatients. Prolonged administration, seesection 10.1.1.Overdosage:seeEmergency Treatment of Poisoning", "contra-indications": "children under 16 years (Reye\u2019s syndrome, see below); previous or active peptic ulceration, haemophilia; severe cardiac failure; not for\r\ntreatment of gout", "hepatic impairment": "avoid in severe impairment\u2014increased risk of gastro-intestinal\r\nbleeding", "doses": ["acute migraine,adultover\r\n20 years 1 sachet in water at onset of attack, repeated after 2 hours\r\nif necessary (max. 3 sachets in 24 hours);adultunder 20 years andchildnot recommended"], "pregnancy": "high doses may be related to intrauterine growth\r\nrestriction and teratogenic effects; impaired platelet function with\r\nrisk of haemorrhage, and delayed onset and increased duration of labour\r\nwith increased blood loss, can occur if used during delivery; avoid\r\nanalgesic doses if possible in last few weeks (low doses probably\r\nnot harmful); with high doses, closure of fetal ductus arteriosus\r\nin utero and possibly persistent pulmonary hypertension of newborn;\r\nkernicterus in jaundiced neonates", "breast-feeding": "avoid\u2014possible risk of Reye\u2019s syndrome; regular\r\nuse of high doses could impair platelet function and produce hypoprothrombinaemia\r\nin infant if neonatal vitamin K stores low"}, "LOFEXIDINE HYDROCHLORIDE": {"indications": "management of symptoms of opioid withdrawal", "name": "LOFEXIDINE HYDROCHLORIDE", "renal impairment": "caution in chronic impairment", "cautions": "severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, bradycardia, hypotension (monitor pulse rate and blood pressure); history of QT prolongation, concomitant administration of drugs that prolong QT interval; metabolic disturbances; withdraw gradually over 2\u20134 days (or longer) to minimise\r\nrisk of rebound hypertension and associated symptoms; depression;interactions:Appendix\r\n1 (lofexidine)", "side-effects": "dry mucous membranes; hypotension, bradycardia;\r\ndizziness, drowsiness; QT-interval prolongation also reported", "doses": ["adultandchildover 12 years, initially 800\u00a0micrograms daily\r\nin divided doses, increased as necessary in steps of 400\u2013800\u00a0micrograms\r\ndaily to max. 2.4\u00a0mg daily in divided doses; max. single dose 800\u00a0micrograms;\r\nrecommended duration of treatment 7\u201310 days if no opioid use (but\r\nlonger may be required)"], "pregnancy": "use only if benefit outweighs risk\u2014no information\r\navailable", "breast-feeding": "use only if benefit outweighs risk\u2014no information\r\navailable"}, "ANGIOTENSIN-II RECEPTOR ANTAGONISTS": {"interactions": {"extra": "", "bad": 1, "interaction": "excretion of  lithium reduced by angiotensin-II receptor antagonists (increased plasma concentration)", "name": "Angiotensin-II Receptor Antagonists", "backrefs": ["Angiotensin-II Receptor Antagonists"]}}, "MIANSERIN": {"interactions": {"extra": "", "bad": 1, "interaction": " phenytoin reduces plasma concentration of mianserin ", "name": "Mianserin", "backrefs": ["Mianserin"]}}, "PYRIDOSTIGMINE": {"interactions": {"extra": "", "bad": 0, "interaction": " propranolol antagonises effects of pyridostigmine ", "name": "Pyridostigmine", "backrefs": ["Pyridostigmine"]}}, "CINNARIZINE": {"indications": "vestibular disorders, such as vertigo,\r\ntinnitus, nausea, and vomiting in M\u00e9ni\u00e8re\u2019s disease; motion sickness", "name": "CINNARIZINE", "renal impairment": "use with caution\u2014no information available", "cautions": "section 3.4.1; also Parkinson\u2019s disease", "side-effects": "section 3.4.1; alsorarelyweight gain, sweating, lichen planus, and lupus-like\r\nskin reactions", "contra-indications": "section 3.4.1", "hepatic impairment": "section 3.4.1", "doses": ["Vestibular disorders, 30\u00a0mg 3 times daily;child5\u201312 years 15\u00a0mg 3 times daily", "Motion sickness, 30\u00a0mg 2 hours before travel then 15\u00a0mg every\r\n8 hours during journey if necessary;child5\u201312 years, 15\u00a0mg 2 hours before travel then 7.5\u00a0mg every 8 hours\r\nduring journey if necessary"], "pregnancy": "section 3.4.1", "breast-feeding": "section 3.4.1"}, "OESTROGENS": {"interactions": {"extra": "Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see section 7.3.1", "bad": 1, "interaction": " nevirapine accelerates metabolism of oestrogens (reduced contraceptive effect\u2014see section 7.3.1)", "name": "Oestrogens", "backrefs": ["Oestrogens"]}}, "NICORANDIL": {"indications": "prophylaxis and treatment of stable angina (including risk reduction\r\nof acute coronary syndromes in patients at high risk)", "name": "NICORANDIL", "interactions": {"extra": "", "bad": 1, "interaction": "possible increased hypotensive effect when  vardenafil given with nicorandil\u2014avoid concomitant use", "name": "Nicorandil", "backrefs": ["Nicorandil"]}, "cautions": "hypovolaemia; low systolic blood pressure; acute pulmonary\r\noedema; acute myocardial infarction with\r\nacute left ventricular failure and low filling pressures;interactions:Appendix 1 (nicorandil)", "side-effects": "nausea, vomiting, rectal bleeding, cutaneous vasodilation\r\nwith flushing, increase in heart rate (at high doses), dizziness,\r\nheadache (especially on initiation, usually transitory), weakness;less commonlyoral ulceration, hypotension, myalgia, angioedema;rarelyintestinal ulceration, anal ulceration, abdominal\r\npain, hepatitis, cholestasis, jaundice, skin ulceration, rash, pruritus", "contra-indications": "cardiogenic shock; left ventricular failure with low filling pressures; hypotension", "doses": ["Initially 10\u00a0mg twice daily (if susceptible to headache\r\n5\u00a0mg twice daily); usual dose 10\u201320\u00a0mg twice daily; up to 30\u00a0mg twice\r\ndaily may be used"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "no information available\u2014manufacturer advises\r\navoid"}, "PYRIDOSTIGMINE BROMIDE": {"indications": "myasthenia gravis", "name": "PYRIDOSTIGMINE BROMIDE", "renal impairment": "reduce dose; excreted by kidney", "cautions": "see underNeostigmine; weaker muscarinic action", "side-effects": "see underNeostigmine", "contra-indications": "see underNeostigmine", "doses": ["By mouth, 30\u2013120\u00a0mg at suitable intervals\r\nthroughout day, total daily dose 0.3\u20131.2\u00a0g (but see also notes above);childunder 18 years, seeBNF for Children"], "pregnancy": "see underNeostigmine", "breast-feeding": "see underNeostigmine"}, "HYDROCHLOROTHIAZIDE": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  fluconazole increased by hydrochlorothiazide ", "name": "Hydrochlorothiazide", "backrefs": ["Hydrochlorothiazide"]}}, "BOCEPREVIR": {"indications": "in combination with ribavirin and peginterferon alfa for chronic\r\nhepatitis C infection of genotype 1 in patients with compensated liver\r\ndisease", "name": "BOCEPREVIR", "interactions": {"extra": "", "bad": 1, "interaction": " ketoconazole increases plasma concentration of boceprevir ", "name": "Boceprevir", "backrefs": ["Drospirenone", "Boceprevir"]}, "cautions": "monitor full blood count before starting\r\ntreatment and then on weeks 4 and 8 of treatment, then as indicated\r\nclinically; predisposition to QT interval\r\nprolongation (including concomitant use with other drugs known to\r\nprolong QT interval);interactions:Appendix 1 (boceprevir)", "side-effects": "in combination with ribavirin and peginterferon\r\nalfa, anaemia, nausea, vomiting, abdominal pain, gastro-oesophageal\r\nreflux, flatulence, diarrhoea, constipation, haemorrhoids, dry mouth,\r\ndisturbances in taste and smell, mouth ulcers, stomatitis, tooth disorder,\r\npalpitation, blood pressure changes, syncope, peripheral oedema, hypertriglyceridaemia,\r\ncough, dyspnoea, dizziness, headache, decreased appetite, weight loss,\r\nanxiety, depression, insomnia, agitation, amnesia, asthenia, hypoaesthesia,\r\nparaesthesia, tremor, influenza-like symptoms, hyperglycaemia, hypothyroidism,\r\nchanges in libido, erectile dysfunction, polyuria, leucopenia, thrombocytopenia,\r\narthralgia, myalgia, muscle spasms, hyperuricaemia, visual disturbances,\r\ndry eyes, tinnitus, alopecia, rash, pruritus, hyperhidrosis, psoriasis;less commonlygingivitis, tongue discoloration, hypersalivation,\r\ndysphagia, pancreatitis, colitis, hyperbilirubinaemia, arrhythmias,\r\nvenous thromboembolism, flushing, pallor, dysphonia, hyperaesthesia,\r\nhomicidal and suicidal ideation, hyperthyroidism, amenorrhoea, menorrhagia,\r\ndysuria, hypokalaemia, hypercalcaemia, gout, retinal ischaemia, retinopathy,\r\nconjunctival haemorrhage, eye pain, increased lacrimation, photophobia,\r\nhearing impairment, photosensitivity, skin ulceration;rarelycholecystitis, acute myocardial infarction, coronary artery disease,\r\npericarditis, pleural fibrosis, respiratory failure, bipolar disorder,\r\nhallucinations, encephalopathy, thyroid neoplasms, aspermia, sarcoidosis", "contra-indications": "autoimmune hepatitis", "doses": ["In combination with ribavirin and peginterferon alfa,adultover 18 years, 800\u00a0mg 3 times daily (for duration\r\nof treatment consult product literature)", "If a dose is more than 6 hours late,\r\nthe missed dose should not be taken and the next dose should be taken\r\nat the normal time"], "pregnancy": "manufacturer advises avoid; see also under Ribavirin", "breast-feeding": "manufacturer advises avoid; present in milk\r\ninanimalstudies"}, "SODIUM PICOSULFATE": {"indications": "constipation; bowel evacuation before\r\nabdominal radiological and endoscopic procedures on the colon, and\r\nsurgery (section 1.6.5); acts within 6\u201312 hours", "name": "SODIUM PICOSULFATE", "cautions": "seenotes above; active inflammatory\r\nbowel disease (avoid if fulminant)", "side-effects": "seenotes above", "contra-indications": "seenotes above; severe dehydration", "doses": ["5\u201310\u00a0mg at night;child(but seesection\r\n1.6) 1 month\u20134 years 2.5\u201310\u00a0mg once daily, adjusted according\r\nto response; 4\u201318 years 2.5\u201320\u00a0mg once daily, adjusted according to\r\nresponse", "Sodium picosulfate doses in BNF may differ\r\nfrom those in product literature"], "pregnancy": "seePregnancy", "breast-feeding": "not known to be present in milk but manufacturer\r\nadvises avoid unless potential benefit outweighs risk"}, "MEASLES, MUMPS AND RUBELLA VACCINE, LIVE": {"indications": "immunisation against measles, mumps,\r\nand rubella", "name": "MEASLES, MUMPS AND RUBELLA VACCINE, LIVE", "cautions": "seesection 14.1; also,\r\nafter immunoglobulin administration or blood transfusion, leave an\r\ninterval of at least 3 months before MMR immunisation as antibody\r\nresponse to measles component may be reduced\u2014see alsoAnti-D (Rh0) immunoglobulin;interactions:Appendix 1 (vaccines)", "side-effects": "seesection 14.1andnotes above; alsoless commonlysleep disturbances, unusual crying in infants; also reported peripheral\r\nand optic neuritis", "contra-indications": "seesection 14.1", "doses": ["By intramuscularordeep subcutaneous\r\ninjection,adultandchildover 9 months (but see alsonotes above), primary\r\nimmunisation, 2 doses each of 0.5\u00a0mL, seeImmunisation Schedule, section 14.1; see alsonotes abovefor use\r\nin outbreaks, for contacts of cases, and for travel"], "pregnancy": "avoid pregnancy for at least 1 month after vaccination;\r\nsee alsosection 14.1", "breast-feeding": "seesection 14.1"}, "DANTROLENE": {"interactions": {"extra": "", "bad": 0, "interaction": " memantine possibly modifies effects of dantrolene ", "name": "Dantrolene", "backrefs": ["Dantrolene"]}}, "PSEUDOEPHEDRINE HYDROCHLORIDE": {"indications": "seenotes above", "name": "PSEUDOEPHEDRINE HYDROCHLORIDE", "renal impairment": "use with caution in mild to moderate impairment;\r\navoid in severe impairment", "cautions": "seenotes above", "side-effects": "nausea, vomiting, hypertension, tachycardia, headache,\r\nanxiety, restlessness, insomnia;rarelyhallucinations,\r\nrash;very rarelyangle-closure glaucoma; urinary\r\nretention also reported", "hepatic impairment": "use with caution in severe impairment", "doses": ["60\u00a0mg 3\u20134 times daily;child6\u201312 years 30\u00a0mg 3\u20134 times daily"], "pregnancy": "defective closure of the abdominal wall (gastroschisis)\r\nreported very rarely in newborns after first trimester exposure", "breast-feeding": "amount too small to be harmful"}, "TERBINAFINE": {"indications": "fungal skin infections", "name": "TERBINAFINE", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  ciclosporin possibly reduced by terbinafine ", "name": "Terbinafine", "backrefs": ["Terbinafine"]}, "cautions": "avoid contact with eyes", "side-effects": "see notes above", "doses": ["Apply thinly 1\u20132 times daily for up to 1 week in tinea\r\npedis, 1\u20132 weeks in tinea corporis and tinea cruris, 2 weeks in cutaneous\r\ncandidiasis and pityriasis versicolor; review after 2 weeks;childseeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014animalstudies suggest\r\nno adverse effects", "breast-feeding": "manufacturer advises avoid\u2014present in milk,\r\nbut less than 5% of the dose is absorbed after topical application\r\nofterbinafine; avoid application to mother\u2019s chest"}, "TELAPREVIR": {"indications": "in combination with ribavirin and peginterferon alfa for chronic\r\nhepatitis C infection of genotype 1 in patients with compensated liver\r\ndisease", "name": "TELAPREVIR", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of inhaled and intranasal  fluticasone possibly increased by telaprevir ", "name": "Telaprevir", "backrefs": ["Telaprevir"]}, "cautions": "monitor full blood count, platelets, electrolytes,\r\nserum creatinine, uric acid, and liver and thyroid function tests\r\nbefore starting treatment and then on weeks 2, 4, 8, and 12 of treatment,\r\nthen as indicated clinically; electrolyte disturbances; prolongation\r\nof QT interval, bradycardia, heart failure with reduced left ventricular\r\nejection fraction, concomitant use with other drugs known to prolong\r\nQT interval; congenital or family history of QT interval prolongation,\r\nfamily history of sudden death; effectiveness of hormonal contraceptives\r\nreduced during treatment and for 2 months after stopping telaprevir\u2014effective\r\nnon-hormonal methods of contraception necessary during this time (see\r\nalso Cautions underRibavirin);interactions:Appendix 1 (telaprevir)", "side-effects": "in combination with ribavirin and peginterferon\r\nalfa, rash (including eczema and rarely Stevens-Johnson syndrome;\r\nsee also Rash above), pruritus, anaemia, nausea, vomiting, diarrhoea,\r\nhaemorrhoids, anal fissure, hyperbilirubinaemia, taste disturbances,\r\nsyncope, peripheral oedema, hypothyroidism, hypokalaemia, thrombocytopenia,\r\nlymphopenia, hyperuricaemia;less commonlyproctitis,\r\ngout, retinopathy, urticaria", "hepatic impairment": "manufacturer advises avoid in moderate to severe impairment", "doses": ["In combination with ribavirin and peginterferon alfa,adultover 18 years, 750\u00a0mg every 8 hours (for duration\r\nof treatment consult product literature)", "If a dose is more than 4 hours late,\r\nthe missed dose should not be taken and the next dose should be taken\r\nat the normal time"], "pregnancy": "manufacturer advises avoid; see Cautions above and\r\nalso see underRibavirin", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "ZUCLOPENTHIXOL": {"indications": "schizophrenia and other psychoses", "name": "ZUCLOPENTHIXOL", "renal impairment": "seenotes above; halve\r\ndose in renal failure", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects and possibly neurotoxicity when  lithium given with zuclopenthixol ", "name": "Zuclopenthixol", "backrefs": ["Moxifloxacin", "Zuclopenthixol"]}, "cautions": "seenotes above; avoid\r\nin acute porphyria (section 9.8.2)", "side-effects": "seenotes above; urinary\r\nfrequency or incontinence; weight loss (less common than weight gain)", "contra-indications": "seenotes above; apathetic\r\nor withdrawn states", "hepatic impairment": "seenotes above; halve\r\ndose and consider serum-level monitoring", "doses": ["By mouth, initially 20\u201330\u00a0mg daily in divided\r\ndoses, increasing to a max. of 150\u00a0mg daily if necessary; usual maintenance\r\ndose 20\u201350\u00a0mg daily; max. single dose 40\u00a0mg;elderly(or debilitated) initially quarter to half adult dose;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ZANAMIVIR": {"indications": "see notes above", "name": "ZANAMIVIR", "cautions": "asthma and chronic\r\npulmonary disease (risk of bronchospasm\u2014short-acting bronchodilator\r\nshould be available; avoid in severe asthma unless close\r\nmonitoring possible and appropriate facilities available to treat\r\nbronchospasm); uncontrolled chronic illness; other inhaled drugs should be administered beforezanamivir)", "side-effects": "rash;less commonlybronchospasm,\r\ndyspnoea, angioedema, urticaria;rarelyStevens-Johnson\r\nsyndrome, toxic epidermal necrolysis; also reported neuropsychiatric\r\ndisorders (especially in children and adolescents)", "doses": ["By inhalation of powder, post-exposure\r\nprophylaxis of influenza,adultandchildover 5 years, 10\u00a0mg once daily for 10 days", "Prevention of influenza during an epidemic,adultandchildover 5 years, 10\u00a0mg once\r\ndaily for up to 28 days", "Treatment of influenza,adultandchildover 5 years, 10\u00a0mg twice\r\ndaily for 5 days (for up to 10 days if resistance to oseltamivir suspected\r\n[unlicensed duration])"], "pregnancy": "use only if potential benefit outweighs risk (e.g.\r\nduring a pandemic); see alsonotes above", "breast-feeding": "amount probably too small to be harmful; use\r\nonly if potential benefit outweighs risk (e.g. during a pandemic);\r\nsee alsonotes above"}, "FLUNISOLIDE": {"side-effects": "seenotes above", "indications": "prophylaxis and treatment of allergic rhinitis", "name": "FLUNISOLIDE", "cautions": "seenotes above", "doses": ["adult, 50\u00a0micrograms (2\r\nsprays) into each nostril twice daily, increased if necessary to max.\r\n3 times daily then reduced for maintenance;child5\u201314 years initially 25\u00a0micrograms (1 spray) into each nostril up\r\nto 3 times daily"]}, "ISOMETHEPTENE": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by isometheptene ", "name": "Isometheptene", "backrefs": ["Adrenergic Neurone Blockers", "Isometheptene", "Bromocriptine"]}}, "ANTIHISTAMINES": {"interactions": {"extra": "Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)", "bad": 0, "interaction": "effect of  betahistine theoretically antagonised by antihistamines ", "name": "Antihistamines", "backrefs": ["Antihistamines", "Antihistamines, Sedating", "Betahistine", "Antihistamines, Non-sedating", "Histamine"]}}, "MISOPROSTOL": {"indications": "see notes above and under Dose", "name": "MISOPROSTOL", "cautions": "inflammatory bowel disease; conditions where hypotension might precipitate severe\r\ncomplications (e.g. cerebrovascular disease, cardiovascular disease)", "side-effects": "diarrhoea (may occasionally be severe and require\r\nwithdrawal, reduced by giving single doses not exceeding 200\u00a0micrograms\r\nand by avoiding magnesium-containing antacids); also reported: abdominal\r\npain, dyspepsia, flatulence, nausea and vomiting, abnormal vaginal\r\nbleeding (including intermenstrual bleeding, menorrhagia, and postmenopausal\r\nbleeding), rashes, dizziness", "contra-indications": "planning pregnancy (important:see Women of Childbearing Age, and\r\nalso Pregnancy, below)", "doses": ["Benign gastric and duodenal ulceration and NSAID-associated\r\nulceration,adultover 18 years, 800\u00a0micrograms\r\ndaily (in 2\u20134 divided doses) with breakfast (or main meals) and at\r\nbedtime; treatment should be continued for at least 4 weeks and may\r\nbe continued for up to 8 weeks if required", "Prophylaxis of NSAID-induced gastric and duodenal ulcer,adultover 18 years, 200\u00a0micrograms 4 times daily\r\n(if not tolerated, reduced to 200\u00a0micrograms 2\u20133 times daily, but\r\nless effective)"], "pregnancy": "avoid\u2014potent uterine stimulant (has been used to\r\ninduce abortion); teratogenic risk in first trimester;important:see also Women of Childbearing Age, above", "breast-feeding": "present in milk, but amount probably too small\r\nto be harmful"}, "RALTEGRAVIR": {"indications": "HIV infection in combination with other\r\nantiretroviral drugs", "name": "RALTEGRAVIR", "interactions": {"extra": "", "bad": 1, "interaction": " omeprazole increases plasma concentration of raltegravir\u2014avoid concomitant use", "name": "Raltegravir", "backrefs": ["Raltegravir"]}, "cautions": "risk factors for myopathy or rhabdomyolysis; chronic hepatitis B or C (greater risk of hepatic side-effects);interactions: Appendix 1 (raltegravir)", "side-effects": "diarrhoea, nausea, vomiting, abdominal pain, flatulence,\r\nhypertriglyceridaemia, dizziness, headache, insomnia, abnormal dreams,\r\nasthenia, rash (Stevens-Johnson syndrome reported);less commonlygastritis, hepatitis, pancreatitis, dry mouth, gastro-oesophageal\r\nreflux, taste disturbances, pain on swallowing, peptic ulcer, constipation,\r\nrectal bleeding, lipodystrophy (seeLipodystrophy Syndrome), palpitation, ventricular extrasystoles, bradycardia, hypertension,\r\nflushing, chest pain, oedema, dysphonia, epistaxis, nasal congestion,\r\ndrowsiness, anxiety, appetite changes, confusion, impaired memory\r\nand attention, depression, pyrexia, chills, carpal tunnel syndrome,\r\ntremor, peripheral neuropathy, erectile dysfunction, gynaecomastia,\r\nmenopausal symptoms, osteopenia, renal failure, nocturia, polydipsia,\r\nanaemia, thrombocytopenia, neutropenia, arthralgia, myalgia, rhabdomyolysis,\r\nvisual disturbances, tinnitus, gingivitis, glossitis, acne, pruritus,\r\nhyperhidrosis, dry skin, skin papilloma, and alopecia;also\r\nreportedsuicidal ideation; see alsoOsteonecrosis", "hepatic impairment": "manufacturer advises caution in severe impairment\u2014no\r\ninformation available", "doses": ["400\u00a0mg twice daily;child16\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "seeBreast-feeding"}, "ANTHRAX VACCINE": {"indications": "pre-exposure immunisation against anthrax;\r\npost-exposure immunisation (see notes above)", "name": "ANTHRAX VACCINE", "cautions": "seesection 14.1", "side-effects": "seesection 14.1", "contra-indications": "seesection 14.1", "doses": ["By intramuscular injectionin deltoid region,\r\ninitial course 3 doses of 0.5\u00a0mL at intervals of 3 weeks followed\r\nby a fourth dose after an interval of 6 months; booster, 0.5\u00a0mL every\r\n12 months"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "3.1.4 Compound bronchodilator preparations": {"name": "3.1.4 Compound bronchodilator preparations", "doses": ["bronchospasm in chronic obstructive pulmonary disease,by inhalation of nebulised solution,adultandchildover 12 years, 1 vial (2.5\u00a0mL)\r\n3\u20134 times daily"]}, "DULOXETINE": {"indications": "moderate to severe stress urinary incontinence\r\nin women; major depressive disorder (section 4.3.4); diabetic neuropathy (section 4.3.4); generalised anxiety disorder (section 4.3.4)", "name": "DULOXETINE", "renal impairment": "avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  5HT1 agonists given with duloxetine ", "name": "Duloxetine", "backrefs": ["5HT1-receptor Agonists", "Amitriptyline", "Tryptophan", "Clomipramine", "Duloxetine"]}, "cautions": "elderly; cardiac disease; hypertension (avoid if uncontrolled); history of mania; history of seizures; raised intra-ocular\r\npressure, susceptibility to angle-closure\r\nglaucoma; bleeding disorders or concomitant use of drugs that increase risk of bleeding;interactions: Appendix 1 (duloxetine)", "side-effects": "nausea, vomiting, dyspepsia, constipation, diarrhoea,\r\nabdominal pain, weight changes, decreased appetite, flatulence, dry\r\nmouth; palpitation, hot flush; insomnia, abnormal dreams, paraesthesia,\r\ndrowsiness, anxiety, headache, dizziness, fatigue, weakness, tremor,\r\nnervousness, anorexia; sexual dysfunction; visual disturbances; sweating,\r\npruritus;less commonlygastritis, halitosis, hepatitis,\r\nbruxism, tachycardia, hypertension, postural hypotension, syncope,\r\nraised cholesterol, vertigo, taste disturbance, cold extremities,\r\nimpaired temperature regulation, impaired attention, movement disorders,\r\nmuscle twitching, musculoskeletal pain,  thirst, stomatitis, hypothyroidism,\r\nurinary disorders, and photosensitivity;rarelymania;very rarelyangle-closure glaucoma;also reportedsupraventricular arrhythmia, chest pain, hallucinations, suicidal\r\nbehaviour (seeSuicidal Behaviour and Antidepressant\r\nTherapy),\r\nseizures, hypersensitivity reactions including urticaria, angioedema,\r\nrash (including Stevens-Johnson syndrome) and anaphylaxis, hyponatraemia\r\n(seeHyponatraemia and Antidepressant\r\nTherapy)", "hepatic impairment": "manufacturer advises avoid", "doses": ["adultover 18 years, 40\u00a0mg\r\ntwice daily, assess for benefit and tolerability after 2\u20134 weeks", "Initial dose of 20\u00a0mg twice daily for 2 weeks\r\ncan minimise side-effects"], "pregnancy": "toxicity inanimalstudies\u2014avoid\r\nin patients with stress urinary incontinence; risk of neonatal withdrawal\r\nsymptoms if used near term", "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "BIVALIRUDIN": {"indications": "unstable angina or non-ST-segment elevation\r\nmyocardial infarction in patients planned for urgent or early intervention;\r\nanticoagulation for patients undergoing percutaneous coronary intervention\r\n(including patients with ST-segment elevation myocardial infarction\r\nundergoing primary percutaneous coronary intervention)", "name": "BIVALIRUDIN", "renal impairment": "forpercutaneous coronary intervention, reduce rate of infusion to 1.4\u00a0mg/kg/hour if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2and monitor blood clotting parameters; foracute\r\ncoronary syndromesandpercutaneous coronary intervention, avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "exposure tolepirudin(theoretical risk fromlepirudinantibodies); brachytherapy procedures; concomitant use of drugs that increase risk of bleeding", "side-effects": "bleeding (discontinue), thrombosis, ecchymosis;less commonlynausea, vomiting, tachycardia, bradycardia,\r\nhypotension, angina, dyspnoea, allergic reactions (including isolated\r\nreports of anaphylaxis), headache, thrombocytopenia, anaemia, back\r\nand chest pain, and injection-site reactions", "contra-indications": "severe hypertension; subacute bacterial endocarditis; active bleeding; bleeding disorders", "doses": ["Unstable angina or non-ST-segment elevation myocardial\r\ninfarction (in addition to aspirin and clopidogrel), initiallyby intravenous injection, 100\u00a0micrograms/kg thenby\r\nintravenous infusion250\u00a0micrograms/kg/hour (for up to 72\r\nhours in medically managed patients); patients proceeding to percutaneous\r\ncoronary intervention or coronary artery bypass surgerywithoutcardiopulmonary bypass, additional bolus doseby intravenous\r\ninjection500\u00a0micrograms/kg, thenby intravenous infusion1.75\u00a0mg/kg/hour for duration of procedure; following percutaneous\r\ncoronary intervention, reduce infusion rate to 250\u00a0micrograms/kg/hour\r\nfor 4\u201312 hours as necessary; patients proceeding to coronary artery\r\nbypass surgerywithcardiopulmonary bypass, discontinue\r\nintravenous infusion 1 hour before procedure and treat with unfractionated\r\nheparin", "Anticoagulation in patients undergoing percutaneous coronary\r\nintervention (in addition to aspirin and clopidogrel), initiallyby intravenous injection, 750\u00a0micrograms/kg thenby\r\nintravenous infusion1.75\u00a0mg/kg/hour for up to 4 hours after\r\nprocedure; a reduced infusion rate of 250\u00a0micrograms/kg/hour may be\r\ncontinued for a further 4\u201312 hours if necessary"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "FERROUS FUMARATE": {"side-effects": "seenotes above", "indications": "iron-deficiency anaemia", "name": "FERROUS FUMARATE", "cautions": "interactions:Appendix 1 (iron)", "doses": ["1 tablet daily"]}, "BAMBUTEROL HYDROCHLORIDE": {"indications": "asthma and other conditions associated\r\nwith reversible airways obstruction", "name": "BAMBUTEROL HYDROCHLORIDE", "renal impairment": "reduce initial dose by half if eGFR less than 50\u00a0mL/minute/1.73m2", "cautions": "seenotes above", "side-effects": "seenotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["20\u00a0mg once daily at bedtime if patient has previously\r\ntolerated beta2agonists; other patients, initially 10\u00a0mg\r\nonce daily at bedtime, increased if necessary after 1\u20132 weeks to 20\u00a0mg\r\nonce daily;childnot recommended"], "pregnancy": "manufacturer advises avoid\u2014no information available;\r\nsee alsosection 3.1", "breast-feeding": "seesection 3.1"}, "BENZYLPENICILLIN SODIUM": {"indications": "throat\r\ninfections, otitis media, endocarditis, meningococcal disease, pneumonia,\r\ncellulitis (Table 1,section 5.1); anthrax;\r\nintrapartum prophylaxis against group B streptococcal infection; see\r\nalso notes above", "name": "BENZYLPENICILLIN SODIUM", "renal impairment": "reduce dose\u2014consult product literature; high doses may\r\ncause cerebral irritation, convulsions, or coma", "cautions": "history of allergy; false-positive urinary glucose (if tested for reducing substances);interactions:Appendix 1 (penicillins)", "side-effects": "hypersensitivity reactions including urticaria,\r\nfever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like\r\nreaction;rarelyCNS toxicity including convulsions\r\n(especially with high doses or in severe renal impairment), interstitial\r\nnephritis, haemolytic anaemia, leucopenia, thrombocytopenia, and coagulation\r\ndisorders; also reported diarrhoea (including antibiotic-associated\r\ncolitis)", "contra-indications": "penicillin\r\nhypersensitivity", "doses": ["By intramuscularorby slow intravenous injectionorby infusion, 0.6\u20131.2\u00a0g every 6 hours, increased if necessary\r\nin more serious infections (single doses over 1.2\u00a0g intravenous route\r\nonly; see also below);neonateunder\r\n7 days, 25\u00a0mg/kg every 12 hours, dose doubled in severe infection;neonate7\u201328 days, 25\u00a0mg/kg every 8 hours, dose doubled\r\nin severe infection;child1 month\u201318\r\nyears, 25\u00a0mg/kg every 6 hours (increased in severe infection to 50\u00a0mg/kg\r\nevery 4\u20136 hours (max. 2.4\u00a0g every 4 hours); intravenous route recommended\r\nin neonates and infants", "Endocarditis (in combination with another antibacterial if necessary,\r\nsee Table 1,section 5.1),by slow intravenous injectionorby infusion, 1.2\u00a0g every 4 hours,\r\nincreased if necessary (e.g. in enterococcal endocarditis or if benzylpenicillin\r\nused alone) to 2.4\u00a0g every 4 hours;child1 month\u201318 years seeBNF for Children", "Anthrax (in combination with other antibacterials, see alsosection 5.1.12),by slow intravenous injectionorby infusion, 2.4\u00a0g every 4 hours;childunder 18 years seeBNF for Children", "Intrapartum prophylaxis against group B streptococcal infection,by slow intravenous injectionorby infusion, initially 3\u00a0g then 1.5\u00a0g every 4 hours until\r\ndelivery", "Meningitis, meningococcal disease,by slow intravenous\r\ninjectionorby infusion,\r\n2.4\u00a0g every 4 hours;neonate, 75\u00a0mg/kg\r\nevery 8 hours;child1 month\u201318 years,\r\n50\u00a0mg/kg every 4\u20136 hours (max. 2.4\u00a0g every 4 hours)", "Important.If meningococcal\r\ndisease (meningitis with non-blanching rash or meningococcal septicaemia)\r\nis suspected, a single dose ofbenzylpenicillinshould be given before transferring the patient to hospital urgently,\r\nso long as this does not delay the transfer. If a patient with suspected\r\nbacterial meningitis without non-blanching rash cannot be transferred\r\nto hospital urgently, a single dose of benzylpenicillin should be\r\ngiven before the transfer. Suitable doses of benzylpenicillin by intravenous\r\ninjection (or by intramuscular injection) are:adult1.2\u00a0g;infantunder 1 year 300\u00a0mg;child1\u20139 years 600\u00a0mg, 10 years and over as for\r\nadult. Inpenicillin allergy,cefotaxime(section 5.1.2) may be an alternative;chloramphenicol(section 5.1.7) may be used if there is a history\r\nof anaphylaxis to penicillins", "By intrathecal injection,notrecommended", "Benzylpenicillindoses\r\nin BNF may differ from those in product literature"], "pregnancy": "not known to be harmful", "breast-feeding": "trace amounts in milk, but appropriate to use"}, "MYCOPHENOLATE": {"interactions": {"extra": "", "bad": 0, "interaction": "oral  iron reduces absorption of mycophenolate ", "name": "Mycophenolate", "backrefs": ["Mycophenolate"]}}, "RETINOIDS": {"interactions": {"extra": "", "bad": 1, "interaction": "possible increased risk of benign intracranial hypertension when  tetracyclines given with retinoids (avoid concomitant use)", "name": "Retinoids", "backrefs": ["Retinoids"]}}, "LOPINAVIR": {"interactions": {"extra": "In combination with ritonavir as Kaletra\u00ae (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)\u2014see also Ritonavir", "bad": 1, "interaction": " nevirapine possibly reduces plasma concentration of lopinavir\u2014consider increasing dose of lopinavir", "name": "Lopinavir", "backrefs": ["Lopinavir", "Chlorphenamine"]}}, "PHENOXYBENZAMINE HYDROCHLORIDE": {"indications": "hypertensive episodes in phaeochromocytoma", "name": "PHENOXYBENZAMINE HYDROCHLORIDE", "renal impairment": "use with caution", "cautions": "elderly; congestive\r\nheart failure; severe ischaemic heart disease (see also Contra-indications); cerebrovascular disease (avoid if history of cerebrovascular accident); monitor\r\nblood pressure regularly during infusion; carcinogenic inanimals; avoid in acute porphyria (section 9.8.2); avoid extravasation (irritant\r\nto tissues)", "side-effects": "postural hypotension with dizziness and marked\r\ncompensatory tachycardia, lassitude, nasal congestion, miosis, inhibition\r\nof ejaculation; rarely gastro-intestinal disturbances; decreased sweating\r\nand dry mouth after intravenous infusion; idiosyncratic profound hypotension\r\nwithin few minutes of starting infusion; convulsions following rapid\r\nintravenous infusion also reported", "contra-indications": "history of cerebrovascular accident; during recovery period after myocardial infarction (usually\r\n3\u20134 weeks); avoid infusion in hypovolaemia", "doses": ["byintravenous infusion(preferably through\r\nlarge vein), adjunct in severe shock (but rarely used) and phaeochromocytoma,\r\n1\u00a0mg/kg daily over at least 2 hours; do not repeat within 24 hours\r\n(intensive care facilities needed)"], "pregnancy": "hypotension may occur in newborn", "breast-feeding": "may be present in milk"}, "ANTIHISTAMINES, NON-SEDATING": {"interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of non-sedating antihistamines ", "name": "Antihistamines, Non-sedating", "backrefs": []}}, "Other compounds": {"name": "Other compounds", "doses": ["Peyronie\u2019s disease, scleroderma, 12\u00a0g daily in divided doses after\r\nfood"]}, "MAGNESIUM TRISILICATE": {"indications": "dyspepsia", "name": "MAGNESIUM TRISILICATE", "renal impairment": "seenotes above; magnesium\r\ntrisilicate mixture has a high sodium content", "cautions": "seenotes above;interactions: Appendix 1 (antacids)", "side-effects": "diarrhoea, belching due to liberated carbon dioxide;\r\nsilica-based renal stones reported on long-term treatment", "contra-indications": "see underMagnesium Carbonate", "hepatic impairment": "seenotes above", "doses": ["10\u201320\u00a0mL in water 3 times daily or as required;child5\u201312 years, 5\u201310\u00a0mL in water 3 times daily\r\nor as required"]}, "PENTOXIFYLLINE": {"indications": "peripheral vascular disease (but see notes above); venous leg ulcers\r\n[unlicensed indication] (Appendix A5.8.7)", "name": "PENTOXIFYLLINE", "renal impairment": "reduce dose by 30\u201350% if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of bleeding  when  ketorolac given with pentoxifylline (avoid concomitant use)", "name": "Pentoxifylline", "backrefs": ["Pentoxifylline"]}, "cautions": "hypotension, coronary artery disease; avoid in acute\r\nporphyria (section 9.8.2);interactions:Appendix 1\r\n(pentoxifylline)", "side-effects": "nausea, vomiting, diarrhoea, dizziness, agitation,\r\nsleep disturbances, headache;rarelyangina, hypotension;very rarelybleeding;also reportedintrahepatic\r\ncholestasis, tachycardia, flushing, thrombocytopenia", "contra-indications": "cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial infarction, severe cardiac\r\narrhythmias", "hepatic impairment": "manufacturer advises reduce dose in severe impairment", "doses": ["400\u00a0mg 2\u20133 times daily"], "pregnancy": "manufacturer advises avoid\u2014no information available", "breast-feeding": "present in milk\u2014manufacturer advises use only\r\nif potential benefit outweighs risk"}, "13.2.1.1 Emollient bath and shower preparations": {"name": "13.2.1.1 Emollient bath and shower preparations", "doses": ["for topical treatment of eczema including eczema at risk\r\nfrom infection, add 1\u20132 capfuls/bath (infantover 6 months 1\u00a0mL); do not use undiluted"]}, "CELIPROLOL": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin reduces plasma concentration of celiprolol ", "name": "Celiprolol", "backrefs": ["Celiprolol"]}}, "DASATINIB": {"indications": "seenotes above", "name": "DASATINIB", "interactions": {"extra": "", "bad": 0, "interaction": " ketoconazole possibly increases plasma concentration of dasatinib ", "name": "Dasatinib", "backrefs": ["Dasatinib"]}, "cautions": "seesection 8.1; susceptibility to QT-interval prolongation\r\n(correct hypokalaemia or hypomagnesaemia before starting treatment); risk of cardiac dysfunction (monitor closely);interactions: Appendix 1 (dasatinib)", "side-effects": "seesection 8.1; also diarrhoea, anorexia, weight\r\nchanges, abdominal pain, taste disturbance, constipation, dyspepsia,\r\ncolitis, gastritis; arrhythmias, congestive heart failure, hypertension,\r\nchest pain, flushing, haemorrhage (including gastro-intestinal and\r\nCNS haemorrhage), palpitation; dyspnoea, pulmonary hypertension, cough,\r\noedema (more common in patients over 65 years old), pleural effusion;\r\ndepression, dizziness, headache, insomnia, neuropathy; influenza-like\r\nsymptoms; musculoskeletal pain; visual disturbances; tinnitus; acne,\r\ndry skin, sweating, pruritus, dermatitis, urticaria;less\r\ncommonlypancreatitis, hepatitis, cholestasis, cholecystitis,\r\noesophagitis, hypotension, transient ischaemic attack, thrombophlebitis,\r\nsyncope, asthma, seizures, amnesia, tremor, drowsiness, gynaecomastia,\r\nirregular menstruation, urinary frequency, proteinuria, hypocalcaemia,\r\nrhabdomyolysis, hypersensitivity reactions (including erythema nodosum),\r\nphotosensitivity, and pigmentation and nail disorders;rarelycor pulmonale; thrombosis and interstitial lung disease also reported", "hepatic impairment": "manufacturer advises caution in hepatic impairment", "doses": ["Chronic phase chronic myeloid leukaemia,adultover 18 years 100\u00a0mg once daily, increased\r\nif necessary to max. 140\u00a0mg once daily", "Accelerated and blast phase chronic myeloid leukaemia,\r\nacute lymphoblastic leukaemia,adultover 18 years 140\u00a0mg once daily, increased if necessary to max.\r\n180\u00a0mg once daily"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies; effective\r\ncontraception required during treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "RANOLAZINE": {"indications": "as adjunctive therapy in the treatment\r\nof stable angina in patients inadequately controlled or intolerant\r\nof first-line antianginal therapies", "name": "RANOLAZINE", "renal impairment": "use with caution if eGFR 30\u201380\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of ranolazine\u2014manufacturer of ranolazine advises avoid concomitant use", "name": "Ranolazine", "backrefs": ["Ranolazine"]}, "cautions": "moderate to severe congestive heart failure; QT interval prolongation; elderly; body-weight less than 60\u00a0kg;interactions:Appendix 1 (ranolazine)", "side-effects": "constipation, nausea, vomiting; dizziness, headache,\r\nasthenia;less commonlyabdominal pain, weight loss,\r\ndry mouth, dyspepsia, flatulence; hot flush, hypotension, syncope,\r\nprolonged QT interval, peripheral oedema; dysponea, cough, epistaxis;\r\nlethargy, hypoaesthesia, drowsiness, tremor, anxiety, insomnia, anorexia;\r\ndysuria, haematuria, chromaturia; dehydration; pain in extremities,\r\nmuscle cramp, joint swelling; visual disturbance; tinnitus; pruritus,\r\nsweating;rarelypancreatitis, erosive duodenitis;\r\ncold extremities; throat tightness; amnesia, loss of consciousness,\r\ndisorientation; erectile dysfunction; parosmia, impaired hearing;\r\nallergic dermatitis, urticaria, rash", "hepatic impairment": "use with caution in mild impairment; avoid in moderate\r\nand severe impairment", "doses": ["adultover 18 years, initially\r\n375\u00a0mg twice daily, increased after 2\u20134 weeks to 500\u00a0mg twice daily\r\nand then adjusted according to response to max. 750\u00a0mg twice daily\r\n(reduce dose to 375\u2013500\u00a0mg twice daily if not tolerated)"], "pregnancy": "manufacturer advises avoid unless essential\u2014no information\r\navailable", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "SODIUM CHLORIDE": {"indications": "oral hygiene,\r\nseenotes above", "name": "SODIUM CHLORIDE", "doses": ["extemporaneous preparations should be prepared according\r\nto the following formula: sodium chloride 1.5\u00a0g,sodium bicarbonate1\u00a0g, concentrated peppermint emulsion 2.5\u00a0mL, double-strength chloroform\r\nwater 50\u00a0mL, water to 100\u00a0mL"]}, "IMIDAPRIL": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin reduces plasma concentration of active metabolite of imidapril (reduced antihypertensive effect)", "name": "Imidapril", "backrefs": ["Imidapril"]}}, "LEVOMENTHOL": {"indications": "pruritus", "name": "LEVOMENTHOL", "doses": ["apply 1\u20132 times daily"]}, "TICAGRELOR": {"indications": "in combination with aspirin for the prevention of atherothrombotic\r\nevents in patients with acute coronary syndrome", "name": "TICAGRELOR", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of ticagrelor\u2014manufacturer of ticagrelor advises avoid concomitant use", "name": "Ticagrelor", "backrefs": ["Ergot Alkaloids", "Sertraline", "Ticagrelor"]}, "cautions": "patients at increased risk of bleeding\r\n(e.g. from recent trauma, surgery, gastro-intestinal bleeding, or\r\ncoagulation disorders); concomitant use\r\nof drugs that increase risk of bleeding; discontinue 7 days before elective surgery if antiplatelet effect\r\nnot desirable; bradycardia, sick sinus syndrome, or second- or third-degree AV block (unless pacemaker fitted); asthma  or chronic obstructive pulmonary\r\ndisease; history of hyperuricaemia; monitor renal function 1 month after initiation", "side-effects": "dyspnoea, haemorrhage, bruising;less\r\ncommonlynausea, vomiting, diarrhoea, abdominal pain, dyspepsia,\r\ngastritis, dizziness, headache, rash, pruritus;rarelyconstipation, paraesthesia, confusion, hyperuricaemia, raised serum\r\ncreatinine, vertigo", "contra-indications": "active bleeding; history of intracranial haemorrhage", "hepatic impairment": "avoid in moderate or severe impairment\u2014no information\r\navailable", "doses": ["adultover 18 years, (with\r\naspirin\u2014seenotes above) initially 180\u00a0mg as a single dose,\r\nthen 90\u00a0mg twice daily"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "AZTREONAM": {"indications": "Gram-negative infections includingPseudomonas aeruginosa,Haemophilus influenzae, andNeisseria\r\nmeningitidis", "name": "AZTREONAM", "renal impairment": "if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2, usual initial\r\ndose of injection, then half normal dose; if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2, usual initial dose of injection, then one-quarter normal\r\ndose", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  coumarins possibly enhanced by aztreonam ", "name": "Aztreonam", "backrefs": ["Aztreonam"]}, "cautions": "hypersensitivity to beta-lactamantibiotics;interactions:Appendix 1 (aztreonam)", "side-effects": "Rarelygastro-intestinal bleeding, antibiotic-associated\r\ncolitis, jaundice, hepatitis, hypotension, chest pain, dyspnoea, seizures,\r\nparaesthesia, confusion, dizziness, asthenia, headache, insomnia,\r\nbreast tenderness, blood disorders (including thrombocytopenia and\r\nneutropenia), myalgia, diplopia, tinnitus, halitosis; also reported\r\nnausea, vomiting, abdominal pain, diarrhoea, mouth ulcers,\r\ntaste disturbances, flushing, bronchospasm, rash (including toxic\r\nepidermal necrolysis and erythema multiforme)", "contra-indications": "aztreonamhypersensitivity", "hepatic impairment": "use injection with caution and monitor liver function", "doses": ["By deep intramuscular injectionorby intravenous injectionover 3\u20135 minutesorby intravenous infusion, 1\u00a0g every 8 hoursor2\u00a0g every 12 hours; 2\u00a0g every 6\u20138 hours for severe infections\r\n(including systemicPseudomonas aeruginosaand\r\nlung infections in cystic fibrosis); single doses over 1\u00a0g intravenous\r\nroute only", "Urinary-tract infections, 0.5\u20131\u00a0g every 8\u201312 hours", "childover 1 week,by\r\nintravenous injectionorinfusion, 30\u00a0mg/kg every 6\u20138 hours increased in severe infections for child\r\nof 2 years or older to 50\u00a0mg/kg every 6\u20138 hours; max. 8\u00a0g daily", "Gonorrhoea, cystitis,by intramuscular injection, 1\u00a0g as a single dose", "Chronic pulmonaryPseudomonas aeruginosainfection in patients with cystic fibrosis,by inhalation\r\nof nebulised solution,adultover 18 years, 75\u00a0mg 3 times daily (at least 4 hours apart) for\r\n28 days; if additional courses required, a minimum of 28 days without\r\naztreonam nebuliser solution recommended between courses"], "pregnancy": "no information available; manufacturer of injection\r\nadvises avoid; manufacturer of powder for nebuliser solution advises\r\navoid unless essential", "breast-feeding": "amount in milk probably too small to be harmful"}, "TRIPOTASSIUM DICITRATOBISMUTHATE": {"indications": "benign gastric and duodenal ulceration;\r\nsee alsoHelicobacter pyloriinfection,section 1.3", "name": "TRIPOTASSIUM DICITRATOBISMUTHATE", "renal impairment": "avoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  tetracyclines reduced by tripotassium dicitratobismuthate ", "name": "Tripotassium Dicitratobismuthate", "backrefs": ["Tripotassium Dicitratobismuthate"]}, "cautions": "seenotes above;interactions:Appendix 1 (tripotassium dicitratobismuthate)", "side-effects": "may darken tongue and blacken faeces;less commonlynausea, vomiting, diarrhoea, constipation,\r\nrash, and pruritus reported", "doses": ["2 tablets twice dailyor1 tablet 4 times\r\ndaily; taken for 28 days followed by further 28 days if necessary;\r\nmaintenance not indicated but course may be repeated after interval\r\nof 1 month;childnot recommended"], "pregnancy": "manufacturer advises avoid on theoretical grounds", "breast-feeding": "no information available"}, "TIAGABINE": {"indications": "seenotes above", "name": "TIAGABINE", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin reduces plasma concentration of tiagabine ", "name": "Tiagabine", "backrefs": ["Tiagabine"]}, "cautions": "avoid in acute porphyria (section 9.8.2); avoid abrupt withdrawal;interactions:Appendix 1 (tiagabine)", "side-effects": "diarrhoea; dizziness, tiredness, nervousness,\r\ntremor, impaired concentration, emotional lability, speech impairment;rarelyconfusion, depression, drowsiness, psychosis, non-convulsive\r\nstatus epilepticus, bruising, and visual disturbances; suicidal ideation;\r\nleucopenia also reported", "hepatic impairment": "in mild to moderate impairment reduce dose, prolong\r\nthe dose interval, or both; avoid in severe impairment", "doses": ["Adjunctive therapy,adultandchildover 12 years, initially\r\n5\u201310\u00a0mg daily in 1\u20132 divided doses, increased in steps of 5\u201310\u00a0mg\r\ndaily at weekly intervals; usual maintenance dosewith enzyme-inducing\r\ndrugs, 30\u201345\u00a0mg daily in 2\u20133 divided doses; initial maintenance\r\ndosewithout enzyme-inducing drugs, 15\u201330\u00a0mg daily\r\nin 2\u20133 divided doses"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "COLESTIPOL": {"interactions": {"extra": "Other drugs should be taken at least 1 hour before or 4\u20136 hours after colestipol to reduce possible interference with absorption ", "bad": 0, "interaction": "absorption of  thyroid hormones reduced by colestipol ", "name": "Colestipol", "backrefs": ["Colestipol"]}}, "ETRAVIRINE": {"indications": "in combination with other antiretroviral\r\ndrugs (including a boosted protease inhibitor) for HIV infection resistant\r\nto other non-nucleoside reverse transcriptase inhibitors and protease\r\ninhibitors", "name": "ETRAVIRINE", "interactions": {"extra": "", "bad": 1, "interaction": " nevirapine possibly reduces plasma concentration of etravirine\u2014avoid concomitant use", "name": "Etravirine", "backrefs": ["Etravirine"]}, "cautions": "interactions:Appendix 1 (etravirine)", "side-effects": "rash (including Stevens-Johnson syndrome rarely\r\nand toxic epidermal necrolysis very rarely; see also Hypersensitivity\r\nReactions above); gastro-oesophageal reflux, nausea, abdominal pain,\r\nflatulence, gastritis; myocardial infarction, hypertension; peripheral\r\nneuropathy; diabetes, hyperlipidaemia (see alsoLipodystrophy Syndrome); renal failure; anaemia;less commonlypancreatitis,\r\nhaematemesis, hepatitis, angina, bronchospasm, drowsiness, malaise,\r\ngynaecomastia, blurred vision, dry mouth, and sweating; also reported,\r\nhaemorrhagic stroke and hypersensitivity reactions; see alsoOsteonecrosis", "contra-indications": "acute porphyria (but\r\nseesection 9.8.2)", "hepatic impairment": "manufacturer advises caution in moderate impairment;\r\navoid in severe impairment\u2014no information available; greater risk\r\nof hepatic side-effects in chronic hepatitis B or C", "doses": ["adultover 18 years, 200\u00a0mg\r\ntwice daily after food", "If a dose is more than 6 hours late,\r\nthe missed dose should not be taken and the next dose should be taken\r\nat the normal time"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "seeBreast-feeding"}, "DOXAPRAM": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of arrhythmias when  volatile liquid general anaesthetics given with doxapram (avoid doxapram for at least 10 minutes after volatile liquid general anaesthetics)", "name": "Doxapram", "backrefs": ["Anaesthetics, General (volatile liquids)", "Sympathomimetics", "Doxapram"]}}, "TORASEMIDE": {"indications": "oedema (seenotes above), hypertension", "name": "TORASEMIDE", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; also\r\ndry mouth;rarelylimb paraesthesia", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["Oedema, 5\u00a0mg once daily, preferably in the morning, increased\r\nif required to 20\u00a0mg once daily; usual max. 40\u00a0mg daily", "Hypertension, 2.5\u00a0mg daily, increased if necessary to 5\u00a0mg once\r\ndaily"], "pregnancy": "manufacturer advises avoid\u2014toxicity inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "PANCURONIUM BROMIDE": {"indications": "neuromuscular blockade (long duration) for surgery or during intensive\r\ncare", "name": "PANCURONIUM BROMIDE", "renal impairment": "use with caution; prolonged duration of block", "cautions": "seenotes above", "side-effects": "seenotes above", "hepatic impairment": "possibly slower onset, higher dose requirement, and\r\nprolonged recovery time", "doses": ["To avoid excessive dosage in obese patients,\r\ndose should be calculated on the basis of ideal body-weight", "Intubation,by intravenous injection,adultandchildover\r\n1 month, initially 100\u00a0micrograms/kg then 20\u00a0micrograms/kg as required;neonateseeBNF for Children", "Intensive care,by intravenous injection, initially\r\n100\u00a0micrograms/kg (optional) then 60\u00a0micrograms/kg every 60\u201390 minutes"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CEFPODOXIME": {"indications": "see under Dose", "name": "CEFPODOXIME", "renal impairment": "increase dose interval to every 24 hours if eGFR 10\u201340\u00a0mL/minute/1.73\u00a0m2; increase dose interval to every 48 hours if eGFR less than\r\n10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " histamine H2-antagonists reduce absorption of cefpodoxime ", "name": "Cefpodoxime", "backrefs": ["Cefpodoxime"]}, "cautions": "see underCefaclor;interactions:Appendix 1 (cephalosporins)", "side-effects": "see underCefaclor", "contra-indications": "see underCefaclor", "doses": ["Upper respiratory-tract infections (but in pharyngitis\r\nand tonsillitis reserved for infections which are recurrent, chronic,\r\nor resistant to other antibacterials), 100\u00a0mg twice daily (200\u00a0mg\r\ntwice daily in sinusitis);child15\r\ndays\u20136 months 4\u00a0mg/kg every 12 hours, 6 months\u20132 years 40\u00a0mg every\r\n12 hours, 3\u20138 years 80\u00a0mg every 12 hours, over 9 years 100\u00a0mg every\r\n12 hours", "Lower respiratory-tract infections (including bronchitis and\r\npneumonia), 100\u2013200\u00a0mg twice daily;child15 days\u20136 months 4\u00a0mg/kg every 12 hours, 6 months\u20132 years 40\u00a0mg\r\nevery 12 hours, 3\u20138 years 80\u00a0mg every 12 hours, over 9 years 100\u00a0mg\r\nevery 12 hours", "Skin and soft-tissue infections, 200\u00a0mg twice daily;child15 days\u20136 months 4\u00a0mg/kg every 12 hours, 6\r\nmonths\u20132 years 40\u00a0mg every 12 hours, 3\u20138 years 80\u00a0mg every 12 hours,\r\nover 9 years 100\u00a0mg every 12 hours", "Uncomplicated urinary-tract infections, 100\u00a0mg twice daily (200\u00a0mg\r\ntwice daily in uncomplicated upper urinary-tract infections);child15 days\u20136 months 4\u00a0mg/kg every 12 hours, 6\r\nmonths\u20132 years 40\u00a0mg every 12 hours, 3\u20138 years 80\u00a0mg every 12 hours,\r\nover 9 years 100\u00a0mg every 12 hours"], "pregnancy": "see underCefaclor", "breast-feeding": "present in milk in low concentration\u2014manufacturer\r\nadvises avoid"}, "EFAVIRENZ": {"indications": "HIV infection in combination with other antiretroviral drugs", "name": "EFAVIRENZ", "renal impairment": "manufacturer advises caution in severe renal failure\u2014no\r\ninformation available", "interactions": {"extra": "", "bad": 0, "interaction": " nevirapine reduces plasma concentration of efavirenz ", "name": "Efavirenz", "backrefs": ["Efavirenz"]}, "cautions": "elderly; history\r\nof mental illness or seizures; monitor liver function if receiving other\r\nhepatotoxic drugs;interactions:Appendix\r\n1 (efavirenz)", "side-effects": "rash including Stevens-Johnson syndrome (see Rash\r\nabove); abdominal pain, diarrhoea, nausea, vomiting; anxiety, depression,\r\nsleep disturbances, abnormal dreams, dizziness, headache, fatigue,\r\nimpaired concentration (administration at bedtime especially in first\r\n2\u20134 weeks reduces CNS effects); pruritus;less commonlypancreatitis, hepatitis, flushing, psychosis, mania, suicidal ideation,\r\namnesia, ataxia, tremor, convulsions, gynaecomastia, blurred vision,\r\ntinnitus;rarelyhepatic failure, photosensitivity;\r\nalso reported raised serum cholesterol (seeLipodystrophy Syndrome); see alsoOsteonecrosis", "contra-indications": "acute porphyria (but\r\nseesection 9.8.2)", "hepatic impairment": "in mild liver disease, monitor for dose related side-effects\r\n(e.g. CNS effects) and monitor liver function; avoid in moderate to\r\nsevere impairment; greater risk of hepatic side-effects in chronic\r\nhepatitis B or C", "doses": ["720\u00a0mg once daily;child3\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid (effective contraception\r\nrequired during treatment and for 12 weeks after treatment); use efavirenz\r\nonly if no alternative available", "breast-feeding": "seeBreast-feeding"}, "BLEOMYCIN": {"indications": "squamous cell carcinoma; see alsonotes above", "name": "BLEOMYCIN", "renal impairment": "reduce dose by half if serum-creatinine 177\u2013354\u00a0micromol/litre;\r\nreduce dose further if serum-creatinine greater than 354\u00a0micromol/litre", "interactions": {"extra": "", "bad": 0, "interaction": "absorption of  digoxin tablets possibly reduced by bleomycin ", "name": "Bleomycin", "backrefs": ["Bleomycin"]}, "cautions": "seesection 8.1andnotes above; caution in handling\u2014irritant\r\nto tissues;interactions: Appendix\r\n1 (bleomycin)", "side-effects": "seesection 8.1andnotes above", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic and carcinogenic inanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ALFUZOSIN": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of alfuzosin\u2014avoid concomitant use", "name": "Alfuzosin", "backrefs": ["Alfuzosin"]}}, "AMILORIDE HYDROCHLORIDE": {"indications": "oedema; potassium conservation when used as an adjunct to thiazide\r\nor loop diuretics for hypertension, congestive heart failure, or hepatic\r\ncirrhosis with ascites", "name": "AMILORIDE HYDROCHLORIDE", "renal impairment": "monitor plasma-potassium concentration (high risk of\r\nhyperkalaemia in renal impairment); manufacturers advise avoid in\r\nsevere impairment", "cautions": "monitor\r\nelectrolytes; diabetes mellitus; elderly;interactions:Appendix 1 (diuretics)", "side-effects": "abdominal pain, gastro-intestinal bleeding, dry\r\nmouth, thirst, diarrhoea, constipation, anorexia, jaundice, dyspepsia,\r\nflatulence, vomiting, nausea, angina, arrhythmias, palpitation, postural\r\nhypotension, dyspnoea, cough, nasal congestion, confusion, headache,\r\ninsomnia, weakness, tremor, agitation, dizziness, malaise, paraesthesia,\r\nencephalopathy, urinary disturbances, sexual dysfunction, hyperkalaemia,\r\nmuscle cramp, arthralgia, visual disturbance, raised intra-ocular\r\npressure, tinnitus, alopecia, pruritus, rash", "contra-indications": "hyperkalaemia; anuria; Addison\u2019s disease", "doses": ["Used alone, initially 10\u00a0mg dailyor5\u00a0mg\r\ntwice daily, adjusted according to response; max. 20\u00a0mg daily", "With other diuretics, congestive heart failure and hypertension,\r\ninitially 5\u201310\u00a0mg daily; cirrhosis with ascites, initially 5\u00a0mg daily"], "pregnancy": "not used to treat gestational hypertension", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "CICLOSPORIN": {"indications": "see under Dose; severe acute ulcerative\r\ncolitis (section 1.5.3); transplantation and graft-versus-host\r\ndisease (section 8.2.2)", "name": "CICLOSPORIN", "renal impairment": "see Cautions above", "interactions": {"extra": "", "bad": 0, "interaction": "in vitro studies suggest a possible interaction between  docetaxel and ciclosporin (consult docetaxel product literature)", "name": "Ciclosporin", "backrefs": ["Macrolides", "Carvedilol", "Ursodeoxycholic Acid", "Orlistat", "Mannitol", "Idarubicin", "Modafinil", "Bezafibrate", "Terbinafine", "Etoposide", "Sulfadiazine", "Fenofibrate", "Vitamin E", "Ciclosporin", "Mitoxantrone", "Epirubicin", "Griseofulvin", "Ezetimibe", "Doxorubicin"]}, "cautions": "section 8.2.2", "side-effects": "section 8.2.2", "hepatic impairment": "section 8.2.2", "doses": ["Short-term treatment (usually for max. 8 weeks but\r\ncan be longer under specialist supervision) of severe atopic dermatitis\r\nwhere conventional therapy ineffective or inappropriate, administered\r\nin accordance with expert advice,by mouth,adultandchildover\r\n16 years, initially 2.5\u00a0mg/kg daily in 2 divided doses, if good initial\r\nresponse not achieved within 2 weeks, increase rapidly to max. 5\u00a0mg/kg\r\ndaily; initial dose of 5\u00a0mg/kg daily in 2 divided doses if very severe;childunder 16 years seeBNF for Children", "Severe psoriasis where conventional therapy ineffective\r\nor inappropriate, administered in accordance with expert advice,by mouth,adultandchildover 16 years, initially 2.5\u00a0mg/kg daily in\r\n2 divided doses, increased gradually to max. 5\u00a0mg/kg daily if no improvement\r\nwithin 1 month (discontinue if response still insufficient after 6\r\nweeks); initial dose of 5\u00a0mg/kg daily justified if rapid control required;childunder 16 years seeBNF for Children", "For preparations and counselling and\r\nfor advice on conversion between the preparations, seesection 8.2.2"], "pregnancy": "seeImmunosuppressant Therapy", "breast-feeding": "section 8.2.2"}, "DEMECLOCYCLINE HYDROCHLORIDE": {"indications": "see notes above; also inappropriate secretion of antidiuretic hormone,section 6.5.2", "name": "DEMECLOCYCLINE HYDROCHLORIDE", "renal impairment": "seenotes above", "cautions": "seenotes above, but photosensitivity\r\nmore common (avoid exposure to sunlight or sun lamps)", "side-effects": "seenotes above; also\r\nreversible nephrogenic diabetes insipidus, acute renal failure", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; max.\r\n1\u00a0g daily in divided doses", "doses": ["150\u00a0mg every 6 hoursor300\u00a0mg every\r\n12 hours"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "ELETRIPTAN": {"indications": "treatment of acute migraine", "name": "ELETRIPTAN", "renal impairment": "reduce initial dose to 20\u00a0mg; max. 40\u00a0mg in 24 hours;\r\navoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of eletriptan (risk of toxicity)\u2014avoid concomitant use", "name": "Eletriptan", "backrefs": ["Eletriptan"]}, "cautions": "see under5HT1-receptor agonistsabove;interactions: Appendix 1 (5HT1agonists)", "side-effects": "see under5HT1-receptor\r\nagonistsabove; also abdominal pain, dry mouth, dyspepsia;\r\ntachycardia, palpitation; drowsiness, headache; pharyngitis, rhinitis,\r\nchills; myasthenia, myalgia; sweating;less commonlydiarrhoea, glossitis, thirst, anorexia, taste disturbance; dyspnoea,\r\nyawning, oedema, agitation, confusion, euphoria, depression, insomnia,\r\ndepersonalisation, tremor, dysarthria, stupor, movement disorders,\r\nhypertonia, urinary frequency, arthralgia, photophobia, visual disturbances,\r\ntinnitus, rash, and pruritus;rarelyconstipation,\r\noesophagitis, bradycardia, asthma, syncope, lymphadenopathy, and menorrhagia;\r\nischaemic colitis and hypertension also reported", "contra-indications": "see under5HT1-receptor\r\nagonistsabove; previous cerebrovascular accident or transient\r\nischaemic attack; arrhythmias; heart\r\nfailure; peripheral vascular disease", "hepatic impairment": "avoid in severe impairment", "doses": ["adultover 18 years, 40\u00a0mg\r\nrepeated after 2 hours if migraine recurs (patient not responding\r\nto initial dose should not take second dose for same attack); increase\r\nto 80\u00a0mg for subsequent attacks if 40-mg dose inadequate; max. 80\u00a0mg\r\nin 24 hours"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014avoid breast-feeding for 24\r\nhours"}, "CLADRIBINE": {"indications": "seenotes aboveand under preparations", "name": "CLADRIBINE", "renal impairment": "regular monitoring recommended", "cautions": "seesection 8.1andnotes above; use irradiated blood\r\nonly", "side-effects": "seesection 8.1andnotes above; also constipation, diarrhoea,\r\nabdominal pain, flatulence; oedema, tachycardia; cough, dyspnoea;\r\ndizziness, insomnia, anxiety, headache; chills, asthenia, malaise;\r\nmyalgia, arthralgia; sweating, rash, pruritus, and purpura", "hepatic impairment": "regular monitoring recommended", "doses": ["SeeDoses"], "pregnancy": "avoid (teratogenic inanimalstudies);\r\nmanufacturer advises that men should not father children during and\r\nfor 6 months after treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "LOSARTAN POTASSIUM": {"indications": "hypertension (including reduction of stroke risk in hypertension\r\nwith left ventricular hypertrophy); chronic heart failure when ACE\r\ninhibitors are unsuitable or contra-indicated; diabetic nephropathy\r\nin type 2 diabetes mellitus (see also notes above)", "name": "LOSARTAN POTASSIUM", "cautions": "seenotes above; severe heart failure", "side-effects": "see notes above; vertigo;less commonlygastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea,\r\nheadache, sleep disorders, malaise, urticaria, pruritus, rash;rarelyhepatitis, atrial fibrillation, cerebrovascular accident,\r\nsyncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough,\r\ndepression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia,\r\narthralgia, myalgia, renal impairment, rhabdomyolysis, tinnitus, photosensitivity,\r\nand vasculitis (including Henoch-Sch\u00f6nlein purpura)", "hepatic impairment": "consider dose reduction in mild to moderate impairment;\r\nmanufacturer advises avoid in severe impairment\u2014no information available", "doses": ["Hypertension, diabetic nephropathy in type 2 diabetes\r\nmellitus, usually 50\u00a0mg once daily (intravascular volume depletion,\r\ninitially 25\u00a0mg once daily); if necessary increased after several\r\nweeks to 100\u00a0mg once daily;elderlyover 75 years initially 25\u00a0mg daily", "Chronic heart failure, initially 12.5\u00a0mg once daily, increased\r\nat weekly intervals to max. 150\u00a0mg once daily if tolerated"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "CANNABIS EXTRACT": {"indications": "adjunct in moderate to severe spasticity in multiple sclerosis (specialist\r\nuse only)", "name": "CANNABIS EXTRACT", "renal impairment": "manufacturer advises more frequent monitoring in significant\r\nimpairment\u2014possible risk of prolonged or enhanced effect", "interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of hypertension and tachycardia when  tricyclics given with cannabis extract ", "name": "Cannabis Extract", "backrefs": ["Cannabis Extract"]}, "cautions": "significant cardiovascular disease; history of epilepsy; monitor\r\noral mucosa\u2014interrupt treatment if lesions or persistent soreness;interactions: Appendix 1 (cannabis extract)", "side-effects": "increased or decreased appetite, taste disturbance,\r\nconstipation, diarrhoea, nausea, vomiting, dry mouth, mouth ulcers,\r\noral pain, dizziness, vertigo, malaise, depression, disorientation,\r\ndissociation, mood disturbance, amnesia, impaired attention, drowsiness,\r\ndysarthria, blurred vision;less commonlyabdominal\r\npain, oromucosal and tooth discoloration, stomatitis, palpitation,\r\ntachycardia, hypertension, pharyngitis, syncope, hallucinations, paranoia,\r\ndelusions, suicidal thoughts;also reportedanxiety,\r\nseizures", "contra-indications": "personal or family history of psychosis; history\r\nof other severe psychiatric disorder", "hepatic impairment": "manufacturer advises more frequent monitoring in significant\r\nimpairment\u2014possible risk of prolonged or enhanced effect", "doses": ["Consult product literature"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risks, and recommends effective contraception during and\r\nfor 3 months after treatment in men and women", "breast-feeding": "avoid\u2014present in milk"}, "PILOCARPINE": {"indications": "see notes above; dry mouth (section 12.3.5)", "name": "PILOCARPINE", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of arrhythmias when  beta-blockers given with pilocarpine ", "name": "Pilocarpine", "backrefs": ["Pilocarpine"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["apply 1\u20131.5\u00a0cm gel once daily at bedtime"]}, "SALICYLATES": {"indications": "mild oral and perioral lesions", "contra-indications": "children under 16 years", "name": "SALICYLATES", "cautions": "not to be applied to dentures\u2014leave at\r\nleast 30 minutes before re-insertion of dentures; frequent\r\napplication, especially in children, may give rise to salicylate poisoning", "doses": ["adultandchildover 16 years, apply 3\u20134 times daily; max.\r\nduration 7 days"]}, "DIETHYLSTILBESTROL": {"indications": "seenotes above", "name": "DIETHYLSTILBESTROL", "cautions": "cardiovascular disease", "side-effects": "sodium retention with oedema, thromboembolism,\r\njaundice, feminising effects in men; see also notes above", "hepatic impairment": "avoid; see also Combined Hormonal Contraceptives (section 7.3.1)", "doses": ["Breast cancer, 10\u201320\u00a0mg daily", "Prostate cancer, 1\u20133\u00a0mg daily"], "pregnancy": "in first trimester, high doses associated with vaginal\r\ncarcinoma, urogenital abnormalities, and reduced fertility in female\r\noffspring; increased risk of hypospadias in male offspring"}, "ANTICOAGULANTS": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of haemorrhage when  ketorolac given with anticoagulants (avoid concomitant use, including low-dose heparins)", "name": "Anticoagulants", "backrefs": ["Anticoagulants"]}}, "SUXAMETHONIUM CHLORIDE": {"indications": "neuromuscular blockade (short duration)", "name": "SUXAMETHONIUM CHLORIDE", "cautions": "seenotes above; hypersensitivity to other neuromuscular blocking drugs; patients with cardiac, respiratory, or neuromuscular disease; raised intra-ocular pressure (avoid in penetrating\r\neye injury); severe sepsis (risk of hyperkalaemia);interactions:Appendix 1 (muscle relaxants)", "side-effects": "seenotes above; also increased\r\ngastric pressure; hyperkalaemia; postoperative muscle pain, myoglobinuria,\r\nmyoglobinaemia; increased intra-ocular pressure; flushing, rash;rarelyarrhythmias, cardiac arrest; bronchospasm, apnoea,\r\nprolonged respiratory depression; limited jaw mobility;very\r\nrarelyanaphylactic reactions, malignant hyperthermia;also reportedhypertension, hypotension, rhabdomyolysis", "contra-indications": "family history of malignant hyperthermia, hyperkalaemia; major trauma, severe burns, neurological disease\r\ninvolving acute wasting of major muscle, prolonged\r\nimmobilisation\u2014risk of hyperkalaemia, personal or family history of congenital\r\nmyotonic disease, Duchenne muscular dystrophy, low plasma-cholinesterase activity (including severe liver disease, see Hepatic Impairment)", "hepatic impairment": "prolonged apnoea may occur in severe liver disease\r\nbecause of reduced hepatic synthesis of pseudocholinesterase", "doses": ["By intravenous injection,adult, 1\u20131.5\u00a0mg/kg;childunder 1 year, 2\u00a0mg/kg;child1\u201318\r\nyears, 1\u00a0mg/kg", "By intramuscular injection(onset in 2\u20133 minutes),child1 month\u20131 year, up to 4\u20135\u00a0mg/kg;child1\u201312 years, up to 4\u00a0mg/kg; max. 150\u00a0mg", "Doses of suxamethonium in BNF may differ\r\nfrom those in product literature"], "pregnancy": "mildly prolonged maternal neuromuscular blockade\r\nmay occur", "breast-feeding": "unlikely to be present in breast milk in significant\r\namounts (ionised at physiological pH); breast-feeding may be resumed\r\nonce the mother recovered from neuromuscular block"}, "CO-TRIMOXAZOLE": {"indications": "seerestrictionsabove", "name": "CO-TRIMOXAZOLE", "renal impairment": "use half normal dose if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2and\r\nif plasma-sulfamethoxazole concentration cannot be monitored", "cautions": "maintain adequate fluid intake; avoid\r\nin blood disorders (unless under specialist supervision); monitor blood counts on prolonged treatment; discontinue immediately if blood disorders or rash\r\ndevelop; predisposition to folate deficiency or hyperkalaemia; elderly (seeRestrictionson the\r\nuse of Co-trimoxazole above); asthma; G6PD deficiency (section 9.1.5); avoid in infants under 6 weeks\r\n(except for treatment or prophylaxis of pneumocystis pneumonia);interactions:Appendix 1 (trimethoprim,sulfamethoxazole)", "side-effects": "nausea, diarrhoea; headache; hyperkalaemia; rash\r\n(very rarely including Stevens-Johnson syndrome, toxic epidermal necrolysis,\r\nphotosensitivity)\u2014discontinue immediately;less commonlyvomiting;very rarelyglossitis, stomatitis, anorexia,\r\nliver damage (including jaundice and hepatic necrosis), pancreatitis,\r\nantibiotic-associated colitis, myocarditis, cough and shortness of\r\nbreath, pulmonary infiltrates, aseptic meningitis, depression, convulsions,\r\nperipheral neuropathy, ataxia, tinnitus, vertigo, hallucinations,\r\nhypoglycaemia, blood disorders (including leucopenia, thrombocytopenia,\r\nmegaloblastic anaemia, eosinophilia), hyponatraemia, renal disorders\r\nincluding interstitial nephritis, arthralgia, myalgia, vasculitis,\r\nsystemic lupus erythematosus and uveitis; rhabdomyolysis reported\r\nin HIV-infected patients", "contra-indications": "acute porphyria (section 9.8.2)", "hepatic impairment": "manufacturer advises avoid in severe liver disease", "doses": ["By mouth, 960\u00a0mg every 12 hours;child, every 12 hours, 6 weeks\u20135 months, 120\u00a0mg;\r\n6 months\u20135 years, 240\u00a0mg; 6\u201312 years, 480\u00a0mg", "By intravenous infusion, 960\u00a0mg every 12 hours\r\nincreased to 1.44\u00a0g every 12 hours in severe infections;child36\u00a0mg/kg daily in 2 divided doses increased\r\nto 54\u00a0mg/kg daily in severe infections", "Treatment ofPneumocystis jirovecii(Pneumocystis carinii) infections (undertaken where facilities\r\nfor appropriate monitoring available\u2014consult microbiologist and product\r\nliterature),by mouthorby\r\nintravenous infusion,adultandchildover 4 weeks, 120\u00a0mg/kg\r\ndaily in 2\u20134 divided doses for 14\u201321 days", "Prophylaxis ofPneumocystis jirovecii(Pneumocystis carinii) infections,by mouth, 960\u00a0mg once daily (may be reduced to 480\u00a0mg once daily to improve\r\ntolerance)or960\u00a0mg on alternate days (3 times a\r\nweek)or960\u00a0mg twice daily on alternate days (3\r\ntimes a week);child6 weeks\u20135 months,\r\n120\u00a0mg twice daily on 3 consecutive or alternate days per weekoron 7 days per week; 6 months\u20135 years, 240\u00a0mg; 6\u201312 years,\r\n480\u00a0mg", "480\u00a0mg ofco-trimoxazoleconsists of sulfamethoxazole 400\u00a0mg andtrimethoprim80\u00a0mg"], "pregnancy": "teratogenic risk in first trimester (trimethoprim\r\na folate antagonist). Neonatal haemolysis and methaemoglobinaemia\r\nin third trimester; fear of increased risk of kernicterus in neonates\r\nappears to be unfounded", "breast-feeding": "small risk of kernicterus in jaundiced infants\r\nand of haemolysis in G6PD-deficient infants (due to sulfamethoxazole)"}, "LIRAGLUTIDE": {"indications": "seenotes above", "name": "LIRAGLUTIDE", "renal impairment": "avoid if eGFR less than 60\u00a0mL/minute/1.73\u00a0m2\u2014limited experience", "cautions": "discontinue if symptoms of acute pancreatitis\r\n(persistent, severe abdominal pain);interactions:Appendix 1 (antidiabetics)", "side-effects": "gastro-intestinal disturbances including nausea,\r\nvomiting, constipation, diarrhoea, dyspepsia, abdominal pain and distension,\r\nflatulence, gastritis, gastro-oesophageal reflux disease, decreased\r\nappetite; headache, dizziness, fatigue; fever, bronchitis, nasopharyngitis;\r\nhypoglycaemia; injection site reactions;also reportedacute pancreatitis, thyroid neoplasm, goitre, increased blood calcitonin,\r\nangioedema", "contra-indications": "ketoacidosis; inflammatory bowel disease; diabetic gastroparesis", "hepatic impairment": "avoid\u2014limited experience", "doses": ["By subcutaneous injection,adultover 18 years, initially 0.6\u00a0mg once daily,\r\nincreased after at least 1 week to 1.2\u00a0mg once daily, further increased\r\nif necessary after an interval of at least 1 week to max. 1.8\u00a0mg once\r\ndaily", "Dose of concomitant sulfonylurea may need\r\nto be reduced"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014no information available"}, "GABAPENTIN": {"indications": "monotherapy and adjunctive treatment of focal seizures with or without\r\nsecondary generalisation; peripheral neuropathic pain (section 4.7.3); migraine prophylaxis [unlicensed] (section 4.7.4.2)", "name": "GABAPENTIN", "renal impairment": "reduce dose to 0.6\u20131.8\u00a0g daily in 3 divided doses if\r\neGFR 50\u201380\u00a0mL/minute/1.73\u00a0m2; reduce dose to 300\u2013900\u00a0mg\r\ndaily in 3 divided doses if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; reduce dose to 300\u00a0mg on alternate days (up to max. 600\u00a0mg daily)\r\nin 3 divided doses if eGFR 15\u201330\u00a0mL/minute/1.73\u00a0m2; reduce\r\ndose to 300\u00a0mg on alternate days (up to max. 300\u00a0mg daily) in 3 divided\r\ndoses if eGFR less than 15\u00a0mL/minute/1.73\u00a0m2\u2014consult product\r\nliterature", "interactions": {"extra": "", "bad": 0, "interaction": " antacids reduce absorption of gabapentin ", "name": "Gabapentin", "backrefs": ["Gabapentin"]}, "cautions": "avoid abrupt withdrawal; elderly; diabetes mellitus; mixed seizures (including absences); false positive\r\nreadings with some urinary protein tests; history of psychotic illness;interactions:Appendix 1 (gabapentin)", "side-effects": "nausea, vomiting, gingivitis, diarrhoea, abdominal\r\npain, dyspepsia, constipation, dry mouth or throat, flatulence, weight\r\ngain, increased appetite, anorexia, hypertension, vasodilatation,\r\noedema, dyspnoea, cough, pharyngitis, hostility, confusion, emotional\r\nlability, depression, vertigo, anxiety, nervousness, abnormal thoughts,\r\ndrowsiness, dizziness, malaise, ataxia, convulsions, movement disorders, speech disorder,\r\namnesia, tremor, insomnia, headache, paraesthesia, nystagmus, abnormal\r\nreflexes, fever, flu syndrome, impotence, leucopenia, arthralgia,\r\nmyalgia, twitching, visual disturbances, rhinitis, rash, pruritus,\r\nacne;less commonlypalpitation;also reportedpancreatitis, hepatitis, hallucinations, blood glucose fluctuations\r\nin patients with diabetes, breast hypertrophy, gynaecomastia, acute\r\nrenal failure, incontinence, thrombocytopenia, tinnitus, Stevens-Johnson\r\nsyndrome, alopecia, hypersensitivity syndrome; suicidal ideation", "doses": ["Epilepsy, 300\u00a0mg once daily on day 1, then 300\u00a0mg\r\ntwice daily on day 2, then 300\u00a0mg 3 times daily on day 3orinitially 300\u00a0mg 3 times daily on day 1; then increased according\r\nto response in steps of 300\u00a0mg (in 3 divided doses) every 2\u20133 days;\r\nusual dose 0.9\u20133.6\u00a0g daily in 3 divided doses (max. 4.8\u00a0g daily in\r\n3 divided doses);child6\u201312 years\r\n(adjunctive therapy only) initially 10\u00a0mg/kg (max. 300\u00a0mg) once daily\r\non day 1, then 10\u00a0mg/kg (max. 300\u00a0mg) twice daily on day 2, then 10\u00a0mg/kg\r\n(max. 300\u00a0mg) 3 times daily on day 3; usual dose 25\u201335\u00a0mg/kg daily\r\nin 3 divided doses; max. 70\u00a0mg/kg daily in 3 divided doses;child2\u20136 years seeBNF for Children", "Neuropathic pain,adultover 18 years, 300\u00a0mg once daily on day 1, then 300\u00a0mg twice daily\r\non day 2, then 300\u00a0mg 3 times daily on day 3orinitially\r\n300\u00a0mg 3 times daily on day 1, then increased according to response\r\nin steps of 300\u00a0mg (in 3 divided doses) every 2\u20133 days up to max.\r\n3.6\u00a0g daily", "Migraine prophylaxis [unlicensed], initially 300\u00a0mg\r\ndaily, increased according to response up to 2.4\u00a0g daily in divided\r\ndoses"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "DICOBALT EDETATE": {"side-effects": "hypotension, tachycardia, and vomiting; anaphylactoid\r\nreactions including facial and laryngeal oedema and cardiac abnormalities", "indications": "severe poisoning with cyanides", "name": "DICOBALT EDETATE", "cautions": "owing to toxicity to be used only for\r\ndefinite cyanide poisoning when patient tending to lose, or has lost,\r\nconsciousness;notto\r\nbe used as a precautionary measure", "doses": ["By intravenous injection,adult300\u00a0mg over 1 minute (5 minutes if condition\r\nless serious) followed immediately by 50\u00a0mL ofglucoseintravenous infusion 50%; if response inadequate a second dose of\r\nboth may be given, but risk of cobalt toxicity;childconsult the National Poisons Information Service"]}, "LYMECYCLINE": {"indications": "see notes above", "name": "LYMECYCLINE", "renal impairment": "seenotes above", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  diuretics advised by manufacturer of lymecycline ", "name": "Lymecycline", "backrefs": ["Lymecycline"]}, "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["408\u00a0mg every 12 hours, increased to 1.224\u20131.632\u00a0g daily\r\nin severe infections", "Acne, 408\u00a0mg daily for at least 8 weeks"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "VINBLASTINE SULPHATE": {"indications": "seenotes above", "name": "VINBLASTINE SULPHATE", "cautions": "seesection 8.1andnotes above; caution in handling;interactions:Appendix 1 (vinblastine)", "side-effects": "seesection 8.1andnotes above; irritant to tissues", "contra-indications": "seesection 8.1andnotes above", "hepatic impairment": "dose reduction may be necessary", "doses": ["SeeDoses"], "pregnancy": "avoid (limited experience suggests fetal harm; teratogenic\r\ninanimalstudies); see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "NATEGLINIDE": {"indications": "type 2 diabetes mellitus in combination with metformin (section 6.1.2.2) when metformin alone inadequate", "name": "NATEGLINIDE", "interactions": {"extra": "", "bad": 0, "interaction": " rifampicin reduces plasma concentration of nateglinide ", "name": "Nateglinide", "backrefs": ["Nateglinide"]}, "cautions": "substitute insulin during intercurrent\r\nillness (such as myocardial infarction, coma, infection,\r\nand trauma) and during surgery (omit nateglinide on morning of surgery\r\nand recommence when eating and drinking normally); elderly, debilitated and malnourished\r\npatients;interactions:Appendix 1\r\n(antidiabetics)", "side-effects": "hypoglycaemia; hypersensitivity reactions including\r\npruritus, rashes and urticaria", "contra-indications": "ketoacidosis", "hepatic impairment": "caution in moderate hepatic impairment; avoid in severe\r\nimpairment\u2014no information available", "doses": ["adultover 18 years, initially\r\n60\u00a0mg 3 times daily within 30 minutes before main meals, adjusted\r\naccording to response up to max. 180\u00a0mg 3 times daily"], "pregnancy": "avoid\u2014toxicity inanimalstudies", "breast-feeding": "avoid\u2014present in milk inanimalstudies"}, "INTERFERON GAMMA": {"interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  vaccines advised by manufacturer of interferon gamma ", "name": "Interferon Gamma", "backrefs": ["Interferon Gamma"]}}, "ANTIDEPRESSANTS, SSRI (RELATED)": {"interactions": {"extra": "", "bad": 1, "interaction": " moclobemide should not be started for at least 1 week after stopping SSRI-related antidepressants ", "name": "Antidepressants, SSRI (related)", "backrefs": []}}, "ISOFLURANE": {"indications": "seenotes above", "name": "ISOFLURANE", "interactions": {"extra": "", "bad": 0, "interaction": "enhanced hypotensive effect when  calcium-channel blockers given with isoflurane ", "name": "Isoflurane", "backrefs": ["Isoflurane"]}, "cautions": "seenotes above;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Induction of anaesthesia,by inhalationusing specifically calibrated vaporiser, in oxygen ornitrous\r\noxide\u2013oxygen, increased gradually according to response\r\nfrom 0.5% to 3%", "Maintenance of anaesthesia,by inhalationusing\r\nspecifically calibrated vaporiser, 1\u20132.5% innitrous oxide\u2013oxygen; an additional 0.5\u20131% may be required when given with oxygen\r\nalone; caesarean section, 0.5\u20130.75% innitrous oxide\u2013oxygen"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "TIMOLOL": {"indications": "seenotes above", "name": "TIMOLOL", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply twice daily; long-acting preparations, apply once\r\ndaily"]}, "CALCIPOTRIOL": {"indications": "see under Dose", "name": "CALCIPOTRIOL", "cautions": "seenotes above; avoid use on face; avoid excessive exposure\r\nto sunlight and sunlamps", "side-effects": "see notes above; also photosensitivity, dry skin;rarelyfacial or perioral dermatitis", "contra-indications": "seenotes above", "doses": ["Plaque psoriasis, apply ointment once or twice daily;\r\nmax. 100\u00a0g weekly (less withscalp solution, see\r\nbelow);childover 6 years, apply twice\r\ndaily; 6\u201312 years max. 50\u00a0g weekly; over 12 years max. 75\u00a0g weekly", "Patient information leaflet forDovonex\u00aeointment advises liberal application (but note\r\nmax. recommended weekly dose, above)", "Scalp psoriasis, apply scalp solution twice daily; max. 60\u00a0mL\r\nweekly (less withointment, see below);childunder 18 years seeBNF for Children", "When preparations used together max. totalcalcipotriol5\u00a0mg in any one week (e.g. scalp solution\r\n60\u00a0mL with ointment 30\u00a0gorscalp solution 30\u00a0mL\r\nwith ointment 60\u00a0g)"], "pregnancy": "manufacturers advise avoid unless essential", "breast-feeding": "no information available"}, "NSAIDS": {"interactions": {"extra": "See also Aspirin. Interactions do not generally apply to topical NSAIDs\r\n", "bad": 1, "interaction": "excretion of  lithium reduced by NSAIDs (increased risk of toxicity)", "name": "NSAIDs", "backrefs": ["NSAIDs", "Potassium Canrenoate", "Prasugrel", "Heparins"]}}, "EPTIFIBATIDE": {"indications": "in combination with aspirin and unfractionated heparin for the prevention\r\nof early myocardial infarction in patients with unstable angina or\r\nnon-ST-segment-elevation myocardial infarction and with last episode\r\nof chest pain within 24 hours (use under specialist supervision)", "name": "EPTIFIBATIDE", "renal impairment": "reduce infusion to 1\u00a0microgram/kg/minute if eGFR 30\u201350\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of bleeding when  iloprost given with eptifibatide ", "name": "Eptifibatide", "backrefs": ["Iloprost", "Eptifibatide"]}, "cautions": "risk of bleeding, concomitant drugs that increase risk of bleeding\u2014discontinue immediately if uncontrolled serious bleeding; measure baseline prothrombin time, activated partial\r\nthromboplastin time, platelet count, haemoglobin, haematocrit and\r\nserum creatinine; monitor haemoglobin,\r\nhaematocrit and platelets within 6 hours after start of treatment\r\nthen at least once daily; discontinue if\r\nthrombolytic therapy, intra-aortic balloon pump or emergency cardiac\r\nsurgery necessary", "side-effects": "bleeding manifestations;very rarelyanaphylaxis and rash", "contra-indications": "abnormal bleeding within 30 days, major surgery or severe trauma within 6 weeks, stroke within\r\nlast 30 days or any history of haemorrhagic\r\nstroke, intracranial disease (aneurysm, neoplasm or arteriovenous\r\nmalformation), severe hypertension, haemorrhagic diathesis, increased prothrombin\r\ntime or INR, thrombocytopenia", "hepatic impairment": "avoid in severe liver disease\u2014increased risk of bleeding", "doses": ["Initiallyby intravenous injection, 180\u00a0micrograms/kg,\r\nthenby intravenous infusion, 2\u00a0micrograms/kg/minute\r\nfor up to 72 hours (up to 96 hours if percutaneous coronary intervention\r\nduring treatment)"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "BALSALAZIDE SODIUM": {"indications": "treatment of mild to moderate ulcerative colitis and maintenance\r\nof remission", "name": "BALSALAZIDE SODIUM", "renal impairment": "manufacturer advises avoid in moderate to severe impairment", "cautions": "seenotes above; also history of asthma;interactions:Appendix\r\n1 (aminosalicylates)", "side-effects": "see notes above; also cholelithiasis", "contra-indications": "seenotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["Acute attack, 2.25\u00a0g 3 times daily until remission occurs\r\nor for up to max. 12 weeks", "Maintenance, 1.5\u00a0g twice daily, adjusted according to response\r\n(max. 6\u00a0g daily)", "childunder 18 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid", "breast-feeding": "monitor infant for diarrhoea"}, "SOTALOL HYDROCHLORIDE": {"indications": "life-threatening arrhythmias including\r\nventricular tachyarrhythmias; symptomatic non-sustained ventricular\r\ntachyarrhythmias; prophylaxis of paroxysmal atrial tachycardia or\r\nfibrillation, paroxysmal AV re-entrant tachycardias (both nodal and\r\ninvolving accessory pathways), and paroxysmal supraventricular tachycardia\r\nafter cardiac surgery; maintenance of sinus rhythm following cardioversion\r\nof atrial fibrillation or flutter", "name": "SOTALOL HYDROCHLORIDE", "renal impairment": "use half normal dose if eGFR 30\u201360\u00a0mL/minute/1.73\u00a0m2; use one-quarter normal dose if eGFR 10\u201330\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "cautions": "see underPropranolol Hydrochloride; correct hypokalaemia, hypomagnesaemia,\r\nor other electrolyte disturbances; severe or prolonged\r\ndiarrhoea", "side-effects": "see underPropranolol Hydrochloride; arrhythmogenic (pro-arrhythmic) effect (torsade de pointes\u2014increased\r\nrisk in women)", "contra-indications": "see underPropranolol Hydrochloride; congenital\r\nor acquired long QT syndrome; torsade\r\nde pointes; renal failure", "doses": ["By mouthwith ECG monitoring and\r\nmeasurement of corrected QT interval, arrhythmias, initially 80\u00a0mg\r\ndaily in 1\u20132 divided doses increased gradually at intervals of 2\u20133\r\ndays to usual dose of 160\u2013320\u00a0mg daily in 2 divided doses; higher\r\ndoses of 480\u2013640\u00a0mg daily for life-threatening ventricular arrhythmias\r\nunder specialist supervision"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "Other compound alginate preparations": {"name": "Other compound alginate preparations", "doses": ["adultandchildover 12 years, 5\u201310\u00a0mL after meals and at bedtime;child2\u201312 years, 2.5\u20135\u00a0mL after meals and at bedtime\r\n(under medical advice only)"]}, "GRANISETRON": {"indications": "see under Dose", "name": "GRANISETRON", "cautions": "QT-interval prolongation (avoid concomitant use of drugs that prolong QT interval)", "side-effects": "constipation, nausea, diarrhoea, vomiting, abdominal\r\npain; headache, drowsiness, asthenia; fever;rarelyhepatic dysfunction, chest pain, arrhythmia;very rarelyanorexia, dizziness, insomnia, agitation, movement disorders, and\r\nrash", "doses": ["Nausea and vomiting induced by cytotoxic chemotherapy\r\nor radiotherapy,by mouth, 1\u20132\u00a0mg within 1 hour before\r\nstart of treatment, then 2\u00a0mg daily in 1\u20132 divided doses during treatment;\r\nwhen intravenous infusion also used, max. combined total 9\u00a0mg in 24\r\nhours;child20\u00a0micrograms/kg (max.\r\n1\u00a0mg) within 1 hour before start of treatment, then 20\u00a0micrograms/kg\r\n(max. 1\u00a0mg) twice daily for up to 5 days during treatment", "By intravenous injection(diluted in 15\u00a0mLsodium chloride0.9% and given over not less than 30 seconds)orby intravenous infusion(over 5 minutes),\r\nprevention, 3\u00a0mg before start of cytotoxic therapy (up to 2 additional\r\n3-mg doses may be given within 24 hours); treatment, as for prevention\r\n(the two additional doses must not be given less than 10 minutes apart);\r\nmax. 9\u00a0mg in 24 hours;child,by intravenous infusion, (over 5 minutes), prevention, 40\u00a0micrograms/kg\r\n(max. 3\u00a0mg) before start of cytotoxic therapy; treatment, as for prevention\u2014one\r\nadditional dose of 40\u00a0micrograms/kg (max. 3\u00a0mg) may be given within\r\n24 hours (not less than 10 minutes after initial dose)", "Postoperative nausea and vomiting,by intravenous injection(diluted to 5\u00a0mL and given over 30 seconds), prevention, 1\u00a0mg before\r\ninduction of anaesthesia; treatment, 1\u00a0mg, given as for prevention;\r\nmax. 2\u00a0mg in one day;childnot recommended"], "pregnancy": "use only when compelling reasons\u2014no information available", "breast-feeding": "avoid\u2014no information available"}, "GLUCAGON": {"indications": "see notes above and under Dose", "name": "GLUCAGON", "cautions": "seenotes above, insulinoma, glucagonoma; ineffective\r\nin chronic hypoglycaemia, starvation, and adrenal insufficiency", "side-effects": "nausea, vomiting, abdominal pain, hypokalaemia,\r\nhypotension, rarely hypersensitivity reactions", "contra-indications": "phaeochromocytoma", "doses": ["Insulin-induced hypoglycaemia,by subcutaneous,intramuscular,orintravenous\r\ninjection,adultandchildover 8 years (or body-weight over 25\u00a0kg), 1\u00a0mg;childunder 8 years (or body-weight under 25\u00a0kg),\r\n500\u00a0micrograms; if no response within 10 minutes intravenousglucosemust be given", "Diagnostic aid, consult product literature", "Beta-blocker poisoning, seeEmergency Treatment of Poisoning", "1\u00a0unit ofglucagon= 1\u00a0mg\r\nofglucagon"]}, "ERIBULIN": {"indications": "seenotes above", "name": "ERIBULIN", "renal impairment": "consider dose reduction if creatinine clearance less\r\nthan 40\u00a0mL/minute", "interactions": {"extra": "", "bad": 0, "interaction": " phenytoin possibly reduces plasma concentration of eribulin ", "name": "Eribulin", "backrefs": ["Eribulin"]}, "cautions": "seesection 8.1andnotes above; susceptibility to\r\nQT-interval prolongation (including electrolyte disturbances, concomitant\r\nuse of drugs that prolong QT-interval);interactions: Appendix 1 (eribulin)", "side-effects": "seesection 8.1andnotes above", "hepatic impairment": "reduce dose", "doses": ["SeeDoses"], "pregnancy": "avoid unless essential (teratogenic inanimal\r\nsudies); ensure effective contraception during and for up\r\nto 3 months after treatment in men or women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "ASENAPINE": {"indications": "treatment of moderate to severe manic\r\nepisodes associated with bipolar disorder", "name": "ASENAPINE", "renal impairment": "use with caution if eGFR less than 15\u00a0mL/min/1.73\u00a0m2\u2014no information available", "interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  paroxetine possibly increased by asenapine ", "name": "Asenapine", "backrefs": ["Asenapine"]}, "cautions": "seesection 4.2.1; also\r\ndementia with Lewy Bodies", "side-effects": "seesection 4.2.1; also\r\ntaste disturbance, tongue swelling, glossodynia, anxiety, speech disturbance,\r\ndysphagia, transient oral hypoaesthesia and paraesthesia, rhabdomyolysis", "hepatic impairment": "use with caution in moderate impairment; avoid in severe\r\nimpairment", "doses": ["Monotherapy,adultover\r\n18 years initially 10\u00a0mg twice daily, reduced to 5\u00a0mg twice daily\r\naccording to response", "Combination therapy,adultover\r\n18 years initially 5\u00a0mg twice daily, increased if necessary to 10\u00a0mg\r\ntwice daily according to response"], "pregnancy": "use only if potential benefit outweighs risk\u2014toxicity\r\ninanimalstudies", "breast-feeding": "avoid\u2014no information available"}, "MESALAZINE": {"indications": "treatment of mild to moderate ulcerative colitis and maintenance\r\nof remission; see also under preparations", "name": "MESALAZINE", "renal impairment": "use with caution; avoid if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2", "cautions": "seenotes above; elderly;interactions:Appendix 1\r\n(aminosalicylates)", "side-effects": "see notes above", "contra-indications": "seenotes above", "hepatic impairment": "avoid in severe impairment", "doses": ["mild ulcerative colitis affecting sigmoid colon and rectum,adultandchildover\r\n12 years, 2\u00a0metered applications (mesalazine 2\u00a0g) into the rectum\r\nat bedtime or in 2 divided doses"], "pregnancy": "negligible quantities cross placenta", "breast-feeding": "diarrhoea reported but negligible amounts detected\r\nin breast milk; monitor infant for diarrhoea"}, "5HT1-RECEPTOR AGONISTS": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  duloxetine given with 5HT1 agonists ", "name": "5HT1-receptor Agonists", "backrefs": []}}, "EPIRUBICIN": {"interactions": {"extra": "", "bad": 1, "interaction": " ciclosporin increases plasma concentration of epirubicin ", "name": "Epirubicin", "backrefs": ["Epirubicin"]}}, "PIMECROLIMUS": {"indications": "short-term treatment of mild to moderate atopic eczema (including\r\nflares) when topical corticosteroids cannot be used; see alsonotes above", "name": "PIMECROLIMUS", "cautions": "UV light (avoid excessive exposure to\r\nsunlight and sunlamps), avoid other topical\r\ntreatments except emollients at treatment site; alcohol consumption (risk of facial flushing and skin irritation)", "side-effects": "burning sensation, pruritus, erythema, skin infections\r\n(including folliculitis andless commonlyimpetigo,\r\nherpes simplex and zoster, molluscum contagiosum);rarelypapilloma, skin discoloration, local reactions including pain, paraesthesia,\r\npeeling, dryness, oedema, and worsening of eczema; skin malignancy\r\nreported", "contra-indications": "contact with eyes and mucous membranes, application under occlusion, infection at\r\ntreatment site; congenital epidermal barrier\r\ndefects; generalised erythroderma; immunodeficiency; concomitant\r\nuse with drugs that cause immunosuppression (may be prescribed in\r\nexceptional circumstances by specialists); application to malignant or potentially malignant skin lesions", "doses": ["Short-term treatment, apply twice daily until symptoms\r\nresolve (stop treatment if eczema worsens or no response after 6 weeks);childunder 2 years not recommended"]}, "POTASSIUM AMINOBENZOATE": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  sulfonamides inhibited by potassium aminobenzoate ", "name": "Potassium Aminobenzoate", "backrefs": ["Sulfonamides", "Potassium Aminobenzoate"]}}, "MICONAZOLE": {"indications": "see preparations", "name": "MICONAZOLE", "interactions": {"extra": "", "bad": 1, "interaction": "possible increased risk of myopathy when  simvastatin given with miconazole\u2014avoid concomitant use", "name": "Miconazole", "backrefs": ["Miconazole", "Glipizide"]}, "cautions": "avoid in acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(antifungals, imidazole)", "side-effects": "nausea, vomiting; rash;with buccal tablets, abdominal pain, taste disturbance, burning sensation at application\r\nsite, pruritus, and oedema;with oral gel,very rarelydiarrhoea (usually on long-term treatment),\r\nhepatitis, toxic epidermal necrolysis, and Stevens-Johnson syndrome", "contra-indications": "with oral gel, impaired swallowing reflex in infants, first 5\u20136 months\r\nof life of an infant born preterm", "hepatic impairment": "avoid", "doses": ["prevention and treatment of oral and intestinal fungal\r\ninfections, 5\u201310\u00a0mL in the mouth after food 4 times daily, retained\r\nnear oral lesions before swallowing;child4 months\u20132 years 2.5\u00a0mL twice daily, smeared around the mouth; 2\u20136\r\nyears 5\u00a0mL twice daily, retained near lesions before swallowing; over\r\n6 years 5\u00a0mL 4 times daily, retained near lesions before swallowing", "Treatment should be continued for 48 hours\r\nafter lesions have healed"], "pregnancy": "manufacturer advises avoid if possible\u2014toxicity at\r\nhigh doses inanimalstudies", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "SOLIFENACIN SUCCINATE": {"indications": "urinary frequency, urgency and urge\r\nincontinence", "name": "SOLIFENACIN SUCCINATE", "renal impairment": "max. 5\u00a0mg daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2in\r\nthose already taking itraconazole, ketoconazole, nelfinavir, or ritonavir", "cautions": "seenotes above; neurogenic bladder disorder", "side-effects": "seenotes above; also\r\ngastro-oesophageal reflux, oedema", "contra-indications": "seenotes above", "hepatic impairment": "max. 5\u00a0mg daily in moderate impairment; avoid in moderate\r\nimpairment in those already taking itraconazole, ketoconazole, nelfinavir,\r\nor ritonavir; avoid in severe impairment", "doses": ["adultover 18 years, 5\u00a0mg\r\ndaily, increased if necessary to 10\u00a0mg once daily", "Max. 5\u00a0mg daily with concomitantitraconazole,ketoconazole,nelfinavir, orritonavir"], "pregnancy": "manufacturer advises caution\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "HYOSCINE BUTYLBROMIDE": {"indications": "symptomatic relief of gastro-intestinal or genito-urinary disorders\r\ncharacterised by smooth muscle spasm; bowel colic and excessive respiratory\r\nsecretions (seeBowel Colic and Excessive\r\nRespiratory Secretions)", "name": "HYOSCINE BUTYLBROMIDE", "cautions": "seenotes above", "side-effects": "see notes above", "contra-indications": "seenotes above", "doses": ["By mouth(but poorly absorbed, see\r\nnotes above), smooth muscle spasm, 20\u00a0mg 4 times daily;child6\u201312 years, 10\u00a0mg 3 times daily", "Irritable bowel syndrome, 10\u00a0mg 3 times daily, increased if\r\nrequired up to 20\u00a0mg 4 times daily", "By intramuscularorslow intravenous injection, acute spasm and spasm\r\nin diagnostic procedures, 20\u00a0mg repeated after 30 minutes if necessary\r\n(may be repeated more frequently in endoscopy), max. 100\u00a0mg daily;child2\u201318 years seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk", "breast-feeding": "amount too small to be harmful"}, "CARBETOCIN": {"indications": "prevention of uterine atony after caesarean\r\nsection", "name": "CARBETOCIN", "renal impairment": "manufacturer advises avoid", "cautions": "hyponatraemia; cardiovascular disease (avoid if severe); migraine; asthma", "side-effects": "nausea, vomiting, abdominal pain, metallic taste;\r\nflushing, hypotension, chest pain; dyspnoea; headache, tremor, dizziness;\r\nanaemia; back pain; pruritus; feeling of warmth, chills; tachycardia\r\nand sweating also reported", "contra-indications": "pre-eclampsia and eclampsia; epilepsy", "hepatic impairment": "manufacturer advises avoid", "doses": ["Byslow intravenous injectionover 1 minute,\r\na single dose of 100\u00a0micrograms, as soon as possible after delivery,\r\npreferably before removal of placenta"]}, "NORFLOXACIN": {"indications": "see under Dose", "name": "NORFLOXACIN", "renal impairment": "use 400\u00a0mg once daily if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of norfloxacin (increased plasma concentration)", "name": "Norfloxacin", "backrefs": ["Norfloxacin"]}, "cautions": "seenotes above;interactions:Appendix 1 (quinolones)", "side-effects": "seenotes above; also tinnitus, epiphora;rarelypancreatitis;very rarelyarrhythmias; also reported, polyneuropathy and\r\nexfoliative dermatitis", "contra-indications": "seenotes above", "doses": ["\u2018Lower\u2019 urinary-tract infections, 400\u00a0mg twice daily for\r\n7\u201310 days (for 3 days for uncomplicated infections in women)", "Chronic relapsing \u2018lower\u2019 urinary-tract infections, 400\u00a0mg twice\r\ndaily for up to 12 weeks; may be reduced to 400\u00a0mg once daily if adequate\r\nsuppression within first 4 weeks", "Chronic prostatitis, 400\u00a0mg twice daily for 28 days"], "pregnancy": "seenotes above", "breast-feeding": "no information available\u2014manufacturer advises\r\navoid"}, "OXYMETAZOLINE": {"interactions": {"extra": "", "bad": 1, "interaction": "hypotensive effect of  adrenergic neurone blockers antagonised by oxymetazoline ", "name": "Oxymetazoline", "backrefs": ["Oxymetazoline"]}}, "MELATONIN": {"indications": "insomnia (short-term use)", "name": "MELATONIN", "renal impairment": "no information available\u2014use with caution", "interactions": {"extra": "", "bad": 0, "interaction": " cimetidine increases plasma concentration of melatonin ", "name": "Melatonin", "backrefs": ["Melatonin"]}, "cautions": "autoimmune disease (manufacturer\r\nadvises avoid\u2014no information available);interactions:Appendix 1 (melatonin)", "side-effects": "less commonlyabdominal pain,\r\ndyspepsia, dry mouth, mouth ulceration, weight gain, hypertension,\r\nchest pain, malaise, dizziness, restlessness, nervousness, irritability,\r\nanxiety, migraine, proteinuria, glycosuria, pruritus, rash, dry skin;rarelythirst, flatulence, halitosis, salivation, vomiting,\r\ngastritis, hypertriglyceridaemia, angina, palpitation, syncope, hot\r\nflushes, aggression, impaired memory, restless legs syndrome, paraesthesia,\r\nmood changes, priapism, increased libido, prostatitis, polyuria, haematuria,\r\nleucopenia, thrombocytopenia, electrolyte disturbances, muscle spasm,\r\narthritis, lacrimation, visual disturbances, nail disorder", "hepatic impairment": "clearance reduced\u2014avoid", "doses": ["adultover 55 years, 2\u00a0mg\r\nonce daily 1\u20132 hours before bedtime for up to 13 weeks;child1 month\u201318 years seeBNF for Children"], "pregnancy": "no information available\u2014avoid", "breast-feeding": "present in milk\u2014avoid"}, "ORAL PROGESTOGEN-ONLY CONTRACEPTIVES": {"indications": "contraception", "name": "ORAL PROGESTOGEN-ONLY CONTRACEPTIVES", "cautions": "arterial disease; sex-steroid dependent\r\ncancer; past ectopic pregnancy; malabsorption syndromes; active trophoblastic disease (until return to normal of urine- and\r\nplasma-gonadotrophin concentration)\u2014seek specialist advice; systemic lupus erythematosus with positive (or unknown)\r\nantiphospholipid antibodies; functional\r\novarian cysts; history of jaundice in pregnancy;interactions:seenotes aboveand Appendix 1 (progestogens)", "side-effects": "menstrual\r\nirregularities (see also notes above); nausea, vomiting, headache,\r\ndizziness, breast discomfort, depression, skin disorders, disturbance\r\nof appetite, weight changes, changes in libido", "contra-indications": "undiagnosed vaginal bleeding; severe\r\narterial disease; acute porphyria (section 9.8.2);history of breast\r\ncancer but can be used after 5 years if no evidence of disease and\r\nnon-hormonal contraceptive methods unacceptable", "hepatic impairment": "caution in severe liver disease and recurrent cholestatic jaundice; avoid in liver tumour", "doses": ["1 tablet daily at same time each day, starting on day\r\n1 of cycle then continuously; if administration delayed for 3 hours\r\n(12 hours forCerazette\u00ae) or more it should be\r\nregarded as a \u2018missed pill\u2019, see notes above"], "pregnancy": "not known to be harmful", "breast-feeding": "progestogen-only contraceptives do not affect\r\nlactation; see alsoAfter Childbirth"}, "BUPIVACAINE": {"interactions": {"extra": "", "bad": 1, "interaction": " propranolol increases risk of bupivacaine toxicity", "name": "Bupivacaine", "backrefs": ["Levobupivacaine", "Bupivacaine"]}}, "ZOLPIDEM TARTRATE": {"indications": "insomnia (short-term use\u2014up to 4 weeks)", "name": "ZOLPIDEM TARTRATE", "renal impairment": "use with caution", "cautions": "depression, muscle weakness and myasthenia gravis, history of drug oralcoholabuse; elderly; avoid prolonged use (and abrupt withdrawal\r\nthereafter);interactions:Appendix 1 (anxiolytics\r\nand hypnotics)", "side-effects": "diarrhoea, nausea, vomiting, dizziness, headache,\r\ndrowsiness, hallucination, agitation, asthenia, amnesia; dependence,\r\nmemory disturbances, nightmares, depression, confusion, perceptual\r\ndisturbances or diplopia, tremor, ataxia, falls, skin reactions, changes\r\nin libido; paradoxical effects (seeParadoxical Effects), muscular weakness, and sleep-walking also reported", "contra-indications": "obstructive sleep apnoea, acute or severe\r\nrespiratory depression, marked neuromuscular\r\nrespiratory weakness including unstable myasthenia\r\ngravis, psychotic illness", "hepatic impairment": "can precipitate coma; reduce dose to 5\u00a0mg (avoid if\r\nsevere impairment)", "doses": ["adultover 18 years, 10\u00a0mg\r\nat bedtime;elderly(or debilitated)\r\n5\u00a0mg"], "pregnancy": "avoid regular use (risk of neonatal withdrawal symptoms);\r\nhigh doses during late pregnancy or labour may cause neonatal hypothermia,\r\nhypotonia, and respiratory depression", "breast-feeding": "small amounts present in milk\u2014avoid"}, "FENOPROFEN": {"indications": "pain and inflammation in rheumatic disease and other\r\nmusculoskeletal disorders; mild to moderate pain", "name": "FENOPROFEN", "renal impairment": "seenotes above", "cautions": "seenotes above", "side-effects": "seenotes above; upper respiratory-tract infection,\r\nnasopharyngitis, and cystitis also reported", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["300\u2013600\u00a0mg 3\u20134 times daily; max. 3\u00a0g daily;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful; see alsonotes above"}, "NITROUS OXIDE": {"indications": "seenotes above", "name": "NITROUS OXIDE", "interactions": {"extra": "", "bad": 1, "interaction": "antifolate effect of  methotrexate increased by nitrous oxide\u2014avoid concomitant use", "name": "Nitrous Oxide", "backrefs": ["Nitrous Oxide"]}, "cautions": "seenotes above;interactions:Appendix 1 (anaesthetics, general)", "side-effects": "seenotes above", "doses": ["Maintenance of anaesthesia in conjunction with other anaesthetic\r\nagents,by inhalationusing suitable anaesthetic apparatus,\r\n50\u201366% in oxygen", "Analgesia,by inhalationusing suitable apparatus,\r\nup to 50% in oxygen, according to the patient\u2019s needs"], "pregnancy": "may depress neonatal respiration if used during delivery", "breast-feeding": "breast-feeding can be resumed as soon as mother\r\nhas recovered sufficiently from anaesthesia"}, "PHENYTOIN": {"indications": "all forms of epilepsy except absence seizures;\r\nstatus epilepticus (section 4.8.2); trigeminal neuralgia ifcarbamazepineinappropriate (see alsosection 4.7.3)", "name": "PHENYTOIN", "interactions": {"extra": "", "bad": 0, "interaction": "neurotoxicity may occur when  lithium given with phenytoin without increased plasma concentration of lithium", "name": "Phenytoin", "backrefs": ["Rifamycins", "Enteral Foods", "Disulfiram", "Tiagabine", "Ondansetron", "Retigabine", "Thyroid Hormones", "Mianserin", "Vigabatrin", "Abacavir", "Vitamin D", "Furosemide", "Carbonic Anhydrase Inhibitors", "Zonisamide", "Fluvastatin", "Ethosuximide", "Phenytoin", "Tibolone", "Eribulin", "Rufinamide", "Toremifene"]}, "cautions": "cross-sensitivity reported with carbamazepine (see alsoAntiepileptic Hypersensitivity\r\nSyndrome);  avoid abrupt withdrawal; HLA-B*1502 allele in individuals\r\nof Han Chinese or Thai origin\u2014avoid unless essential (increased risk\r\nof Stevens-Johnson syndrome); manufacturer recommends blood counts\r\n(but evidence of practical value uncertain); consider vitamin D supplementation in patients who are immobilised\r\nfor long periods or who have inadequate sun exposure or dietary intake\r\nof calcium; enteral feeding (interrupt\r\nfeeding for 2 hours before and after dose; more frequent monitoring\r\nmay be necessary); avoid in acute porphyria (section 9.8.2);interactions:seeInteractionsin section 4.8.1 and Appendix 1 (phenytoin)", "side-effects": "nausea, vomiting, constipation, drowsiness, insomnia,\r\ntransient nervousness, tremor, paraesthesia, dizziness, headache,\r\nanorexia; gingival hypertrophy and tenderness (maintain good oral\r\nhygiene); rash (discontinue; if mild re-introduce cautiously but discontinue\r\nimmediately if recurrence), acne, hirsutism, coarsening of facial\r\nappearance;rarelyhepatotoxicity (discontinue immediately\r\nand do not readminister), peripheral neuropathy, dyskinesia, lymphadenopathy,\r\nosteomalacia (see Cautions); blood disorders (including megaloblastic\r\nanaemia, leucopenia, thrombocytopenia, and aplastic anaemia), polyarteritis\r\nnodosa, lupus erythematosus, Stevens-Johnson syndrome, and toxic epidermal\r\nnecrolysis;also reportedpolyarthropathy, pneumonitis,\r\ninterstitial nephritis, hypersensitivity syndrome (seeAntiepileptic Hypersensitivity\r\nSyndrome);\r\nsuicidal ideation", "hepatic impairment": "reduce dose to avoid toxicity", "doses": ["By mouth, initially 3\u20134\u00a0mg/kg dailyor150\u2013300\u00a0mg daily (as a single doseorin 2 divided doses) increased gradually as necessary (with plasma-phenytoinconcentration monitoring); usual dose 200\u2013500\u00a0mg\r\ndaily (exceptionally, higher doses may be used);childinitially 5\u00a0mg/kg daily in 2 divided doses, usual dose range 4\u20138\u00a0mg/kg\r\ndaily (max. 300\u00a0mg daily)", "Take preferably with or after food"], "pregnancy": "changes in plasma-protein binding make interpretation\r\nof plasma-phenytoin concentrations difficult\u2014monitor unbound fraction;\r\nsee alsoPregnancy", "breast-feeding": "seeBreast-feeding"}, "PLERIXAFOR": {"indications": "seenotes above", "name": "PLERIXAFOR", "renal impairment": "reduce dose to 160\u00a0micrograms/kg daily if creatinine\r\nclearance 20\u201350\u00a0mL/minute; no information available if creatinine\r\nclearance less than 20\u00a0mL/minute", "cautions": "monitor platelet and white blood cell\r\ncount", "side-effects": "gastro-intestinal disturbances, dry mouth, oral\r\nhypoaesthesia; dizziness, headache, insomnia, fatigue; arthralgia,\r\nmusculoskeletal pain; erythema, sweating; injection-site reactions;less commonlyhypersensitivity reactions including dyspnoea\r\nand periorbital swelling", "doses": ["By subcutaneous injection,adultover 18 years, 240\u00a0micrograms/kg daily 6\u201311\r\nhours before initiation of apheresis; usual duration 2\u20134 days (max.\r\n7 days)"], "pregnancy": "manufacturer advises avoid unless essential and use\r\neffective contraception during treatment\u2014teratogenic inanimalstudies", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "DAPSONE": {"indications": "leprosy, dermatitis\r\nherpetiformis;Pneumocystis jirovecii(Pneumocystis carinii) pneumonia (section 5.4.8)", "name": "DAPSONE", "interactions": {"extra": "", "bad": 0, "interaction": " probenecid reduces excretion of dapsone (increased risk of side-effects)", "name": "Dapsone", "backrefs": ["Dapsone"]}, "cautions": "cardiac or pulmonary\r\ndisease; anaemia (treat severe anaemia before starting); susceptibility to haemolysis including G6PD deficiency (section 9.1.5); avoid in acute porphyria (section 9.8.2);interactions:Appendix 1\r\n(dapsone)", "side-effects": "(dose-related and uncommon at doses used for leprosy),\r\nhaemolysis, methaemoglobinaemia, neuropathy, allergic dermatitis (rarely\r\nincluding toxic epidermal necrolysis and Stevens-Johnson syndrome),\r\nanorexia, nausea, vomiting, tachycardia, headache, insomnia, psychosis,\r\nhepatitis, agranulocytosis;dapsonesyndrome (rash\r\nwith fever and eosinophilia)\u2014discontinue immediately (may progress\r\nto exfoliative dermatitis, hepatitis, hypoalbuminaemia, psychosis\r\nand death)", "doses": ["Leprosy, 1\u20132\u00a0mg/kg daily, seenotes above", "Dermatitis herpetiformis, see specialist literature"], "pregnancy": "folic acid 5\u00a0mg daily should be given to mother throughout\r\npregnancy; neonatal haemolysis and methaemoglobinaemia reported in\r\nthird trimester", "breast-feeding": "haemolytic anaemia; although significant amount\r\nin milk, risk to infant very small unless infant is G6PD deficient"}, "FAMOTIDINE": {"indications": "see under Dose", "name": "FAMOTIDINE", "renal impairment": "use normal dose every 36\u201348 hours or use half normal\r\ndose if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2; seizures reported\r\nvery rarely", "interactions": {"extra": "", "bad": 1, "interaction": "manufacturer of  erlotinib advises avoid concomitant use with famotidine ", "name": "Famotidine", "backrefs": ["Famotidine"]}, "cautions": "seenotes above;interactions:Appendix 1 (histamine H2-antagonists)\r\nand notes above", "side-effects": "see notes above; also constipation;less\r\ncommonlydry mouth, nausea, vomiting, flatulence, taste disorders,\r\nanorexia, fatigue;very rarelychest tightness, interstitial\r\npneumonia, seizures, paraesthesia", "doses": ["Benign gastric and duodenal ulceration, treatment, 40\u00a0mg\r\nat night for 4\u20138 weeks; maintenance (duodenal ulceration), 20\u00a0mg at\r\nnight", "Reflux oesophagitis, 20\u201340\u00a0mg twice daily for 6\u201312\u00a0weeks; maintenance,\r\n20\u00a0mg twice daily", "childnot recommended"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "present in milk\u2014not known to be harmful but\r\nmanufacturer advises avoid"}, "NEOMYCIN": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  methotrexate possibly reduced by neomycin ", "name": "Neomycin", "backrefs": ["Neomycin", "Vitamin A", "Phenoxymethylpenicillin"]}}, "PARALDEHYDE": {"interactions": {"extra": "", "bad": 1, "interaction": "risk of toxicity when  disulfiram given with paraldehyde ", "name": "Paraldehyde", "backrefs": ["Paraldehyde"]}}, "BERACTANT": {"side-effects": "seenotes above", "indications": "treatment of respiratory distress syndrome in preterm neonates over\r\n700\u00a0g; prophylaxis of respiratory distress syndrome in preterm neonates\r\nless than 32 weeks post-menstrual age", "name": "BERACTANT", "cautions": "seenotes aboveand consult product literature", "doses": ["By endotracheal tube, phospholipid 100\u00a0mg/kg\r\nequivalent to a volume of 4\u00a0mL/kg, preferably within 8 hours of birth\r\n(preferably within 15 minutes of birth for prophylaxis); dose may\r\nbe repeated within 48 hours at intervals of at least 6 hours for up\r\nto 4 doses"]}, "SELENIUM": {"indications": "selenium deficiency", "interactions": {"extra": "", "bad": 0, "interaction": " ascorbic acid possibly reduces absorption of selenium (give at least 4 hours apart)", "name": "Selenium", "backrefs": ["Ascorbic acid", "Selenium"]}, "name": "SELENIUM", "cautions": "interactions:Appendix 1 (selenium)", "doses": ["By mouthorby\r\nintramuscular injectionorby intravenous\r\ninjection, 100\u2013500\u00a0micrograms daily"]}, "CLOMIPRAMINE": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased serotonergic effects when  duloxetine given with clomipramine ", "name": "Clomipramine", "backrefs": ["Clomipramine"]}}, "AMINOGLYCOSIDES": {"interactions": {"extra": "", "bad": 0, "interaction": "possible increased risk of nephrotoxicity when  cephalosporins given with aminoglycosides ", "name": "Aminoglycosides", "backrefs": ["Aminoglycosides"]}}, "ALUMINIUM HYDROXIDE": {"indications": "hyperphosphataemia; dyspepsia (section 1.1)", "name": "ALUMINIUM HYDROXIDE", "interactions": {"extra": "", "bad": 0, "interaction": "risk of intestinal obstruction when  polystyrene sulphonate resins given with aluminium hydroxide ", "name": "Aluminium Hydroxide", "backrefs": ["Aluminium Hydroxide", "Polystyrene Sulphonate Resins"]}, "cautions": "seenotes above;interactions:Appendix 1 (antacids)", "side-effects": "constipation; hyperaluminaemia", "doses": ["phosphate-binding agent in renal failure, 4\u201320 capsules\r\ndaily in divided doses with meals"]}, "CHORIOGONADOTROPIN ALFA": {"indications": "see notes above", "name": "CHORIOGONADOTROPIN ALFA", "cautions": "acute porphyria (section 9.8.2)", "side-effects": "nausea, vomiting, abdominal pain; headache, tiredness;\r\ninjection-site reactions; ovarian hyperstimulation syndrome; rarely\r\ndiarrhoea, depression, irritability, breast pain; ectopic pregnancy\r\nand ovarian torsion reported", "contra-indications": "ovarian enlargement or cyst (unless caused\r\nby polycystic ovarian disease); ectopic pregnancy in previous 3 months; active thromboembolic disorders; hypothalamus,\r\npituitary, ovarian, uterine or mammary malignancy", "doses": ["By subcutaneous injection, according to\r\npatient\u2019s response"]}, "NITRATES": {"interactions": {"extra": "", "bad": 1, "interaction": "possible increased hypotensive effect when  vardenafil given with nitrates\u2014avoid concomitant use", "name": "Nitrates", "backrefs": ["Nitrates"]}}, "NEDOCROMIL SODIUM": {"side-effects": "burning and stinging; distinctive taste reported", "indications": "allergic conjunctivitis; seasonal keratoconjunctivitis", "name": "NEDOCROMIL SODIUM", "doses": ["Seasonal and perennial conjunctivitis,adultandchildover\r\n6 years, apply twice daily increased if necessary to 4 times daily;\r\nmax. 12 weeks treatment for seasonal allergic conjunctivitis", "Seasonal keratoconjunctivitis,adultandchildover 6 years, apply 4 times\r\ndaily"]}, "DROPERIDOL": {"indications": "prevention and treatment of postoperative\r\nnausea and vomiting", "name": "DROPERIDOL", "renal impairment": "in postoperative nausea and vomiting, max. 625\u00a0micrograms\r\nrepeated every 6 hours as required; for nausea and vomiting caused\r\nby opioid analgesics in postoperative patient-controlled analgesia,\r\nreduce dose", "interactions": {"extra": "", "bad": 1, "interaction": "increased risk of ventricular arrhythmias when  sulpiride given with droperidol\u2014avoid concomitant use", "name": "Droperidol", "backrefs": ["Droperidol"]}, "cautions": "section 4.2.1; also chronic obstructive pulmonary disease or respiratory failure; electrolyte disturbances; history of alcohol abuse; continuous pulse oximetry required if risk of ventricular arrhythmia\u2014continue\r\nfor 30 minutes following administration;interactions: Appendix 1 (droperidol)", "side-effects": "section 4.2.1; also\r\nanxiety, cardiac arrest, hallucinations, and inappropriate antidiuretic\r\nhormone secretion", "contra-indications": "section 4.2.1; QT-interval prolongation (avoid concomitant\r\nadministration of drugs that prolong QT interval); hypokalaemia; hypomagnesaemia; bradycardia", "hepatic impairment": "in postoperative nausea and vomiting, max. 625\u00a0micrograms\r\nrepeated every 6 hours as required; for nausea and vomiting caused\r\nby opioid analgesics in postoperative patient-controlled analgesia,\r\nreduce dose", "doses": ["Prevention and treatment of postoperative nausea and vomiting,adultover 18 years,by intravenous injection, 0.625\u20131.25\u00a0mg (elderly625\u00a0micrograms)\r\n30 minutes before end of surgery, repeated every 6 hours as required;childover 2 years (second-line use only) 20\u201350\u00a0micrograms/kg\r\n(max. 1.25\u00a0mg)", "Prevention of nausea and vomiting caused by opioid analgesics\r\nin postoperative patient-controlled analgesia (PCA),adultover 18 years,by intravenous injection, 15\u201350\u00a0micrograms of droperidol for every 1\u00a0mg of morphine in PCA\r\n(max. 5\u00a0mg droperidol daily);elderlyreduce dose"], "pregnancy": "section 4.2.1", "breast-feeding": "limited information available\u2014avoid repeated\r\nadministration"}, "NICARDIPINE HYDROCHLORIDE": {"indications": "prophylaxis of angina; mild to moderate hypertension", "name": "NICARDIPINE HYDROCHLORIDE", "renal impairment": "start with small dose", "cautions": "withdraw if ischaemic pain occurs\r\nor existing pain worsens within 30 minutes of initiating treatment\r\nor increasing dose; congestive heart failure or significantly impaired left ventricular function; elderly;interactions:Appendix 1 (calcium-channel blockers)", "side-effects": "dizziness, headache, peripheral oedema, flushing,\r\npalpitation, nausea; also gastro-intestinal disturbances, drowsiness,\r\ninsomnia, tinnitus, hypotension, rashes, dyspnoea, paraesthesia, frequency\r\nof micturition; thrombocytopenia, depression and impotence reported;overdosage, seeEmergency Treatment of Poisoning", "contra-indications": "cardiogenic shock; advanced aortic stenosis; unstable or acute attacks of angina; avoid within 1 month of myocardial infarction; acute porphyria (section 9.8.2)", "hepatic impairment": "half-life prolonged in severe impairment\u2014may need dose\r\nreduction", "doses": ["Initially 20\u00a0mg 3 times daily, increased, after at least\r\nthree days, to 30\u00a0mg 3 times daily (usual range 60\u2013120\u00a0mg daily)"], "pregnancy": "may inhibit labour; toxicity inanimalstudies; manufacturer advises avoid, but risk to fetus should be\r\nbalanced against risk of uncontrolled maternal hypertension", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "CODEINE PHOSPHATE": {"indications": "mild to moderate pain; diarrhoea (section 1.4.2); cough suppression (section 3.9.1)", "name": "CODEINE PHOSPHATE", "renal impairment": "seenotes above", "cautions": "seenotes above; also cardiac arrhythmias; acute abdomen; gallstones", "side-effects": "seenotes above; also\r\nabdominal pain, anorexia, seizures, malaise, hypothermia, antidiuretic\r\neffect, and muscle fasciculation; pancreatitis also reported", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["By mouth, 30\u201360\u00a0mg every 4 hours when necessary,\r\nto a max. of 240\u00a0mg daily;child1\u201312\r\nyears, 3\u00a0mg/kg daily in divided doses", "By intramuscular injection, 30\u201360\u00a0mg every 4\r\nhours when necessary"], "pregnancy": "seenotes above", "breast-feeding": "amount usually too small to be harmful; however\r\nmothers vary considerably in their capacity to metabolise codeine\u2014risk\r\nof morphine overdose in infant"}, "CHLORAMPHENICOL": {"indications": "bacterial infection in otitis externa (but seenotes above)", "name": "CHLORAMPHENICOL", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  tacrolimus possibly increased by chloramphenicol ", "name": "Chloramphenicol", "backrefs": ["Hydroxocobalamin", "Chloramphenicol"]}, "cautions": "avoid prolonged use (seenotes above)", "side-effects": "high incidence of sensitivity reactions to vehicle", "doses": ["ear, apply 2\u20133 drops 2\u20133 times daily"]}, "BACILLUS CALMETTE-GU\u00c9RIN VACCINE": {"indications": "immunisation against tuberculosis", "name": "BACILLUS CALMETTE-GU\u00c9RIN VACCINE", "cautions": "seesection 14.1;interactions:Appendix 1 (vaccines)", "side-effects": "seesection 14.1andnotes above;alsoat the injection\r\nsite, subcutaneous abscess, prolonged ulceration;rarelydisseminated complications such as osteitis or osteomyelitis", "contra-indications": "seesection 14.1;alsoneonate in household contact with known or suspected case of active\r\ntuberculosis; generalised septic skin conditions (for patients with eczema, lesion-free site should\r\nbe used)", "doses": ["By intradermal injectionadultandchildover\r\n1 year, 0.1\u00a0mL;neonateandchildunder 1 year, 0.05\u00a0mL", "Skin is stretched\r\nbetween thumb and forefinger and needle (size 25G or 26G) inserted\r\n(bevel upwards) for about 3\u00a0mm into superficial layers of dermis (almost\r\nparallel with surface). Needle should be short with short bevel (can\r\nusually be seen through epidermis during insertion). Tense raised\r\nblanched bleb showing tips of hair follicles is sign of correct injection;\r\n7\u00a0mm bleb \u2261 0.1\u00a0mL injection, 3\u00a0mm bleb \u2261 0.05\u00a0mL injection; if considerable\r\nresistance not felt, needle too deep and should be removed and reinserted\r\nbefore giving more vaccine.", "To be injected at insertion of deltoid muscle onto humerus (keloid\r\nformation more likely with sites higher on arm); tip\r\nof shoulder should beavoided."], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "INTERFERON BETA": {"indications": "seenotes aboveand under preparations", "name": "INTERFERON BETA", "renal impairment": "seenotes above", "cautions": "seenotes aboveand consult product literature", "side-effects": "seenotes aboveand consult product literature", "contra-indications": "seenotes aboveand consult product literature", "hepatic impairment": "seenotes above", "doses": ["for relapsing, remitting multiple sclerosis, consult product\r\nliterature"], "pregnancy": "avoid unless potential benefit outweighs risk (toxicity\r\ninanimalstudies); effective contraception required\r\nduring treatment\u2014consult product literature", "breast-feeding": "avoid\u2014no information available"}, "EDROPHONIUM CHLORIDE": {"indications": "see under Dose; myasthenia gravis (section 10.2.1)", "name": "EDROPHONIUM CHLORIDE", "cautions": "section 10.2.1; atropine should\r\nalso be given", "side-effects": "section 10.2.1", "contra-indications": "section 10.2.1", "doses": ["Brief reversal of non-depolarising neuromuscular blockade,by intravenous injectionover several minutes, 500\u2013700\u00a0micrograms/kg\r\n(after or with atropine)", "Diagnosis of dual block,by intravenous injection, 10\u00a0mg"], "pregnancy": "section 10.2.1", "breast-feeding": "section 10.2.1"}, "NILOTINIB": {"indications": "seenotes above", "name": "NILOTINIB", "interactions": {"extra": "", "bad": 1, "interaction": "avoidance of  ritonavir advised by manufacturer of nilotinib ", "name": "Nilotinib", "backrefs": ["Nilotinib"]}, "cautions": "seesection 8.1; history of pancreatitis; susceptibility to QT-interval prolongation (including\r\nelectrolyte disturbances, concomitant use of drugs that prolong QT\r\ninterval);interactions:Appendix 1\r\n(nilotinib)", "side-effects": "seesection 8.1; also abdominal pain, constipation,\r\ndiarrhoea, dyspepsia, flatulence, anorexia, weight changes; palpitation,\r\nQT-interval prolongation, hypertension, oedema, flushing; dyspnoea,\r\ncough, dysphonia; headache, fatigue, asthenia, dizziness, paraesthesia,\r\ninsomnia, vertigo; hypomagnesaemia, hyperkalaemia, blood glucose changes;\r\nbone pain, arthralgia, muscle spasm; urticaria, erythema, hyperhidrosis,\r\ndry skin, rash, pruritus;less commonlyhepatitis,\r\npancreatitis, dry mouth, chest pain, cardiac failure, arrhythmias,\r\npericardial effusion, coronary artery disease, cardiomegaly, cardiac\r\nmurmur, bradycardia, hypertensive crisis, haemorrhage, melaena, haematoma,\r\npleural effusion, interstitial lung disease, migraine, hypoaesthesia,\r\nhyperaesthesia, depression, anxiety, tremor, influenza-like symptoms,\r\nhyperthyroidism, breast pain, gynaecomastia, erectile dysfunction,\r\ndysuria, urinary frequency, hypokalaemia, hyponatraemia, hypocalcaemia,\r\nhypophosphataemia, dehydration,  decreased visual acuity, conjunctivitis,\r\ndry eyes, epistaxis, and ecchymosis", "hepatic impairment": "manufacturer advises caution", "doses": ["Newly diagnosed chronic myeloid leukaemia, chronic phase,adultover 18 years, 300\u00a0mg twice daily", "Chronic and accelerated phase chronic myeloid leukaemia (see\r\nnotes above),adultover\r\n18 years, 400\u00a0mg twice daily"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies; effective\r\ncontraception required during treatment; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid\u2014present in milk inanimalstudies"}, "TOCILIZUMAB": {"indications": "see underCytokine Modulatorsabove", "name": "TOCILIZUMAB", "renal impairment": "manufacturer advises monitor renal function closely in\r\nmoderate or severe impairment", "interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of live  vaccines with tocilizumab (see under Active Immunity, section 14.1)", "name": "Tocilizumab", "backrefs": ["Tocilizumab"]}, "cautions": "predisposition to infection or history of recurrent or chronic infection; interrupt treatment if serious infection occurs; history of intestinal ulceration or diverticulitis; monitor hepatic transaminases every 4\u20138 weeks for\r\nfirst 6 months, then every 12 weeks; monitor\r\nneutrophil and platelet counts 4\u20138 weeks after starting treatment\r\nand then as indicated; low platelet or absolute neutrophil\r\ncount (discontinue if absolute neutrophil count less than 0.5 \u00d7 109/litre or platelet count less than 50 \u00d7 103/microlitre); monitor lipid profile 4\u20138 weeks after starting treatment and then\r\nas indicated; monitor for demyelinating\r\ndisorders;interactions: Appendix 1\r\n(tocilizumab)", "side-effects": "abdominal pain, mouth ulceration, gastritis, raised\r\nhepatic transaminases; dizziness, peripheral oedema, hypertension,\r\nhypercholesterolaemia; headache; infection (including upper respiratory-tract\r\ninfection); antibody formation, hypersensitivity, leucopenia, neutropenia;\r\nrash, pruritus;less commonlygastric ulcer, gastro-intestinal\r\nperforation, hypertriglyceridaemia, hypothyroidism, nephrolithiasis,\r\ninfusion related reactions, anaphylaxis, and thrombocytopenia also\r\nreported", "contra-indications": "severe active infection (see also Cautions); do not initiate if absolute neutrophil count\r\nless than 2 \u00d7 109/litre (see also Cautions)", "hepatic impairment": "manufacturer advises caution (see also Dose below)", "doses": ["By intravenous infusion,adultover 18 years, 8\u00a0mg/kg (max. 800\u00a0mg) once every\r\n4 weeks; for details of dose adjustment in patients with liver enzyme\r\nabnormalities, or low absolute neutrophil or platelet count, consult\r\nproduct literature"], "pregnancy": "manufacturer advises avoid unless essential (toxicity\r\ninanimalstudies); effective contraception required\r\nduring and for 3 months after treatment", "breast-feeding": "manufacturer advises use only if potential benefit\r\noutweighs risk \u2014no information available"}, "FORMOTEROL FUMARATE": {"indications": "reversible airways obstruction (including nocturnal asthma and prophylaxis\r\nof exercise-induced bronchospasm) in patients requiring long-term\r\nregular bronchodilator therapy, see alsoManagement of Chronic Asthma\r\ntable;\r\nchronic obstructive pulmonary disease", "name": "FORMOTEROL FUMARATE", "cautions": "seenotes above", "side-effects": "seenotes above;very rarelyQT-\r\ninterval prolongation; taste disturbances, nausea, dizziness, rash,\r\nand pruritus also reported", "doses": ["by inhalation of powder, chronic asthma,\r\n6\u201312\u00a0micrograms 1\u20132 times daily, increased up to 24\u00a0micrograms twice\r\ndaily if necessary; occasionally up to 72\u00a0micrograms daily may be\r\nneeded (max. single dose 36\u00a0micrograms); reassess treatment if additional\r\ndoses required on more than 2 days a week;child6\u201318 years, 6\u201312\u00a0micrograms 1\u20132 times daily; occasionally up to\r\n48\u00a0micrograms daily may be needed (max. single dose 12\u00a0micrograms)\r\n(see alsoCHM advice)"], "pregnancy": "seesection 3.1", "breast-feeding": "seesection 3.1"}, "POTASSIUM BICARBONATE": {"indications": "seenotes above", "name": "POTASSIUM BICARBONATE", "renal impairment": "close monitoring required\u2014high risk of hyperkalaemia;\r\navoid in severe impairment", "cautions": "elderly; cardiac\r\ndisease;interactions:Appendix 1 (potassium\r\nsalts)", "side-effects": "nausea, vomiting, abdominal pain, diarrhoea, and\r\nflatulence", "contra-indications": "hypochloraemia; plasma-potassium concentration above 5\u00a0mmol/litre", "doses": ["Seenotes above"]}, "RILUZOLE": {"indications": "to extend life in patients with amyotrophic lateral sclerosis, initiated\r\nby specialists experienced in the management of motor neurone disease", "name": "RILUZOLE", "renal impairment": "avoid\u2014no information available", "cautions": "history of abnormal hepatic function\r\n(consult product literature for details)", "side-effects": "nausea, vomiting, diarrhoea, abdominal pain; tachycardia;\r\nasthenia, headache, dizziness, drowsiness, oral paraesthesia;less commonlyinterstitial lung disease, pancreatitis, angioedema,\r\nand anaemia;rarelyneutropenia;very rarelyhepatitis", "hepatic impairment": "avoid; see also under Cautions", "doses": ["50\u00a0mg twice daily;childnot recommended"], "pregnancy": "avoid\u2014no information available", "breast-feeding": "avoid\u2014no information available"}, "MOCLOBEMIDE": {"indications": "depressive illness; social anxiety disorder", "name": "MOCLOBEMIDE", "interactions": {"extra": "", "bad": 1, "interaction": "risk of CNS toxicity when  rizatriptan given with moclobemide (avoid rizatriptan for 2 weeks after moclobemide)", "name": "Moclobemide", "backrefs": ["Moclobemide", "Antidepressants, SSRI (related)"]}, "cautions": "avoid in agitated or excited patients (or give with sedative for\r\nup to 2\u20133 weeks), thyrotoxicosis, may provoke\r\nmanic episodes in bipolar disorders;interactions:seenotes aboveand Appendix\r\n1 (moclobemide)", "side-effects": "sleep disturbances, dizziness, gastro-intestinal\r\ndisorders, headache, restlessness, agitation; paraesthesia, dry mouth,\r\nvisual disturbances, oedema, skin reactions, confusional states reported;rarelyraised liver enzymes, galactorrhoea; hyponatraemia\r\n(see Hyponatraemia and Antidepressant Therapy,section 4.3)", "contra-indications": "acute confusional states, phaeochromocytoma", "hepatic impairment": "reduce dose in severe disease", "doses": ["Depression, initially 300\u00a0mg daily usually in divided\r\ndoses after food, adjusted according to response; usual range 150\u2013600\u00a0mg\r\ndaily;childnot recommended", "Social anxiety disorder, initially 300\u00a0mg daily increased on\r\nfourth day to 600\u00a0mg daily in 2 divided doses, continued for 8\u201312\r\nweeks to assess efficacy;childnot\r\nrecommended"], "pregnancy": "seenotes above", "breast-feeding": "amount too small to be harmful, but patient\r\ninformation leaflet advises avoid"}, "SALICYLIC ACID": {"indications": "fungal nail infections, particularly\r\ntinea; hyperkeratotic skin disorders (section 13.5.2); warts and calluses (section 13.7)", "name": "SALICYLIC ACID", "cautions": "avoid broken or inflamed skin", "side-effects": "see notes above", "doses": ["adultandchildover 5 years, apply twice daily and after washing"], "pregnancy": "avoid"}, "OLSALAZINE SODIUM": {"indications": "treatment of mild ulcerative colitis and maintenance of remission", "name": "OLSALAZINE SODIUM", "renal impairment": "use with caution; manufacturer advises avoid in significant\r\nimpairment", "cautions": "seenotes above;interactions:Appendix 1 (aminosalicylates)", "side-effects": "see notes above; watery diarrhoea common; also\r\nreported, tachycardia, palpitation, pyrexia, blurred vision, and photosensitivity", "contra-indications": "seenotes above", "doses": ["adultandchildover 12 years, acute attack, 1\u00a0g daily in divided\r\ndoses after meals increased if necessary over 1 week to max. 3\u00a0g daily\r\n(max. single dose 1\u00a0g); maintenance, 500\u00a0mg twice daily after meals", "childunder 12 years seeBNF for Children"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk", "breast-feeding": "monitor infant for diarrhoea"}, "INOSINE PRANOBEX": {"indications": "see under Dose", "name": "INOSINE PRANOBEX", "renal impairment": "manufacturer advises caution; metabolised to uric acid", "cautions": "history of gout or hyperuricaemia", "side-effects": "reversible increase in serum and urinary uric\r\nacid;less commonlynausea, vomiting, epigastric\r\ndiscomfort, headache, vertigo, fatigue, arthralgia, rashes and itching;rarelydiarrhoea, constipation, anxiety, sleep disturbances,\r\nand polyuria", "doses": ["Mucocutaneous herpes simplex, 1\u00a0g 4 times daily for 7\u201314\r\ndays", "Adjunctive treatment of genital warts, 1\u00a0g 3 times daily for\r\n14\u201328 days", "Subacute sclerosing panencephalitis, 50\u2013100\u00a0mg/kg daily in 6\r\ndivided doses"], "pregnancy": "manufacturer advises avoid"}, "DEXTROPROPOXYPHENE": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir increases plasma concentration of dextropropoxyphene (risk of toxicity)\u2014avoid concomitant use", "name": "Dextropropoxyphene", "backrefs": ["Dextropropoxyphene"]}}, "HISTAMINE H2-ANTAGONISTS": {"interactions": {"extra": "", "bad": 0, "interaction": "absorption of  itraconazole reduced by histamine H2-antagonists ", "name": "Histamine H2-antagonists", "backrefs": ["Histamine H2-antagonists", "Cefpodoxime"]}}, "FIBRATES": {"interactions": {"extra": "", "bad": 0, "interaction": "may be improved glucose tolerance and an additive effect when  insulin given with fibrates ", "name": "Fibrates", "backrefs": ["Fibrates"]}}, "RIVASTIGMINE": {"indications": "mild to moderate dementia in Alzheimer\u2019s disease or in Parkinson\u2019s\r\ndisease", "name": "RIVASTIGMINE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "effects of  non-depolarising muscle relaxants antagonised by rivastigmine ", "name": "Rivastigmine", "backrefs": ["Rivastigmine"]}, "cautions": "gastric or duodenal ulcers (or susceptibility to ulcers); monitor body-weight; sick sinus syndrome, conduction\r\nabnormalities; history of asthma or chronic obstructive pulmonary\r\ndisease; history of seizures; bladder outflow obstruction;interactions:Appendix 1 (parasympathomimetics)", "side-effects": "nausea, vomiting, diarrhoea, dyspepsia, anorexia,\r\nweight loss, increased salivation, abdominal pain, bradycardia, dizziness,\r\nheadache, drowsiness, malaise, agitation, anxiety, tremor, confusion,\r\ninsomnia, extrapyramidal symptoms (and worsening of Parkinson\u2019s disease),\r\nsweating;less commonlyatrial fibrillation, AV block,\r\ndepression, syncope;rarelygastric and duodenal\r\nulceration, angina, seizures, rash;very rarelygastro-intestinal\r\nhaemorrhage, pancreatitis, tachycardia, hypertension, hallucinations;also reporteddehydration, hepatitis, restlessness, aggression,\r\nsick sinus syndrome", "hepatic impairment": "use with caution", "doses": ["By mouth, initially 1.5\u00a0mg twice daily,\r\nincreased in steps of 1.5\u00a0mg twice daily at intervals of at least\r\n2 weeks according to response and tolerance; usual range 3\u20136\u00a0mg twice\r\ndaily; max. 6\u00a0mg twice daily; if treatment interrupted for more than\r\nseveral days, treatment should be retitrated from 1.5\u00a0mg twice daily", "By transdermal application, initially apply 4.6\u00a0mg/24\r\nhours patch to clean, dry, non-hairy, non-irritated skin on back,\r\nupper arm, or chest, removing after 24 hours and siting a replacement\r\npatch on a different area (avoid using the same area for 14 days);\r\nif well tolerated increase to 9.5\u00a0mg/24 hours patch daily after at\r\nleast 4 weeks; if treatment interrupted for more than several days,\r\ntreatment should be retitrated from 4.6\u00a0mg/24 hours patch", "When switching from oral to transdermal therapy,\r\npatients taking 3\u20136\u00a0mg by mouth daily should initially switch to 4.6\u00a0mg/24\r\nhours patch (then titrate as above); patients taking 9\u201312\u00a0mg by mouth\r\ndaily should switch to 9.5\u00a0mg/24 hours patch. The first patch should\r\nbe applied on the day following the last oral dose"]}, "CANAKINUMAB": {"indications": "seenotes above", "name": "CANAKINUMAB", "renal impairment": "limited information available but manufacturer advises\r\nno dose adjustment required", "cautions": "history of recurrent infection or predisposition to infection; monitor neutrophil count before starting treatment, 1\u20132 months after\r\nstarting treatment, and periodically thereafter; patients should receive all recommended vaccinations (including pneumococcal\r\nand inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs\r\nrisk\u2014consult product literature andsection 14.1for further information", "side-effects": "vertigo, increased susceptibility to infection,\r\ninjection-site reactions", "contra-indications": "severe active infection (see also Cautions); neutropenia; concomitant use with tumour necrosis factor inhibitors (possible\r\nincreased risk of infections)", "hepatic impairment": "no information available", "doses": ["By subcutaneous injection,adultandchildover\r\n4 years, body-weight 15\u201340\u00a0kg, 2\u00a0mg/kg every 8 weeks; if response\r\ninadequate 7 days after starting treatment, consider a second dose\r\nof 2\u00a0mg/kg; if a full response is then achieved, subsequent dosing\r\nshould be 4\u00a0mg/kg every 8 weeks; body-weight over 40\u00a0kg, 150\u00a0mg every\r\n8 weeks; if response inadequate 7 days after starting treatment, consider\r\na second dose of 150\u00a0mg; if a full response is then achieved,\r\nsubsequent dosing should be 300\u00a0mg every 8 weeks"], "pregnancy": "manufacturer advises avoid unless potential benefit\r\noutweighs risk; effective contraception required during treatment\r\nand for up to 3 months after last dose", "breast-feeding": "consider if benefit outweighs risk\u2014not known\r\nif present in human milk"}, "BUPRENORPHINE": {"indications": "adjunct in the treatment of opioid dependence;\r\npremedication, peri-operative analgesia, analgesia in other situations\r\n(section 4.7.2)", "name": "BUPRENORPHINE", "renal impairment": "see notes insection 4.7.2", "interactions": {"extra": "", "bad": 0, "interaction": " ritonavir possibly increases plasma concentration of buprenorphine ", "name": "Buprenorphine", "backrefs": ["Buprenorphine"]}, "cautions": "see Buprenorphine insection 4.7.2andnotes above; caution if pre-existing\r\nliver enzyme abnormalities, hepatitis B or C infection,\r\nor concomitant use of hepatotoxic drugs", "side-effects": "see Buprenorphine,section 4.7.2", "contra-indications": "see notes insection 4.7.2", "hepatic impairment": "see notes insection 4.7.2", "doses": ["By sublingual administration,adultandchildover\r\n16 years, initially, 0.8\u20134\u00a0mg on day 1, adjusted if necessary by 2\u20134\u00a0mg\r\ndaily to usual dose of 12\u201324\u00a0mg daily (max. 32\u00a0mg daily); withdraw\r\ngradually"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "BISOPROLOL": {"interactions": {"extra": "", "bad": 0, "interaction": " rifampicin accelerates metabolism of bisoprolol (plasma concentration  significantly reduced)", "name": "Bisoprolol", "backrefs": ["Bisoprolol"]}}, "DONEPEZIL": {"interactions": {"extra": "", "bad": 0, "interaction": "effects of  non-depolarising muscle relaxants possibly antagonised by donepezil ", "name": "Donepezil", "backrefs": ["Donepezil"]}}, "INDAPAMIDE": {"indications": "essential hypertension", "name": "INDAPAMIDE", "renal impairment": "seenotes above", "cautions": "seenotes above; also acute porphyria (section 9.8.2)", "side-effects": "seenotes above; also\r\npalpitation, diuresis with doses above 2.5\u00a0mg daily", "contra-indications": "seenotes above; also hypersensitivity to sulfonamides", "hepatic impairment": "seenotes above", "doses": ["hypertension, 1 tablet daily, preferably in the morning"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014manufacturer advises avoid"}, "BETAINE": {"indications": "(specialist use only) adjunctive treatment of homocystinuria", "name": "BETAINE", "cautions": "monitor plasma-methionine concentration\r\nbefore and during treatment\u2014interrupt treatment\r\nif symptoms of cerebral oedema occur", "side-effects": "less commonlygastro-intestinal\r\ndisorders, anorexia, reversible cerebral oedema (see Cautions), agitation,\r\ndepression, personality disorder, sleep disturbances, urinary incontinence,\r\nalopecia, and urticaria", "doses": ["adultandchildover 10 years, 3\u00a0g twice daily, adjusted according\r\nto response; max. 20\u00a0g/day;childunder\r\n10 years 50\u00a0mg/kg twice daily, dose and frequency adjusted according\r\nto response; max. 75\u00a0mg/kg twice daily"], "pregnancy": "manufacturer advises avoid unless essential\u2014limited\r\ninformation available", "breast-feeding": "manufacturer advises caution\u2014no information\r\navailable"}, "CLOBETASONE BUTYRATE": {"indications": "eczemas and dermatitis of all types;\r\nmaintenance between courses of more potentcorticosteroids", "name": "CLOBETASONE BUTYRATE", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "doses": ["Apply thinly 1\u20132 times daily"]}, "TETRABENAZINE": {"indications": "see Dose", "name": "TETRABENAZINE", "renal impairment": "use with caution", "interactions": {"extra": "", "bad": 0, "interaction": "increased risk of extrapyramidal side-effects when  metoclopramide given with tetrabenazine ", "name": "Tetrabenazine", "backrefs": ["Tetrabenazine"]}, "cautions": "avoid abrupt withdrawal; susceptibility to QT-interval\r\nprolongation (including concomitant use of drugs that prolong QT interval);interactions:Appendix 1 (tetrabenazine)", "side-effects": "dysphagia, nausea, vomiting, diarrhoea, constipation,\r\nhypotension, depression, anxiety, insomnia, confusion, drowsiness,\r\nparkinsonism;less commonlyaltered consciousness\r\nlevel, extrapyramidal disorders, hyperthermia;rarelyneuroleptic malignant syndrome;very rarelyrhabdomyolysis;also reporteddry mouth, dyspepsia, bradycardia, disorientation,\r\nagitation, dizziness, amnesia, ataxia", "contra-indications": "depression, parkinsonism, phaeochromocytoma,\r\nprolactin-dependent tumours", "hepatic impairment": "use half initial dose and slower dose titration in\r\nmild to moderate impairment; use with caution in severe impairment", "doses": ["Movement disorders due to Huntington\u2019s chorea, hemiballismus,\r\nsenile chorea, and related neurological conditions, initially 25\u00a0mg\r\n3 times daily, increased by 25\u00a0mg every 3\u20134 days as tolerated to max.\r\n200\u00a0mg daily", "Lower initial doses may be necessary in elderly\r\npatients", "Moderate to severe tardive dyskinesia, initially 12.5\u00a0mg daily,\r\ngradually increased according to response"], "pregnancy": "avoid unless essential\u2014toxicity inanimalstudies", "breast-feeding": "avoid"}, "ISOCARBOXAZID": {"indications": "depressive illness", "name": "ISOCARBOXAZID", "renal impairment": "use with caution", "cautions": "see underPhenelzine", "side-effects": "see underPhenelzine", "contra-indications": "see underPhenelzine", "hepatic impairment": "avoid in hepatic impairment; see alsonotes above", "doses": ["Initially 30\u00a0mg daily in single or divided doses until\r\nimprovement occurs (increased after 4 weeks if necessary to max. 60\u00a0mg\r\ndaily for 4\u20136 weeks under close supervision), then reduced to usual\r\nmaintenance dose 10\u201320\u00a0mg daily (but up to 40\u00a0mg daily may be required);elderly5\u201310\u00a0mg daily;childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "avoid"}, "EMTRICITABINE": {"indications": "HIV infection\r\nin combination with other antiretroviral drugs", "name": "EMTRICITABINE", "renal impairment": "reduce dose if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2; consult product literature", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  lamivudine advised by manufacturer of emtricitabine ", "name": "Emtricitabine", "backrefs": ["Emtricitabine"]}, "cautions": "seenotes above; also on discontinuation, monitor patients with hepatitis B (risk of exacerbation\r\nof hepatitis);interactions:Appendix\r\n1 (emtricitabine)", "side-effects": "see notes above; also abnormal dreams, pruritus,\r\nand hyperpigmentation", "hepatic impairment": "seenotes aboveand Cautions\r\nabove", "doses": ["See preparations"], "pregnancy": "seePregnancy", "breast-feeding": "seeBreast-feeding"}, "PANCREATIN": {"indications": "see above", "name": "PANCREATIN", "interactions": {"extra": "", "bad": 0, "interaction": "hypoglycaemic effect of  acarbose antagonised by pancreatin ", "name": "Pancreatin", "backrefs": ["Pancreatin"]}, "cautions": "seeaboveand (for higher-strength preparations) seebelow", "side-effects": "see above and (for higher-strength preparations)\r\nsee below", "doses": ["adultandchildover 15 years, 1\u20132 capsules with meals and\r\n1 capsule with snacks, swallowed whole or contents taken with water\r\nor mixed with soft food (then swallowed immediately without chewing)"], "pregnancy": "not known to be harmful"}, "ZOLPIDEM": {"interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases plasma concentration of zolpidem (risk of extreme sedation and respiratory depression\u2014avoid concomitant use)", "name": "Zolpidem", "backrefs": ["Zolpidem"]}}, "DIPHTHERIA-CONTAINING VACCINES": {"indications": "seenotes above", "name": "DIPHTHERIA-CONTAINING VACCINES", "cautions": "seesection 14.1and see also individual components\r\nof vaccines", "side-effects": "seesection 14.1; also\r\nrestlessness, sleep disturbances, and unusual crying in infants", "contra-indications": "seesection 14.1and see also individual components\r\nof vaccines", "doses": ["prophylaxis, not recommended therefore no dose stated\r\n(see notes above)"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "GLUCOSAMINE": {"indications": "symptomatic relief of mild to moderate osteoarthritis of the knee", "name": "GLUCOSAMINE", "interactions": {"extra": "", "bad": 1, "interaction": "anticoagulant effect of  warfarin enhanced by glucosamine (avoid concomitant use)", "name": "Glucosamine", "backrefs": ["Glucosamine"]}, "cautions": "impaired glucose tolerance (monitor blood-glucose\r\nconcentration before treatment and periodically thereafter); predisposition to cardiovascular disease (monitor\r\ncholesterol); asthma;interactions: Appendix 1 (glucosamine)", "side-effects": "nausea, abdominal pain, dyspepsia, flatulence,\r\ndiarrhoea, constipation, drowsiness, headache, fatigue;less\r\ncommonlyflushing, rash, pruritus;also reportedvisual disturbances, hair loss", "contra-indications": "shellfish allergy", "doses": ["adultover 18 years, 1\u00a0tablet\r\nonce daily; review treatment if no benefit after 2\u20133 months"], "pregnancy": "manufacturers advise avoid\u2014no information available", "breast-feeding": "manufacturers advise avoid\u2014no information available"}, "NEOMYCIN SULPHATE": {"indications": "bacterial skin infections", "name": "NEOMYCIN SULPHATE", "renal impairment": "see Cautions above", "cautions": "large areas, see below", "side-effects": "sensitisation (see alsonotes above)", "contra-indications": "neonates", "doses": ["apply up to 3 times daily (short-term use)"]}, "BISOPROLOL FUMARATE": {"indications": "see under Dose", "name": "BISOPROLOL FUMARATE", "renal impairment": "reduce dose if eGFR less than 20\u00a0mL/minute/1.73\u00a0m2(max. 10\u00a0mg daily)", "cautions": "see underPropranolol Hydrochloride; ensure heart failure not worsening before increasing\r\ndose", "side-effects": "see underPropranolol Hydrochloride; alsoless commonlydepression, muscle weakness,\r\nand cramp;rarelyhypertriglyceridaemia, syncope,\r\nand hearing impairment;very rarelyconjunctivitis", "contra-indications": "see underPropranolol Hydrochloride; also acute or decompensated heart failure requiring intravenous\r\ninotropes; sino-atrial block", "hepatic impairment": "max. 10\u00a0mg daily in severe impairment", "doses": ["Hypertension and angina, usually 10\u00a0mg once daily (5\u00a0mg\r\nmay be adequate in some patients); max. 20\u00a0mg daily", "Adjunct in heart failure (section 2.5.5), initially 1.25\u00a0mg once daily (in the morning)\r\nfor 1 week then, if well tolerated, increased to 2.5\u00a0mg once daily\r\nfor 1 week, then 3.75\u00a0mg once daily for 1 week, then 5\u00a0mg once daily\r\nfor 4 weeks, then 7.5\u00a0mg once daily for 4 weeks, then 10\u00a0mg once daily;\r\nmax. 10\u00a0mg daily"], "pregnancy": "seenotes above", "breast-feeding": "seenotes above"}, "COLCHICINE": {"indications": "acute gout; short-term prophylaxis during initial therapy withallopurinoland uricosuric drugs; prophylaxis of familial\r\nMediterranean fever (recurrent polyserositis)", "name": "COLCHICINE", "renal impairment": "reduce dose or increase dosage interval if eGFR 10\u201350\u00a0mL/minute/1.73\u00a0m2; avoid if eGFR less than 10\u00a0mL/minute/1.73\u00a0m2", "interactions": {"extra": "", "bad": 1, "interaction": " ritonavir possibly increases risk of colchicine toxicity\u2014suspend or reduce dose of colchicine (avoid concomitant use in hepatic or renal impairment)", "name": "Colchicine", "backrefs": ["Colchicine"]}, "cautions": "seenotes above; also elderly; gastro-intestinal disease; cardiac disease;interactions:Appendix 1 (colchicine)", "side-effects": "nausea, vomiting, and abdominal pain; excessive\r\ndoses may cause profuse diarrhoea, gastro-intestinal haemorrhage,\r\nrash, renal and hepatic damage;rarelyperipheral\r\nneuritis, inhibition of spermatogenesis, myopathy, alopecia, and with\r\nprolonged treatment blood disorders", "contra-indications": "blood disorders", "hepatic impairment": "use with caution", "doses": ["Acute gout, 500\u00a0micrograms 2\u20134 times daily until\r\nsymptoms relieved, max. 6\u00a0mg per course; course not to be repeated\r\nwithin 3 days", "Prevention of gout attacks during initial treatment\r\nwithallopurinolor uricosuric drugs, 500\u00a0micrograms\r\ntwice daily", "Prophylaxis of familial\r\nMediterranean fever [unlicensed], 0.5\u20132\u00a0mg once daily", "BNF doses may differ from those in the product\r\nliterature"], "pregnancy": "avoid\u2014teratogenicity inanimalstudies", "breast-feeding": "present in milk but no adverse effects reported;\r\nmanufacturers advise caution"}, "MITOTANE": {"indications": "seenotes above", "name": "MITOTANE", "renal impairment": "manufacturer advises caution in mild to moderate impairment\u2014monitoring\r\nof plasma-mitotane concentration recommended; avoid in severe impairment", "interactions": {"extra": "", "bad": 0, "interaction": "avoidance of  spironolactone advised by manufacturer of mitotane (antagonism of effect)", "name": "Mitotane", "backrefs": ["Mitotane", "Spironolactone"]}, "cautions": "seesection 8.1andnotes above; risk of accumulation\r\nin overweight patients; monitor plasma-mitotane\r\nconcentration\u2014consult product literature; avoid in acute porphyria (section 9.8.2);interactions: Appendix 1 (mitotane)", "side-effects": "seesection 8.1andnotes above; also gastro-intestinal disturbances\r\n(including nausea, vomiting, diarrhoea, epigastric discomfort), anorexia,\r\nliver disorders; hypercholesterolaemia, hypertriglyceridaemia; ataxia,\r\nconfusion, asthenia, myasthenia, paraesthesia, drowsiness, neuropathy,\r\ncognitive impairment, movement disorder, dizziness, headache; gynaecomastia;\r\n prolonged bleeding time, leucopenia, thrombocytopenia, anaemia; rash;rarelyhypersalivation, hypertension, postural hypotension,\r\nflushing, pyrexia, haematuria, proteinuria, haemorrhagic cystitis,\r\nhypouricaemia, visual disturbances, and ocular disorders", "hepatic impairment": "manufacturer advises caution in mild to moderate impairment\u2014monitoring\r\nof plasma-mitotane concentration recommended; avoid in severe impairment", "doses": ["adultover 18 years, initially\r\n2\u20133\u00a0g daily, (up to 6\u00a0g daily in severe illness) in 2\u20133 divided doses,\r\nadjusted according to plasma-mitotane concentration; reduce dose or\r\ninterrupt treatment  if signs of toxicity; discontinue if inadequate\r\nresponse after 3 months", "Plasma-mitotane concentration for optimum\r\nresponse 14\u201320\u00a0mg/litre"], "pregnancy": "manufacturer advises avoid\u2014women of childbearing\r\nage should use effective contraception during and after treatment;\r\nsee alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "discontinue breast-feeding"}, "BUPRENORPHINE WITH NALOXONE": {"indications": "adjunct in the treatment of opioid\r\ndependence", "name": "BUPRENORPHINE WITH NALOXONE", "renal impairment": "use with caution if eGFR less than 30\u00a0mL/minute/1.73\u00a0m2", "cautions": "seeBuprenorphine", "side-effects": "see under Buprenorphine insection 4.7.2and Naloxone insection 15.1.7; also weight loss, arthralgia;less commonlyyawning, heat stroke, hypothermia, vaginitis,\r\nanaemia, thrombocytopenia, leucopenia, lymphadenopathy, leucocytosis,\r\nhaematuria, urinary calculus, conjunctivitis, exfoliative dermatitis,\r\nacne, skin nodule, alopecia", "contra-indications": "see notes insection 4.7.2", "hepatic impairment": "use lower initial doses and titrate dose carefully\r\nin mild to moderate impairment; avoid in severe impairment; see alsonotes above", "doses": ["expressed as buprenorphine,adultandchildover 15 years, initially\r\n2\u20134\u00a0mg once daily (an additional dose of 2\u20134\u00a0mg may be administered\r\non day 1 depending on the individual patient\u2019s requirement), increased\r\nin steps of 2\u20138\u00a0mg according to response; max. 24\u00a0mg daily; total\r\nweekly dose may be divided and given on alternate days or 3 times\r\nweekly (but max. 24\u00a0mg daily)", "TheScottish Medicines\r\nConsortiumhas advised (February 2007) thatSuboxone\u00ae should be restricted for use in patients in whom\r\nmethadone is not suitable"], "pregnancy": "reproductive toxicity inanimalstudies\u2014switch\r\nto buprenorphine; see alsonotes above", "breast-feeding": "amount of buprenorphine in breast milk probably\r\ntoo small to be harmful; naloxone not orally bioavailable; see alsonotes above"}, "PROMETHAZINE TEOCLATE": {"indications": "nausea, vertigo, labyrinthine disorders,\r\nmotion sickness (acts longer than the hydrochloride)", "name": "PROMETHAZINE TEOCLATE", "renal impairment": "use with caution", "cautions": "section 3.4.1; severe coronary artery disease; asthma, bronchitis, bronchiectasis; Reye\u2019s syndrome", "side-effects": "section 3.4.1", "contra-indications": "section 3.4.1", "hepatic impairment": "section 3.4.1", "doses": ["25\u201375\u00a0mg, max. 100\u00a0mg, daily;child5\u201310 years, 12.5\u201337.5\u00a0mg daily", "Motion sickness prevention,adultandchildover 10 years, 25\u00a0mg at\r\nbedtime on night before travelor25\u00a0mg 1\u20132 hours\r\nbefore travel;child5\u201310 years, 12.5\u00a0mg\r\nat bedtime on night before travelor12.5\u00a0mg 1\u20132\r\nhours before travel", "Motion sickness treatment,adultandchildover 10 years, 25\u00a0mg at\r\nonset, then 25\u00a0mg at bedtime for 2 days;child5\u201310 years, 12.5\u00a0mg at onset, then 12.5\u00a0mg at bedtime for 2 days", "Severe vomiting during pregnancy [unlicensed], 25\u00a0mg at bedtime,\r\nincreased if necessary to max. 100\u00a0mg daily (but see alsoVomiting During Pregnancy)"], "pregnancy": "section 3.4.1", "breast-feeding": "section 3.4.1"}, "ZOPICLONE": {"indications": "insomnia (short-term use\u2014up to 4 weeks)", "name": "ZOPICLONE", "renal impairment": "start with small doses in severe impairment; increased\r\ncerebral sensitivity", "interactions": {"extra": "", "bad": 0, "interaction": " rifampicin significantly reduces plasma concentration of zopiclone ", "name": "Zopiclone", "backrefs": ["Zopiclone"]}, "cautions": "elderly; muscle\r\nweakness and myasthenia gravis, history of drug abuse, psychiatric illness; avoid prolonged use (risk of tolerance\r\nand withdrawal symptoms);interactions:Appendix 1 (anxiolytics and hypnotics)", "side-effects": "taste disturbance;less commonlynausea, vomiting; dizziness, drowsiness, dry mouth, headache;rarelyamnesia, confusion, depression, hallucinations, nightmares;very rarelylight headedness, incoordination; paradoxical\r\neffects (seeParadoxical Effects) and sleep-walking also reported", "contra-indications": "marked neuromuscular respiratory\r\nweakness including unstable myasthenia gravis, respiratory failure, severe sleep\r\napnoea syndrome", "hepatic impairment": "can precipitate coma; reduce dose (avoid if severe\r\nimpairment)", "doses": ["adultover 18 years, 7.5\u00a0mg\r\nat bedtime;elderlyinitially 3.75\u00a0mg\r\nat bedtime increased if necessary"], "pregnancy": "avoid regular use (risk of neonatal withdrawal symptoms);\r\nhigh doses during late pregnancy or labour may cause neonatal hypothermia,\r\nhypotonia, and respiratory depression", "breast-feeding": "present in milk\u2014avoid"}, "CHOLERA VACCINE": {"indications": "seenotes above", "name": "CHOLERA VACCINE", "cautions": "seesection 14.1andnotes above", "side-effects": "seesection 14.1; alsorarelyrespiratory symptoms such as rhinitis and cough;very rarelysore throat, insomnia", "contra-indications": "seesection 14.1; also acute gastro-intestinal illness", "doses": ["adultandchildover 6 years 2 doses separated by an interval\r\nof 1\u20136 weeks;child2\u20136 years 3 doses\r\neach separated by an interval of 1\u20136 weeks", "If more than 6 weeks have elapsed between\r\ndoses, the primary course should be restarted", "A single booster dose can be given 2 years after primary course\r\nfor adults and children over 6 years, and 6 months after primary course\r\nfor children 2\u20136 years. If more than 2 years have elapsed since the\r\nlast vaccination, the primary course should be repeated", "Dissolve effervescent sodium bicarbonate\r\ngranules in a glassful of water (approximately 150\u00a0mL). For adults\r\nand children over 6 years, add vaccine suspension to make one dose.\r\nFor child 2\u20136 years, discard half (approximately 75\u00a0mL) of the solution,\r\nthen add vaccine suspension to make one dose. Drink within 2 hours.\r\nFood, drink, and other oral medicines should be avoided for 1 hour\r\nbefore and after vaccination"], "pregnancy": "seesection 14.1", "breast-feeding": "seesection 14.1"}, "TEMSIROLIMUS": {"indications": "seenotes above", "name": "TEMSIROLIMUS", "renal impairment": "manufacturer advises caution in severe impairment\u2014no\r\ninformation available", "interactions": {"extra": "The main active metabolite of temsirolimus is sirolimus\u2014see also interactions of sirolimus and consult product literature", "bad": 1, "interaction": " ketoconazole increases plasma concentration of active metabolite of temsirolimus\u2014avoid concomitant use", "name": "Temsirolimus", "backrefs": ["Temsirolimus"]}, "cautions": "seenotes above; monitor respiratory\r\nfunction; monitor blood lipids;interactions:Appendix 1 (temsirolimus)", "side-effects": "seesection 8.1; also abdominal pain, diarrhoea,\r\nanorexia, taste disturbance, gastro-intestinal haemorrhage, bowel\r\nperforation, dysphagia; hypertension, oedema, thrombosis, thrombophlebitis;\r\ncough, dyspnoea, chest pain, interstitial lung disease, hypersensitivity\r\nreactions (seenotes above); insomnia, anxiety, depression,\r\ndrowsiness, paraesthesia, dizziness, asthenia; increased susceptibility\r\nto infection (including urinary-tract infection and pneumonia), pyrexia;\r\nhyperglycaemia; renal failure; hypophosphataemia, hypokalaemia, hypercholesterolaemia,\r\nhyperlipidaemia; myalgia, arthralgia; eye disorders; rhinitis, epistaxis;\r\nskin disorders (including rash and acne), folliculitis, impaired wound\r\nhealing;less commonlyintracerebral bleeding", "hepatic impairment": "use with caution; in renal cell carcinoma, reduce dose\r\nin severe impairment (consult product literature); in mantle cell\r\nlymphoma, avoid in moderate or severe impairment", "doses": ["SeeDoses"], "pregnancy": "manufacturer advises avoid (toxicity inanimalstudies); ensure effective contraception during treatment in men\r\nand women; see alsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises discontinue breast-feeding"}, "MEPACRINE": {"interactions": {"extra": "", "bad": 0, "interaction": "plasma concentration of  primaquine increased by mepacrine (increased risk of toxicity)", "name": "Mepacrine", "backrefs": ["Primaquine", "Mepacrine"]}}, "TIPRANAVIR": {"indications": "HIV infection resistant to other protease inhibitors, in combination\r\nwith other antiretroviral drugs in patients previously treated with\r\nantiretrovirals", "name": "TIPRANAVIR", "interactions": {"extra": "", "bad": 0, "interaction": "caution with  vardenafil advised by manufacturer of tipranavir ", "name": "Tipranavir", "backrefs": ["Tipranavir"]}, "cautions": "seenotes above; also patients at risk of increased bleeding from trauma, surgery or other\r\npathological conditions; concomitant use\r\nof drugs that increase risk of bleeding;interactions:Appendix 1 (tipranavir)", "side-effects": "see notes above; also dyspnoea, anorexia, peripheral\r\nneuropathy, influenza-like symptoms, renal impairment and photosensitivity;rarelydehydration", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above; also\r\nmanufacturer advises caution in mild impairment; avoid in moderate\r\nor severe impairment\u2014no information available", "doses": ["with low-dose ritonavir,child2\u201312 years seeBNF for Children"], "pregnancy": "manufacturer advises use only if potential benefit\r\noutweighs risk\u2014toxicity inanimalstudies", "breast-feeding": "seeBreast-feeding"}, "DEFERIPRONE": {"indications": "seenotes above", "name": "DEFERIPRONE", "renal impairment": "manufacturer advises caution\u2014no information available", "cautions": "monitor neutrophil count weekly and discontinue treatment if neutropenia develops; monitor plasma-zinc concentration", "side-effects": "gastro-intestinal disturbances (reducing dose\r\nand increasing gradually may improve tolerance), increased appetite;\r\nheadache; red-brown urine discoloration; neutropenia, agranulocytosis;\r\nzinc deficiency; arthropathy", "contra-indications": "history of agranulocytosis or recurrent neutropenia", "hepatic impairment": "manufacturer advises monitor liver function\u2014interrupt\r\ntreatment if persistent elevation in serum alanine aminotransferase", "doses": ["adultandchildover 6 years 25\u00a0mg/kg 3 times daily (max. 100\u00a0mg/kg\r\ndaily)"], "pregnancy": "manufacturer advises avoid before intended conception\r\nand during pregnancy\u2014teratogenic and embryotoxic inanimalstudies; contraception advised in women of child-bearing potential", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "TEMOPORFIN": {"indications": "advanced head and neck squamous cell carcinoma refractory to, or\r\nunsuitable for, other treatments", "name": "TEMOPORFIN", "interactions": {"extra": "", "bad": 1, "interaction": "increased skin photosensitivity when topical  fluorouracil used with temoporfin ", "name": "Temoporfin", "backrefs": ["Temoporfin"]}, "cautions": "seesection 8.1; avoid exposure of skin and eyes\r\nto direct sunlight or bright indoor light for at least 15 days after\r\nadministration; avoid prolonged exposure\r\nof injection site arm to direct sunlight for 6 months after administration, if extravasation occurs protect area from light for\r\nat least 3 months;interactions:Appendix\r\n1 (temoporfin)", "side-effects": "seesection 8.1; also constipation, dysphagia;\r\nhaemorrhage, oedema; giddiness, trismus, facial pain; injection site\r\npain, blistering, scarring, erythema, skin necrosis, hyperpigmentation,\r\nphotosensitivity (see Cautions above; sunscreens ineffective)", "contra-indications": "seesection 8.1; acute porphyria (section 9.8.2) or other diseases\r\nexacerbated by light; elective surgery or ophthalmic slit-lamp\r\nexamination for 30 days after administration; concomitant photosensitising treatment", "doses": ["SeeDoses"], "pregnancy": "toxicity inanimalstudies\u2014manufacturer\r\nadvises avoid pregnancy for at least 3 months after treatment; see\r\nalsoPregnancy and Reproductive\r\nFunction", "breast-feeding": "manufacturer advises avoid breast-feeding for\r\nat least 1 month after treatment\u2014no information available"}, "ISPAGHULA HUSK": {"indications": "see notes above", "name": "ISPAGHULA HUSK", "cautions": "adequate fluid intake should be maintained to avoid\r\nintestinal obstruction\u2014it may be necessary to supervise elderly or\r\ndebilitated patients or those with intestinal narrowing or decreased\r\nmotility", "side-effects": "flatulence, abdominal distension, gastro-intestinal\r\nobstruction or impaction; hypersensitivity reported", "contra-indications": "difficulty\r\nin swallowing, intestinal obstruction, colonic atony, faecal impaction", "doses": ["1 sachet in 150\u00a0mL water 1\u20133 times daily, preferably after\r\nmeals;child(but seesection\r\n1.6) 6\u201312 years \u00bd\u20131\u00a0level 5-mL spoonful in water 1\u20133 times\r\ndaily, preferably after meals"]}, "DEXIBUPROFEN": {"indications": "pain and inflammation associated with osteoarthritis and other musculoskeletal\r\ndisorders; mild to moderate pain and inflammation including dysmenorrhoea\r\nand dental pain", "name": "DEXIBUPROFEN", "renal impairment": "reduce initial dose; avoid if eGFR less than 30\u00a0mL/minute/1.73m2; see alsonotes above", "cautions": "seenotes above", "side-effects": "seenotes above", "contra-indications": "seenotes above", "hepatic impairment": "seenotes above", "doses": ["600\u2013900\u00a0mg daily in up to 3 divided doses; increased if\r\nnecessary to max. 1.2\u00a0g daily (900\u00a0mg daily for dysmenorrhoea); max.\r\nsingle dose 400\u00a0mg (300\u00a0mg for dysmenorrhoea);childnot recommended"], "pregnancy": "seenotes above", "breast-feeding": "present in milk\u2014but risk to infant minimal;\r\nsee alsonotes above"}, "PIPOTIAZINE": {"interactions": {"extra": "", "bad": 1, "interaction": "avoid concomitant use of  clozapine with depot formulation of pipotiazine as cannot be withdrawn quickly if neutropenia occurs", "name": "Pipotiazine", "backrefs": ["Pipotiazine"]}}, "ESOMEPRAZOLE": {"indications": "see under Dose", "name": "ESOMEPRAZOLE", "renal impairment": "manufacturer advises caution in severe renal insufficiency", "interactions": {"extra": "", "bad": 1, "interaction": "plasma concentration of  saquinavir possibly increased by esomeprazole\u2014manufacturer of saquinavir advises avoid concomitant use", "name": "Esomeprazole", "backrefs": ["Esomeprazole"]}, "cautions": "seenotes above;interactions:Appendix 1 (proton pump inhibitors)", "side-effects": "seenotes above", "hepatic impairment": "in severe hepatic impairment max. 20\u00a0mg daily (child1\u201312 years max. 10\u00a0mg daily); for severe peptic\r\nulcer bleeding in severe hepatic impairment, initial intravenous infusion\r\nof 80\u00a0mg, then by continuous intravenous infusion, 4\u00a0mg/hour for 72\r\nhours", "doses": ["By mouthduodenal ulcer associated\r\nwithHelicobacter pylori, seeRecommended Regimens forHelicobacter pyloriEradication", "NSAID-associated gastric ulcer,adultover 18 years, 20\u00a0mg once daily for 4\u20138 weeks; prophylaxis in patients\r\nwith an increased risk of gastroduodenal complications who require\r\ncontinued NSAID treatment, 20\u00a0mg daily", "Gastro-oesophageal reflux disease (in the presence of erosive\r\nreflux oesophagitis),adultandchildover 12 years, 40\u00a0mg once daily for 4 weeks,\r\ncontinued for further 4 weeks if not fully healed or symptoms persist;\r\nmaintenance 20\u00a0mg daily;child1\u201312\r\nyears, body-weight 10\u201320\u00a0kg, 10\u00a0mg once daily for 8 weeks; body-weight\r\nover 20\u00a0kg, 10\u201320\u00a0mg once daily for 8 weeks", "Symptomatic treatment of gastro-oesophageal reflux disease (in\r\nthe absence of oesophagitis),adultandchildover 12 years, 20\u00a0mg once\r\ndaily for up to 4 weeks, then 20\u00a0mg daily when required;child1\u201312 years, body-weight over 10\u00a0kg, 10\u00a0mg once\r\ndaily for up to 8 weeks", "Zollinger\u2013Ellison syndrome,adultover 18 years, initially 40\u00a0mg twice daily, adjusted according to\r\nresponse; usual range 80\u2013160\u00a0mg daily (above 80\u00a0mg in 2 divided doses)", "By intravenous injectionover at\r\nleast 3 minutesorby intravenous infusion,adultover 18 years, gastro-oesophageal\r\nreflux disease, 40\u00a0mg once daily; symptomatic reflux disease without\r\noesophagitis, treatment of NSAID-associated gastric ulcer, prevention\r\nof NSAID-associated gastric or duodenal ulcer, 20\u00a0mg daily; continue\r\nuntil oral administration possible", "Severe peptic ulcer bleeding (following endoscopic\r\ntreatment),adultover 18 years, initialintravenous infusionof 80\u00a0mg over 30 minutes, thenby continuous intravenous infusion8\u00a0mg/hour for 72 hours,\r\nthenby mouth40\u00a0mg once daily for 4 weeks"], "pregnancy": "manufacturer advises caution\u2014no information available", "breast-feeding": "manufacturer advises avoid\u2014no information available"}, "MESNA": {"indications": "seenotes above", "name": "MESNA", "cautions": "false positive urinary ketones; false positive or false negative urinary erythrocytes", "side-effects": "nausea, vomiting, colic, diarrhoea, fatigue, headache,\r\nlimb and joint pains, depression, irritability, rash, hypotension\r\nand tachycardia;rarelyhypersensitivity reactions\r\n(more common in patients with auto-immune disorders)", "contra-indications": "hypersensitivity to thiol-containing\r\ncompounds", "doses": ["Calculated according to oxazaphosphorine (cyclophosphamideorifosfamide) treatment\u2014consult product literature"], "pregnancy": "not known to be harmful; see alsoPregnancy and Reproductive\r\nFunction"}, "ANAESTHETICS, GENERAL (VOLATILE LIQUIDS)": {"interactions": {"extra": "", "bad": 1, "interaction": "increased risk of arrhythmias when  doxapram given with volatile liquid general anaesthetics (avoid doxapram for at least 10 minutes after volatile liquid general anaesthetics)", "name": "Anaesthetics, General (volatile liquids)", "backrefs": []}}, "3.8 Aromatic inhalations": {"name": "3.8 Aromatic inhalations", "doses": ["add one teaspoonful to a pint of hot,notboiling, water and inhale the vapour"]}}
